











Closing Research Gaps for  
Cerebral Palsy Prevention and 




Emily Sarah Shepherd 
 
Thesis submitted for the degree of Doctor of Philosophy 
 
Discipline of Obstetrics and Gynaecology 
Adelaide Medical School 
Faculty of Health and Medical Sciences 












LIST OF CITATIONS 4 
First author publications included in thesis 4 
First author presentations related to thesis 4 
Chief investigator grants related to thesis 5 
 
LIST OF TABLES 6 
 










CHAPTER 1: LITERATURE REVIEW 13 
Cerebral palsy: a vision of prevention 13 
Definition and diagnosis 13 
Prevalence 14 
Causes and risk factors 15 
Consequences 16 
Antenatal, intrapartum and neonatal prevention 17 
How antenatal, intrapartum and neonatal prevention might work 19 
Research question: What is the current evidence regarding antenatal, intrapartum and 
neonatal preventive interventions for cerebral palsy? 20 
Challenges of assessing preventive strategies for cerebral palsy 20 
Cerebral palsy registries for preventive research 21 
Research question: Can a nationwide cerebral palsy registry be used for long-term 
randomised trial follow up? 22 
The antenatal magnesium sulphate for fetal neuroprotection research cycle: closing the 
research gaps 22 
Early signs of promise: observational studies 22 
Five randomised controlled trials and a Cochrane review 23 
Guidelines and implementation studies 26 
Maternal adverse effects of antenatal magnesium sulphate: a systematic review 28 
Potential neonatal adverse effects of antenatal magnesium sulphate 28 
Research question: Is antenatal magnesium sulphate associated with adverse neonatal 
outcomes? 29 
Summary of literature review and identified research questions 30 
Thesis aims 30 
 
CHAPTER 2: ANTENATAL AND INTRAPARTUM INTERVENTIONS FOR 
PREVENTING CEREBRAL PALSY: AN OVERVIEW OF COCHRANE 
SYSTEMATIC REVIEWS 31 
Statement of authorship 31 
Published paper 33 
 
CHAPTER 3: NEONATAL INTERVENTIONS FOR PREVENTING CEREBRAL 
PALSY: AN OVERVIEW OF COCHRANE SYSTEMATIC REVIEWS 112 
Statement of authorship 112 




CHAPTER 4: LINKING DATA FROM A LARGE CLINICAL TRIAL WITH THE 
AUSTRALIAN CEREBRAL PALSY REGISTER 253 
Statement of authorship 253 
Published paper 255 
 
CHAPTER 5: ANTENATAL MAGNESIUM SULPHATE AND ADVERSE 
NEONATAL OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS 261 
Statement of authorship 261 
Published paper 263 
 
CHAPTER 6: OVERALL CONCLUSIONS 300 
Summary of findings from studies within this thesis 300 
Antenatal, intrapartum and neonatal interventions for preventing cerebral palsy: two 
overviews of Cochrane systematic reviews (Chapters 2 and 3) 300 
Linking data from a large perinatal clinical trial with the Australian Cerebral Palsy 
Register for long-term follow up (Chapter 4) 301 
Antenatal magnesium sulphate and adverse neonatal outcomes: a systematic review 
and meta-analysis (Chapter 5) 302 
Implications for practice and research from studies within this thesis 302 
Final conclusions 304 
 
APPENDICES 305 
Appendix 1: Other publications, presentations and grants during candidature related to 
thesis 305 
Appendix 2: Appendices for Chapter 2 publication 306 
Ongoing reviews 306 
Reviews awaiting further classification 308 
Appendix 3: Appendices for Chapter 3 publication 329 
Ongoing reviews 329 
Reviews awaiting further classification 337 
Appendix 4: Supporting information for Chapter 4 publication 369 
Table S1: Birth state/territory cerebral palsy (CP) register status and 2-year outcomes 
for children with a CP diagnosis in the ACTOMgSO4 at 2 years 369 
Table S2: Birth state/territory cerebral palsy (CP) register status and 2-year outcomes 
for children without a CP diagnosis in the ACTOMgSO4 at 2 years 371 
Appendix 5: Supporting information for Chapter 5 publication 373 
S1 Appendix. Forest plots and funnel plots for comparisons 1-8 373 
S1 Fig. Risk of bias for randomised controlled trials 405 
S1 PRISMA Checklist 406 
S1 Table. Characteristics of included studies 410 
S2 Table. Risk of bias of included studies 470 
S3 Table. Adverse outcomes from non-randomised studies 506 
S4 Table. Adverse outcomes from case reports 558 
S1 Text. Protocol 563 
S2 Text. Search strategies 572 
S3 Text. Articles excluded at full-text screening due to absence of English translation 575 
S4 Text. References for included studies 577 
 






LIST OF CITATIONS 
 
First author publications included in thesis 
 
Shepherd, E, Salam, RA, Middleton, P, Makrides, M, McIntyre, S, Badawi, N & Crowther, CA 
2017, 'Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of 
Cochrane systematic reviews', Cochrane Database of Systematic Reviews, Issue 8, Art. No.: 
CD012077. 
Preceded by: Shepherd, E, Middleton, P, Makrides, M, McIntyre, S, Badawi, N & Crowther, CA 
2016, 'Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of 
Cochrane systematic reviews (Protocol)', Cochrane Database of Systematic Reviews, Issue 2, Art. 
No.: CD012077. 
 
Shepherd, E, Salam, RA, Middleton, P, Han, S, Makrides, M, McIntyre, S, Badawi, N & Crowther, 
CA 2018, 'Neonatal interventions for preventing cerebral palsy: an overview of Cochrane systematic 
reviews', Cochrane Database of Systematic Reviews, Issue 6, Art. No.: CD012409. 
Preceded by: Shepherd, E, Middleton, P, Makrides, M, McIntyre, S, Badawi, N & Crowther, CA 
2016, 'Neonatal interventions for preventing cerebral palsy: an overview of Cochrane systematic 
reviews (Protocol)', Cochrane Database of Systematic Reviews, Issue 10, Art. No.: CD012409. 
 
Shepherd, E, Salam, RA, Manhas, D, Synnes, A, Middleton, P, Makrides, M & Crowther, CA 2019, 
'Antenatal magnesium sulphate and adverse neonatal outcomes: A systematic review and meta-
analysis', PLoS Medicine, vol. 16, no. 12, p. e1002988. 
 
Shepherd, E, McIntyre, S, Smithers-Sheedy, H, Ashwood, P, Sullivan, TR, te Velde, A, Doyle, 
LW, Makrides, M, Middleton, P & Crowther CA 2020, ‘Linking data from a large clinical trial with 
the Australian Cerebral Palsy Register’, Developmental Medicine and Child Neurology, advance 
online publication, DOI: 10.1111/dmcn.14556. 
 
First author presentations related to thesis 
 
Shepherd, E. Magnesium sulphate update. Australian Cerebral Palsy Register Policy Group 
Meeting. March 2016: Adelaide, Australia.  
 
Shepherd, E, Salam, R, Middleton, P, Makrides, M, McIntyre, S, Badawi, N & Crowther, CA. 
Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane 
systematic reviews. Perinatal Society of Australia and New Zealand Congress. April 2017: 
Canberra, Australia. 
 
Shepherd, E, Salam, RA, Middleton, P, Makrides, M, McIntyre, S, Badawi, N & Crowther, CA. 
Neonatal interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews. 
Perinatal Society of Australia and New Zealand Congress. April 2017: Canberra, Australia. 
 
Shepherd, E, McIntyre, S, Ashwood, P, Middleton, P, Makrides, M & Crowther, CA. Comparison 
of cerebral palsy diagnoses between the Australian Cerebral Palsy Register and a large clinical trial. 
Australasian Academy of Cerebral Palsy and Developmental Medicine Conference. March 2020: 
Perth, Australia. 
 
Shepherd, E, McIntyre, S, Smithers-Sheedy, H, Ashwood, P, Sullivan, TR, te Velde, A, Doyle, 
LW, Makrides, M, Middleton, P & Crowther, CA. Linking data from a large maternal perinatal 
clinical trial with the Australian Cerebral Palsy Register for long-term follow up. Perinatal Society 
of Australia and New Zealand Congress. Accepted 2020. 
 
Shepherd, E, Salam, RA, Manhas, D, Synnes, A, Middleton, P, Makrides, M & Crowther, CA. 
Antenatal magnesium sulphate and adverse neonatal outcomes: a systematic review and meta-




Chief investigator grants related to thesis 
 
Bain, E, Middleton, P & Crowther, CA. Research Foundation of Cerebral Palsy Alliance: PG0914 
– Interventions during the antenatal and neonatal period to prevent cerebral palsy: an overview of 
Cochrane systematic reviews. 2015-2016. A$22,000. 
 
Shepherd, E, Middleton, P, Makrides, M & Crowther, CA. Research Foundation of Cerebral Palsy 
Alliance: PG2015 – Neonatal and infant adverse effects of antenatal magnesium sulphate for 











Number Title Page(s) 
Table 1 Antenatal, intrapartum and neonatal interventions assessed in Cochrane 
reviews that may mediate cerebral palsy risk 
18-19 
Table 2 Characteristics of randomised controlled trials assessing antenatal 
magnesium sulphate for fetal neuroprotection 
24 
Table 3 Summary of guideline recommendations for antenatal magnesium 





Number Title Page(s) 
Table 1 Characteristics of excluded reviews 58-60 
Table 2 Characteristics of included reviews 60-69 
Table 3 Risk of bias assessments from included reviews 70-72 
Table 4 AMSTAR assessments for included reviews 72-74 
Table 5 ROBIS assessments for included reviews 74-75 
Table 6 Summary of findings: all comparisons measuring cerebral palsy 75-87 
Table 7 Summary of findings: subgroup or sensitivity analyses of select 
comparisons for cerebral palsy 
87-93 
Table 8 Summary of findings: all comparisons measuring cerebral palsy or 
death 
93 
Table 9 Summary of findings: all comparisons measuring severity of cerebral 
palsy 
94-97 
Table 10 Summary of findings: all comparisons measuring other composite 
outcomes that include cerebral palsy as a component 
97-108 




Number Title Page(s) 
Table 1 Characteristics of excluded reviews 146-150 
Table 2 Characteristics of included reviews 150-179 
Table 3 Risk of bias assessments from included reviews 180-189 
Table 4 AMSTAR assessments for included reviews 189-194 
Table 5 ROBIS assessments for included reviews 194-197 
Table 6 Cerebral palsy 197-213 
Table 7 Cerebral palsy: subgroup or sensitivity analyses 213-217 
Table 8 Cerebral palsy or death 217-219 
Table 9 Severity of cerebral palsy 219-220 
Table 10 Other composite outcomes that include cerebral palsy as a component 220-247 








Number Title Page 
Table 1 Perinatal characteristics of ACTOMgSO4 children eligible for linkage 257 
Table 2 Diagnoses of cerebral palsy in ACTOMgSO4 at 2 years, and on ACPR 





Number Title Page(s) 
Table 1 Adverse outcome estimates from randomised controlled trials: 
Comparison 1 – Magnesium sulphate versus placebo or no treatment 
271-272 
Table 2 Subgroup analyses based on indication for use from randomised 
controlled trials: Comparison 1 – Magnesium sulphate versus placebo or 
no treatment 
272 
Table 3 Subgroup analyses based on regimen characteristics from randomised 
controlled trials: Comparison 1 – Magnesium sulphate versus placebo or 
no treatment 
273 
Table 4 Adverse outcome estimates from randomised controlled trials: 
Comparison 2 – Lower versus higher dose regimens of magnesium 
sulphate 
274 
Table 5 Subgroup analyses based on indication for use from randomised 
controlled trials: Comparison 2 – Lower versus higher dose regimens of 
magnesium sulphate 
274 
Table 6 Adverse outcome estimates from randomised controlled trials: 
Comparisons 3-8 
276-277 
Table 7 Perinatal death from non-randomised studies 279 
Table 8 Summary of outcomes from non-randomised studies 280-283 




Number Title Page 












Number Title Page 




Number Title Page 




Number Title Page 
Figure 1 Flow diagram of included studies 268 







ACOG: American College of Obstetricians and Gynecologists 
ACPR: Australian Cerebral Palsy Register 
ACTOMgSO4: Australasian Collaborative Trial of Magnesium Sulphate 
BEAM: Beneficial Effects of Antenatal Magnesium Sulfate  
CDC: Centers for Disease Control and Prevention 
CFCS: Communication Function Classification System 
CI: confidence interval 
CP: cerebral palsy 
EDACS: Eating and Drinking Ability Classification System 
GMFCS: Gross Motor Function Classification System 
GMFM: Gross Motor Function Measure 
GMH: germinal matrix haemorrhage 
GMs: General Movements 
HINE: Hammersmith Infant Neurological Examination 
IVH: intraventricular haemorrhage 
KCE: Belgian Health Care Knowledge Centre 
MACS: Manual Ability Classification System 
MAGENTA: Magnesium sulphate at 30 to 34 weeks’ gestational age: neuroprotection trial 
MAGPIE: Magnesium Sulphate for Prevention of Eclampsia 
MAG-CP: MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy 
MagNET: Magnesium and Neurologic Endpoints Trial 
MRI: magnetic resonance imaging 
NCC-WCH: National Collaborating Centre for Women's and Children's Health 
OR: odds ratio 
PReCEPT: PREventing Cerebral palsy in Pre Term labour 
PREMAG: Prevention of Cerebral Palsy by Magnesium Sulphate  
PVL: periventricular leukomalacia 
RCPI: Royal College of Physicians of Ireland 
RCT: randomised controlled trial 
RR: risk ratio 
SCPE: Surveillance of Cerebral Palsy in Europe 
SD: standard deviation 
SMFM: Society for Maternal-Fetal Medicine 
WHO: World Health Organization 










Cerebral palsy (CP) is the leading cause of physical disability in childhood. Despite emerging 
evidence that the prevalence of CP has begun to decline, approximately one in 500 babies continue 
to be affected worldwide. While causes and risk factors for CP are well established, potential 
preventive interventions are under-researched. 
 
Aims 
1. To summarise and interpret the evidence regarding antenatal and intrapartum interventions for 
preventing CP. 
2. To summarise and interpret the evidence regarding neonatal interventions for preventing CP. 
3. To link data from a maternal perinatal randomised controlled trial (RCT) with a nationwide CP 
register to identify children with CP. 
4. To assess whether antenatal magnesium sulphate is associated with perinatal death or other 
adverse neonatal outcomes. 
 
Methods 
To achieve the above aims, the following methodologies were employed: 
1. An overview of Cochrane reviews regarding antenatal and intrapartum interventions for CP 
prevention. 
2. An overview of Cochrane reviews regarding neonatal interventions for CP prevention. 
3. A de-identified linkage of Australasian Collaborative Trial of Magnesium Sulphate 
(ACTOMgSO4) and Australian Cerebral Palsy Register (ACPR) data. 
4. A systematic review of RCTs and non-randomised studies assessing antenatal magnesium 
sulphate, perinatal death and other adverse neonatal outcomes. 
 
Results 
1. The overview of antenatal and intrapartum interventions included 15 Cochrane reviews, with 
CP data from 27 RCTs (32,490 children). Magnesium sulphate for women at risk of very preterm 
birth for fetal neuroprotection reduced CP risk (high-quality evidence). CP risk was probably 
increased (moderate-quality evidence, 2 reviews), probably not changed (moderate-quality 
evidence, 1 review), or unclear (low- to very low-quality evidence, 11 reviews) with other 
interventions assessed. 
2. The overview of neonatal interventions included 43 Cochrane reviews, with CP data from 96 
RCTs (15,885 children). Therapeutic hypothermia in late preterm or term neonates with 
hypoxic-ischaemic encephalopathy reduced CP risk (high-quality evidence), and prophylactic 
methylxanthines for endotracheal extubation in preterm neonates probably reduced CP risk 
(moderate-quality evidence). CP risk was probably increased (moderate-quality evidence, 2 
reviews), probably not changed (moderate-quality evidence, 5 reviews), or unclear (low- to very 
low-quality evidence, 26 reviews) with other interventions assessed. 
3. Linkage of data from 913 ACTOMgSO4 children (born 1996-2000) and the ACPR was achieved. 
Differences in ACTOMgSO4 (at 2 years) and ACPR (up to 5 years) CP diagnoses were 
identified; attributed to limitations in CP diagnostic methods, and register under-ascertainment 
in this era. 
4. The systematic review of adverse neonatal outcomes included 40 RCTs (19,265 women and 
their babies), 138 non-randomised studies, and 19 case reports. Perinatal death was not increased 
with antenatal magnesium sulphate in RCTs. RCTs showed no clear increased risks of other 
adverse neonatal outcomes; non-randomised studies identified a limited number of outcomes 
necessitating further evaluation. 
 
Conclusions 
Antenatal magnesium sulphate for fetal neuroprotection in women at risk of very preterm birth, and 
therapeutic hypothermia in late preterm or term neonates with hypoxic-ischaemic encephalopathy 
reduce the risk of CP. There is an urgent need for further research regarding the effects of other 
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CHAPTER 1: LITERATURE REVIEW 
 
Cerebral palsy: a vision of prevention 
 
Definition and diagnosis 
 
‘Cerebral palsy’ (CP) was originally defined by clinical description, at a time when there was little 
knowledge of aetiology or pathology (Korzeniewski et al. 2018). Discussion regarding definition 
and classification was first recorded in English, French and German medical literature in the 
nineteenth century; for over 150 years, exactly what the term CP describes was debated (Morris 
2007). Definitions adopted by CP registries internationally have commonly included those proposed 
by Bax in the 1960s (Bax 1964), Mutch and colleagues in the 1990s (Mutch et al. 1992) and more 
recently, by Rosenbaum and colleagues (a revised version of Bax 1964) (Rosenbaum et al. 2007); 
"Cerebral palsy describes a group of permanent disorders of the development of movement and 
posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred 
in the developing fetal or infant brain. The motor disorders of cerebral palsy are often accompanied 
by disturbances of sensation, perception, cognition, communication, and behaviour, by epilepsy and 
by secondary musculoskeletal problems" (Rosenbaum et al. 2007). 
 
Today, CP is still a clinical description, but many registries and surveillance programs, including in 
Australia, highlight the key elements that reflect the core features provided in definitions to date 
(and proposed by the Surveillance of Cerebral Palsy in Europe (SCPE 2000)): it is an ‘umbrella 
term’; it is permanent but not unchanging; it involves a disorder of movement and/or posture and of 
motor function; it is due to a non-progressive interference, lesion or abnormality; the interference, 
lesion or abnormality arose in the developing or immature brain (ACPR Group 2018; Smithers-
Sheedy et al. 2014). 
 
CP can be described by its motor type and body parts distribution (topography). Primary and 
secondary motor types include spasticity, dyskinesia, ataxia and hypotonia, and these are determined 
by a combination of structured neurological and motor assessments with observations corroborated 
by imaging findings in some cases (Stanley, Blair & Alberman 2000). In regards to topography of 
spasticity (the predominant primary motor type), hemiplegia (unilateral involvement), diplegia 
(bilateral involvement with the lower limbs more affected than the upper limbs), and quadriplegia 
(bilateral involvement with the upper limbs more or equally involved) are frequently used terms, 
with monoplegia and triplegia occasionally reported as separate entities or grouped with hemiplegia 
and quadriplegia, respectively (Stanley, Blair & Alberman 2000). 
 
In response to the need for a standardised system to classify the severity of movement disability 
among individuals with CP, the Gross Motor Function Classification System (GMFCS) was 
developed (Palisano et al. 1997), and has since become the principal way to classify gross motor 
dysfunction, with uptake into research and clinical practice internationally (Gray, Ng & Bartlett 
2010; Morris & Bartlett 2004). The GMFCS describes the gross movement ability of children in one 
of five ordinal levels (and provides descriptions for each level across five age bands: less than two 
years; two to four years; four to six years; six to 12 years; 12 to 18 years). Children in level I can 
perform activities similarly to their age-matched peers, with some difficulty with speed, balance and 
coordination (general heading: ‘Walks without limitations’), while children in level V have 
difficulty controlling their head and trunk posture in most positions and achieving any voluntary 
control of movement (general heading: ‘Transported in a manual wheelchair’) (Palisano et al. 1997). 
Unlike classifications based on topography and motor type, the GMFCS has been shown to be a 
valid, reliable, stable and clinically relevant method for classification and, in conjunction with the 
Gross Motor Function Measure (GMFM), prediction of motor function in CP (Gray, Ng & Bartlett 
2010; Morris & Bartlett 2004). 
 
Since the development of the GMFCS, further progress has been made in classifying children’s 
motor abilities, with the Manual Ability Classification System (MACS) providing a method 




2006). Additionally, the Communication Function Classification System (CFCS) provides a method 
to evaluate communication capacity within ‘real-life’ situations (Hidecker et al. 2011), and the 
Eating and Drinking Ability Classification System (EDACS) provides a method to assess the eating 
and drinking performance of children with CP (Sellers et al. 2014). Use of these standardised, 
reliable and complementary systems together draws a comprehensive picture of the functional 
performance in daily life of individuals with CP, to inform both research and clinical practice 
(Compagnone et al. 2014; Hidecker et al. 2012; Paulson & Vargus-Adams 2017). 
 
Historically, a ‘wait and see’ approach to CP diagnosis was common, up to and beyond the perceived 
‘latent’ period of 12 to 24 months, where it was believed that CP could not be identified accurately 
(te Velde et al. 2019). This provided time to “to rule out other diagnoses, delay the delivery of bad 
news or provide time for the child to grow out of it” (McIntyre et al. 2011). As CP is an umbrella 
term covering different clinical manifestations and aetiologies, the possibility for diagnosis reversal 
has been well recognised: “motor abnormalities detected in early childhood may subsequently lessen 
in degree, change in kind, or disappear altogether” (Nelson & Ellenberg 1982). Reports of children 
‘outgrowing’ or ‘losing’ early CP diagnoses in later childhood began decades ago (Nelson & 
Ellenberg 1982), and continue today (Chen et al. 2019). 
 
Recently, in recognition of the importance of early CP diagnosis in facilitating prompt referral for 
diagnostic-specific interventions (Byrne et al. 2019; Novak & Morgan 2019; te Velde et al. 2019), 
a comprehensive systematic review was conducted (Novak et al. 2017). This systematic review 
summarised the evidence base for the development of 2017 international clinical practice guidelines, 
which support early, accurate diagnosis and intervention in CP (Novak et al. 2017). Where 
appropriate, a diagnosis is now possible under the age of six months. As there is no one diagnostic 
tool, a combination of clinical history, neuroimaging (magnetic resonance imaging (MRI), 86-89% 
sensitivity), standardised neurological assessments (such as the Hammersmith Infant Neurological 
Examination (HINE), 90% sensitivity), and standardised motor assessments (particularly Prechtl’s 
Qualitative Assessment of General Movements (GMs) before five months’ corrected age, 98% 
sensitivity) are suggested, to enable the most accurate, earliest, diagnosis to be made (Novak et al. 




Despite variation in definitions and classifications of CP, there is wide agreement that it is the most 
common physical disability in childhood. In a meta-analysis, including 19 studies, the global pooled 
birth prevalence was 2.11 per 1,000 live births (95% confidence interval (CI) 1.98 to 2.25); a 
cumulative meta-analysis demonstrated stability in the prevalence over 10 years (Oskoui et al. 
2013). Similar trends and relative stability of rates over time have been shown in geographical 
regions which have used consistent methods of ascertainment for 20 years or more (in countries such 
as Australia, Sweden and England), with most published estimates of total population birth 
prevalence in the region of 2 per 1,000 (Stavsky et al. 2017). In low and middle-income countries, 
birth prevalence estimates of CP have tended to be similar or higher compared with high-income 
countries (Kakooza-Mwesige et al. 2017; Khandaker et al. 2019), however, it is difficult to 
meaningfully compare rates, with very few such countries using registries or surveillance programs. 
Within individual countries, prevalence rates vary among different population groups. For example, 
in Australia, the birth prevalence of CP among the Aboriginal and/or Torres Strait Islander 
(Indigenous) population is significant higher compared with the  non-Indigenous population (Blair 
et al. 2016). There is now emerging evidence, including from Australia (Galea et al. 2019), Europe 
(Hollung et al. 2018; Sellier et al. 2016), Canada (Robertson et al. 2017), and Japan (Touyama et al. 
2016) that the birth prevalence and severity of CP have begun to decline for the first time. 
 
In line with knowledge regarding risk factors for CP (discussed below), variations in prevalence 
rates are observed, such as when stratifying by gestational age or birthweight. In the aforementioned 
meta-analysis, the birth prevalence was highest for children weighing 1,000 to 1,499 grams at birth 
(59.18 per 1,000 live births) and born before 28 weeks’ gestation (111.80 per 1,000 live births) 





Causes and risk factors 
 
For approximately 6% of individuals with CP, their brain injury is believed to have occurred during 
a recognised event more than 28 days after birth and before the age of two to five; commonly, a 
cerebrovascular accident, spontaneous, associated with surgery or with complications of cardiac 
defects (ACPR Group 2018). For the remaining 94% of individuals with CP, their brain injury is 
believed to have occurred during the antenatal or the neonatal period of development, that is, during 
pregnancy, or within the first 28 days of life (ACPR Group 2018). 
 
The pathogenesis of such brain injury is known to be complex and multifactorial, with interrelated 
pathways contributing to cellular dysfunction and death, including accumulation of reactive oxygen 
species, the release of excitatory amino acids, energy depletion and apoptosis (Inder & Volpe 2000; 
Vexler & Ferriero 2001). There are multiple causes of brain injury, including hypoxia-ischaemia 
(characterised by reduced oxygen in the blood combined with reduced blood flow to the brain), 
haemorrhage, infection, maldevelopment and metabolic derangement (Volpe 2001). Brain hypoxia 
(deficiency of oxygen) and ischaemia (insufficient blood supply) may lead to different 
neuropathology in babies born preterm and at term – with cerebral white matter injury predominating 
in preterm babies, and neuronal cell injury in term babies (Volpe 2001). Injury to the developing 
brain is known to be associated with long-term sequelae, including CP, as well as other hearing, 
sight, speech and behavioural disorders, seizures, and intellectual disabilities (Vexler & Ferriero 
2001). 
 
Preterm birth (before 37 weeks’ gestation) is one of the principal risk factors for CP and associated 
neurodevelopmental disabilities (Himpens et al. 2008; Oskoui et al. 2013; van Lieshout et al. 2017). 
The degree of prematurity is associated with vulnerability of cerebral white matter, and is predictive 
of an increasing risk of white matter injury such as periventricular leukomalacia (PVL), and of 
intraventricular haemorrhage (IVH) (Larroque et al. 2003) – established risk factors for the 
development of CP (Gotardo et al. 2019; Saliba & Marret 2001). Although preterm birth is 
acknowledged as a major risk factor for CP, with over 40% of individuals with CP born preterm 
(compared with approximately 10% of the general population), most individuals with CP (50% to 
60%) are born at term (ACPR Group 2018). 
 
Studies on possible antenatal, intrapartum and neonatal risk factors for CP for preterm and term born 
individuals are abundant (with some risk factors reported more consistently than others). While a 
great number of potential risk factors for CP have been identified, their commonality is that 
separately, or in combination, they influence potentially preventable pathways to brain injury. Risk 
factors, in additional to preterm birth, often reported in the literature include: factors prior to 
conception, such as: low and advanced maternal age, high parity, nulliparity, a short or long inter-
pregnancy interval, a history of stillbirth, multiple miscarriages, neonatal death or preterm birth, 
family history of CP and other genetic predispositions, low socioeconomic status, and pre-existing 
maternal conditions (e.g. intellectual disability and epilepsy); factors in early pregnancy, such as: 
male gender, multiple gestation, congenital malformations or birth defects, and infections (e.g. 
toxoplasmosis, rubella, cytomegalovirus, and herpes simplex virus); factors during pregnancy, such 
as: maternal disease (e.g. thyroid disorders), pregnancy complications (e.g. high blood pressure, pre-
eclampsia, placenta praevia, placental abruption, and other placental abnormalities), intrauterine 
infection/inflammation and chorioamnionitis, intrauterine growth restriction, and other precursors 
to preterm birth; and factors around the time of birth and neonatal period, such as: acute intrapartum 
hypoxic events and neonatal encephalopathy, neonatal brain injury (e.g. IVH, PVL and 
hydrocephalus), strokes or seizures, cardiovascular disorders (e.g. patent ductus arteriosus and 
hypotension), vascular abnormalities (e.g. arteriovenous malformation), respiratory disorders and 
associated prolonged ventilation (e.g. for respiratory distress syndrome or bronchopulmonary 
dysplasia), infection (e.g. sepsis and necrotising enterocolitis), metabolic or endocrine disorders (e.g. 
hypoglycaemia and hypothyroidism), neonatal jaundice, and exposure to interventions (e.g. high 
dose dexamethasone), along with inborn errors of metabolism, particular syndromes or 
chromosomal abnormalities (Jacobsson & Hagberg 2004; Korzeniewski et al. 2018; McIntyre et al. 





Common risk factors in the post-neonatal period (some of which also contribute in the neonatal 
period) include: infection (e.g. meningitis/encephalitis, or severe infection and subsequent 
dehydration), head injury (e.g. from traffic accidents, other traumatic injury, or non-accidental 
injury), vascular episodes (e.g. post-cardiac or brain surgery), and other events (e.g. near drowning 
or near sudden infant death) (Cans et al. 2004; Germany et al. 2013). 
 
Research has shown that contrary to earlier beliefs, birth asphyxia is a relatively rare cause of CP 
(Blair & Stanley 1988; Ellenberg & Nelson 2013). A growing body of evidence now suggests that 
genetic abnormalities contribute to the development of CP in some cases (MacLennan, Thompson 
& Gecz 2015; Moreno-De-Luca, Ledbetter & Martin 2012; O'Callaghan et al. 2009; Oskoui et al. 
2015; van Eyk et al. 2019). While previously, only 1% to 2% of CP cases were linked to a causative 
genetic mutation, recent studies have shown that between 14% and 31% of cases have possible 
causative single gene mutations or clinically relevant copy number variants respectively 
(MacLennan, Thompson & Gecz 2015). Possible genetic mutations and variants associated with CP 
are likely to be heterogeneous (van Eyk et al. 2019). However, they can similarly trigger pathways 
(either directly, or in the case of genetic susceptibility, when certain risk factors are present), leading 
to non-progressive neuropathology associated with motor dysfunction, and CP (MacLennan, 
Thompson & Gecz 2015). 
 
In low- and middle-income countries, the risk factors and causes of CP are known to differ from 
those in high-income countries. With few survivors following very preterm birth in low- and middle-
income countries, birth asphyxia, maternal Rhesus alloimmunisation or inherited disorders and 
subsequent bilirubin encephalopathy are more common risk factors for CP (Donald et al. 2015; 
Lagunju & Fatunde 2009; Monokwane et al. 2017). Additionally, in low- and middle-income 
countries, there are higher proportions of children with postnatally acquired CP, compared with in 
high-income countries, particularly associated with post-infectious brain damage (following 
meningitis, septicaemia and other conditions such as malaria) (Donald et al. 2015; Lagunju & 
Fatunde 2009; Monokwane et al. 2017). 
 
Though there is currently no known cure for CP, with increasing knowledge of risk factors and 
causal pathways, there is now heightened hope for the development and implementation of primary 
preventive strategies: “we are on the move… the vision of prevention and cure no longer seems an 




CP is the leading cause of physical disability in children. Though traditionally regarded as a 
paediatric condition, it is now recognised that CP is a condition with life-long impact – a ‘lifespan 
condition’ – and thus the outcomes of individuals with CP across the life course need to be 
considered, for example, when planning and directing interventions in childhood (Colver 2016; 
Colver, Fairhurst & Pharoah 2014; Makris, Dorstyn & Crettenden 2019). 
 
Regarding life expectancy, most individuals with CP will survive to adulthood, with some studies 
suggesting life expectancy can be broadly similar to that of the general population (Colver 2016; 
Strauss et al. 2008). Higher mortality has, however, been shown for individuals with CP and co-
existing morbidities (including severe intellectual impairment, difficulties swallowing and scoliosis) 
(Colver 2016; Strauss et al. 2008). Survival is poorest in those with the most severe motor 
dysfunction (GMFCS level V) (Hutton & Pharoah 2006). Findings related to quality of life in 
individuals with CP have been variable. In a recent systematic review and meta-analysis of 11 
observational studies (10 cross-sectional studies and one longitudinal study), physical quality of life 
was shown to be significantly impaired for individuals with CP (Makris, Dorstyn & Crettenden 
2019). The effects of CP on psychological and social quality of life however, were inconsistent. The 
review also demonstrated a tendency for parents’ assessments of quality of life for children with CP 
to be lower than children’s own assessments (Makris, Dorstyn & Crettenden 2019). 
 
Frequently used definitions for CP importantly acknowledge common concomitant impairments, 




disability and epilepsy (Colver 2016; Rosenbaum et al. 2007). A systematic review and meta-
analysis of 30 observational studies (predominately retrospective cohort studies based on data from 
population-based CP registries) reported, for example, that among children with CP “3 in 4 were in 
pain; 1 in 2 had an intellectual disability; 1 in 3 could not walk; 1 in 3 had a hip displacement; 1 in 
4 could not talk; 1 in 4 had epilepsy; 1 in 4 had a behavior disorder; 1 in 4 had bladder control 
problems; 1 in 5 had a sleep disorder; 1 in 5 dribbled; 1 in 10 were blind; 1 in 15 were tube-fed; and 
1 in 25 were deaf” (Novak et al. 2012). 
 
Economic studies have estimated lifetime costs of CP, including health care costs (such as primary 
health care, hospital care and pharmaceuticals), social care costs (such as specialised education and 
housing) and productivity costs (the cost for society when individuals never enter, or leave the labour 
market) as €860,000 for men and €800,000 for women in Denmark (in 2000) (Kruse et al. 2009), 
and US$921,000 for individuals in the United States (in 2003) (CDC 2004). In Australia, the annual 
financial cost of CP at a national level was estimated as A$1.47 billion (in 2007); the value of lost 
wellbeing (disability and premature death) was a further A$2.4 billion (Access Economics 2008). A 
recent systematic review, including 22 studies (all original articles, reporting costs, cost estimates, 
cost burden and/or expenditure related to CP), highlighted the significant costs incurred by families 
and the welfare system, to facilitate participation of individuals with CP (e.g. school and community 
engagement), along with a strong positive relationship between CP severity and expenditure 
(Tonmukayakul et al. 2018). 
 
The impact of CP is considerable – not only for individuals, but for families, carers, communities 
and societies. Accordingly, the identification of primary preventive measures continues to be 
recognised as a top priority, by individuals with CP and their families, clinicians and researchers 
(McIntyre, Novak & Cusick 2010). 
 
Antenatal, intrapartum and neonatal prevention 
 
Research efforts focused on ‘moving towards a future without CP’ have increasingly focused on 
understanding the causes of CP. As it is now widely recognised that causes may differ, for example, 
by gestational age (i.e. for preterm and term born children), and also by clinical subtype of CP 
(Nelson & Chang 2008), it is reasonable to consider that successful preventive interventions may 
therefore also vary according to different aetiologies or risk factors. For example, spastic diplegia is 
the most common subtype of CP in preterm born children, most often caused by white matter injury 
initiated by cerebral ischaemia and/or maternal intrauterine infection and fetal systemic 
inflammation; quadriplegic CP, especially with dyskinesia, is a subtype of CP sometimes related to 
acute asphyxia around the time of birth (Nelson & Chang 2008). 
 
Primary preventive interventions may include strategies close to the cause of brain damage (e.g. 
antenatal magnesium sulphate prior to preterm birth for fetal neuroprotection), strategies directed at 
preventing distal components on a causal pathway to CP (e.g. melatonin during pregnancy for 
intrauterine growth restriction), or public health strategies for the general population (e.g. 
periconceptional folate supplementation to reduce birth defects) (IMPACT for CP 2015). There are 
a broad range of antenatal, intrapartum and neonatal health care interventions (with varying primary 
aims or indications) that could influence CP risk (the examples, assessed in Cochrane systematic 






Table 1: Antenatal, intrapartum and neonatal interventions assessed in Cochrane reviews that may 
mediate CP risk 
 
Intervention category Example interventions 
Nutrition interventions in 
pregnancy 
Periconceptional folate (De-Regil et al. 2015); omega-3 fatty 
acids (Middleton et al. 2018); vitamins C and E (Rumbold et al. 
2015a; Rumbold et al. 2015b); vitamin D (De-Regil et al. 
2016); zinc (Ota et al. 2015) 
Behaviour/advice 
interventions in pregnancy 
Advice for reducing alcohol or drug consumption (Stade et al. 
2009); for supporting smoking cessation (Chamberlain et al. 
2017) 
Interventions for predicting 
or preventing preterm birth 
Fetal fibronectin testing (Berghella & Saccone 2019b); cervical 
assessment by ultrasound (Berghella & Saccone 2019a); 
cervical cerclage (Alfirevic, Stampalija & Medley 2017); 
antenatal administration of progesterone (Dodd et al. 2013); 
acute tocolytic therapy and/or maintenance therapy (i.e. 
magnesium sulphate (Crowther et al. 2014); calcium channel 
blockers (nifedipine) (Flenady et al. 2014b); oxytocin receptor 
antagonists (atosiban) (Flenady et al. 2014a); betamimetics 
(terbutaline) (Neilson, West & Dowswell 2014); cyclo-
oxygenase inhibitors (indomethacin) (Reinebrant et al. 2015)) 
Interventions prior to preterm 
or term birth for fetal 
neuroprotection 
Antenatal corticosteroids (Roberts et al. 2017); magnesium 
sulphate (Doyle et al. 2009); creatine (Dickinson et al. 2014); 
melatonin (Wilkinson, Shepherd & Wallace 2016); allopurinol 
(Martinello et al. 2017) 
Interventions for screening 
and managing fetal growth 
and well-being in pregnancy 
Symphysial fundal height measurement for detecting abnormal 
fetal growth (Robert Peter et al. 2015); ultrasound for fetal 
assessment in early pregnancy (Whitworth, Bricker & Mullan 
2015); routine ultrasound in late pregnancy (Bricker, Medley & 
Pratt 2015); antenatal cardiotocography for fetal assessment 
(Grivell et al. 2015); fetal and umbilical Doppler ultrasound 
(Alfirevic, Stampalija & Medley 2015) 
Interventions for diagnosing 
or preventing fetal 
compromise in labour 
Intermittent auscultation of fetal heart rate (Martis et al. 2017); 
continuous cardiotocography for electric fetal heart rate 
monitoring (Alfirevic et al. 2017); fetal electrocardiogram 
(Neilson 2015); fetal pulse oximetry (East et al. 2014) 
Interventions for infection 
during pregnancy 
Prevention of congenital infections (i.e. toxoplasmosis (Di 
Mario et al. 2013)); interventions for urinary tract infections 
(Schneeberger et al. 2015; Smaill & Vazquez 2019; Vazquez & 
Abalos 2011); interventions for lower genital tract infections 
(Brocklehurst et al. 2013; Sangkomkamhang et al. 2015) 
Interventions for preterm or 
term prelabour rupture of 
membranes 
Planned early birth (vs. expectant management) (Bond et al. 
2017; Middleton et al. 2017); antibiotics (Kenyon, Boulvain & 
Neilson 2013; Wojcieszek, Stock & Flenady 2014); tocolytics 
(Mackeen et al. 2014) 
Other specific interventions 
for medical problems in 
pregnancy 
Screening and subsequent management for thyroid dysfunction 
(Spencer et al. 2015); anti-D administration for preventing 
Rhesus alloimmunisation in Rh-negative women (McBain, 
Crowther & Middleton 2015); interventions for the treatment of 
mild to moderate (Abalos et al. 2018), or severe hypertension 
(Duley, Meher & Jones 2013), and for the prevention (i.e. 
antioxidants (Rumbold et al. 2008); antiplatelet agents (Duley et 
al. 2019)) and treatment of pre-eclampsia or eclampsia (i.e. 
magnesium sulphate (Duley et al. 2010a); diazepam (Duley et 




interventions for placental praevia (Neilson 2003a), or 
abruption (Neilson 2003b) 
Interventions for neonates 
following birth asphyxia or 
with evidence of hypoxic 
ischaemic encephalopathy 
Cooling (Jacobs et al. 2013); anticonvulsants (Young, Berg & 
Soll 2016); allopurinol (Chaudhari & McGuire 2012) 
Interventions for preventing 
or treating neonatal seizures 
Anticonvulsants (Booth & Evans 2004) 
Interventions for preventing 
or treating neonatal 
respiratory distress 
syndrome, and for respiratory 
function 
Exogenous surfactant (Rojas-Reyes, Morley & Soll 2012); early 
or late postnatal corticosteroids (Doyle et al. 2017; Doyle, 
Ehrenkranz & Halliday 2014); targeting higher (vs. lower) 
arterial oxygen saturations (Askie et al. 2017); caffeine 
(Henderson-Smart & De Paoli 2010a, 2010b) 
Interventions for preventing 
or treating hypoglycaemia 
Oral dextrose gel (Weston et al. 2016) 
Interventions for preventing 
or treating jaundice 
Phototherapy (Okwundu, Okoromah & Shah 2012) 
Interventions for preventing 
or treating neonatal infection 
 
Prophylactic (vs. selective) antibiotics (such as for term born 
babies of mothers with risk factors (Ungerer et al. 2004); or 
neonates with catheters (Jardine, Inglis & Davies 2008)); 
antibiotics for bacterial meningitis (Shah, Ohlsson & Shah 
2012); antibiotics for suspected late-onset sepsis (Gordon & 
Jeffery 2005); intravenous immunoglobulin (Ohlsson & Lacy 
2015) 
Other specific interventions 
in the neonatal period 
particularly for preterm born 
babies 
Kangaroo mother care (Conde-Agudelo & Diaz-Rossello 2016); 
early developmental interventions post-discharge (Spittle et al. 
2015) 
 
How antenatal, intrapartum and neonatal prevention might work 
 
Advances in research into several factors that modify the risk of CP suggest many opportunities for 
prevention. Some of the main strategies focus on preventing preterm birth, or protecting the 
developing fetal or neonatal brain through the antenatal, intrapartum or neonatal administration of 
neuroprotective agents (Favrais et al. 2014; Jameson & Bernstein 2019). 
 
For example, because preterm birth and neurodevelopmental outcomes are so strongly associated, it 
is possible that interventions to prolong gestation or reduce the risk of preterm birth will also reduce 
the risk of CP (Chang 2015; Iams et al. 2008; O'Shea 2008). Specific approaches, with clear evidence 
of benefit to prevent preterm birth in specific populations of pregnant women include: midwife-led 
continuity models of care for pregnant women (Sandall et al. 2016); zinc supplementation for 
pregnant women without systemic illness (Ota et al. 2015); screening for lower genital tract 
infections for pregnant women less than 37 weeks’ gestation, without signs of labour, bleeding or 
infection (Sangkomkamhang et al. 2015); and cervical cerlage for women with singleton 
pregnancies at high risk of preterm birth (Alfirevic, Stampalija & Medley 2017) (Medley et al. 
2018). Possible benefits for the prevention of preterm birth have also been shown, for example, with 
group antenatal care for pregnant women (Catling et al. 2015); antibiotics for pregnant women with 
asymptomatic bacteriuria (Smaill & Vazquez 2019); and vitamin D supplements for pregnant 
women without pre-existing conditions such as diabetes (De-Regil et al. 2016) (Medley et al. 2018). 
 
For women with an immediate risk of preterm birth, it is possible that antenatal interventions aimed 
at protecting the fetal brain from injury will also reduce CP risk. For example, antenatal 
corticosteroids to accelerate fetal lung maturation in women at risk of preterm birth have been shown 
to be neuroprotective (Roberts et al. 2017). Beyond antenatal corticosteroids and magnesium 
sulphate (Doyle et al. 2009) a range of other potential antenatally administered agents, such as 




(Dickinson et al. 2014), may enhance the ability of the preterm or term developing fetal brain to 
withstand brain damage and in doing so, reduce CP risk (Ellery et al. 2018; Jameson & Bernstein 
2019; Robertson et al. 2012). 
 
There are numerous other antenatal and intrapartum interventions with potential to contribute to CP 
prevention, which may work through modifying known risk factors; for example: identification and 
subsequent management of maternal thyroid dysfunction (both hypo- and hyper-thyroidism) in 
pregnancy (Spencer et al. 2015); prevention, identification and treatment of hypertension and pre-
eclampsia in pregnancy (Abalos et al. 2018; Duley et al. 2010a; Duley, Henderson-Smart & Chou 
2010; Duley et al. 2010b; Duley et al. 2019; Duley, Meher & Jones 2013); and fetal monitoring 
(intermittent auscultation, cardiotocography, electrocardiogram, fetal pulse oximetry) in labour for 
early recognition or prevention of birth asphyxia (Alfirevic et al. 2017; East et al. 2014; Martis et al. 
2017; Neilson 2015). 
 
For many individuals born at or near term who develop CP, their neonatal course was seemingly 
unremarkable, with the exception of those following perinatal asphyxia and with neonatal 
encephalopathy (brain injury due to cerebral hypoxia and ischemia prior to birth) (O'Shea 2008). 
For these neonates, therapeutic hypothermia, applied selectively to the head (as a ‘cooling cap’) or 
to the whole body, is one such intervention with the potential to influence CP risk (Jacobs et al. 
2013).  Beyond cooling, there are a range of other interventions, such as melatonin and 
erythropoietin (including to be used as adjuvant therapy with cooling) which may contribute to CP 
prevention, either through protecting against secondary cell death and brain damage following 
hypoxic-ischaemic insult, or through treating the underlying cause(s) of encephalopathy (such as 
infection) (Robertson et al. 2012). 
 
For preterm and very low birthweight neonates, or other groups of neonates (such as those with 
hypoglycaemia) who are at increased risk of brain injury, there are many pharmacological and non-
pharmacological interventions in the neonatal period that may mediate CP risk (O'Shea 2008). These 
interventions differ in their primary aims (such as maintaining adequate ventilation (e.g. through the 
treatment of apnoea of prematurity with caffeine (Henderson-Smart & De Paoli 2010a, 2010b)); 
maintaining normal metabolic status (e.g. through the treatment of neonatal hypoglycaemia with 
dextrose gel (Weston et al. 2016)); or controlling neonatal seizures (e.g. through use of 
anticonvulsants (Booth & Evans 2004))). However, each may contribute to CP prevention through 
reducing the likelihood or severity of brain injury, and thus of long-term neurodevelopmental 
sequelae. 
 
Research question: What is the current evidence regarding antenatal, intrapartum 
and neonatal preventive interventions for cerebral palsy? 
 
Recognising that risk factors and causes of CP differ, there is a need to systematically consider all 
potentially relevant interventions for their ability to contribute to prevention. With increasing 
numbers of randomised controlled trials (RCTs) and the explosion of systematic reviews, ‘wading 
through’ available evidence can be challenging and overwhelming (Hartling, Vandermeer & 
Fernandes 2014; Hunt et al. 2018; Lunny et al. 2017). Overviews or ‘umbrella reviews’ of 
interventions for CP prevention could provide a higher level synthesis of the plethora of potential 
preventive interventions. To our knowledge, no ‘overviews’ have brought together the evidence 
around interventions for CP prevention from Cochrane reviews together into coherent documents to 
be used by researchers, funding bodies, policy makers, clinicians and consumers to aid decision 
making and evidence implementation. 
 
Challenges of assessing preventive strategies for cerebral palsy 
 
Despite the recognised potential for a range of antenatal, intrapartum and neonatal interventions to 
alter CP risk, there is evidence that only a minority of RCTs assessing these interventions are able 
to report on long-term neurodevelopmental health outcomes, including CP (Murray, Stock & 




progesterone, cervical cerclage or pessaries, tocolytics and antibiotics), there is little evidence 
reporting on the long-term outcomes of these strategies. Very few RCTs of preterm birth prevention 
report long-term follow up to two years of age, and even fewer beyond that time point (Murray, 
Stock & Norman 2017). 
 
In a systematic review of 249 maternal and perinatal intervention RCTs that were designed to 
improve neonatal outcomes, 209 (84%) did not perform long-term follow up beyond the initial 
hospital discharge (Teune et al. 2013). When longer-term follow up was conducted (40 RCTs, 16%), 
an adequate power calculation for longer-term child outcomes was rarely reported (six RCTs, 15%), 
and commonly, not all eligible children were approached or included for follow up (rates varied 
from 11% to 100%) (Teune et al. 2013). Methods used for follow up also differed across RCTs; 
although 28 of the 40 RCTs assessed childhood neurodevelopment, some used questionnaire(s) only, 
others assessment(s) only, and some a combination. In a further review of 22 Cochrane systematic 
reviews of interventions in babies at risk of CP, ‘neurodevelopmental outcomes’ (e.g. CP, blindness, 
deafness, intellectual impairment) were reported to be the second most frequent review outcomes of 
interest (Hines et al. 2015). However, only a minority of the 203 included RCTs (22, 11%) were 
able to report these data (Hines et al. 2015). This review concluded that “[RCTs] did not routinely 
collect the long-term data required to provide information on CP as an outcome. This has resulted 
in lost opportunities for gathering more definitive answers from studies of the highest level of 
evidence about treatment effectiveness” (Hines et al. 2015). 
 
While follow up rates of maternal perinatal RCTs have been low and relatively stable (Teune et al. 
2013), there has been increasing acknowledgement of the importance of assessing longer-term 
outcomes, including CP (Doyle & Saigal 2009; van 't Hooft et al. 2016). In a systematic review 
(conducted almost two decades ago) assessing choice of primary outcomes for interventions for 
preterm birth prevention, none of the 103 included RCTs or 33 included systematic reviews reported 
long-term neurodevelopmental morbidity (including CP), as a primary outcome (Zhang & Schmidt 
2001). However, in a recent core outcome set for studies evaluating preterm birth prevention, 
developed with international multidisciplinary involvement, ‘late neurodevelopmental morbidity’ 
was one of 13 maternal and neonatal core outcomes specified (van 't Hooft et al. 2016).  
 
The challenges of long-term follow up are numerous and well recognised. The actual costs of 
conducting follow up assessments of children are high, and increase with the ages of the children 
(Doyle et al. 2015). These costs are much higher than researchers commonly request or are awarded. 
For example, while approximately A$400-500 per participant may be budgeted for two year 
paediatric and psychological assessments in a follow up study, the average staff costs alone have 
been estimated at in excess of A$700 (Doyle et al. 2015). When funded, there are further hurdles to 
follow up, including families declining to participate or non-attendance following consent (Teune et 
al. 2013). Failure to attend follow up appointments is common, leading to further costs associated 
with employing staff where assessments do not occur and re-booking appointments. Travel to other 
locations, such as children’s homes or schools for assessments, to improve follow up rates, adds 
further expense (Doyle et al. 2015). However, children most difficult to follow up are those with, on 
average, poorer neurodevelopmental outcomes (Callanan et al. 2001; Doyle et al. 2018), and thus 
high follow up rates are crucial. When follow up is conducted, methods of examination, ages at 
assessments, and outcome definitions vary within and between RCTs (Hines et al. 2015; Teune et 
al. 2013). This creates further hurdles in the meaningful evaluation of preventive strategies for 
adverse neurodevelopmental outcomes, including CP. 
 
Cerebral palsy registries for preventive research 
 
With increasing obstacles of long-term outcome assessment, there is growing interest in the use of 
alternative strategies to follow up children from maternal perinatal intervention RCTs. One potential 
approach is linkage of RCT data to routine/administrative datasets or disease-specific registries 
(McCord et al. 2018), such as CP registries. While use of such data may present hurdles, including 
practical (regulatory and ethical), and methodological (dataset) barriers, there are great potential 
benefits, particularly surrounding feasibility – reducing time, resources and thus costs (McCord et 




with literature searches spanning 1945 to 2016, identified only 133 RCTs utilising this approach 
(Fitzpatrick et al. 2018). Five (4%) of the 133 original RCTs assessed interventions in pregnant 
women or neonates; none reported on child neurodevelopment, including CP. The review concluded 
that “Against a background of more than 20 000 randomized trials registered each year… a small 
number of reports of trials that had been extended by linkage to registry and administrative data to 
evaluate long-term outcomes of trial interventions [were identified]…Trial extension by linkage to 
routinely collected data is a versatile, underused approach that may add critical insights beyond 
those of the original trial. Some beneficial and harmful outcomes of interventions are captured only 
in the extension phase of randomized trials” (Fitzpatrick et al. 2018). 
 
In an international survey of 27 CP registries or surveillance systems from 11 countries across three 
geographical regions (Australia, Europe and North America), all reported the key aim of being a 
‘resource for CP research’, including “identifying CP as a long term outcome” (Goldsmith et al. 
2016). Of current research themes being investigated by the registers/surveillance systems, ‘the 
evaluation of interventions’ was reported by 40% (Goldsmith et al. 2016). 
 
The Australian CP Register (ACPR) is an electronic database, established in 2008, and securely 
uploaded from each state and territory CP registry (ACPR Group 2018). This includes data from 
long-standing CP registries in Western Australia (established in 1979), Victoria (1987) and South 
Australia (1998), and newer (as recently as 2006) registries in New South Wales/Australian Capital 
Territory, Queensland, Tasmania, and the Northern Territory. To be included on the ACPR, a child’s 
motor impairment must fulfil criteria contained in the definitional elements for CP (Rosenbaum et 
al. 2007; SCPE 2000). Children’s CP is ‘confirmed’ when they reach five years of age. Where new 
information becomes available, cases may be updated leading to inclusion or exclusion. Along with 
monitoring the incidence and prevalence of CP, one of the ACPR’s stated aims is to facilitate the 
evaluation of preventive strategies (ACPR Group 2018). 
 
Research question: Can a nationwide cerebral palsy registry be used for long-term 
randomised trial follow up? 
 
There are lost opportunities to determine the effects of maternal and perinatal interventions on CP, 
and a need to explore other strategies to facilitate RCT follow up. To date, data linkage of a large 
RCT with the ACPR for childhood CP follow up has not been conducted. The Australasian 
Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) was a multi-centred RCT assessing 
magnesium sulphate prior to very preterm birth, for preventing paediatric mortality and CP (as is 
discussed further below). 
 
The antenatal magnesium sulphate for fetal neuroprotection research cycle: closing 
the research gaps 
 
Early signs of promise: observational studies 
 
Two landmark observational studies published in the 1990s provided the first descriptions of an 
association between in utero exposure to magnesium sulphate and a reduced risk of perinatal brain 
injury and CP (Kuban et al. 1992; Nelson & Grether 1995). Kuban and colleagues conducted a 
prospective cohort study (449 babies born less than 1,501 grams), to test the hypothesis that babies 
born to mothers with pre-eclampsia were at a reduced risk of IVH (Kuban et al. 1992). In an 
unexpected finding, antenatal magnesium sulphate was associated with a reduced risk of germinal 
matrix haemorrhage (GMH)-IVH: 18.9% (68/359) of babies born to mothers who had not received 
magnesium sulphate developed GMH-IVH, compared with only 4.4% (4/90) of babies born to 
mothers who had received magnesium sulphate (Kuban et al. 1992). In a later retrospective case-
control study (881 babies born less than 1,500 grams), Nelson and Grether assessed whether 
antenatal exposure to magnesium sulphate (indicated for pre-eclampsia or tocolysis) was associated 
with a reduced risk of CP (Nelson & Grether 1995). The ‘control’ children (without a CP diagnosis) 




‘cases’ (children with CP) (36.0% vs. 7.1%); the odds ratio (OR 0.14; 95% CI 0.05 to 0.51) 
suggested a substantial protective effect (Nelson & Grether 1995). 
 
Many subsequent observational studies have supported the potential neuroprotective effects of 
antenatal magnesium sulphate, demonstrating reductions in the risk of PVL (FineSmith et al. 1997; 
Wiswell et al. 1996), IVH (Wiswell et al. 1996), CP (Boyle et al. 2000; Grether et al. 1996; Hauth 
et al. 1995; Matsuda et al. 2000; Schendel et al. 1996) and perinatal mortality (Grether et al. 1998). 
Inconsistencies have however existed, with a number of studies not reporting benefits for IVH 
(Canterino et al. 1999; Kimberlin et al. 1998; Leviton et al. 1997; Paneth et al. 1997; Weintraub et 
al. 2001), CP (Boyle et al. 2000; Grether et al. 2000; O'Shea, Klinepeter & Dillard 1998; Paneth et 
al. 1997; Wilson-Costello et al. 1998), or mortality (Kimberlin et al. 1998). Encouragingly, in a 
systematic review and meta-analysis of 11 observational studies (five retrospective cohort studies 
and six case-control studies), reduced risks of mortality (risk ratio (RR) 0.73, 95% CI 0.61 to 0.89; 
five studies, 2,796 children) and CP (OR 0.64, 95% CI 0.47 to 0.89; four studies, 913 children) for 
children following antenatal magnesium sulphate were shown (Wolf et al. 2012). 
 
Five randomised controlled trials and a Cochrane review 
 
Due to the limitations and discrepancies of findings from previous observational studies, a need to 
establish reliable evidence, through the conduct of RCTs, was realised. From 1995 to 2004, five 
placebo-controlled RCTs including a total of 6,145 babies were conducted, testing the hypothesis 
that antenatal magnesium sulphate reduces the risk of perinatal brain injury, CP, and mortality in 
preterm born children (Crowther et al. 2003; Magpie Trial Follow-Up Study Collaborative Group 
2007; Marret et al. 2008; Mittendorf et al. 2002; Rouse et al. 2008). The primary aim of four RCTs, 
(ACTOMgSO4 (led by researchers at The University of Adelaide and The University of Melbourne) 
(Crowther et al. 2003); Beneficial Effects of Antenatal Magnesium Sulfate (BEAM) (Rouse et al. 
2008); Magnesium and Neurologic Endpoints Trial (MagNET) (Mittendorf et al. 2002); Prevention 
of Cerebral Palsy by Magnesium Sulphate (PREMAG) (Marret et al. 2008; Marret et al. 2007)) was 
fetal neuroprotection, although one RCT (MagNET (Mittendorf et al. 2002)) had a second tocolytic 
arm. The primary aim of the fifth RCT (Magnesium Sulphate for Prevention of Eclampsia 
(MAGPIE) (Altman et al. 2002)) was the prevention of eclampsia, however long-term outcomes 
were reported in the follow up study (Magpie Trial Follow-Up Study Collaborative Group 2007). 
There was diversity in the inclusion criteria for the RCTs, and in the antenatal magnesium sulphate 






Table 2: Characteristics of RCTs assessing antenatal magnesium sulphate for fetal neuroprotection 
 
RCT Participants Magnesium sulphate 
regimen(s) 




USA (single centre) 
149 women randomised 
 
25-33 weeks’ GA; singleton 
or twins; in PTL; cervical 
dilatation > 4 cm (NP arm); 
cervical dilatation ≤ 4 cm (T 
arm) 
4 g IV ‘bolus’ LD; no MD; no 
repeat dosing (NP arm); 4 g 
IV ‘bolus’ LD; 2-3 g/hour IV 
MD; no repeat dosing (T arm) 
 




Australia and New Zealand 
(16 centres) 
1,062 women randomised 
 
< 30 weeks’ GA; singleton or 
higher order pregnancies; 
delivery expected within 24 
hours 
4 g IV LD (20 minutes); 1 
g/hour IV MD until birth or 
24 hours whichever came 
first; no retreatment 
 
PREMAG (Marret et al. 2008; 
Marret et al. 2007) 
 
1997-2003 
France (13 centres) 
573 women randomised 
 
< 33 weeks’ GA; singleton, 
twins, or triplets; delivery 
planned or expected within 24 
hours 
4 g IV LD (30 minutes); no 
MD; no retreatment 
BEAM (Rouse et al. 2008) 
 
1997-2004 
USA (20 centres) 
 
2,241 women randomised 
 
24 to < 32 weeks’ GA; 
singleton or twins; high risk 
for spontaneous delivery: 
PPROM, PTL (dilatation 4-8 
cm) or indicated preterm 
delivery within 2-24 hours 
6 g IV LD (20-30 minutes); 2 
g/hour IV MD until birth or 
12 hours whichever came 
first; retreatment: if < 6 hours 
had transpired MD resumed; 
if ≥ 6 hours had transpired 
additional LD given 
 
MAGPIE (Altman et al. 2002; 
Magpie Trial Follow-Up 




International (33 countries, 
175 centres) 
1,544 women randomised 
(subset randomised < 37 
weeks’ GA) 
 
Undelivered; singleton or 
higher order pregnancies; pre-
eclampsia; uncertainty 
whether to use magnesium 
sulphate 
4 g IV LD (10-15 minutes); 
MD of either 1 g/hour IV for 
24 hours or 5 g/4 hours IM for 
24 hours; no retreatment 
 
Abbreviations: ACTOMgSO4: Australasian Collaborative Trial of Magnesium Sulphate; BEAM: 
Beneficial Effects of Antenatal Magnesium Sulfate; g: gram; GA: gestational age; IM: 
intramuscular; IV: intravenous; LD: loading dose; MagNET: Magnesium and Neurologic Endpoints 
Trial; MAGPIE: Magnesium Sulphate for Prevention of Eclampsia; MD: maintenance dose; NP: 
neuroprotective; PREMAG: Prenatal Magnesium Sulfate for Neuroprotection in Preterm Infants; 
PPROM: preterm premature rupture of the membranes; PTL: preterm labour; RCT: randomised 
controlled trial; T: tocolytic; USA: United States of America 
 
The primary and secondary outcomes of the five RCTs included death, and varying manifestations 
of neurologic injury, including CP. Considering the outcomes of death, CP, or a composite measure 
of death or CP, a number of the RCTs reported a possible reduction in the risk of CP (Crowther et 
al. 2003; Magpie Trial Follow-Up Study Collaborative Group 2007; Marret et al. 2008), and death 
or CP (Crowther et al. 2003; Marret et al. 2008; Rouse et al. 2008), for preterm born children exposed 
to magnesium sulphate. BEAM was the only RCT to individually show a statistically significant 





In the meta-analysis of the RCTs in the 2009 Cochrane systematic review, ‘Magnesium sulphate for 
women at risk of preterm birth for neuroprotection of the fetus,’ magnesium sulphate administered 
specifically with a neuroprotective intent, was shown to substantially decrease the risk of death or 
CP for preterm children (RR 0.85, 95% CI 0.74 to 0.98; four RCTs, 4,446 children) (Doyle et al. 
2009). Overall magnesium sulphate significantly reduced the risk of CP; a 32% relative risk 
reduction (RR 0.68, 95% CI 0.54 to 0.87; five RCTs, 6,145 children). This review revealed 
convincingly the neuroprotective role for magnesium sulphate given to women at risk of preterm 
birth, reporting that 63 babies (95% CI 44 to 155) would need to be exposed to antenatal magnesium 
sulphate to benefit one baby by avoiding CP; the corresponding number needed to treat to prevent 
one preterm baby dying or developing CP was 42 (Doyle et al. 2009). Crucial reassurance was 
provided, with no increased risk of perinatal mortality observed, opposing earlier concern from the 
MagNET RCT (Mittendorf et al. 1997). 
 
Subsequent systematic reviews and meta-analyses evaluating antenatal magnesium sulphate for fetal 
neuroprotection have reached similar conclusions (Conde-Agudelo & Romero 2009; Costantine & 
Weiner 2009; Zeng et al. 2016). Most recently, in an individual participant data meta-analysis of the 
aforementioned five RCTs, the benefits of antenatal magnesium sulphate were seen regardless of 
the reason for preterm birth, with minimal variation in effect across different gestational ages, and 
treatment regimens (Crowther et al. 2017). Despite this conclusive benefit demonstrated in 
numerous systematic reviews and meta-analyses, a Trial Sequential Analysis – a statistical method 
proposed for the purpose of managing the probability of type I (false positive) and type II (false 
negative) errors primarily arising when meta-analyses are updated (Wetterslev, Jakobsen & Gluud 
2017) – suggested that additional data would be valuable to improve precision of results (Huusom 
et al. 2011). Thus, another RCT of antenatal magnesium sulphate for CP prevention at 24 to 32 
weeks’ gestation was undertaken; results are awaited following its completion in August 2019 
(Huusom et al. 2012; Wolf et al. 2015). Given the uncertainty as to whether the benefits of antenatal 
magnesium sulphate apply at higher gestational ages, the MAGENTA RCT (Magnesium sulphate 
at 30 to 34 weeks’ gestational age: neuroprotection trial, led by The University of Adelaide and The 
University of Auckland), was also conducted, with completion expected in 2020 (Crowther et al. 
2013b). 
 
In a cost-effectiveness analysis, using multiple decision tree models and probabilistic sensitivity 
analyses, administration of magnesium sulphate for fetal neuroprotection to women at imminent risk 
of very preterm birth (at less than 32 weeks’ gestation) was shown to be a cost-effective strategy 
from a societal perspective, and likely from a health system perspective (Bickford et al. 2013). 
Health system and societal savings for each quality-adjusted life year gained were estimated to be 
C$2,242 and C$112,602 respectively, while estimated savings for each case of CP averted were 
C$30,942 and C$1,554,198 respectively (in 2011) (Bickford et al. 2013). A recent systematic review 
of economic studies of interventions for CP confirmed “The economic case for administration of 
magnesium sulfate for imminent preterm birth is compelling, achieving both health gain and cost 
savings” (Shih et al. 2018). 
 
As there is evidence to suggest that early childhood assessments do not always detect CP, and that 
later assessments may facilitate diagnoses, to date, two of the five RCTs have reported on longer-
term follow up of children to school age. At a mean age of 11 years (range 7 to 14), 431 (73%) 
children eligible for follow up from PREMAG were assessed using a parent-completed 
neuropsychomotor developmental questionnaire (Chollat et al. 2014). Though no clear differences 
were observed between groups, rates of a number of outcomes including motor dysfunction or death, 
behavioural disorders, cognitive difficulties, school grade repetition and education services were 
lower in children born to mothers who received magnesium sulphate (Chollat et al. 2014). The 
childhood follow up of ACTOMgSO4 assessed outcomes at school age (mean 8.4 years (standard 
deviation (SD): 1.0; range 6 to 11)) and involved a series of blinded paediatric, motor, and 
psychological assessments, and parent and teacher questionnaires (Doyle et al. 2014). Likewise, no 
clear differences in neurological, cognitive, behavioural, growth or functional outcomes were 
observed between groups; a similar rate of CP was shown (Doyle et al. 2014). It was however, only 
possible to assess 63% of children (due to sites not participating in the follow up study, families 




While an absence of clear longer-term benefits (or harms) was observed in these two RCTs, both 
had sub-optimal follow up rates. Ideally, further RCTs will report longer-term follow up allowing 
pooling of school-age data. 
 
Guidelines and implementation studies 
 
Following the compelling evidence from RCTs and systematic reviews showing that antenatal 
magnesium sulphate is an effective neuroprotective agent for the preterm fetus, in many countries, 
including Australia and New Zealand (led by researchers at The University of Adelaide) (The 
Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel 2010), Canada 
(Magee et al. 2011; Magee et al. 2019) the United States (ACOG Committee on Obstetric Practice 
& SMFM 2010, 2016), Ireland (RCPI & Directorate of Strategy and Clinical Care Health Service 
Executive 2013), Belgium (KCE et al. 2014), the United Kingdom (NCC-WCH 2015) and France 
(Sentilhes et al. 2017) clinical practice guidelines and/or opinion papers have provided 
recommendations for the use of this therapy. In its 2015 recommendations on interventions to 
improve preterm birth outcomes, the World Health Organization (WHO) provided a strong 
recommendation supporting the use of magnesium sulphate for women at risk of imminent very 
preterm birth for prevention of CP (WHO 2015). A recent systematic review and critical appraisal 
of guidelines for antenatal magnesium sulphate for fetal neuroprotection clearly showed that all 
seven identified guidelines supported the use of this therapy for CP prevention (Jayaram et al. 2019). 
 
As systematic reviews and meta-analyses have not supported a particular upper gestational age or 
dosing regimen (Crowther et al. 2017; Doyle et al. 2009), guidance has varied. In the absence of a 
clear ‘optimal dose,’ the lower dose regimens that were employed in RCTs (Crowther et al. 2003; 
Marret et al. 2007), have been commonly recommended. Table 3 summarises protocols for the 
administration of antenatal magnesium sulphate according to clinical practice guidelines (adapted 






Table 3: Summary of guideline recommendations for antenatal magnesium sulphate for fetal 
neuroprotection 
 
Guideline Released GA Magnesium sulphate regimen 
 
Australia and New Zealand 
(The Antenatal Magnesium 
Sulphate for Neuroprotection 
Guideline Development Panel 
2010) 
2010 < 30 
weeks 
4 g LD; 1 g/hour MD for 24 hours or 
until birth; retreatment possible 
 
USA (ACOG Committee on 







“Physicians… should develop specific 
guidelines regarding… treatment 
regimens… in accordance with one of 
the larger trials” 
Canada (Magee et al. 2011; 






4 g LD; with or without 1 g/hour MD 
for 24 hours or until birth; insufficient 
evidence to recommend retreatment 
Ireland (RCPI & Directorate 
of Strategy and Clinical Care 
Health Service Executive 
2013) 
2013 < 32 
weeks 
4 g LD; 1 g/hour MD for 24 hours or 
until birth; retreatment possible 
Belgium (KCE et al. 2014) 2014 < 32 
weeks 
IV for 24 hours maximum (LD and 
MD not specified); retreatment 
recommendation not specified 










4 g LD; 1 g/hour MD for 24 hours or 
until birth; retreatment 
recommendation not specified 
WHO (WHO 2015) 2015 < 32 
weeks 
Insufficient evidence to recommend 
regimen 
France (Sentilhes et al. 2017) 2017 < 32 
weeks 
4 g LD; 1 g/hour MD for 12 hours or 
until birth; retreatment 
recommendation not specified 
Abbreviations: ACOG: American College of Obstetrician and Gynecologists; g: gram; GA: 
gestational age; IV: intravenous; KCE: Belgian Health Care Knowledge Centre; LD: loading dose; 
MD: maintenance dose; NCC-WCH: National Collaborating Centre for Women’s and Children’s 
Health; RCPI: Royal College of Physicians of Ireland; SMFM: Society for Maternal-Fetal Medicine; 
USA: United States of America; WHO: World Health Organization 
 
It is recognised that “the transfer of valid and relevant research findings into routine practice is 
unpredictable and tends to be slow and haphazard” (Penney & Foy 2007). Thus, to support the 
implementation of clinical practice guidelines, in a number of countries, including Australia (WISH: 
Working to Improve Survival and Health for babies born very preterm, led by researchers at The 
University of Adelaide) (Crowther et al. 2013a), Canada (MAG-CP: MAGnesium sulphate for fetal 
neuroprotection to prevent Cerebral Palsy) (Teela et al. 2015), and the United Kingdom (PReCEPT: 
PREventing Cerebral palsy in Pre Term labour) (Burhouse et al. 2017), knowledge translation 
projects have been undertaken. 
 
In the last decade, since publication of clinical practice guidelines, and with support of knowledge 
translation projects, widespread implementation of antenatal magnesium sulphate for fetal 
neuroproection and CP prevention has been observed. Variable uptake, however, continues to be 
demonstrated in retrospective and prospective audit and cohort studies, including from centres in 
Australia (Bain et al. 2013a; Ow et al. 2012; Parker, Sethna & Kent 2017; Siwicki et al. 2015) and 
New Zealand (Pang 2017; Tan & Groom 2015), the United States (Gibbins et al. 2013), Canada (De 




surveys of health professionals/centres, including from Australia and New Zealand (Bain et al. 
2013b; Bousleiman et al. 2015; De Silva et al. 2015; Gatman, May & Crowther 2019; Middleton et 
al. 2013), the United States (Bousleiman et al. 2015) and Canada (De Silva et al. 2015). 
 
Maternal adverse effects of antenatal magnesium sulphate: a systematic review 
 
Given the extensive use of antenatal magnesium sulphate in obstetrics, to prevent or treat pre-
eclampsia (beneficial) (Duley et al. 2010a), for tocolysis for women in and following threatened 
preterm labour (not beneficial) (Crowther et al. 2014), and most recently, for fetal neuroprotection 
and CP prevention (beneficial) (Doyle et al. 2009), the potential adverse effects for women are well 
known. 
 
High-quality evidence regarding maternal adverse effects of antenatal magnesium sulphate can be 
drawn from a systematic review, including 143 publications (21 RCTs, 14 non-randomised 
comparative studies, 32 case series, and 74 reports of individual cases) (Bain, Middleton & Crowther 
2013). Reassuringly, the review showed that antenatal magnesium sulphate was not associated with 
increased risks of maternal death, cardiac arrest or respiratory arrest; individual case reports, did, 
however support an association between iatrogenic overdose of magnesium sulphate and life-
threatening consequences (Bain, Middleton & Crowther 2013). Appropriate administration was 
shown to increase the risk of ‘any adverse maternal effects’ (minor) (RR 4.62, 95% CI 2.42 to 8.83; 
four RCTs, 13,322 women), and treatment cessation due to adverse effects (minor) (RR 2.77, 95% 
CI 2.32 to 3.30; five RCTs, 13,666 women) (Bain, Middleton & Crowther 2013). This review 
concluded that for each antenatal indication for use, further RCTs designed to determine optimal 
regimens (aimed at achieving maximal effectiveness with minimal adverse effects) may be 
beneficial, and called for vigilance in the use of this therapy, in order to ensure women’s safety 
(Bain, Middleton & Crowther 2013). 
 
A further integrative review, including 24 studies (14 RCTs, nine prospective cohort studies, and 
one case-control study), assessed maternal adverse effects of magnesium sulphate, however 
specifically focused on treatment for pre-eclampsia or eclampsia in low- and middle-income 
countries (Smith et al. 2013). This review similarly revealed reassuring findings regarding safety, 
demonstrating infrequent occurrences of the most severe adverse effects (Smith et al. 2013). A more 
recent systematic review, focused on safety reporting in 60 RCTs in women with pre-eclampsia (23 
assessing magnesium sulphate), demonstrated the regular omission of adverse effect data (Duffy et 
al. 2018). Only one of the 20 RCTs reporting serious adverse reactions to magnesium sulphate, and 
none of the 15 RCTs reporting mild adverse reactions to magnesium sulphate, were judged to have 
adequately presented these data (Duffy et al. 2018). 
 
Potential neonatal adverse effects of antenatal magnesium sulphate 
 
With the increased, widespread use of antenatal magnesium sulphate for fetal neuroprotection, 
concern has been raised about potential unintended adverse neonatal outcomes. In an evaluation of 
barriers and enablers to implementing antenatal magnesium sulphate in Australia and New Zealand 
(as part of the aforementioned WISH Project), the uncertainty surrounding adverse effects for 
neonates was specifically raised by health professionals, particularly neonatologists, as a potential 
barrier to increased use (Bain et al. 2015). In an assessment of health professionals’ attitudes towards 
high-risk obstetric medications in the United States, the fear of adverse effects with antenatal 
magnesium sulphate was also noted as a barrier to administration (Bousleiman et al. 2015). 
 
Magnesium has fundamental roles in many cellular process (such as gating of calcium channels; 
muscle contraction; neuronal activity; control of vasomotor tone; cardiac excitability; and 
neurotransmitter release) (Fawcett, Haxby & Male 1999), and thus above normal magnesium 
concentrations (associated with magnesium sulphate therapy), could plausibly be associated with 
fetal or neonatal adverse effects. Magnesium is known to cross the placenta readily, with fetal and 
neonatal serum concentrations correlated with maternal serum magnesium concentrations (Sherwin 
et al. 2014), and/or total maternal dose of magnesium sulphate received (Borja-Del-Rosario et al. 





In the Cochrane systematic reviews assessing magnesium sulphate for pre-eclampsia (Duley et al. 
2010a), fetal neuroprotection (Doyle et al. 2009), and preterm labour tocolysis (Crowther et al. 
2014), no clear increased risks of adverse neonatal outcomes with antenatal magnesium sulphate 
were shown, however a possible increase in death (fetal, neonatal or infant) with prolonged use for 
tocolysis was observed (RR 4.56, 95% CI 1.00 to 20.86; two RCTs, 257 babies) (Crowther et al. 
2014). These reviews were, however, restricted to assessing RCT evidence, and a limited number of 
pre-specified outcomes. 
 
Increasingly observational studies have reported risks of adverse neonatal outcomes with antenatal 
magnesium sulphate, necessitating further evaluation. For example, a retrospective cohort study (of 
6,654 women and their babies) observed increasing maternal serum magnesium concentrations 
(given for pre-eclampsia) to be associated with lower one and five-minute Apgar scores, and higher 
risks of intubation in the delivery room, admission to special care nursery and neonatal hypotonia 
(Abbassi-Ghanavati et al. 2012). Two retrospective cohort studies (of 160 neonates born at less than 
28 weeks gestation; and 954 neonates born 500 to 1,000 grams), suggested antenatal magnesium 
sulphate exposure (given for pre-eclampsia or for tocolysis) was associated with an increased risk 
of neonatal patent ductus arteriosus (del Moral et al. 2007; Katayama et al. 2011). Further, a  
retrospective cohort study (of 155 neonates born less than 1,000 grams) demonstrated an association 
between magnesium sulphate (given for fetal neuroprotection) and spontaneous intestinal 
perforation (Rattray et al. 2014). A number of studies (including retrospective cohort studies and 
case reports) have shown an association between prolonged magnesium sulphate exposure (given 
for tocolysis) and abnormal neonatal bone metabolism (Yokoyama et al. 2010), and rarely, bone 
fracture at birth (Wedig et al. 2006). 
 
Recently, a systematic review (including two RCTs and 16 observational studies) summarised the 
effects of antenatal magnesium sulphate for treating pre-eclampsia, fetal neuroprotection, or preterm 
labour tocolysis specifically on fetal heart rate (Nensi et al. 2014). This review suggested a small 
negative effect on fetal heart rate, variability and accelerative pattern, “not sufficient clinically to 
warrant medical intervention” (Nensi et al. 2014). 
 
Research question: Is antenatal magnesium sulphate associated with adverse neonatal 
outcomes? 
 
There is current uncertainty surrounding the potential for unintended neonatal adverse effects 
following antenatal magnesium sulphate treatment, warranting further evaluation. To date, a 
systematic review of all available evidence surrounding antenatal magnesium sulphate and adverse 
neonatal outcomes has not been conducted. Implementation of magnesium sulphate for CP 
prevention can be strengthened, and safety improved, if clinical practice guidelines and their 






Summary of literature review and identified research questions 
 
CP is the most common physical disability in childhood, affecting approximately one in 500 babies 
worldwide, with devastating long-term consequences. For 94% of individuals with CP, their brain 
injury occurred during pregnancy, labour, or the first 28 days of life; and there are diverse risk factors 
and aetiologies. Magnesium sulphate is one of the first interventions shown in RCTs and systematic 
reviews to prevent CP when given to women prior to very preterm birth. 
 
This literature review has identified the following research gaps that need to be addressed: 
 
1. What is the current evidence regarding antenatal, intrapartum and neonatal preventive 
interventions for CP? 
 
It is important to bring together existing evidence surrounding all potential antenatal, intrapartum 
and neonatal preventive interventions for CP, to assist researchers and funding bodies, policy 
makers, clinicians and families in their decision making. 
 
2. Can a nationwide CP registry be used for long-term RCT follow up? 
 
It is imperative to explore alternative strategies by which to assess the impact of maternal perinatal 
interventions on CP, such as through linkage of RCT and CP registry data. 
 
3. Is antenatal magnesium sulphate associated with adverse neonatal outcomes? 
 
It is essential to address a research gap surrounding antenatal magnesium sulphate for CP prevention, 
to aid ongoing research translation efforts. Specifically, a systematic evaluation of whether antenatal 





To address these identified research gaps, the specific aims of this thesis are: 
 
1. To summarise and interpret the evidence from Cochrane systematic reviews regarding the 
effects of antenatal and intrapartum interventions for preventing CP (Chapter 2). 
 
2. To summarise and interpret the evidence from Cochrane systematic reviews regarding effects 
of neonatal interventions for preventing CP (Chapter 3). 
 
3. To link data from a large maternal perinatal RCT (ACTOMgSO4) with a nationwide CP registry 
(ACPR) to identify children with CP (Chapter 4). 
 
4. To conduct a comprehensive systematic review to assess whether antenatal magnesium sulphate 
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A B S T R A C T
Background
Cerebral palsy is an umbrella term encompassing disorders of movement and posture, attributed to non-progressive disturbances
occurring in the developing fetal or infant brain. As there are diverse risk factors and causes, no one strategy will prevent all cerebral
palsy. Therefore, there is a need to systematically consider all potentially relevant interventions for their contribution to prevention.
Objectives
To summarise the evidence from Cochrane reviews regarding the effects of antenatal and intrapartum interventions for preventing
cerebral palsy.
Methods
We searched the Cochrane Database of Systematic Reviews on 7 August 2016, for reviews of antenatal or intrapartum interventions
reporting on cerebral palsy. Two authors assessed reviews for inclusion, extracted data, assessed review quality, using AMSTAR and
ROBIS, and quality of the evidence, using the GRADE approach. We organised reviews by topic, and summarised findings in text and
tables. We categorised interventions as effective (high-quality evidence of effectiveness); possibly effective (moderate-quality evidence
of effectiveness); ineffective (high-quality evidence of harm or of lack of effectiveness); probably ineffective (moderate-quality evidence
of harm or of lack of effectiveness); and no conclusions possible (low- to very low-quality evidence).
Main results
We included 15 Cochrane reviews. A further 62 reviews pre-specified the outcome cerebral palsy in their methods, but none of the
included randomised controlled trials (RCTs) reported this outcome. The included reviews were high quality and at low risk of bias.
They included 279 RCTs; data for cerebral palsy were available from 27 (10%) RCTs, involving 32,490 children. They considered
interventions for: treating mild to moderate hypertension (two) and pre-eclampsia (two); diagnosing and preventing fetal compromise
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in labour (one); preventing preterm birth (four); preterm fetal maturation or neuroprotection (five); and managing preterm fetal
compromise (one). Quality of evidence ranged from very low to high.
Effective interventions: high-quality evidence of effectiveness
There was a reduction in cerebral palsy in children born to women at risk of preterm birth who received magnesium sulphate for
neuroprotection of the fetus compared with placebo (risk ratio (RR) 0.68, 95% confidence interval (CI) 0.54 to 0.87; five RCTs; 6145
children).
Probably ineffective interventions: moderate-quality evidence of harm
There was an increase in cerebral palsy in children born to mothers in preterm labour with intact membranes who received any
prophylactic antibiotics versus no antibiotics (RR 1.82, 95% CI 0.99 to 3.34; one RCT; 3173 children). There was an increase in
cerebral palsy in children, who as preterm babies with suspected fetal compromise, were born immediately compared with those for
whom birth was deferred (RR 5.88, 95% CI 1.33 to 26.02; one RCT; 507 children).
Probably ineffective interventions: moderate-quality evidence of lack of effectiveness
There was no clear difference in the presence of cerebral palsy in children born to women at risk of preterm birth who received repeat
doses of corticosteroids compared with a single course (RR 1.03, 95% CI 0.71 to 1.50; four RCTs; 3800 children).
No conclusions possible: low- to very low-quality evidence
Low-quality evidence found there was a possible reduction in cerebral palsy for children born to women at risk of preterm birth who
received antenatal corticosteroids for accelerating fetal lung maturation compared with placebo (RR 0.60, 95% CI 0.34 to 1.03; five
RCTs; 904 children). There was no clear difference in the presence of cerebral palsy with interventionist care for severe pre-eclampsia
versus expectant care (RR 6.01, 95% CI 0.75 to 48.14; one RCT; 262 children); magnesium sulphate for pre-eclampsia versus placebo
(RR 0.34, 95% CI 0.09 to 1.26; one RCT; 2895 children); continuous cardiotocography for fetal assessment during labour versus
intermittent auscultation (average RR 1.75, 95% CI 0.84 to 3.63; two RCTs; 13,252 children); prenatal progesterone for prevention
of preterm birth versus placebo (RR 0.14, 95% CI 0.01 to 3.48; one RCT; 274 children); and betamimetics for inhibiting preterm
labour versus placebo (RR 0.19, 95% CI 0.02 to 1.63; one RCT; 246 children).
Very low-quality found no clear difference for the presence of cerebral palsy with any antihypertensive drug (oral beta-blockers) for
treatment of mild to moderate hypertension versus placebo (RR 0.33, 95% CI 0.01 to 8.01; one RCT; 110 children); magnesium
sulphate for prevention of preterm birth versus other tocolytic agents (RR 0.13, 95% CI 0.01 to 2.51; one RCT; 106 children); and
vitamin K and phenobarbital prior to preterm birth for prevention of neonatal periventricular haemorrhage versus placebo (RR 0.77,
95% CI 0.33 to 1.76; one RCT; 299 children).
Authors’ conclusions
This overview summarises evidence from Cochrane reviews on the effects of antenatal and intrapartum interventions on cerebral
palsy, and can be used by researchers, funding bodies, policy makers, clinicians and consumers to aid decision-making and evidence
translation. We recommend that readers consult the included Cochrane reviews to formally assess other benefits or harms of included
interventions, including impacts on risk factors for cerebral palsy (such as the reduction in intraventricular haemorrhage for preterm
babies following exposure to antenatal corticosteroids).
Magnesium sulphate for women at risk of preterm birth for fetal neuroprotection can prevent cerebral palsy. Prophylactic antibiotics
for women in preterm labour with intact membranes, and immediate rather than deferred birth of preterm babies with suspected fetal
compromise, may increase the risk of cerebral palsy. Repeat doses compared with a single course of antenatal corticosteroids for women
at risk of preterm birth do not clearly impact the risk of cerebral palsy.
Cerebral palsy is rarely diagnosed at birth, has diverse risk factors and causes, and is diagnosed in approximately one in 500 children.
To date, only a small proportion of Cochrane reviews assessing antenatal and intrapartum interventions have been able to report on
this outcome. There is an urgent need for long-term follow-up of RCTs of interventions addressing risk factors for cerebral palsy, and
consideration of the use of relatively new interim assessments (including the General Movements Assessment). Such RCTs must be
rigorous in their design, and aim for consistency in cerebral palsy outcome measurement and reporting to facilitate pooling of data, to
focus research efforts on prevention.
P L A I N L A N G U A G E S U M M A R Y
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Interventions during pregnancy and childbirth for preventing cerebral palsy: an overview of Cochrane reviews
What is the issue?
Cerebral palsy is a term that includes a group of conditions affecting people’s ability to move, and is the most common physical disability
in childhood. Cerebral palsy is usually due to events before, during, or after childbirth that lead to injury in babies’ developing brains.
There is no single cause of cerebral palsy. For many children, the cause of cerebral palsy is unclear, however, there are many known
risk factors. The biggest risk factor is birth before 37 weeks of pregnancy (preterm birth). Other risk factors for mothers include some
medical conditions (including thyroid problems), abnormalities of the placenta, pre-eclampsia (high blood pressure and protein in
the urine), and some bacterial and viral infections. For babies, risk factors include congenital and genetic abnormalities, having a low
birthweight or growth restricted as a fetus, being a twin or triplet, some infections, and prolonged loss of oxygen during birth.
Why is this important?
As there are different risk factors and causes for cerebral palsy, it is likely that various different interventions (treatments) may be
needed to prevent cerebral palsy by reducing risk factors. This overview summarises the evidence about preventing cerebral palsy from
Cochrane reviews of interventions during pregnancy and childbirth.
What evidence did we find?
We searched for evidence on 7 August 2016. We identified 15 Cochrane reviews that assessed interventions during pregnancy or
childbirth that reported on cerebral palsy, with information from 27 randomised controlled trials involving 32,490 children. The
reviews were all high quality, but the quality of the evidence about cerebral palsy ranged from very low to high.
The interventions assessed were for treating mild to moderate hypertension (two reviews), treating pre-eclampsia (two reviews),
diagnosing or preventing fetal compromise (when the unborn baby may not be well) during labour (one review), preventing preterm
birth (four reviews), maturing or protecting babies’ lungs or brains before preterm birth (five reviews), and managing fetal compromise
of preterm babies (one review).
We found high-quality evidence that one intervention was effective for cerebral palsy prevention: preterm children born to mothers
who received magnesium sulphate before birth were less likely to develop cerebral palsy than children whose mothers received a placebo
(five trials, 6145 children).
We found moderate-quality evidence that two interventions were probably ineffective, and could cause harm: (i) children born to
mothers who had received antibiotics for preterm labour when their waters had not broken were more likely to develop cerebral palsy
than children whose mothers did not receive antibiotics (one trial, 3173 children); and (ii) preterm children who were born immediately
when there was suspected fetal compromise were more likely to develop cerebral palsy than those for whom birth was postponed (one
trial, 507 children).
We found moderate-quality evidence that there was no clear difference in the chance of children to develop cerebral palsy whether their
mothers received one or more courses of corticosteroids before preterm birth (four trials, 3800 children).
There was low-quality evidence as to whether the other interventions prevented, increased, or had no impact on cerebral palsy, although
we did find that children born to mothers who received corticosteroids to help mature their lungs before preterm birth were potentially
less likely to develop cerebral palsy than those born to mothers who received a placebo (five trials, 904 children).
What does this mean?
We identified one intervention that was effective in preventing cerebral palsy (magnesium sulphate before preterm birth), two that
appeared to cause harm (preventive antibiotics for women in preterm labour when their waters have not broken, and immediate birth
for preterm babies with suspected compromise), and one that did not appear to make a clear difference (more than one course of
corticosteroids before preterm birth). For the other interventions assessed, there was not enough evidence to reach any conclusions.
Further good quality randomised controlled trials, assessing interventions that might impact cerebral palsy risk factors, with long-term
follow-up to measure cerebral palsy, are needed. We identified over 60 other Cochrane reviews that may provide more information in
the future.
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B A C K G R O U N D
Description of the condition
Cerebral palsy: definition and prevalence
Cerebral palsy was originally defined by clinical description, at a
time when there was little knowledge of causes, risk factors, or
pathology. Discussion on the definition and classification was first
recorded in English, French, and German medical literature in the
nineteenth century; for over 150 years, there has been debate about
what the term ‘cerebral palsy’ actually describes (Morris 2007).
Definitions adopted by international cerebral palsy registries have
commonly included those proposed by Bax in the 1960s (Bax
1964), Mutch and colleagues in the 1990s (Mutch 1992), and
more recently, by Rosenbaum and colleagues (a revised version of
Bax 1964): “Cerebral palsy describes a group of permanent disor-
ders of the development of movement and posture, causing activ-
ity limitation, that are attributed to non-progressive disturbances
that occurred in the developing fetal or infant brain. The mo-
tor disorders of cerebral palsy are often accompanied by distur-
bances of sensation, perception, cognition, communication, and
behaviour, by epilepsy, and by secondary musculoskeletal prob-
lems” (Rosenbaum 2007).
Today, cerebral palsy is still a clinical description, but registries and
surveillance programmes, such as those in Australia, the United
Kingdom, and Europe, highlight five key elements that reflect the
core features of cerebral palsy, provided in definitions, and pro-
posed by the Surveillance of Cerebral Palsy in Europe (SCPE): (i)
it is an ‘umbrella term’; (ii) it is permanent but not unchanging;
(iii) it involves a disorder of movement, posture, motor function,
or a combination; (iv) it is due to a non-progressive interference,
lesion, or abnormality; and (v) the interference, lesion, or abnor-
mality arose in the developing or immature brain (Cans 2000;
Mutch 1992; Rosenbaum 2007; Smithers-Sheedy 2014). As cere-
bral palsy is defined by clinical description, which may change
over time, a longer time span for diagnosis is considered useful
to confirm that the condition meets the criteria for cerebral palsy,
and to accurately describe the motor impairment. Thus, final as-
certainment for surveillance programmes across the world range
from four to 12 years, with many considering data to be ’com-
plete’ at or near five years (Smithers-Sheedy 2014). While average
age for diagnosis has been around 18 months, recent evidence has
suggested that cerebral palsy may be reliably detected in high-risk
infants as early as three to four months post-term age, using tests
such as Prechtl’s General Movements Assessment and medical res-
onance imaging (Bosanquet 2013; Morgan 2016).
Cerebral palsy can be described by its motor type and body parts
distribution (topography). Primary and secondary motor types in-
clude spasticity, dyskinesia, ataxia, and hypotonia, which are deter-
mined by a combination of structured neurological and motor as-
sessments, with observations sometimes corroborated by imaging
findings (Cans 2000; Rosenbaum 2007; Sanger 2003). Spasticity
is the predominant primary motor type. Frequently used terms to
describe the topography are hemiplegia (unilateral involvement),
diplegia (bilateral involvement), with the lower limbs more af-
fected than the upper limbs, and quadriplegia (bilateral involve-
ment), with the upper limbs more or equally involved. Monople-
gia and triplegia are occasionally reported as separate entities, or
grouped with hemiplegia and quadriplegia, respectively (Howard
2005; Sankar 2005).
Today, the Gross Motor Function Classification System (GMFCS)
is used internationally as the principal way to classify gross motor
function (Morris 2004; Palisano 1997; Wood 2000). It describes
the gross movement ability of children in one of five ordinal lev-
els, and provides descriptions for each level across five age bands:
less than two years; two to four years; four to six years; six to 12
years; 12 to 18 years (Wood 2000). Unlike classifications based on
motor type and topography, the GMFCS has been shown to be a
valid, reliable, stable, and clinically relevant method for classifica-
tion, and in conjunction with the Gross Motor Function Measure
(GMFM), for prediction (after the age of two) of motor function
in cerebral palsy (Palisano 1997; Wood 2000). The Manual Abil-
ity Classification System (MACS) provides a method analogous
to the GMFCS for assessing the ability of children with cerebral
palsy to handle objects (Eliasson 2006), and the Communication
Function Classification System (CFCS) assists in evaluating the
communication capacity in real-life situations for children with
cerebral palsy (Hidecker 2011). One can draw a comprehensive
picture of functional performance in daily life for individuals with
cerebral palsy by using the GMFCS, MACS, and CFCS together,
to inform both research and clinical practice (Compagnone 2014;
Hidecker 2012).
Despite variation in definitions and classifications of cerebral palsy,
there is wide agreement that it is the most common physical
disability in childhood. In a recent meta-analysis of 19 studies,
the global pooled birth prevalence was 2.11 per 1000 live births
(95% confidence interval 1.98 to 2.25); a cumulative meta-analy-
sis demonstrated stability in the prevalence over the past 10 years
(Oskoui 2013). Similar trends and relative stability of rates over
time have been shown in geographical regions “with CP Registers”
that have used consistent methods of ascertainment, with most
published estimates of total population birth prevalence around
two per 1000 live births (Blair 2006). In low- and middle-income
countries, birth prevalence estimates have tended to be in a similar
range, or higher, but it is difficult to meaningfully compare rates,
since very few of these countries use registries or surveillance pro-
grammes (Blair 2006; Cans 2000; Colver 2014). However, there
is now emerging evidence, including from Australia and Europe,
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that birth prevalence and severity of the condition are starting to
decline for the first time (Reid 2016; Sellier 2015). Rate varia-
tions have also been observed, particularly when stratified by ges-
tational age or birthweight. In the aforementioned meta-analysis,
the prevalence was highest in children weighing 1000 to 1499 g at
birth (59.18 per 1000 live births), and for children born before 28
weeks of gestation (111.80 per 1000 live births; Oskoui 2013).
Cerebral palsy: causes and risk factors
For approximately 6% of individuals with cerebral palsy, their
brain injury is believed to have been acquired during a recognised
event at least 28 days after birth and before the age of two to
five; commonly, a cerebrovascular accident, spontaneous, associ-
ated with surgery or with complications of cardiac defects, or ac-
cidental and non-accidental head injuries (ACPR Group 2013).
For the remaining 94% of individuals with cerebral palsy, their
brain injury is believed to have occurred during the antenatal or
the neonatal period of infant development, that is, during preg-
nancy, or within the first 28 days of life (ACPR Group 2013).
The pathogenesis of such brain injury is complex and multifacto-
rial, with interrelated pathways contributing to cellular dysfunc-
tion and death, including accumulation of reactive oxygen species,
the release of excitatory amino acids, energy depletion, and apopto-
sis (Inder 2000; Vexler 2001). There are multiple causes of brain in-
jury, including hypoxia-ischaemia (characterised by reduced oxy-
gen in the blood combined with reduced blood flow to the brain),
haemorrhage, infection, maldevelopment, and metabolic derange-
ment (Volpe 2000). Brain hypoxia (deficiency of oxygen) and is-
chaemia (insufficient blood supply) may lead to different neu-
ropathology in infants born preterm and at term, with cerebral
white matter injury predominating in preterm infants, and neu-
ronal cell injury in term infants (Volpe 2000). Injury to the de-
veloping brain is known to be associated with long-term seque-
lae, including cerebral palsy, as well as hearing, sight, speech, and
behavioural disorders, seizures, and intellectual disabilities (Vexler
2001).
Preterm birth is one of the principal risk factors for cerebral palsy
and associated neurosensory disabilities (Himpens 2008; Oskoui
2013). The degree of prematurity is associated with vulnerability
of cerebral white matter, and is predictive of an increasing risk of
white matter injury (such as periventricular leukomalacia), and in-
traventricular haemorrhage (Larroque 2003), established risk fac-
tors for the development of cerebral palsy (Saliba 2001). Although
preterm birth is acknowledged as a major risk factor for cerebral
palsy, with over 40% of individuals with cerebral palsy being born
preterm (compared with approximately 8% of the general popu-
lation), most individuals with cerebral palsy (50% to 60%) are in
fact, born at term (ACPR Group 2013).
Studies on possible risk factors for cerebral palsy for preterm- and
term-born individuals are abundant (with some risk factors re-
ported more consistently than others). Evidence now suggests that
70% to 80% of cerebral palsy cases are associated with antenatal
factors, with birth asphyxia playing a relatively minor role (Blair
1988; Ellenberg 2013; MacLennan 2015). Risk factors, in addi-
tional to preterm birth, often reported in the literature include: (a)
factors prior to conception, such as: young or advanced maternal
age, high parity, nulliparity, a short or long inter-pregnancy inter-
val, a history of stillbirth, multiple miscarriages, neonatal death,
or premature birth, family history of cerebral palsy and other ge-
netic predispositions, low socioeconomic status, and pre-existing
maternal conditions (e.g. intellectual disability, and epilepsy); (b)
factors in early pregnancy, such as: male gender, multiple gesta-
tion, congenital malformations or birth defects, and infections
(i.e. TORCH complex: toxoplasmosis (parasite), other infections,
rubella, cytomegalovirus, herpes simplex virus); (c) factors dur-
ing pregnancy, such as: maternal disease (e.g. thyroid disorders),
pregnancy complications (e.g. high blood pressure, pre-eclampsia,
placenta praevia, placental abruption, and other placental abnor-
malities), intrauterine infection or inflammation and chorioam-
nionitis, intrauterine growth restriction, and other precursors to
preterm birth; and (d) factors around the time of birth and neona-
tal period, such as: an acute intrapartum hypoxic event, meconium
aspiration, stroke, seizures, hypoglycaemia, jaundice, and infec-
tion, along with inborn errors of metabolism (such as glucose-
6-phosphate dehydrogenase deficiency), particular syndromes, or
chromosomal abnormalities (Jacobsson 2004; McIntyre 2011;
McIntyre 2013; Nelson 2008b; Smithers-Sheedy 2014).
In low- and middle-income countries, the causes and risk factors
for cerebral palsy are known to differ considerably (Blair 2006).
With few survivors of very preterm birth in such countries, com-
mon risk factors are birth asphyxia and maternal Rhesus alloimmu-
nisation, or inherited disorders, such as glucose-6-phosphate de-
hydrogenase deficiency and subsequent bilirubin encephalopathy,
and there are much higher proportions of children with postna-
tally acquired cerebral palsy, particularly associated with postinfec-
tious brain damage following meningitis, septicaemia, and other
conditions, such as malaria (Blair 2006; Lagunju 2009).
While a great number of potential risk factors for cerebral palsy
have been identified, their commonality is that separately, or in
combination, they may lead to injury to the developing brain. A
growing body of evidence now suggests that genetic abnormal-
ities may also contribute to the development of cerebral palsy
(Moreno-De-Luca 2012; Oskoui 2015; O’Callaghan 2009). Pre-
viously, only 1% to 2% of cerebral palsy cases were linked to a
causative genetic mutation, but recent studies have shown that up
to 14% have single gene mutations and 31% have copy number
variations that may be at fault (MacLennan 2015). Possible genetic
mutations and variants associated with cerebral palsy are likely to
be heterogeneous, but they both trigger pathways (either directly,
or in the case of genetic susceptibility, when certain risk factors
are present), leading to non-progressive neuropathology associated
with motor dysfunction and cerebral palsy (MacLennan 2015).
Though there is currently no known cure for cerebral palsy, increas-
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ing knowledge of risk factors and causal pathways had increased
the hope for the development and implementation of primary pre-
ventive strategies: “we are on the move… the vision of prevention
and cure no longer seems an unattainable goal” (Badawi 2013).
Cerebral palsy: consequences
Cerebral palsy is the leading cause of physical disability in children.
Though traditionally regarded as a paediatric condition, it is now
recognised that cerebral palsy is a condition with life-long impact -
a ‘lifespan condition’ - and thus, the outcomes of individuals with
cerebral palsy across the life course are considered when planning
and directing interventions in childhood (Colver 2014).
Most individuals with cerebral palsy will survive to adulthood,
with some studies suggesting life expectancy can be broadly sim-
ilar to that of the general population if a child reaches adoles-
cence (Colver 2012). For known cases of antenatally- or neona-
tally-acquired cerebral palsy, the 20-year survival rate has been es-
timated to be approximately 90%, however, strong associations
between increasing motor impairment, severe intellectual impair-
ment, number of severe impairments, and early mortality have
been shown (Blair 2001; Hemming 2005; Reid 2012). While a
mixed picture in overall survival trends has been presented to date,
some improvements in survival have been observed over time for
two groups of individuals with cerebral palsy with the most severe
disabilities - children who are largely immobile and fed by others,
and adults who are dependent on gastrostomy feeding (Strauss
2008).
Today’s frequently used definitions importantly acknowledge co-
occurring impairments, diseases, and functional limitations, which
are common among individuals with cerebral palsy, including
hearing, sight, and speech disorders, intellectual disability and
epilepsy (Rosenbaum 2007). A recent systematic review estimated,
for example, that among children with cerebral palsy, “1 in 2 had an
intellectual disability… 1 in 4 could not talk; 1 in 4 had epilepsy;
1 in 4 had a behaviour disorder… 1 in 10 were blind… and 1 in
25 were deaf” (Novak 2012).
Economic studies have estimated lifetime costs of cerebral palsy,
including healthcare costs (such as primary health care, hospital
care, and pharmaceuticals), social care costs (such as specialised
education and housing), and productivity costs (the cost for society
when an individual never enters the labour market, or leaves it) as
EUR860,000 for men and EUR800,000 for women in Denmark
(in 2000; Kruse 2009), and USD921,000 for individuals in the
United States (in 2003; CDC 2004). In Australia, the financial
cost of cerebral palsy was estimated AUD1.47 billion (in 2007);
the value of lost well-being (disability and premature death) was a
further AUD2.4 billion (Access Economics 2008).
The impacts of cerebral palsy are considerable, not only for indi-
viduals, but for families, carers, communities, and societies (Davis
2010). Accordingly, individuals with cerebral palsy and their fam-
ilies, clinicians and researchers recognise that identification of pri-
mary preventive measures continues to be a key priority (McIntyre
2010).
Description of the interventions
Antenatal or intrapartum approaches to prevention
of cerebral palsy
Research efforts aimed at moving towards a future without cere-
bral palsy have increasingly focused on understanding the causes
of cerebral palsy. As it is now widely recognised that causes differ,
for example, by gestational age (i.e. for preterm- and term-born
children), and clinical subtype of cerebral palsy (Nelson 2008),
it is reasonable to consider that successful primary preventive in-
terventions may also vary according to different aetiologies and
causal factors. For example, spastic diplegia is the most common
subtype of cerebral palsy in preterm infants, most often caused by
white matter injury initiated by cerebral ischaemia, maternal in-
trauterine infection, or fetal systemic inflammation; quadriplegic
cerebral palsy, especially with dyskinesia, is a subtype of cerebral
palsy sometimes related to acute asphyxia during the birth process
(Nelson 2008).
Primary preventive interventions may include public health strate-
gies for the general population (e.g. periconceptional folate sup-
plementation to reduce birth defects), strategies directed at pre-
venting distal components on a causal pathway to cerebral palsy
(e.g. melatonin for small-for-gestational age in pregnancy), and
strategies closer to the proximal cause of brain damage (e.g. mag-
nesium sulphate for neuroprotection immediately prior to very
preterm birth; IMPACT for CP 2011).
Therefore, we considered a broad range of antenatal and intra-
partum interventions* in this overview, with varying primary aims
and indications, which may mediate the risk of cerebral palsy. The
examples presented below are not an exhaustive list, but include:
• nutrition interventions in pregnancy, e.g. periconceptional
folate supplementation; marine oil, and other prostaglandin
precursors; vitamins C and E;
• behaviour or advice interventions in pregnancy, e.g.
reducing alcohol and drug consumption; supporting smoking
cessation; promoting hand-washing;
• interventions for predicting or preventing preterm birth
(including subsequent management strategies), e.g. fetal
fibronectin testing; cervical assessment by ultrasound; risk-
scoring systems; transfer to a hospital with neonatal intensive
care unit facilities; cervical cerclage; cervical pessary; prenatal
administration of progesterone; acute tocolytic and maintenance
therapy (i.e. magnesium sulphate; calcium channel blockers
(nifedipine); oxytocin receptor antagonists (atosiban);
betamimetics (terbutaline); cyclo-oxygenase (COX) inhibitors
(indomethacin));
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• interventions prior to preterm or term birth for fetal
neuroprotection, e.g. antenatal corticosteroids; repeat doses of
corticosteroids; thyrotropin-releasing hormone added to
corticosteroids; magnesium sulphate; creatine; melatonin;
phenobarbital; vitamin K;
• screening and management of fetal growth and well-being
in pregnancy, e.g. fetal movement counting for assessment of
well-being; symphysial fundal height (SFH) measurement for
detecting abnormal fetal growth; ultrasound for fetal assessment
in early pregnancy; routine ultrasound in late pregnancy;
antenatal cardiotocography for fetal assessment; fetal and
umbilical Doppler ultrasound; utero-placental Doppler
ultrasound; interventions for impaired fetal growth;
• diagnosing and preventing fetal compromise in labour, e.g.
intermittent auscultation (IA) of fetal heart rate; continuous
cardiotocography (CTG) for electric fetal heart rate monitoring
(EFM); fetal electrocardiogram (ECG); fetal pulse oximetry;
patient safety programmes;
• interventions for infection during pregnancy, e.g. TORCH,
urinary tract infections, other vaginal infections (i.e. bacterial
vaginosis);
• interventions for preterm and term pre-labour rupture of
membranes, e.g. planned early birth (versus expectant
management); antibiotics; tocolytics;
• other specific interventions for medical problems in
pregnancy and labour, e.g. screening and subsequent
management for thyroid dysfunction; anti-D administration for
preventing Rhesus alloimmunisation in Rh-negative women;
interventions for the treatment of mild to moderate, or severe
hypertension, and for the prevention (i.e. antioxidants;
antiplatelet agents) and treatment of pre-eclampsia or eclampsia
(i.e. magnesium sulphate; lytic cocktail; diazepam; phenytoin);
interventions for placenta praevia or placental abruption;
interventions for uterine rupture or cord prolapse.
*We will not consider interventions in the neonatal period (such
as cooling for newborns with hypoxic ischaemic encephalopathy
(Jacobs 2013)), as these interventions will be assessed in a separate
overview which will be focused specifically on neonatal interven-
tions for prevention of cerebral palsy (Shepherd 2016).
How the intervention might work
Advances in research into several factors that modify the risk of
cerebral palsy in infants suggest many opportunities for preven-
tion, with some of the main strategies focusing on the preven-
tion of preterm birth, or protection of the developing fetal brain
through antenatal administration of neuroprotective agents.
For example, because preterm birth and neurodevelopmental out-
comes are so strongly associated (ACPR Group 2013; Oskoui
2013), it is possible that interventions to prolong gestation or re-
duce the risk of preterm birth will also reduce the risk of cere-
bral palsy (Chang 2015; O’Shea 2008). Specific approaches, sup-
ported by high level evidence, for prolonging pregnancy and pre-
venting preterm birth include: interventions for primary preven-
tion of preterm birth (e.g. smoking cessation programmes for the
general population); interventions for secondary prevention of in-
dicated preterm birth (e.g. antiplatelet drugs (low-dose aspirin)
for the prevention of pre-eclampsia); interventions for secondary
prevention of spontaneous preterm birth (e.g. progesterone and
cervical cerclage for women at increased risk of preterm birth due
to a prior preterm birth, or where a short cervix has been identi-
fied on ultrasound); and tertiary interventions, for women with
immediate risk of preterm birth (e.g. antibiotics for women with
preterm rupture of membranes; and calcium channel blockers and
an oxytocin antagonist (atosiban) for women with preterm labour;
Iams 2008; O’Shea 2008).
For women with immediate risk of preterm birth, it is possible that
antenatal interventions aimed at protecting the developing fetal
brain from injury will also reduce the risk of cerebral palsy. For
example, antenatal corticosteroids to accelerate fetal lung matura-
tion in women at risk of preterm birth have also been shown to
be neuroprotective, reducing the risk of intraventricular haemor-
rhage and periventricular leukomalacia (Chang 2015; Iams 2008;
O’Shea 2008). Magnesium sulphate is another drug administered
antenatally, with the potential to mediate the risk of cerebral palsy
by protecting the developing fetal brain from injury, such as in-
traventricular haemorrhage (Chang 2015; Nelson 2008; O’Shea
2008). Beyond antenatal corticosteroids and magnesium sulphate,
a range of other antenatally administered agents, such as mela-
tonin, creatine, and allopurinol, may enhance the ability of the
preterm or term developing fetal brain to withstand brain damage,
and in doing so, reduce the risk of cerebral palsy (Chang 2015;
Robertson 2012).
There are numerous other antenatal and intrapartum interven-
tions with the potential to contribute to the prevention of cerebral
palsy in preterm and term infants by modifying known risk factors
for cerebral palsy, for example: identification and subsequent man-
agement of maternal thyroid dysfunction (both hypo- and hyper-
thyroidism) in pregnancy, identification and treatment of hyper-
tension and pre-eclampsia in pregnancy, and identification and
management of perinatal infections (including chorioamnionitis)
in pregnancy.
Why it is important to do this overview
A multitude of individual studies and Cochrane reviews assessing a
broad range of antenatal or intrapartum interventions (with vary-
ing primary aims and indications) recognise the potential for the
interventions of interest to mediate the risk of cerebral palsy. With
the acknowledgement that a multiplicity of risk factors impact on
the risk of cerebral palsy, and that causes of cerebral palsy differ,
there is a need to systematically consider all potentially relevant
interventions for their ability to contribute to prevention. To our
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knowledge, there is no published overview that has assembled and
summarised the evidence from Cochrane reviews on interventions
for the prevention of cerebral palsy in one coherent document, to
be used by researchers, funding bodies, policy makers, clinicians,
and consumers to aid decision making and evidence translation.
O B J E C T I V E S
The objective of this overview was to summarise the evidence
from Cochrane reviews regarding the effects of antenatal and in-
trapartum interventions for preventing cerebral palsy, and to assess
the effects of these interventions on associated outcomes, includ-
ing severity and type of cerebral palsy.
M E T H O D S
Criteria for considering reviews for inclusion
In this overview, we included Cochrane reviews of antenatal or
intrapartum interventions, where cerebral palsy was reported as a
primary or secondary outcome, or as part of a composite outcome,
with data reported for cerebral palsy from at least one of the trials
included in the review.
We identified relevant Cochrane protocols for future inclusion,
and classified them as ’Ongoing reviews’ (Appendix 1).
We listed reviews that pre-specified cerebral palsy as a primary
or secondary outcome, but had no data reported from included
trials as ’Reviews awaiting further classification’, which will be re-
considered in future updates of the overview (Appendix 2).
We made note of the publication and search dates of the reviews,
however, we did not attempt to update the individual reviews. We
contacted the Cochrane Pregnancy and Childbirth Editorial Base
to identify any relevant new reviews or review updates that were in
progress, in order to include the most up-to-date versions of the
reviews, if and where possible.
Participants
We considered reviews assessing interventions in pregnant women.
Interventions
We considered all types of interventions used in the antenatal or
intrapartum period, compared with placebo, no treatment, or an
alternative intervention.
We planned to include pharmacological, medical, nutritional, be-
havioural, and educational interventions (see Description of the
interventions for further descriptions of possible interventions).
Outcomes of interest
Primary
• Cerebral palsy (however defined by review authors and
trialists).
Secondary
• Cerebral palsy or death (e.g. in early childhood, and at the
latest time point measured).
• Severity of cerebral palsy (e.g. according to: Gross Motor
Function Classification System (GMFCS); Manual Ability
Classification System (MACS); Communication Function
Classification System (CFCS)).
• Other composite outcomes that included cerebral palsy as a
component.
• Type of cerebral palsy (e.g. according to topography
(diplegia; hemiplegia; quadriplegia; monoplegia; triplegia), or
motor type (spastic; dyskinetic; ataxic)).
• Motor dysfunction (e.g. in infancy and early childhood,
and at the latest time point measured; however defined by review
authors and trialists)
Search methods for identification of reviews
We searched the Cochrane Database of Systematic Reviews, using
the term ‘cerebral palsy’, on 7 August 2016. We searched ‘all text’,
and did not limit our search to ‘title, abstract, or keywords’. We
did not apply any language or date restrictions. No other databases
were searched. We managed citations retrieved through the search
with Covidence (Covidence 2015).
Data collection and analysis
We followed the methodology for data collection and synthesis
from Chapter 22 of the Cochrane Handbook of Systematic Reviews
of Interventions (Higgins 2011). Where appropriate, we prepared
the overview using Covidence and Review Manager 5 software
(Covidence 2015; RevMan 2014).
Selection of reviews
Two overview authors independently assessed all potential reviews
we identified. We resolved any disagreement through discussion,
or if required, we consulted a third author.
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Data extraction and management
Two overview authors independently extracted data from the re-
views using a pre-defined data extraction form. We resolved dis-
crepancies through discussion. Where any information from the
reviews was unclear or missing, we accessed the published papers
of the individual studies.
We extracted information on the following.
• Review characteristics:
◦ review title and authors;
◦ date that the review was last assessed as up-to-date;
◦ number of included trials, number of participants
(women and infants) in the trials and their characteristics (e.g.
countries where the trials were conducted and inclusion criteria
for the trials);
◦ quality of the included trials (as reported by the review
authors; see Assessment of methodological quality of included
reviews);
◦ interventions and comparisons relevant to this
overview;
◦ all pre-specified outcomes relevant to this overview;
◦ any other characteristics required to assess and report
on review quality (see Assessment of methodological quality of
included reviews).
• Statistical summaries:
◦ the summary intervention effects (including the
pooled effects (e.g. risk ratios (RR), odds ratios (OR) or mean
differences (MD) as reported in the individual reviews), 95%
confidence intervals (CIs), and numbers of studies and
participants contributing data to each pooled effect) for
outcomes relevant to this overview (N.B. if the summary statistic
(RR or OR) has been calculated using a random-effects analysis,
the results are presented as the ’average’ treatment effect);
◦ information required to assess and report on the
quality of the evidence for the intervention effects extracted
above (see Assessment of methodological quality of included
reviews);
◦ results of any subgroup or sensitivity analyses
conducted by the review authors, for our primary outcome.
If there were no meta-analyses in a review, and therefore, no sta-
tistical summaries, we extracted the narrative text relating to the
results for our overview outcomes.
When cerebral palsy was reported as part of a composite outcome,
we extracted any available data on cerebral palsy. Where it was not
possible to extract only the cerebral palsy data, we reported the
composite outcome data; however, we reported it separately, as a
secondary outcome.
Assessment of methodological quality of included
reviews
Quality of included reviews
We assessed the methodological quality of each systematic review
using the AMSTAR (A Measurement Tool to Assess Reviews) in-
strument (Shea 2009). AMSTAR evaluates the methods used in a
review against 11 distinct criteria and assesses the degree to which
review methods are unbiased. Each item on AMSTAR is rated as
yes (clearly done), no (clearly not done), cannot answer, or not
applicable. These criteria are as follows.
1. Was an a priori design provided?
2. Was there duplicate study selection and data extraction?
3. Was a comprehensive literature search performed?
4. Was the status of publication used as an inclusion criterion?
5. Was a list of studies (included and excluded) provided?
6. Were the characteristics of the included studies provided?
7. Was the scientific quality of the included studies assessed
and documented?
8. Was the scientific quality of the included studies used
appropriately in formulating conclusions?
9. Were the methods used to combine the findings of studies
appropriate?
10. Was the likelihood of publication bias assessed?
11. Was the conflict of interest stated?
For all items except item 4, a rating of ’yes’ was considered ad-
equate. For item 4, a rating of ‘no’ was considered adequate. A
review that adequately met all of the 11 criteria was considered to
be a review of the highest quality. For this overview, we considered
reviews that achieved scores of between 8 to 11 as high quality;
scores of 4 to 7 as medium quality; and scores of 0 to 3 as low
quality.
To further assess the risk of bias of the systematic reviews, we
used the new ROBIS (Risk Of Bias In Systematic reviews) tool
(Whiting 2014). The tool considers risk of bias across four key
domains.
1. Study eligibility criteria.
2. Identification and selection of studies.
3. Data collection and study appraisal.
4. Synthesis and findings.
A series of questions within each of the domains elicits information
about possible limitations of the systematic review, leading to a
judgement about the concerns within that domain (low, high, or
unclear). Assessors then consider the risk of bias of the review as a
whole, with signalling questions and information to support the
overall judgement of risk of low, high or unclear bias (Whiting
2014).
Two overview authors independently assessed the quality of the
included reviews; another overview author verified this assessment.
We resolved differences through discussion.
Quality of included studies within reviews
We did not reassess the quality of included studies within reviews
but reported study quality according to the review authors’ as-
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sessment. When individual studies were included in two or more
Cochrane reviews, we reported this, along with any variation in
the review authors’ assessments of study quality. We collected this
information during the data extraction process.
Quality of evidence in included reviews
We assessed the quality of the evidence for our primary outcome
(cerebral palsy) and secondary review outcomes using the GRADE
approach, as outlined in the GRADE Handbook (Schünemann
2013). We reported the quality of evidence as assessed by the
review authors (who were in the best position to assess quality given
their familiarity with the study-level data), using ‘Summary of
findings’ tables from the reviews if provided. Where necessary, we
constructed tables using GRADEpro GDT software (GRADEpro
GDT 2015). The GRADE system assesses the following features
for the evidence found for important outcomes.
• Study limitations (risk of bias): internal validity of the
evidence.
• Inconsistency: heterogeneity or variability in the estimates
of effect across studies.
• Indirectness: degree of differences between population,
intervention, comparator, for the intervention and outcome of
interest.
• Imprecision (random error): extent to which confidence in
the effect estimate is adequate to support a particular decision.
• Publication bias: degree of selective publication of studies.
The GRADE system rates the quality of the evidence as:
• High (further research is very unlikely to change confidence
in the estimate of effect).
• Moderate (further research is likely to have an important
impact on confidence in the estimate of effect and may change
the estimate).
• Low (further research is very likely to have an important
impact on confidence in the estimate of effect and is likely to
change the estimate).
• Very low (any estimate of effect is very uncertain).
Data synthesis
We used a narrative description of the characteristics of the in-
cluded Cochrane reviews.
We summarised the main results of the included reviews by cate-
gorising their findings in the following framework, organised by
antenatal or intrapartum intervention, and by intervention topic.
This approach was used in previous Cochrane and non-Cochrane
overviews (i.e. Farquhar 2015; Lassi 2015). A similar approach was
also used in Jones 2012, in which interventions were categorised
as ’what works’, ’what may work’, and ’insufficient evidence to
make a judgement’.
• Effective interventions: indicated that the review found
high-quality evidence of effectiveness for an intervention.
• Possibly effective interventions: indicated that the review
found moderate-quality evidence of effectiveness for an
intervention, but more evidence is needed.
• Ineffective interventions: indicated that the review found
high-quality evidence of lack of effectiveness (or harm) for an
intervention.
• Probably ineffective interventions: indicated that the review
found moderate-quality evidence suggesting lack of effectiveness
(or harm) for an intervention, but more evidence is needed.
• No conclusions possible: indicated that the review found
low or very low-quality evidence, or insufficient evidence to
comment on the effectiveness or safety of an intervention.
The choice of category was based on the quality of the evidence for
cerebral palsy. We used separate assessments for different compar-
isons if required (e.g. where one intervention was compared with
both placebo (or no treatment) and an alternative intervention).
R E S U L T S
Our search of the Cochrane Database of Systematic Reviews identi-
fied 500 protocols and reviews. Following our review of titles and
abstracts, we excluded 381 protocols and reviews, and assessed the
full-text of 119 protocols and reviews.
We excluded 33 reviews that did not pre-specify cerebral palsy as a
primary or secondary review outcome (see Table 1: Characteristics
of excluded studies).
We listed 71 protocols and reviews in the appendices.
• Appendix 1, Ongoing reviews, lists nine Cochrane protocols
that have pre-specified cerebral palsy as a primary or secondary
outcome, and will be considered for inclusion in future updates
of the overview when they are published as full reviews.
• Appendix 2, Reviews awaiting further classification,
summarises the 62 Cochrane reviews that pre-specified cerebral
palsy as a primary or secondary outcome, but the included trials
had no data reported on this outcome; these reviews will again be
considered for inclusion in future updates of the overview.
We included 15 reviews in this overview. See Figure 1. Review flow
diagram, for details.
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Figure 1. Review flow diagram.
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Description of included reviews
Of the 15 included reviews:
• two focused on the treatment of mild to moderate
hypertension:
◦ antihypertensive drug therapy for mild to moderate
hypertension during pregnancy (Abalos 2014);
◦ oral beta-blockers for mild to moderate hypertension
during pregnancy (Magee 2003).
• two assessed interventions for the treatment of pre-
eclampsia:
◦ interventionist versus expectant care for severe pre-
eclampsia between 24 and 34 weeks’ gestation (Churchill 2013);
◦ magnesium sulphate and other anticonvulsants for
women with pre-eclampsia (Duley 2010).
• one focused on interventions for the diagnosis and
prevention of fetal compromise in labour:
◦ continuous cardiotocography (CTG) as a form of
electronic fetal monitoring (EFM) for fetal assessment during
labour (Alfirevic 2013).
• four assessed interventions for the prevention of preterm
birth:
◦ prenatal administration of progesterone for preventing
preterm birth in women considered to be at risk of preterm birth
(Dodd 2013);
◦ prophylactic antibiotics for inhibiting preterm labour
with intact membranes (Flenady 2013);
◦ magnesium sulphate for preventing preterm birth in
threatened preterm labour (Crowther 2014);
◦ betamimetics for inhibiting preterm labour (Neilson
2014).
• five focused on interventions prior to preterm birth for fetal
maturation or neuroprotection:
◦ vitamin K prior to preterm birth for preventing
neonatal periventricular haemorrhage (Crowther 2010);
◦ phenobarbital prior to preterm birth for preventing
neonatal periventricular haemorrhage (Crowther 2010a);
◦ magnesium sulphate for women at risk of preterm
birth for neuroprotection of the fetus (Doyle 2009);
◦ repeat doses of prenatal corticosteroids for women at
risk of preterm birth for improving neonatal health outcomes
(Crowther 2015);
◦ antenatal corticosteroids for accelerating fetal lung
maturation for women at risk of preterm birth (Roberts 2006).
• one focused on interventions for the management of
preterm fetal compromise:
◦ immediate versus deferred delivery of the preterm
baby with suspected fetal compromise for improving outcomes
(Stock 2016).
The number of randomised controlled trials (RCT) in the 15
reviews ranged from one (Stock 2016) to 49 (Abalos 2014). The
number of women in each RCT ranged from 425 (Churchill 2013)
to 37,715 (Alfirevic 2013). In total, there were 279 randomised
trials, involving over 101,098 women and their babies.
One third (five) of the 15 reviews had conducted searches between
August 2013 and August 2016, and were considered up-to-date
(Crowther 2014; Crowther 2015; Flenady 2013; Neilson 2014;
Stock 2016). The other 10 reviews had latest search dates ranging
from August 2008 to April 2013.
See Table 2, Characteristics of included reviews and Table 3, Risk
of bias assessments from included reviews, for further details of
the characteristics of the 15 included reviews.
Methodological quality of included reviews
According to AMSTAR criteria:
1. all reviews pre-specified their design;
2. all reviews reported duplicate study selection and data
extraction;
3. all reviews performed a comprehensive literature search;
4. all reviews considered grey literature;
5. all reviews provided lists of included and excluded studies;
6. all reviews provided the characteristics of the included
studies;
7. all reviews assessed and documented the scientific quality of
the included studies;
8. all reviews used scientific quality of the included studies
appropriately in formulating conclusions;
9. 11 reviews combined the findings of studies using
appropriate methods; in three reviews, fixed-effect meta-analyses
were used despite the presence of substantial statistical
heterogeneity; one review had only one included trial;
10. 11 reviews assessed the likelihood of publication bias (or
pre-specified which methods they would use if 10 or more trials
were included in a meta-analysis);
11. three reviews clearly reported conflict of interests or
potential sources of support for both the review and included
studies.
See Table 4: AMSTAR assessments for included reviews, for further
details.
When assessed against the ROBIS domains, all reviews were con-
sidered at low risk of bias across the study eligibility criteria, iden-
tification and selection of studies, and data collection and study
appraisal domains. Three of the reviews received an unclear risk
of bias rating for the synthesis and findings domain (based on use
of fixed-effect meta-analyses in the presence of substantial statis-
tical heterogeneity). See Table 5: ROBIS assessments for included
reviews, for further details.
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Overall, all 15 included reviews were judged to be of high quality
according to AMSTAR criteria, with scores ranging from 8 to 11,
and at a low risk of bias, according to ROBIS domains.
Effect of interventions
We have summarised the main results of the included reviews be-
low. They are organised by intervention topic and categorised in
the framework discussed under Data synthesis, based on the qual-
ity of the evidence for the presence of cerebral palsy, the primary
outcome.
For further details and ’Summary of findings’ tables for the out-
comes of interest, see Table 6, All comparisons measuring cerebral
palsy; Table 7, Subgroup or sensitivity analyses of select compar-
isons for cerebral palsy; Table 8, All comparisons measuring cere-
bral palsy or death; Table 9, All comparisons measuring severity
of cerebral palsy; Table 10, All comparisons measuring other com-
posite outcomes that include cerebral palsy as a component; and
Table 11, All comparisons measuring motor dysfunction.
Interventions for the treatment of mild to moderate
hypertension
No conclusions possible: very low-quality evidence
Very low-quality evidence in both the Abalos 2014 and Magee
2003 reviews showed no clear difference for the presence of cerebral
palsy at one year when any antihypertensive drug was compared
with a placebo (Abalos 2014), or when an oral beta-blocker was
compared with placebo (Magee 2003), in the treatment of mild
to moderate hypertension during pregnancy (risk ratio (RR) 0.33,
95% confidence interval (CI) 0.01 to 8.01; one trial; 110 children;
Table 6). The two reviews included the same trial, and made similar
judgements regarding trial quality.
Interventions for the treatment of pre-eclampsia
No conclusions possible: low-quality evidence
Low-quality evidence in the Churchill 2013 review showed no
clear difference for the presence of cerebral palsy at two years when
interventionist care was compared with expectant (delayed deliv-
ery) care for severe pre-eclampsia between 24 and 34 weeks’ ges-
tation (RR 6.01, 95% CI 0.75 to 48.14; one trial; 262 children;
Table 6).
Low-quality evidence in the Duley 2010 review showed no clear
difference for the presence of severe cerebral palsy at 18 months
when magnesium sulphate was compared with placebo for women
with pre-eclampsia (RR 0.34, 95% CI 0.09 to 1.26; one trial;
2895 children; Table 6; Table 9).
Low-quality evidence in the Duley 2010 review also showed no
clear difference in neurosensory disability (composite outcome
that included cerebral palsy) at 18 months (RR 0.77, 95% CI 0.38
to 1.58; one trial; 3283 children; Table 10), or in death or neu-
rosensory disability at 18 months (RR 1.06, 95% CI 0.90 to 1.25;
one trial; 3283 children; Table 10) when magnesium sulphate was
compared with placebo for women with pre-eclampsia.
Interventions for the diagnosis and prevention of fetal
compromise in labour
No conclusions possible: low-quality evidence
Low-quality evidence in the Alfirevic 2013 review showed no clear
difference for the presence of cerebral palsy in early childhood (be-
tween 18 months and four years) when continuous cardiotocogra-
phy was compared with intermittent auscultation for fetal assess-
ment during labour (average RR 1.75, 95% CI 0.84 to 3.63; two
trials; 13,252 children; Table 6).
Alfirevic 2013 conducted subgroup analyses for the presence of
cerebral palsy, based on pregnancy risk status, onset of labour,
gestational age, number of babies, access to fetal blood sampling,
parity, and and only high quality trials, however, did not identify
any clear subgroup differences (Table 7).
Interventions for the prevention of preterm birth
Probably ineffective interventions: moderate-quality
evidence of harm
Moderate-quality evidence in the Flenady 2013 review showed an
increase in cerebral palsy in mid-childhood (at seven years) for
children born to mothers who received any prophylactic antibi-
otics versus no antibiotics for inhibiting preterm labour with in-
tact membranes (RR 1.82, 95% CI 0.99 to 3.34; one trial; 3173
children; Table 6).
Subgroup analysis for this outcome, based on type of antibiotic did
not reveal clear subgroup differences (Table 7). Additional analyses
were conducted for this outcome, comparing (i) any macrolide an-
tibiotics (including macrolide antibiotics used as a single agent or
in combination with other types of antibiotics) versus no macrolide
antibiotics (including use of any non-macrolide antibiotics or no
antibiotics), and (ii) any beta-lactam antibiotics (including beta-
lactam antibiotics used as a single agent or in combination with
other types of antibiotics) versus no beta-lactam antibiotics (in-
cluding use of any non-beta-lactam antibiotics or no antibiotics).
An increase in cerebral palsy in mid-childhood (at seven years) was
observed for children born to mothers who received any macrolide
versus no macrolide antibiotics, and any beta-lactam versus no
beta-lactam antibiotics (Table 7).
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No conclusions possible: low- to very low-quality evidence
Low-quality evidence in the Dodd 2013 review showed no clear
difference for the presence of cerebral palsy at four years when pre-
natal administration of progesterone was compared with placebo
for preventing preterm birth in women with a previous history
of spontaneous preterm birth (RR 0.14, 95% CI 0.01 to 3.48;
one trial; 274 children; Table 6). A subgroup analysis was planned
for this outcome based on route of administration, however, only
one trial was included, which used intramuscular administration
(Table 7).
Low-quality evidence in the Neilson 2014 review showed no clear
difference for the presence of cerebral palsy in children at 18
months when betamimetics were compared with placebo for in-
hibiting preterm labour (RR 0.19, 95% CI 0.02 to 1.63; one trial;
246 children; Table 6).
Very-low quality evidence in the Crowther 2014 review showed
no clear difference for the presence of cerebral palsy in children at
18 months when magnesium sulphate was compared with other
tocolytic agents for preventing preterm birth in threatened preterm
labour (RR 0.13, 95% CI 0.01 to 2.51; one trial; 106 children;
Table 6).
Very low-quality evidence in the Crowther 2014 review also
showed no clear difference for serious infant outcomes (includ-
ing cerebral palsy) when magnesium sulphate was compared with
other tocolytic agents for preventing preterm birth in threatened
preterm labour (RR 2.47, 95% CI 0.69 to 8.81; one trial; 106
children; Table 10).
There was also low-quality evidence in the Dodd 2013 review
showing no clear difference in motor impairment for children
at four years when prenatal administration of progesterone was
compared with placebo for preventing preterm birth in women
with a previous history of spontaneous preterm birth (RR 0.64,
95% CI 0.11 to 3.76; one trial; 274 children; Table 11).
Interventions prior to preterm birth for fetal
maturation or neuroprotection
Effective interventions: high-quality evidence of effectiveness
High-quality evidence in the Doyle 2009 review showed a reduc-
tion in cerebral palsy at 18 months to two years for children born to
women at risk of preterm birth who received magnesium sulphate
compared with placebo for neuroprotection of the fetus (RR 0.68,
95% CI 0.54 to 0.87; five trials; 6145 children; Table 6). Subgroup
analyses for cerebral palsy based on intent (neuroprotective, pre-
eclampsia, tocolytic), single or multiple pregnancy, gestational age
at randomisation, loading dose, maintenance dose, and whether
re-treatment was permitted, showed no clear subgroup differences
(Table 7); the results did not substantially change when they only
included studies with high antenatal corticosteroid use, nor when
they performed a sensitivity analysis based on trial quality (Table
7).
High-quality evidence from Doyle 2009 review also showed a re-
duction in moderate to severe cerebral palsy at two years (RR 0.64,
95% CI 0.44 to 0.92; three trials; 4387 children; Table 9), and
in substantial gross motor dysfunction at 18 months to two years
(RR 0.61, 95% CI 0.44 to 0.85; four trials; 5980 children; Table
11); though no clear differences were shown for death or cerebral
palsy at 18 months to two years (average RR 0.94, 95% CI 0.78
to 1.12; five trials; 6145 children; Table 8), any neurologic im-
pairment at 18 months to two years (RR 1.01, 95% CI 0.86 to
1.19; two trials; 2848 children; Table 10), death or any neurologic
impairment (composite outcomes that included cerebral palsy) at
18 months to two years (RR 1.00, 95% CI 0.91 to 1.11; two trials;
2848 children; Table 10), or death or major neurological disability
at 18 months to two years (RR 1.02, 95% CI 0.90 to 1.15; two
trials; 2848 children; Table 10).
Moderate-quality evidence from Doyle 2009 showed no clear dif-
ferences for mild cerebral palsy at two years (RR 0.74, 95% CI
0.52 to 1.04; three trials; 4387 children; Table 9), moderate cere-
bral palsy at two years (RR 0.66, 95% CI 0.34 to 1.28; two trials;
1943 children; Table 9), severe cerebral palsy at two years (RR
0.82, 95% CI 0.37 to 1.82; two trials; 1943 children; Table 9),
major neurological disability at 18 months or two years (RR 1.07;
95% CI 0.82 to 1.40; two trials, 2848 children) (Table 10), or
death or substantial gross motor dysfunction for children at 18
months to two years (average RR 0.92, 95% CI 0.75 to 1.12;
four trials; 5980 children; Table 11) when magnesium sulphate
was compared with placebo for women at risk of preterm birth for
neuroprotection of the fetus.
Probably ineffective interventions: moderate-quality
evidence of lack of effectiveness
Moderate-quality evidence in the Crowther 2015 review showed
no clear difference in cerebral palsy at 18 months to three years
when repeat doses of corticosteroids were compared with a single
course for women at risk of preterm birth (RR 1.03, 95% CI 0.71
to 1.50; four trials; 3800 children; Table 6).
High-quality evidence from the Crowther 2015 review also
showed no clear differences for survival free of any disability at 18
months to two years (RR 1.01, 95% CI 0.97 to 1.05; two trials;
3155 children; Table 10), disability at two years (RR 0.98, 95%
CI 0.83 to 1.16; one trial; 999 children; Table 10), or composite
serious outcome at 18 months to two years (RR 0.99, 95% CI 0.87
to 1.12; two trials; 3164 children; Table 10) when repeat doses of
corticosteroids were compared with a single course for women at
risk of preterm birth;
Low-quality evidence from Crowther 2015 showed no clear dif-
ferences for survival free of major neurosensory disability (a com-
posite outcome that included cerebral palsy) for children at two
to three years (average RR 1.01, 95% CI 0.92 to 1.11; two trials;
1317 children; Table 10) and major neurosensory disability at two
to three years (average RR 1.08, 95% CI 0.31, 3.76; two trials;
14Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
48
1256 children; Table 10) when repeat doses of corticosteroids were
compared with a single course for women at risk of preterm birth.
No conclusions possible: low- to very low-quality evidence
Low-quality evidence in the Crowther 2010a review, showed no
clear difference in the presence of cerebral palsy in early childhood
(between 18 months and three years) when phenobarbital was
compared with placebo or no treatment, and given prior to preterm
birth to prevent neonatal periventricular haemorrhage (RR 0.71,
95% CI 0.40 to 1.28; two trials; 517 children; Table 6). Crowther
2010a had planned to conduct a sensitivity analysis, excluding
trials with inadequate concealment of allocation of treatment; the
results did not change as the one included trial was retained in the
analysis (Table 7).
Very low-quality evidence in the Crowther 2010a review also
showed no clear difference in other neuromotor impairment for
children at three years when phenobarbital was compared with no
treatment prior to preterm birth for preventing neonatal periven-
tricular haemorrhage (RR 0.67, 95% CI 0.13 to 3.49; one trial;
96 children; Table 11).
Very low-quality evidence from two reviews, showed no clear dif-
ference in the presence of cerebral palsy in mid-childhood (at
seven years) when vitamin K was compared with placebo prior to
preterm birth for preventing neonatal periventricular haemorrhage
(Crowther 2010), and when phenobarbital was compared with
placebo prior to preterm birth for preventing neonatal periven-
tricular haemorrhage (Crowther 2010a; RR 0.77, 95% CI 0.33
to 1.76; one trial; 299 children; Table 6). These two reviews in-
cluded the same trial (which assessed a combination intervention),
and made similar judgements regarding trial quality. Both reviews
planned to conduct a sensitivity analysis excluding trials with in-
adequate concealment of allocation of treatment; the results did
not change as the one included trial was retained in the analysis
(Table 7).
Low-quality evidence in the Roberts 2006 review showed a possi-
ble reduction in cerebral palsy between two and six years for chil-
dren born to women at risk of preterm birth who received ante-
natal corticosteroids compared with placebo for accelerating fetal
lung maturation (RR 0.60;,95% CI 0.34 to 1.03; five trials; 904
children; Table 6). A subgroup analysis for cerebral palsy, based
on decade of recruitment, revealed no clear subgroup differences
(Table 7).
Very low-quality evidence from Roberts 2006 review also showed
no clear difference in neurodevelopmental delay at two years when
antenatal corticosteroids were compared with placebo for accel-
erating fetal lung maturation for women at risk of preterm birth
(RR 0.64, 95% CI 0.14 to 2.98; one trial; 82 children; Table 10).
Interventions for the management of preterm fetal
compromise
Probably ineffective interventions: moderate-quality
evidence of harm
Moderate-quality evidence in the Stock 2016 review showed an
increase in cerebral palsy at or after two years for children, who
as preterm babies with suspected fetal compromise,were born im-
mediately, compared with those for whom birth was deferred (RR
5.88, 95% CI 1.33 to 26.02; one trial; 507 children; Table 6).
Low-quality evidence from the Stock 2016 review also showed no
clear differences in death or disability at or after two years (RR
1.22, 95% CI 0.85 to 1.75; one trial; 573 children; Table 10),
neurodevelopmental impairment at or after two years (RR 1.72,
95% CI 0.86 to 3.41; one trial; 507 children; Table 10), or death or
severe disability at six to 13 years (RR 0.82, 95% CI 0.48 to 1.40;
one trial; 302 children; Table 10) when immediate delivery of the
preterm baby with suspected fetal compromise was compared with
deferred delivery.
D I S C U S S I O N
Summary of main results
This overview included 15 Cochrane reviews, involving 279 ran-
domised controlled trials and 101,098 children. Data for cerebral
palsy were available from 27 (10%) randomised controlled trials
involving 32,490 (32%) children.
Effective interventions: high-quality evidence of effectiveness:
high-quality evidence showed a reduction in cerebral palsy for
children born to women at risk of preterm birth who received
magnesium sulphate compared with placebo for neuroprotection
of the fetus.
Probably ineffective interventions: moderate-quality evidence
of harm: moderate-quality evidence showed an increase in cerebral
palsy for children born to mothers who received any prophylac-
tic antibiotics versus no antibiotics for inhibiting preterm labour
with intact membranes. Moderate-quality evidence also showed
an increase in cerebral palsy for children who, as preterm babies
with suspected fetal compromise, were born immediately com-
pared with those for whom birth was deferred.
Probably ineffective interventions: moderate-quality evidence
of lack of effectiveness: moderate-quality evidence showed no
clear difference in cerebral palsy when repeat doses of corticos-
teroids were compared with a single course for women at risk of
preterm birth.
No conclusions possible: low- to very low-quality evidence:
• Low-quality evidence showed a possible reduction in
cerebral palsy for children born to women at risk of preterm
birth who received antenatal corticosteroids compared with
placebo for accelerating fetal lung maturation.
• Low-quality evidence showed no clear difference for
cerebral palsy with interventionist care versus expectant care for
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severe pre-eclampsia; magnesium sulphate versus placebo for pre-
eclampsia; continuous cardiotocography versus intermittent
auscultation for fetal assessment during labour; prenatal
progesterone versus placebo for preventing preterm birth; and
betamimetics versus placebo for inhibiting preterm labour.
• Very low-quality evidence showed no clear difference for
cerebral palsy with any antihypertensive drug versus placebo, or
with an oral beta-blocker versus placebo for mild to moderate
hypertension; with magnesium sulphate versus other tocolytic
agents for preventing preterm birth; and with vitamin K and
phenobarbital versus placebo prior to preterm birth for
preventing neonatal periventricular haemorrhage.
Overall completeness and applicability of
evidence
This overview summarises published Cochrane reviews assessing
antenatal and intrapartum interventions and their effects on cere-
bral palsy. Interventions in the neonatal period are the focus of a
companion overview (Shepherd 2016).
We were only able to include 15 reviews (representing less than
3% of the 546 Pregnancy and Childbirth reviews in the Cochrane
Database of Systematic Reviews), which reported data on our pri-
mary outcome, cerebral palsy. We identified an additional nine
protocols that have pre-specified cerebral palsy as a primary or
secondary outcome and will be considered for inclusion in future
updates of the overview when they are published as full reviews.
These protocols plan to assess a variety of interventions including:
interventions for treating hypertension (guided imagery), prevent-
ing (with melatonin) or treating pre-eclampsia (melatonin; epidu-
ral therapy; planned caesarean section versus planned vaginal de-
livery), for preventing preterm labour or birth (progestogens for
multiple pregnancy; hypnosis), for diagnosing and preventing fe-
tal compromise in labour (intermittent auscultation of fetal heart
rate in labour), and for induction of labour (amniotomy plus in-
travenous oxytocin). See Appendix 1, Ongoing reviews. We were
unable to include an additional 62 reviews assessing a wide range
of antenatal and intrapartum interventions, because although they
recognised the potential impact of the interventions of interest on
cerebral palsy (through pre-specifying cerebral palsy as a review
outcome), none of the included trials within these reviews reported
on this outcome. We have summarised the main conclusions of
these reviews in Appendix 2, Reviews awaiting further classifica-
tion, and will again consider them for inclusion in future updates
of the overview.
Although the 15 reviews in this overview included 279 randomised
trials, involving over 101,098 women and their babies, the body
of evidence for our review was substantially reduced because the
included reviews (and trials) did not report on our outcomes of
interest. For our primary outcome, cerebral palsy, we have included
data from all 15 reviews, but from 27 randomised trials, or only
10% of the trials within the included reviews.
The body of evidence for our secondary outcomes was further re-
duced, with six reviews reporting data on a composite outcome in-
cluding cerebral palsy, three on motor dysfunction, two on severity
of cerebral palsy, and one of the 15 reviews reporting data on cere-
bral palsy or death. None of our included reviews reported specif-
ically on the type of cerebral palsy. For the majority of our out-
comes, data were reported in the reviews by only one or two trials,
up to a maximum of five trials, for the majority of interventions
assessed. Thus, there were too few data to reach firm conclusions
on the effects on cerebral palsy and our secondary outcomes. Un-
surprisingly, for the majority of the reviews, data related to cerebral
palsy was commonly shorter-term (reported at one to two years
of age), with longer-term follow up less commonly reported (only
three reviews reported on cerebral palsy at seven years). Defini-
tions or criteria for a diagnosis of cerebral palsy, where reported,
and assessment methods, varied substantially between and within
trials; often this information was not reported in the reviews.
We did not attempt to make indirect comparisons in order to ad-
dress questions concerning the relative performance of difference
antenatal or intrapartum interventions. This would not have been
appropriate, due to the variety of interventions (and control con-
ditions) assessed in different populations, for various indications.
Rather, we aimed to systematically consider all potentially relevant
interventions for their ability to contribute to the prevention of
cerebral palsy. Within this overview, we have not attempted to
duplicate details of participants, interventions (and control condi-
tions) in individual trials. Consulting the individual reviews and
trials is encouraged to obtain more information on these factors.
The scope of this overview was limited to effects of interven-
tions on cerebral palsy, and a restricted number of pre-specified
secondary outcomes, including the composite outcome ’cerebral
palsy or death’, in recognition of the competing risks of death
and survival with neurosensory disability. In order to assess the
effects (benefits or harms) of the included interventions on other
outcomes (including perinatal death), readers are encouraged to
refer to the included Cochrane reviews themselves. For example,
while this overview showed low-quality evidence of a possible re-
duction in cerebral palsy for children born to women at risk of
preterm birth who received antenatal corticosteroids for acceler-
ating fetal lung maturation, the recently updated Roberts 2017
review assessed additional outcomes, and has revealed reductions
in perinatal death, neonatal death, respiratory distress syndrome,
moderate to severe respiratory distress syndrome, intraventricular
haemorrhage, necrotising enterocolitis, need for mechanical ven-
tilation, and systemic infections in the first 48 hours of life. The
review concluded that the findings support “the continued use of
a single course of antenatal corticosteroids to accelerate fetal lung
maturation in women at risk of preterm birth” (Roberts 2017).
Quality of the evidence
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All of the included reviews were assessed to be of high quality and at
low risk of bias with the AMSTAR and ROBIS tools (Table 4; Table
5). Although the two tools differ in their approaches to assessing
review quality or risk of bias, they led to similar assessments. All
of the reviews assessed the risk of bias of the included randomised
trials, the majority using current guidance as outlined in Chapter
8 of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). The quality of the randomised trials was variable
within and between the reviews (Table 3).
Two of the 15 reviews used the GRADE approach to assess the
quality of evidence for review outcomes (Alfirevic 2013; Stock
2016). For the other reviews, we used the GRADE system to rate
the quality of evidence, incorporating the assessments of study
limitations (risk of bias) reported by the review authors. For our
primary outcome, cerebral palsy, the quality of the evidence ranged
from very low to high, similarly for our secondary outcomes.
Downgrading of the quality was most commonly due to study
limitations (risk of bias), and imprecision (small sample sizes, low
number of events, and wide confidence intervals). As our overview
outcomes were assessed through longer-term follow-up of antena-
tal or intrapartum interventions, the potential for bias relating to
attrition (which could occur due to children lost to follow-up dif-
fering systematically from those followed-up), was an important
consideration when rating the quality of evidence. The summary
of findings for the quality of evidence for each outcome are set out
in Table 6: Cerebral palsy; Table 8: Cerebral palsy or death; Table
9: Severity of cerebral palsy; Table 10: Other composite outcomes
that include cerebral palsy as a component; and Table 11: Motor
dysfunction.
Potential biases in the overview process
We were aware that there were risks of introducing bias at all stages
of the overview process, and took a number of steps to minimise
this. All included Cochrane reviews used a protocol that aimed
to minimise bias; we also developed a protocol for our overview.
At least two overview authors independently assessed reviews for
inclusion, carried out data extraction and quality assessment, and
assessed the quality of the evidence using the GRADE approach.
One potential source of bias relates to authors of this overview
being authors of some of the included reviews. As pre-specified
in our protocol, data extraction and quality assessment for these
reviews were carried out by two overview authors who were not
authors of the individual reviews.
We undertook a comprehensive search of the Cochrane Database of
Systematic Reviews without language or date restrictions, and iden-
tified published reviews, as well as planned and ongoing reviews
(protocols). We did not search other databases, and thus it is possi-
ble that non-Cochrane systematic reviews assessing antenatal and
intrapartum interventions, and reporting on cerebral palsy, have
been conducted but not identified. It is also possible that Cochrane
reviews assessing interventions that could have potential to impact
cerebral palsy risk (see Description of the interventions for fur-
ther discussion of various interventions) may not have acknowl-
edged this by including cerebral palsy as a review outcome. Thus,
data from relevant randomised trials assessing these interventions
would not have been identified and included in this overview.
Based on our search strategy, even Cochrane reviews that pre-spec-
ified outcomes such as ’impaired long-term growth and develop-
ment in infancy and childhood’ (e.g. Abalos 2014), but subse-
quently reported specifically on ’cerebral palsy’ have been captured
in our search, and included. However, reviews that reported on
long-term neurodevelopmental outcomes without any mention of
’cerebral palsy’ would not have been identified, which highlights
the need for all Cochrane reviews to provide clear definitions ac-
companying any outcome measures reported.
While our included reviews were judged to be of high method-
ological quality and at low risk of bias, not all were considered ’up-
to-date’, with only one third conducting searches in the past four
years; similarly, not all of the ’Reviews awaiting further classifica-
tion’ were ’up-to-date’. Thus, it is possible that additional trials
assessing antenatal and intrapartum interventions and reporting
on cerebral palsy have been published, but not yet included in the
relevant Cochrane reviews; it is also possible that additional trials
have been conducted but are not yet published. If and when such
trials are included in the relevant Cochrane review, they will be
incorporated into this overview.
Agreements and disagreements with other
studies or reviews
We did not identify any other overviews or systematic reviews
specifically designed to assess antenatal and intrapartum interven-
tions for preventing cerebral palsy.
In regards to cerebral palsy prevention for children born preterm,
World Health Organization (WHO) recommendations focused
on improving the outcomes of preterm birth have recently been
released, based on up-to-date systematic reviews for priority ques-
tions (WHO 2015). These guidelines assessed a number of in-
terventions that were included in this review, and reached similar
conclusions. Specifically, a strong recommendation was made for
the use of magnesium sulphate for women at risk of imminent
preterm birth before 32 weeks of gestation for prevention of cere-
bral palsy in the infant and child, which was based on which was
based on high quality evidence for cerebral palsy. A strong rec-
ommendation was also made against the use of routine antibiotic
administration for women in preterm labour with intact amniotic
membranes and no clinical signs of infection, based on moderate-
quality evidence for cerebral palsy (WHO 2015).
McIntyre 2013 conducted a systematic review of cohort and case-
control studies focused on identifying risk factors for cerebral palsy
in children born at term, with an aim to assess whether the po-
tential for prevention of these risk factors has been adequately ex-
plored. They identified antenatal risk factors that included placen-
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tal dysfunction or abnormalities, major and minor birth defects
and low birthweight, while intrapartum risk factors were meco-
nium aspiration, caesarean section, vacuum or breech delivery.
Strategies for possible prevention of cerebral palsy in children born
at term were only recognised to currently exist for two of these risk
factors: reducing low birthweight (reducing heavy alcohol con-
sumption during pregnancy), and reducing meconium aspiration
(amnioinfusion in settings with limited perinatal surveillance; cur-
tailment of post-term pregnancy). This review highlighted that
prevention strategies for cerebral palsy in term born infants are
urgently required, and called for heightened efforts focused on
preventing identified risk factors, and thus, interrupting pathways
to cerebral palsy.
A systematic review by Hines 2015 was designed to systematically
review meta-analyses and randomised trials of interventions for
infants at risk of cerebral palsy, to determine if consensus existed in
study endpoints. The review identified that of the 685 Cochrane
Pregnancy and Childbirth or Neonatal reviews published at the
time, 177 addressed acknowledged risk factors for cerebral palsy
(such as preterm birth, pre-eclampsia, or neonatal infection). A
sample of 22 reviews, with 165 included randomised trials were
selected, which addressed interventions such as fetal monitoring
during labour; preventing preterm labour, hypertension, and pre-
eclampsia; timing of umbilical cord clamping; maternal or neona-
tal infection, or both; minimising permanent brain injury; infant
respiratory function; and glutamine supplementation. Hines 2015
identified that of the 22 reviews, 18 specified neurodevelopmen-
tal outcomes, such as cerebral palsy, blindness, deafness, or intel-
lectual impairment, but of the 203 relevant randomised trials in
those reviews, only 22 (11%) contributed data to meta-analyses
for these outcomes. Similar to our overview, Hines 2015 identified
an urgent need for long-term follow-up after such antenatal and
intrapartum interventions, and concluded that “Variation in out-
come measurement and long-term follow-up has hampered the
ability of RCTs to contribute data on important outcomes for CP,
resulting in lost opportunities to measure the impact of maternal
and neonatal interventions”.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This overview summarises the evidence from Cochrane reviews
of randomised controlled trials regarding the effects of antenatal
and intrapartum intervention on cerebral palsy, and can be used
by researchers, funding bodies, policy makers, clinicians, and con-
sumers to aid decision-making and evidence translation.
There is high-quality evidence that magnesium sulphate for neu-
roprotection of the fetus, given to women at risk of preterm birth,
can prevent cerebral palsy better than placebo. Moderate-quality
evidence shows that any prophylactic antibiotics for women in
preterm labour with intact membranes may increase the risk of
cerebral palsy more than no antibiotics. Moderate-quality evidence
shows that immediate birth of preterm babies with suspected fetal
compromise may increase the risk of cerebral palsy more than de-
ferred birth. There is moderate-quality evidence showing no clear
difference in the risk of cerebral palsy between repeat doses of cor-
ticosteroids and a single course for women at risk of preterm birth.
No conclusions were possible for other interventions assessed in
this overview, because of low- to very-low quality evidence.
The scope of this overview was limited to the effects of interven-
tions on cerebral palsy, and pre-specified secondary review out-
comes. Consultation of the included Cochrane reviews is required
to formally assess additional benefits and harms of these interven-
tions, including impacts on risk factors for cerebral palsy, (such as
the reduction in intraventricular haemorrhage for preterm babies
following exposure to antenatal corticosteroids).
Implications for research
This overview highlights areas where there was insufficient evi-
dence to draw conclusions on the effects of several antenatal and
intrapartum interventions on cerebral palsy, and it should be used
to generate research questions and priorities. As cerebral palsy is
rarely diagnosed at birth, has diverse risk and causal factors, and
is diagnosed in approximately one in 500 children, it is a chal-
lenging outcome for investigators of such interventions to mea-
sure and report. To date, a small proportion of Cochrane reviews
assessing antenatal and intrapartum interventions have been able
to report on cerebral palsy, which may be due to a number of rea-
sons, including: a lack of primary research (with few randomised
trials of antenatal and intrapartum interventions conducting long-
term follow-up of children), lack of reporting on cerebral palsy by
randomised trials, lack of reporting on cerebral palsy by relevant
Cochrane reviews (due to not pre-specifying it as an outcome of
interest, not clearly defining long-term follow-up results, or not
being ’up-to-date’), or the absence of Cochrane reviews assessing
relevant interventions.
With greater understanding of the diverse risk factors and causes
of cerebral palsy, there is an urgent need for long-term follow-up
of interventions addressing risk factors for cerebral palsy, as well
as a need to consider the use of relatively new interim assessments
(such as the General Movements Assessment), to measure impact
on cerebral palsy. Such studies must be rigorous in their design,
and aim for consistency in cerebral palsy outcome measurement
and reporting to facilitate pooling of outcome data, therefore,
informing research efforts aimed at prevention of cerebral palsy.
A C K N O W L E D G E M E N T S
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A D D I T I O N A L T A B L E S
Table 1. Characteristics of excluded reviews
Review ID Reason for exclusion
Abou El Senoun 2014 Secondary neonatal outcomes included:
• Disability at time of childhood follow-up (as defined by authors).
• Serious disability (as defined by authors) after two years.
No outcome data for these outcomes.
Bricker 2015 Primary outcomes included:
• Neurodevelopment at age two.
No outcome data for this outcome.
Buchanan 2010 Secondary neonatal outcomes included:
• Disability at time of childhood follow-up.
No outcome data for this outcome.
Chapman 2014 No outcomes focused on development or disability at follow-up
Crowley 2016 Secondary infant outcomes included:
• Neurodevelopmental delay at 12 months and 24 months.
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Table 1. Characteristics of excluded reviews (Continued)
No outcome data for this outcome.
Dare 2006 foetal, neonatal, and infant outcomes included:
• Disability at time of childhood follow-up.
No outcome data for this outcome
East 2014 Primary outcomes included:
• Long-term neurodevelopmental outcome.
No outcome data for this outcome.
Gomi 2015 No outcomes focused on development or disability at follow-up
Han 2013 Primary outcomes included:
• Any neurological disability at follow-up.
No outcome data for this outcome.
Hofmeyr 2015 Primary outcomes included:
• Perinatal or infant death (excluding fatal anomalies) or disability in childhood.
Secondary long-term infant outcomes included:
• Disability in childhood, as defined by trial authors.
No outcome data for these outcomes.
Hopkins 2002 No outcomes focused on development or disability at follow-up
Kenyon 2013 Secondary outcome included:
• Long-term health outcomes (as defined by trial authors) after at least two years.
Outcome data only reported for ’Serious childhood disability at seven years’
Khunpradit 2011 Secondary outcomes include:
• Neonatal neurodevelopment.
No outcome data for this outcome.
Kiiza 2015 Protocol.
Secondary baby outcomes will include:
• Long-term neurodevelopmental outcome.
Lewin 2010 No outcomes focused on development or disability at follow-up
Lutomski 2015 No outcomes focused on development or disability at follow-up
Mackeen 2014 No outcomes focused on development or disability at follow-up
Neilson 2003 No outcomes focused on development or disability at follow-up
Olsen 2012 No outcomes focused on development or disability at follow-up
Othman 2007 No outcomes focused on development or disability at follow-up
Sangkomkamhang 2015 No outcomes focused on development or disability at follow-up
25Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
59
Table 1. Characteristics of excluded reviews (Continued)
Say 1996 No outcomes focused on development or disability at follow-up
Say 1996a No outcomes focused on development or disability at follow-up
Say 1996b No outcomes focused on development or disability at follow-up
Say 1996c No outcomes focused on development or disability at follow-up
Say 2001 No outcomes focused on development or disability at follow-up
Say 2003 No outcomes focused on development or disability at follow-up
Say 2003a No outcomes focused on development or disability at follow-up
Say 2003b No outcomes focused on development or disability at follow-up
Siegfried 2011 No outcomes focused on development or disability at follow-up
Siriwachirachai 2014 No outcomes focused on development or disability at follow-up
Stan 2013 Secondary outcomes included:
• Long-term sequelae: neurologic impairment and chronic lung disease.
No outcome data for this outcome.
Thomas 2007 Outcomes included:
• Adverse neonatal outcomes in terms of longer-term neurological outcomes.
No outcome data for this outcome.
Table 2. Characteristics of included reviews
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Table 2. Characteristics of included reviews (Continued)
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Table 2. Characteristics of included reviews (Continued)
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Table 2. Characteristics of included reviews (Continued)
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Table 2. Characteristics of included reviews (Continued)
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Abbreviation: RCT: randomised controlled trial
35Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
69
Table 3. Risk of bias assessments from included reviews
Review ID Summary of trial limitations (risk of bias)
Abalos 2014 Sequence generation: 12 RCTs low risk; 35 RCTs unclear risk; 2 RCTs high risk
Allocation concealment: 17 RCTs low risk; 32 RCTs unclear risk
Blinding (participants and personnel): 10 RCTs low risk; 1 RCT unclear risk; 38 RCTs high risk
Blinding (outcome assessors): 10 RCTs low risk; 2 RCTs unclear risk; 37 RCTs high risk
Incomplete outcome data: 45 RCTs low risk; 4 RCTs high risk
Selective reporting: 9 RCTs low risk; 40 RCTs unclear risk
Other: 23 RCTs low risk; 24 RCTs unclear risk; 2 RCTs high risk
Overall: “Overall, the quality of the studies included in this review is moderate to poor”
Alfirevic 2013 Sequence generation: 3 RCTs low risk; 8 RCTs unclear risk; 2 RCTs high risk
Allocation concealment: 3 RCTs low risk; 6 RCTs unclear risk; 4 RCTs high risk
Blinding (participants and personnel): 13 RCTs high risk
Blinding (outcome assessors): 12 RCTs unclear risk; 1 RCT high risk
Incomplete outcome data: 8 RCTs low risk; 3 RCTs unclear risk; 2 RCTs high risk
Selective reporting: 13 RCTs high risk
Other: 13 RCTs low risk
Overall: Only 2 RCTs were judged to be of high quality.
“The overall quality of the evidence can best be described as low to moderate”
Churchill 2013 Sequence generation: 3 RCTs low risk; 1 RCT unclear risk
Allocation concealment: 3 RCTs low risk; 1 RCT unclear risk
Blinding (participants and personnel): 1 RCT low risk; 3 RCTs unclear risk
Blinding (outcome assessors): 1 RCT low risk; 3 RCTs unclear risk
Incomplete outcome data: 1 RCT low risk; 2 RCTs unclear risk; 1 RCT high risk
Selective reporting: 4 RCTs low risk
Other: 1 RCT low risk; 2 RCTs unclear; 1 RCT high risk
Overall: “Overall, two trials were judged to have a low risk of bias, one was unclear and one a high risk of bias”
Crowther 2010 Sequence generation: 2 RCTs low risk; 4 RCTs unclear risk; 2 RCTs high risk
Allocation concealment: 7 RCTs unclear risk; 1 RCT high risk
Blinding: 2 RCTs low risk; 1 RCT unclear risk; 5 RCTs high risk
Incomplete outcome data: 3 RCTs low risk; 4 RCTs unclear risk; 1 RCT high risk
Selective reporting: 6 RCTs low risk; 2 RCTs unclear risk
Other: 5 RCTs low risk; 2 RCTs unclear risk; 1 RCT high risk
Overall: “The trials were of variable quality.”
Crowther 2010a Sequence generation: 1 RCT low risk; 4 RCTs unclear risk; 4 RCTs high risk
Allocation concealment: 7 RCTs unclear risk; 1 RCT high risk; 1 RCT: not reported
Blinding: 4 RCTs low risk; 1 RCT unclear risk; 4 RCTs high risk
Incomplete outcome data: 1 RCT low risk; 5 RCTs unclear risk; 3 RCTs high risk
Selective reporting: 9 RCTs low risk
Other: 6 RCTs low risk; 1 RCT unclear risk; 2 RCTs high risk
Overall: “Poor-quality trials contribute excessively to the weight in the overall analysis due to the higher rate of
adverse outcomes in those trials”
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Table 3. Risk of bias assessments from included reviews (Continued)
Crowther 2014 Sequence generation: 15 RCTs low risk; 18 RCTs unclear risk; 4 RCTs high risk
Allocation concealment: 6 RCTs low risk; 27 RCTs unclear risk; 4 RCTs high risk
Blinding (participants and personnel): 4 RCTs low risk; 7 RCTs unclear risk; 26 RCTs high risk
Blinding (outcome assessors): 1 RCT low risk; 35 RCTs unclear risk; 1 RCT high risk
Incomplete outcome data: 20 RCTs low risk; 15 RCTs unclear risk; 2 RCTs high risk
Selective reporting: 11 RCTs low risk; 19 RCTs unclear risk; 7 RCTs high risk
Other: 17 RCTs low risk; 20 RCTs unclear risk
Overall: “Overall, we judged the included trials to be of moderate to high risk of bias”
Crowther 2015 Sequence generation: 8 RCTs low risk; 2 RCTs unclear risk
Allocation concealment: 10 RCTs low risk
Blinding (participants and personnel): 9 RCTs low risk; 1 RCT high risk
Blinding (outcome assessors): 4 RCTs low risk; 6 RCTs unclear risk
Incomplete outcome data: 7 RCTs low risk; 3 RCTs unclear risk
Selective reporting: 9 RCTs low risk; 1 RCT unclear risk
Other: 7 RCTs low risk; 3 RCTs high risk
Overall: “Overall, the included trials were assessed as having a low to moderate risk of bias”
Dodd 2013 Sequence generation: 23 RCTs low risk; 13 RCTs unclear risk
Allocation concealment: 23 RCTs low risk; 13 RCTs unclear risk
Blinding (participants and personnel): 24 RCTs low risk; 7 RCTs unclear risk; 4 RCTs high risk
Blinding (outcome assessors): 15 RCTs low risk; 17 RCTs unclear risk; 4 RCTs high risk
Incomplete outcome data: 31 RCTs low risk; 5 RCTs unclear risk
Selective reporting: 25 RCTs low risk; 10 RCTs unclear risk; 1 RCT high risk
Other: 21 RCTs low risk; 15 RCTs unclear risk
Overall: “The overall quality of the included trials varied from good to fair”
Doyle 2009 Sequence generation: 4 RCTs low risk; 1 RCT unclear risk
Allocation concealment: 4 RCTs low risk; 1 RCT unclear risk
Blinding: 3 RCTs low risk; 2 RCT unclear risk
Incomplete outcome data: 2 RCTs low risk; 3 RCT unclear risk
Selective reporting: 4 RCTs low risk; 1 RCT unclear risk
Overall: “Overall, the methodological quality of the trials was relatively good, with a low risk of bias. However,
the quality was better, and the risk of bias lower, in some studies compared with others”
Duley 2010 Sequence generation: 6 RCTs low risk; 9 RCTs unclear risk
Allocation concealment: 5 RCTs low risk; 9 RCTs unclear risk; 1 RCT high risk
Blinding: 4 RCTs low risk; 3 RCTs unclear risk; 8 RCTs high risk
Incomplete outcome data: 7 RCTs low risk; 3 RCTs unclear risk; 5 RCTs high risk
Overall: “The quality of the studies included in this review ranged from excellent to poor. However, most of the
poor quality studies were small. The large study comparing magnesium sulphate with placebo was of high quality”
Flenady 2013 Sequence generation: 7 RCTs low risk; 7 RCTs unclear risk
Allocation concealment: 9 RCTs low risk; 5 RCTs unclear risk
Blinding (participants and personnel): 12 RCTs low risk; 2 RCTs high risk
Blinding (outcome assessors): 12 RCTs low risk; 2 RCTs high risk
Incomplete outcome data: 13 RCTs low risk; 1 RCT unclear risk (long-term: 1 RCT low risk; 13 RCTs unclear
risk)
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Table 3. Risk of bias assessments from included reviews (Continued)
Selective reporting: 12 RCTs low risk; 2 RCTs unclear risk
Other: 13 RCTs low risk; 1 RCT unclear risk
Overall: “Overall the quality of the included trials was good”
Magee 2003 Allocation concealment: adequate in 5 RCT
Double blinding (of physicians and patients) for outcome assessment: 7 RCTs
For maternal and pregnancy outcomes, follow up of greater than 90%: 20 RCTs
Overall: “The quality of these trials was poor”
Neilson 2014 Sequence generation: 12 RCTs low risk; 16 RCTs unclear risk
Allocation concealment: 7 RCTs low risk; 21 RCTs unclear risk
Blinding (participants and personnel): 15 RCTs low risk; 1 RCTs unclear risk; 12 RCTs high risk
Blinding (outcome assessors): 9 RCTs low risk; 8 RCTs unclear risk; 11 RCTs high risk
Incomplete outcome data: 16 RCTs low risk; 10 RCTs unclear risk; 2 RCTs high risk
Selective reporting: 1 RCT low risk; 26 RCTs unclear risk; 1 RCT high risk
Other: 8 RCTs low risk; 19 RCTs unclear risk; 1 RCT high risk
Overall: not detailed
Roberts 2006 Allocation concealment: 8 RCTs: A (adequate); 12 RCTs: B (unclear); 1 RCT: C (inadequate)
Overall: not detailed
Stock 2016 Sequence generation: 1 RCT low risk
Allocation concealment: 1 RCT low risk
Blinding (participants and personnel): 1 RCT high risk
Blinding (outcome assessors): 1 RCT low risk
Incomplete outcome data: 1 RCT low risk (high for childhood outcomes)
Selective reporting: 1 RCT low risk
Other: 1 RCT high risk
Overall: “large study of good quality”
Abbreviation: RCT: randomised controlled trial
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Table 4. AMSTAR assessments for included reviews (Continued)
Magee
2003
√ √ √ √ √ √ √ √






























: item adequately addressed; ?: unclear whether item addressed; ×: item not adequately addressed
Table 5. ROBIS assessments for included reviews









Abalos 2014 Low risk Low risk Low risk Low risk LOW RISK
Alfirevic 2013 Low risk Low risk Low risk Low risk LOW RISK
Churchill 2013 Low risk Low risk Low risk Low risk LOW RISK
Crowther 2010 Low risk Low risk Low risk Low risk LOW RISK
Crowther 2010a Low risk Low risk Low risk Low risk LOW RISK
Crowther 2014 Low risk Low risk Low risk Low risk LOW RISK
Crowther 2015 Low risk Low risk Low risk Low risk LOW RISK
Dodd 2013 Low risk Low risk Low risk Low risk LOW RISK
Doyle 2009 Low risk Low risk Low risk Low risk LOW RISK
Duley 2010 Low risk Low risk Low risk Unclear risk LOW RISK
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Table 5. ROBIS assessments for included reviews (Continued)
Flenady 2013 Low risk Low risk Low risk Low risk LOW RISK
Magee 2003 Low risk Low risk Low risk Unclear risk LOW RISK
Neilson 2014 Low risk Low risk Low risk Low risk LOW RISK
Roberts 2006 Low risk Low risk Low risk Unclear risk LOW RISK
Stock 2016 Low risk Low risk Low risk Low risk LOW RISK
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26.02)
507 (1 RCT) MODERATE study limita-
tions (-1): 1
RCT at high
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Abbreviations: CI: confidence intervals; IA: intermittent auscultation; RCT: randomised controlled trial; RR: risk ratio; CI: confidence
interval
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Table 7. Summary of findings: subgroup or sensitivity analyses of select comparisons for cerebral palsy (Continued)
Number of
babies

































Parity Both or not
specified

















df = 1 (P =
0.22), I² =
34%

































































df = 2 (P =
0.49), I² = 0.
0%
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Abbreviations: CI: confidence intervals; RCT: randomised controlled trial; RR: risk ratio















































Abbreviations: CI: confidence intervals; RCT: randomised controlled trial; RR: risk ratio
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Abbreviations: CI: confidence intervals; RCT: randomised controlled trial; RR: risk ratio
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Table 10. Summary of findings: all comparisons measuring other composite outcomes that include cerebral palsy as a component
(Continued)
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Table 10. Summary of findings: all comparisons measuring other composite outcomes that include cerebral palsy as a component
(Continued)
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Abbreviations: CI: confidence intervals; DQ: developmental quotient; IQ: intelligence quotient; IVH: intraventricular haemorrhage;
MDI: mental development index; PVL: periventricular leukomalacia; RCT: randomised controlled trial; RR: risk ratio; SD: standard
deviation
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Abbreviations: CI: confidence intervals; RCT: randomised controlled trial; RR: risk ratio
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A B S T R A C T
Background
Cerebral palsy is an umbrella term that encompasses disorders of movement and posture attributed to non-progressive disturbances
occurring in the developing foetal or infant brain. As there are diverse risk factors and aetiologies, no one strategy will prevent cerebral
palsy. Therefore, there is a need to systematically consider all potentially relevant interventions for prevention.
Objectives
Primary
To summarise the evidence from Cochrane Systematic Reviews regarding effects of neonatal interventions for preventing cerebral palsy
(reducing cerebral palsy risk).
Secondary
To summarise the evidence from Cochrane Systematic Reviews regarding effects of neonatal interventions that may increase cerebral
palsy risk.
Methods
We searched the Cochrane Database of Systematic Reviews (27 November 2016) for reviews of neonatal interventions reporting on
cerebral palsy. Two review authors assessed reviews for inclusion, extracted data, and assessed review quality (using AMSTAR and
ROBIS) and quality of the evidence (using the GRADE approach). Reviews were organised by topic; findings were summarised in text
and were tabulated. Interventions were categorised as effective (high-quality evidence of effectiveness); possibly effective (moderate-
quality evidence of effectiveness); ineffective (high-quality evidence of harm); probably ineffective (moderate-quality evidence of harm
or lack of effectiveness); and no conclusions possible (low- to very low-quality evidence).
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Main results
Forty-three Cochrane Reviews were included. A further 102 reviews pre-specified the outcome cerebral palsy, but none of the included
randomised controlled trials (RCTs) reported this outcome. Included reviews were generally of high quality and had low risk of bias, as
determined by AMSTAR and ROBIS. These reviews involved 454 RCTs; data for cerebral palsy were available from 96 (21%) RCTs
involving 15,885 children. Review authors considered interventions for neonates with perinatal asphyxia or with evidence of neonatal
encephalopathy (3); interventions for neonates born preterm and/or at low or very low birthweight (33); and interventions for other
specific groups of ’at risk’ neonates (7). Quality of evidence (GRADE) ranged from very low to high.
Interventions for neonates with perinatal asphyxia or with evidence of neonatal encephalopathy
Effective interventions: high-quality evidence of effectiveness
Researchers found a reduction in cerebral palsy following therapeutic hypothermia versus standard care for newborns with hypoxic
ischaemic encephalopathy (risk ratio (RR) 0.66, 95% confidence interval (CI) 0.54 to 0.82; seven trials; 881 children).
No conclusions possible: very low-quality evidence
One review observed no clear differences in cerebral palsy following therapeutic hypothermia versus standard care.
Interventions for neonates born preterm and/or at low or very low birthweight
Possibly effective interventions: moderate-quality evidence of effectiveness
Researchers found a reduction in cerebral palsy with prophylactic methylxanthines (caffeine) versus placebo for endotracheal extubation
in preterm infants (RR 0.54, 95% CI 0.32 to 0.92; one trial; 644 children).
Probably ineffective interventions: moderate-quality evidence of harm
Researchers reported an increase in cerebral palsy (RR 1.45, 95% CI 1.06 to 1.98; 12 trials; 1452 children) and cerebral palsy in
assessed survivors (RR 1.50, 95% CI 1.13 to 2.00; 12 trials; 959 children) following early (at less than eight days of age) postnatal
corticosteroids versus placebo or no treatment for preventing chronic lung disease in preterm infants.
Probably ineffective interventions: moderate-quality evidence of lack of effectiveness
Trial results showed no clear differences in cerebral palsy following ethamsylate versus placebo for prevention of morbidity and mortality
in preterm or very low birthweight infants (RR 1.13, 95% CI 0.64 to 2.00; three trials, 532 children); volume expansion versus no
treatment (RR 0.76, 95% CI 0.48 to 1.20; one trial; 604 children); gelatin versus fresh frozen plasma (RR 0.94, 95% CI 0.52 to 1.69;
one trial, 399 children) for prevention of morbidity and mortality in very preterm infants; prophylactic indomethacin versus placebo for
preventing mortality and morbidity in preterm infants (RR 1.04, 95% CI 0.77 to 1.40; four trials; 1372 children); synthetic surfactant
versus placebo for respiratory distress syndrome in preterm infants (RR 0.76, 95% CI 0.55 to 1.05; five trials; 1557 children); or
prophylactic phototherapy versus standard care (starting phototherapy when serum bilirubin reached a pre-specified level) for preventing
jaundice in preterm or low birthweight infants (RR 0.96, 95% CI 0.50 to 1.85; two trials; 756 children).
No conclusions possible: low- to very low-quality evidence
No clear differences in cerebral palsy were observed with interventions assessed in 21 reviews.
Interventions for other specific groups of ’at risk’ neonates
No conclusions possible: low- to very low-quality evidence
Review authors observed no clear differences in cerebral palsy with interventions assessed in five reviews.
Authors’ conclusions
This overview summarises evidence from Cochrane Systematic Reviews regarding effects of neonatal interventions on cerebral palsy, and
can be used by researchers, funding bodies, policy makers, clinicians, and consumers to aid decision-making and evidence translation.
To formally assess other benefits and/or harms of included interventions, including impact on risk factors for cerebral palsy, review of
the included Reviews is recommended.
Therapeutic hypothermia versus standard care for newborns with hypoxic ischaemic encephalopathy can prevent cerebral palsy, and
prophylactic methylxanthines (caffeine) versus placebo for endotracheal extubation in preterm infants may reduce cerebral palsy risk.
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Early (at less than eight days of age) postnatal corticosteroids versus placebo or no treatment for preventing chronic lung disease in
preterm infants may increase cerebral palsy risk.
Cerebral palsy is rarely identified at birth, has diverse risk factors and aetiologies, and is diagnosed in approximately one in 500 children.
To date, only a small proportion of Cochrane Systematic Reviews assessing neonatal interventions have been able to report on this
outcome. There is an urgent need for long-term follow-up of RCTs of such interventions addressing risk factors for cerebral palsy
(through strategies such as data linkage with registries) and for consideration of the use of relatively new interim assessments (including
the General Movements Assessment). Such RCTs must be rigorous in their design and must aim for consistency in cerebral palsy
outcome measurement and reporting to facilitate pooling of data and thus to maximise research efforts focused on prevention.
P L A I N L A N G U A G E S U M M A R Y
Interventions for babies from birth to one month of life for preventing cerebral palsy: an overview of Cochrane Systematic
Reviews
What is the issue?
’Cerebral palsy’ is a term that includes a group of conditions affecting people’s ability to move; it is the most common physical disability
in childhood. Cerebral palsy is usually due to events before, during, or after childbirth that lead to injury to babies’ developing brains.
No single cause of cerebral palsy is known. For many children, the cause of cerebral palsy is unclear, but many risk factors are known.
The biggest risk factor is preterm birth (birth before 37 weeks of pregnancy). Other risk factors during the neonatal period (birth to
one month of life) include prolonged loss of oxygen during birth; brain injury; strokes or seizures; disorders of the heart, blood vessels,
airways, and lungs; prolonged mechanical assistance for breathing; some infections; jaundice (yellow discolouration of the skin and
eyes due to excess bilirubin in the blood); and some syndromes or abnormalities of chromosomes (structures that hold genes).
Why is this important?
As there are different risk factors for and causes of cerebral palsy, it is likely that different interventions may be needed to prevent
cerebral palsy by reducing risk factors. This overview summarises evidence about preventing cerebral palsy that has been presented in
Cochrane Systematic Reviews of interventions during the neonatal period.
What evidence did we find?
We searched for evidence on 27 November 2016, and identified 43 Cochrane Reviews assessing interventions during the neonatal
period that reported some information on cerebral palsy. These Reviews were all of moderate to high quality, but the quality of the
evidence about cerebral palsy ranged from very low to high. Three Reviews assessed interventions for newborn babies who may have
had a lack of oxygen at or around the time of birth; 33 Reviews assessed interventions for babies born preterm or at low birthweight;
and seven Reviews assessed interventions for other groups of newborn babies at risk of injury to their brains (such as newborn babies
with low blood sugar at birth).
We found that one intervention was effective for cerebral palsy prevention. Newborn babies who may have had a lack of oxygen at or
around the time of birth who had induced hypothermia (cooling of their body or just their brain) were less likely to develop cerebral
palsy than babies who did not receive hypothermia (seven trials; 881 children; high-quality evidence). We found that one intervention
was possibly effective for cerebral palsy prevention. Preterm newborns who received methylxanthines (caffeine) when weaning from
machine-assisted breathing (extubation from mechanical ventilation) was planned were less likely to develop cerebral palsy than babies
who received a placebo (one trial; 644 children; moderate-quality evidence). We found one intervention that was probably ineffective
and may cause harm: Preterm newborns who received early (at less than eight days of age) corticosteroids to prevent chronic lung disease
were more likely to develop cerebral palsy than babies who received a placebo (12 trials; 959 children; moderate-quality evidence). We
found that five other interventions were probably ineffective (did not prevent or increased the chance of cerebral palsy) (moderate-
quality evidence). Review authors did not find enough evidence to say whether the other interventions prevented, increased, or had no
impact on cerebral palsy (low- or very low-quality evidence).
What does this mean?
This overview identified one intervention that was effective in preventing cerebral palsy (induced hypothermia for newborn babies who
may have had a lack of oxygen), one that was possibly effective for preventing cerebral palsy (caffeine for preterm babies weaning from
machine-assisted breathing), one that appeared to cause harm (corticosteroids at less than eight days of age for preterm babies to prevent
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chronic lung disease), and five that did not appear to make a difference. For the other interventions assessed, there was not enough
evidence to allow conclusions. It is important that additional good quality trials assessing interventions that might impact cerebral
palsy risk factors conduct long-term follow-up to measure the impact of these interventions. We identified over 100 other Cochrane
Reviews that may in the future provide information on interventions during the neonatal period for preventing cerebral palsy if they
include long-term follow-up.
B A C K G R O U N D
Description of the condition
Cerebral palsy: definition and prevalence
‘Cerebral palsy’ was originally (and continues to be) defined by
clinical description at a time when there was little knowledge of
aetiology or pathology (Morris 2007). Today, many registries and
surveillance programmes, including those in Australia, the United
Kingdom, and Europe, highlight five key elements of cerebral
palsy: It is an ‘umbrella term’; it is permanent but not unchang-
ing; it involves a disorder of movement or posture or both, and
of motor function; it is due to a non-progressive interference, le-
sion, or abnormality; and the interference, lesion, or abnormality
arose in the developing or immature brain (Cans 2000; Mutch
1992; Rosenbaum 2007; Smithers-Sheedy 2014). As cerebral palsy
is defined by clinical description, which may change over time,
a longer time span for diagnosis is considered useful to confirm
that the condition meets criteria for cerebral palsy and to accu-
rately describe the motor impairment. Thus, final ascertainment
for surveillance programmes across the world ranges from four to
12 years, with many considering data to be ’complete’ at or near
five years (Smithers-Sheedy 2014). Although average age at diag-
nosis has been around 18 months, recent evidence has suggested
that cerebral palsy may be reliably detected as early as three to four
months’ post term age via tests such as Prechtl’s Qualitative As-
sessment of General Movements and medical resonance imaging
(Bosanquet 2013; Morgan 2016).
Cerebral palsy is the most common physical disability in child-
hood. In a recent meta-analysis, including 19 studies (with varying
ages of ascertainment), the global pooled prevalence was 2.11 per
1000 live births (95% confidence interval (CI) 1.98 to 2.25); a
cumulative meta-analysis demonstrated stability over the past 10
years (Oskoui 2013). Similar rates have been reported in countries
that have used consistent methods of ascertainment for over 20
years (such as Australia, Sweden, and England), with most pub-
lished estimates in the region of 2 per 1000 (Blair 2006). In low-
and middle-income countries, prevalence estimates have tended
to be in a similar range or higher (Blair 2006; Cans 2000). How-
ever, emerging evidence, including rates from Australia and Eu-
rope, now shows that overall rates and severity of the condition
are starting to decline for the first time (Reid 2015; Sellier 2015).
Cerebral palsy: causes and risk factors
Brain injury was acquired during an event more than 28 days af-
ter birth in approximately 6% of individuals with cerebral palsy
(ACPR Group 2013). In the remaining 94% of individuals, brain
injury occurred during pregnancy, at birth, or over the first 28 days
of life (ACPR Group 2013). Preterm birth is one of the principal
risk factors for cerebral palsy and associated neurosensory disabili-
ties (Himpens 2008; Oskoui 2013), with over 40% of individuals
with cerebral palsy born preterm (ACPR Group 2013). However,
more than half of all individuals with cerebral palsy are born at
term (ACPR Group 2013).
Studies on antenatal, intrapartum, and neonatal risk factors for
cerebral palsy are abundant. Although a great number of risk fac-
tors have been identified, their commonality is that separately, or
in combination, they influence potentially preventable pathways
to brain injury. Risk factors commonly reported include (i) factors
before conception (e.g. low or advanced maternal age, high parity,
nulliparity, a short or long interpregnancy interval, a history of
stillbirth, multiple miscarriages, neonatal death or preterm birth,
family history of cerebral palsy and other genetic predispositions,
low socioeconomic status, pre-existing maternal conditions (such
as epilepsy or intellectual disability)); (ii) factors in early pregnancy
(e.g. male sex, multiple gestation, congenital malformations or
birth defects, infections (such as TORCH complex - toxoplasmosis
(parasite), other infections, rubella, cytomegalovirus, herpes sim-
plex virus)); (iii) factors during pregnancy (e.g. maternal disease
(such as thyroid disorders), pregnancy complications (such as pre-
eclampsia, placenta praevia, and placental abruption), intrauter-
ine infection or inflammation and chorioamnionitis, intrauterine
growth restriction, other precursors to preterm birth); and (iv) fac-
tors around the time of birth and the neonatal period (e.g. acute in-
trapartum hypoxic events and neonatal encephalopathy, neonatal
brain injury (such as intraventricular haemorrhage, periventricular
leucomalacia, and hydrocephalus), strokes or seizures, cardiovas-
cular disorders (such as patent ductus arteriosus and hypotension),
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respiratory disorders, associated prolonged ventilation (such as for
respiratory distress syndrome or bronchopulmonary dysplasia), in-
fection (such as sepsis and necrotising enterocolitis), metabolic or
endocrine disorders (such as hypoglycaemia and hypothyroidism),
neonatal jaundice along with inborn errors of metabolism, par-
ticular syndromes or chromosomal abnormalities) (Badawi 2005;
Dixon 2002; Drougia 2007; Jacobsson 2004; McIntyre 2011;
McIntyre 2013; Murphy 1997; Nelson 2008; Tran 2005; Walstab
2004).
Research has shown that contrary to previous beliefs, birth as-
phyxia is a relatively rare cause of cerebral palsy (Blair 1988;
Ellenberg 2013). A growing body of evidence suggests that ge-
netic abnormalities contribute in some cases (MacLennan 2015;
Moreno-De-Luca 2012; O’Callaghan 2009; Oskoui 2015). Com-
mon risk factors in the post-neonatal period (some of which
also contribute in the neonatal period) include infection (such as
meningitis/encephalitis, or severe infection and subsequent severe
dehydration), head injury (such as from traffic accidents, other
traumatic injury, or non-accidental injury), vascular episodes (such
as post cardiac or brain surgery), and other events (such as near
drowning or near sudden infant death) (Cans 2004; Germany
2013).
Cerebral palsy: consequences
Cerebral palsy, the leading cause of physical disability for children,
is a condition with lifelong impact. Most individuals will survive
to adulthood, and some studies suggest that life expectancy can
be similar to that of the general population (Colver 2012). For
known cases of antenatally or neonatally acquired cerebral palsy,
the 20-year survival rate has been estimated at 90%. However,
strong associations between increasing motor impairment, severe
intellectual impairment, number of severe impairments, and early
mortality have been shown (Blair 2001; Hemming 2005; Reid
2012). Frequently used definitions for cerebral palsy acknowledge
common co-occurring impairments, diseases, and functional lim-
itations (Rosenbaum 2007). A recent systematic review estimated
that among children with cerebral palsy, “1 in 2 had an intellectual
disability…1 in 4 could not talk; 1 in 4 had epilepsy; 1 in 4 had
a behavior disorder…1 in 10 were blind…and 1 in 25 were deaf”
(Novak 2012).
Economic studies have estimated lifetime costs of cerebral palsy,
including healthcare, social care, and productivity costs, as EUR
860,000 for men and EUR 800,000 for women in Denmark (in
2000) (Kruse 2009), and as USD 921,000 for individuals in the
United States (in 2003) (CDC 2004). In Australia, the financial
cost of cerebral palsy was estimated as AUD 1.47 billion (in 2007),
and the value of lost well-being a further AUD 2.4 billion (Access
Economics 2008).
The impact of cerebral palsy is considerable (Davis 2010). Ac-
cordingly, identification of primary preventive measures has been
regarded as a key priority among individuals with cerebral palsy,
their families, clinicians, and researchers (McIntyre 2010).
Description of the interventions
Neonatal approaches to prevention of cerebral palsy
Research efforts aimed at prevention of cerebral palsy have in-
creasingly focused on understanding the causes of cerebral palsy.
As it is now widely recognised that causes differ, for example, by
gestational age (e.g. for preterm and term-born children) and by
clinical subtype of cerebral palsy, it is reasonable to consider that
successful primary preventive interventions will also vary accord-
ing to different aetiologies or causal factors.
In this overview, therefore, we will include a broad range of neona-
tal interventions (with varying primary aims or indications) that
may mediate cerebral palsy risk, including (but not limited to):
1. interventions for neonates following birth asphyxia or with
evidence of encephalopathy (e.g. cooling; erythropoietin;
darbepoetin; allopurinol; melatonin; magnesium sulphate;
anticonvulsants; xenon; naloxone; dopamine; fluid restriction;
acupuncture; umbilical cord stem cells);
2. interventions for neonates with neurological disorders, such
as intracranial haemorrhage or post-haemorrhagic hydrocephalus
(e.g. heparin; antithrombin; phenobarbital; diuretic therapy;
erythropoietin; repeated lumbar or ventricular punctures); or
those with seizures (anticonvulsants);
3. interventions for neonates requiring resuscitation (e.g. air or
oxygen for positive-pressure ventilation; lower or higher oxygen
concentrations titrated to target oxygen saturations; face mask,
laryngeal mask airway, nasal airway or endotracheal intubation;
positive end-expiratory pressure; respiratory function
monitoring);
4. interventions for neonates with cardiovascular disorders,
such as hypotension (e.g. corticosteroids; inotropes; early volume
expansion; adrenaline; dopamine; dobutamine) or patent ductus
arteriosus (e.g. ibuprofen; indomethacin; fluid restriction;
surgical ligation);
5. interventions for neonates with respiratory disorders, such
as apnoea of prematurity (e.g. kinaesthetic stimulation;
methylxanthines (caffeine)); respiratory distress syndrome (e.g.
early or delayed, prophylactic or selective, protein-containing or
protein-free, animal-derived or synthetic pulmonary surfactant;
thyroid hormones; continuous distending pressure); or
bronchopulmonary dysplasia (chronic lung disease) (e.g. early or
late, inhaled or systemic, postnatal corticosteroids);
6. interventions for gastrointestinal tract disorders, such as
necrotising enterocolitis (e.g. lactoferrin; probiotics; antibiotics;
immunoglobulin; peritoneal drainage; laparotomy);
7. interventions for neonates with infection, such as for
control of general infection (e.g. chlorhexidine skin or cord care;
patient isolation for infection; gowning by attendants and
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visitors in newborn nurseries); fungal and protozoal infections
(e.g. prophylactic antifungal agents; antifungal therapy for
invasive fungal infection); viral infections (e.g. antiviral agents
for treatment of herpes simplex virus or cytomegalovirus
infection); or bacterial infections (e.g. intravenous
immunoglobulin for prevention of infection, or for suspected or
proven infection; antibiotics for suspected early- or late-onset
sepsis; intraventricular antibiotics for meningitis; prophylactic
antibiotics for ventilated newborns);
8. interventions for neonates with metabolic or endocrine
disorders, such as disorders of carbohydrate metabolism (e.g. oral
dextrose gel for hypoglycaemia; insulin for hyperglycaemia) or
thyroid disorders (postnatal thyroid hormones);
9. interventions for neonates with jaundice and liver disorders
(e.g. phototherapy);
10. interventions focused on nutrition or metabolism for high-
risk neonates (i.e. preterm or low birthweight neonates, or both)
including enteral nutrition interventions (e.g. high protein
intake; donor breast milk; nutrient-enriched formula; multi-
nutrient fortification of human breast milk; responsive or
scheduled feeding), parenteral nutrition interventions (e.g. early
or late, high or low amino acid administration), or vitamin or
mineral supplementation (e.g. glutamine; arginine; iodine;
vitamin E);
11. interventions for neurodevelopmental care or physical
environment management (or both) for neonates (e.g.
developmental care to reduce stressors in the neonatal nursery;
kangaroo mother care; massage; co-bedding in the neonatal
nursery; early developmental programmes post discharge to
prevent motor and cognitive impairments); and
12. interventions for all neonates at birth, such as newborn
screening for inborn errors of metabolism.
We will not consider interventions in the antenatal or intrapartum
period (such as magnesium sulphate for foetal neuroprotection
(Doyle 2009)), as these interventions will be assessed in a separate
overview (Shepherd 2016, under review).
How the intervention might work
Advances in research into several factors that modify the risk of
cerebral palsy suggest many opportunities for prevention, with the
main neonatal strategies focusing on protection of the immature
brain through administration of neuroprotective agents or thera-
pies.
For many individuals born at or near term who develop cere-
bral palsy, their neonatal course has been seemingly unremarkable,
with the exception of those following perinatal asphyxia and with
neonatal encephalopathy (brain injury that may be due to cerebral
hypoxia and ischaemia before birth) (Badawi 2005; O’Shea 2008).
For these neonates, therapeutic hypothermia, applied selectively
to the head (as a ‘cooling cap’) or to the whole body, is one such
intervention that can mediate cerebral palsy risk (O’Shea 2008).
Beyond cooling, a range of other interventions (including those
used as adjuvant therapy with cooling) may contribute to cere-
bral palsy prevention by protecting against secondary cell death
and brain damage following hypoxic-ischaemic insult (Robertson
2012), or by treating the underlying cause(s) of encephalopathy
(such as infection or metabolic derangement).
For preterm and very low birthweight neonates, and for other
groups of neonates (such as those with hypoglycaemia) who are
at increased risk of brain injury, many pharmacological and non-
pharmacological interventions in the neonatal period may medi-
ate cerebral palsy risk (O’Shea 2008). Although these interven-
tions differ in their primary aims (such as maintaining adequate
ventilation (e.g. through treatment of apnoea of prematurity with
caffeine); maintaining normal metabolic status (e.g. through treat-
ment of neonatal hypoglycaemia with dextrose gel); or controlling
neonatal seizures (e.g. through use of anticonvulsants)), each may
contribute to cerebral palsy prevention by reducing the likelihood
or severity of brain injury, and thus of long-term neurodevelop-
mental sequelae.
Why it is important to do this overview
A multitude of individual studies and Cochrane Systematic Re-
views assessing a broad range of neonatal interventions (with vary-
ing primary aims or indications) acknowledge the potential for
the intervention of interest to influence cerebral palsy risk. With
awareness that there are many and varied risk factors for cerebral
palsy, and that causes of cerebral palsy differ, there is a need to
systematically consider all potentially relevant interventions for
their ability to contribute to reducing cerebral palsy risk. As new
data suggest possible declining rates and severity of cerebral palsy,
it is important to examine the different interventions that may,
together, contribute to these observations.
To our knowledge, to date, no ‘overview’ has brought together
the evidence around neonatal interventions for cerebral palsy pre-
vention from Cochrane Systematic Reviews into a single coher-
ent document to be used by researchers, funding bodies, policy
makers, clinicians, and consumers to aid decision-making and ev-
idence implementation.
Although the objective of this overview is to summarise the ev-
idence from Cochrane Systematic Reviews regarding effects of
neonatal interventions for preventing cerebral palsy, it is also im-
portant to consider whether such interventions may, instead, ac-
tually contribute to increasing cerebral palsy risk.
Is an overview the right approach?
We have followed the Editorial Decision Tree proposed by the
Cochrane Comparing Multiple Interventions Methods Group to
establish whether our review would better fit an overview format
or an intervention review format, specifically:
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1. we will review systematic reviews, instead of individual
trials;
2. we will not compare multiple interventions with the
intention of drawing inferences about the comparative
effectiveness of these interventions; and
3. we intend to present a map of evidence from systematic
reviews but with no attempt to rank the interventions.
On the basis of these points, the Editorial Decision Tree recom-
mends an overview as the appropriate format for this review.
O B J E C T I V E S
Primary
To summarise the evidence from Cochrane Systematic Reviews
regarding effects of neonatal interventions for preventing cerebral
palsy (reducing cerebral palsy risk).
Secondary
To summarise the evidence from Cochrane Systematic Reviews
regarding effects of neonatal interventions that may increase cere-
bral palsy risk.
M E T H O D S
Criteria for considering reviews for inclusion
In this overview of systematic reviews, we included only published
Cochrane Systematic Reviews of neonatal interventions for which
cerebral palsy was reported as a primary or secondary review out-
come. We identified Cochrane protocols and titles for future in-
clusion and classified them as ’Ongoing reviews’ (in an Appendix).
We made note of publication and search dates of the reviews;
however, we did not attempt to update the individual systematic
reviews.
Participants
We considered reviews that included:
1. neonates with perinatal asphyxia or with evidence of
neonatal encephalopathy; and
2. neonates born preterm or at low or very low birthweight (or
both preterm and low/very low birthweight neonates).
We also included reviews that included other groups of ’at risk’
neonates (e.g. neonates with hypoglycaemia), so long as the inter-
vention assessed in the Cochrane Systematic Review was recog-
nised by the review authors as having the potential to influence
cerebral palsy risk - cerebral palsy had to be pre-specified as a pri-
mary or secondary outcome in the review.
Interventions
We considered all types of interventions used in the neonatal pe-
riod compared with placebo, no treatment, or an alternative in-
tervention.
We included both pharmacological and non-pharmacological in-
terventions (see Description of the interventions for further de-
scription of possible interventions).
Outcomes of interest
Primary
1. Cerebral palsy (regardless of criteria used for diagnosis by
review authors or trialists, and regardless of age at diagnosis;
however, we have reported any variation)
Secondary
1. Cerebral palsy or death (regardless of criteria used for
diagnosis by review authors or trialists, and regardless of age at
diagnosis; however, we have reported any variation)
2. Severity of cerebral palsy (e.g. according to Gross Motor
Function Classification System (GMFCS); Manual Ability
Classification System (MACS); Communication Function
Classification System (CFCS))
3. Type of cerebral palsy (e.g. according to topography
(diplegia; hemiplegia; quadriplegia; monoplegia; triplegia) or
motor type (spastic; dyskinetic; ataxic))
4. Motor dysfunction (regardless of criteria used for diagnosis
by review authors or trialists, and regardless of age at diagnosis;
however, we have reported any variation)
5. Other composite outcomes that include cerebral palsy as a
component (regardless of criteria used for diagnosis by review
authors or trialists, and regardless of age at diagnosis; however,
we have reported any variation)
To be included, a review had to pre-specify our overview’s primary
outcome - cerebral palsy (or a composite outcome that included
cerebral palsy*) as a primary or secondary systematic review out-
come - and must have reported data for this outcome from at least
one of the included trials in the review.
We listed reviews that pre-specified cerebral palsy as a primary or
secondary systematic review outcome but provided no reported
data from included trials on this outcome as ’Reviews awaiting
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further classification’, and we will reconsider these reviews in future
updates of the overview.
* When possible, we extracted data related to cerebral palsy from
any composite outcomes that included cerebral palsy. When it was
not possible to extract only cerebral palsy data from such composite
outcomes, we reported the composite outcome data; however, we
reported these separately from the data for our primary outcome
(i.e. as a secondary outcome).
Search methods for identification of reviews
We searched the Cochrane Database of Systematic Reviews on 27
November 2016, using the term ’cerebral palsy’. We used the
search term to search ’all text’, not limited to ’title, abstract, or
keywords’. We did not apply any language or date restrictions.
We searched no other databases. We managed citations retrieved
through the search by using Covidence (Covidence 2015).
Data collection and analysis
We based our data collection and synthesis methods on Chapter 22
of the Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2011). When appropriate, we prepared the overview using
Covidence (Covidence 2015) and Review Manager 5 software (
RevMan 2014).
Selection of reviews
Two overview authors independently assessed for inclusion all po-
tential systematic reviews identified by the search. We resolved
disagreements through discussion, or, if required, we consulted a
third member of the overview team.
Data extraction and management
Two overview authors independently extracted data from the re-
views using a pre-defined data extraction form. We resolved dis-
crepancies through discussion or, if needed, through consultation
with a third overview author. When information regarding review
outcomes was unclear or missing, we accessed the published pa-
pers of individual studies for further details.
We extracted information on the following.
1. Review characteristics.
i) Review title and authors.
ii) Date that the review was last assessed as up-to-date.
iii) Number of included trials and numbers of participants
(neonates) in the trials and their characteristics (e.g. countries in
which the trials were conducted, trial inclusion criteria).
iv) Quality of the included trials (as reported by the
review authors; see ’Quality of studies included within reviews’
below under Assessment of methodological quality of included
reviews).
v) Interventions and comparisons relevant to this
overview.
vi) All pre-specified outcomes relevant to this overview
(their definitions, and whether they were primary or secondary
outcomes in the included reviews).
vii) Any other characteristics required to assess and report
on review quality (see ’Quality of included reviews’ under
Assessment of methodological quality of included reviews).
2. Statistical summaries*.
i) Summary intervention effects (including pooled
effects (e.g. risk ratios (RRs), odds ratios (ORs), or mean
differences (MDs) as reported in the individual reviews), 95%
confidence intervals (CIs), and numbers of studies and
participants contributing data to each pooled effect) from
comparisons and for outcomes relevant to this overview.
ii) Information required to assess and report on the
quality of evidence for the intervention effects extracted above
(see ’Quality of evidence in included reviews’ under Assessment
of methodological quality of included reviews).
* When review authors were not able to perform meta-analyses and
therefore did not report statistical summaries, we extracted from
those reviews the narrative text related to results for our overview
outcomes.
Assessment of methodological quality of included
reviews
Quality of included reviews
We assessed the methodological quality of each systematic review
using the AMSTAR (A Measurement Tool to Assess Systematic
Reviews) instrument (Shea 2009). AMSTAR evaluates the meth-
ods used in a review against 11 distinct criteria and assesses the
degree to which review methods are unbiased. Each item on AM-
STAR is rated as ’yes’ (clearly done), ’no’ (clearly not done), ’can-
not answer’, or ’not applicable’. These criteria were as follows:
1. Was an ‘a priori’ design provided?
2. Was there duplicate study selection and data extraction?
3. Was a comprehensive literature search performed?
4. Was status of the publication used as an inclusion criterion?
5. Was a list of studies (included and excluded) provided?
6. Were the characteristics of included studies provided?
7. Was the scientific quality of included studies assessed and
documented?
8. Was the scientific quality of included studies used
appropriately in formulating conclusions?
9. Were the methods used to combine the findings of studies
appropriate?
10. Was the likelihood of publication bias assessed?
11. Was conflict of interest stated?
For all items except item 4, we considered a rating of ’yes’ as
adequate. For item 4, we considered a rating of ’no’ as adequate.
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We considered a review that adequately met all of the 11 criteria to
be a review of the highest quality (Shea 2009). For this overview, we
considered reviews that achieved scores of 8 to 11 as high quality;
scores of 4 to 7 as medium quality; and scores of 0 to 3 as low
quality.
To further assess risk of bias of the systematic reviews, we addi-
tionally used the new ROBIS (Risk of Bias in Systematic Reviews)
tool (Whiting 2015). This tool considers risk of bias across four
key domains.
1. Study eligibility criteria.
2. Identification and selection of studies.
3. Data collection and study appraisal.
4. Synthesis and findings.
A series of questions within each domain elicited information
about possible limitations of the systematic review, leading to a
judgement about concerns within that domain (low, high, or un-
clear). We then considered risk of bias of the review as a whole,
using signalling questions and information to support the overall
judgement of risk of bias (low, high, or unclear) (Whiting 2015).
Two overview authors independently assessed the quality of in-
cluded reviews using AMSTAR and ROBIS, and another overview
author verified this assessment. We resolved differences through
discussion or, if needed, through consultation with a third
overview author.
We also noted and reported for each review the publication and
search dates.
Quality of studies included within reviews
We did not reassess the quality of studies included within reviews
but instead reported study quality according to review authors’
assessments. We collected this information during the data extrac-
tion process.
Quality of evidence in included reviews
We assessed/reported the quality of evidence for our primary out-
come (cerebral palsy) and for secondary review outcomes using
the GRADE approach, as outlined in the GRADE handbook. We
reported the quality of evidence as assessed by systematic review
authors (who were in the best position to assess quality, given their
familiarity with study-level data) by using GRADEPro ’Summary
of findings’ tables from the reviews if provided (or when neces-
sary, we constructed such tables using the GRADEpro Guideline
Development Tool). The GRADE system assesses the following
features for the evidence found for important outcomes.
1. Study limitations (risk of bias): internal validity of the
evidence.
2. Inconsistency: heterogeneity or variability in estimates of
effect across studies.
3. Indirectness: degrees of difference between populations,
interventions, and comparators for the intervention and the
outcome of interest.
4. Imprecision (random error): extent to which confidence in
the effect estimate is adequate to support a particular decision.
5. Publication bias: degree of selective publication of studies.
The GRADE system rates the quality of evidence as follows.
1. High (further research is very unlikely to change confidence
in the estimate of effect).
2. Moderate (further research is likely to have an important
impact on confidence in the estimate of effect and may change
the estimate).
3. Low (further research is very likely to have an important
impact on confidence in the estimate of effect and is likely to
change the estimate).
4. Very low (any estimate of effect is very uncertain).
Data synthesis
We prepared a narrative description of characteristics of the in-
cluded Cochrane Reviews. We organised Review findings by
groups of neonates when possible as follows: interventions for
neonates with perinatal asphyxia or with evidence of neonatal en-
cephalopathy; interventions for neonates born preterm and at low
or very low birthweight; and interventions for other specific groups
of ’at risk’ neonates.
We summarised the main results of included reviews by categoris-
ing their findings in the following framework (as has been used
within previous Cochrane and non-Cochrane overviews, such as
Farquhar 2015 and Lassi 2015).
1. Effective interventions: indicating that the review found
high-quality evidence of effectiveness for an intervention.
2. Possibly effective interventions (more evidence needed):
indicating that the review found moderate-quality evidence of
effectiveness for an intervention, but more evidence is needed.
3. Ineffective interventions: indicating that the review found
high-quality evidence of lack of effectiveness for an intervention.
4. Probably ineffective interventions (more evidence needed):
indicating that the review found moderate-quality evidence
suggesting lack of effectiveness for an intervention, but more
evidence is needed.
5. No conclusions possible: indicating that the review found
low- or very low-quality evidence, or insufficient evidence to
comment on the effectiveness of an intervention.
We based the choice of category on quality of evidence for the pri-
mary overview outcome (cerebral palsy). We used separate assess-
ments for different comparisons (e.g. when one intervention was
compared both with placebo (or no treatment) and with an alter-
native intervention). This approach to summarising the evidence
was based on an earlier Cochrane overview (Jones 2012), which
categorised interventions as ’What works,’ ’What may work’, and
’Insufficient evidence to make a judgement’.
R E S U L T S
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Our search of the Cochrane Database of Systematic Reviews yielded
513 protocols and reviews. Following title and abstract review, we
excluded 303 protocols or reviews and assessed the full text of 210
protocols or reviews.
We excluded 25 reviews that did not pre-specify cerebral palsy as a
primary or secondary review outcome (see Table 1, ’Characteristics
of excluded studies’).
We listed an additional 142 protocols and reviews in the Appen-
dices.
1. Appendix 1 (’Ongoing reviews’) lists 40 Cochrane protocols
that pre-specified cerebral palsy as a primary or secondary
outcome; we will consider these protocols for inclusion in future
updates of the overview when they have been published as full
reviews.
2. Appendix 2 (’Reviews awaiting further classification’)
summarises the 102 Cochrane Reviews that pre-specified cerebral
palsy as a primary or secondary outcome but reported no data
from included trials on this outcome; again, we will consider
these reviews for inclusion in future updates of the overview.
We therefore included 43 reviews in this overview. See Figure 1.
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Figure 1. Study flow diagram.
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Description of included reviews
Of the 43 included reviews:
1. Three reviews focused on interventions for neonates with
perinatal asphyxia or with evidence of neonatal encephalopathy,
categorised under the Cochrane Neonatal ’Neonatal care’ topic.
i) Asphyxia: ’Allopurinol for preventing mortality and
morbidity in newborn infants with hypoxic-ischaemic
encephalopathy’ (Chaudhari 2012); ’Cooling for newborns with
hypoxic ischaemic encephalopathy’ (Jacobs 2013); ’Prophylactic
barbiturate use for the prevention of morbidity and mortality
following perinatal asphyxia’ (Young 2016).
2. Thirty-three reviews focused on interventions for neonates
born preterm and/or at low or very low birthweight, categorised
under the following Cochrane Neonatal ’Neonatal care’ topics.
i) Haemorrhage: periventricular/intraventricular:
’Ethamsylate for the prevention of morbidity and mortality in
preterm or very low birth weight infants’ (Hunt 2010); ’Postnatal
phenobarbital for the prevention of intraventricular haemorrhage
in preterm infants’ (Smit 2013).
ii) Hypotension: ’The effect of inotropes on morbidity and
mortality in preterm infants with low systemic or organ blood
flow’ (Osborn 2007b).
iii) Fluid therapy: ’Early volume expansion for prevention
of morbidity and mortality in very preterm infants’ (Osborn
2004).
iv) Patent ductus arteriosus: ’Prophylactic intravenous
indomethacin for preventing mortality and morbidity in preterm
infants’ (Fowlie 2010); ’Ibuprofen for the treatment of patent
ductus arteriosus in preterm or low birth weight (or both)
infants’ (Ohlsson 2015).
v) Blood disorders: ’Early erythropoietin for preventing
red blood cell transfusion in preterm and/or low birth weight
infants’ (Ohlsson 2014); ’Low versus high haemoglobin
concentration threshold for blood transfusion for preventing
morbidity and mortality in very low birth weight infants’ (Whyte
2011).
vi) Nitric oxide: ’Inhaled nitric oxide for respiratory failure
in preterm infants’ (Barrington 2010).
vii) Apneoa: ’Methylxanthine treatment for apnoea in
preterm infants’ (Henderson-Smart 2010b); ’Prophylactic
methylxanthine for prevention of apnoea in preterm infants’
(Henderson-Smart 2010c).
viii) Respiratory distress syndrome: ’Inositol in preterm
infants at risk for or having respiratory distress syndrome’
(Howlett 2015); ’Animal derived surfactant extract for treatment
of respiratory distress syndrome’ (Seger 2009); ’Synthetic
surfactant for respiratory distress syndrome in preterm infants’
(Soll 2000); ’Prophylactic protein free synthetic surfactant for
preventing morbidity and mortality in preterm infants’ (Soll
2010).
ix) Mechanical ventilation: ’Elective high frequency
oscillatory ventilation versus conventional ventilation for acute
pulmonary dysfunction in preterm infants’ (Cools 2015);
’Continuous distending pressure for respiratory distress in
preterm infants’ (Ho 2015); ’Prophylactic methylxanthines for
endotracheal extubation in preterm infants’ (Henderson-Smart
2010).
x) Bronchopulmonary dysplasia: ’Early (< 8 days) postnatal
corticosteroids for preventing chronic lung disease in preterm
infants’ (Doyle 2014b); ’Moderately early (7 to 14 days)
postnatal corticosteroids for preventing chronic lung disease in
preterm infants’ (Halliday 2003); ’Late (> 7 days) postnatal
corticosteroids for chronic lung disease in preterm infants’
(Doyle 2014); ’Early administration of inhaled corticosteroids
for preventing chronic lung disease in ventilated very low birth
weight preterm neonates’ (Shah 2012); ’Vitamin A
supplementation to prevent mortality and short- and long-term
morbidity in very low birth weight infants’ (Darlow 2016).
xi) Necrotising enterocolitis: ’Probiotics for prevention of
necrotizing enterocolitis in preterm infants’ (AlFaleh 2014);
’Arginine supplementation for prevention of necrotising
enterocolitis in preterm infants’ (Shah 2007).
xii) Fungal infections: ’Prophylactic systemic antifungal
agents to prevent mortality and morbidity in very low birth
weight infants’ (Cleminson 2015).
xiii) Jaundice: ’Prophylactic phototherapy for preventing
jaundice in preterm or low birth weight infants’ (Okwundu
2012).
xiv) Parenteral feeding: ’Glutamine supplementation to
prevent morbidity and mortality in preterm infants’ (Moe-Byrne
2016).
xv) Other neonatal care (including thermal environment and
developmental care): ’Thyroid hormones for preventing
neurodevelopmental impairment in preterm infants’ (Osborn
2001); ’Prophylactic postnatal thyroid hormones for prevention
of morbidity and mortality in preterm infants’ (Osborn 2007);
’Sound reduction management in the neonatal intensive care
unit for preterm or very low birth weight infants’ (Almadhoob
2015); ’Kangaroo mother care to reduce morbidity and mortality
in low birthweight infants’ (Conde-Agudelo 2016); ’Early
developmental intervention programmes provided post hospital
discharge to prevent motor and cognitive impairment in preterm
infants’ (Spittle 2015).
3. Seven reviews focused on interventions for other specific
groups of ’at risk’ neonates, categorised under the following
Cochrane Neonatal ’Neonatal care’ topics.
i) Pulmonary hypertension: ’Endothelin receptor
antagonists for persistent pulmonary hypertension in term and
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late preterm infants’ (More 2016).
ii) Resuscitation: ’Air versus oxygen for resuscitation of
infants at birth’ (Tan 2005).
iii) Nitric oxide: ’Nitric oxide for respiratory failure in
infants born at or near term’ (Finer 2006).
iv) Mechanical ventilation: ’Long versus short inspiratory
times in neonates receiving mechanical ventilation’ (Kamlin
2003); ’Volume-targeted versus pressure-limited ventilation in
the neonate’ (Wheeler 2010) (although in these reviews, relevant
outcome data were from neonates born preterm and/or at low or
very low birthweight only).
v) Herpes simplex: ’Antiviral agents for treatment of
herpes simplex virus infection in neonates’ (Jones 2009).
vi) Hypoglycaemia: ’Oral dextrose gel for the treatment of
hypoglycaemia in newborn infants’ (Weston 2016).
The 43 reviews included between one - as in Almadhoob 2015,
Osborn 2007b, and Shah 2007 - and 33 - as in Ohlsson 2015 -
randomised controlled trials, and between 34 - as in Almadhoob
2015 - and 5529 - as in AlFaleh 2014 - infants. In total, the 43
reviews included 454 randomised trials, involving 63,977 infants.
One-third (14) of the 43 reviews had conducted searches (and were
considered ’up-to-date’) in the past three years (November 2013
to November 2016) (AlFaleh 2014; Almadhoob 2015; Cleminson
2015; Conde-Agudelo 2016; Cools 2015; Darlow 2016; Ho 2015;
Howlett 2015; Moe-Byrne 2016; More 2016; Ohlsson 2015;
Spittle 2015; Weston 2016; Young 2016). The other 29 reviews
had latest search end dates ranging from May 1998 - in Soll 2000
- to August 2013 - in Doyle 2014b.
See Table 2 and Table 3 for further details of the characteristics of
the 43 included reviews (including review IDs and titles, search
dates and when the review was last assessed as up-to-date, num-
bers of randomised controlled trials and infants included, inter-
ventions and comparisons examined, overview outcomes reported,
and summary of included trial limitations (risk of bias)).
Methodological quality of included reviews
We rated the quality of included reviews using the AMSTAR and
ROBIS tools (Shea 2009 and Whiting 2015, respectively).
With regards to AMSTAR criteria:
1. 41/43 reviews clearly pre-specified their design; for two
reviews, this was unclear, with no reference made/access given to
pre-specified published protocols (Seger 2009; Soll 2000);
2. 40/43 reviews clearly reported duplicate study selection and
data extraction; for three reviews, it was unclear as to whether
two independent review authors were involved in study selection
and data extraction (Halliday 2003; Osborn 2001; Soll 2000);
3. 42/43 reviews performed a comprehensive literature search;
one review searched only one electronic database (in addition to
electronic searching and handsearching of meeting abstracts)
(Finer 2006);
4. all reviews considered grey literature;
5. 41/43 reviews provided lists of both included and excluded
studies; two reviews did not mention excluded studies and
therefore provided no list (Henderson-Smart 2010; Shah 2007);
6. all reviews provided the characteristics of included studies;
7. all reviews assessed and documented the scientific quality of
included studies;
8. 42/43 reviews clearly used scientific quality of included
studies appropriately in formulating conclusions; one review did
not clearly incorporate the quality of included studies into the
conclusions (Barrington 2010);
9. 35/38 reviews combined the findings of studies using
appropriate methods; three reviews provided no/limited
discussion and/or exploration of substantial statistical
heterogeneity present in some review meta-analyses and did not
use a random-effects model (Halliday 2003; Okwundu 2012;
Soll 2000); for five reviews, review authors found this item to be
’not applicable’ and conducted no meta-analyses (Almadhoob
2015; Jones 2009; More 2016; Osborn 2007b; Shah 2007);
10. 18/43 reviews assessed the likelihood of publication bias; 25
reviews did not assess publication bias likelihood and/or did not
pre-specify methods to be used if 10 or more trials were included
in meta-analyses (AlFaleh 2014; Barrington 2010; Cools 2015;
Finer 2006; Fowlie 2010; Halliday 2003; Henderson-Smart
2010; Henderson-Smart 2010b; Henderson-Smart 2010c; Ho
2015; Hunt 2010; Jacobs 2013; Jones 2009; Kamlin 2003;
Okwundu 2012; Osborn 2001; Osborn 2004; Osborn 2007;
Seger 2009; Shah 2007; Soll 2000; Soll 2010; Spittle 2015; Tan
2005; Wheeler 2010);
11. 2/43 reviews clearly reported conflicts of interest/potential
sources of support for both the review and the included studies
(Jacobs 2013; Weston 2016); the remaining 41 reviews did not
report conflicts of interests/sources of support for the included
studies (AlFaleh 2014; Almadhoob 2015; Barrington 2010;
Chaudhari 2012; Cleminson 2015; Conde-Agudelo 2016; Cools
2015; Darlow 2016; Doyle 2014; Doyle 2014b; Finer 2006;
Fowlie 2010; Halliday 2003; Henderson-Smart 2010;
Henderson-Smart 2010b; Henderson-Smart 2010c; Ho 2015;
Howlett 2015; Hunt 2010; Jones 2009; Kamlin 2003;
Moe-Byrne 2016; More 2016; Ohlsson 2014; Ohlsson 2015;
Okwundu 2012; Osborn 2001; Osborn 2004; Osborn 2007;
Osborn 2007b; Seger 2009; Shah 2007; Shah 2012; Smit 2013;
Soll 2000; Soll 2010; Spittle 2015; Tan 2005; Wheeler 2010;
Whyte 2011; Young 2016).
See Table 4 for further details.
With regards to ROBIS domains:
1. 40 reviews were considered to have ’low risk of bias’ across
study eligibility criteria, data collection and study appraisal, and
synthesis and findings domains, and 39 were considered to have
’low risk of bias’ for the identification and selection of studies
domain;
2. three reviews were considered to have ’unclear risk of bias’
for the study eligibility criteria domain; as above, two reviews
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provided no reference/access to pre-specified published protocols
(Seger 2009; Soll 2000); and one review made a notable protocol
deviation related to the inclusion criteria (Almadhoob 2015);
3. three reviews were considered to have ’unclear risk of bias’
for both the identification and selection of studies domain and
the data collection and study appraisal domain because review
authors did not clearly specify whether two independent review
authors were involved in selection of studies, data collection, and
study appraisal (Halliday 2003; Osborn 2001; Soll 2000); one
further review was considered to have ’unclear risk of bias’ for the
identification and selection of studies domain, as above, owing to
concern regarding comprehensiveness of the search (Finer 2006);
and
4. finally, three reviews were considered to have ’unclear risk of
bias’ for the synthesis and findings domain owing to the presence
of substantial statistical heterogeneity (with use of a fixed-effect
model) in some review meta-analyses that was not clearly
explained/explored (Halliday 2003; Okwundu 2012; Soll 2000).
See Table 5 for additional details.
Overall, all 41 included reviews were judged to be of ’high quality’
according to AMSTAR (with scores ranging from 8 to 11 out
of 11, or from 7 to 9 out of 10), and two were judged to be of
’moderate quality’ (with scores of 6 and 7 out of 11) (Halliday
2003; Soll 2000); according to ROBIS, 40 reviews were judged
to have ’low risk of bias’, and three to have ’unclear risk of bias’
(Finer 2006; Osborn 2001; Soll 2000).
Effect of interventions
Below, we have summarised the main results of the included re-
views by categorising their findings according to the framework
discussed under Data synthesis, organised by groups of neonates
and ’Neonatal care’ topics.
For further details, including outcome definitions and judgements
supporting the quality of the evidence for each outcome, see Table
6 (cerebral palsy); Table 7 (cerebral palsy: subgroup or sensitivity
analyses); Table 8 (cerebral palsy or death); Table 9 (severity of
cerebral palsy); Table 10 (other composite outcomes that include
cerebral palsy); and Table 11 (motor dysfunction).
Interventions for neonates with perinatal asphyxia or
evidence of neonatal encephalopathy
Effective interventions: high-quality evidence of effectiveness
Neonatal care: treating asphyxia
High-quality evidence from the Jacobs 2013 review showed a re-
duction in cerebral palsy among survivors assessed at 18 to 24
months following therapeutic hypothermia versus standard care
for newborns with hypoxic-ischaemic encephalopathy (risk ratio
(RR) 0.66, 95% confidence interval (CI) 0.54 to 0.82; seven trials;
881 children) (Table 6). Subgroup analysis based on method of
cooling (e.g. selective head cooling with mild hypothermia, whole
body cooling) showed no clear subgroup differences (Chi² = 0.01,
df = 1 (P = 0.93), I² = 0.0%) (Table 7). Low-quality evidence from
Jacobs 2013 also showed no clear differences for cerebral palsy at
six to seven years following therapeutic hypothermia versus stan-
dard care (RR 0.60, 95% CI 0.31 to 1.18; one trial; 121 children)
(Table 6). High-quality evidence from Jacobs 2013 showed reduc-
tions in death or major disability among survivors assessed at 18 to
24 months (RR 0.75, 95% CI 0.68 to 0.83; eight trials; 1344 chil-
dren), major neurodevelopmental disability at 18 to 24 months
(RR 0.77, 95% CI 0.63 to 0.94; eight trials; 1344 children), ma-
jor neurodevelopmental disability among survivors assessed at 18
to 24 months (RR 0.67, 95% CI 0.55 to 0.80; eight trials; 917
children), and neuromotor delay among survivors assessed at 18
to 24 months (RR 0.75, 95% CI 0.59 to 0.94; six trials; 657
children) (Table 10; Table 11). Low-quality evidence suggested
no clear differences for death or moderate to severe disability at
six to seven years (RR 0.81, 95% CI 0.64 to 1.04; one trial; 190
children) nor for moderate to severe disability at six to seven years
(RR 0.92, 95% CI 0.57 to 1.48; one trial; 119 children) following
therapeutic hypothermia versus standard care (Table 10).
No conclusions possible: very low-quality evidence
Neonatal care: treating asphyxia
Very low-quality evidence from the Young 2016 review suggested
no clear differences for cerebral palsy at three to six years with
barbiturates (phenobarbital) versus conventional therapy for pre-
vention of morbidity and mortality following perinatal asphyxia
(RR 0.58, 95% CI 0.19 to 1.70; two trials; 69 children) (Table 6).
Very low-quality evidence from Young 2016 also suggested a re-
duction in death or major neurodevelopmental disability at three
years (RR 0.33, 95% CI 0.14 to 0.78; one trial; 31 children) and
in major neurodevelopmental disability at three years (RR 0.24,
95% CI 0.06 to 0.92; one trial; 31 children) following barbiturates
(phenobarbital) versus conventional therapy (Table 10).
Very low-quality evidence from the Chaudhari 2012 review sug-
gested no clear differences for severe quadriplegia among survivors
at 18 months or at four to eight years following allopurinol ver-
sus placebo or no drug for preventing mortality and morbidity
among newborn infants with hypoxic-ischaemic encephalopathy
(RR 0.59, 95% CI 0.28 to 1.27; three trials; 73 children) (Table 9).
Very low-quality evidence from Chaudhari 2012 also suggested no
clear differences for death or severe neurodevelopmental disability
among survivors at 18 months or at four to eight years following
allopurinol versus placebo (RR 0.78, 95% CI 0.56 to 1.08; three
trials; 110 children) (Table 10).
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Interventions for neonates born preterm and/or at
low or very low birthweight
Possibly effective interventions: moderate-quality evidence
of effectiveness
Neonatal care: mechanical ventilation
Moderate-quality evidence from the Henderson-Smart 2010 re-
view showed a reduction in cerebral palsy at 18 to 21 months’
corrected age with prophylactic methylxanthines (caffeine) versus
placebo for endotracheal extubation in preterm infants (RR 0.54,
95% CI 0.32 to 0.92; one trial; 644 children) (Table 6). Moderate-
quality evidence from Henderson-Smart 2010 also showed a re-
duction in death or major disability at 18 to 21 months’ corrected
age with prophylactic methylxanthines (caffeine) versus placebo
(RR 0.85, 95% CI 0.73 to 0.99; one trial; 676 children) (Table
10).
Probably ineffective interventions: moderate-quality
evidence of harm
Neonatal care: preventing bronchopulmonary dysplasia
Moderate-quality evidence from the Doyle 2014b review showed
an increase in cerebral palsy at 11 months to seven to nine years
(RR 1.45, 95% CI 1.06 to 1.98; 12 trials; 1452 children) and in
cerebral palsy among survivors assessed at 11 months to seven to
nine years (RR 1.50, 95% CI 1.13 to 2.00; 12 trials; 959 children)
following early (less than eight days of age) postnatal corticos-
teroids versus placebo or no treatment for preventing chronic lung
disease in preterm infants (Table 6). Subgroup analysis based on
type of corticosteroid used (i.e. dexamethasone, hydrocortisone)
suggested no clear subgroup differences for cerebral palsy at 11
months to seven to nine years (Chi² = 2.96, df = 1 (P = 0.09),
I² = 66%); however, a possible subgroup difference was identi-
fied that was based on the type of corticosteroid used for cerebral
palsy among survivors assessed at 11 months to seven to nine years
(Chi² = 3.99, df = 1 (P = 0.05), I² = 75%), with an increase in risk
specifically observed in the dexamethasone (not the hydrocorti-
sone) subgroup (Table 7). Moderate-quality evidence from Doyle
2014b also showed no clear differences for cerebral palsy or death
at 11 months to seven to nine years (RR 1.09, 95% CI 0.92 to
1.25; 12 trials; 1452 children) (Table 8) nor for death or major
neurosensory disability at 18 to 22 months to 53 months (RR
1.05, 95% CI 0.93 to 1.17; seven trials; 1233 children) (Table
10); Bayley Scales of Infant Development Psychomotor Develop-
mental Index less than minus two standard deviations below the
mean at 18 to 22 months or at 25 months (RR 1.17, 95% CI
0.85 to 1.60; three trials; 842 children); or Bayley Scales of Infant
Development Psychomotor Developmental Index less than minus
two standard deviations below the mean among tested survivors
at 18 to 22 months or at 25 months (RR 1.17, 95% CI 0.87 to
1.57; three trials; 528 children) with early postnatal corticosteroids
versus placebo or no treatment (Table 11). Low-quality evidence
from Doyle 2014b suggested no clear differences between major
neurosensory disability at 18 to 22 months to 53 months (RR
1.16, 95% CI 0.94 to 1.43; seven trials; 1233 children) and ma-
jor neurosensory disability among survivors examined at 18 to 22
months to 53 months (RR 1.14, 95% CI 0.94 to 1.38; seven trials;
799 children) with early postnatal corticosteroids versus placebo
or no treatment (Table 10).
Probably ineffective interventions: moderate-quality
evidence of lack of effectiveness
Neonatal care: preventing haemorrhage:
periventricular/intraventricular
Moderate-quality evidence from the Hunt 2010 review showed
no clear differences for cerebral palsy among surviving children
available for follow-up at two years up to 3.5 to 4.2 years follow-
ing ethamsylate versus placebo for prevention of morbidity and
mortality in preterm or very low birthweight infants (RR 1.13,
95% CI 0.64 to 2.00; three trials; 532 children) (Table 6), nor
on further subgroup analysis of infants born at less than 31 com-
pleted weeks at less than 1500 grams (RR 0.82, 95% CI 0.38 to
1.75; two trials; 328 children) (Table 7). Moderate-quality evi-
dence from Hunt 2010 also showed no clear differences for neu-
rodevelopmental disability at two years of age among surviving
children available for follow-up (RR 0.79, 95% CI 0.53 to 1.17;
three trials; 532 children), and low-quality evidence suggested no
clear differences for death or any disability by two years of age
among children with known outcome at any point in time (RR
0.96, 95% CI 0.82 to 1.11; seven trials; 1334 children) following
ethamsylate versus placebo (Table 10).
Neonatal care: fluid therapy
Moderate-quality evidence from the Osborn 2004 review showed
no clear differences for cerebral palsy among survivors at two years
following volume versus no treatment (RR 0.76, 95% CI 0.48
to 1.20; one trial; 604 children) and gelatin versus fresh frozen
plasma (RR 0.94, 95% CI 0.52 to 1.69; one trial; 399 children)
for prevention of morbidity and mortality in very preterm infants
(Table 6). Formal subgroup analyses in Osborn 2004 were not
applicable based on timing of treatment, types of infants enrolled,
or methodological quality (with the one included trial for this out-
come using early treatment (less than 24 hours of age) in unse-
lected preterm infants (not selected on the basis of cardiovascular
compromise) and providing complete follow-up for neurodevel-
opmental outcomes (RR 0.76, 95% CI 0.48 to 1.20; one trial;
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604 children, as in main analysis)) (Table 7). Moderate-quality
evidence from Osborn 2004 also showed no clear differences be-
tween volume versus no treatment for severe neurodevelopmental
disability among survivors at two years (RR 0.80, 95% CI 0.52 to
1.23; one trial; 604 children) or for death or severe neurodevel-
opmental disability among survivors at two years (RR 1.00, 95%
CI 0.80 to 1.24; one trial; 776 children); or between gelatin ver-
sus fresh frozen plasma for severe neurodevelopmental disability
among survivors at two years (RR 0.99, 95% CI 0.57 to 1.72;
one trial; 399 children) or for death or severe neurodevelopmental
disability among survivors at two years (RR 1.11, 95% CI 0.86 to
1.43; one trial; 518 children) (Table 10).
Neonatal care: preventing/treating patent ductus arteriosus
Moderate-quality evidence from the Fowlie 2010 review showed
no clear differences for cerebral palsy at 18 to 54 months (RR
1.04, 95% CI 0.77 to 1.40; four trials; 1372 children) or at eight
years (RR 1.24, 95% CI 0.59 to 2.62; one trial; 304 children) fol-
lowing prophylactic indomethacin versus placebo for preventing
mortality and morbidity in preterm infants (Table 6). Moderate-
quality evidence from Fowlie 2010 also showed no clear differ-
ences for death or severe neurodevelopmental disability at 18 to
36 months following prophylactic indomethacin versus placebo
(RR 1.02, 95% 0.90 to 1.15; three trials; 1491 children) (Table
10).
Neonatal care: treating respiratory distress syndrome
Moderate-quality evidence from the Soll 2000 review showed no
clear differences in cerebral palsy among survivors examined at one
year (RR 0.76, 95% CI 0.55 to 1.05; five trials; 1557 children)
(Table 6) nor in moderate to severe cerebral palsy among survivors
examined at one year following synthetic surfactant versus placebo
for respiratory distress syndrome in preterm infants (RR 0.75,
95% CI 0.48 to 1.16; five trials; 1557 children) (Table 9).
Neonatal care: preventing jaundice
Moderate-quality evidence from the Okwundu 2012 review
showed no clear differences for cerebral palsy in all infants (birth-
weight < 2500 grams) at one year or at 18 months following pro-
phylactic phototherapy versus standard care (starting photother-
apy when serum bilirubin reached a pre-specified level) for pre-
venting jaundice in preterm or low birthweight infants (RR 0.96,
95% CI 0.50 to 1.85; two trials; 756 children) (Table 6). Very
low-quality evidence suggested no clear differences for cerebral
palsy among all infants (birthweight < 1000 grams) at 18 months
(RR 0.29, 95% CI 0.04 to 2.27; one trial; 30 children) (Table 6).
Okwundu 2012 reported in text that “Secondary reports emanat-
ing from Brown 1985 at six-year follow-up also showed that there
was no significant difference in the rate of cerebral palsy between
the phototherapy and control group” (not graded). Moderate-
quality evidence from Okwundu 2012 did however show a reduc-
tion in neurodevelopmental impairment at 18 to 22 months fol-
lowing prophylactic phototherapy versus standard care (RR 0.85,
95% CI 0.74 to 0.99; one trial; 1804 children) (Table 10).
No conclusions possible: low-quality evidence
Neonatal care: preventing/treating blood disorders
Low-quality evidence from Ohlsson 2014 suggested no clear dif-
ferences for cerebral palsy at 18 to 22 months’ corrected age in
children examined following darbepoetin alfa versus placebo for
preventing red blood cell transfusion in preterm and/or low birth-
weight infants (RR 0.08, 95% CI 0.00 to 1.40; one trial; 51 chil-
dren) (Table 6).
Low-quality evidence from Whyte 2011 suggested no clear dif-
ferences for cerebral palsy at 18 to 21 months’ follow-up among
survivors following transfusion at a restrictive (low haemoglobin)
versus a liberal (high haemoglobin) threshold for preventing mor-
bidity and mortality in very low birthweight infants (RR 1.29,
95% CI 0.55 to 3.03; one trial; 335 children) (Table 6). Low-qual-
ity evidence from Whyte 2011 also suggested no clear differences
for any neurosensory impairment at 18 to 21 months’ follow-up
among survivors (RR 1.31, 95% CI 0.90 to 1.90; one trial; 328
children) nor for death or severe morbidity at 18 to 21 months’
follow-up (Mental Development Index component defined < 70)
(RR 1.17, 95% CI 0.94 to 1.47; one trial; 421 children); however,
moderate-quality evidence showed a possible increase in death or
severe morbidity at 18 to 21 months’ follow-up (Mental Devel-
opment Index component defined < 85) (RR 1.21, 95% CI 1.01
to 1.44; one trial; 421 children) with transfusion at a restrictive
(low haemoglobin) versus a liberal (high haemoglobin) threshold
(Table 10).
Neonatal care: nitric oxide
Low-quality evidence from Barrington 2010 suggested no clear
differences following inhaled nitric oxide versus placebo or no
treatment for respiratory failure in preterm infants for cerebral
palsy at 18 to 22 months (trial entry before three days based on
oxygenation) (RR 1.85, 95% CI 0.93 to 3.71; two trials; 209 chil-
dren); cerebral palsy at two years’ corrected age or at 30 months
(trial entry after three days based on bronchopulmonary dysplasia
risk) (RR 1.10, 95% CI 0.54 to 2.23; two trials; 498 children); or
cerebral palsy at one or two years’ corrected age (trials of routine
use in intubated preterm infants) (RR 0.94, 95% CI 0.51 to 1.70;
two trials; 593 children) (Table 6). Low- to very low-quality ev-
idence from Barrington 2010 also suggested no clear differences
for neurodevelopmental disability at 18 to 22 months (trial en-
try before three days based on oxygenation) (RR 1.05, 95% CI
0.78 to 1.40; two trials; 208 children), neurodevelopmental dis-
ability at two years’ corrected age or at 30 months (trial entry after
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three days based on bronchopulmonary dysplasia risk) (RR 0.90,
95% CI 0.74 to 1.09; two trials; 498 children), or neurodevelop-
mental disability at one or two years’ corrected age (trials of rou-
tine use in intubated preterm infants) (RR 0.90, 95% CI 0.72 to
1.13; two trials; 593 children) following inhaled nitric oxide versus
placebo or no treatment (Table 10). Moderate-quality evidence
from Barrington 2010 also showed no clear differences for Bay-
ley Mental or Psychomotor Developmental Index less than minus
two standard deviations below the mean at two years’ corrected
age (trials of routine use in intubated preterm infants) following
inhaled nitric oxide versus placebo (RR 0.56, 95% CI 0.33 to
0.93; one trial; 138 children) (Table 11).
Neonatal care: preventing/treating apnoea
Low-quality evidence from the Henderson-Smart 2010b review
suggested no clear differences for cerebral palsy at 18 to 21 months’
corrected age following caffeine versus placebo for treatment of
apnoea in preterm infants (RR 0.60, 95% CI 0.29 to 1.25;
one trial; 729 children) (Table 6). Low-quality evidence from
Henderson-Smart 2010b also suggested no clear differences in
death or major disability at 18 to 21 months’ corrected age fol-
lowing caffeine versus placebo (RR 0.85, 95% CI 0.71 to 1.01;
one trial; 767 children) (Table 10).
Low-quality evidence from the Henderson-Smart 2010c review
suggested no clear differences for cerebral palsy at 18 to 21 months’
corrected age following caffeine versus placebo for prevention
of apnoea in preterm infants (RR 1.03, 95% CI 0.43 to 2.49;
one trial; 415 children) (Table 6). Low-quality evidence from
Henderson-Smart 2010c also suggested no clear differences in
death or major disability at 18 to 21 months’ corrected age fol-
lowing caffeine versus placebo (RR 1.00, 95% CI 0.80 to 1.24;
one trial; 423 children) (Table 10).
Neonatal care: preventing respiratory distress syndrome
Low-quality evidence from the Soll 2010 review suggested no clear
differences for cerebral palsy at one to two years following prophy-
lactic protein-free synthetic surfactant versus placebo for prevent-
ing morbidity and mortality in preterm infants (RR 0.93, 95% CI
0.64 to 1.33; four trials; 670 children) (Table 6). Subgroup analy-
ses were conducted that were based on surfactant product (Exosurf
Neonatal, DPPC/HDL; Burroughs Wellcome, Research Triangle
Park, North Carolina, USA); however, formal tests for subgroup
differences were not applied in the review (Table 7). Low-quality
evidence from Soll 2010 also suggested no clear differences for
moderate or severe cerebral palsy at one or two years following
prophylactic protein-free synthetic surfactant versus placebo (RR
0.92, 95% CI 0.53 to 1.59; four trials; 670 children) (Table 9).
Neonatal care: mechanical ventilation
Low-quality evidence from the Wheeler 2010 review suggested no
clear differences for severe disability at six to 18 months and at 22
months (RR 0.86, 95% CI 0.47 to 1.59; two trials; 209 children),
for severe disability at 22 months or at death (RR 0.54, 95% CI
0.27 to 1.06; one trial; 109 children) (Table 10), and for gross
motor developmental issues (RR 1.00, 95% CI 0.47 to 2.14; one
trial; 128 children) (Table 11) following volume-targeted versus
pressure-limited ventilation in the neonate.
Neonatal care: preventing/treating bronchopulmonary
dysplasia
Low-quality evidence from the Doyle 2014 review suggested no
clear differences for cerebral palsy at one to three years (RR 1.06,
95% CI 0.76 to 1.50; 14 trials; 876 children), cerebral palsy at one
to three years among survivors assessed (RR 1.05, 95% CI 0.75 to
1.47; 14 trials; 631 children), cerebral palsy at latest age reported
(one year up to 17 years) (RR 1.12, 95% CI 0.79 to 1.60; 15
trials; 855 children), or cerebral palsy at latest age reported among
survivors assessed (one year up to 17 years) (RR 1.12, 95% CI
0.79 to 1.58; 15 trials; 591 children) following late (more than
seven days of age) postnatal corticosteroids versus placebo or no
treatment for chronic lung disease in preterm infants (Table 6).
Low-quality evidence from Doyle 2014 also suggested no clear
differences for cerebral palsy or death at one to three years (RR
0.92, 95% CI 0.76 to 1.12; 14 trials; 876 children), cerebral palsy
or death at latest age reported (one year up to 17 years) (RR 0.95,
95% CI 0.77 to 1.16; 15 trials; 855 children) (Table 8), major
neurosensory disability at one year corrected age up to 11 years
(RR 1.17, 95% CI 0.85 to 1.60; eight trials; 655 children), major
neurosensory disability among survivors assessed at one year cor-
rected age up to 11 years (RR 1.10, 95% CI 0.81 to 1.50; eight
trials; 480 children), death or major neurosensory disability at one
year corrected age up to 11 years (RR 1.10, 95% CI 0.81 to 1.50;
eight trials; 655 children) (Table 10), Bayley Scales of Infant De-
velopment Psychomotor Development Index less than minus two
standard deviations below the mean at one year corrected age (RR
0.78, 95% CI 0.34 to 1.80; one trial; 118 children), or Bayley
Scales of Infant Development Psychomotor Development Index
less than minus two standard deviations below the mean among
survivors assessed at one year corrected age (RR 0.67, 95% CI
0.30 to 1.50; one trial; 90 children) (Table 11) with late postnatal
corticosteroids versus placebo or no treatment.
Low-quality evidence from the Darlow 2016 review suggested no
clear differences for neurodevelopmental impairment at 18 to 24
months following supplemental vitamin A versus a sham injection
to prevent mortality and short- and long-term morbidity in very
low birthweight infants (RR 0.89, 95% CI 0.74 to 1.08; one trial;
538 children) (Table 10). Moderate-quality evidence also showed
no clear differences for death or neurodevelopmental impairment
at 18 to 24 months following supplemental vitamin A versus a
sham injection (RR 0.92, 95% CI 0.81 to 1.05; one trial; 687
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children) (Table 10).
Neonatal care: preventing necrotising enterocolitis
Low-quality evidence from the Shah 2007 review suggested no
clear differences for cerebral palsy at 36 months’ post-menstrual
age following arginine supplementation versus placebo for pre-
vention of necrotising enterocolitis in preterm infants (RR 0.88,
95% CI 0.21 to 3.80; one trial; 135 children) (Table 6). Low-
quality evidence from Shah 2007 also suggested no clear differ-
ences for major neurodevelopmental disability at 36 months’ post-
menstrual age following arginine supplementation versus placebo
(RR 0.65, 95% CI 0.23 to 1.83; one trial; 132 children) (Table
10).
Neonatal care: preventing/treating fungal infection
Low-quality evidence from the Cleminson 2015 review suggested
no clear differences for cerebral palsy at 18 to 22 months post
term following use of a systemic antifungal agent versus placebo to
prevent mortality and morbidity in very low birthweight infants
(RR 0.96, 95% CI 0.45 to 2.03; one trial; 219 children) (Table
6). Low-quality evidence from Cleminson 2015 also suggested no
clear differences for neurodevelopmental impairment (composite)
at 18 to 22 months following use of a systemic antifungal agent
versus placebo (RR 1.13, 95% CI 0.71 to 1.81; one trial; 171
children) (Table 10).
Neonatal care: parenteral feeding
Moe-Byrne 2016 assessed glutamine supplementation versus
placebo to prevent morbidity and mortality in preterm infants and
reported the following: “van den Berg 2005 reported neurodevel-
opmental outcomes for infants aged two years post term. Out-
comes assessed included...incidence of cerebral palsy... No signif-
icant differences between the glutamine and the control groups
were reported for any of these individual outcomes” (not graded)
(Table 6). Low-quality evidence from the Moe-Byrne 2016 review
also suggested no clear differences for neurodevelopmental im-
pairment at two years post term following glutamine supplemen-
tation versus placebo (RR 1.07, 95% CI 0.59 to 1.92; one trial;
72 children) (Table 10).
Neonatal care: other
Low-quality evidence from both the Osborn 2001 and Osborn
2007 reviews suggested no clear differences for cerebral palsy at
5.7 years following prophylactic thyroid hormones versus placebo
for prevention of morbidity and mortality in preterm infants (RR
0.72, 95% CI 0.28 to 1.84; one trial; 156 children) (Table 6). In
Osborn 2007, subgroup analyses based on dosing strategy, timing,
and methodological quality were not possible for this outcome,
with the one included trial using T4 8 mcg/kg/d, on days 1 to 42,
commencing within 48 hours, and being of adequate methodolog-
ical quality (Table 7). Low-quality evidence from both Osborn
2001 and Osborn 2007 also suggested no clear differences for
cerebral palsy or death at 5.7 years following prophylactic thyroid
hormones versus placebo (RR 0.70, 95% CI 0.43 to 1.14; one
trial; 200 children) (Table 8).
Low-quality evidence from the Conde-Agudelo 2016 review sug-
gested no clear differences for cerebral palsy at 12 months’ cor-
rected age following kangaroo mother care versus conventional
neonatal care to reduce morbidity and mortality among low birth-
weight infants (RR 0.65, 95% CI 0.21 to 2.02; one trial; 588
children) (Table 6).
Low-quality evidence from the Spittle 2015 review suggested no
clear differences for cerebral palsy at 18 months to six years fol-
lowing early developmental intervention versus standard follow-
up post hospital discharge to prevent motor and cognitive impair-
ment in preterm infants (RR 0.82, 95% CI 0.52 to 1.27; seven
trials; 985 children) (Table 6). Subgroup analyses based on com-
mencement of intervention (inpatient, post hospital discharge),
focus of intervention (parent-infant relationship and infant devel-
opment, infant development), and quality of studies (high-quality
studies, lower-quality studies) were performed for this outcome;
however, formal subgroup interaction tests were not applied in the
review (Table 7). Low-quality evidence from Spittle 2015 also sug-
gested no clear differences for motor outcome at school age (five
years) following early developmental intervention versus standard
follow-up (RR 1.12, 95% CI 0.87 to 1.44; two trials; 333 chil-
dren) (Table 11).
No conclusions possible: very low-quality evidence
Neonatal care: preventing haemorrhage:
periventricular/intraventricular
Very low-quality evidence from the Smit 2013 review suggested
no clear differences for severe neurodevelopmental impairment at
27 months (RR 1.44, 95% CI 0.41 to 5.04; one trial; 101 chil-
dren) nor for mild neurodevelopmental impairment at 27 months
(RR 0.57, 95% CI 0.15 to 2.17; one trial; 101 children) following
phenobarbital versus no treatment for prevention of intraventric-
ular haemorrhage in preterm infants (Table 10).
Neonatal care: treating hypotension
Very low-quality evidence from the Osborn 2007b review sug-
gested no clear differences for cerebral palsy at three years among
survivors assessed following dobutamine versus dopamine in
preterm infants with low superior vena cava flow (RR 0.16, 95%
CI 0.01 to 2.64; one trial; 13 children) (Table 6). Very low-quality
evidence from Osborn 2007b also suggested no clear differences
for disability at three years among survivors (RR 0.10, 95% 0.01
to 1.56; one trial; 13 children), for death or disability at three years
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(RR 0.79, 0.57 to 1.11; one trial; 37 children), or for death or
disability at latest follow-up (one to three years) (RR 0.95, 95% CI
0.66 to 1.38; one trial; 41 children) following dobutamine versus
dopamine (Table 10).
Neonatal care: treating patent ductus arteriosus
Very low-quality evidence from Ohlsson 2015 suggested no clear
differences for moderate or severe cerebral palsy at 18 to 24 months
following oral ibuprofen versus intravenous ibuprofen for treat-
ment of patent ductus arteriosus in preterm or low birthweight
(or both) infants (RR 1.35, 95% CI 0.24 to 7.48; one trial; 57
children) (Table 6).
Neonatal care: preventing blood disorders
Very low-quality evidence from Ohlsson 2014 suggested no clear
differences for cerebral palsy at 18 to 22 months’ corrected age
among children examined following erythropoietin versus placebo
for preventing red blood cell transfusion in preterm and/or low
birthweight infants (RR 0.66, 95% CI 0.31 to 1.37; two trials; 153
children) (Table 6). Very low-quality evidence from Ohlsson 2014
also suggested no clear differences for any neurodevelopmental
impairment at 18 to 22 months’ corrected age among children
examined (RR 0.97, 95% CI 0.62 to 1.51; one trial; 99 children)
(Table 10) nor for Psychomotor Developmental Index less than
70 at 18 to 22 months’ corrected age among children examined
(RR 2.33, 95% CI 0.98 to 5.53; one trial; 90 children) following
erythropoietin versus placebo (Table 11).
Neonatal care: preventing/treating respiratory distress
syndrome
Very low-quality evidence from Howlett 2015 suggested no clear
differences for major neural developmental impairment at one year
corrected age (RR 0.53, 95% CI 0.24 to 1.16; one trial; 169 chil-
dren) (Table 10) nor for minor neural developmental impairment
at one year corrected age (RR 0.84, 95% CI 0.38 to 1.86; one trial;
169 children) following inositol supplementation (repeat doses)
versus placebo in preterm infants at risk for or having respiratory
distress syndrome (Table 11).
Very low-quality evidence from Seger 2009 suggested no clear
differences for cerebral palsy at one and two years’ corrected age
following animal-derived surfactant extract versus no treatment for
respiratory distress syndrome (RR 0.88, 95% CI 0.34 to 2.27; one
trial; 73 children) (Table 6). Subgroup analysis based on surfactant
product for this outcome was not applicable, with the one included
trial using porcine surfactant extract (Table 7). Very low-quality
evidence from Seger 2009 also suggested no clear differences for
major developmental disability among survivors at one and two
years’ corrected age following animal-derived surfactant extract
versus no treatment (RR 3.30, 95% 0.14 to 26.78; one trial; 73
children) (Table 10).
Neonatal care: mechanical ventilation
Very low-quality evidence from the Ho 2015 review suggested no
clear differences for cerebral palsy at nine to 15 years following
continuous distending pressure versus standard care for respiratory
distress in preterm infants (RR 5.0, 95% CI 0.26 to 97.37; one
trial; 36 children) (Table 6). Subgroup analysis based on type of
continuous distending pressure was not possible for this outcome,
with the only included trial using continuous negative pressure
(Table 7). Very low-quality evidence from Ho 2015 also suggested
no clear differences for death or severe disability at nine to 15 years
(RR 1.33, 95% CI 0.34, 5.17; one trial; 38 children), for severe
disability at nine to 15 years (RR 1.06, 95% CI 0.24 to 4.57;
one trial; 37 children), or for any disability at nine to 15 years
(RR 0.62, 95% CI 0.31 to 1.21; one trial; 37 children) following
continuous distending pressure versus standard care (Table 10).
Very low-quality evidence from the Kamlin 2003 review suggested
no clear differences for cerebral palsy among survivors at less than
33 weeks’ gestation, at birth, and at 18 months following long ver-
sus short inspiratory times among neonates receiving mechanical
ventilation (RR 2.9, 95% CI 0.97 to 8.65; one trial; 177 children)
(Table 6).
Neonatal care: preventing bronchopulmonary dysplasia
Very low-quality evidence from the Halliday 2003 review sug-
gested no clear differences for cerebral palsy at 12 months’ cor-
rected age up to 90 months (RR 1.03, 95% CI 0.47 to 2.24; four
trials; 204 children) nor for cerebral palsy among survivors assessed
at 12 months’ corrected age up to 90 months (RR 0.83, 95%
CI 0.39 to 1.74; four trials; 130 children) following moderately
early (between seven and 14 days of age) postnatal corticosteroids
versus placebo or no treatment for preventing chronic lung dis-
ease in preterm infants (Table 6). Very low-quality evidence from
Halliday 2003 also suggested no clear differences for cerebral palsy
or death at 12 months’ corrected age up to 90 months (RR 0.83,
95% CI 0.55 to 1.23; four trials; 204 children) (Table 8), for ma-
jor neurosensory disability at 15 months’ corrected age up to 90
months (RR 1.26, 95% CI 0.45 to 3.49; two trials; 96 children),
for major neurosensory disability among survivors assessed at 15
months’ corrected age up to 90 months (RR 0.89, 95% CI 0.38
to 2.10; two trials; 56 children), or for death or major neurosen-
sory disability at 15 months’ corrected age up to 90 months (RR
1.02, 95% CI 0.66 to 1.56; two trials; 96 children) with moder-
ately early postnatal corticosteroids versus placebo or no treatment
(Table 10).
Very low-quality evidence from the Shah 2012 review suggested
no clear differences in cerebral palsy at three years with early in-
haled corticosteroids versus placebo for preventing chronic lung
disease among ventilated very low birthweight preterm neonates
(RR 1.33, 95% CI 0.33 to 5.42; one trial; 56 children) (Table 6).
Very low-quality evidence from Shah 2012 also suggested no clear
differences for mean developmental index less than two standard
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deviations of the mean on the Bayley Scales of Infant Develop-
ment with early inhaled corticosteroids versus placebo (RR 1.25,
95% CI 0.37 to 4.17; one trial; 56 children) (Table 11).
Neonatal care: preventing necrotising enterocolitis
Very low-quality evidence from the AlFaleh 2014 review suggested
no clear differences for mental retardation and cerebral palsy at six
years following probiotics versus control (distilled water) for pre-
vention of necrotising enterocolitis in preterm infants (RR 1.02,
95% CI 0.15 to 6.94; one trial; 85 children) (Table 10).
Neonatal care: other
Very low-quality evidence from the Almadhoob 2015 review sug-
gested no clear differences for cerebral palsy at 18 to 22 months’
corrected age with use of silicone earplugs versus no earplugs in the
neonatal intensive care unit for preterm or very low birthweight
infants (RR 3.0, 95% CI 0.14 to 63.15; one trial; 14 children)
(Table 6).
No conclusions possible: not graded
Neonatal care: mechanical ventilation
The Cools 2015 review assessed elective high-frequency oscillatory
ventilation versus conventional ventilation for acute pulmonary
dysfunction in preterm infants. Cools 2015 did not perform a
meta-analysis for the outcome cerebral palsy, with age and methods
of assessment varying between studies, and rather reported the
results for three separate trials in text, as below (not graded) (Table
6).
1. “Neurodevelopmental status was assessed at 16 to 24
months’ corrected age in 77% of survivors of the HIFI 1989
study (185 HFOV and 201 CV) using Bayley psychometric tests
and central nervous system examinations... The rate of cerebral
palsy was 11% in both groups”.
2. “Moriette 2001 assessed neuromotor outcome at the
corrected age of two years in 192 of 212 survivors (90%) using a
physician questionnaire...the risk of spastic cerebral palsy was
significantly lower for infants ventilated with HFOV (4% versus
17%; OR 0.87, 95% CI 0.79 to 0.96), even after adjustment for
multiple factors. Survival without cerebral palsy was significantly
more likely in the HFOV group than in the CV group (OR
1.89, 95% CI 1.04 to 3.44)”.
3. “Sun 2014 assessed neurodevelopmental outcomes at 18
months’ corrected age in 145 infants of the HFOV group (84%
of survivors) and in 143 infants of the CV group (86% of
survivors). Cerebral palsy occurred significantly less in the
HFOV group (3% versus 10% in the CV group, P = 0.03)”.
Interventions for other specific groups of ’at risk’
neonates
No conclusions possible: low-quality evidence
Neonatal care: treating pulmonary hypertension
Low-quality evidence from the More 2016 review suggested no
clear differences for cerebral palsy at six months following use
of endothelin receptor antagonists versus placebo for persistent
pulmonary hypertension in term and late preterm infants (RR
0.09, 95% CI 0.00 to 1.61; one trial; 37 children) (Table 6).
Low-quality evidence from More 2016 also suggested no clear
differences for adverse neurological outcomes at six months with
use of endothelin receptor antagonists versus placebo (RR 0.07,
95% CI 0.00,1.20; one trial; 37 children) (Table 11).
Neonatal care: nitric oxide
Low-quality evidence from the Finer 2006 review suggested no
clear differences for cerebral palsy among survivors at 13 or 18 to
24 months following inhaled nitric oxide versus placebo for res-
piratory failure in infants born at or near term (RR 1.02, 95% CI
0.49 to 2.14; two trials; 299 children) (Table 6). Finer 2006 also
reported on an additional trial not included in the meta-analysis
for this outcome: “This group [Wessel 1996] has now published
follow up data, including neurodevelopmental outcomes, which
were obtained by telephone interview of 60 of the 83 survivors
of the original trial. The interview was conducted between one
and four years of age... Although cerebral palsy [was] reported it
is unclear how [it] was defined... It is not, therefore, possible to
add any of these data to the meta-analysis, but they do appear
to show no evidence of neurodevelopmental impairment due to
inhaled nitric oxide therapy” (not graded). Low-quality evidence
from Finer 2006 also suggested no clear differences for neurode-
velopmental disability among survivors at 13 or 18 to 24 months
(RR 0.97, 95% CI 0.66 to 1.44; two trials; 301 children) (Table
10) nor for Bayley Psychomotor Developmental Index more than
two standard deviations below the mean at 13 or 18 to 24 months
(RR 1.09, 95% CI 0.58 to 2.03; two trials; 283 children) (Table
11) following inhaled nitric oxide versus placebo.
No conclusions possible: very low-quality evidence
Neonatal care: resuscitation
Very low-quality evidence from the Tan 2005 review suggested
no clear differences for cerebral palsy among those followed up
at 18 to 24 months following room air versus 100% oxygen for
resuscitation of infants at birth (RR 1.34, 95% CI 0.55 to 3.24;
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one trial; 213 children) (Table 6). Very low-quality evidence from
Tan 2005 also suggested no clear differences in not walking among
those followed up at 18 to 24 months following room air versus
100% oxygen (RR 1.03, 95% CI 0.04 to 2.25; one trial; 213
children) (Table 11).
Neonatal care: nitric oxide
Very low-quality evidence from the Finer 2006 review suggested
no clear differences for cerebral palsy among survivors at 18 to
24 months following inhaled nitric oxide versus placebo for res-
piratory failure among infants with diaphragmatic hernias born
at or near term (RR 8.33, 95% CI 0.45 to 154.78; one trial; 22
children) (Table 6).
Neonatal care: treating herpes simplex
Very low-quality evidence from the Jones 2009 review suggested
no clear differences in cerebral palsy in central nervous system her-
pes simplex virus (HSV) neonatal infection up to three years by
HSV serotype: HSV-1 (no events, one trial, nine children) and
HSV-2 (RR 1.07, 95% CI 0.49 to 2.33; one trial; 14 children)
following acyclovir versus vidarabine for treatment of HSV infec-
tion in neonates (Table 6). Very low-quality evidence from Jones
2009 also suggested no clear differences for abnormal neurode-
velopment at approximately one year of age (RR 1.50, 95% 0.62
to 3.65; one trial; 56 children) nor for abnormal neurodevelop-
ment or death at approximately one year of age (RR 0.86, 95% CI
0.60 to 1.22; one trial; 56 children) following vidarabine versus
placebo; and abnormal neurodevelopment at approximately one
year of age (RR 0.82, 95% 0.50 to 1.34; one trial; 202 children) or
abnormal neurodevelopment or death at approximately one year
of age (RR 0.79, 95% CI 0.57 to 1.10; one trial; 202 children)
following acyclovir versus vidarabine (Table 10).
Neonatal care: treating hypoglycaemia
Very low-quality evidence from the Weston 2016 review suggested
no clear differences in cerebral palsy at age two years following
dextrose gel versus placebo for treatment of hypoglycaemia in new-
born infants (RR 5.16, 95% CI 0.25 to 106.12; one trial; 183
children) (Table 6). Very low-quality evidence from Weston 2016
also suggested no clear differences in major neurosensory disability
at two years (RR 6.27, 95% CI 0.77 to 51.03; one trial; 184 chil-
dren) nor in any developmental disability at two years (RR 1.11,
95% CI 0.75 to 1.63; one trial; 184 children) following dextrose
gel versus placebo (Table 10).
D I S C U S S I O N
Summary of main results
This review included 43 Cochrane Reviews with outcome data
for cerebral palsy available from meta-analyses of data from 96
randomised controlled trials (RCTs) involving 15,885 children.
Interventions for neonates with perinatal asphyxia or with ev-
idence of neonatal encephalopathy
1. Effective interventions (high-quality evidence of
effectiveness): High-quality evidence showed a reduction in
cerebral palsy following therapeutic hypothermia versus standard
care for newborns with hypoxic ischaemic encephalopathy.
2. No conclusions possible: very low-quality evidence: Very
low-quality evidence suggested no clear differences in cerebral
palsy following barbiturates (phenobarbital) versus conventional
therapy for prevention of morbidity and mortality following
perinatal asphyxia.
Interventions for neonates born preterm and/or at low or very
low birthweight
1. Possibly effective interventions (moderate-quality
evidence of effectiveness): Moderate-quality evidence showed a
reduction in cerebral palsy with prophylactic methylxanthines
(caffeine) versus placebo for endotracheal extubation in preterm
infants.
2. Probably ineffective interventions (moderate-quality
evidence of harm): Moderate-quality evidence showed an
increase in cerebral palsy and cerebral palsy among survivors
assessed following early (less than eight days) postnatal
corticosteroids versus control for preventing chronic lung disease
in preterm infants.
3. Probably ineffective interventions (moderate-quality
evidence of lack of effectiveness): Moderate-quality evidence
showed no clear differences in cerebral palsy following
ethamsylate versus placebo for prevention of morbidity and
mortality in preterm or very low birthweight infants; volume
versus no treatment and gelatin versus fresh frozen plasma for
prevention of morbidity and mortality in very preterm infants;
prophylactic indomethacin versus placebo or no drug for
preventing mortality and morbidity in preterm infants; synthetic
surfactant versus placebo for respiratory distress syndrome in
preterm infants; or prophylactic phototherapy versus standard
care (starting phototherapy when serum bilirubin reached a pre-
specified level) for preventing jaundice in preterm or low
birthweight infants.
4. No conclusions possible (low- to very low-quality
evidence): Low- to very low-quality evidence suggested no clear
differences for cerebral palsy following dobutamine versus
dopamine in preterm infants with low superior vena cava flow;
oral ibuprofen versus intravenous ibuprofen for treatment of
patent ductus arteriosus in preterm or low birthweight (or both)
infants; darbepoetin alfa versus placebo and erythropoietin
versus placebo for preventing red blood cell transfusion in
preterm and/or low birthweight infants; transfusion at a
restrictive (low haemoglobin) versus a liberal (high haemoglobin)
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threshold for preventing morbidity and mortality in very low
birthweight infants; inhaled nitric oxide versus placebo or no
treatment for respiratory failure in preterm infants; caffeine
versus placebo for treatment of apnoea in preterm infants;
caffeine versus placebo for prevention of apnoea in preterm
infants; animal-derived surfactant extract versus no treatment for
treatment of respiratory distress syndrome; prophylactic protein-
free synthetic surfactant versus placebo for preventing morbidity
and mortality in preterm infants; continuous distending pressure
versus standard care for respiratory distress in preterm infants;
long versus short inspiratory times in neonates receiving
mechanical ventilation; moderately early (between seven and 14
days of age) postnatal corticosteroids versus placebo or no
treatment for preventing chronic lung disease in preterm infants;
late (more than seven days of age) postnatal corticosteroids
versus placebo or no treatment for chronic lung disease in
preterm infants; early inhaled corticosteroids versus placebo for
preventing chronic lung disease in ventilated very low
birthweight preterm neonates; arginine supplementation versus
placebo for prevention of necrotising enterocolitis in preterm
infants; systemic antifungal agents versus placebo for prevention
of mortality and morbidity in very low birthweight infants;
prophylactic thyroid hormones versus placebo for prevention of
morbidity and mortality in preterm infants; use of silicone
earplugs versus no earplugs in the neonatal intensive care unit for
preterm or very low birthweight infants; kangaroo mother care
versus conventional neonatal care to reduce morbidity and
mortality in low birthweight infants; and early developmental
intervention versus standard follow-up post hospital discharge to
prevent motor and cognitive impairment in preterm infants.
Interventions for other specific groups of ’at risk’ neonates
1. No conclusions possible (low- to very low-quality
evidence): Low- to very low-quality evidence suggested no clear
differences for cerebral palsy following endothelin receptor
antagonists versus placebo for persistent pulmonary hypertension
in term and late preterm infants; inhaled nitric oxide versus
placebo for respiratory failure in infants born at or near term;
room air versus 100% oxygen for resuscitation of infants at birth;
acyclovir versus vidarabine for treatment of HSV infection in
neonates; and dextrose gel versus placebo for treatment of
hypoglycaemia in newborn infants.
Overall completeness and applicability of
evidence
This overview summarises published Cochrane Systematic Re-
views assessing neonatal interventions reporting on cerebral palsy
and does not consider interventions in the antenatal or intra-
partum period, which is the focus of a companion overview
(Shepherd 2016).
We were able to include only 43 reviews (representing less than
13% of the 343 Neonatal reviews in the Cochrane Database of
Systematic Reviews). We identified an additional 40 protocols that
have pre-specified cerebral palsy as a primary or secondary out-
come and will be considered for inclusion in future updates of the
overview when they have been published as full reviews. These
protocols plan to assess a variety of interventions (see Appendix 1:
’Ongoing reviews’). We were not able to include an additional 102
reviews assessing a wide range of neonatal interventions, although
we recognised the potential impact of the intervention of interest
on cerebral palsy (through pre-specifying cerebral palsy as a review
outcome); none of the included trials within these reviews reported
on this outcome. We summarised the main conclusions of these
reviews in Appendix 2 (’Reviews awaiting further classification’)
and will again consider them for inclusion in future updates of the
overview. In total, the 43 reviews included 454 RCTs involving
infants.
Although the 43 reviews in this overview included 454 randomised
trials involving over 63,977 infants, the body of evidence for our
review was substantially reduced by the fact that the included
reviews (and trials) did not report on our overview outcomes. For
our primary outcome - cerebral palsy - we included data from
meta-analyses of 35 reviews involving 96 randomised trials, or
only 21% of the trials within the included reviews.
The body of evidence for our secondary outcomes was further
reduced for the composite outcome including cerebral palsy (30
reviews), motor dysfunction (12 reviews), cerebral palsy or death
(five reviews), and severity of cerebral palsy (three reviews). None of
our included reviews reported specifically on type of cerebral palsy.
For most of our outcomes, reviews reported data from only one
or two trials, up to a maximum of 15 trials. Thus, review authors
often presented too few data to permit firm conclusions on effects
on cerebral palsy and on our secondary outcomes. For most of the
included reviews, data related to cerebral palsy were commonly
short term (reported at one to three years of age), and longer-
term follow-up was less commonly reported (although follow-up
to 17 years was reported). Included reviews often did not report
information regarding definitions nor criteria for cerebral palsy
diagnosis and assessment methods.
We did not attempt to make indirect comparisons to address ques-
tions concerning the relative performance of different neonatal
interventions. Rather we aimed to systematically consider all po-
tentially relevant interventions for their ability to contribute to
prevention of cerebral palsy. Within this overview, we did not at-
tempt to duplicate details of participants and interventions (and
control conditions) in individual trials. The reader may refer to
these individual reviews and trials for more information on these
factors. Further, the scope of this overview was limited to effects
of interventions on cerebral palsy (and a restricted number of pre-
specified secondary review outcomes). To assess effects (benefits or
harms) of the included interventions on other outcomes, readers
are encouraged to refer to the included Cochrane Reviews them-
selves. For example, although low-quality evidence presented in
this overview suggested no clear differences in cerebral palsy fol-
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lowing kangaroo mother care, the Conde-Agudelo 2016 review re-
ported moderate-quality evidence of benefit for outcomes includ-
ing mortality, severe infection/sepsis, hypothermia, weight gain,
and breastfeeding, and thus supports the use of kangaroo mother
care for low birthweight infants as an alternative to conventional
neonatal care (mainly in resource-limited settings). Similarly, al-
though very low-quality evidence in this overview suggested no
clear differences in cerebral palsy following dextrose gel for treat-
ment of hypoglycaemia, the Weston 2016 review found moderate-
quality evidence of benefit for outcomes including mother-infant
separation and breastfeeding, and thus concluded that oral dex-
trose therapy should be considered first-line treatment for neonates
with hypoglycaemia.
Although our overview could demonstrate high-quality evidence
of a reduction in cerebral palsy following therapeutic hypother-
mia for newborns with hypoxic-ischaemic encephalopathy (Jacobs
2013), the incidence of death and disability, including cerebral
palsy, remains high despite therapy. Thus, optimisation of hy-
pothermia strategies or adjuvant therapies is urgently needed to
further improve outcomes. A range of possible agents such as
antiepileptic drugs (including topiramate), xenon, erythropoietin,
melatonin, magnesium sulphate, and cord blood continue to be
under investigation (AAP 2014; Robertson 2012).
Quality of the evidence
We assessed almost all of the included reviews to be of high quality
and to have low risk of bias using the AMSTAR and ROBIS tools
(see Table 4: AMSTAR assessments for included reviews; and Table
5: ROBIS assessments for included reviews). Although these two
tools differ in their approaches to assessing review quality or risk of
bias, findings of these assessments were similar. All of the included
reviews assessed risk of bias of included randomised trials (most
used current guidance as outlined in Chapter 8 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011)),
and the quality of randomised trials was variable within and be-
tween reviews (see Table 3: Risk of bias assessments from included
reviews). Six of the 43 reviews used the GRADE approach to as-
sess the quality of evidence for overview outcomes (Darlow 2016;
Moe-Byrne 2016; More 2016; Okwundu 2012; Weston 2016;
Young 2016). For the other reviews, we used the GRADE system
to rate the quality of evidence and incorporated assessments of
study limitations (risk of bias) as reported by the review authors.
For our primary review outcome - cerebral palsy - evidence ranged
from very low to high quality, and for our secondary review out-
comes, quality of evidence varied similarly. Downgrading of qual-
ity was most commonly due to study limitations (risk of bias) and
imprecision (small sample sizes, low numbers of events, and wide
confidence intervals). Findings regarding the quality of evidence
for each outcome are set out in Table 6: Cerebral palsy; Table 8:
Cerebral palsy or death; Table 9: Severity of cerebral palsy; Table
10: Other composite outcomes that include cerebral palsy as a
component; and Table 11: Motor dysfunction.
Potential biases in the overview process
We were aware of risks of introducing bias at all stages of the
overview process, and we took several steps to minimise this, in-
cluding developing a Cochrane overview protocol. At least two
overview authors independently assessed reviews for inclusion,
carried out data extraction and quality assessment, and assessed
the quality of evidence using the GRADE approach. A potential
source of bias is related to the fact that one overview author (Nadia
Badawi) is an author of one of the included reviews (Jones 2009).
As pre-specified in our protocol, two other overview authors, who
were not authors of this review, carried out data extraction and
quality assessment for this review.
We undertook a comprehensive search of the Cochrane Database of
Systematic Reviews without applying language or date restrictions,
and we identified published reviews, as well as planned/ongoing
reviews (protocols). We did not search other databases; thus it is
possible that non-Cochrane systematic reviews assessing neonatal
interventions and reporting on cerebral palsy have been conducted
but were not identified. It is also the case that Cochrane Reviews
assessing interventions that could have the potential to impact
cerebral palsy risk (see Description of the interventions for fur-
ther discussion of various interventions) may not have acknowl-
edged this through inclusion of cerebral palsy as a review out-
come. Thus, data from relevant randomised trials assessing these
interventions will not have been identified and included in this
overview. Based on our search strategy, even Cochrane Reviews
that pre-specified outcomes such as ’long-term growth and neu-
rodevelopment’ (Cools 2015) but subsequently reported specifi-
cally on ’cerebral palsy’ were captured in our search and were in-
cluded in this overview. However, reviews that have reported on
long-term neurodevelopmental outcomes without any mention of
’cerebral palsy’ will not have been identified; this highlights the
need for all Cochrane Reviews to provide clear definitions accom-
panying any reported outcome measures.
Although we judged almost all of our included reviews to be of high
quality and to have low risk of bias, we did not consider all as ’up-
to-date’, with only approximately one-third conducting searches
in the past three years; similarly, not all of the ’Reviews awaiting
further classification’ were ’up-to-date’. Thus, it is possible that
additional trials assessing neonatal interventions and reporting on
cerebral palsy have been published but have not yet been included
in relevant Cochrane Reviews; it is also possible that additional
trials have been conducted but have not yet been published. If/
when such trials are included in relevant Cochrane Reviews, we
will incorporate them into an update of this overview.
23Neonatal interventions for preventing cerebral palsy: an overview of Cochrane Systematic Reviews (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
138
Agreements and disagreements with other
studies or reviews
We have not identified any other overviews or systematic reviews
specifically designed to assess neonatal interventions for preventing
cerebral palsy.
McIntyre 2013 conducted a systematic review of cohort and case-
control studies that focused on identifying risk factors for cerebral
palsy in children born at term and aimed to assess whether the po-
tential for prevention of these risk factors has been adequately ex-
plored. Intrapartum and neonatal risk factors identified included
birth asphyxia, neonatal seizures, respiratory distress syndrome,
hypoglycaemia, jaundice, and infections including meningitis and
sepsis. It is recognised that a strategy for prevention of cerebral
palsy currently exists for only one of these risk factors - hypother-
mia for birth asphyxia - as was identified in this overview. McIntyre
2013 highlighted that prevention strategies are urgently required.
A further recent systematic review - Hadders-Algra 2016 - focused
on early interventions in infants younger than 12 months’ cor-
rected age with or at very high risk for cerebral palsy (such as on
the basis of a lesion of the brain - periventricular leucomalacia
or intraventricular haemorrhage, or definitely abnormal general
movements). This review included seven studies of moderate to
high quality assessing interventions such as neurodevelopmental
treatment only, multi-sensory stimulation, developmental stimu-
lation, and multi-faceted interventions combining developmental
stimulation, support of parent-infant interaction, and neurodevel-
opmental treatment (Hadders-Algra 2016). Hadders-Algra 2016
concluded that although two suggestions emerged (dosing may be
critical for effectiveness; multi-faceted interventions may offer the
best opportunities), current evidence is limited.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This overview summarises the evidence from Cochrane Systematic
Reviews of randomised controlled trials regarding effects of neona-
tal interventions on cerebral palsy, and can be used by researchers,
funding bodies, policy makers, clinicians, and consumers to aid
decision-making and evidence translation.
High-quality evidence shows that therapeutic hypothermia versus
standard care for newborns with hypoxic-ischaemic encephalopa-
thy can reduce cerebral palsy. Moderate-quality evidence shows
that prophylactic methylxanthines (caffeine) versus placebo for
endotracheal extubation in preterm infants may also reduce cere-
bral palsy risk. Moderate-quality evidence shows that early (less
than eight days of age) postnatal corticosteroids versus placebo or
no treatment for preventing chronic lung disease in preterm in-
fants may increase cerebral palsy risk. In addition, moderate-qual-
ity evidence shows no clear differences in cerebral palsy risk with
ethamsylate versus placebo for prevention of morbidity and mor-
tality in preterm or very low birthweight infants; volume versus
no treatment and gelatin versus fresh frozen plasma for prevention
of morbidity and mortality in very preterm infants; prophylactic
indomethacin versus placebo for prevention of mortality and mor-
bidity in preterm infants; synthetic surfactant versus placebo for
respiratory distress syndrome in preterm infants; or prophylactic
phototherapy versus standard care (starting phototherapy when
serum bilirubin reached a pre-specified level) for preventing jaun-
dice in preterm or low birthweight infants. No conclusions were
possible for other interventions assessed in this overview because
evidence was of low to very low quality.
The scope of this overview was limited to the effects of inter-
ventions on cerebral palsy (and pre-specified secondary overview
outcomes); consultation of the included Cochrane Reviews is rec-
ommended to formally assess additional benefits and/or harms of
these interventions.
Implications for research
This overview highlights areas for which evidence is insufficient to
permit conclusions on the effects of several neonatal interventions
on cerebral palsy. These topics can be used to generate research
questions and priorities. As cerebral palsy is rarely identified at
birth, has diverse risk factors and aetiologies, and is diagnosed in
approximately one in 500 children, it is a challenging outcome for
investigators of such interventions to measure and report on. To
date, a small proportion of Cochrane Reviews assessing neonatal
interventions have reported on cerebral palsy; this may be due
to a number of factors, including lack of primary research (with
few randomised trials of neonatal interventions conducting long-
term follow-up of children), lack of reporting on cerebral palsy by
randomised trials, lack of reporting on cerebral palsy by relevant
Cochrane Reviews (i.e. not pre-specifying it as an outcome of
interest, not clearly defining long-term follow-up results reported,
or not being ’up-to-date’), and the absence of Cochrane Reviews
assessing relevant interventions.
With greater understanding of the diverse risk factors and aetiolo-
gies of cerebral palsy, there is an urgent need for long-term fol-
low-up of interventions to address risk factors for cerebral palsy.
In light of the challenges associated with long-term follow-up of
randomised trials, new strategies to measure impact on cerebral
palsy, such as data linkage with cerebral palsy registries, should be
applied. Additionally, there is a need to consider the use of rela-
tively new interim assessments (such as the General Movements
Assessment). Such studies must be rigorous in their design and
should aim for consistency in cerebral palsy outcome measure-
ment and reporting to facilitate pooling of outcome data and thus
aid research efforts aimed at prevention of cerebral palsy.
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A D D I T I O N A L T A B L E S
Table 1. Characteristics of excluded reviews
Review ID and title Reason for exclusion
Atherton 2012
Email for clinical communication between patients/caregivers and
healthcare professionals
Wrong participants (not neonates):
1. “We included all healthcare professionals, patients and
caregivers regardless of age, gender and ethnicity. We considered
participants originating the email communication, receiving the
email communication and copied into the email
communication”
Barlow 2015
Parent-infant psychotherapy for improving parental and infant
mental health
Wrong participants (not neonates):
1. “We included studies involving parent-infant dyads in
which the parent was experiencing mental health problems,
domestic abuse or substance dependency, with or without the
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Table 1. Characteristics of excluded reviews (Continued)
infant showing signs of attachment or dysregulation problems,
or both attachment and dysregulation problems. We included all
infants irrespective of the presence of problems such as low
birthweight, prematurity or disabilities. We included studies
targeting infants and toddlers in which the mean age of the
infant participants was 24 months or less at the point of referral.
We included studies targeting all parents (i.e. including fathers,
birth parents, adoptive and kinship parents, but not foster
parents)”
Bredemeyer 2012
Body positioning for spontaneously breathing preterm infants
with apnoea
Secondary outcomes pre-specified include the following:
1. Short-term motor development up to about 12 months’
corrected age, as measured by a validated assessment tool
2. Longer-term motor development up to about 2 years’
corrected age, as measured by a validated assessment tool
3. Neurodevelopment assessed at about 2 years’ corrected age,
as measured by a validated assessment tool
No outcome data for these outcomes
Brown 2016
C-reactive protein for diagnosing late-onset infection in newborn
infants
Protocol for diagnostic test accuracy review
Carr 2003
G-CSF and GM-CSF for treating or preventing neonatal infec-
tions
Secondary outcomes pre-specified include:
1. Long-term outcomes: death and disability at or > 1 year
from birth
No outcome data for cerebral palsy (single study results reported
“cognition, language and social developmental performance scores
were within the normal range for age and motor deficits were
’typical of high-risk, low birth weight neonates’. However there
was no comparison made between G-CSF and control infants”
Davis 2001
Intravenous dexamethasone for extubation of newborn infants
No pre-specified outcome focused on development/disability at
follow-up
Ethawi 2016
High-frequency jet ventilation vs high-frequency oscillatory ven-
tilation for pulmonary dysfunction in preterm infants
Secondary neonatal outcomes pre-specified include:
1. Neurodevelopmental outcomes including motor, mental,
and sensory outcomes at 2 years of age (study author defined)
No outcome data for this outcome (no included trials)
Hancock 2013
Treatment of infantile spasms
Outcomes pre-specified include:
1. Long-term psychomotor development
No outcome data for cerebral palsy (single-study results reported
related to BSID; VABS; ’cognitive development’; Japanese Tumor
Scale; DDST)
Jones 2003
Antiviral therapy for symptomatic congenital cytomegalovirus in-
fection in neonates and infants up to 3 months of age
Protocol
Primary outcomes pre-specified include:
1. Mortality at 1 year of life and the presence of cognitive,
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Table 1. Characteristics of excluded reviews (Continued)
developmental, audiological, motor, or visual impairment upon
completion of therapy, at follow-up at 1 year of life, and in later
childhood
Lewin 2010
Lay health workers in primary and community health care for
maternal and child health and management of infectious diseases
No pre-specified outcome focused on development/disability at
follow-up
Malviya 2013
Surgical vs medical treatment with cyclo-oxygenase inhibitors for
symptomatic patent ductus arteriosus in preterm infants
Secondary outcomes pre-specified include:
1. Neurodevelopmental outcome (neurodevelopmental
outcome assessed by a standardised and validated assessment
tool, a child developmental specialist, or both) at any age
(outcome data will be grouped at 6, 9, 12, 18, 24 months, if
available)
No outcome data for this outcome
Morag 2016
Cycled light in the intensive care unit for preterm and low birth-
weight infants
Secondary outcomes pre-specified include:
1. Long-term outcomes: growth and neurodevelopment,
including visual and auditory outcomes at any age as reported by
study authors using standardised and validated tests
No outcome data for these outcomes
Okwundu 2014
Transcutaneous screening for hyperbilirubinaemia in neonates
Protocol
No pre-specified outcome focused on development/disability at
follow-up
Pammi 2011
Granulocyte transfusions for neonates with confirmed or sus-
pected sepsis and neutropaenia
Primary outcomes pre-specified include:
1. Neurological outcome at 1 year of age or later
(neurodevelopmental outcome as assessed by any validated test)
No outcome data for this outcome
Pammi 2015
Molecular assays for diagnosis of sepsis in neonates
Protocol for diagnostic test accuracy review
Pammi 2015b
Pentoxifylline for treatment of sepsis and necrotising enterocolitis
in neonates
Secondary outcomes pre-specified include:
1. Neurological outcome at 2 or more years of age
(neurodevelopmental outcome as assessed by a validated test)
No outcome data for this outcome
Scholefield 2013
Hypothermia for neuroprotection in children after cardiopul-
monary arrest
Primary outcomes pre-specified include:
1. Best neurological outcome at hospital discharge and within
the first year as assessed by the Paediatric Cerebral Performance
Category score and other validated outcome scores for use in
children (e.g. VABS)
No outcome data for these outcomes (no included trials)
Shah 2012
Intraventricular antibiotics for bacterial meningitis in neonates
Secondary outcomes pre-specified include:
1. Neurodevelopmental outcome (neurodevelopmental
outcome as assessed by a standardised and validated assessment
tool or a child developmental specialist, or both) at any age
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(outcome data will be grouped at 12, 18, and 24 months, if
available)
No outcome data for this outcome
Suresh 2003
Metalloporphyrins for treatment of unconjugated hyperbilirubi-
naemia in neonates
Outcomes pre-specified include:
1. Presence of neurodevelopmental sequelae (i.e. any sensory,
motor, cognitive, psychological, or behavioural impairment
reported on follow-up any time after the neonatal period)
2. Degree of such neurodevelopmental impairment (expressed
as mean or median scores on tests of neurodevelopmental
function performed any time after the neonatal period)
No outcome data for these outcomes
Thukral 2015
Periodic change of body position under phototherapy in term and
late preterm neonates with hyperbilirubinaemia
Protocol
Secondary outcomes pre-specified include:
1. Incidence of BIND (proportion). BIND or subtle
encephalopathy shall be defined as neurological, cognitive,
learning, or movement disorders; isolated hearing loss; or
auditory dysfunction in the presence of hyperbilirubinaemia
(Bergman 1985; Hyman 1969; Johnson 1974; Rubin 1979;
Scheldt 1977)
Upadhyay 2016
Short-duration vs standard-duration antibiotic regimens for treat-
ment of neonatal bacterial infection
Protocol
Secondary outcomes pre-specified include:
1. Survival without major disability at 18 to 24 months’
corrected age (proportion)
Ward 2003
Steroid therapy for meconium aspiration syndrome in newborn
infants
Primary outcomes pre-specified include:
1. Long-term growth and neurodevelopmental outcomes
assessed at age 1, 2, and 5 years with validated assessment tools
No outcome data for this outcome
Whitelaw 2001
Diuretic therapy for newborn infants with post-haemorrhagic ven-
tricular dilatation
Outcomes pre-specified include:
1. Moderate to severe long-term motor disability at 1 to 3
years of age
2. Combined outcome: death or (moderate to severe) long-
term disability at 1 to 3 years of age
Data reported for these outcomes; no outcome data for cerebral
palsy. “The larger trial showed that acetazolamide and furosemide
treatment resulted in a borderline increase in the risk for motor
impairment at one year (RR 1.27, 95% CI 1.02 - 1.58; RD 0.16,
95% CI 0.02 - 0.31), but did not significantly affect the risk for
the combined outcome of delay, disability or motor impairment
among survivors, or the risk of the combined outcome of death,
delay, disability or impairment at one year”
Whitelaw 2001b
Repeated lumbar or ventricular punctures in newborns with in-
traventricular haemorrhage
Outcomes pre-specified include:
1. Surviving with major disability for 12 months or longer in
survivors
2. Surviving with multiple neurodevelopmental impairments
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Table 1. Characteristics of excluded reviews (Continued)
Data reported for these outcomes; no outcome data for cerebral
palsy. “The tables and figures show that none of the trials found
a significant effect of CSF tapping on a) need for shunt b) death
c) major disability in survivors d) multiple disability in survivors
e) death or disability. Similarly, meta-analysis of the results of all
included trials shows no significant effect of CSF tapping on any
of these outcomes”
Woodgate 2001
Permissive hypercapnia for prevention of morbidity and mortality
in mechanically ventilated newborn infants
Outcomes pre-specified include:
1. Neurodevelopmental outcome
No outcome data for this outcome
Abbreviations: BIND: bilirubin-induced neurological dysfunction; BSID: Bayley Scales of Infant Development; CI: confidence interval;
CSF: cerebrospinal fluid; DDST: Denver Developmental Screening Test; G-CSF: granulocyte-colony stimulating factor; GM-CSF:
granulocyte-macrophage colony-stimulating factor; RD: risk difference; RR: risk ratio; VABS: Vineland Adaptive Behavior Scales.
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Table 2. Characteristics of included reviews (Continued)
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Neonatal care: haemorrhage: periventricular/intraventricular
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Table 2. Characteristics of included reviews (Continued)
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Table 2. Characteristics of included reviews (Continued)
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Table 2. Characteristics of included reviews (Continued)
1 RCT; Turkey:
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Table 2. Characteristics of included reviews (Continued)
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Table 2. Characteristics of included reviews (Continued)
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Table 2. Characteristics of included reviews (Continued)
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Table 2. Characteristics of included reviews (Continued)
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Table 2. Characteristics of included reviews (Continued)
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Table 2. Characteristics of included reviews (Continued)
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Table 2. Characteristics of included reviews (Continued)
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Table 2. Characteristics of included reviews (Continued)
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Table 2. Characteristics of included reviews (Continued)
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Table 2. Characteristics of included reviews (Continued)
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Abbreviations: BP: blood pressure; BPD: bronchopulmonary dysplasia; BSID: Bayley Scales of Infant Development; CNS: central
nervous system; ECHO: echocardiogram; g: grams; G-6PD: glucose-6-phosphate dehydrogenase; HSV: herpes simplex virus; IPPV:
intermittent positive-pressure ventilation; IV: intravenous; LBW: low birthweight; MDI: Mental Development Index; Movement-
ABC: Movement Assessment Battery for Children; NICU: neonatal intensive care unit; NO: nitric oxide; PDA: patent ductus
arteriosus; PDI: Psychomotor Development Index; PMA: post-menstrual age; PPHN: persistent pulmonary hypertension of the
newborn; RCT: randomised controlled trial; Rh: Rhesus; SBF: systemic blood flow; SD: standard deviation; SVC: superior vena
cava; VLBW: very low birthweight.
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Table 3. Risk of bias assessments from included reviews
Review ID and title Summary of trial limitations (risk of bias)*
Neonatal care: asphyxia
Chaudhari 2012
Allopurinol for preventing mortality and morbidity in newborn
infants with hypoxic-ischaemic encephalopathy
Random sequence generation: 2 RCTs low risk; 1 RCT unclear
risk
Allocation concealment: 3 RCTs low risk
Blinding: 2 RCTs low risk; 1 RCT high risk
Incomplete outcome data: 3 RCTs low risk
Overall: “Although small, the trials were generally of good
methodological quality”
Jacobs 2013
Cooling for newborns with hypoxic-ischaemic encephalopathy
Random sequence generation: 9 RCTs low risk; 1 RCT unclear
risk; 1 RCT high risk
Allocation concealment: 8 RCTs low risk; 2 RCTs unclear risk;
1 RCT high risk
Blinding (participants and personnel): 11 RCTs high risk
Blinding (outcome assessors): 10 RCTs low risk; 1 RCT unclear
risk
Incomplete outcome data: 6 RCTs low risk; 1 RCT unclear risk;
4 RCTs high risk
Selective reporting: 11 RCTs low risk
Overall: “Several limitations of the available evidence should be
noted”
Young 2016
Prophylactic barbiturate use for the prevention of morbidity and
mortality following perinatal asphyxia
Random sequence generation: 7 RCTs low risk; 2 RCTs unclear
risk
Allocation concealment: 4 RCTs low risk; 4 RCTs unclear risk;
1 RCT high risk
Blinding: 4 RCTs unclear risk; 5 RCTs high risk
Incomplete outcome data: 6 RCTs low risk; 2 RCTs unclear risk;
1 RCT high risk
Selective reporting: 9 RCTs low risk
Neonatal care: haemorrhage: periventricular/intraventricular
Hunt 2010
Ethamsylate for the prevention of morbidity and mortality in
preterm or very low birth weight infants
Adequate sequence generation: 4 RCTs yes; 2 RCTs unclear; 1
RCT no
Allocation concealment: 3 RCTs yes; 2 RCT unclear; 2 RCTs no
Blinding: 4 RCTs yes; 3 RCTs unclear
Incomplete outcome data addressed: 5 RCTs yes; 1 RCT un-
clear; 1 RCT no
Free of selective reporting: 7 RCTs yes
Free of other bias: 7 RCTs yes
Smit 2013
Postnatal phenobarbital for the prevention of intraventricular
haemorrhage in preterm infants
Random sequence generation: 5 RCTs low risk; 6 RCTs unclear
risk; 1 RCT high risk
Allocation concealment: 4 RCTs low risk; 7 RCTs unclear risk;
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Table 3. Risk of bias assessments from included reviews (Continued)
1 RCT high risk
Blinding (participants and personnel): 2 RCTs low risk; 10
RCTs high risk
Blinding (outcome assessors): 6 RCTs low risk; 6 RCTs unclear
risk
Incomplete outcome data: 8 RCTs low risk; 4 RCTs unclear risk
Selective reporting: 2 RCTs low risk; 10 RCTs unclear risk
Neonatal care: hypotension
Osborn 2007b
The effect of inotropes on morbidity and mortality in preterm
infants with low systemic or organ blood flow
Adequate sequence generation: 1 RCT yes
Allocation concealment: 1 RCT yes
Blinding (outcomes): 1 RCT yes
Blinding (intervention): 1 RCT yes
Incomplete outcome data addressed: 1 RCT yes
Free of selective reporting: 1 RCT yes
Free of other bias: 1 RCT yes
Overall: “The study was of adequate methodology”
Neonatal care: fluid therapy
Osborn 2004
Early volume expansion for prevention of morbidity and mortality
in very preterm infants
Adequate randomisation: 7 RCTs yes; 1 RCT unclear
Allocation concealment: 7 RCTs yes; 1 RCT unclear
Blinding of intervention: 1 RCT yes; 7 RCTs no
Blinding of measurement: 3 RCTs yes; 1 RCT unclear; 4 RCTs
no
Losses to follow-up: 5 RCTs none; 1 RCT unclear; 2 RCTs yes
Neonatal care: patent ductus arteriosus
Fowlie 2010
Prophylactic intravenous indomethacin for preventing mortality
and morbidity in preterm infants
Blinding of randomisation: 12 RCTs yes; 7 RCTs can’t tell
Blinding of intervention: 16 RCTs yes; 2 RCTs can’t tell; 1 RCT
no
Blinding of outcome assessment: 16 RCTs yes; 2 RCTs can’t tell;
1 RCT no
Complete follow-up (short-term outcomes): 18 RCTs yes; 1
RCT no
Overall: “Overall, the quality of the trials was good”
Ohlsson 2015
Ibuprofen for the treatment of patent ductus arteriosus in preterm
or low birth weight (or both) infants
Random sequence generation: 9 RCTs low risk; 24 RCTs unclear
risk
Allocation concealment: 18 RCTs low risk; 14 RCTs unclear
risk; 1 RCT high risk
Blinding: 6 RCTs low risk; 7 RCTs unclear risk; 20 RCTs high
risk
Incomplete outcome data: 28 RCTs low risk; 3 RCTs unclear
risk; 2 RCTs high risk
Selective reporting: 5 RCTs low risk; 28 RCTs unclear risk
Other: 29 RCTs low risk; 4 RCTs unclear risk
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Table 3. Risk of bias assessments from included reviews (Continued)
Overall: “Study quality was variable…we identified concerns
about bias in most individual studies and therefore for the group
of studies included as well”
Neonatal care: blood disorders
Ohlsson 2014
Early erythropoietin for preventing red blood cell transfusion in
preterm and/or low birth weight infants
Random sequence generation: 8 RCTs low: risk; 19 RCTs un-
clear risk
Allocation concealment: 13 RCTs low risk; 14 RCTs unclear risk
Blinding: 12 RCTs low risk; 3 RCTs unclear risk; 12 RCTs high
risk
Incomplete outcome data: 23 RCTs low risk; 2 RCTs unclear
risk; 2 RCTs high risk
Selective reporting: 1 RCT low risk; 26 RCTs unclear risk
Other: 26 RCTs low risk; 1 RCT unclear risk
Whyte 2011
Low versus high haemoglobin concentration threshold for blood
transfusion for preventing morbidity and mortality in very low
birth weight infants
Allocation concealment: 4 RCTs low risk; 1 RCT unclear risk
Blinding: 1 RCT unclear risk; 4 RCTs high risk
Incomplete outcome data: 3 RCTs low risk; 1 RCT unclear risk;
1 RCT high risk
Selective reporting: 1 RCT low risk; 3 RCTs unclear risk; 1 RCT
high risk
Overall: “This review consists of five randomised controlled trials
in which there appears to be no allocation bias; the overall level
of evidence is high”
Neonatal care: pulmonary hypertension
More 2016
Endothelin receptor antagonists for persistent pulmonary hyper-
tension in term and late preterm infants
Random sequence generation: 1 RCT low risk; 1 RCT unclear
risk
Allocation concealment: 2 RCT unclear risk
Blinding (participants and personnel): 2 RCTs low risk
Blinding (outcome assessors): 2 RCTs low risk
Incomplete outcome data: 1 RCT low risk; 1 RCT high risk
Selective reporting: 1 RCT low risk; 1 RCT unclear risk
Other: 2 RCTs low risk
Overall: “the quality of evidence was considered low because of the




Air versus oxygen for resuscitation of infants at birth
Concealment of allocation: 2 RCTs yes; 3 RCTs no
Blinding of intervention: 2 RCTs yes; 3 RCTs no
Blinding of outcome assessment: 2 RCTs yes; 3 RCTs no
Completeness of follow-up (short-term): 4 RCTs yes; 1 RCT
no
Completeness of follow-up (long-term): 3 RCTs no; 2 RCTs
unclear
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Table 3. Risk of bias assessments from included reviews (Continued)
Neonatal care: nitric oxide
Barrington 2010
Inhaled nitric oxide for respiratory failure in preterm infants
Allocation concealment: 12 RCTs low risk; 2 RCTs unclear risk
Blinding: 7 RCTs low risk; 7 RCTs high risk
Incomplete outcome data: 14 RCTs low risk
Selective reporting: 8 RCTs low risk; 6 RCTs not reported
Other: 3 RCTs low risk; 4 RCTs high risk; 7 RCTs not reported
Finer 2006
Nitric oxide for respiratory failure in infants born at or near term
Masking of allocation: 10 RCTs yes; 4 RCTs cannot tell
Masking of intervention: 6 RCTs yes; 8 RCTs no
Masking of outcome assessment: 6 RCTs yes; 1 RCT can’t tell;
7 RCTs no
Completeness of follow-up: 13 RCTs yes; 1 RCT can’t tell
Overall: “The overall quality of these studies is quite variable”
Neonatal care: apnoea
Henderson-Smart 2010b
Methylxanthine treatment for apnoea in preterm infants
Random sequence generation: 1 RCT high risk; 5 RCTs not
reported
Allocation concealment: 2 RCTs low risk; 2 RCTs unclear risk;
2 RCTs high risk
Blinding: 4 RCTs low risk; 2 RCTs high risk
Incomplete outcome data: 3 RCTs low risk; 1 RCT unclear risk;
2 RCTs high risk
Selective reporting: 2 RCTs low risk; 1 RCT unclear risk; 2 RCTs
high risk; 1 RCT not reported
Overall: “There was variation in trial design”
Henderson-Smart 2010c
Prophylactic methylxanthine for prevention of apnoea in preterm
infants
Allocation concealment: 3 RCTs low risk
Blinding: 3 RCTs low risk
Incomplete outcome data: 3 RCTs low risk
Selective reporting: 2 RCTs low risk; 1 RCT not reported
Overall: “Three studies are generally of high quality”
Neonatal care: respiratory distress syndrome
Howlett 2015
Inositol in preterm infants at risk for or having respiratory distress
syndrome
Random sequence generation: 1 RCT low risk; 3 RCTs unclear
risk
Allocation concealment: 2 RCTs low risk; 2 RCTs unclear risk
Blinding: 2 RCTs low risk; 2 RCTs unclear risk
Incomplete outcome data: 4 RCTs low risk
Selective reporting: 3 RCTs low risk; 1 RCT unclear risk
Other: 3 RCTs high risk; 1 RCT low risk
Overall: “Study quality varied and interim analyses had occurred
in all trials”
Seger 2009
Animal derived surfactant extract for treatment of respiratory dis-
tress syndrome
Blinding of randomisation: 10 RCTs yes; 3 RCTs not described
Blinding of intervention: 8 RCTs yes; 1 RCT not described; 4
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Table 3. Risk of bias assessments from included reviews (Continued)
RCTs no
Blinding of outcome measurement: 6 RCTs yes; 4 RCTs not
described; 2 RCTs no; 1 RCT not reported
Complete follow-up (short-term): 13 RCTs yes
Complete follow-up (long-term): 4 RCTs yes; 9 RCTs no
Overall: “studies are of high methodological quality”
Soll 2000
Synthetic surfactant for respiratory distress syndrome in preterm
infants
Blinding of randomisation: 6 RCTs yes
Blinding of intervention: 5 RCTs yes; 1 RCT no
Blinding of outcome measurement: 5 RCTs yes; 1 RCT no
Complete follow-up (short term): 6 RCTs yes
Complete follow-up (long term): 80 to 100%
Soll 2010
Prophylactic protein free synthetic surfactant for preventing mor-
bidity and mortality in preterm infants
Adequate sequence generation: 6 RCTs unclear: 1 RCT not
reported
Allocation concealment: 7 RCTs yes
Blinding of intervention: 5 RCTs yes; 1 RCT unclear; 1 RCT
no
Blinding of outcome measurement: 6 RCTs yes; 1 RCT no
Incomplete outcome data addressed: 5 RCTs yes; 2 RCTs un-
clear
Free of selective reporting: 7 RCTs yes
Free of other bias: 7 RCTs yes
Neonatal care: mechanical ventilation
Cools 2015
Elective high frequency oscillatory ventilation versus conventional
ventilation for acute pulmonary dysfunction in preterm infants
Random sequence generation: 11 RCTs low risk; 8 RCTs unclear
risk
Allocation concealment: 7 RCTs low risk; 12 RCTs unclear risk
Blinding of participants and personnel: 19 RCTs high risk
Blinding of outcome assessment: 7 RCTs low risk; 12 RCTs
unclear risk
Incomplete outcome data: 19 RCTs low risk
Overall: “The quality of the studies was generally high”
Ho 2015
Continuous distending pressure for respiratory distress in preterm
infants
Random sequence generation: 2 RCTs low risk; 3 RCTs unclear
risk; 1 RCT high risk
Allocation concealment: 4 RCTs low risk; 1 RCT unclear risk;
1 RCT high risk
Blinding (intervention): 6 RCTs high risk
Blinding (short term outcomes): 6 RCTs high risk (1 RCT low
risk for long term outcomes)
Incomplete outcome data (short term outcomes): 3 RCTs low
risk; 3 RCTs unclear risk (1 RCT low risk for long-term outcomes)
Selective reporting: 2 RCTs low risk; 4 RCTs unclear risk
Other: 6 RCTs unclear risk
Overall: “These data should be interpreted with caution as in the
studies reviewed, the numbers of infants were small, blinding of
treatment was not possible and blinding of the outcome assess-
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Table 3. Risk of bias assessments from included reviews (Continued)
ment was reported in only one study for the outcomes in child-
hood, thus possibly introducing bias”
Henderson-Smart 2010
Prophylactic methylxanthines for endotracheal extubation in
preterm infants
Sequence generation: 1 RCT low risk; 6 RCTs not reported
Allocation concealment: 6 RCTs low risk; 1 RCT unclear risk
Blinding: 6 RCTs low risk; 1 RCT high risk
Incomplete outcome data: 3 RCTs low risk; 3 RCTs high risk; 1
RCT not reported
Selective reporting: 4 RCTs low risk; 2 RCTs high risk; 1 RCT
not reported
Other: 1 RCT low risk; 6 RCTs not reported
Kamlin 2003
Long versus short inspiratory times in neonates receiving mechan-
ical ventilation
Concealment of allocation: 1 RCT yes; 1 RCT cannot tell; 3
RCTs no
Blinding of intervention: 5 RCTs no
Blinding of outcome measurement: 3 RCTs no; 2 RCTs some
Completeness of follow-up (short term outcomes): 5 RCTs yes
Wheeler 2010
Volume-targeted versus pressure-limited ventilation in the
neonate
Sequence generation: 6 RCTs low risk; 6 RCTs unclear risk
Allocation concealment: 11 RCTs low risk; 1 RCT unclear risk
Blinding: 12 RCTs high risk
Incomplete outcome data: 12 RCTs low risk
Selective reporting: 10 RCTs low risk; 1 RCT unclear risk; 1
RCT high risk
Other: 5 RCTs low risk; 5 RCTs unclear risk; 2 RCTs high risk
Overall: “There are no major concerns about the methodology
used in the twelve trials included in this review”
Neonatal care: bronchopulmonary dysplasia
Doyle 2014b
Early (< 8 days) postnatal corticosteroids for preventing chronic
lung disease in preterm infants
Random sequence generation: 15 RCTs low risk; 14 RCTs un-
clear risk
Allocation concealment: 27 RCTs low risk; 2 RCTs unclear risk
Blinding of participants and personnel: 23 RCTs low risk; 2
RCTs unclear risk; 4 RCTs high risk
Blinding of outcome assessment: 23 RCTs low risk; 2 RCTs
unclear risk; 4 RCTs high risk
Incomplete outcome data: 28 RCTs low risk; 1 RCT unclear risk
Overall: “Overall the risk of bias was low for most studies”
Halliday 2003
Moderately early (7-14 days) postnatal corticosteroids for prevent-
ing chronic lung disease in preterm infants
Blinding of randomisation/allocation concealment: 7 RCTs
yes/low risk
Blinding of intervention: 5 RCTs yes; 2 RCTs no
Blinding of outcome measurement: 5 RCTs yes; 1 RCT some;
1 RCT cannot tell
Complete follow-up: 6 RCTs yes/almost; 1 RCT no
Overall: “the methodological quality of the studies to determine
long-term outcome is limited in some cases”
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Table 3. Risk of bias assessments from included reviews (Continued)
Doyle 2014
Late (> 7 days) postnatal corticosteroids for chronic lung disease
in preterm infants
Random sequence generation: 12 RCTs low risk; 9 RCTs unclear
risk
Allocation concealment: 17 RCTs low risk; 4 RCTs unclear risk
Blinding of participants and personnel: 15 RCTs low risk; 4
RCTs unclear risk; 2 RCTs high risk
Blinding of outcome assessment: 16 RCTs low risk; 4 RCTs
unclear risk; 1 RCT high risk
Incomplete outcome data: 20 RCTs low risk; 1 RCT unclear risk
Overall: “Overall the risk of bias was low for most studies”
Shah 2012
Early administration of inhaled corticosteroids for preventing
chronic lung disease in ventilated very low birth weight preterm
neonates
Random sequence generation: 7 RCTs unclear risk
Allocation concealment: 7 RCTs low risk
Blinding of participants and personnel: 7 RCTs low risk
Blinding of outcome assessment: 1 RCT low risk; 6 RCTs un-
clear risk
Incomplete outcome data: 6 RCTs low risk; 1 RCT unclear risk
Overall: “Overall, the studies included for this review were of high
methodological quality”
Darlow 2016
Vitamin A supplementation to prevent mortality and short- and
long-term morbidity in very low birth weight infants
Random sequence generation: 9 RCTs low risk; 2 RCTs unclear
risk
Allocation concealment: 8 RCTs low risk; 3 RCTs unclear risk
Blinding: 6 RCTs low risk; 2 RCTs unclear risk; 3 RCTs high risk
Incomplete outcome data: 9 RCTs low risk; 1 RCT unclear risk;
1 RCT high risk
Selective reporting: 8 RCTs low risk; 2 RCTs unclear risk; 1 RCT
high risk
Other: 2 RCTs low risk; 6 RCTs unclear risk; 2 RCTs high risk;
1 RCT not reported
Neonatal care: infections: necrotising enterocolitis
AlFaleh 2014
Probiotics for prevention of necrotising enterocolitis in preterm
infants
Random sequence generation: 15 RCTs low risk; 8 RCTs unclear
risk; 1 RCT high risk
Allocation concealment: 11 RCTs low risk; 12 RCTs unclear
risk; 1 RCT high risk
Blinding: 15 RCTs low risk; 9 RCTs unclear risk
Incomplete outcome data: 21 RCTs low risk; 2 RCTs unclear
risk; 1 RCT high risk
Selective reporting: 17 RCTs low risk; 6 RCTs high risk; 1 RCT
not reported
Other: 14 RCTs low risk; 10 RCTs not reported
Overall: “Eleven of our included trials were classified as high qual-
ity trials”
Shah 2007
Arginine supplementation for prevention of necrotising entero-
colitis in preterm infants
Masking of randomisation: 1 RCT yes
Masking of intervention: 1 RCT yes
Masking of outcome assessment: 1 RCT yes
Completeness of follow-up: 1 RCT yes
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Table 3. Risk of bias assessments from included reviews (Continued)
Overall: “The methodological quality of the included study was
good”
Neonatal care: infections: fungal infections
Cleminson 2015
Prophylactic systemic antifungal agents to prevent mortality and
morbidity in very low birth weight infants
Allocation concealment: 12 RCTs low risk; 3 RCTs unclear risk
Blinding of participants and personnel: 10 RCTs low risk; 3
RCTs unclear risk; 2 RCTs high risk
Blinding of outcome assessment: 10 RCTs low risk; 3 RCTs
unclear risk; 2 RCTs high risk
Incomplete outcome data: 15 RCTs low risk
Overall: “The included trials were generally of good methodolog-
ical quality”
Neonatal care: infections: herpes simplex
Jones 2009
Antiviral agents for treatment of herpes simplex virus infection in
neonates
Allocation concealment: 1 RCT unclear; 1 RCT inadequate
Overall: “The two trials... have a number of methodological flaws”
Neonatal care: jaundice
Okwundu 2012
Prophylactic phototherapy for preventing jaundice in preterm or
low birth weight infants
Random sequence generation: 4 RCTs low risk; 3 RCTs unclear
risk; 2 RCTs high risk
Allocation concealment: 3 RCTs low risk; 4 RCTs unclear risk;
2 RCTs high risk
Blinding: 1 RCT low risk; 2 RCTs unclear risk; 6 RCTs high risk
Incomplete outcome data: 8 RCTs low risk; 1 RCT high risk
Selective reporting: 2 RCTs low risk; 7 RCTs unclear risk
Other: 7 RCTs low risk
Overall: “In general, the overall methodological quality of the
included studies was acceptable”
Neonatal care: hypoglycaemia
Weston 2016
Oral dextrose gel for the treatment of hypoglycaemia in newborn
infants
Random sequence generation: 1 RCT low risk; 1 RCT unclear
risk
Allocation concealment: 1 RCT low risk; 1 RCT unclear risk
Blinding of participants and personnel: 1 RCT low risk; 1 RCT
unclear risk
Blinding of outcome assessors: 1 RCT low risk; 1 RCT unclear
risk
Incomplete outcome data: 1 RCT low risk; 1 RCT high risk
Selective reporting: 1 RCT low risk; 1 RCT unclear risk
Other: 1 RCT low risk; 1 RCT unclear risk
Neonatal care: parenteral feeding
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Table 3. Risk of bias assessments from included reviews (Continued)
Moe-Byrne 2016
Glutamine supplementation to prevent morbidity and mortality
in preterm infants
Random sequence generation: 8 RCTs low risk; 3 RCTs unclear
risk; 1 RCT high risk
Allocation concealment: 8 RCTs low risk; 2 RCTs unclear risk;
2 RCTs high risk
Blinding: 10 RCTs low risk; 2 RCTs unclear risk
Incomplete outcome data: 8 RCTs low risk; 2 RCTs unclear risk;
2 RCTs high risk
Overall: “in general the trials were of good quality”
Neonatal care: other
Osborn 2001
Thyroid hormones for preventing neurodevelopmental impair-
ment in preterm infants
Blinding of randomisation/allocation concealment: 4 RCTs
yes; 1 RCT no
Blinding of intervention: 4 RCTs yes; 1 RCT no
Blinding of outcome assessment: 4 RCTs yes; 1 RCT not stated
Complete follow-up: 2 RCTs yes; 3 RCTs no
Overall: “four studies... were of good methodology”
Osborn 2007
Prophylactic postnatal thyroid hormones for prevention of mor-
bidity and mortality in preterm infants
Allocation concealment: 4 RCTs low risk
Blinding of intervention: 4 RCTs yes
Blinding of outcome assessment: 3 RCTs yes; 1 RCT probably
Complete follow-up: 3 RCTs yes; 1 RCT no
Overall: “All studies... were of adequate methodology”
Almadhoob 2015
Sound reduction management in the neonatal intensive care unit
for preterm or very low birth weight infants
Random sequence generation: 1 RCT low risk
Allocation concealment: 1 RCT low risk
Blinding of participants and personnel: 1 RCT high risk
Blinding of outcome assessment: 1 RCT low risk
Incomplete outcome data: 1 RCT low risk
Selective reporting: 1 RCT low risk
Other: 1 RCT low risk
Overall: “We considered the overall risk of bias to be low”
Conde-Agudelo 2016
Kangaroo mother care to reduce morbidity and mortality in low
birthweight infants
Random sequence generation: 21 RCTs low risk
Allocation concealment: 10 RCTs low risk; 11 RCTs unclear risk
Blinding of participants and personnel: 21 RCTs high risk
Blinding of outcome assessment: 2 RCTs low risk; 15 RCTs
unclear risk; 4 RCTs high risk
Incomplete outcome data: 14 RCTs low risk; 3 RCTs unclear
risk; 4 RCTs high risk
Selective reporting: 16 RCTs low risk; 3 RCTs unclear risk; 2
RCTs high risk
Other: 15 RCTs low risk; 3 RCTs unclear risk; 3 RCTs high risk
Overall: “The methodological quality of the included trials was
mixed”
Spittle 2015
Early developmental intervention programmes provided post hos-
pital discharge to prevent motor and cognitive impairment in
Random sequence generation: 11 RCTs low risk; 8 RCTs unclear
risk; 5 RCTs high risk; 1 RCT not reported
Allocation concealment: 11 RCTs low risk; 9 RCTs unclear risk;
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Table 3. Risk of bias assessments from included reviews (Continued)
preterm infants 5 RCTs high risk
Blinding of participants and personnel: 2 RCTs low risk; 4
RCTs unclear risk; 19 RCTs high risk
Blinding of outcome assessment: 21 RCTs low risk; 3 RCTs
unclear risk; 1 RCT high risk
Incomplete outcome data: 12 RCTs low risk; 4 RCTs unclear
risk; 9 RCT high risk
Selective reporting: 3 RCTs unclear risk; 6 RCT high risk; 16
RCTs not reported
Overall: “The methodological quality of included studies was
variable”
Abbreviations: RCT: randomised controlled trial.
*We have reported only the risk of bias components assessed and reported in the included reviews.


























































































Neonatal care: haemorrhage: periventricular/intraventricular
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Table 4. AMSTAR assessments for included reviews (Continued)
Hunt
2010






















Neonatal care: fluid therapy
Osborn
2004





Neonatal care: patent ductus arteriosus
Fowlie
2010





























Neonatal care: pulmonary hypertension
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Table 4. AMSTAR assessments for included reviews (Continued)
More
2016






















































Neonatal care: respiratory distress syndrome
Howlett
2015
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√ √ √ √ √ √












Neonatal care: mechanical ventilation
Cools
2015
















√ √ √ √
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Neonatal care: bronchopulmonary dysplasia
Doyle
2014b
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Table 4. AMSTAR assessments for included reviews (Continued)
Doyle
2014



















Neonatal care: infections: necrotising enterocolitis
AlFaleh
2014







√ √ √ √
?
√ √ √













Neonatal infections: herpes simplex
Jones
2009
√ √ √ √ √ √ √ √
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Table 4. AMSTAR assessments for included reviews (Continued)
Weston
2016
























































Table 5. ROBIS assessments for included reviews
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Table 5. ROBIS assessments for included reviews (Continued)
Chaudhari 2012 Low risk Low risk Low risk Low risk LOW RISK
Jacobs 2013 Low risk Low risk Low risk Low risk LOW RISK
Young 2016 Low risk Low risk Low risk Low risk LOW RISK
Neonatal care: haemorrhage: periventricular/intraventricular
Hunt 2010 Low risk Low risk Low risk Low risk LOW RISK
Smit 2013 Low risk Low risk Low risk Low risk LOW RISK
Neonatal care: hypotension
Osborn 2007b Low risk Low risk Low risk Low risk LOW RISK
Neonatal care: fluid therapy
Osborn 2004 Low risk Low risk Low risk Low risk LOW RISK
Neonatal care: patent ductus arteriosus
Fowlie 2010 Low risk Low risk Low risk Low risk LOW RISK
Ohlsson 2015 Low risk Low risk Low risk Low risk LOW RISK
Neonatal care: blood disorders
Ohlsson 2014 Low risk Low risk Low risk Low risk LOW RISK
Whyte 2011 Low risk Low risk Low risk Low risk LOW RISK
Neonatal care: pulmonary hypertension
More 2016 Low risk Low risk Low risk Low risk LOW RISK
Neonatal care: resuscitation
Tan 2005 Low risk Low risk Low risk Low risk LOW RISK
Neonatal care: nitric oxide
Barrington 2010 Low risk Low risk Low risk Low risk LOW RISK
Finer 2006 Low risk Unclear risk Low risk Low risk UNCLEAR RISK
Neonatal care: apnoea
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Table 5. ROBIS assessments for included reviews (Continued)
Henderson-Smart
2010b
Low risk Low risk Low risk Low risk LOW RISK
Henderson-Smart
2010c
Low risk Low risk Low risk Low risk LOW RISK
Neonatal care: respiratory distress syndrome
Howlett 2015 Low risk Low risk Low risk Low risk LOW RISK
Seger 2009 Unclear risk Low risk Low risk Low risk LOW RISK
Soll 2000 Unclear risk Unclear risk Unclear risk Unclear risk UNCLEAR RISK
Soll 2010 Low risk Low risk Low risk Low risk LOW RISK
Neonatal care: mechanical ventilation
Cools 2015 Low risk Low risk Low risk Low risk LOW RISK
Ho 2015 Low risk Low risk Low risk Low risk LOW RISK
Henderson-Smart
2010
Low risk Low risk Low risk Low risk LOW RISK
Kamlin 2003 Low risk Low risk Low risk Low risk LOW RISK
Wheeler 2010 Low risk Low risk Low risk Low risk LOW RISK
Neonatal care: bronchopulmonary dysplasia
Doyle 2014b Low risk Low risk Low risk Low risk LOW RISK
Halliday 2003 Low risk Unclear risk Unclear risk Unclear risk LOW RISK
Doyle 2014 Low risk Low risk Low risk Low risk LOW RISK
Shah 2012 Low risk Low risk Low risk Low risk LOW RISK
Darlow 2016 Low risk Low risk Low risk Low risk LOW RISK
Neonatal infections: necrotising enterocolitis
AlFaleh 2014 Low risk Low risk Low risk Low risk LOW RISK
Shah 2007 Low risk Low risk Low risk Low risk LOW RISK
Neonatal infections: fungal infections
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Table 5. ROBIS assessments for included reviews (Continued)
Cleminson 2015 Low risk Low risk Low risk Low risk LOW RISK
Neonatal infections: herpes simplex
Jones 2009 Low risk Low risk Low risk Low risk LOW RISK
Neonatal care: jaundice
Okwundu 2012 Low risk Low risk Low risk Unclear risk LOW RISK
Neonatal care: hypoglycaemia
Weston 2016 Low risk Low risk Low risk Low risk LOW RISK
Neonatal care: parenteral feeding
Moe-Byrne 2016 Low risk Low risk Low risk Low risk LOW RISK
Neonatal care: other
Osborn 2001 Low risk Unclear risk Unclear risk Low risk UNCLEAR RISK
Osborn 2007 Low risk Low risk Low risk Low risk LOW RISK
Almadhoob 2015 Unclear risk Low risk Low risk Low risk LOW RISK
Conde-Agudelo
2016
Low risk Low risk Low risk Low risk LOW RISK
Spittle 2015 Low risk Low risk Low risk Low risk LOW RISK







































881 (7 RCTs) HIGH Not
downgraded
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Table 6. Cerebral palsy (Continued)
Cerebral palsy




































































at 2 years up















532 (3 RCTs) MODERATE Imprecision (-
1):
wide CI cross-
ing line of no
effect
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604 (1 RCT) MODERATE Imprecision (-
1):
wide CI cross-


















399 (1 RCT) MODERATE Imprecision (-
1):
wide CI cross-
ing line of no
effect
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304 (1 RCT) MODERATE Imprecision (-
1):
wide CI cross-

























57 (1 RCT) VERY LOW Study limita-
tions (-1): 1
RCT at un-






































153 (2 RCTs) VERY LOW Study limita-
tions (-1): 1
RCT at un-
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ing line of no
effect































































































593 (2 RCTs) LOW Study limita-
tions (-1)






ing line of no
effect
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299 (2 RCTs) LOW Study limita-
tions (-1)










ing line of no
effect
“This group has now published follow up data, including neurodevelopmental
outcomes, which were obtained by telephone interview of 60 of the 83 survivors
of the original trial. The interview was conducted between one and four years of
age... Although cerebral palsy [was] reported it is unclear how [it] was defined... It
is not, therefore, possible to add any of these data to the meta-analysis, but they



















(0/14) (2/8) RR 8.33 (0.45
to 154.78)
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ing the line of
no effect













Cerebral palsy 1. “Neurodevelopmental status was assessed at 16 to 24
months corrected age in 77% of survivors of the HIFI 1989
study (185 HFOV & 201 CV) using Bayley psychometric tests
and central nervous system examinations... The rate of cerebral
palsy was 11% in both groups”
2. “Moriette 2001 assessed neuromotor outcome at the
corrected age of two years in 192 of 212 survivors (90%) using a
physician questionnaire... the risk of spastic cerebral palsy was
significantly lower for infants ventilated with HFOV (4%
versus 17%; OR 0.87, 95% CI 0.79 to 0.96), even after
adjustment for multiple factors. Survival without cerebral
palsy was significantly more likely in the HFOV group than
in the CV group (OR 1.89, 95% CI 1.04 to 3.44)”
3. “Sun 2014 assessed neurodevelopmental outcomes at 18
months of corrected age in 145 infants of the HFOV group
(84% of survivors) and in 143 infants of the CV group (86% of
survivors). Cerebral palsy occurred significantly less in the
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at 9 to 15 years
(0/18) (2/18) RR 5.0 (0.26
to 97.37)
36 (1 RCT) VERY LOW Study limita-
tions (-1): 1
RCT at un-

































































177 ( 1 RCT) VERY LOW Study limita-
tions: 1 RCT









ing line of no
effect; 1 small
RCT
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204 (4 RCTs) VERY LOW Study limita-
tions (-1)

























130 (4 RCTs) VERY LOW Study limita-
tions (-1)
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ing line of no
effect
Cerebral palsy
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Table 6. Cerebral palsy (Continued)



































































ing line of no
effect; 1 small
RCT




















135 (1 RCT) LOW Imprecision (-
2):
wide CI cross-
ing line of no
effect; 1 small
RCT














219 (1 RCT) LOW Imprecision (-
2):
wide CI cross-
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post term ing line of no
effect; 1 small
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“Secondary reports emanating from Brown 1985 at six-year fol-
low-up also showed that there was no significant difference in














at age 2 years
(0/93) (2/90) RR 5.16 (0.25
to 106.12)








ing line of no
effect; 1 small
RCT













“van den Berg 2005 reported neurodevelopmental outcomes for
infants aged two years post term. Outcomes assessed included..
. incidence of cerebral palsy... No significant differences between
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156 (1 RCT) LOW Imprecision (-
2):
wide CI cross-

























at 18 to 22
months’ cor-
rected age
(0/7) (1/7) RR 3.0 (0.14
to 63.15)



































588 (1 RCT) LOW Study limita-
tion (-1): 1
RCT with un-
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ing line of no
effect
Abbreviations: BPD: bronchopulmonary dysplasia; CI: confidence interval; CNS: central nervous system; CV: conventional ventilation;
ELBW: extremely low birthweight; g: grams; GRADE: Grades of Recommendation, Assessment, Development and Evaluation;
HFOV: high-frequency oscillatory ventilation; HSV: herpes simplex virus; NO: nitric oxide; OR: odds ratio; P: P value; qRCT:
quasi-randomised controlled trial; RCT: randomised controlled trial; RR: risk ratio.



















































df = 1 (P =
0.93), I² = 0.
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(0/18) (2/18) RR 5.0 (0.
26 to 97.37)
36 (1 RCT) Not applica-
ble
Neonatal care: bronchopulmonary dysplasia
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Abbreviations: CI: confidence interval; DPPC/HDL: dipalmitoylphosphatidylcholine/high-density lipoprotein; g: grams; P: P value;
RCT: randomised controlled trial; RR: risk ratio; T4: thyroxine.
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204 (4 RCTs) VERY LOW Study limita-
tions (-1)
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200 (1 RCT) LOW Imprecision (-
2):
wide CI cross-
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Abbreviations: CI: confidence interval; GRADE: Grades of Recommendation, Assessment, Development and Evaluation; RCT: ran-
domised controlled trial; RR: risk ratio.













































73 (3 RCTs) VERY LOW Study limita-
tions (-1): 1
RCT with un-
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Table 9. Severity of cerebral palsy (Continued)
2010) ation (typical
relative risk 0.









ing the line of
no effect
Abbreviations: CI: confidence interval; GRADE: Grades of Recommendation, Assessment, Development and Evaluation; RCT: ran-
domised controlled trial; RR: risk ratio.
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110 (3 RCTs) VERY LOW Study limita-
tions (-1): 1
RCT with un-
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Table 10. Other composite outcomes that include cerebral palsy as a component (Continued)
Moderate-to-
severe disabil-
ity at 6 to 7
years (defined
as IQ ≥ 2
SD below the
mean, a GMF





























































































31 (1 RCT) VERY LOW Study limita-
tions (-1): un-
blinded study;
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532 (3 RCTs) MODERATE Imprecision (-
1):
wide CI cross-
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effect
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604 (1 RCT) MODERATE Imprecision (-
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wide CI cross-


















399 (1 RCT) MODERATE Imprecision (-
1):
wide CI cross-






























776 (1 RCT) MODERATE Imprecision (-
1):
wide CI cross-
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wide CI cross-
ing line of no
effect
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Table 10. Other composite outcomes that include cerebral palsy as a component (Continued)
fants (Osborn
2004)












































































































328 (1 RCT) LOW Study limita-
tions (-1): 1
RCT at high
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208 (2 RCTs) LOW Imprecision (-
2): wide CI
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593 (2 RCT) VERY LOW Study limita-
tions (-1)
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301 (2 RCTs) LOW Study limita-
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ing line of no
effect; 1 small
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38 (1 RCT) VERY LOW Study limita-
tions (-1): 1
RCT at un-









































37 (1 RCT) VERY LOW Study limita-
tions (-1): 1
RCT at un-









ing line of no
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37 (1 RCT) VERY LOW Study limita-
tions (-1): 1
RCT at un-
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effect; 1 small
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Table 10. Other composite outcomes that include cerebral palsy as a component (Continued)
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wide CI cross-
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799 (7 RCTs) LOW Study limita-
tions (-1): 2
RCTs at un-
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Table 10. Other composite outcomes that include cerebral palsy as a component (Continued)



































































96 (2 RCTs) VERY LOW Study limita-
tions (-1)





























56 (2 RCTs) VERY LOW Study limita-
tions (-1)
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96 (2 RCTs) VERY LOW Study limita-
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655 (8 RCTs) LOW Study limita-
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Abbreviations: BSID: Bayley Scales of Infant Development; CDI: Child Development Inventory; CI: confidence interval; DAS:
Differential Ability Scales; DDST: Denver Developmental Screening Test; DQ: development quotient; GMDS: Griffiths Mental
Development Scales; GMF: gross motor function; GRADE: Grades of Recommendation, Assessment, Development and Evaluation;
IQ: intelligence quotient; MDI: Mental Development Index; PDI: Psychomotor Development Index; RCT: randomised controlled
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trial; RR: risk ratio; SD: standard deviation; VA: visual acuity; VABS: Vineland Adaptive Behaviour Scales; WASI: Wechsler
Abbreviated Scale of Intelligence; WISC: Wechsler Intelligence Scale for Children.
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Table 11. Motor dysfunction (Continued)
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Abbreviations: BSID: Bayley Scales of Infant Development; CI: confidence interval; GRADE: Grades of Recommendation, Assessment,
Development and Evaluation; MDI: Mental Development Index; Movement ABC: Movement Assessment Battery for Children;
PDI: Psychomotor Development Index; qRCT: quasi-randomised controlled trial; RCT: randomised controlled trial; RR: risk ratio;
SD: standard deviation
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AIM To link data from a large maternal perinatal trial with the Australian Cerebral Palsy
Register (ACPR) to identify children with cerebral palsy (CP).
METHOD Deidentified data from the Australasian Collaborative Trial of Magnesium Sulphate
(ACTOMgSO4) and the ACPR were linked. Children born from 1996 to 2000 at Australian
hospitals who survived and had 2-year paediatric assessments were included. Children
identified with CP in: (1) both the ACTOMgSO4 (2y) and the ACPR (5y), (2) the ACTOMgSO4
only, and (3) the ACPR only were compared.
RESULTS We included 913 children (492 males, 421 females; mean gestational age at birth
27.8wks [standard deviation 2.1wks]; range 23.0–40.0wks). Eighty-four children received a CP
diagnosis: 35 by the ACTOMgSO4 and the ACPR, 29 by the ACTOMgSO4 only, and 20 by the
ACPR only. The ACTOMgSO4 diagnosed 76.2% (95% confidence interval [CI] 65.9–84.1) and
the ACPR identified 65.5% (95% CI 54.7–74.9). Children born in states/territories with long-
standing versus more recently established registers were more likely to be included on the
ACPR (p<0.05).
INTERPRETATION Linking deidentified perinatal trial data with the ACPR was achieved.
Limitations of both strategies for identifying children with CP in this era (late 1990s and early
2000s) probably explain many of the differences observed, and inform future linkage studies
and evaluations of CP-preventive interventions.
Long-term follow-up of maternal perinatal interventions is
crucial, with many neurodevelopmental disabilities and
other morbidities associated with perinatal complications
only becoming apparent in, or beyond, childhood.1 How-
ever, only a minority of randomized trials assessing such
interventions are able to report on long-term neurodevel-
opmental health, including cerebral palsy (CP). In a sys-
tematic review of 249 perinatal intervention trials, only 40
(16%) reported outcomes beyond the initial neonatal hos-
pital discharge.2 Although there is increasing recognition
of the importance of assessing longer-term outcomes,1,3
follow-up rates remain low.2 In a systematic review of 22
Cochrane studies of interventions in infants at risk of CP,
‘neurodevelopmental outcomes’ (e.g. CP, blindness, deaf-
ness, intellectual impairment) were the second most fre-
quently reviewed outcomes of interest.4 Only a minority of
included randomized trials (22 out of 203, 11%), however,
reported these data.4 Similarly, our own recent Cochrane
overviews of reviews found that few relevant antenatal or
intrapartum5 (15 out of 77, 19%) and neonatal6 (43 out of
145, 30%) randomized trials reported CP as an outcome.
Challenges associated with long-term follow-up are well
recognized and numerous. Costs may be prohibitive or
underestimated.7 Loss to follow-up may compromise inter-
pretation of outcomes, as the children most difficult to fol-
low-up are known to have comparatively poorer
neurodevelopmental outcomes.8,9 Further, follow-up meth-
ods, ages of assessment, and outcome definitions vary
within and between trials.2,4–6 These hurdles in the mean-
ingful evaluation of preventive strategies for adverse neu-
rodevelopmental outcomes, including CP, have triggered
growing interest in the use of alternative strategies to fol-
low-up children from maternal perinatal intervention trials.
One potential approach is linkage of trial data to routine/
© 2020 Mac Keith Press DOI: 10.1111/dmcn.14556 1
255
administrative data sets or disease-specific registries,10 such
as the Australian Cerebral Palsy Register (ACPR).
Thus, we aimed to assess the utility of linking data from
a large maternal perinatal clinical trial with the ACPR to
identify children with CP. The Australasian Collaborative
Trial of Magnesium Sulphate (ACTOMgSO4) was a ran-
domized trial assessing magnesium sulphate before very
preterm birth, for preventing paediatric mortality and CP,
and was initially funded to follow-up children to these pri-
mary endpoints, at 2 years corrected age.11
METHOD
Design
The current study was a deidentified linkage of existing
data from the ACTOMgSO4 and the ACPR.
Participants and setting
Full details of the ACTOMgSO4 have been reported.
11
Briefly, 1062 females with a singleton, twin, triplet, or
quadruplet pregnancy at less than 30 weeks’ gestation, for
whom birth was planned or expected within 24 hours, were
randomized at 16 maternity hospitals in Australia or New
Zealand, between 1996 and 2000, either to intravenous
magnesium sulphate (n=535) or to saline placebo (n=527).
The pregnant females, health professionals, and outcome
assessors were blinded to allocation. Of 1262 fetuses, 1255
were alive at randomization, and 1061 children survived to
2 years corrected age, where the primary outcomes of
(1) death, (2) CP, and (3) the combined outcome (death or
CP) were determined. Surviving children were assessed by
a developmental paediatrician and psychologist, and par-
ents or caregivers completed questionnaires about their
children’s development. The criteria for CP included
abnormalities of tone, deep tendon or Babinski reflexes,
and impaired motor function. CP severity was described
(before the Gross Motor Function Classification System12)
as mild (disability in ambulant children interfering only
slightly with normal daily activities), moderate (children
attempting to walk at 2y, with or without assisted devices),
or severe (children likely to remain non-ambulant).13
For data linkage, we included children at 13 Australian
hospitals, who survived, and who had paediatric assess-
ments at 2 years. We excluded children born at three hos-
pitals in New Zealand, who died before 2 years, or who
did not have 2-year paediatric assessments.
Data collection and linkage
Data from eligible children within the ACTOMgSO4 data-
base were linked with ACPR data. Established in 2008, the
ACPR is an electronic database, securely uploaded from
each state and territory CP register.14 This includes data
from long-standing CP registers in Western Australia
(established in 1979), Victoria (1987), and South Australia
(1998), and newer (as recently as 2006) registers in New
South Wales/Australian Capital Territory, Queensland,
Tasmania, and the Northern Territory. The processes for
notification to add inclusion in the CP registers vary across
states and territories in line with local ethics and legislative
requirements. To be included in any CP register, a child’s
motor impairment must meet a definition for CP current
at the time (as diagnosed by a health professional, com-
monly a paediatrician), which includes the following key
elements: (1) an umbrella term for a group of disorders; (2)
a condition that is permanent but not unchanging; (3)
involves a disorder of movement and/or posture and of
motor function; (4) caused by a non-progressive interfer-
ence, lesion, or abnormality; (5) the interference, lesion, or
abnormality originated in the immature brain.15,16 Chil-
dren’s CP is again ‘confirmed’ when they reach 5 years of
age; thereafter records are considered ‘complete’. Where
new information becomes available, cases may be updated,
leading to inclusion or exclusion. Along with monitoring
CP incidence and prevalence, one of the ACPR’s key aims
is to facilitate the evaluation of preventive strategies.14
For data linkage, the ACTOMgSO4 coordinating centre
provided the ACPR with a password-protected data set
including the following variables for eligible children: (1)
child’s date of birth; (2) mother’s date of birth; (3) child’s
hospital of birth; (4) child’s birth order number (multiple
births); (5) child’s gestational age at birth (weeks and days);
(6) child’s birthweight (g). To ensure participant anonym-
ity and confidentiality, personal details were not provided,
and each child retained their unique ACTOMgSO4 identi-
fier. Using multiple-step deterministic linkage proce-
dures,17 the ACPR identified potential matches on the
basis of the variables in the above order. Complete
matches were individuals who matched on the first four
variables. If there were missing data, the fifth and sixth
variables were used. After extraction of the CP diagnoses
from the register, the ACPR returned the data set.
Statistical analysis
CP diagnoses were grouped by: (1) diagnosis in both the
ACTOMgSO4 and on the ACPR, (2) in the ACTOMgSO4
only, and (3) on the ACPR only. We assessed CP diag-
noses for all children, and separately for children born in
states with long-standing versus more recently established
CP registers. We used univariate logistic regression models
to explore whether birth state/territory register status, and
movement- and/or posture-related outcomes at the
ACTOMgSO4 2-year assessments, predicted later ACPR
inclusion. Two-year outcomes included those from paedi-
atric assessment (CP, including severity and type, not walk-
ing freely, decreased or increased limb tone, ankle clonus
more than five beats, positive Babinski response, limited
dorsiflexion of ankle, limited hip abduction, limited hip
extension), psychological assessment (Psychomotor Devel-
opmental Index corrected score of the Bayley Scales of
What this paper adds
• Randomized trial data were linked with the Australian Cerebral Palsy Regis-
ter.
• Trial (2y) and register (up to 5y) diagnoses of cerebral palsy (CP) differed.
• States with long-standing registers were more likely to include children with
CP.
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Infant Development, Second Edition),18 and parental ques-
tionnaire (receipt of care from physiotherapist or occupa-
tional therapist, difficulty walking, sitting, using hands, and
with head control). The models were fitted separately
according to CP status in the ACTOMgSO4 and used gen-
eralized estimating equations to account for clustering due
to multiple births. Associations were described using odds
ratios with 95% confidence intervals (CIs). Data were anal-
ysed in SPSS version 21.0 (IBM SPSS Statistics for Win-
dows, IBM Corp., Armonk, NY, USA).
Ethics approval and consent
Ethical approval was granted by the Women’s and Chil-
dren’s Health Network Human Research Ethics Commit-
tee (HREC/16/WCHN/18), and research governance by
the Women’s and Children’s Hospital (SSA/16/WCHN/
057). As conditions of 2.3.10 of the National Statement on
Ethical Conduct in Human Research were met, and all
families had given written informed consent to participate
in the ACTOMgSO4,
11 a waiver of consent was approved.
All state and territory CP register data custodians agreed
to the use of ACPR data for linkage, and a waiver of con-
sent was provided by the Cerebral Palsy Alliance Human
Research and Ethics Committee (project waiver number
2016-03-01).
RESULTS
Of 1061 children who survived to 2 years corrected age,
we excluded 135 born in New Zealand, and 13 who did
not have 2-year paediatric assessments. We thus included
913 children. Their perinatal characteristics are presented
in Table 1.
CP diagnoses
Of 913 eligible children, the ACTOMgSO4 diagnosed 64
(7.0%) with CP at 2 years, and the ACPR identified 55
(6.0%) children with CP at 5 years. Some children with
CP diagnoses were identified by both the ACTOMgSO4
and the ACPR (n=35), others only by the ACTOMgSO4
(n=29) or only by the ACPR (n=20). Thus 84 children
were identified with CP by the ACTOMgSO4 and/or the
ACPR. The ACTOMgSO4 diagnosed 76.2% (95% CI
65.9–84.1) of the 84 children, and the ACPR identified
65.5% (95% CI 54.7–74.9). The remaining 829 children
did not have CP diagnoses either by the ACTOMgSO4 or
the ACPR (Table 2).
Of 46 children with a CP diagnosis (by the
ACTOMgSO4 and/or the ACPR) in states with long-s-
tanding CP registers, the ACTOMgSO4 diagnosed 65.2%
(95% CI 50.4–77.6) (n=30), and the ACPR 80.4% (95%
CI 66.4–89.5) (n=37). Of 38 children with CP diagnoses
(by the ACTOMgSO4 and/or the ACPR) in states/territo-
ries with more recently established registers, the
ACTOMgSO4 diagnosed 89.5% (95% CI 75.1–96.0)
(n=34), and the ACPR identified 47.4% (95% CI 32.3–
63.0) (n=18) (Table 2).
Children with a CP diagnosis in the ACTOMgSO4
Of 64 children with a CP diagnosis at 2 years in the
ACTOMgSO4, those born in states with long-standing CP
registers were more likely to be included on the ACPR (at
5y) than those born in states/territories with more recently
established registers. Children judged to have a ‘definitely
yes’ CP status at 2 years (vs a ‘probably yes’ CP status),
with difficulty walking (paediatric assessment), and using
their hands (parental assessment) were more likely to be
included on the ACPR. No further associations between 2-
year movement and/or posture outcomes assessed and
ACPR inclusion at 5 years were observed (Table S1, online
supporting information). Of the 29 children with a CP
diagnosis in the ACTOMgSO4, not included on the
ACPR, at 2 years, 19 (65.5%) were judged to have ‘mild’,
nine (31.0%) ‘moderate’, and one (3.4%) ‘severe’ CP; no
clear association between CP severity and ACPR inclusion
was observed, however.





Mean gestational age (SD) at birth,
completed wks
27.8 (2.1)
Preterm birth <30wks 872 (95.5)
Preterm birth <37wks 905 (99.1)
Mean birthweight (SD), g 1079.4 (375.4)
Male sex 492 (53.9)
Multiple pregnancy 262 (28.7)
Data are n (%) unless otherwise specified. ACTOMgSO4,
Australasian Collaborative Trial of Magnesium Sulphate; SD,
standard deviation.
Table 2: Diagnoses of cerebral palsy (CP) in ACTOMgSO4 at 2 years, and
on ACPR at 5 years
Australian children from ACTOMgSO4 (n=913) n (%)
CP diagnosis (any) 84 (9.2)
CP in ACTOMgSO4 and on ACPR 35
CP in ACTOMgSO4 only 29
CP on ACPR only 20
No CP diagnosis 829 (90.8)
Children born in states with long-standing CP registers
from ACTOMgSO4 (n=449) n (%)
CP diagnosis (any) 46 (10.2)
CP in ACTOMgSO4 and on ACPR 21
CP in ACTOMgSO4 only 9
CP on ACPR only 16
No CP diagnosis 403 (89.8)
Children born in states/territories with more recently
established CP registers from ACTOMgSO4 (n=464) n (%)
CP diagnosis (any) 38 (8.2)
CP in ACTOMgSO4 and on ACPR 14
CP in ACTOMgSO4 only 20
CP on ACPR only 4
No CP diagnosis 426 (91.8)
ACTOMgSO4, Australasian Collaborative Trial of Magnesium
Sulphate; ACPR, Australian Cerebral Palsy Register.
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Children without a CP diagnosis in the ACTOMgSO4
Of 849 children not diagnosed with CP at 2 years in the
ACTOMgSO4, those born in states with long-standing CP
registers were more likely to be included on the ACPR (at
5y) than those born in states/territories with more recently
established registers (Table S2, online supporting informa-
tion). Children with a ‘definitely no’ CP status at 2 years
(vs a ‘probably no’ CP status) were less likely to be
included on the ACPR. Difficulty walking (paediatric and
parental assessments) and using hands (parental assess-
ment), decreased limb tone and limited dorsiflexion of the
ankle (paediatric assessment), and receipt of care from a
physiotherapist or occupational therapist (parental report)
were all associated with ACPR inclusion. Bayley Scales of
Infant Development, Second Edition Psychomotor Devel-
opmental Index corrected score was associated with ACPR
inclusion; children included on the ACPR had a lower
mean score overall than those not on the ACPR. For the
remaining outcomes assessed, no clear associations with
ACPR inclusion at 5 years were observed (Table S2).
DISCUSSION
With increasing challenges of long-term maternal perinatal
intervention follow-up, there is growing interest in the use
of routine data or registries to assess child health and
development. This approach may have important advan-
tages, including relatively low cost compared with primary
data collection in costly trial follow-up assessments.7,10 We
report the first data linkage of a large maternal perinatal
clinical trial (ACTOMgSO4) with a nationwide CP register
(ACPR) to identify children with CP.
Of almost 1000 Australian children included in this
study (born 1996–2000), the ACTOMgSO4 diagnosed 64
with CP at 2 years, and linkage with the ACPR identified
55 children to have CP up to 5 years. In total, 84 children
were identified to have a CP diagnosis in the
ACTOMgSO4 and/or via the ACPR. Using these data,
prevalence rates of CP ranged from 6.0% to 9.2%; compa-
rable to recently reported Australian birth prevalence rates
for similar gestational ages and years.19
Although we successfully linked these data, we did iden-
tify notable discrepancies in children diagnosed with CP
through the ACTOMgSO4 and those identified by the
ACPR, with only 42% (n=35) of the 84 CP diagnoses con-
sidered ‘matches’. Findings of exploratory analyses (assess-
ing whether birth state/territory status, and movement
and/or posture-related outcomes at the ACTOMgSO4 2-
year assessments predicted later ACPR inclusion) should
be interpreted with caution; small numbers led to relatively
imprecise results. Limitations in both strategies for identi-
fying children with CP in the late 1990s may account for
the differences and warrant discussion.
The ACTOMgSO4 diagnosed 29 children with CP who
were not on the ACPR; there are a variety of potential rea-
sons. While the three long-standing registers (established
before 1998) have achieved population-level ascertainment,
the remaining registers (established as recently as 2006—
well after trial completion) are considered under-ascer-
tained.14 Although notable gains have been made in retro-
spective case ascertainment by these newer registers, for
the relevant birth years, there are probably some ‘missing’
cases/matches.14,19 In line with this, we observed an associ-
ation between register status and ACPR inclusion, with
children (with and without ACTOMgSO4 CP diagnoses)
born in states with long-standing CP registers being more
likely to be included on the ACPR.
Missing ACPR data for variables used for linkage (such
as gestational age at birth and birthweight) in these earlier
birth years, and our obligation to ensure participant anon-
ymity and confidentiality, precluded the determination of a
small number (n=2) of potential ‘matches’. From the
under-ascertained registers, there were ACPR registrations
with complete CP data, but missing data on all/many link-
age variables, preventing any matching. Thus, linking with
identifiable data would have facilitated this study. It is pos-
sible that some children with a diagnosis in the
ACTOMgSO4 were ‘considered’ for ACPR registration,
but ultimately not included on the ACPR; deidentified
linkage also precluded knowledge of this. Under-ascertain-
ment by the ACPR could also relate to factors including
relocation of families internationally; however, we were not
able to quantify the impact of such losses to follow-up in
this deidentified study. With continued improvements in
ACPR ascertainment and considerably fewer missing data
with prospective data collection, these factors may be less
important in future linkages with contemporary trial
cohorts.
Beyond ACPR data limitations for relevant birth years,
possible reasons for differences observed relate to the
descriptive nature of a CP diagnosis, and shortcomings of
diagnostic methods used at the time. CP is an umbrella
term, covering different clinical manifestations and aetiolo-
gies. Registers contributing to the ACPR only consider
cases ‘confirmed’ when children reach 5 years of age,14
acknowledging that new information (or different interpre-
tation of information) may lead to alternative diagnoses or
exclusion. The possibility of diagnosis reversal is well rec-
ognized, particularly for high risk children born preterm
—‘motor abnormalities detected in early childhood may
subsequently lessen in degree, change in kind, or disappear
altogether’.20 Previous studies, including those from the
South Australian21 and Canadian22 CP registers, have
highlighted small proportions of children with CP notifica-
tions, later confirmed to have non-CP diagnoses, for exam-
ple, progressive genetic conditions or syndromes and
metabolic diseases excluded by definition, and developmen-
tal or gross motor delay. In 2016, Korzeniewski et al.
described the ‘transient’ nature of a CP diagnosis, with
40% (17 out of 43) of children with ‘non-disabling’ CP at
2 years having CP at school age (6–9y), compared with
98% (47 out of 48) of those with ‘disabling’ CP.23 In con-
trast, Chen et al. found no association between CP motor
severity and loss of a diagnosis over time (between 2y and
5y) among 1683 children with a Canadian CP Registry
4 Developmental Medicine & Child Neurology 2020
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notification.22 In our study, although we did not observe
an association between CP severity at 2 years and later
ACPR inclusion, of note 66% (19/29) of children diag-
nosed with CP in the ACTOMgSO4, not subsequently on
the ACPR, were considered to have mild CP.
An important further explanation for the differences
observed relates to improvements in diagnostic methods
used. Today, a CP diagnosis (including interim use of a
‘high risk of CP’ diagnosis) can be made according to rec-
ommendations within 2017 international clinical practice
guidelines.24 Where appropriate, including with congru-
ence of findings, a diagnosis is possible under the age of
6 months using predictive tools. As there is no single diag-
nostic tool, a combination of clinical history, neuroimaging
(magnetic resonance imaging, 86–89% sensitivity), stan-
dardized neurological assessments (such as the Hammer-
smith Infant Neurological Examination, 90% sensitivity),
and standardized motor assessments (particularly Prechtl’s
Qualitative Assessment of General Movements before 5mo
corrected age, 98% sensitivity) are suggested, to make the
most accurate, earliest diagnosis.24,25
While the importance of early diagnosis, particularly for
facilitating early intervention, is now recognized, tradition-
ally a CP diagnosis was made much later.24,25 A ‘wait and
see’ approach was common (up to and beyond the per-
ceived ‘latent’ period of 12–24mo, where it was believed
CP could not be identified accurately24), providing time ‘to
rule out other diagnoses, delay the delivery of bad news, or
provide time for the child to grow out of it’.26 Within the
ACTOMgSO4, CP diagnoses were made at a single paedi-
atric examination at 2 years.13 While being the most accu-
rate available approach, it has recognized limitations. We
observed associations between CP status at 2 years in the
ACTOMgSO4 (‘probably yes’ vs ‘definitely yes’ for CP
diagnoses; and ‘probably no’ vs ‘definitely no’ for non-CP
diagnoses) and later ACPR inclusion at 5 years, emphasiz-
ing difficulties in making firm diagnoses in the late 1990s
and early 2000s.
The ACPR identified 20 children with CP not diagnosed
at 2 years in the ACTOMgSO4. We found associations
between a variety of possible indicators of movement and/
or posture dysfunction at 2 years in the ACTOMgSO4 and
subsequent ACPR inclusion at 5 years. For example, chil-
dren without CP diagnoses in the ACTOMgSO4, but with
parental reports of difficulty walking and using their hands,
who received care from physiotherapists and/or occupa-
tional therapists, were more likely to be on the ACPR.
This may represent the presence of ‘milder’ degrees of
motor dysfunction among these children, not sufficient to
flag CP diagnoses at the time of the trial, in the context of
the previously discussed diagnostic limitations.
Our study provides a firm basis for further linkages of
clinical trials with the ACPR for childhood follow-up. All
ACPR contributing registers are expected to achieve popu-
lation-level ascertainment in the coming years, and further
research on the use of ACPR CP diagnoses for long-term
outcome assessment in preventive trials is recommended.
Future trials assessing preventive interventions for CP
should consider pre-specification of linkage with CP regis-
ter data in their protocols, participant information sheets,
and consent forms, enabling the use of identifiable data.
Maternal perinatal trials assessing CP are urged to follow
the international clinical practice guidelines for early, accu-
rate diagnosis.24
CONCLUSION
We have conducted the first deidentified data linkage of a
large maternal perinatal randomized trial with the ACPR.
Limitations of both strategies in the late 1990s and early
2000s for identifying children with CP probably explain
many of the differences observed (with fewer than half of
all CP diagnoses identified by both the trial and the
ACPR). Further linkage studies, of contemporary trial
cohorts, will progress our understanding of the ‘criterion
standard’ strategy for assessing long-term follow-up of CP
after maternal perinatal interventions; and, together with
recent advances in early, accurate CP diagnosis, they will
aid in the future evaluation of preventive strategies.
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There is widespread, increasing use of magnesium sulphate in obstetric practice for pre-
eclampsia, eclampsia, and preterm fetal neuroprotection; benefit for preventing preterm
labour and birth (tocolysis) is unproven. We conducted a systematic review and meta-analy-
sis to assess whether antenatal magnesium sulphate is associated with unintended adverse
neonatal outcomes.
Methods and findings
CINAHL, Cochrane Library, LILACS, MEDLINE, Embase, TOXLINE, and Web of Science,
were searched (inceptions to 3 September 2019). Randomised, quasi-randomised, and
non-randomised trials, cohort and case–control studies, and case reports assessing antena-
tal magnesium sulphate for pre-eclampsia, eclampsia, fetal neuroprotection, or tocolysis,
compared with placebo/no treatment or a different magnesium sulphate regimen, were
included. The primary outcome was perinatal death. Secondary outcomes included pre-
specified and non-pre-specified adverse neonatal outcomes. Two reviewers screened
5,890 articles, extracted data, and assessed risk of bias following Cochrane Handbook and
RTI Item Bank guidance. For randomised trials, pooled risk ratios (RRs) or mean differ-
ences, with 95% confidence intervals (CIs), were calculated using fixed- or random-effects
meta-analysis. Non-randomised data were tabulated and narratively summarised. We
included 197 studies (40 randomised trials, 138 non-randomised studies, and 19 case
reports), of mixed quality. The 40 trials (randomising 19,265 women and their babies) were
conducted from 1987 to 2018 across high- (16 trials) and low/middle-income countries (23
trials) (1 mixed). Indications included pre-eclampsia/eclampsia (24 trials), fetal neuroprotec-
tion (7 trials), and tocolysis (9 trials); 18 trials compared magnesium sulphate with placebo/
no treatment, and 22 compared different regimens. For perinatal death, no clear difference
in randomised trials was observed between magnesium sulphate and placebo/no treatment
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(RR 1.01; 95% CI 0.92 to 1.10; 8 trials, 13,654 babies), nor between regimens. Eleven of
138 non-randomised studies reported on perinatal death. Only 1 cohort (127 babies; moder-
ate to high risk of bias) observed an increased risk of perinatal death with >48 versus�48
grams magnesium sulphate exposure for tocolysis. No clear secondary adverse neonatal
outcomes were observed in randomised trials, and a very limited number of possible
adverse outcomes warranting further consideration were identified in non-randomised stud-
ies. Where non-randomised studies observed possible harms, often no or few confounders
were controlled for (moderate to high risk of bias), samples were small (200 babies or
fewer), and/or results were from subgroup analyses. Limitations include missing data for
important outcomes across most studies, heterogeneity of included studies, and inclusion of
published data only.
Conclusions
Our findings do not support clear associations between antenatal magnesium sulphate for
beneficial indications and adverse neonatal outcomes. Further large, high-quality studies
(prospective cohorts or individual participant data meta-analyses) assessing specific out-
comes, or the impact of regimen, pregnancy, or birth characteristics on these outcomes,
would further inform safety recommendations. PROSPERO: CRD42013004451.
Author summary
Why was this study done?
• Magnesium sulphate is widely used in pregnancy, considered effective for maternal neu-
roprotection in pre-eclampsia/eclampsia and for fetal neuroprotection (cerebral palsy
prevention) in women at risk of preterm birth, and ineffective for preventing preterm
birth or labour (tocolysis).
• It is important to understand whether this treatment, when given to women in preg-
nancy, is associated with any unintended adverse outcomes for babies.
What did the researchers do and find?
• This systematic review incorporates the findings of 197 studies (including 40 rando-
mised controlled trials) that reported on adverse outcomes for babies whose mothers
were treated with magnesium sulphate in pregnancy.
• Meta-analysis of randomised controlled trials showed no clear difference in the risk of
perinatal death between babies whose mothers were treated with magnesium sulphate
and those whose mothers received placebo/no treatment, or between different magne-
sium sulphate regimens.
• No clear adverse outcomes for babies were observed in randomised trials, and a very
limited number of possible adverse outcomes warranting further consideration were
identified in non-randomised studies.
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What do these findings mean?
• Magnesium sulphate in pregnancy, when given for the beneficial indications of mater-
nal or fetal neuroprotection, is not associated with an increased risk of perinatal death
or other adverse outcomes for babies.
• Further investigation into specific adverse outcomes, and the impact of particular treat-
ment regimen, pregnancy, and/or birth characteristics, would further inform safety
recommendations.
Introduction
Antenatal magnesium sulphate is commonly used in obstetric practice. Systematic reviews and
clinical practice guidelines support its use when given for maternal neuroprotection in pre-
eclampsia or eclampsia [1–3] and for neuroprotection of the fetus in women at risk of preterm
birth (for cerebral palsy prevention) [4–7]. Despite continued use in some countries [8], avail-
able evidence does not support its role in preventing preterm birth in women with, or follow-
ing, threatened preterm labour (for tocolysis) [7,9].
Concerns surrounding possible unintended adverse outcomes for fetuses or neonates fol-
lowing exposure to antenatal magnesium sulphate emerged over 50 years ago [10,11], and
uncertainty persists today. While the clinical consequences of hypermagnesemia, related to
increased serum concentrations, are well known and documented (such as lethargy, drowsi-
ness, flushing, nausea, vomiting, muscle weakness, loss of deep tendon reflexes, hypotension,
apnoea, coma, cardiac arrest, and, ultimately, death [12]), whether neonates are at risk of such
adverse outcomes following exposure to antenatal magnesium sulphate is unclear.
We have systematically reviewed the maternal adverse effects of different antenatal magne-
sium sulphate regimens [13], and a further systematic review has summarised the effects
specifically on fetal heart rate [14]. To our knowledge, a broad evaluation of evidence sur-
rounding potential unintended neonatal adverse outcomes, informed by current guidance
[15–17], has not previously been conducted. Implementation of this treatment may be
strengthened, and its safety improved, if guidelines and recommendations for practice can be
based on such knowledge.
The aim of our study, therefore, was to conduct a comprehensive systematic review to assess
whether antenatal magnesium sulphate is associated with perinatal death and other unin-
tended adverse neonatal outcomes.
Methods
We conducted a systematic review following the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guideline; the relevant checklist is provided in S1
PRISMA Checklist. Prior to conduct, this systematic review was registered with PROSPERO
(International Prospective Register of Systematic Reviews; CRD42013004451) [18]. The Aus-
tralian Cerebral Palsy Alliance Research Foundation–funded review protocol is available in
S1 Text. Ethical approval was not required.
Antenatal magnesium sulphate and adverse neonatal outcomes
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Search strategy
Comprehensive searches of the bibliographic databases CINAHL, Cochrane Library, LILACS,
MEDLINE, Embase, TOXLINE, and Web of Science were undertaken from their respective
inceptions to 3 September 2019, using combinations of MeSH and free text terms. The search
strategies are available in S2 Text. No date or language restrictions were applied; however,
because of logistical constraints, for non-English papers, only those with an available English
abstract or full-text translation were retrieved. The reference lists of eligible articles were
checked for additional reports.
Inclusion criteria
We included randomised and quasi-randomised controlled trials as well as non-randomised
controlled studies (non-randomised trials, cohort studies, and case–control studies), and case
reports. We excluded cross-sectional studies and case series. We included studies available as
abstracts only, along with full-text publications.
We included neonates who were exposed to antenatal magnesium sulphate, regardless of
their gestational age at exposure or birth. We included studies where antenatal magnesium sul-
phate was given for pre-eclampsia or eclampsia, for neuroprotection of the fetus, or for tocoly-
sis. We excluded studies where magnesium sulphate was given as an adjuvant during obstetric
anaesthesia. We included intervention studies in which magnesium sulphate was compared
with no treatment, placebo, or a different magnesium sulphate regimen. We included observa-
tional studies where magnesium sulphate was assessed as an ‘exposure’. We excluded studies
where magnesium sulphate was compared with another therapy (for example, diazepam for
pre-eclampsia or eclampsia, or nifedipine for tocolysis).
We included studies that reported on adverse outcomes for neonates, however defined. The
primary outcome was perinatal death. Secondary outcomes included pre-specified adverse
outcomes (based on non-systematic literature review: stillbirth, neonatal death or death up to
hospital discharge, low Apgar scores at 1 and 5 minutes, need for active resuscitation at birth,
respiratory depression, spontaneous intestinal perforation, patent ductus arteriosus, hypoten-
sion, lethargy, hypotonia or hyporeflexia, osteopenia or bone fractures, neonatal intensive care
unit admission, and duration of neonatal care unit admission), along with other non-pre-spec-
ified adverse neonatal outcomes.
Study selection
After screening all titles and abstracts, we obtained full-text articles for studies that appeared to
meet the inclusion criteria. All full-text articles were assessed for inclusion. Each stage was car-
ried out by 2 reviewers, and we resolved any discrepancies through discussion, or, if required,
we consulted a third reviewer.
Data extraction and management
For included studies, data were extracted using a standardised form, including information
regarding design, participants, the magnesium sulphate regimen(s), the control/comparison if
applicable, neonatal adverse outcomes reported, results relevant to the review, and the risk of
bias. For all randomised trials, all case reports, and 60% of non-randomised studies, extraction
was carried out by 2 reviewers (for 40% of non-randomised studies, extractions were checked
by a second reviewer), and we resolved discrepancies through discussion, or, if required, we
consulted a third reviewer.
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Assessment of risk of bias
Quality appraisal of intervention studies was undertaken utilising established guidelines pro-
vided in the Cochrane Handbook for Systematic Reviews of Interventions [19]. The quality
assessment of observational studies was guided by the RTI Item Bank [20].
Data synthesis and analysis
Data analyses were undertaken by study design. Statistical analyses for randomised trials
were performed using Review Manager, version 5.3 [21]. We present quantitative data from
individual studies as risk ratios (RRs) for dichotomous outcomes and mean differences
(MDs) for continuous outcomes, with 95% confidence intervals (CIs). For all outcomes, we
carried out analyses as far as possible on an intention-to-treat basis. Pooled estimates were
calculated using fixed-effects meta-analysis (Mantel-Haenszel method) where there was a
sufficient quantity of data, with clinical homogeneity. Where there was substantial statistical
heterogeneity (where I2 was greater than 30% and either T2 was greater than 0 or there was a
low P value [less than 0.10] in the χ2 test), summary estimates were calculated using ran-
dom-effects meta-analysis. Where there were 10 or more trials in a meta-analysis, we investi-
gated reporting biases (such as publication bias) using funnel plots, which we assessed
visually.
Separate comparisons were performed for those studies assessing magnesium sulphate ver-
sus no treatment/placebo and those comparing different magnesium sulphate regimens. For
our primary review outcome (perinatal death) and other mortality outcomes, we conducted
subgroup analyses based on indication for use and characteristics of the magnesium sulphate
loading and maintenance dose regimens, as these factors were considered likely to influence
outcomes. It was not possible to conduct subgroup analyses based on other pregnancy or birth
characteristics (gestational age at magnesium sulphate administration, birthweight, mode of
birth, and concomitant maternal treatments) due to paucity of data. We assessed subgroup dif-
ferences by interaction tests available within Review Manager, and, where applicable, we have
quoted the χ2 statistic and P value, and the interaction test I2 value.
For observational studies (non-randomised trials, cohort studies, and case–control studies),
we present effect estimates where possible as adjusted RRs or odds ratios if reported with 95%
CIs, unadjusted RRs or odds ratios with 95% CIs, P values only, or percentages (rates), in tabu-
lar format; we used narrative synthesis to summarise the studies. Data from case reports were
grouped according to common adverse outcomes, tabulated, and summarised narratively.
Results
Study selection
The results of the search strategy, including the sources of the studies, their assessment, and
final inclusion are shown in Fig 1. The database searching identified 5,890 records, and other
searching identified a further 11 records. Review of the titles and abstracts and exclusion of
irrelevant and duplicate records yielded 777. Of these, we excluded 572 for the documented
reasons (see S3 Text for list of records excluded due to absence of an English translation). We
included a total of 205 articles, relating to 197 studies. See S4 Text for references for all
included studies. In the case of multiple publications from the same study, we included the
report with the most relevant data as the primary reference, and only included further publica-
tions as secondary references if they provided additional relevant data.
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Evidence from randomised controlled trials
Forty randomised trials were included, the characteristics of which are detailed in S1 Table,
and the risk of bias assessments are summarised in Fig 2, S1 Fig, and S2 Table [22–61]. The tri-
als assessed a range of different magnesium sulphate regimens with varying control groups,
and are therefore assessed under 8 different comparisons:
Fig 1. Flow diagram of included studies. Flow diagram showing the flow of records through the different phases of the review, indicating the number
of records identified, included and excluded, and the reasons for exclusions.
https://doi.org/10.1371/journal.pmed.1002988.g001
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1. Magnesium sulphate versus placebo or no treatment (18 trials)
2. Lower versus higher dose regimens of magnesium sulphate (8 trials)
3. Intramuscular (IM) versus intravenous (IV) maintenance dose of magnesium sulphate (5
trials)
4. Loading versus loading and maintenance dose of magnesium sulphate (5 trials)
5. Serial IV boluses versus continuous IV infusion of magnesium sulphate (1 trial)
6. Short versus standard maintenance of magnesium sulphate (1 trial)
7. Slower versus standard rate of loading dose infusion of magnesium sulphate (1 trial)
8. Weaning versus no weaning of maintenance of magnesium sulphate (1 trial)
The methodological quality of the 40 trials varied considerably. Considering selection bias,
18 trials were at low risk, reporting adequate methods for sequence generation and allocation
concealment. Twelve and 8 trials received an unclear judgement for 1 and 2 of the selection
bias domains, respectively. Two trials appeared to be quasi-randomised and thus were at high
risk of selection bias. Twelve trials were at low risk of performance and detection bias (with
blinding of participants, personnel, and outcome assessors); 21 were at high risk of both per-
formance and detection bias (all trials of different magnesium sulphate regimens, with no
reported blinding), and the remaining 7 trials had an unclear judgement for 1 or 2 of the blind-
ing domains. The majority of trials (31) were at low risk of attrition bias for neonatal outcome
data, though for 9 trials, this was unclear. Only 5 trials were at low risk of reporting bias, 1 was
at high risk of reporting bias, and for the remaining 34 trials, selective reporting was unclear.
Magnesium sulphate versus placebo or no treatment
This comparison included 18 trials. The indication for use of magnesium sulphate in 6 trials
was the prevention of eclampsia [30,32,39,43,48,61]; in 6 trials, fetal neuroprotection
[28,36,45,47,51,54]; and in 6 trials, the prevention of preterm birth (tocolysis) [33–35,38,40,46].
Fig 2. Risk of bias for randomised controlled trials. Risk of bias graph showing judgements about each risk of bias item presented as percentages
across the 40 included randomised trials.
https://doi.org/10.1371/journal.pmed.1002988.g002
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Magnesium sulphate regimens assessed varied considerably: 4-gram IV loading dose only (2
trials), 4-gram IV loading dose and 1-gram-per-hour IV maintenance dose (4 trials), 4-gram
IV loading dose and 2-gram-per-hour IV maintenance (4 trials), 6-gram IV loading dose and
2-gram-per-hour IV maintenance dose (6 trials), and 4-gram IV and 10-gram IM loading dose
and 5-gram IM maintenance dose every 4 hours (2 trials), with duration of treatment generally
ranging from 12 to 24 hours. Fourteen trials compared magnesium sulphate with a placebo,
while 4 trials had a no-treatment comparison (see Table 1 and S1 Appendix for effect estimates,
forest plots, and funnel plots).
No clear difference was seen between magnesium sulphate and placebo/no treatment for
the primary review outcome perinatal death (RR 1.01; 95% CI 0.92 to 1.10; 8 trials, 13,654
babies; analysis 1.1), nor for stillbirth, neonatal death (no obvious asymmetry observed on
visual assessment of funnel plot), death later than 28 days but before discharge, early neonatal
death, or late neonatal death (Table 1; S1 Appendix). When considering indication for use, the
tocolysis subgroup showed an increase in perinatal death (RR 7.99; 95% CI 1.00 to 63.49; 2 tri-
als, 257 babies; analysis 1.1.1) that was not observed in the pre-eclampsia or fetal neuroprotec-
tion subgroups. The subgroup interaction test, however, did not indicate a differential effect
according to treatment indication (χ2 = 4.07, P = 0.13, I2 = 50.8%). For the remaining mortality
outcomes, subgroup interaction tests did not indicate differential treatment effects according
to indication for administration (see Tables 2 and 3 for effect estimates for individual sub-
groups and results from subgroup interaction tests).
Babies exposed to antenatal magnesium sulphate had a 67% relative increase in the risk of
having an Apgar score less than 7 at 1 minute (RR 1.67; 95% CI 1.02 to 2.73; 2 trials, 199 babies;
analysis 1.7), and over 2 times the risk of need for volume expansion compared with babies
not exposed (RR 2.03; 95% CI 1.01 to 4.10; 1 trial, 87 babies; analysis 1.28). A subgroup of
babies born less than 32 weeks gestation exposed to antenatal magnesium sulphate had a 62%
relative reduction in the risk of intracerebral echodensity, compared with babies not exposed
(RR 0.38; 95% CI 0.19 to 0.79; 1 trial, 1,613 babies; analysis 1.46). While a difference in intrace-
rebral echolucency was not observed in all babies, a 39% relative reduction was seen for babies
born less than 32 weeks exposed to antenatal magnesium sulphate (RR 0.61; 95% CI 0.38 to
0.97; 1 trial, 1,613 babies; analysis 1.47.2) (Table 1; S1 Appendix).
There were no clear differences between magnesium sulphate and placebo/no treatment for
all remaining secondary outcomes reported (Table 1; S1 Appendix).
Lower versus higher dose regimens
This comparison included 8 trials, with 6 assessing magnesium sulphate for treatment of
eclampsia or severe pre-eclampsia [22,23,44,52,56,59], and 2 for the prevention of preterm
birth (tocolysis) [26,60]. Regimens assessed varied: lower dose regimens included a 4- to
10-gram loading dose with a 0.625- to 2-gram-per-hour maintenance dose; higher dose regi-
mens assessed included a 4- to 14-gram loading dose with a 1.25- to 5-gram-per-hour mainte-
nance dose (see Table 4 and S1 Appendix for effect estimates and forest plots).
No clear differences between the lower and higher dose regimens of magnesium sulphate
were seen for the primary review outcome perinatal death (RR 1.01; 95% CI 0.75 to 1.36; 6 tri-
als, 543 babies; analysis 2.1), nor for stillbirth or neonatal death (Table 4; S1 Appendix). For all
mortality outcomes, subgroup interaction tests did not indicate differential treatment effects
according to indication for administration of antenatal magnesium sulphate (see Table 5 for
effect estimates for individual subgroups and results from subgroup interaction tests).
Babies exposed to the lower dose versus higher dose regimens of magnesium sulphate had
an increased risk of neonatal intensive care unit admission (RR 1.75; 95% CI 1.06 to 2.88; 5
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Table 1. Adverse outcome estimates from randomised controlled trials: Comparison 1—Magnesium sulphate versus placebo or no treatment.
Outcome Studies Participants Method (I2) RR (95% CI)
1.1 Perinatal death 8 13,654 F (23%) 1.01 (0.92, 1.10)
1.2 Stillbirth 9 12,340 F (0%) 0.99 (0.87, 1.12)
1.3 Neonatal death 11 12,987 F (21%) 1.00 (0.86, 1.17)
1.4 Death > 28 days, before discharge 5 10,691 F (0%) 0.96 (0.60, 1.53)
1.5 Early neonatal death 1 9,024 F (NA) 1.09 (0.86, 1.37)
1.6 Late neonatal death 1 9,024 F (NA) 1.54 (0.95, 2.49)
1.7 Apgar score < 7 at 1 minute 2 199 F (17%) 1.67 (1.02, 2.73)
1.8 Apgar score < 7 at 5 minutes 5 12,729 F (0%) 1.02 (0.92, 1.14)
1.9 Meconium at birth 1 210 F (NA) 1.55 (0.89, 2.72)
1.10 Intubated at birth 3 11,364 F (30%) 0.95 (0.87, 1.04)
1.11 Resuscitation in the delivery room
1.11.1 Any 1 2,416 F (NA) 0.99 (0.96, 1.03)
1.11.2 Oxygen bag, mask, or both 1 2,416 F (NA) 1.07 (0.98, 1.17)
1.11.3 Chest compressions 1 2,416 F (NA) 1.11 (0.73, 1.71)
1.12 Respiratory distress syndrome 7 3,639 R (46%) 0.95 (0.79, 1.14)
1.13 Transient tachypnoea of the newborn 2 243 F (0%) 0.96 (0.52, 1.77)
1.14 Surfactant 1 87 F (NA) 0.88 (0.62, 1.24)
1.15 Mechanical ventilation 5 12,751 R (63%) 1.01 (0.94, 1.09)
1.16 Non-invasive ventilation 1 688 F (NA) 1.03 (0.93, 1.15)
1.17 Oxygen required 1 153 F (NA) 0.95 (0.67, 1.35)
1.18 Chronic lung disease 5 4,513 F (0%) 1.06 (0.96, 1.17)
1.19 Apnoea and bradycardia 2 841 F (0%) 1.23 (0.98, 1.53)
1.20 Pneumothorax 1 87 F (NA) 2.44 (0.26, 22.52)
1.21 Pulmonary haemorrhage 1 87 F (NA) 2.44 (0.52, 11.41)
1.22 Necrotising enterocolitis 8 4,804 F (0%) 1.21 (0.98, 1.51)
1.23 Sepsis 4 2,694 R (31%) 0.83 (0.54, 1.28)
1.24 Hypoglycaemia on NICU admission 1 34 F (NA) 0.63 (0.06, 6.34)
1.25 Poor feeding 1 90 F (NA) No events
1.26 Patent ductus arteriosus 3 2,536 F (26%) 0.97 (0.80, 1.17)
1.27 Hypotension 2 3,103 F (22%) 1.03 (0.89, 1.19)
1.28 Volume expansion 1 87 F (NA) 2.03 (1.01, 4.10)
1.29 Mean blood pressure < 10th centile in the first 24 hours 1 87 F (NA) 1.30 (0.67, 2.53)
1.30 Superior vena cava flow < 41 ml/kg/min in the first 24 hours 1 87 F (NA) 1.22 (0.62, 2.40)
1.31 Right ventricular output < 120 ml/kg/min in the first 24 hours 1 87 F (NA) 1.08 (0.51, 2.30)
1.32 Dobutamine 1 87 F (NA) 1.73 (0.84, 3.57)
1.33 Dopamine 1 87 F (NA) 2.17 (0.62, 7.62)
1.34 Any inotrope 1 87 F (NA) 1.54 (0.82, 2.92)
1.35 Retinopathy of prematurity 1 2,415 F (NA) 0.99 (0.85, 1.14)
1.36 Generalised hypotonicity 1 2,415 F (NA) 1.03 (0.77, 1.37)
1.37 Seizures 4 11,397 F (0%) 0.78 (0.57, 1.06)
1.38 Hyperbilirubinaemia 1 90 F (NA) 2.00 (0.19, 21.28)
1.39 Intraventricular haemorrhage 10 4,891 F (0%) 0.95 (0.85, 1.06)
1.40 Intraventricular haemorrhage, grade 3 or 4 6 3,769 F (19%) 0.81 (0.60, 1.09)
1.41 Periventricular leucomalacia 4 4,225 F (0%) 0.93 (0.68, 1.28)
1.42 Any white matter injury 1 665 F (NA) 0.87 (0.62, 1.22)
1.43 Severe white matter injury 1 688 F (NA) 0.85 (0.55, 1.32)
1.44 Severe white matter injury or death 1 688 F (NA) 0.92 (0.66, 1.28)
(Continued)
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Table 1. (Continued)
Outcome Studies Participants Method (I2) RR (95% CI)
1.45 Persistent parenchymal echogenicity 1 8,260 F (NA) 1.09 (0.66, 1.81)
1.46 Echodensity in children born < 32 weeks 1 1,613 F (NA) 0.38 (0.19, 0.79)
1.47 Echolucency
1.47.1 In all children 1 1,776 F (NA) 0.62 (0.37, 1.03)
1.47.2 In children born < 32 weeks 1 1,613 F (NA) 0.61 (0.38, 0.97)
1.48 Ventriculomegaly 2 10,036 F (0%) 0.98 (0.68, 1.42)
1.49 Any of echodensity, echolucency, intraventricular haemorrhage, periventricular haemorrhage, or
ventriculomegaly
1.49.1 In all children 1 1,776 F (NA) 0.85 (0.69, 1.06)
1.49.2 In children born < 32 weeks 1 1,613 F (NA) 0.92 (0.78, 1.09)
1.50 Composite adverse outcome 1 1,776 F (NA) 0.62 (0.37, 1.03)
1.51 NICU admission 3 8,519 F (17%) 1.00 (0.95, 1.06)
1.52 Intensive care unit stay (days) 1 120 MD, F (NA) 0.02 (−0.17, 0.21)




1.54 Special care baby unit admission > 7 days or death 1 9,024 F (NA) 1.01 (0.95, 1.08)
1.55 Special care baby unit admission > 7 days 1 8,260 F (NA) 1.02 (0.93, 1.11)
1.56 Still in hospital at 6 weeks 1 9,024 F (NA) 0.99 (0.06, 15.80)
Statistically significant effect estimates in bold. Test for heterogeneity represented by I2 statistic; where I2 > 30%, summary estimates were calculated using random-
effects meta-analysis.
CI, confidence interval; F, fixed-effects; MD, mean difference; NA, not applicable; NICU, neonatal intensive care unit; R, random-effects; RR, risk ratio.
https://doi.org/10.1371/journal.pmed.1002988.t001
Table 2. Subgroup analyses based on indication for use from randomised controlled trials: Comparison 1—Magnesium sulphate versus placebo or no treatment.
Outcome and subgroup Studies Participants Method (I2) RR (95% CI) χ2, P value, I2
1.1 Perinatal death
1.1.1 Tocolysis 2 257 F (NA) 7.99 (1.00, 63.49) 4.07, 0.13, 50.8%
1.1.2 Pre-eclampsia 2 9,259 F (0%) 1.01 (0.91, 1.13)
1.1.3 Fetal neuroprotection 4 4,138 F (0%) 0.96 (0.80, 1.15)
1.2 Stillbirth
1.2.1 Tocolysis 2 257 F (NA) 5.70 (0.28, 116.87) 1.45, 0.49, 0%
1.2.2 Pre-eclampsia 3 9,961 F (8%) 0.99 (0.87, 1.12)
1.2.3 Fetal neuroprotection 4 2,122 F (0%) 0.85 (0.40, 1.80)
1.3 Neonatal death
1.3.1 Tocolysis 4 445 R (61%) 0.78 (0.11, 5.67) 0.48, 0.79, 0%
1.3.2 Pre-eclampsia 2 9,259 R (35%) 1.03 (0.64, 1.65)
1.3.3 Fetal neuroprotection 5 3,283 R (0%) 0.86 (0.68, 1.08)
1.4 Death > 28 days, before discharge
1.4.1 Tocolysis 3 412 F (0%) 0.76 (0.19, 3.09) 0.37, 0.83, 0%
1.4.2 Pre-eclampsia 1 9,024 F (NA) 1.13 (0.55, 2.31)
1.4.3 Fetal neuroprotection 1 1,255 F (NA) 0.88 (0.44, 1.74)
Statistically significant effect estimates in bold. Test for heterogeneity represented by I2 statistic; where I2 > 30%, summary estimates were calculated using random-
effects meta-analysis. Result of test subgroup differences represented by χ2 statistic, P value, and I2 statistic.
CI, confidence interval; F, fixed-effects; NA, not applicable; R, random-effects; RR, risk ratio.
https://doi.org/10.1371/journal.pmed.1002988.t002
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trials, 409 babies; analysis 2.17). On average, babies exposed to the lower dose regimen had a
longer duration of stay in the neonatal intensive care unit compared with those exposed to the
higher dose regimen (MD 3.10 days; 95% CI 0.78 to 5.42; 1 trial, 104 babies; analysis 2.18)
(Table 4; S1 Appendix).
Table 3. Subgroup analyses based on regimen characteristics from randomised controlled trials: Comparison 1—Magnesium sulphate versus placebo or no
treatment.
Outcome or subgroup Studies Participants Method (I2) RR (95% CI) χ2, P value, I2
Subgroups based on LD
1.1 Perinatal death
1.1.4 4-g IV LD 5 2,259 R (42%) 0.96 (0.62, 1.49) 0.57, 0.75, 0%
1.1.5 6-g IV LD 1 2,136 R (NA) 1.12 (0.85, 1.47)
1.1.6 4-g IV and 10-g IM LD 2 9,259 R (0%) 1.01 (0.91, 1.12)
1.2 Stillbirth
1.2.4 4-g IV LD 6 2,961 F (0%) 1.25 (0.85, 1.84) 1.57, 0.21, 36.1%
1.2.5 6-g IV LD 1 120 F (NA) No events
1.2.6 4-g IV and 10-g IM LD 2 9,259 F (0%) 0.96 (0.84, 1.10)
1.3 Neonatal death
1.3.4 4-g IV LD 6 2,294 R (7%) 0.86 (0.64, 1.16) 0.44, 0.80, 0%
1.3.5 6-g IV LD 3 1,434 R (2%) 0.83 (0.48, 1.44)
1.3.6 4-g IV and 10-g IM LD 2 9,259 R (35%) 1.03 (0.64, 1.65)
1.4 Death > 28 days, before discharge
1.4.4 4-g IV LD 3 1,514 F (0%) 0.81 (0.43, 1.53) 0.81, 0.67, 0%
1.4.5 6-g IV LD 1 153 F (NA) 2.47 (0.10, 59.70)
1.4.6 4-g IV and 10-g IM LD 1 9,024 F (NA) 1.13 (0.55, 2.31)
Subgroups based on MD
1.1 Perinatal death
1.1.7 LD only 2 747 R (0%) 0.92 (0.59, 1.44) 2.73, 0.44, 0%
1.1.8 1-g/hour IV MD 1 1,255 R (NA) 0.81 (0.60, 1.09)
1.1.9 2–5-g/hour IV MD 3 2,393 R (71%) 2.27 (0.35, 14.55)
1.1.10 5-g/4-hour IM MD 2 9,259 R (0%) 1.01 (0.91, 1.12)
1.2 Stillbirth
1.2.7 LD only 2 747 F (0%) 0.96 (0.22, 4.17) 2.50, 0.48, 0%
1.2.8 1-g/hour IV MD 2 1,957 F (9%) 1.22 (0.81, 1.83)
1.2.9 2–5-g/hour IV MD 3 377 F (0%) 5.70 (0.28, 116.87)
1.2.10 5-g/4-hour IM MD 2 9,259 F (0%) 0.96 (0.84, 1.10)
1.3 Neonatal death
1.3.7 LD only 2 747 R (0%) 0.93 (0.58, 1.47) 0.72, 0.87, 0%
1.3.8 1-g/hour IV MD 1 1,255 R (NA) 0.81 (0.59, 1.11)
1.3.9 2–5-g/hour IV MD 6 1,726 R (41%) 0.84 (0.30, 2.33)
1.3.10 5-g/4-hour IM MD 2 9,259 R (35%) 1.03 (0.64, 1.65)
1.4 Death > 28 days, before discharge
1.4.7 1-g/hour IV MD 1 1,255 F (NA) 0.88 (0.44, 1.74) 0.37, 0.83, 0%
1.4.8 2–5-g/hour IV MD 3 412 F (0%) 0.76 (0.19, 3.09)
1.4.9 5-g/4-hour IM MD 1 9,024 F (NA) 1.13 (0.55, 2.31)
Test for heterogeneity represented by I2 statistic; where I2 > 30%, summary estimates were calculated using random-effects meta-analysis. Result of test subgroup
differences represented by χ2 statistic, P value, and I2 statistic.
CI, confidence interval; F, fixed-effects; g, gram; IM, intramuscular; IV, intravenous; LD, loading dose; MD, maintenance dose; NA, not applicable; R, random-effects;
RR, risk ratio.
https://doi.org/10.1371/journal.pmed.1002988.t003
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No clear differences were seen between the lower and higher dose regimens of magnesium
sulphate for the remaining secondary outcomes reported (Table 4; S1 Appendix).
IM versus IV maintenance dose
This comparison included 5 trials, all assessing magnesium sulphate for the prevention or
treatment of eclampsia [27,31,49,55,58]. Regimens assessed included Bhattacharjee’s regimen
Table 4. Adverse outcome estimates from randomised controlled trials: Comparison 2—Lower versus higher dose regimens of magnesium sulphate.
Outcome Studies Participants Method (I2) RR (95% CI)
2.1 Perinatal death 6 543 F (0) 1.01 (0.75, 1.36)
2.2 Stillbirth 5 471 F (0) 0.94 (0.61, 1.45)
2.3 Neonatal death 6 535 F (0) 1.12 (0.57, 2.22)
2.4 Apgar score < 7 at 1 minute 3 302 F (0) 0.96 (0.68, 1.35)
2.5 Apgar score < 7 at 5 minutes 3 302 R (35%) 1.41 (0.54, 3.65)
2.6 Resuscitation 1 64 F (NA) 1.00 (0.22, 4.59)
2.7 Respiratory distress syndrome 2 154 R (53%) 1.97 (0.76, 5.15)
2.8 Respiratory depression 1 50 F (NA) 0.33 (0.04, 2.99)
2.9 Respiratory disorders 1 64 F (NA) 1.08 (0.87, 1.33)
2.10 Mechanical ventilation 1 64 F (NA) 2.00 (0.39, 10.16)
2.11 Bradycardia 1 104 F (NA) 3.85 (0.45, 33.29)
2.12 Jaundice 1 50 F (NA) 1.25 (0.38, 4.12)
2.13 Hypoglycaemia 1 104 F (NA) 0.96 (0.06, 14.98)
2.14 Hypocalcaemia 1 104 F (NA) 2.89 (0.12, 69.32)
2.15 Hypotonia 1 50 F (NA) 0.14 (0.02, 1.08)
2.16 Requirement for calcium gluconate 1 50 F (NA) 0.25 (0.06, 1.06)
2.17 NICU admission 5 409 F (6%) 1.75 (1.06, 2.88)
2.18 NICU stay (days) 1 104 MD, F (NA) 3.10 (0.78, 5.42)
Statistically significant effect estimates in bold. Test for heterogeneity represented by I2 statistic; where I2 > 30%, summary estimates were calculated using random-
effects meta-analysis.
CI, confidence interval; F, fixed-effects; MD, mean difference; NA, not applicable; NICU, neonatal intensive care unit; R, random-effects; RR, risk ratio.
https://doi.org/10.1371/journal.pmed.1002988.t004
Table 5. Subgroup analyses based on indication for use from randomised controlled trials: Comparison 2—Lower versus higher dose regimens of magnesium
sulphate.
Outcome and subgroup Studies Participants Method (I2) RR (95% CI) χ2, P value, I2
2.1 Perinatal death
2.1.1 Tocolysis 1 104 F (NA) 2.25 (0.61, 8.21) 1.63, 0.20, 38.6%
2.1.2 Pre-eclampsia/eclampsia 5 439 F (0%) 0.94 (0.70, 1.28)
2.2 Stillbirth
2.2.1 Tocolysis 1 104 F (NA) 0.96 (0.06, 14.98) 0.00, 0.99, 0%
2.2.2 Pre-eclampsia/eclampsia 4 367 F (0%) 0.94 (0.60, 1.46)
2.3 Neonatal death
2.3.1 Tocolysis 1 104 F (NA) 2.89 (0.61, 13.65) 1.99, 0.16, 49.6%
2.3.2 Pre-eclampsia/eclampsia 5 431 F (0%) 0.82 (0.37, 1.82)
Test for heterogeneity represented by I2 statistic; where I2 > 30%, summary estimates were calculated using random-effects meta-analysis. Result of test subgroup
differences represented by χ2 statistic, P value, and I2 statistic.
CI, confidence interval; F, fixed-effects; NA, not applicable; RR, risk ratio.
https://doi.org/10.1371/journal.pmed.1002988.t005
Antenatal magnesium sulphate and adverse neonatal outcomes
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002988 December 6, 2019 12 / 37
274
(4-gram IV loading dose; 6-gram IV maintenance dose every 8 hours), Dhaka regimen
(4-gram IV and 6-gram IM loading dose; 2.5-gram IM maintenance dose every 4 hours),
Pritchard’s regimen (4-gram IV and 10-gram IM loading dose; 5-gram IM maintenance dose
every 4 hours), Zuspan’s regimen (4-gram IV loading dose; 1-gram IV maintenance dose
every hour), and Sibai’s regimen (6-gram IV loading dose; 2-gram IV maintenance dose every
hour) (all maintenance doses were for 24 hours after birth or last seizure) (see Table 6 and S1
Appendix for effect estimates and forest plots).
No clear differences were observed for
• Pritchard’s versus Zuspan’s regimen for the primary review outcome perinatal death (RR
0.94; 95% CI 0.66 to 1.32; 2 trials, 353 babies; analysis 3.1.1), nor for stillbirth or neonatal
death;
• Pritchard’s versus Sibai’s regimen for the primary review outcome perinatal death (RR 0.90;
95% CI 0.53 to 1.53; 1 trial, 115 babies; analysis 3.1.2), nor for stillbirth or neonatal death;
• Pritchard’s versus Bhattacharjee’s regimen for the primary review outcome perinatal death
(RR 1.28; 95% CI 0.61 to 2.65; 1 trial, 107 babies; analysis 3.1.3), nor for stillbirth or neonatal
death;
• Dhaka versus Zuspan’s regimen for the primary review outcome perinatal death (RR 0.57;
95% CI 0.16 to 2.08; 1 trial, 41 babies; analysis 3.1.4), nor for stillbirth or neonatal death
(Table 6; S1 Appendix).
No clear differences were observed for Pritchard’s versus Zuspan’s regimen, Pritchard’s ver-
sus Sibai’s regimen, or Dhaka versus Zuspan’s regimen for the remaining secondary outcomes
reported (Table 6; S1 Appendix).
Loading dose versus loading and maintenance doses
This comparison included 5 trials, all assessing magnesium sulphate for the prevention or
treatment of eclampsia [25,41,50,53,57]. Trials compared a cumulative 8-, 10-, or 14-gram
loading dose (4 grams IV and 4 to 10 grams IM) with Dhaka or Pritchard’s regimen (see
descriptions above; and see Table 6 and S1 Appendix for effect estimates and forest plots).
No clear differences for loading dose only versus loading and maintenance dose regimens
were seen for the primary review outcome perinatal death (average RR 0.94; 95% CI 0.33 to
2.72; 3 trials, 632 babies; analysis 4.1), nor for stillbirth, neonatal death, or neonatal death at
less than 7 days (Table 6; S1 Appendix).
No clear differences for loading dose only versus loading and maintenance dose regimens
were seen for the remaining secondary outcomes reported (Table 6; S1 Appendix).
Serial IV boluses versus continuous IV maintenance dose
This comparison included 1 trial, assessing magnesium sulphate for the treatment of severe
pre-eclampsia, and compared a serial intravenous bolus regimen (6-gram IV loading dose, and
2-gram IV bolus over 10 minutes every 2 hours as maintenance) with a continuous infusion
(4-gram IV loading dose, and 1-gram-per-hour continuous IV maintenance dose) [37] (see
Table 6 and S1 Appendix for effect estimates and forest plots).
No clear differences between the serial bolus and continuous infusion regimens were seen
for the primary review outcome perinatal death (RR 0.44; 95% CI 0.08 to 2.34; 1 trial, 197
babies; analysis 5.1), nor for stillbirth or neonatal death (Table 6; S1 Appendix).
No clear differences between the serial bolus and continuous infusion regimens were seen
for the remaining secondary outcomes reported (Table 6; S1 Appendix).
Antenatal magnesium sulphate and adverse neonatal outcomes
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002988 December 6, 2019 13 / 37
275
Table 6. Adverse outcome estimates from randomised controlled trials: Comparisons 3–8.
Outcome and subgroup Studies Participants Method (I2) RR (95% CI)
Comparison 3: IM versus IV maintenance dose of magnesium sulphate (pre-eclampsia/eclampsia)
3.1 Perinatal death
3.1.1 Pritchard’s versus Zuspan’s regimen 2 353 F (0%) 0.94 (0.66, 1.32)
3.1.2 Pritchard’s versus Sibai’s regimen 1 115 F (NA) 0.90 (0.53, 1.53)
3.1.3 Pritchard’s versus Bhattacharjee’s regimen 1 107 F (NA) 1.28 (0.61, 2.65)
3.1.4 Dhaka versus Zuspan’s regimen 1 41 F (NA) 0.57 (0.16, 2.08)
3.2 Stillbirth
3.2.1 Pritchard’s versus Zuspan’s regimen 1 114 F (NA) 0.79 (0.44, 1.40)
3.2.2 Pritchard’s versus Sibai’s regimen 2 133 F (0%) 0.80 (0.46, 1.41)
3.2.3 Pritchard’s versus Bhattacharjee’s regimen 1 107 F (NA) 1.18 (0.38, 3.63)
3.2.4 Dhaka versus Zuspan’s regimen 1 41 F (NA) 0.24 (0.03, 1.95)
3.3 Neonatal death
3.3.1 Pritchard’s versus Zuspan’s regimen 1 114 F (NA) 2.52 (0.27, 23.47)
3.3.2 Pritchard’s versus Sibai’s regimen 1 115 F (NA) 2.56 (0.27, 23.93)
3.3.3 Pritchard’s versus Bhattacharjee’s regimen 1 107 F (NA) 1.37 (0.47, 4.06)
3.3.4 Dhaka versus Zuspan’s regimen 1 41 F (NA) 1.90 (0.19, 19.40)
3.4 Apgar score < 7 at 1 minute
3.4.1 Dhaka versus Zuspan’s regimen 1 41 F (NA) 0.32 (0.10, 1.01)
3.5 Apgar score < 7 at 5 minutes
3.5.1 Dhaka versus Zuspan’s regimen 1 41 F (NA) 0.38 (0.08, 1.74)
3.6 Respiratory distress syndrome
3.6.1 Dhaka versus Zuspan’s regimen 1 41 F (NA) 0.76 (0.24, 2.44)
3.7 Jaundice
3.7.1 Dhaka versus Zuspan’s regimen 1 41 F (NA) 0.76 (0.24, 2.44)
3.8 Hypotonia
3.8.1 Dhaka versus Zuspan’s regimen 1 41 F (NA) 0.48 (0.10, 2.32)
3.9 NICU admission
3.9.1 Pritchard’s versus Zuspan’s regimen 1 114 F (NA) 0.98 (0.35, 2.73)
3.9.2 Pritchard’s versus Sibai’s regimen 1 115 F (NA) 1.00 (0.36, 2.78)
3.9.3 Dhaka versus Zuspan’s regimen 1 41 F (NA) 0.76 (0.24, 2.44)
Comparison 4: Loading dose versus loading and maintenance doses of magnesium sulphate (pre-eclampsia/eclampsia)
4.1 Perinatal death 3 632 R (63%) 0.94 (0.33, 2.72)
4.2 Stillbirth 3 803 F (26%) 1.10 (0.77, 1.58)
4.3 Neonatal death 2 462 F (0%) 0.78 (0.43, 1.41)
4.4 Neonatal death < 7 days 1 402 F (NA) 0.73 (0.30, 1.77)
4.5 Apgar score < 7 at 0 minutes 1 52 F (NA) 1.07 (0.32, 3.54)
4.6 Apgar score < 7 at 1 minute 1 52 F (NA) 0.86 (0.06, 12.98)
4.7 Apgar score < 7 at 5 minutes 2 406 F (NA) 1.61 (0.72, 3.62)
4.8 NICU admission for respiratory distress 2 397 F (0%) 1.02 (0.63, 1.65)
4.9 NICU admission for early onset sepsis 1 80 F (NA) 1.00 (0.06, 15.44)
4.10 NICU admission for late onset sepsis 1 80 F (NA) 3.00 (0.13, 71.51)
4.11 NICU admission for meconium aspiration syndrome 1 80 F (NA) 1.00 (0.06, 15.44)
4.12 NICU admission for birth asphyxia 1 80 F (NA) 0.33 (0.01, 7.95)
4.13 NICU admission 3 435 F (0%) 0.94 (0.77, 1.15)
Comparison 5: Serial intravenous boluses versus continuous intravenous maintenance of magnesium sulphate (pre-eclampsia)
5.1 Perinatal death 1 197 F (NA) 0.44 (0.08, 2.34)
5.2 Stillbirth 1 197 F (NA) 0.29 (0.01, 7.09)
(Continued)
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Short versus standard maintenance course
This comparison included 1 trial, assessing magnesium sulphate for the treatment of eclamp-
sia. Both groups received a 4-gram IV and 10-gram IM loading dose, followed by either a short
maintenance course (2 doses of 5 grams IM 4 hours apart after birth or last seizure) or a stan-
dard maintenance course (5 grams IM every 4 hours for 24 hours after birth or last seizure)
[29].
No clear difference between the short and standard maintenance course regimens was seen
for stillbirth. No clear difference between the short and standard maintenance course regimens
was seen for the only other secondary outcome reported, birth asphyxia (see Table 6 and S1
Appendix for effect estimates and forest plots).
Slower versus standard rate of loading dose
This comparison included 1 trial, assessing magnesium sulphate for fetal neuroprotection, and
compared a slower (over 60 minutes) versus standard (over 20 minutes) rate of administering
a 4-gram IV loading dose of magnesium sulphate (all women received a 1-gram-per-hour
maintenance dose for 24 hours or until birth) [24].
No clear difference between a slower and standard rate of loading dose administration was
seen for stillbirth (see Table 6 and S1 Appendix for effect estimate and forest plot).
Weaning versus no weaning
This comparison included 1 trial, assessing magnesium sulphate for the prevention of preterm
birth (tocolysis), and compared weaning (by 1 gram IV per 4 hours) versus not weaning mag-
nesium sulphate (all women received a 6-gram IV loading dose, and 2- to 3.5-gram IV mainte-
nance dose per hour until tocolysis was achieved) [42].
No clear difference between weaning and no weaning was seen for Apgar score less than 7
at 5 minutes (see Table 6 and S1 Appendix for effect estimate and forest plot).
Table 6. (Continued)
Outcome and subgroup Studies Participants Method (I2) RR (95% CI)
5.3 Neonatal death 1 197 F (NA) 0.58 (0.10, 3.42)
5.4 Intubated at birth 1 197 F (NA) 0.88 (0.29, 2.62)
5.5 Mechanical ventilation 1 197 F (NA) 0.44 (0.11, 1.70)
5.6 Bradycardia (<110 bpm) 1 197 F (NA) 0.44 (0.08, 2.34)
5.7 Special care baby unit admission 1 197 F (NA) 0.84 (0.53, 1.35)
Comparison 6: Short versus standard maintenance course of magnesium sulphate (eclampsia)
6.1 Stillbirth 1 98 F (NA) 0.87 (0.41, 1.82)
6.2 Birth asphyxia 1 98 F (NA) 0.83 (0.24, 2.92)
Comparison 7: Slower versus standard rate of loading dose of magnesium sulphate (fetal neuroprotection)
7.1 Stillbirth 1 51 F (NA) 0.35 (0.01, 8.12)
Comparison 8: Weaning versus no weaning of magnesium sulphate (tocolysis)
8.1 Apgar score < 7 at 5 minutes 1 141 F (NA) 0.65 (0.22, 1.90)
Test for heterogeneity represented by I2 statistic; where I2 > 30%, summary estimates were calculated using random-effects meta-analysis. Bhattacharjee’s regimen: 4-g
IV LD; 6-g IV/8 hours MD. Dhaka regimen: 4-g IV and 6-g IM LD; 2.5-g IM/4-hour MD. Pritchard’s regimen: 4-g IV and 10-g IM LD; 5-g IM/4-hour MD. Sibai’s
regimen: 6-g IV LD; 2-g IV/hour MD. Zuspan’s regimen: 4-g IV LD; 1-g IV/hour MD. All MDs for 24 hours after birth/last seizure.
bpm, beats per minute; CI, confidence interval; F, fixed-effects; g, gram; IM, intramuscular; IV, intravenous; LD, loading dose; MD, maintenance dose; NA, not
applicable; NICU, neonatal intensive care unit; R, random-effects; RR, risk ratio.
https://doi.org/10.1371/journal.pmed.1002988.t006
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Evidence from non-randomised comparative studies
One hundred thirty-eight non-randomised studies were included: 5 non-randomised trials, 35
prospective cohort studies (7 with nested case–control analyses), 82 retrospective cohort stud-
ies (16 with nested case–control analyses), 8 non-concurrent cohort studies, and 8 case–con-
trol studies [62–199]. The characteristics of the studies and risk of bias assessments are
detailed in S1 and S2 Tables.
There was substantial variation in the characteristics of these studies regarding participants,
indications for use of magnesium sulphate (prevention or treatment of eclampsia: 30 studies;
prevention of preterm birth (tocolysis): 28 studies; fetal neuroprotection: 25 studies; combina-
tion of aforementioned indications: 38 studies; unclear: 17 studies), comparison groups, out-
comes assessed (and their definitions), and analysis methods employed. Methodological
quality (specifically in relation to the risk of bias for reported review outcomes of interest) also
differed across the studies, with overall judgements of unclear (specifically when only abstracts
were available), high, moderate to high, and moderate risk of bias assigned to 43 studies, 49
studies, 35 studies, and 11 studies, respectively. The most common concerns across studies
related to the potential for confounding (with no attempt to balance allocation between groups
or match groups, and/or important confounding variables not taken into account in relevant
outcome analyses), detection bias (with the consistent implementation of valid and reliable
measures being unclear, and/or the absence of blinding of exposure or outcome assessors),
and performance bias (with protocols not available to assess important variations).
The primary review outcome, perinatal death, was reported by 11 of the 138 non-rando-
mised studies, 10 of which showed either a possible reduction (or lower rate) or no clear differ-
ence (or similar rate) in perinatal death among babies exposed to magnesium sulphate
compared with no magnesium sulphate or a different magnesium sulphate regimen. A possible
increase in perinatal death, specifically among babies exposed to>48 versus�48 grams of
magnesium sulphate for tocolysis was shown in in the 11th study (retrospective cohort of 127
babies, moderate to high risk of bias) [183]. See Table 7 and S3 Table for summaries of individ-
ual study results.
For the majority of secondary pre-specified and non-pre-specified adverse neonatal out-
comes reported, the results from non-randomised studies were consistent with those observed
in randomised controlled trials, with no clear differences (and in some cases, possible benefits
of magnesium sulphate) observed. The direction of the findings (no clear difference, possible
benefit, possible harm, or mixed) from the non-randomised studies are summarised in
Table 8, with the detailed individual study results provided in S3 Table.
Seventeen of the 138 non-randomised studies (14 at moderate or moderate to high risk of
bias, and 3 at unclear risk of bias [abstracts only]) observed a possible increase in the risk of
adverse neonatal outcomes with antenatal magnesium sulphate, with some consideration of
important confounding variables in relevant outcome analyses
[68,73,84,90,106,108,109,129,132,134,140,152,153,173,180,184,191]. Potential increased risks
with antenatal magnesium sulphate of 4 outcomes (discussed below) were observed by more
than 1 study. For the remaining outcomes (nosocomial infection [184], enteral feeding intoler-
ance [68], respiratory disease composite [153], pulmonary interstitial emphysema [191], early
germinal matrix/intraventricular haemorrhage [180], thalamostriate or mineralising vasculo-
pathy [152], and a composite neonatal adverse outcome [73]), single studies reported possible
harms.
Potential increased risk of neonatal death before intensive care unit discharge, and of a
composite outcome of neonatal death before intensive care unit discharge and/or necrotising
enterocolitis, was shown among a subgroup of babies born less than 26 weeks gestation with
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the use of antenatal magnesium sulphate for fetal neuroprotection (293 babies, in a retrospec-
tive cohort of 697 babies born less than 28 weeks gestation) [129]. A possible increased risk of
the composite outcome spontaneous intestinal perforation or neonatal death was also shown
among a subgroup of babies born less than 25 weeks gestation with higher cumulative
Table 7. Perinatal death from non-randomised studies.
Study; design Participants Comparisons Results summary
Adama-Hondegla
2013; RCS with CCS
(N)
178 babies born to women with
eclampsia
(1) Babies living at seventh day of life, N = 147 babies,
versus (2) stillbirths and neonatal deaths in first 7
days, N = 31 babies
MgSO4 exposure: aOR 1.04, P > 0.05
Alexander 2006;
PCS
87 babies born to women with
eclampsia
(1) No gestational hypertension, no MgSO4, N = 49
babies, versus (2) gestational hypertension, MgSO4,
N = 11 babies, versus (3) gestational hypertension, no
MgSO4, N = 27 babies
Perinatal death: 6.1% (3/49) versus 0% (0/11) versus
11.1% (3/27)
Cawyer 2019; RCS 2,468 babies born to women with
pre-eclampsia >32 weeks GA
(1) MgSO4, N = 1,353 babies, versus (2) no MgSO4,
N = 1,115 babies
Perinatal or neonatal death: 0.1% (2/1,353) versus
0.2% (2/1,115), P = 1.00
Chowdhury 2009;
PCS
529 babies born to women with
eclampsia
(1) MgSO4 Pritchard’s regimen, N = 406 babies,
versus (2) MgSO4 low dose IV regimen, N = 123
babies
Perinatal death: OR 1.58, 95% CI 0.93–2.61,
P = 0.075
Jung 2018; RCS 184 babies born to women with
ROM <32 weeks GA
(1) MgSO4 for tocolysis, N = 143 babies, versus (2) no
MgSO4, N = 41 babies
Perinatal death: Overall: 7.0% (10/143) versus 19.5%
(8/41), P = 0.0375; ROM at 23 to 27+6 weeks GA:
14.3% (9/63) versus 36.8% (7/19), P = 0.0651; ROM
at 28 to 31+6 weeks GA: 1.25% (1/80) versus 4.5%
(1/22), P = 0.9051
Kamilya 2005; CCS
(N)
1,205 babies born to women with
eclampsia
(1) Birth year 2002–2004 (almost universal MgSO4),
N = 481 babies, versus (2) birth year 1995–1997 (no
MgSO4), N = 724 babies





396 babies born to women with
intrapartum clinical
chorioamnionitis
(1) MgSO4 for fetal neuroprotection, N = 192 babies,
versus (2) placebo, N = 204 babies
Stillbirth or death by 1 year: Overall: aRR 1.68, 95%
CI 0.85–3.32;�28 weeks GA: aRR 1.34, 95% CI
0.47–2.73
Mitani 2011; RCS 425 babies born between 22 and
31 weeks GA
(1) MgSO4 for tocolysis, N = 236 babies, versus (2) no
MgSO4, N = 189 babies




103 babies born to women with
severe pre-eclampsia or eclampsia
Severe pre-eclampsia: (1) 10-g MgSO4 LD, N = 25
babies, versus (2) 14-g MgSO4 LD, N = 30 babies
Perinatal death, unclear reporting: Severe pre-
eclampsia: (1) PMR 240 per 1,000 (6 deaths) versus
(2) PMR 35 per 1,000 (1 death)
Eclampsia: (1) 10-g MgSO4 LD, N = 29 babies, versus
(2) 14-g MgSO4 LD, N = 19 babies
Perinatal death, unclear reporting: Eclampsia: (1)




127 babies born between 700 and
1,249 g, to women who received
MgSO4 for tocolysis
(1) Perinatal deaths, N = 18 babies, versus (2)
survivors, N = 109 babies
MgSO4 > 48 g: 72.2% (13/18) versus 45.0% (49/
109), P = 0.03; MgSO4� 48 g versus >48 g
(multivariable model): OR 4.72, 95% CI 1.12 to
19.97, P = 0.035
(1) MgSO4� 24 g, N = 43 babies, versus (2) MgSO4
> 24 to� 48 g, N = 25 babies, versus (3) MgSO4 > 48
g, N = 59 babies
Perinatal death (Cochrane–Armitage trend test, 1
versus 2 versus 3): 7.0% (3/43) versus 8.0% (2/25)
versus 22.0% (13/59), P = 0.03; perinatal death (1
versus 2): 7.0% (3/43) versus 8.0% (2/25), P = 1.0
Young 1977; NRT 144 babies born to women with
pre-eclampsia or eclampsia
(1) MgSO4 IV bolus MD (2 g over 10 minutes every
1–2 hours), N = 97 babies, versus (2) MgSO4
continuous IV MD (1 g per hour), N = 47 babies
Perinatal death: 2.1% (2/97) versus 2.1% (1/47)
The bold studies were judged to be of higher quality (moderate to high risk of bias) and presented results adjusted for confounders for the relevant outcome; other
studies were judged to be at high or unclear risk of bias and/or did not present adjusted results for the relevant outcome.
aOR, adjusted odds ratio; aRR, adjusted risk ratio; CCS(N), nested case–control study; CI, confidence interval; g, gram; GA, gestational age; IUFD, intrauterine fetal
demise; IV, intravenous; LD, loading dose; MD, maintenance dose; MgSO4, magnesium sulphate; NRT, non-randomised trial; OR, odds ratio; PCS, prospective cohort
study; PMR, perinatal mortality ratio; RCS, retrospective cohort study; RCT, randomised controlled trial; ROM, rupture of the membranes.
https://doi.org/10.1371/journal.pmed.1002988.t007
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Table 8. Summary of outcomes from non-randomised studies.
Outcome Direction of effect for magnesium sulphate versus no magnesium sulphate or a different regimen
Studies showing no clear difference Studies showing possible
benefit
Studies showing possible harm
Stillbirth Brazy 1982; Chowdhury 2009�; Jung 2018^ Jung 2018^; Shamsuddin 2005� Das 2015�
Neonatal death or death before
discharge
Alston 2016; Ambadkar 2019; Basu 2012;
Bertello Grecco 2019�; Brazy 1982; Canterino
1999; Chowdhury 2009�; De Jesus 2015; del
Moral 2007; de Veciana 1995; Drassinower
2015; Elimian 2002�; Elliott 2003; Farkouh
2001; Gibbins 2013; Girsen 2015; Gonzalez-
Quintero 2001; Hechtman 2002�; Hong 2019;
James 2015; Jazayeri 2003; Jung 2018;
Kamyar 2015a; Kamyar 2015b; Kamyar
2016a; Kamyar 2016b^; Kimberlin 1998;
Lee 2013; Lloreda-Garcia 2016; Mikhael
2019�; Morag 2016; Narasimhulu 2017;
Nassar 2006�; Özlü 2019; Paneth 1997;
Rantonen 2001; Shalabi 2017^; Shokry 2010;
Suh 2015; Weisz 2015^; Whitsel 2004;
Yokoyama 2010
Downey 2017; Garcia Alonso
2018; Grether 1998; Shalabi
2017^; Stockley 2018; Weisz
2015^
Das 2015�;Kamyar 2016b^; Lipsitz 1971�; Rattray
2014; Rauf 2017
Apgar score < 7 at 1 minute
(or� 5)
Chun 2014^; Gibbins 2013; Lloreda-Garcia
2016; Mitani 2011; Morag 2016; Narasimhulu
2017
Chun 2014^; Das 2015�; Girsen 2015; Lipsitz
1971�
Apgar score < 7 at 5 minutes (or
�5 or <6)
Canterino 1999; Chun 2014^; Cuff 2018�; de
Veciana 1995; Drassinower 2015; Elimian
2002�; Gibbins 2013; Jung 2018; Lloreda-
Garcia 2016; McPherson 2014�; Mitani 2011;
Narasimhulu 2017; Nassar 2006�; Nelson
1995; Okusanya 2012�; Rhee 2012; Schanler
1997; Stockley 2018; Weisz 2015�
Jeanneteau 2014; Shalabi 2017 Chun 2014^; Das 2015�; Girsen 2015; Lipsitz
1971�; Morag 2016
Birth asphyxia McGuiness 1980 Shamsuddin 2005�
Meconium at birth Greenberg 2013; Jazayeri 2003
Intubation Basu 2012; De Jesus 2015; Derks 2016;
Morag 2016; Narasimhulu 2017; Weisz
2015�^
Bajaj 2018; Drassinower 2015;
Weisz 2015^
Das 2015�; Rauf 2017; Weisz 2015�^
Intubation (duration) de Veciana 1995 O Reilly 2016^ O Reilly 2016�^
Resuscitation Basu 2012; Brookfield 2015�; De Jesus 2015;
Garcia Alonso 2018; Gibbins 2013; Lloreda-
Garcia 2016; McPherson 2014�; Narasimhulu
2017; Özlü 2019; Weisz 2015�^
Bajaj 2018; De Silva 2018 Lipsitz 1971�; Weisz 2015^
Oxygen bag, mask, or both
(resuscitation)





Drassinower 2015; Stockley 2018; Weisz
2015�^
Bajaj 2018; Weisz 2015^
Adrenaline (resuscitation) Stockley 2018; Weisz 2015�^ Jeanneteau 2014; Weisz 2015^
Score for Neonatal Acute
Physiology > 10 or 20 in first 24
hours
Stockley 2018; Weisz 2015^ Deering 2005; Shalabi 2017;
Weisz 2015�^
Delayed adaptation Lai 2017; Riaz 1998 Brazy 1982
Respiratory distress syndrome Alston 2016; Ambadkar 2019; Bozkurt 2016;
Brookfield 2016; Canterino 1999; De Jesus
2015; de Veciana 1995^; Drassinower 2015;
Elimian 2002�; Girsen 2015; Gonzalez-
Quintero 2001; Gursoy 2015; Imamoglu
2014; Jazayeri 2003; Jung 2018; Kamyar
2015a; Lee 2013; McPherson 2014�; Mitani
2011; Rantonen 2001; Schanler 1997; Shokry
2010; Suh 2015; Yokoyama 2010
de Veciana 1995^; Özlü 2019
(Continued)
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Table 8. (Continued)
Outcome Direction of effect for magnesium sulphate versus no magnesium sulphate or a different regimen
Studies showing no clear difference Studies showing possible
benefit
Studies showing possible harm
Respiratory depression Bertello Grecco 2019� Das 2015�
Surfactant use delValle 1998; Elimian 2002�; Garcia Alonso
2018; Lloreda-Garcia 2016; Rantonen 2001;
Shokry 2010; Weisz 2015�
Ventilation Brookfield 2016; De Jesus 2015^;
Drassinower 2015; Garcia Alonso 2018;
Girsen 2015; Havranek 2011; James 2015; Lee
2013; Lloreda-Garcia 2016^; McPherson
2014�; Nunes 2018; Özlü 2019; Rantonen
2001; Schanler 1997; Shokry 2010
De Jesus 2015^; Lloreda-Garcia
2016^; Rauf 2017^; Shalabi
2017
Lipsitz 1971�; Lloreda-Garcia 2016^; Rauf 2017^
Ventilation (duration) Black 2006; De Jesus 2015; Kimberlin 1998;
Özlü 2019; Suh 2015
Methylxanthine use or duration Black 2006; Havranek 2011; Imamoglu 2014;
Schanler 1997
Chronic lung disease or
bronchopulmonary dysplasia
Alston 2016; Basu 2012; Bozkurt 2016; De
Jesus 2015; Edwards 2018; Garcia Alonso
2018; James 2015; Jung 2018; Kamyar 2015a;
Kamyar 2016a; McPherson 2014�; Özlü
2019; Shalabi 2017; Stockley 2018; Suh 2015;
Weisz 2015
Narasimhulu 2017; Stetson 2019
Oxygen use (at 28 days, 36
weeks, or discharge)
Kimberlin 1998; Morag 2016; Schanler 1997
Oxygen use (duration) De Jesus 2015; Özlü 2019; Suh 2015
Steroid use (dexamethasone or
hydrocortisone)
Mikhael 2019�; Rantonen 2001; Rattray 2014;
Shalabi 2017
Apnoea Bozkurt 2016; Riaz 1998; Wutthigate 2017�
Pulmonary haemorrhage De Jesus 2015; James 2015
Necrotising enterocolitis Alston 2016; Bozkurt 2016; Brazy 1982; De
Jesus 2015; delValle 1998; de Veciana 1995;
Downey 2017; Edwards 2018; Elimian
2002�; Elliott 2003; Garcia Alonso 2018;
Ghidini 2001; Gursoy 2015; Hong 2019;
James 2015; Jazayeri 2003; Jung 2018;
Kamyar 2015a; Kamyar 2016a; Kamyar
2016b; Kimberlin 1998; Lee 2013; Lloreda-
Garcia 2016; McPherson 2014�; Mikhael
2019�; Morag 2016; Narasimhulu 2017; Özlü
2019; Schanler 1997; Shalabi 2017; Stockley
2018; Suh 2015; Weisz 2015; Yokoyama
2010
Moschos 2001; Wiswell 1996
Spontaneous intestinal
perforation
Downey 2017; Mikhael 2019�; Shalabi 2017 Rattray 2014
Composite of necrotising
enterocolitis/spontaneous
intestinal perforation or death




Hong 2019; Shalabi 2017
Sepsis Alston 2016; Bozkurt 2016; De Jesus 2015;
Elimian 2002�; Girsen 2015; James 2015;
Jazayeri 2003; Jung 2018; Kamyar 2016a;
Lloreda-Garcia 2016; Mikhael 2019�; Morag
2016; Özlü 2019; Rantonen 2001; Riaz 1998;
Stockley 2018; Teng 2006; Weisz 2015
Whitsel 2004
(Continued)
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Table 8. (Continued)
Outcome Direction of effect for magnesium sulphate versus no magnesium sulphate or a different regimen
Studies showing no clear difference Studies showing possible
benefit
Studies showing possible harm
Antibiotic use Elimian 2002�^; Greenberg 2013 Elimian 2002^
Hypoglycaemia Bozkurt 2016; Grimbly 2015
Feeding intolerance Gursoy 2015; Özlü 2019; Riaz 1998 Belden 2017�
Delayed stooling Lloreda-Garcia 2016^ Lloreda-Garcia 2016^ Brazy 1982; Das 2015�
Meconium passage delay Ambadkar 2019; Lloreda-Garcia 2016
Ileus Brazy 1982; Nakamura 1991�
Delayed voiding Sahin 2001 Das 2015�
Patent ductus arteriosus Basu 2012; Bozkurt 2016; delValle 1998;
Elimian 2002�; Garcia Alonso 2018; Gursoy
2015; Imamoglu 2014; James 2015; Katayama
2011�^; Lee 2013�; Özlü 2019; Schanler 1997;
Yokoyama 2010
Qasim 2017 Brazy 1982; del Moral 2007; Gonzalez-Quintero




De Jesus 2015; del Moral 2007; delValle
1998; Katayama 2011�; Lee 2013; Lloreda-
Garcia 2016; Mikhael 2019�; Shalabi 2017;
Suh 2015
Bonta 2000�
Hypotension Brazy 1982; Derks 2016; Drassinower 2015;
Gursoy 2015; Morag 2016; Teng 2006
De Jesus 2015 Narasimhulu 2017
Hypertension Gursoy 2015 Brown 2019
Inotrope use Imamoglu 2014; James 2015; Shokry 2010
Intravenous fluids and/or
nutritional support needed
Greenberg 2013; Rasch 1982
Phototherapy Greenberg 2013; Havranek 2011; Imamoglu
2014
Retinopathy of prematurity Basu 2012; Bozkurt 2016; Cuff 2018�; De
Jesus 2015; Elliott 2003; Garcia Alonso 2018;
Jung 2018; Kamyar 2015a; Kimberlin 1998;
Lee 2013; McPherson 2014�; Narasimhulu
2017; Özlü 2019; Shalabi 2017^; Stockley
2018; Suh 2015; Weisz 2015; Yokoyama
2010
Shalabi 2017^ Rauf 2017
Hypotonia Bertello Grecco 2019�; Drassinower 2015;
Gibbins 2013; Girsen 2015; Nassar 2006�
Ambadkar 2019; Brazy 1982; Das 2015�; Rauf
2017; Riaz 1998
Seizure Drassinower 2015; Girsen 2015; Kimberlin
1998; McPherson 2014�; Rauf 2017
Shokry 2010
Encephalopathy Girsen 2015; Rantonen 2001; Rauf 2017
Intraventricular haemorrhage Alston 2016; Black 2006; De Jesus 2015;
delValle 1998; de Veciana 1995; Drassinower
2015; Edwards 2018; Elliott 2003; Gano
2016; Garcia Alonso 2018; Gasparyan 2017;
Gonzalez-Quintero 2001; Gursoy 2015; Hom
2018; Imamoglu 2014; Jazayeri 2003; Jung
2018^; Kamyar 2015a; Lee 2013; Leviton
1997; Martin 1998; McPherson 2014�; Mitani
2011�; Nassar 2006�; Nelson 1995; Özlü 2019;
Paneth 1997; Schanler 1997; Stetson 2019;
Stockley 2018; Suh 2015; Yokoyama 2010
Jung 2018^; Kuban 1992;
Perlman 1995; Petrova 2012;




grade 3 or 4
del Moral 2007; Downey 2017; Gano 2016;
James 2015; Jung 2018; Kamyar 2016a;
Kimberlin 1998; McPherson 2014�; Mikhael
2019�; Narasimhulu 2017; Özlü 2019;
Rantonen 2001; Stockley 2018; Weintraub
2001
Gasparyan 2017; Perlman 1995;
Sarkar 2009; Wiswell 1996
Cuff 2018�; Khodapanahandeh 2008
(Continued)
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antenatal magnesium sulphate doses for fetal neuroprotection (non-concurrent cohort of 155
babies born less than 1,000 grams) [173].
A possible increased risk of patent ductus arteriosus was observed with magnesium sul-
phate given for pre-eclampsia (retrospective cohort of 81 ‘very low birthweight’ babies; abstract
Table 8. (Continued)
Outcome Direction of effect for magnesium sulphate versus no magnesium sulphate or a different regimen
Studies showing no clear difference Studies showing possible
benefit
Studies showing possible harm
Periventricular leucomalacia Bozkurt 2016; De Jesus 2015; del Moral 2007;
delValle 1998; Garcia Alonso 2018; Jung
2018^; Kamyar 2015a; Kamyar 2016a; Lee
2013; Mitani 2011�; Narasimhulu 2017; Rauf
2017; Suh 2015; Wiswell 1996




Basu 2012; Canterino 1999�; Elimian 2002�
Intraventricular haemorrhage
grade 3 or 4 and/or
periventricular leucomalacia
Bozkurt 2016; Canterino 1999�; Morag 2016;
Shalabi 2017^; Weisz 2015
Koksal 2002; Shalabi 2017^;
Wiswell 1996
Hypocalcaemia Cho 2014; Lee 2015; McGuiness 1980 Narasimhulu 2017
Bone abnormalities Yokoyama 2010 Holcomb 1991�; Matsuda 1997�
Hearing impairment or hearing
test failure
Jung 2018 Leung 2016
Composite adverse outcomes Drassinower 2015; Duffy 2012; Kamyar
2015a; Kamyar 2015b; Kamyar 2015c;
Kamyar 2016a; Mitani 2011�; Narasimhulu
2017; Palatnik 2019; Rizzolo 2019; Sakae
2017�^; Weisz 2015
Boyle 2018; Sakae 2017�^
NICU admission Ambadkar 2019�^; Bertello Grecco 2019�;
Cawyer 2019; Chun 2014^; Gibbins 2013; Lai
2017; McPherson 2014�; Rantonen 2001;
Riaz 1998�
Ambadkar 2019�^; Chun 2014^; Das 2015�;
Girsen 2015; Greenberg 2011�; Greenberg 2013�;
Rhee 2012
NICU duration Gibbins 2013; Girsen 2015; Greenberg 2013;
Jazayeri 2003; Jung 2018; Kimberlin 1998;
Rauf 2017
Narasimhulu 2017
Hospital stay duration Alston 2016; Basu 2012; De Jesus 2015; de
Veciana 1995; Özlü 2019; Riaz 1998; Schanler
1997; Suh 2015
Brazy 1982; Girsen 2015
Other (outcomes reported by
single studies)
Black 2006; Blackwell 2002; Brazy 1982;
Derks 2016; Gano 2016; Girsen 2015;
Greenberg 2013; Havranek 2011; Hong 2019;
Imamoglu 2014; Jeanneteau 2014; Jones
2018; Jung 2018; Katayama 2011�; Kelly
1992; Kimberlin 1998; Lai 2017; Leviton
1997; Lloreda-Garcia 2016; Mittendorf
2005�; Morag 2016; Nassar 2006�; Nunes
2018; Özlü 2019; Paneth 1997; Petrov 2013;
Rantonen 2001; Riaz 1998; Sahin 2001;
Schanler 1997; Shalabi 2017^
Deering 2005; Derks 2016;
Gano 2016; Jeanneteau 2014;
Kimberlin 1998; Mittendorf
2005�; Petrov 2013
Belden 2017�; Brazy 1982; Das 2015�; Katayama
2011; Lai 2017; Lipsitz 1971�; Mittendorf 2009�;
Morag 2015; Morag 2016; Rasch 1982; Shalabi
2017^; Verma 2006�; Weisz 2015; Whitten 2015
The bold studies were judged to be of higher quality (moderate or moderate to high risk of bias) and presented results adjusted for confounders for the relevant
outcomes; other studies were judged to be at high or unclear risk of bias and/or or did not present adjusted results for the relevant outcomes.
�Indicates where studies assessed different magnesium sulphate regimens or 1 or more characteristics of the regimen (such as dose, duration, timing, or indication for
use).
^Indicates where studies demonstrated mixed findings (such as in different subgroups of the population).
NICU, neonatal intensive care unit.
https://doi.org/10.1371/journal.pmed.1002988.t008
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only) [140] or for pre-eclampsia or tocolysis (retrospective cohort of 941 babies born 500 to
1,000 grams) [90]. Further, a possible increased risk of patent ductus arteriosus in babies born
26 weeks gestation or later was shown with cumulative antenatal magnesium sulphate doses
for pre-eclampsia or tocolysis of at least 50 grams (retrospective cohort of 941 babies born 500
to 1,000 grams) [90]. Potential increased risk of symptomatic patent ductus arteriosus, and of
failure of early closure of the ductus arteriosus, was also observed with the use of antenatal
magnesium sulphate for tocolysis (retrospective cohort of 160 babies born less than 28 weeks
gestation, who all received indomethacin prophylaxis) [132].
A potential increased risk of intraventricular haemorrhage grade 3 or 4 was observed with
antenatal magnesium sulphate for tocolysis (case–control study of 121 babies born less than
1,500 grams) [134], and with a higher dose regimen of antenatal magnesium sulphate for fetal
neuroprotection (6-gram IV loading dose and 2-gram-per-hour IV maintenance dose for 12
hours versus 4-gram IV loading dose only) (retrospective cohort, including 54 babies exposed
to magnesium sulphate within 12 hours of birth) [84].
A possible increased risk of neonatal intensive care unit admission with the use of antenatal
magnesium sulphate for pre-eclampsia was observed (retrospective cohorts of 264 babies and
2,166 babies born at 37 weeks gestation or later) [106,109]. Further increased risks of neonatal
intensive care unit and special care unit admission were observed with higher total hours,
higher total doses, more than 12 hours, and more than 30 grams of antenatal magnesium sul-
phate for pre-eclampsia (retrospective cohort of 242 babies born at 35 weeks gestation or later)
[108].
Evidence from case reports
Nineteen reports describing a total of 134 babies exposed to antenatal magnesium sulphate
with adverse outcomes were included [200–218] (see Table 9; the detailed characteristics of
cases are presented in S4 Table).
Clinical features of neonatal hypermagnesemia, magnesium ‘toxicity’, or magnesium ‘intox-
ication’ at birth were the focus of 5 reports (35 neonates), in which antenatal magnesium sul-
phate was given for pre-eclampsia/eclampsia (with exposure durations and doses ranging
from 3.5 to 46 hours and 11 to 60.4 grams prior to birth, respectively) [202,205,206,213,218],
and were variably described throughout the remaining reports. These included low Apgar
scores, apnoea, cyanosis, hypotonia, and/or hyporeflexia, with or without the need for active
resuscitation and calcium gluconate administration.
Table 9. Summary of main adverse outcomes from case reports.
Outcome Indication for use: studies
Neonatal death Tocolysis: Herschel 2001
Pre-eclampsia/eclampsia: Kurtoglu 2000
Cardiopulmonary arrest after gentamicin exposure following
hypermagnesemia at birth
Pre-eclampsia: L’Hommedieu 1983; Rasch 1981
Clinical features of magnesium ‘toxicity’ or ‘intoxication’ at birth
(such as apnoea, cyanosis, hypotonia, and/or hyporeflexia)
Pre-eclampsia/eclampsia: Brady 1967; Cruz
2009; Lipsitz 1967; Teng 1989
Not clear: Jashi 2014
Microcolon or ‘meconium-plug syndrome’ Pre-eclampsia/eclampsia: Amodio 1986; Krasna
1996; Sokal 1972
Nonoliguric hyperkalaemia Pre-eclampsia: Tanaka 2018
Bone abnormalities with prolonged magnesium sulphate for
tocolysis
Tocolysis: Cumming 1989; Kaplan 2006; Kogan
2003; Lamm 1988; Malaeb 2004
Not clear: Ahmad 2013
https://doi.org/10.1371/journal.pmed.1002988.t009
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Two reports described neonatal death following antenatal magnesium sulphate exposure.
In the first report, death was considered to be related to ‘the toxic effects of magnesium on the
myocardium’ when given for tocolysis (4-gram IV loading dose followed by 2.5-gram-per-
hour IV maintenance dose for approximately 1 day: 51.4 grams total) [204], and in the second,
1 death (of 7) was attributed to ‘overdose’ (unclear dose/regimen) of magnesium sulphate
when given for pre-eclampsia/eclampsia [210].
In the context of hypermagnesemia at birth (following exposure to a total of 24 to 28 grams
of magnesium sulphate for pre-eclampsia), neonatal gentamicin administration for suspected
sepsis was associated with respiratory arrest and cardiac arrest in 2 reports [211,215]. Other
specific adverse outcomes attributed to antenatal magnesium sulphate exposure included
• Microcolon or meconium-plug syndrome (3 reports, 14 neonates, when given for pre-
eclampsia/eclampsia: 25 to 41 grams in the day prior to birth in 1 report; regimen not
described in 2 reports) [201,209,216];
• Nonoliguric hyperkalaemia (1 report, 1 neonate, when given for pre-eclampsia: 0.1 gram to
2 grams per hour IV for 12 days) [217];
• Bone abnormalities (commonly metaphyseal osteopenia, in some cases leading to fracture)
(6 reports, 35 neonates, when given for tocolysis: ranging from 1 to 4 grams per hour for
between 8 and 13 weeks) [200,203,207,208,212,214].
Discussion
Overall, no clear difference in our primary review outcome, perinatal death, was shown in the
randomised trials comparing antenatal magnesium sulphate with placebo/no treatment, nor in
regimen comparisons in randomised trials. While 11 of the 138 non-randomised studies
reported on perinatal death, only 1 cohort study (at moderate to high risk of bias) observed a
possible increased risk of perinatal death, with high-dose (more than 48 grams) antenatal mag-
nesium sulphate exposure for tocolysis [183].
Results for secondary adverse neonatal outcomes were reassuring, with very few clear dif-
ferences observed between antenatal magnesium sulphate and placebo/no treatment or
between different magnesium sulphate regimens. Where possible harms of magnesium sul-
phate were seen, commonly no confounders were taken into account (and studies were judged
to be at high risk of bias), study samples were small (less than 200 babies), and/or differences
were observed in (non-formal) subgroup analyses only. Non-randomised studies identified a
limited number of outcomes justifying further evaluation, such as from large, high-quality
studies (prospective cohorts, individual participant data meta-analyses, or randomised trials of
regimen comparisons). These included neonatal death and intestinal morbidity in very pre-
term neonates with exposure for fetal neuroprotection, patent ductus arteriosus in very pre-
term or very low birthweight neonates with exposure for pre-eclampsia or tocolysis, and
intensive care unit admission in term neonates with exposure for pre-eclampsia. Case reports
suggested an association between neonatal bone abnormalities and long-term, high-dose expo-
sure to antenatal magnesium sulphate for tocolysis.
We are not aware of any other published systematic reviews with a focus on potential
adverse outcomes for neonates following antenatal magnesium sulphate exposure, though we
identified 3 review registrations focused specifically on magnesium sulphate for tocolysis and
the outcomes neonatal respiratory depression (CRD42017058912), patent ductus arteriosus
(CRD42017060049), and bone abnormalities (CRD42017062550) [18]. Three previous system-
atic reviews have assessed ‘adverse events’ [13], ‘side effects’ [219], and ‘safety’ [220] for
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women, and a further systematic review has assessed the effects of antenatal magnesium sul-
phate specifically on fetal heart rate parameters, finding a small negative effect on rate, variabil-
ity, and accelerative pattern, ‘not sufficient clinically to warrant medical intervention’ [14].
Our review findings are consistent with those from the relevant Cochrane reviews compar-
ing antenatal magnesium sulphate with placebo/no treatment, or different magnesium sul-
phate regimens [1,2,4,9,221], though our review includes a wider range of outcomes. As was
observed in our review’s tocolysis subgroup for perinatal death, the Cochrane review assessing
magnesium sulphate for tocolysis demonstrated a borderline increased risk of fetal, neonatal,
or infant death with antenatal magnesium sulphate [9].
A recent non-systematic narrative review evaluated ‘whether antenatal MgSO4 is beneficial
or harmful’ in extremely and very preterm neonates [222]. Relevant systematic reviews, meta-
analyses, randomised controlled trials, and observational studies were retrieved, with a broad
search strategy focused on neuroprotection and cerebral palsy, necrotising enterocolitis, and
spontaneous intestinal perforation. The narrative review suggested that current evidence sup-
ports the neuroprotective role of antenatal magnesium sulphate for preterm neonates, and
that, while the effects are ‘controversial’ and ‘not well established’, a ‘high index of suspicion of
gastrointestinal complications in extremely preterms, particularly < 26 weeks of gestation’ is
recommended [222]. While our review similarly identified a possibility of harm, the relevant
studies were of questionable methodological quality, and our systematic review included addi-
tional reports (of higher quality, and involving much larger cohorts) that indicated no
increased risk of intestinal morbidity.
The findings of this review are reassuring and can be considered in conjunction with those
from relevant reviews demonstrating a clear benefit of antenatal magnesium sulphate [1,2,4],
and current international clinical practice guideline recommendations [3,7]. Our review find-
ings of possible adverse outcomes with long-term, high-dose use for tocolysis have implica-
tions for settings with continued use for this indication [8] in spite of the absence of benefit
shown in systematic reviews and international guidance [7–9].
Strengths and limitations
The main limitations of our review relate to missing data for important outcomes across most
studies, the inclusion of published data only, and the heterogeneity of included studies.
Of the 40 randomised trials included in this review, our primary outcome (perinatal death)
was reported by 22 (55%); it was reported by only 11 (8%) of the 138 included non-randomised
studies. Aside from related mortality outcomes (stillbirth and neonatal death), all other adverse
outcomes were reported sparsely, by less than a third of trials, with many outcomes reported
by single trials only. While a broader range of adverse neonatal outcomes were reported by the
non-randomised studies, apart from neonatal death (50 studies), intraventricular haemorrhage
(39 studies), and necrotising enterocolitis (36 studies), all other outcomes were reported by
less than a fifth of studies, again, with many reported by single studies only.
In addition to missing data for important outcomes across most studies, a further limitation
includes the number of studies with relatively small sample sizes comparing different antenatal
magnesium sulphate regimens. Moreover, many studies assessing antenatal magnesium sul-
phate for relevant indications were not included due to lack of reporting of adverse neonatal
outcomes.
We searched extensively across multiple databases and reviewed reference lists for addi-
tional reports; however, we did not seek unpublished data. Recent evidence has suggested that
while much adverse event information remains unpublished, inclusion of such data generally
does not change the direction or statistical significance of pooled risk estimates [223]. While
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we were not able to fully evaluate non-English publications without available translations for
inclusion, we have provided a list of these for readers to consider (S3 Text).
As the aim of the review was to provide a comprehensive, general view of potential unin-
tended adverse outcomes, we designed this review with broad scope [15,16]. This presented
challenges, including the number of diverse outcomes, inconsistent reporting, and the vast
quantities of heterogeneous data. The study characteristics (including designs, settings, partici-
pating women and neonates, and antenatal magnesium sulphate regimens) varied greatly, and
reporting was commonly incomplete. The ability to conduct subgroup analyses for the rando-
mised trials was limited, and we did not inappropriately pool data from non-randomised stud-
ies. We conducted this review in accordance with recommendations for systematic reviews of
adverse events [15–17], and of randomised and non-randomised studies more generally [224].
Our evaluation thus provides a firm basis for any further, narrowly focused studies of specific
outcomes and characteristics.
Conclusions
In conclusion, our findings do not support any clear associations between perinatal death or
other adverse neonatal outcomes and antenatal magnesium sulphate exposure when given for
the beneficial indications of maternal neuroprotection in pre-eclampsia/eclampsia and fetal
neuroprotection in cerebral palsy prevention. To further inform safety recommendations of
this widely used treatment in pregnancy, future research should be directed towards identified
research gaps surrounding specific adverse neonatal outcomes and the impact of particular
regimen, pregnancy, and/or birth characteristics.
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164. Özlü F, Hacıoğlu C, Büyükkurt S, Yapıcıoğlu H, Satar M. Changes on preterm morbidities with antena-
tal magnesium. Cukurova Med J. 2019; 44(2):502–8. https://doi.org/10.17826/cumj.444238
165. Palatnik A, Liu LY, Lee A, Yee LM. Predictors of early-onset neonatal sepsis or death among new-
borns born at <32 weeks of gestation. J Perinatol. 2019; 39(7):949–55. https://doi.org/10.1038/
s41372-019-0395-9 PMID: 31089257
166. Paneth N, Jetton J, Pinto-Martin J, Susser M. Magnesium sulfate in labor and risk of neonatal brain
lesions and cerebral palsy in low birth weight infants. The Neonatal Brain Hemorrhage Study Analysis
Group. Pediatrics. 1997; 99(5):E1. https://doi.org/10.1542/peds.99.5.e1 PMID: 9113958
167. Perlman J, Fernandez C, Gee J, Leveno K, Risser R. Magnesium sulphate (Mg) administered to moth-
ers with pregnancy-induced hypertension (PIH) is associated with a reduction in periventricular-intra-
ventricular hemorrhage (PV-IVH). Pediatr Res. 1995; 37(4 Pt 2):231A.
168. Petrov V, Lupascu A, Etsco L, Pavlenco A. Maternal and new born hemodynamics after antenatal
administration of magnesium sulfate (MGSO4), as a neuroprotective drug in preterm birth. J Perinat
Med. 2013; 41(Suppl 1):RU350.
169. Petrova A, Mehta R. Magnesium sulfate tocolysis and intraventricular hemorrhage in very preterm
infants. Indian J Pediatr. 2012; 79(1):43–7. https://doi.org/10.1007/s12098-011-0440-y PMID:
21625843
170. Qasim A, Jain S, Dasgupta S. Does antenatal magnesium sulfate increase the likelihood of a hemody-
namically significant patent ductus arteriosus in neonates? J Investig Med. 2017; 65(2):547–8.
171. Rantonen T, Kaapa P, Gronlund J, Ekblad U, Helenius H, Kero P, et al. Maternal magnesium sulfate
treatment is associated with reduced brain-blood flow perfusion in preterm infants. Crit Care Med.
2001; 29(7):1460–5. https://doi.org/10.1097/00003246-200107000-00026 PMID: 11445708
Antenatal magnesium sulphate and adverse neonatal outcomes
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002988 December 6, 2019 34 / 37
296
172. Rasch DK, Huber PA, Richardson CJ, L’Hommedieu CS, Nelson TE, Reddi R. Neurobehavioral
effects of neonatal hypermagnesemia. J Pediatr. 1982; 100(2):272–6. https://doi.org/10.1016/s0022-
3476(82)80654-9 PMID: 7199083
173. Rattray BN, Kraus DM, Drinker LR, Goldberg RN, Tanaka DT, Cotten CM. Antenatal magnesium sul-
fate and spontaneous intestinal perforation in infants less than 25 weeks gestation. J Perinatol. 2014;
34(11):819–22. https://doi.org/10.1038/jp.2014.106 PMID: 24901451
174. Rauf M, Sevil E, Ebru C, Yavuz S, Cemil C. Antenatal magnesium sulfate use for fetal neuroprotection:
experience from a tertiary care hospital in Turkey. Biomed Res. 2017; 28(4):1749–54.
175. Rhee E, Beiswenger T, Oguejiofor CE, James AH. The effects of magnesium sulfate on maternal and
fetal platelet aggregation. J Matern Fetal Neonatal Med. 2012; 25(5):478–83. https://doi.org/10.3109/
14767058.2011.584087 PMID: 21762000
176. Riaz M, Porat R, Brodsky NL, Hurt H. The effects of maternal magnesium sulfate treatment on new-
borns: a prospective controlled study. J Perinatol. 1998; 18(6 Pt 1):449–54. PMID: 9848759
177. Rizzolo A, Shah PS, Boucorian I, Lemyre B, Bertelle V, Pelausa E, et al. Cumulative effect of evi-
dence-based practices on outcomes of preterm infants born at <29 weeks gestational age. Am J
Obstet Gynecol. 2019 Sept 6. https://doi.org/10.1016/j.ajog.2019.08.058 PMID: 31499055
178. Sakae C, Sato Y, Kanbayashi S, Taga A, Emoto I, Maruyama S, et al. Introduction of management
protocol for early-onset severe pre-eclampsia. J Obstet Gynaecol Res. 2017; 43(4):644–52. https://
doi.org/10.1111/jog.13265 PMID: 28150368
179. Sahin H, Akay AF, Bircan MK, Gocmen A, Bircan Z. The first micturition times of the newborns whose
mothers were treated with magnesium sulfate. Int Urol Nephrol. 2001; 32(4):651–3. https://doi.org/10.
1023/a:1014405824678 PMID: 11989558
180. Salafia CM, Minior VK, Rosenkrantz TS, Pezzullo JC, Popek EJ, Cusick W, et al. Maternal, placental,
and neonatal associations with early germinal matrix/intraventricular hemorrhage in infants born
before 32 weeks’ gestation. Am J Perinatol. 1995; 12(6):429–36. https://doi.org/10.1055/s-2007-
994514 PMID: 8579656
181. Sarkar S, Bhagat I, Dechert R, Schumacher RE, Donn SM. Severe intraventricular hemorrhage in pre-
term infants: comparison of risk factors and short-term neonatal morbidities between grade 3 and
grade 4 intraventricular hemorrhage. Am J Perinatol. 2009; 26(6):419–24. https://doi.org/10.1055/s-
0029-1214237 PMID: 19267317
182. Schanler RJ, Smith LG, Burns PA. Effects of long-term maternal intravenous magnesium sulfate ther-
apy on neonatal calcium metabolism and bone mineral content. Gynecol Obstet Invest. 1997;
43(4):236–41. https://doi.org/10.1159/000291864 PMID: 9194621
183. Scudiero R, Khoshnood B, Pryde PG, Lee KS, Wall S, Mittendorf R. Perinatal death and tocolytic mag-
nesium sulfate. Obstet Gynecol. 2000; 96(2):178–82. https://doi.org/10.1016/s0029-7844(00)00893-0
PMID: 10908759
184. Shalabi M, Mohamed A, Lemyre B, Aziz K, Faucher D, Shah PS, et al. Antenatal exposure to magne-
sium sulfate and spontaneous intestinal perforation and necrotizing enterocolitis in extremely preterm
neonates. Am J Perinatol. 2017; 34(12):1227–33. https://doi.org/10.1055/s-0037-1603344 PMID:
28494498
185. Shamsuddin L, Nahar K, Nasrin B, Nahar S, Tamanna S, Kabir RM, et al. Use of parenteral magne-
sium sulphate in eclampsia and severe pre-eclampsia cases in a rural set up of Bangladesh. Bangla-
desh Med Res Counc Bull. 2005; 31(2):75–82. PMID: 16967813
186. Shokry M, Elsedfy GO, Bassiouny MM, Anmin M, Abozid H. Effects of antenatal magnesium sulfate
therapy on cerebral and systemic hemodynamics in preterm newborns. Acta Obstet Gynecol Scand.
2010; 89(6):801–6. https://doi.org/10.3109/00016341003739542 PMID: 20504082
187. Stetson BT, Buhimschi CS, Kellert BA, Hay K, Buhimschi IA, Maitre NL. Comparison of cerebral palsy
severity between 2 eras of antenatal magnesium use. JAMA Pediatr. 2019; 173(2):188–90. https://doi.
org/10.1001/jamapediatrics.2018.3827 PMID: 30508016
188. Stockley EL, Ting JY, Kingdom JC, McDonald SD, Barrett JF, Synnes AR, et al. Intrapartum magne-
sium sulfate is associated with neuroprotection in growth-restricted fetuses. Am J Obstet Gynecol.
2018; 219(6):606e1–8.
189. Suh B, Ko K, Bang J, Oh Y, Lee Y, Lee J, et al. Neonatal outcomes of premature infants who were
delivered from mother with hypertensive disorders of pregnancy and effects of antihypertensive drugs
and MgSO4. Korean J Perinatol. 2015; 26(3):190–9.
190. Teng RJ, Wu TJ, Sharma R, Garrison RD, Hudak ML. Early neonatal hypotension in premature infants
born to preeclamptic mothers. J Perinatol. 2006; 26(8):471–5. https://doi.org/10.1038/sj.jp.7211558
PMID: 16775620
Antenatal magnesium sulphate and adverse neonatal outcomes
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002988 December 6, 2019 35 / 37
297
191. Verma RP, Chandra S, Niwas R, Komaroff E. Risk factors and clinical outcomes of pulmonary intersti-
tial emphysema in extremely low birth weight infants. J Perinatol. 2006; 26(3):197–200. https://doi.org/
10.1038/sj.jp.7211456 PMID: 16493434
192. Weintraub Z, Solovechick M, Reichman B, Rotschild A, Waisman D, Davkin O, et al. Effect of maternal
tocolysis on the incidence of severe periventricular/intraventricular haemorrhage in very low birth-
weight infants. Arch Dis Child Fetal Neonatal Ed. 2001; 85(1):F13–7. https://doi.org/10.1136/fn.85.1.
F13 PMID: 11420315
193. Weisz D, Shivananda S, Asztalos E, Yee W, Synnes A, Lee S, et al. Intrapartum magnesium sulfate
and need for intensive delivery room resuscitation. Arch Dis Child Fetal Neonatal Ed. 2015; 100(1):
F59–65. https://doi.org/10.1136/archdischild-2013-305884 PMID: 25232002
194. Whitsel A, Insel A, Desilva H, Bernstein B. Association of maternal antepartum management with mor-
tality and morbidity of the extremely low birthweight (ELBW) neonate. Am J Obstet Gynecol. 2004;
191(6 Suppl):S75.
195. Whitten A, Ogunyemi D, Betcher K, Nowakowski A, Qu S. What factors predict prolonged neonatal
length of stay in term babies? Int J Gynaecol Obstet. 2015; 131:E462–3.
196. Wiswell TE, Caddell JL, Graziani LJ, Kornhauser MS, Spitzer AR. Maternally-administered magne-
sium sulfate (MgSO4) decreases the incidence of severe necrotizing enterocolitis (NEC) in preterm
infants: a prospective study. Pediatr Res. 1996; 39(4):1501.
197. Wutthigate P, Yangthara B, Siripattanapipong P, Kitsommart R. Correlation between maternal cumu-
lative dose of intrapartum magnesium sulfate and cord blood magnesium level. Southeast Asian J
Trop Med Public Health. 2017; 48(Suppl 2):256–63.
198. Yokoyama K, Takahashi N, Yada Y, Koike Y, Kawamata R, Uehara R, et al. Prolonged maternal mag-
nesium administration and bone metabolism in neonates. Early Hum Dev. 2010; 86(3):187–91. https://
doi.org/10.1016/j.earlhumdev.2010.02.007 PMID: 20226604
199. Young BK, Weinstein HM. Effects of magnesium sulfate on toxemic patients in labor. Obstet Gynecol.
1977; 49(6):681–5. PMID: 865731
200. Ahmad S, Miller M, Slaughter S. Is there any evidence for fetal harm with prolonged used of magne-
sium sulfate in pregnant women? Pharmacoepidemiol Drug Saf. 2013; 22(1):141.
201. Amodio J, Berdon W, Abramson S, Stolar C. Microcolon of prematurity: a form of functional obstruc-
tion. AJR Am J Roentgenol. 1986; 146(2):239–44. https://doi.org/10.2214/ajr.146.2.239 PMID:
3484569
202. Cruz M, Doren A, Fernandez B, Antonio Salinas J, Urzua S, Lui Tapia J. Intoxicación neonatal por sul-
fato de magnesio: caso clı́nico. Rev Chil Pediatr. 2009; 80(3):261–6.
203. Cumming W, Thomas V. Hypermagnesemia: a cause of abnormal metaphyses in the neonate. AJR
Am J Roentgenol. 1989; 152(5):1071–2. https://doi.org/10.2214/ajr.152.5.1071 PMID: 2705341
204. Herschel M, Mittendorf R. Tocolytic magnesium sulfate toxicity and unexpected neonatal death. J Peri-
natol. 2001; 21(4):261–2. https://doi.org/10.1038/sj.jp.7200498 PMID: 11533846
205. Brady J. Magnesium intoxication in a premature infant. Pediatrics. 1967; 40(1):100–3. PMID: 6028888
206. Jashi R, Gorgadze N. Maternal medication part of infant mortality. J Matern Fetal Neonatal Med. 2014;
27:320–1.
207. Kaplan W, Haymond MW, McKay S, Karaviti LP. Osteopenic effects of MgSO4 in multiple pregnan-
cies. J Pediatr Endocrinol Metab. 2006; 19(10):1225–30. https://doi.org/10.1515/jpem.2006.19.10.
1225 PMID: 17172083
208. Kogan JM, Wedig KE, Whitsett JA, Schorry EK. Prolonged prenatal exposure to magnesium sulfate
associated with bone abnormalities mimicking genetic bone disease. Am J Hum Genet. 2003; 73(5
Suppl):590.
209. Krasna IH, Rosenfeld D, Salerno P. Is it necrotizing enterocolitis, microcolon of prematurity, or delayed
meconium plug? A dilemma in the tiny premature infant. J Pediatr Surg. 1996; 31(6):855–8. https://doi.
org/10.1016/s0022-3468(96)90153-0 PMID: 8783123
210. Kurtoglu S, Caksen H, Poyrazoglu MH. Neonatal poisonings in middle Anatolia of Turkey: an analysis
of 72 cases. J Toxicol Sci. 2000; 25(2):115–9. https://doi.org/10.2131/jts.25.115 PMID: 10845189
211. L’Hommedieu CS, Huber P, Rasch DK. Potentiation of magnesium-induced neuromuscular weakness
by gentamicin. Crit Care Med. 1983; 11(1):55–6. https://doi.org/10.1097/00003246-198301000-00015
PMID: 6848309
212. Lamm C, Norton K, Murphy R, Wilkins I, Rabinowitz J. Congenital rickets associated with magnesium
sulfate infusion for tocolysis. J Pediatr. 1988; 113(6):1078–82. https://doi.org/10.1016/s0022-3476(88)
80586-9 PMID: 3193315
Antenatal magnesium sulphate and adverse neonatal outcomes
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002988 December 6, 2019 36 / 37
298
213. Lipsitz P, English I. Hypermagnesemia in the newborn infant. Pediatrics. 1967; 40(5):856–62. PMID:
6075658
214. Malaeb S, Rassi A, Haddad M, Seoud M, Yunis K. Bone mineralization in newborns whose mothers
received magnesium sulphate for tocolysis of preterm labour. Pediatr Radiol. 2004; 34(384–6).
215. Rasch D, Richardson C. Effect of gentamicin on neuromuscular function (NMF) of a hypermagnese-
mic neonate. Pediatr Res. 1981; 15(4):499.
216. Sokal M, Koenigsberger M, Rose J, Berdon W, Santulli T. Neonatal hypermagnesemia and the meco-
nium-plug syndrome. N Engl J Med. 1972; 286(1):823–5.
217. Tanaka K, Mori H, Sakamoto R, Matsumoto S, Mitsubuchi H, Nakamura K, et al. Early-onset neonatal
hyperkalemia associated with maternal hypermagnesemia: a case report. BMC Pediatr. 2018;
15(1):55.
218. Teng R, Liu H, Tsou Yau K. Neonatal hypermagnesemia: report of one case. Acta Paediatr Sin. 1989;
30(5):333–6. PMID: 2637615
219. Smith JM, Lowe RF, Fullerton J, Currie SM, Harris L, Felker-Kantor E. An integrative review of the side
effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management. BMC
Pregnancy Childbirth. 2013; 13:34. https://doi.org/10.1186/1471-2393-13-34 PMID: 23383864
220. Duffy J, Hirsch M, Pealing L, Showell M, Khan KS, Ziebland S, et al. Inadequate safety reporting in
pre-eclampsia trials: a systematic evaluation. Br J Obstet Gynaecol. 2018; 125(7):795–803.
221. McNamara HC, Crowther CA, Brown J. Different treatment regimens of magnesium sulphate for toco-
lysis in women in preterm labour. Cochrane Database Syst Rev. 2015;(12):CD011200. https://doi.org/
10.1002/14651858.CD011200.pub2 PMID: 26662716
222. Garg BD. Antenatal magnesium sulfate is beneficial or harmful in very preterm and extremely preterm
neonates: a new insight. J Matern Fetal Neonatal Med. 2019; 32(12):2084–90. https://doi.org/10.
1080/14767058.2018.1424823 PMID: 29301419
223. Golder S, Loke YK, Wright K, Norman G. Reporting of adverse events in published and unpublished
studies of health care interventions: a systematic review. PLoS Med. 2016; 13(9):e1002127. https://
doi.org/10.1371/journal.pmed.1002127 PMID: 27649528
224. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool
for systematic reviews that include randomised or non-randomised studies of healthcare interventions,
or both. BMJ. 2017; 358:j4008. https://doi.org/10.1136/bmj.j4008 PMID: 28935701
Antenatal magnesium sulphate and adverse neonatal outcomes




CHAPTER 6: OVERALL CONCLUSIONS 
 
Cerebral palsy (CP) remains the leading cause of physical disability in childhood. Despite emerging 
evidence from a number of countries that the birth prevalence of CP has begun to decline for the 
first time, CP continues to affect approximately one in 500 babies worldwide. While risk factors and 
causes of CP are well established, potential preventive interventions are under-researched. 
 
The series of studies in Chapters 2, 3, 4 and 5 of this thesis, focused on CP prevention and antenatal 
magnesium sulphate, have addressed research gaps identified by literature review in Chapter 1. In 
concluding this thesis, the key findings of these studies are provided and the implications for practice 
and research summarised. 
 
Summary of findings from studies within this thesis 
 
Antenatal, intrapartum and neonatal interventions for preventing cerebral palsy: two 
overviews of Cochrane systematic reviews (Chapters 2 and 3) 
 
To address the identified research question ‘What is the current evidence regarding antenatal, 
intrapartum and neonatal preventive interventions for CP?’ two overviews of Cochrane systematic 
reviews were conducted (Shepherd et al. 2018; Shepherd et al. 2017).  
 
These overviews together included 58 moderate- to high-quality Cochrane reviews; data for CP were 
available from 123 randomised controlled trials (RCTs) and 48,375 children. 
 
Effective interventions: high-quality evidence of effectiveness: Magnesium sulphate versus placebo 
given to women at risk of very preterm birth for neuroprotection of the fetus, and therapeutic 
hypothermia versus standard care for neonates with hypoxic-ischaemic encephalopathy, were shown 
to reduce the risk of CP. 
 
Probably effective interventions: moderate-quality evidence of effectiveness: Prophylactic 
methylxanthines (caffeine) versus placebo for endotracheal extubation in preterm neonates were 
shown to probably reduce the risk of CP. 
 
Probably ineffective interventions: moderate-quality evidence of harm: Any prophylactic antibiotics 
versus no antibiotics for women in preterm labour with intact membranes, immediate delivery versus 
deferred birth for preterm neonates with suspected fetal compromise, and early (at less than eight 
days of age) postnatal corticosteroids versus placebo or no treatment for preventing chronic lung 
disease in preterm neonates, were shown to probably increase the risk of CP. 
 
Probably ineffective interventions: moderate-quality evidence of lack of effectiveness: The 
following interventions were shown to probably not impact CP risk: repeat doses of corticosteroids 
versus a single course in women at risk of preterm birth; ethamsylate versus placebo for preventing 
morbidity in preterm or very low birthweight neonates; volume versus no treatment and gelatin 
versus fresh frozen plasma for preventing morbidity and mortality in very preterm neonates; 
prophylactic indomethacin versus placebo or no drug for preventing mortality and morbidity in 
preterm neonates; synthetic surfactant versus placebo for respiratory distress syndrome in preterm 
neonates; and prophylactic phototherapy versus standard care for preventing jaundice in preterm or 
low birthweight neonates. 
 
No conclusions possible: low- to very low-quality evidence: The following interventions were 
shown to have an unclear impact on CP risk: continuous cardiotocography versus intermittent 
auscultation for fetal assessment during labour; any antihypertensive drug versus placebo in women 
with mild to moderate hypertension; oral beta-blockers versus placebo for women in mild to 
moderate hypertension; magnesium sulphate versus placebo in women with pre-eclampsia; 
interventionist care versus expectant care in women with severe pre-eclampsia; betamimetics versus 




magnesium sulphate versus other tocolytic agents for preventing preterm birth; corticosteroids 
versus with placebo for accelerating fetal lung maturation in women at risk of preterm birth; vitamin 
K versus placebo prior to preterm birth for preventing neonatal periventricular haemorrhage; 
phenobarbital versus placebo prior to preterm birth for preventing neonatal periventricular 
haemorrhage; barbiturates (phenobarbital) versus conventional therapy for preventing morbidity and 
mortality following perinatal asphyxia in term and late preterm neonates; darbepoetin alfa versus 
placebo and erythropoietin versus placebo for preventing red blood cell transfusion in preterm or 
low birthweight neonates; transfusion at a restrictive (low haemoglobin) versus a liberal (high 
haemoglobin) threshold for preventing morbidity and mortality in very low birthweight neonates; 
dobutamine versus dopamine in preterm neonates with low superior vena cava flow; oral ibuprofen 
versus intravenous ibuprofen for treating patent ductus arteriosus in preterm or low birthweight (or 
both) neonates; endothelin receptor antagonists versus placebo for persistent pulmonary 
hypertension in term and late preterm neonates; room air versus 100% oxygen for resuscitation of 
neonates at birth; inhaled nitric oxide versus placebo or no treatment for respiratory failure in 
preterm neonates; inhaled nitric oxide versus placebo for respiratory failure in neonates born at or 
near term; caffeine versus placebo for preventing apnoea in preterm neonates; caffeine versus 
placebo for treating apnoea in preterm neonates; prophylactic protein free synthetic surfactant versus 
placebo for preventing morbidity and mortality in preterm neonates; animal-derived surfactant 
extract versus no treatment for treating respiratory distress syndrome in preterm neonates; 
continuous distending pressure versus standard care for respiratory distress in preterm neonates; 
long versus short inspiratory times in neonates receiving mechanical ventilation; early inhaled 
corticosteroids versus placebo for preventing chronic lung disease in ventilated very low birthweight 
preterm neonates; moderately early (between seven and 14 days of age) postnatal corticosteroids 
versus placebo or no treatment for preventing chronic lung disease in preterm neonates; late (more 
than seven days of age) postnatal corticosteroids versus placebo or no treatment for chronic lung 
disease in preterm neonates; arginine supplementation versus placebo for preventing necrotising 
enterocolitis in preterm neonates; systemic antifungal agents versus placebo for preventing mortality 
and morbidity in very low birthweight neonates; acyclovir versus vidarabine for treating herpes 
simplex virus infection in neonates; dextrose gel versus placebo for treating hypoglycaemia in 
neonates; prophylactic thyroid hormones versus placebo for preventing morbidity and mortality in 
preterm neonates; kangaroo mother care versus conventional neonatal care to reduce morbidity and 
mortality in low birthweight neonates; use of silicone earplugs versus no earplugs in the neonatal 
intensive care unit for preterm or very low birthweight neonates; early developmental intervention 
versus standard follow up post hospital discharge to prevent motor and cognitive impairment in 
preterm neonates. 
 
Linking data from a large perinatal clinical trial with the Australian Cerebral Palsy 
Register for long-term follow up (Chapter 4) 
 
To address the second identified research question ‘Can a nationwide CP registry be used for long-
term RCT follow up?’ data from a large maternal perinatal RCT (Australasian Collaborative Trial 
of Magnesium Sulphate (ACTOMgSO4)) were linked with the Australian Cerebral Palsy Register 
(ACPR) (Shepherd et al. 2020).  
 
Linkage of de-identified data from 913 ACTOMgSO4 children (born 1996 to 2000) and the ACPR 
was achieved. 
 
Notable discrepancies in children diagnosed with CP by ACTOMgSO4 (up to two years) and the 
ACPR (up to five years), were identified – some children received a CP diagnosis by ACTOMgSO4 
and the ACPR, and others by ACTOMgSO4 only, or by the ACPR only. 
 
Children born in Australian states/territories with long-standing versus more recently established CP 
registers, and with a ‘definitely yes’ (versus ‘probably yes’) or ‘probably no’ (versus ‘definitely no’) 
CP status at two years in ACTOMgSO4 were more likely to be included on the ACPR up to five 
years. For children without a CP diagnosis at two years in ACTOMgSO4, a variety of indicators of 




tone, and receipt of physiotherapist or occupational therapist care) were also associated with ACPR 
inclusion up to five years. 
 
Differences in the diagnoses observed were attributed to limitations of both strategies for identifying 
children with CP in this era (relating to diagnostic methods used at the time of ACTOMgSO4, and 
under-ascertainment by more recently established ACPR contributing registers). 
 
Antenatal magnesium sulphate and adverse neonatal outcomes: a systematic review 
and meta-analysis (Chapter 5) 
 
To address the final identified research question ‘Is antenatal magnesium sulphate associated with 
adverse neonatal outcomes?’ a systematic review and meta-analysis was conducted (Shepherd et al. 
2019). 
 
The systematic review incorporated findings from 197 studies (40 RCTs randomising 19,265 women 
and their babies, 138 non-randomised studies, and 19 case reports; of mixed quality). 
 
Overall, no clear difference in perinatal death was shown in the RCTs comparing antenatal 
magnesium sulphate with placebo or no treatment, nor in regimen comparisons used in the RCTs. 
Very few non-randomised studies reported perinatal death, and only one suggested a possible 
increased risk of perinatal death with high dose antenatal magnesium sulphate for tocolysis. 
 
Findings for secondary adverse neonatal outcomes were reassuring, with no clear differences shown 
between antenatal magnesium sulphate and placebo or no treatment in RCTs. Non-randomised 
studies identified a limited number of adverse neonatal outcomes, warranting further consideration: 
neonatal death and intestinal morbidity in very preterm neonates with exposure for fetal 
neuroprotection, patent ductus arteriosus in very preterm or very low birthweight neonates with 
exposure for pre-eclampsia or tocolysis, and intensive care unit admission in term neonates with 
exposure for pre-eclampsia. Case reports suggested an association between neonatal bone 
abnormalities and long-term, high dose antenatal magnesium sulphate exposure for tocolysis. 
 
Implications for practice and research from studies within this thesis 
 
The main implications for practice and research from the studies conducted within this thesis are 






Table 1: Research and practice implications from studies conducted within this thesis 
 
Cochrane overviews of antenatal, intrapartum and neonatal interventions for CP prevention 
Practice 
 
 Magnesium sulphate in women at risk of very preterm birth for neuroprotection of the 
fetus, and therapeutic hypothermia for neonates with hypoxic-ischaemic encephalopathy 
can reduce the risk of CP.  
 Prophylactic methylxanthines for endotracheal extubation in preterm neonates can 
probably reduce the risk of CP. 
 These overviews can be used by policy makers, health professionals and consumers to 
aid decision making and evidence translation. 
 As the scope of these overviews was limited to the effects of interventions on CP and 
pre-specified secondary outcomes, consultation of the included reviews is recommended 
to formally assess additional benefits and harms. 
Research  These overviews highlight areas where there is insufficient evidence to draw 
conclusions. 
o There was low- to very low-quality evidence on CP for interventions assessed in 37 
included Cochrane reviews.  
o There was no evidence on CP for interventions assessed in 164 excluded Cochrane 
reviews (that pre-specified CP as a review outcome of interest, but had no CP data 
from RCTs included in the reviews). 
 These overviews can be used by researchers and funding bodies to generate research 
questions and priorities. 
 There is an urgent need for long-term follow up of RCTs addressing risk factors for CP. 
 Future studies must be rigorous in their design and aim for consistency in CP outcome 
measurement and reporting to facilitate pooling of outcome data, to maximise research 
efforts aimed at CP prevention.  
 In light of the challenges associated with long-term follow up, new strategies to measure 
impact on CP, such as data linkage with CP registries, should be further explored. 




 This study provides a firm basis for further linkage studies of data from participants in 
maternal perinatal RCTs with ACPR data for childhood CP assessment.  
 As all ACPR registers are expected to achieve population-level ascertainment in the 
coming years, further research on the use of ACPR CP diagnoses for long-term CP 
assessment in Australian preventive RCTs is recommended. 
 Future RCTs should consider pre-specification of linkage with CP registry data in their 
protocols, participant information sheets and consent forms, enabling the use of 
identifiable data. 
 Maternal perinatal clinicians and researchers assessing CP are urged to follow new 
international clinical practice guidelines for early, accurate diagnosis of CP. 
Systematic review of antenatal magnesium sulphate and adverse neonatal outcomes 
Practice  Antenatal magnesium sulphate, when given for the beneficial indications of maternal 
and fetal neuroprotection (for pre-eclampsia or eclampsia, and CP prevention 
respectively), does not increase the risk of perinatal death or other adverse outcomes for 
neonates. 
 Findings of possible adverse outcomes with long-term, high dose use for tocolysis has 
implications for settings with continued use for this indication, in spite of the absence of 
benefit of treatment. 
Research  Further large, high-quality studies (such as prospective cohort studies, individual 
participant data meta-analyses, or RCTs of regimen comparisons) assessing identified 
adverse neonatal outcomes, and the impact of regimen, pregnancy or birth characteristics 
on these outcomes, will further inform safety recommendations for the use of antenatal 
magnesium sulphate. 
Abbreviations: ACPR: Australian Cerebral Palsy Register; ACTOMgSO4: Australasian 







This thesis has presented a series of studies addressing identified research gaps surrounding CP 
prevention and antenatal magnesium sulphate. Research methodologies used in this thesis included 
two overviews of Cochrane reviews, linkage of a large maternal perinatal RCT with a nationwide 
CP register, and a systematic review of both RCTs and non-randomised studies. 
 
For CP prevention, evidence from this thesis supports the continued implementation of magnesium 
sulphate for fetal neuroprotection in women at risk of very preterm birth, and therapeutic 
hypothermia in neonates with hypoxic-ischaemic encephalopathy for CP prevention. 
 
Based on the research findings presented in this thesis it is clear that current evidence to guide 
practice in the areas of antenatal, intrapartum and neonatal interventions for CP prevention is 
incomplete. Several priorities for future research have been identified, particularly relating to the 
unknown impacts of a range of relevant interventions on CP risk, and the related urgent need for 
further investment in strategies for follow up of participants from maternal perinatal RCTs to enable 
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Protocol citation Overview of pre‐specified outcomes in protocol 
Amorim MMR, Souza ASR, Katz L, Noronha Neto 
C. Planned caesarean section versus planned vaginal 
delivery for severe preeclampsia 
(Protocol). Cochrane Database of Systematic 
Reviews 2011, Issue 11. 
Secondary pre‐specified perinatal and neonatal outcomes include: 
 Long‐term disability: blindness, deafness, seizures, poor growth, neurodevelopmental delay, and cerebral palsy 
Bimbashi A, Duley L, Ndoni E, Dokle A. 
Amniotomy plus intravenous oxytocin for induction 
of labour (Protocol). Cochrane Database of 
Systematic Reviews 2012, Issue 4. 
Primary pre‐specified outcomes for the baby include: 
 Serious neonatal morbidity or perinatal death (e.g. seizures, birth asphyxia defined by trialists, neonatal 
encephalopathy, disability in childhood) 
Secondary pre‐specified outcomes for the baby include: 
 Individual components of serious neonatal morbidity or perinatal death, as listed above (perinatal death, total 
baby death, seizures, birth asphyxia defined by trialists, neonatal encephalopathy, disability in childhood ‐ such 
as neurodevelopmental delay, blind, deaf, cerebral palsy) 
Dodd JM, Grivell RM, O'Brien CM, Dowswell T, 
Deussen AR. Prenatal administration of progestogens 
for preventing preterm birth in women with a 
multiple pregnancy (Protocol). Cochrane Database of 
Systematic Reviews 2016, Issue 1. 
Primary pre‐specified outcomes for the infant include: 
 Major neurodevelopmental disability at childhood follow‐up 
Secondary pre‐specified outcomes for the child include: 
 Major sensorineural disability (defined as any of: legal blindness, sensorineural deafness requiring hearing aids, 
moderate or severe cerebral palsy, developmental delay, or intellectual impairment (defined as developmental 
quotient or intelligence quotient less than two standard deviations below mean)) 
 Cerebral palsy 
Dutta D, Sule M, Ray A. Epidural therapy for the 
treatment of severe pre‐eclampsia in non labouring 
women (Protocol). Cochrane Database of Systematic 
Reviews 2012, Issue 1. 
Secondary pre‐specified outcome for the child include: 
 Long‐term growth and development: blindness, deafness, seizures, poor growth, neurodevelopmental delay, and 
cerebral palsy 
Eke AC, Ezebialu IU, Eleje GU. Hypnosis for 
preventing preterm labour (Protocol). Cochrane 
Database of Systematic Reviews 2012, Issue 11. 
Secondary pre‐specified outcomes for the child include: 
 Major sensorineural disability (defined as any of: legal blindness, sensorineural deafness requiring hearing aids, 
moderate or severe cerebral palsy, developmental delay, or intellectual impairment (defined as developmental 




 Cerebral palsy 
Haruna M, Matsuzaki M, Ota E, Shiraishi M, Hanada 
N, Mori R. Guided imagery for treating hypertension 
in pregnancy (Protocol). Cochrane Database of 
Systematic Reviews 2014, Issue 10. 
Secondary pre‐specified outcomes for the neonate include: 
 Long‐term growth and development: blindness, deafness, seizures, poor growth, neurodevelopmental delay, and 
cerebral palsy 
Hobson SR, Mockler JC, Lim R, Alers NO, Miller 
SL, Wallace EM. Melatonin for preventing pre‐
eclampsia (Protocol). Cochrane Database of 
Systematic Reviews 2015, Issue 5. 
Secondary pre‐specified outcomes for the child include: 
 Long‐term growth and development: blindness, deafness, seizures, poor growth, neurodevelopmental delay, and 
cerebral palsy 
Hobson SR, Mockler JC, Lim R, Alers NO, Miller 
SL, Wallace EM. Melatonin for treating pre‐
eclampsia (Protocol). Cochrane Database of 
Systematic Reviews 2016, Issue 3. 
Secondary pre‐specified outcomes for the child include: 
 Long‐term growth and development: blindness, deafness, seizures, poor growth, neurodevelopmental delay, and 
cerebral palsy 
Martis R, Emilia O, Nurdiati DS. Intermittent 
auscultation (IA) of fetal heart rate in labour for fetal 
well‐being (Protocol). Cochrane Database of 
Systematic Reviews 2010, Issue 9. 
Secondary pre‐specified outcomes for the baby include: 






Reviews awaiting further classification 
 
Review citation Overview outcomes pre‐specified in review with no outcome data Main conclusion(s) of review 
Abdel‐Latif ME, Osborn DA, 
Challis D Cochrane Database of 
Systematic. Intra‐amniotic 
surfactant for women at risk of 
preterm birth for preventing 
respiratory distress in 
newborns. Cochrane Database 
of Systematic Reviews 2010, 
Issue 1. 
Primary outcomes include: 
 Neurodevelopmental disability at 18 months or more 
postnatal age, defined as neurological abnormality, 
including: cerebral palsy on clinical examination; 
developmental delay more than two standard deviations 
below population mean on any standard test of 
development; blindness (visual acuity less than 6/60); or 
deafness (any hearing impairment requiring amplification) at 
any time after term corrected age 
No included trials. 
"We identified no randomised trials that evaluated the effect of intra‐
amniotic instillation of surfactant for women at risk of preterm birth. 
Evidence from animal and observational human studies suggest that 
intra‐amniotic surfactant administration is potentially safe, feasible and 
effective. Well designed trials of intra‐amniotic instillation of 
surfactant for women at risk of preterm birth are needed." 
Bain E, Heatley E, Hsu K, 
Crowther CA. Relaxin for 
preventing preterm birth. 
Cochrane Database of 
Systematic Reviews 2013, Issue 
8. 
Secondary outcomes for the infant/child include: 
 Cerebral palsy 
"There is limited randomised controlled trial evidence available on the 
effect of relaxin during pregnancy for preventing preterm birth for 
women in preterm labour. Evidence from one quasi‐randomised trial 
suggested a reduction in birth within seven days of treatment for 
women receiving relaxin, compared with women in a control group, 
however this trial was at a high risk of bias and included only 30 
women. Thus, there is insufficient evidence to support or refute the use 
of relaxin in women in preterm labour for preventing preterm birth." 
Bain E, Middleton P, Crowther 
CA. Different magnesium 
sulphate regimens for 
neuroprotection of the fetus for 
women at risk of preterm birth. 
Cochrane Database of 
Systematic Reviews 2012, Issue 
2. 
Primary outcomes for the infant/child include: 
 Cerebral palsy (abnormality of tone with motor dysfunction, 
or as defined by trialists) 
 Death or cerebral palsy (as they are competing outcomes, 
this combined outcome is often considered the most 
clinically relevant for assessing neuroprotection) 
Secondary outcomes for the infant/child include: 
 Cerebral palsy (mild, moderate or severe, evaluated 
separately, as defined by trialists) 
 Major neurologic disability (including: moderate or severe 
cerebral palsy (as defined by trialists)) 
No included trials. 
"Although strong evidence supports the use of antenatal magnesium 
sulphate for neuroprotection of the fetus prior to very preterm birth, no 
trials comparing different treatment regimens have been completed. 
Research should be directed towards comparisons of different dosages 
and other variations in regimens, evaluating both maternal and infant 
outcomes." 
Bain E, Pierides KL, Clifton 
VL, Hodyl NA, Stark MJ, 
Secondary outcomes for the infant, child, and for the child as an adult 
include: 
"Based on eight included trials, of moderate quality overall, no firm 




Crowther CA, et al. 
Interventions for managing 
asthma in pregnancy. Cochrane 
Database of Systematic 
Reviews 2014, Issue 10. 
 Any neurodevelopmental disability (blindness, deafness, 
moderate or severe cerebral palsy (however defined by 
authors), or development delay or intellectual impairment 
(defined as developmental quotient or intelligence quotient 
more than two standard deviations below population mean)) 
 Cerebral palsy (however defined by authors) 
pregnancy can be made. Five trials assessing pharmacological 
interventions did not provide clear evidence of benefits or harms to 
support or refute current practice. While inhaled magnesium sulphate 
for acute asthma was shown to reduce exacerbations, this was in one 
small trial of unclear quality, and thus, this finding should be 
interpreted with caution. Three trials assessing non‐pharmacological 
interventions provided some support for the use of such strategies, 
however, were not powered to detect differences in important maternal 
and infant outcomes. While a FENO‐based algorithm reduced 
exacerbations, the effects on perinatal outcomes were less certain, and 
thus, widespread implementation is not yet appropriate. Similarly, 
though positive effects on asthma control were shown with PMR and 
pharmacist‐led management, the evidence to date is insufficient to 
draw definitive conclusions. 
In view of the limited evidence base, further randomised trials are 
required to determine the most effective and safe interventions for 
asthma in pregnancy. Future trials must be sufficiently powered, and 
well‐designed, to allow differences in important outcomes for mothers 
and babies to be detected. The impact on health services requires 
evaluation. Any further trials assessing pharmacological interventions 
should assess novel agents or those used in current practice. 
Encouragingly, at least five trials have been identified as planned or 
underway." 
Bricker L, Reed K, Wood L, 
Neilson JP. Nutritional advice 
for improving outcomes in 
multiple pregnancies. Cochrane 
Database of Systematic 
Reviews 2015, Issue 11. 
Secondary outcomes for the child include: 
 Cerebral palsy 
No included trials. 
"There is no robust evidence from randomised trials to indicate 
whether specialised diets or nutritional advice for women with 
multiple pregnancies do more good than harm. There is a clear need to 
undertake a randomised controlled trial." 
Brocklehurst P, Gordon A, 
Heatley E, Milan SJ. Antibiotics 
for treating bacterial vaginosis 
in pregnancy. Cochrane 
Secondary outcomes for the neonate include: 
 Cerebral palsy at childhood follow‐up 
"Antibiotic treatment can eradicate bacterial vaginosis in pregnancy. 
The overall risk of PTB was not significantly reduced. This review 
provides little evidence that screening and treating all pregnant women 




Database of Systematic 
Reviews 2013, Issue 1. 
screening criteria were broadened to include women with abnormal 
flora there was a 47% reduction in preterm birth, however, this is 
limited to two included studies." 
Brownfoot FC, Gagliardi DI, 
Bain E, Middleton P, Crowther 
CA. Different corticosteroids 
and regimens for accelerating 
fetal lung maturation for women 
at risk of preterm birth. 
Cochrane Database of 
Systematic Reviews 2013, Issue 
8. 
Primary outcomes for the child include: 
 Neurodevelopmental disability at follow‐up (blindness, 
deafness, moderate or severe cerebral palsy (however 
defined by authors), or developmental delay or intellectual 
impairment (defined as developmental quotient or 
intelligence quotient less than two standard deviations below 
population mean) or variously defined) 
Primary outcomes for the child as an adult include: 
 Neurodevelopmental disability at follow‐up (blindness, 
deafness, moderate or severe cerebral palsy (however 
defined by authors), or developmental delay or intellectual 
impairment (defined as developmental quotient or 
intelligence quotient less than two standard deviations below 
population mean), or variously defined 
Secondary outcomes for the child include: 
 Cerebral palsy (however defined by authors) 
"It remains unclear whether one corticosteroid (or one particular 
regimen) has advantages over another. Dexamethasone may have 
some benefits compared with betamethasone, such as less IVH, and a 
shorter length of stay in the NICU. The intramuscular route may have 
advantages over the oral route for dexamethasone, as identified in one 
small trial. Apart from the suggestion that 12‐hour dosing may be as 
effective as 24‐hour dosing of betamethasone, based on one small trial, 
we were unable to make few other conclusions about optimal antenatal 
corticosteroid regimens. No long‐term results were available, except 
for a small subgroup of 18‐month old children in one trial. Trials 
comparing the commonly used corticosteroids are most urgently 
needed, as are trials of dosages and other variations in treatment 
regimens." 
Chawanpaiboon S, Laopaiboon 
M, Lumbiganon P, 
Sangkomkamhang US, 
Dowswell T. Terbutaline pump 
maintenance therapy after 
threatened preterm labour for 
reducing adverse neonatal 
outcomes. Cochrane Database 
of Systematic Reviews 2014, 
Issue 3. 
Secondary outcomes for the neonate include: 
 Neurological sequelae (general intelligence, hearing, vision, 
cerebral palsy, and disability) 
"We found no evidence that terbutaline pump maintenance therapy 
decreased adverse neonatal outcomes. Taken together with the lack of 
evidence of benefit, its substantial expense, and the lack of information 
on the safety of the therapy, the evidence does not support its use in 
the management of arrested preterm labour. Future use should only be 
in the context of well‐conducted, adequately powered randomised 
controlled trials." 
Cluett ER, Burns E. Immersion 
in water in labour and birth. 
Cochrane Database of 
Primary outcomes for the neonate include: 
 Neurological pathology, e.g. seizures, cerebral palsy 
"Evidence suggests that water immersion during the first stage of 
labour reduces the use of epidural or spinal analgesia and duration of 
the first stage of labour. There is limited information for other 




Systematic Reviews 2009, Issue 
2. 
labour, due to intervention and outcome variability. There is no 
evidence of increased adverse effects to the fetus, neonate or woman 
from labouring in water or a water birth. However, the studies are very 
variable and considerable heterogeneity was detected for some 
outcomes. Further research is needed." 
Devane D, Lalor JG, Daly S, 
McGuire W, Smith V. 
Cardiotocography versus 
intermittent auscultation of fetal 
heart on admission to labour 
ward for assessment of fetal 
well‐being. Cochrane Database 
of Systematic Reviews 2012, 
Issue 2. 
Primary outcomes for the infant include: 
 Severe neurodevelopmental disability assessed at greater 
than, or equal to, 12 months of age. We have defined severe 
neurodevelopmental disability as any one or a combination 
of the following: non‐ambulant cerebral palsy, 
developmental delay (developmental quotient less than 70), 
auditory, and visual impairment. Development should have 
been assessed by means of a previously validated tool, such 
as Bayley Scales of Infant Development (Psychomotor 
Developmental Index and Mental Developmental Index) 
"Contrary to continued use in some clinical areas, we found no 
evidence of benefit for the use of the admission cardiotocograph 
(CTG) for low‐risk women on admission in labour. 
We found no evidence of benefit for the use of the admission CTG for 
low‐risk women on admission in labour. Furthermore, the probability 
is that admission CTG increases the caesarean section rate by 
approximately 20%. The data lacked power to detect possible 
important differences in perinatal mortality. However, it is unlikely 
that any trial, or meta‐analysis, will be adequately powered to detect 
such differences. The findings of this review support recommendations 
that the admission CTG not be used for women who are low risk on 
admission in labour. Women should be informed that admission CTG 
is likely associated with an increase in the incidence of caesarean 
section without evidence of benefit." 
Dickinson H, Bain E, Wilkinson 
D, Middleton P, Crowther CA, 
Walker DW. Creatine for 
women in pregnancy for 
neuroprotection of the fetus. 
Cochrane Database of 
Systematic Reviews 2014, Issue 
12. 
Primary outcomes for the infant and child include: 
 Death or any neurosensory disability (at latest time 
reported); this combined outcome recognises the potential 
for competing risks of death or survival with neurological 
problems 
 Neurosensory disability (any of cerebral palsy, blindness, 
deafness, developmental delay or intellectual impairment; at 
latest time reported) 
Secondary outcomes for the infant/child include: 
 Cerebral palsy (any, and graded as severe: including 
children who are non‐ambulant and are likely to remain so; 
moderate: including those children who have substantial 
limitation of movement; mild: including those children 
walking with little limitation of movement) 
No included trials. 
"As we did not identify any randomised controlled trials for inclusion 
in this review, we are unable to comment on implications for practice. 
Although evidence from animal studies has supported a fetal 
neuroprotective role for creatine when administered to the mother 
during pregnancy, no trials assessing creatine in pregnant women for 
fetal neuroprotection have been published to date. If creatine is 
established as safe for the mother and her fetus, research efforts should 
first be directed towards randomised trials comparing creatine with 
either no intervention (ideally using a placebo), or with alternative 
agents aimed at providing fetal neuroprotection (including magnesium 
sulphate for the very preterm infant). If appropriate, these trials should 
then be followed by studies comparing different creatine regimens 




 Death or cerebral palsy 
 Major neurosensory disability (defined as any of: moderate 
or severe cerebral palsy, legal blindness, neurosensory 
deafness requiring hearing aids, or moderate or severe 
developmental delay, or intellectual impairment) 
and adequately powered to evaluate maternal and infant short and 
longer‐term outcomes (including neurodevelopmental disabilities, such 
as cerebral palsy), and should consider utilisation and costs of health 
care." 
Dodd JM, Dowswell T, 
Crowther CA. Specialised 
antenatal clinics for women 
with a multiple pregnancy for 
improving maternal and infant 
outcomes. Cochrane Database 
of Systematic Reviews 2015, 
Issue 11. 
Secondary outcomes for the infant include: 
 Disability at childhood follow‐up (including deafness, 
blindness, neurodisability, or cerebral palsy) 
"There is currently limited information available from randomised 
controlled trials to assess the role of 'specialised' antenatal clinics for 
women with a multiple pregnancy compared with 'standard' antenatal 
care in improving maternal and infant health outcomes. The value of 
'specialised' multiple pregnancy clinics in improving health outcomes 
for women and their infants requires evaluation in appropriately 
powered and designed randomised controlled trials." 
Drakeley AJ, Roberts D, 
Alfirevic Z. Cervical stitch 
(cerclage) for preventing 
pregnancy loss in women. 
Cochrane Database of 
Systematic Reviews 2003, Issue 
1. 
Neonatal outcomes include: 
 Infant and child development ‐ such as cerebral palsy; 
mental retardation, hearing and vision as assessed by 
paediatric follow‐up and attainment of developmental 
milestones (less than one year; less than two years; greater 
than two years 
"The use of a cervical stitch should not be offered to women at low or 
medium risk of mid trimester loss, regardless of cervical length by 
ultrasound. The role of cervical cerclage for women who have short 
cervix on ultrasound remains uncertain as the numbers of randomised 
women are too few to draw firm conclusions. There is no information 
available as to the effect of cervical cerclage or its alternatives on the 
family unit and long term outcome." 
Duckitt K, Thornton S, 
O'Donovan OP, Dowswell T. 
Nitric oxide donors for treating 
preterm labour. Cochrane 
Database of Systematic 
Reviews 2014, Issue 5. 
Primary outcomes for the infant include: 
 Long‐term neurological development (general intelligence, 
hearing, vision, cerebral palsy, and disability, (serious infant 
outcome)) 
"There is currently insufficient evidence to support the routine 
administration of nitric oxide donors in the treatment of threatened 
preterm labour." 
Duley L, Gülmezoglu AM, 
Chou D. Magnesium sulphate 
versus lytic cocktail for 
eclampsia. Cochrane Database 
of Systematic Reviews 2010, 
Issue 9. 
Secondary outcomes for the child include: 
 Long‐term growth and development: blindness, deafness, 
seizures, poor growth, neurodevelopmental delay, and 
cerebral palsy 
"Magnesium sulphate, rather than lytic cocktail, for women with 
eclampsia reduces the risk ratio of maternal death, of further seizures 
and of serious maternal morbidity (respiratory depression, coma, 
pneumonia). Magnesium sulphate is the anticonvulsant of choice for 




Duley L, Henderson‐Smart DJ, 
Chou D. Magnesium sulphate 
versus phenytoin for eclampsia. 
Cochrane Database of 
Systematic Reviews 2010, Issue 
10. 
Secondary outcomes for the child include: 
 Long‐term growth and development: blindness, deafness, 
seizures, poor growth, neurodevelopmental delay, and 
cerebral palsy 
"Magnesium sulphate, rather than phenytoin, for women with 
eclampsia reduces the risk ratio of recurrence of seizures, probably 
reduces the risk of maternal death, and improves outcome for the baby. 
Magnesium sulphate is the drug of choice for women with eclampsia. 
The use of phenytoin should be abandoned." 
Duley L, Henderson‐Smart DJ, 
Meher S. Altered dietary salt for 
preventing pre‐eclampsia, and 
its complications. Cochrane 
Database of Systematic 
Reviews 2005, Issue 4. 
Outcomes for the child include: 
 Long‐term growth and development: blindness, deafness, 
seizures, poor growth, neurodevelopmental delay, and 
cerebral palsy 
"In the absence of evidence that advice to alter salt intake during 
pregnancy has any beneficial effect for prevention of pre‐eclampsia or 
any other outcome, salt consumption during pregnancy should remain 
a matter of personal preference." 
Duley L, Henderson‐Smart DJ, 
Meher S, King JF. Antiplatelet 
agents for preventing pre‐
eclampsia and its complications. 
Cochrane Database of 
Systematic Reviews 2007, Issue 
2. 
Outcomes for the child include: 
 Infant and child development (such as cerebral palsy, 
cognitive delay, deafness, and blindness) 
"Antiplatelet agents, largely low‐dose aspirin, have moderate benefits 
when used for prevention of pre‐eclampsia and its consequences. 
Further information is required to assess which women are most likely 
to benefit, when treatment is best started, and at what dose." 
Duley L, Henderson‐Smart DJ, 
Walker GJA, Chou D. 
Magnesium sulphate versus 
diazepam for eclampsia. 
Cochrane Database of 
Systematic Reviews 2010, Issue 
12. 
Secondary outcomes for the child include: 
 Long‐term growth and development: blindness, deafness, 
seizures, poor growth, neurodevelopmental delay, and 
cerebral palsy 
"Magnesium sulphate for women with eclampsia reduces the risk ratio 
of maternal death and of recurrence of seizures, compared with 
diazepam." 
Duley L, Matar HE, Almerie 
MQ, Hall DR. Alternative 
magnesium sulphate regimens 
for women with pre‐eclampsia 
and eclampsia. Cochrane 
Database of Systematic 
Reviews 2010, Issue 8. 
Secondary outcomes for the baby include: 
 Development in childhood: including cerebral palsy and 
major neurodevelopmental delay 
"Although strong evidence supports the use of magnesium sulphate for 
prevention and treatment of eclampsia, trials comparing alternative 




Duley L, Meher S, Jones L. 
Drugs for treatment of very high 
blood pressure during 
pregnancy. Cochrane Database 
of Systematic Reviews 2013, 
Issue 7. 
Secondary outcomes for the child include: 
 Long‐term growth and development: blindness, deafness, 
seizures, poor growth, neurodevelopmental delay, and 
cerebral palsy 
"Until better evidence is available, the choice of antihypertensive 
should depend on the clinician's experience and familiarity with a 
particular drug; on what is known about adverse effects; and on 
women's preferences. Exceptions are nimodipine, magnesium sulphate 
(although this is indicated for women who require an anticonvulsant 
for prevention or treatment of eclampsia), diazoxide and ketanserin, 
which are probably best avoided." 
Duley L, Williams J, 
Henderson‐Smart DJ. Plasma 
volume expansion for treatment 
of pre‐eclampsia. Cochrane 
Database of Systematic 
Reviews 1999, Issue 4. 
Outcomes for the baby include: 
 Measures of infant and child development (such as cerebral 
palsy) 
"There is insufficient evidence for any reliable estimates of the effects 
of plasma volume expansion for women with pre‐eclampsia." 
Flenady V, Reinebrant HE, 
Liley HG, Tambimuttu EG, 
Papatsonis DNM. Oxytocin 
receptor antagonists for 
inhibiting preterm labour. 
Cochrane Database of 
Systematic Reviews 2014, Issue 
6. 
Primary outcomes include: 
 Serious infant outcome (defined as death or chronic lung 
disease (need for supplemental oxygen at 28 days of life or 
later), grade three or four intraventricular haemorrhage or 
periventricular leukomalacia, major neurosensory disability 
(defined as any of: legal blindness, sensorineural deafness 
requiring hearing aids, moderate or severe cerebral palsy, or 
developmental delay or intellectual impairment (defined as 
developmental quotient (DQ) or intelligence quotient (IQ) 
less than two standard deviations below mean))) 
"This review did not demonstrate superiority of oxytocin receptor 
antagonists (ORA; largely atosiban) as a tocolytic agent compared 
with placebo, betamimetics, or calcium channel blockers (CCB; 
largely nifedipine) in terms of pregnancy prolongation or neonatal 
outcomes, although ORA was associated with less maternal adverse 
effects than treatment with the CCB or betamimetics. The finding of 
an increase in infant deaths, and more births before completion of 28 
weeks of gestation in one placebo‐controlled study warrants caution. 
However, the number of women enrolled at very low gestations was 
small. Due to limitations of small numbers studied and methodological 
quality, further well‐designed randomised controlled trials are needed. 
Further comparisons of ORA versus CCB (which has a better side‐
effect profile than betamimetics) are needed. Consideration of further 
placebo‐controlled studies seems warranted. Future studies of tocolytic 
agents should measure all important short‐ and long‐term outcomes for 
women and infants, and costs." 
Flenady V, Wojcieszek AM, 
Papatsonis DNM, Stock OM, 
Murray L, Jardine LA, et al. 
Calcium channel blockers for 
Primary outcomes include: 
 Serious infant outcome (defined as death or chronic lung 
disease (need for supplemental oxygen at 28 days of life or 
later), grade three or four intraventricular haemorrhage 
"Calcium channel blockers (CCB; mainly nifedipine) for women in 
preterm labour have benefits over placebo or no treatment in terms of 
postponement of birth, thus, theoretically allowing time for 




inhibiting preterm labour and 
birth. Cochrane Database of 
Systematic Reviews 2014, Issue 
6. 
(IVH) or periventricular leukomalacia (PVL), major 
neurosensory disability (defined as any of: legal blindness, 
sensorineural deafness requiring hearing aids, moderate or 
severe cerebral palsy, or developmental delay or intellectual 
impairment (defined as developmental quotient (DQ) or 
intelligence quotient (IQ) less than two standard deviations 
below mean))) 
Secondary outcomes for the infant or child include: 
 Blindness, deafness, cerebral palsy 
care. Calcium channel blockers were shown to have benefits over 
betamimetics with respect to prolongation of pregnancy, serious 
neonatal morbidity, and maternal adverse effects. Calcium channel 
blockers may also have some benefits over ORAs and magnesium 
sulphate, although ORAs results in fewer maternal adverse effects. 
However, it must be noted that no difference was shown in perinatal 
mortality, and data on longer‐term outcomes were limited. Further, the 
lack of blinding of the intervention diminishes the strength of this 
body of evidence. Further well‐designed tocolytic trials are required to 
determine short‐ and longer‐term infant benefit of CCBs over placebo 
or no treatment and other tocolytics, particularly ORAs. Another 
important focus for future trials is identifying optimal dosage regimens 
of different types of CCBs (high versus low, particularly addressing 
speed of onset of uterine quiescence), and formulation (capsules versus 
tablets). All future trials on tocolytics for women in preterm labour 
should employ blinding of the intervention and outcome assessment, 
include measurement of longer‐term effects into early childhood, and 
also costs." 
Grivell RM, Alfirevic Z, Gyte 
GML, Devane D. Antenatal 
cardiotocography for fetal 
assessment. Cochrane Database 
of Systematic Reviews 2015, 
Issue 9. 
Secondary outcomes include: 
 Cerebral palsy at 12 months 
"There is no clear evidence that antenatal CTG improves perinatal 
outcome, but further studies focusing on the use of computerised CTG 
in specific populations of women with increased risk of complications 
are warranted." 
Grivell RM, Wong L, Bhatia V. 
Regimens of fetal surveillance 
for impaired fetal growth. 
Cochrane Database of 
Systematic Reviews 2012, Issue 
6. 
Secondary outcomes for the infant include: 
 Cerebral palsy 
"There is limited evidence from randomised controlled trials to inform 
best practice for fetal surveillance regimens when caring for women 
with pregnancies affected by impaired fetal growth. More studies are 
needed to evaluate the effects of currently used fetal surveillance 
regimens in impaired fetal growth." 
Haas DM, Morgan AM, Deans 
SJ, Schubert FP. Ethanol for 
preventing preterm birth in 
Secondary outcomes for the fetus, neonate, or infant include: 
 Serious infant outcome (defined as death or chronic lung 
disease (need for supplemental oxygen at 28 days of life or 
"This review is based on evidence from twelve studies, which were 
mostly low quality. There is no evidence to suggest that ethanol is an 




threatened preterm labor. 
Cochrane Database of 
Systematic Reviews 2015, Issue 
11. 
later), grade three or four intraventricular hemorrhage or 
periventricular leukomalacia, major neurosensory disability 
(defined as any of: legal blindness, sensorineural deafness 
requiring hearing aids, moderate or severe cerebral palsy, or 
developmental delay or intellectual impairment (defined as 
developmental quotient (DQ) or intelligence quotient (IQ) 
less than two standard deviations below mean))) 
ethanol may be better tolerated than other tocolytics (in this case 
betamimetics), but this result is based on few studies and small sample 
sizes and therefore, should be interpreted with caution. Ethanol 
appears to be inferior to betamimetics for preventing preterm birth in 
threatened preterm labor. Ethanol is generally no longer used in 
current practice, due to safety concerns for the mother and her baby. 
There is no need for new studies to evaluate the use of ethanol for 
preventing preterm birth in threatened preterm labour. However, it 
would be useful for long‐term follow‐up studies on the babies born to 
mothers from the existing studies, in order to assess the risk of long‐
term neurodevelopmental status." 
Heazell AEP, Whitworth M, 
Duley L, Thornton JG. Use of 
biochemical tests of placental 
function for improving 
pregnancy outcome. Cochrane 
Database of Systematic 
Reviews 2015, Issue 11. 
Secondary outcomes for the baby include: 
 Neurodevelopment in childhood (cerebral palsy, 
neurodevelopmental delay) 
"There is insufficient evidence to support the use of biochemical tests 
of placental function to reduce perinatal mortality or increase 
identification of small‐for‐gestational‐age infants. However, we were 
only able to include data from two studies that measured oestrogens 
and hPL. The quality of the evidence was low or very low. Two of the 
trials were performed in the 1970s, on women with a variety of 
antenatal complications, and this evidence cannot be generalised to 
women at low‐risk of complications or groups of women with specific 
pregnancy complications (e.g. fetal growth restriction). Furthermore, 
outcomes described in the 1970s may not reflect what would be 
expected at present. For example, neonatal mortality rates have fallen 
substantially, such that an infant delivered at 28 weeks would have a 
greater chance of survival were those studies repeated; this may affect 
the primary outcome of the meta‐analysis. With data from just two 
studies (740 women), this review is underpowered to detect a 
difference in the incidence of death of a baby or the frequency of a 
small‐for‐gestational‐age infant, as these have a background incidence 
of approximately 0.75% and 10% of pregnancies, respectively. 
Similarly, this review is underpowered to detect differences between 
serious or rare adverse events, such as severe neonatal morbidity. Two 
of the three included studies were quasi‐randomised, with significant 




performance bias, as in one of the two studies contributing data, 
participants receiving standard care did not have venipuncture, so 
clinicians treating participants could identify which arm of the study 
they were in. Future studies should consider more robust 
randomisation methods and concealment of group allocation, and 
should be adequately powered to detect differences in rare adverse 
events. The studies identified in this review examined two different 
analytes: oestrogens and hPL. There are many other placental products 
that could be employed as surrogates of placental function, including: 
placental growth factor (PlGF), human chorionic gonadotrophin 
(hCG), plasma protein A (PAPP‐A), placental protein 13 (PP‐13), 
pregnancy‐specific glycoproteins, and progesterone metabolites, and 
further studies should be encouraged to investigate these other 
placental products. Future randomised controlled trials should test 
analytes identified as having the best predictive reliability for placental 
dysfunction leading to small‐for‐gestational‐age infants and perinatal 
mortality." 
Jahanfar S, Jaafar SH. Effects of 
restricted caffeine intake by 
mother on fetal, neonatal and 
pregnancy outcomes. Cochrane 
Database of Systematic 
Reviews 2015, Issue 6. 
Secondary outcomes include: 
 Cerebral palsy and cognitive impairment 
"There is insufficient evidence to confirm or refute the effectiveness of 
caffeine avoidance on birthweight or other pregnancy outcomes. There 
is a need to conduct high‐quality, double‐blinded RCTs to determine 
whether caffeine has any effect on pregnancy outcome." 
Khanprakob T, Laopaiboon M, 
Lumbiganon P, 
Sangkomkamhang US. Cyclo‐
oxygenase (COX) inhibitors for 
preventing preterm labour. 
Cochrane Database of 
Systematic Reviews 2012, Issue 
10. 
Secondary neonatal outcomes include: 
 Long‐term outcomes, for example developmental delay, 
cerebral palsy, educational attainment, etc. 
"There was very little evidence about using COX‐inhibitors for 
preventing preterm labour. There are inadequate data to make any 
recommendation about using COX‐inhibitor in practice to prevent 
preterm labour. Future research should include follow‐up of the babies 




Lalor JG, Fawole B, Alfirevic 
Z, Devane D. Biophysical 
profile for fetal assessment in 
high risk pregnancies. Cochrane 
Database of Systematic 
Reviews 2008, Issue 1 
Outcomes for the infant include: 
 Disability to include non‐ambulant cerebral palsy at or after 
12 months of age, sensory impairment (visual, hearing), or 
both 
"At present, there is insufficient evidence from randomised trials to 
support the use of biophysical profile (BPP) as a test of fetal well‐
being in high‐risk pregnancies." 
Li W, Tang L, Wu T, Zhang J, 
Liu GJ, Zhou L. Chinese herbal 
medicines for treating pre‐
eclampsia. Cochrane Database 
of Systematic Reviews 2006, 
Issue 2. 
Secondary outcomes for the neonate include: 
 Measures of long‐term growth and development, such as 
important impairment and cerebral palsy 
No included trials. 
"The efficacy and safety of Chinese herbal medicines for treating pre‐
eclampsia remains unclear. There are no randomised controlled trials 
in this field. High‐quality randomised controlled trials are urgently 
required." 
Makrides M, Duley L, Olsen 
SF. Marine oil, and other 
prostaglandin precursor, 
supplementation for pregnancy 
uncomplicated by pre‐eclampsia 
or intrauterine growth 
restriction. Cochrane Database 
of Systematic Reviews 2006, 
Issue 3. 
Outcomes for the baby include: 
 Long‐term follow‐up included measures of neurological and 
developmental outcome (such as cerebral palsy) 
"There is not enough evidence to support the routine use of marine oil, 
or other prostaglandin precursors, supplements during pregnancy to 
reduce the risk of pre‐eclampsia, preterm birth, low birthweight, or 
small‐for‐gestational age." 
McNamara HC, Crowther CA, 
Brown J. Different treatment 
regimens of magnesium 
sulphate for tocolysis in women 
in preterm labour. Cochrane 
Database of Systematic 
Reviews 2015, Issue 12. 
Primary outcomes for the infant or child include: 
 Composite serious infant outcome (defined as death or 
chronic lung disease (oxygen requirement at 28 days of life 
or later); intraventricular haemorrhage (IVH; grade three or 
four), or periventricular leucomalacia (PVL); major 
neurosensory disability (defined as any of legal blindness, 
sensorineural deafness requiring hearing aids, moderate or 
severe cerebral palsy, or developmental delay or intellectual 
impairment (defined as developmental quotient or 
intelligence quotient less than two standard deviations below 
the mean)) 
Secondary outcomes for the child include: 
"There are limited data available (three studies, with data from only 
two studies) comparing different dosing regimens of magnesium 
sulphate given as single agent tocolytic therapy for the prevention of 
preterm birth. There is no evidence examining duration of therapy, 
timing of therapy, and the role for repeat dosing. Downgrading 
decisions for our primary outcome of fetal, neonatal, and infant death 
were based on wide confidence intervals (crossing the line of no 
effect), lack of blinding, and a limited number of studies. No data were 
available for any of our other important outcomes: birth less than 48 
hours after trial entry; composite serious infant outcome; composite 
serious maternal outcome. The data are limited by volume and the 




 Cerebral palsy (mild, moderate, or severe, evaluated 
separately) 
secondary maternal and infant health outcomes were reported on in the 
included studies. No long‐term outcomes were reported. Downgrading 
decisions for the evidence on the risk of respiratory distress were 
based on wide confidence intervals (crossing the line of no effect), and 
lack of blinding. There is some evidence from a single study, 
suggesting a reduction in the length of stay in the neonatal intensive 
care unit and a reduced risk of respiratory distress syndrome, where a 
high‐dose regimen of magnesium sulphate has been compared with a 
low‐dose regimen. However, given that evidence has been drawn from 
a single study (with a small sample size), these data should be 
interpreted with caution. Magnesium sulphate has been shown to be of 
benefit in a wide range of obstetric settings, although it has not been 
recommended for tocolysis. In clinical settings where health benefits 
are established, further trials are needed to address the lack of evidence 
regarding the optimal dose (loading dose and maintenance dose), 
duration of therapy, timing of therapy, and role for repeat dosing, in 
terms of efficacy and safety for mothers and their children. Ongoing 
examination of different regimens with respect to important health 
outcomes is required." 
Meher S, Duley L. Rest during 
pregnancy for preventing pre‐
eclampsia and its complications 
in women with normal blood 
pressure. Cochrane Database of 
Systematic Reviews 2006, Issue 
2. 
Outcomes for the child include: 
 Long‐term growth and development: blindness, deafness, 
seizures, poor growth, neurodevelopmental delay, and 
cerebral palsy 
"Daily rest, with or without nutrient supplementation, may reduce the 
risk of pre‐eclampsia for women with normal blood pressure, although 
the reported effect may reflect bias, random error, or both, rather than 
a true effect. There is no information about outcomes such as perinatal 
mortality and morbidity, maternal morbidity, women's views, adverse 
effects, and costs. Current evidence is insufficient to support 
recommending rest or reduced activity to women for preventing pre‐
eclampsia and its complications. Whether women rest during 
pregnancy should therefore be a matter of personal choice." 
Meher S, Duley L. Progesterone 
for preventing pre‐eclampsia 
and its complications. Cochrane 
Database of Systematic 
Reviews 2006, Issue 4. 
Secondary outcomes for the child include: 
 Long‐term growth and development: blindness, deafness, 
seizures, poor growth, neurodevelopmental delay, and 
cerebral palsy 
"There is insufficient evidence for reliable conclusions about the 
effects of progesterone for preventing pre‐eclampsia and its 
complications. Therefore, progesterone should not be used for this 




Meher S, Duley L. Nitric oxide 
for preventing pre‐eclampsia 
and its complications. Cochrane 
Database of Systematic 
Reviews 2007, Issue 2. 
Outcomes for the child include: 
 Long‐term growth and development: blindness, deafness, 
seizures, poor growth, neurodevelopmental delay, and 
cerebral palsy 
"There is insufficient evidence to draw reliable conclusions about 
whether nitric oxide donors and precursors prevent pre‐eclampsia or 
its complications." 
Meher S, Duley L. Garlic for 
preventing pre‐eclampsia and its 
complications. Cochrane 
Database of Systematic 
Reviews 2006, Issue 3. 
Outcomes for the child include: 
 Long‐term growth and development: blindness, deafness, 
seizures, poor growth, neurodevelopmental delay, and 
cerebral palsy 
"There is insufficient evidence to recommend increased garlic intake 
for preventing pre‐eclampsia and its complications. Although garlic is 
associated with odour, other more serious side‐effects have not been 
reported. Further large randomised trials evaluating the effects of 
garlic are needed before any recommendations can be made to guide 
clinical practice." 
Meher S, Duley L. Exercise or 
other physical activity for 
preventing pre‐eclampsia and its 
complications. Cochrane 
Database of Systematic 
Reviews 2006, Issue 2. 
Outcomes for the child include: 
 Long‐term growth and development: blindness, deafness, 
seizures, poor growth, neurodevelopmental delay, and 
cerebral palsy 
"There is insufficient evidence for reliable conclusions about the 
effects of exercise on prevention of pre‐eclampsia and its 
complications." 
Naik Gaunekar N, Raman P, 
Bain E, Crowther CA. 
Maintenance therapy with 
calcium channel blockers for 
preventing preterm birth after 
threatened preterm labour. 
Cochrane Database of 
Systematic Reviews 2013, Issue 
10. 
Primary outcomes include: 
 Any neurological disability at paediatric follow‐up 
(impairment of vision, hearing, intelligence, or cerebral 
palsy) 
"Based on the current available evidence, maintenance treatment with 
a calcium channel blocker after threatened preterm labour does not 
prevent preterm birth or improve maternal or infant outcomes." 
Nanda K, Cook LA, Gallo MF, 
Grimes DA. Terbutaline pump 
maintenance therapy after 
threatened preterm labor for 
preventing preterm birth. 
Cochrane Database of 
Outcomes for the infant include: 
 Neurological sequelae (general intelligence, hearing, vision, 
cerebral palsy, and disability) 
"Terbutaline pump maintenance therapy has not been shown to 
decrease the risk of preterm birth by prolonging pregnancy. 
Furthermore, the lack of information on the safety of the therapy, as 
well as its substantial expense, argues against its role in the 
management of arrested preterm labor. Future use should only be in 





Systematic Reviews 2002, Issue 
4. 
Neilson JP. Fetal 
electrocardiogram (ECG) for 
fetal monitoring during labour. 
Cochrane Database of 
Systematic Reviews 2015, Issue 
12. 
Secondary outcomes for the fetus include: 
 Cerebral palsy 
"The modest benefits of fewer fetal scalp samplings during labour (in 
settings in which this procedure is performed) and fewer instrumental 
vaginal births have to be considered against the disadvantages of 
needing to use an internal scalp electrode, after membrane rupture, for 
ECG waveform recordings. We found little strong evidence that ST‐
waveform analysis had an effect on the primary outcome measures in 
this systematic review. There was a lack of evidence showing that PR‐
interval analysis improved any outcomes; and a larger future trial may 
possibly demonstrate beneficial effects. There is little information 
about the value of fetal ECG waveform monitoring in preterm fetuses 
in labour. Information about long‐term development of the babies 
included in the trials would be valuable." 
Nguyen TMN, Crowther CA, 
Wilkinson D, Bain E. 
Magnesium sulphate for women 
at term for neuroprotection of 
the fetus. Cochrane Database of 
Systematic Reviews 2013, Issue 
2. 
Primary outcomes for the infant or child include: 
 Death or cerebral palsy 
 Cerebral palsy (abnormality of tone with motor dysfunction 
(as diagnosed at 18 months of age or later)) 
Secondary outcomes for the child include: 
 Any neurological disabilities (defined as developmental 
delay or intellectual impairment, blindness (corrected visual 
acuity worse than 6/60 in the better eye), deafness (hearing 
loss requiring amplification or worse), cerebral palsy, motor 
dysfunction). The severity of the disability due to cerebral 
palsy will be graded into severe, moderate, and mild. Severe 
disability will include children who are non‐ambulant and 
are likely to remain so, moderate disability will comprise 
those children who have substantial limitation of movement, 
and mild disability will comprise those children walking 
with little limitation of movement. The neurosensory 
disabilities imposed by the various sensorineural 
impairments will be classified as severe, moderate, and 
mild, as follows: Severe disability will comprise any of 
"There is currently insufficient evidence to assess the efficacy and 
safety of magnesium sulphate when administered to women for 
neuroprotection of the term fetus. As there has been recent evidence 
for the use of magnesium sulphate for neuroprotection of the preterm 
fetus, high‐quality randomised controlled trials are needed to 
determine the safety profile and neurological outcomes for the term 





severe cerebral palsy, an intelligence quotient (IQ) less than 
three standard deviations (SD) below the mean, or 
blindness. Moderate disability will comprise moderate 
cerebral palsy, deafness, or an IQ from minus three SD to 
less than two SD below the mean. Mild disability will 
comprise mild cerebral palsy or an IQ from minus two SD to 
less than one SD below the mean 
 Major neurological disability (defined as any of: legal 
blindness, neurosensory deafness requiring hearing aids, 
moderate or severe cerebral palsy, or moderate or severe 
developmental delay or intellectual impairment (defined as 
developmental quotient or IQ less than two SD below the 
mean)) 
Ohlsson A, Shah VS, Stade BC. 
Vaginal chlorhexidine during 
labour to prevent early‐onset 
neonatal group B streptococcal 
infection. Cochrane Database of 
Systematic Reviews 2014, Issue 
12. 
Secondary intellectual impairment outcomes include: 
 Long‐term neurological sequelae, which may include 
cognitive delay, cerebral palsy, cortical blindness, deafness, 
hydrocephalus, or a combination 
"The quality of the four included trials varied, as did the risk of bias, 
and the quality of the evidence using GRADE, was very low. Vaginal 
chlorhexidine was not associated with reductions in any of the primary 
outcomes of early‐onset GBS disease (sepsis, meningitis, or both), or 
GBS pneumonia. Vaginal chlorhexidine may reduce GBS colonization 
of neonates. The intervention was associated with an increased risk of 
maternal mild adverse effects. The review currently does not support 
the use of vaginal disinfection with chlorhexidine in labour for 
preventing early‐onset disease. Results should be interpreted with 
caution as the methodological quality of the studies was poor. As 
early‐onset GBS disease is a rare condition, trials with very large 
sample sizes are needed to assess the effectiveness of vaginal 
chlorhexidine, to reduce its occurrence. In the era of intrapartum 
antibiotic prophylaxis, such trials may be difficult to justify, especially 
in developed countries." 
Papatsonis DNM, Flenady V, 
Liley HG. Maintenance therapy 
with oxytocin antagonists for 
inhibiting preterm birth after 
threatened preterm labour. 
Primary outcomes include: 
 Perinatal or infant mortality, or any neurological disability at 
long‐term paediatric follow‐up at two years of age (vision 
impairment, sensorineural deafness requiring hearing aids, 
"There is insufficient evidence to support the use of oxytocin receptor 
antagonists to inhibit preterm birth after a period of threatened or 
actual preterm labour. Any future trials using oxytocin antagonists or 
other drugs as maintenance therapy for preventing preterm birth 




Cochrane Database of 
Systematic Reviews 2013, Issue 
10. 
cerebral palsy, or developmental delay or intellectual 
impairment) 
including reduction of neonatal morbidity and mortality, and long‐term 
infant follow‐up. Future research should also focus on the 
pathophysiological pathways that precede preterm labour." 
Phipps H, de Vries B, Hyett J, 
Osborn DA. Prophylactic 
manual rotation for fetal 
malposition to reduce operative 
delivery. Cochrane Database of 
Systematic Reviews 2014, Issue 
12. 
Secondary outcomes for the neonate and infant include: 
 Severe neurodevelopmental disability in infants (assessed at 
12 months of age or older), defined as any one or 
combination of the following: non‐ambulant cerebral palsy, 
severe developmental delay assessed using validated tools, 
auditory and visual impairment 
"Currently, there is insufficient evidence to determine the efficacy of 
prophylactic manual rotation early in the second stage of labour for 
prevention of operative delivery. One additional study is ongoing. 
Further appropriately designed trials are required to determine the 
efficacy of manual rotation." 
Reinebrant HE, Pileggi‐Castro 
C, Romero CLT, dos Santos 
RAN, Kumar S, Souza JP, et al. 
Cyclo‐oxygenase (COX) 
inhibitors for treating preterm 
labour. Cochrane Database of 
Systematic Reviews 2015, Issue 
6. 
Primary outcomes include: 
 Serious infant outcome ‐ death or major sensorineural 
disability at two years of age (defined as any one or more of 
the following: legal blindness, sensorineural deafness 
requiring hearing aids, moderate or severe cerebral palsy, or 
developmental delay or intellectual impairment (defined as 
developmental quotient or intelligence quotient less than 
two standard deviations below the mean)) 
"In this review, no clear benefit for COX inhibitors was shown over 
placebo or any other tocolytic agents. While some benefit was 
demonstrated in terms of postponement of birth for COX inhibitors 
over placebo and betamimetics, and also maternal adverse effects over 
betamimetics and MgSO4, due to the limitations of small numbers, 
minimal data on safety, lack of longer‐term outcomes, and generally 
low quality of the studies included in this review, we conclude that 
there is insufficient evidence on which to base decisions about the role 
of COX inhibition for women in preterm labour. Further well‐designed 
tocolytic studies are required to determine short‐ and longer‐term 
infant benefit of COX inhibitors over placebo and other tocolytics, 
particularly CCBs and ORAs. Another important focus for future 
studies is identifying whether COX‐2 inhibitors are superior to non‐
selective COX inhibitors. All future studies on tocolytics for women in 
preterm labour should assess longer‐term effects into early childhood 
and also costs." 
Rumbold A, Duley L, Crowther 
CA, Haslam RR. Antioxidants 
for preventing pre‐eclampsia. 
Cochrane Database of 
Systematic Reviews 2008, Issue 
1. 
Secondary outcomes for the child include: 
 Disability during childhood (such as cerebral palsy, 
intellectual disability, hearing disability, and visual 
impairment) 
"Evidence from this review does not support routine antioxidant 
supplementation during pregnancy to reduce the risk of pre‐eclampsia 




Rumbold A, Ota E, Hori H, 
Miyazaki C, Crowther CA. 
Vitamin E supplementation in 
pregnancy. Cochrane Database 
of Systematic Reviews 2015, 
Issue 9. 
Secondary outcomes for the neonate include: 
 Disability at childhood follow‐up (such as cerebral palsy, 
intellectual disability, hearing disability, and visual 
impairment) 
"The data do not support routine vitamin E supplementation in 
combination with other supplements for the prevention of stillbirth, 
neonatal death, preterm birth, pre‐eclampsia, preterm or term PROM, 
or poor fetal growth. Further research is required to elucidate the 
possible role of vitamin E in the prevention of placental abruption. 
There was no convincing evidence that vitamin E supplementation in 
combination with other supplements results in other important benefits 
or harms." 
Rumbold A, Ota E, Nagata C, 
Shahrook S, Crowther CA. 
Vitamin C supplementation in 
pregnancy. Cochrane Database 
of Systematic Reviews 2015, 
Issue 9. 
Secondary outcomes for the child include: 
 Disability at childhood follow‐up (such as cerebral palsy, 
intellectual disability, hearing disability, and visual 
impairment) 
"The data do not support routine vitamin C supplementation alone or 
in combination with other supplements, for the prevention of fetal or 
neonatal death, poor fetal growth, preterm birth, or pre‐eclampsia. 
Further research is required to elucidate the possible role of vitamin C 
in the prevention of placental abruption and pre‐labour rupture of 
membranes. There was no convincing evidence that vitamin C 
supplementation alone or in combination with other supplements 
results in other important benefits or harms." 
Shub A, Walker SP. Planned 
early delivery versus expectant 
management for monoamniotic 
twins. Cochrane Database of 
Systematic Reviews 2015, Issue 
4. 
Secondary outcomes for the infant include: 
 Cerebral palsy 
No included trials. 
"Monoamniotic twins are rare, and there is insufficient randomised 
controlled evidence on which to draw strong conclusions about the 
best management. In their absence, we can refer to historical case 
series and expert consensus. Management plans should take into 
consideration the availability of high‐quality neonatal care if early 
delivery is chosen. Women and their families should be involved in the 
decision‐making about these high‐risk pregnancies. Ongoing, 
multicentre audits of maternal and perinatal outcomes for 
monoamniotic twins are needed in order to inform families and 
clinicians about up‐to‐date perinatal outcomes with contemporary 
obstetric practice. Research should consider the social and economic 
implications of planned interventions, as well as the perinatal 
outcomes." 
Spencer L, Bubner T, Bain E, 
Middleton P. Screening and 
subsequent management for 
Primary outcomes for the infant as a child include: "Though universal screening versus no screening for hypothyroidism 
similarly increased diagnosis and subsequent treatment, no clear 





pregnancy and during 
pregnancy for improving 
maternal and infant health. 
Cochrane Database of 
Systematic Reviews 2015, Issue 
9. 
 Neurosensory disability (any of: cerebral palsy, blindness, 
deafness, developmental delay, intellectual impairment, at 
latest time reported) 
Secondary outcomes for the infant as a child include: 
 Cerebral palsy 
for the infant as a child (IQ less than 85 at three years); data were 
lacking for the other primary outcomes: pre‐eclampsia and preterm 
birth, and for the majority of secondary outcomes, including 
miscarriage and fetal or neonatal death. For outcomes assessed using 
the GRADE approach, the evidence was considered to be moderate or 
high quality, with any downgrading of the evidence based on the 
presence of wide confidence intervals crossing the line of no effect. 
More evidence is needed to assess the benefits or harms of different 
screening methods for thyroid dysfunction in pregnancy, on maternal, 
infant and child health outcomes. Future trials should assess impacts 
on use of health services and costs, and be adequately powered to 
evaluate the effects on short‐ and long‐term outcomes." 
Thinkhamrop J, Hofmeyr GJ, 
Adetoro O, Lumbiganon P, Ota 
E. Antibiotic prophylaxis during 
the second and third trimester to 
reduce adverse pregnancy 
outcomes and morbidity. 
Cochrane Database of 
Systematic Reviews 2015, Issue 
6. 
Secondary outcomes for the neonate pre‐specified include: 
 Childhood cerebral palsy 
"Antibiotic prophylaxis did not reduce the risk of preterm pre‐labour 
rupture of membranes or preterm delivery (apart from in the subgroup 
of women with a previous preterm birth who had bacterial vaginosis). 
Antibiotic prophylaxis given during the second or third trimester of 
pregnancy reduced the risk of postpartum endometritis, term 
pregnancy with pre‐labour rupture of membranes and gonococcal 
infection when given routinely to all pregnant women. Substantial bias 
possibly exists in the review's results because of a high rate of loss to 
follow‐up, and the small numbers of studies included in each of our 
analyses. There is also insufficient evidence on possible harmful 
effects on the baby. Therefore, we conclude that there is not enough 
evidence to support the use of routine antibiotics during pregnancy to 
prevent infectious adverse effects on pregnancy outcomes." 
Turnbull C, Osborn DA. Home 
visits during pregnancy and 
after birth for women with an 
alcohol or drug problem. 
Cochrane Database of 
Systematic Reviews 2012, Issue 
1. 
Outcomes for the infant or child include: 
 Disability (cerebral palsy, sensorineural impairment, or 
significant developmental delay) 
"There is insufficient evidence to recommend the routine use of home 
visits for pregnant or postpartum women with a drug or alcohol 




Utama DP, Crowther CA. 
Transplacental versus direct 
fetal corticosteroid treatment for 
accelerating fetal lung 
maturation where there is a risk 
of preterm birth. Cochrane 
Database of Systematic 
Reviews 2011, Issue 9. 
Secondary outcomes for the infant or child include: 
 Cerebral palsy (however defined by authors) 
No included trials. 
"The available clinical studies carried out so far on animals and 
humans have shown that direct intramuscular injection of 
corticosteroid into the fetus under ultrasound guidance is feasible, but 
data on health outcomes are lacking. Therefore, uncertainty persists as 
to which method could provide better efficacy and safety profile. 
Randomised controlled trials are required, focusing on the benefits and 
harms of transplacental versus direct fetal corticosteroid treatment. 
Until the uncertainties have been answered, it is advisable to stay with 
the current standard of antenatal transplacental maternally 
administered corticosteroid treatment." 
Vogel JP, Nardin JM, Dowswell 
T, West HM, Oladapo OT. 
Combination of tocolytic agents 
for inhibiting preterm labour. 
Cochrane Database of 
Systematic Reviews 2014, Issue 
7. 
Primary outcomes include: 
 Short‐term and long‐term serious infant outcome (see 
definition below), determined by the presence of any of the 
following: death; chronic lung disease (use of supplemental 
oxygen therapy at 36 weeks' postmenstrual age, or at 28 
days of life, or later); grade three or four intraventricular 
haemorrhage or periventricular leukomalacia; major 
sensorineural disability at two years of age, defined as any 
one or more of the following: severe or profound vision 
impairment, sensorineural deafness requiring hearing aids, 
moderate or severe cerebral palsy or developmental delay or 
intellectual impairment (defined as developmental quotient 
or intelligence quotient less than two standard deviations 
below the mean) 
"It is unclear whether a combination of tocolytic drugs for preterm 
labour is more advantageous for women, newborns, or both, due to a 
lack of large, well‐designed trials including the outcomes of interest. 
There are no trials of combination regimens using widely used 
tocolytic agents, such as calcium channel blockers (nifedipine), 
oxytocin receptor antagonists (atosiban), or both. Further trials are 
needed before specific conclusions on use of combination tocolytic 
therapy for preterm labour can be made." 
Waterfall H, Grivell RM, Dodd 
JM. Techniques for assisting 
difficult delivery at caesarean 
section. Cochrane Database of 
Systematic Reviews 2016, Issue 
1. 
Secondary outcomes for the infant include: 
 Cerebral palsy 
"There is currently insufficient information available from randomised 
trials to support or refute the routine or selective use of tocolytic 
agents or instrument to facilitate infant birth at the time of difficult 
caesarean section. There is limited evidence that reverse breech 
extraction may improve maternal and fetal outcomes, though there was 
no difference in primary outcome of infant birth trauma. Further 




Whitworth M, Quenby S. 
Prophylactic oral betamimetics 
for preventing preterm labour in 
singleton pregnancies. Cochrane 
Database of Systematic 
Reviews 2008, Issue 1. 
Primary outcomes include: 
 Death at childhood follow‐up at greater than, or equal to, 12 
months of age (corrected for preterm birth), or severe 
neurodevelopmental disability defined as any one or 
combination of the following: non‐ambulant cerebral palsy, 
developmental delay (developmental quotient less than 70, 
or more than two standard deviations below the mean), 
severe auditory impairment (sensorineural deafness 
requiring hearing aids), or visual impairment (legal 
blindness) 
"There is insufficient evidence to support or refute the use of 
prophylactic oral betamimetics for preventing preterm birth in women 
at high risk of preterm labour with a singleton pregnancy." 
Whitworth M, Quenby S, 
Cockerill RO, Dowswell T. 
Specialised antenatal clinics for 
women with a pregnancy at 
high risk of preterm birth 
(excluding multiple pregnancy) 
to improve maternal and infant 
outcomes. Cochrane Database 
of Systematic Reviews 2011, 
Issue 9. 
Secondary outcomes for the infant include: 
 Disability at childhood follow‐up (including deafness, 
blindness, neurodisability, or cerebral palsy) 
"Specialised antenatal clinics are now an accepted part of care in many 
settings, and carrying out further randomised trials may not be 
possible. Any future research in this area should include psychological 
outcomes, and should focus on which aspects of service provision are 
preferred by women. Such research could underpin further service 
development in this area." 
Wilkinson D, Shepherd E, 
Wallace EM. Melatonin for 
women in pregnancy for 
neuroprotection of the fetus. 
Cochrane Database of 
Systematic Reviews 2016, Issue 
3. 
Primary outcomes for the infant or child include: 
 Death or any neurosensory disability (at latest time 
reported); this combined outcome recognises the potential 
for competing risks of death or survival with neurological 
problems 
 Neurosensory disability (any of: cerebral palsy, blindness, 
deafness, developmental delay or intellectual impairment), 
at latest time reported 
Secondary outcomes for the infant or child include: 
 Cerebral palsy (any, and graded as: severe: including 
children who are non‐ambulant and are likely to remain so; 
moderate: including those children who have substantial 
No included trials. 
"As we did not identify any randomised trials for inclusion in this 
review, we are unable to comment on implications for practice at this 
stage. Although evidence from animals studies has supported a fetal 
neuroprotective role for melatonin when administered to the mother 
during pregnancy, no trials assessing melatonin for fetal 
neuroprotection in pregnant women have been completed to date. 
However, there is currently one ongoing randomised controlled trial 
(with an estimated enrolment target of 60 pregnant women), which 
examines the dose of melatonin, administered to women at risk of 
imminent, very preterm birth (less than 28 weeks' gestation), required 
to reduce brain damage in the white matter of the babies that were 




limitation of movement; mild: including those children 
walking with little limitation of movement) 
 Death or cerebral palsy 
 Major neurosensory disability (defined as any of: moderate 
or severe cerebral palsy, legal blindness, neurosensory 
deafness requiring hearing aids, or moderate or severe 
developmental delay or intellectual impairment) 
research efforts should be directed towards trials comparing melatonin 
with either no intervention (no treatment or placebo), or with 
alternative agents aimed at providing fetal neuroprotection (such as 
magnesium sulphate for the very preterm infant). Such trials should 
evaluate maternal and infant short‐ and longer‐term outcomes 
(including neurosensory disabilities such as cerebral palsy), and 
consider the costs of care." 
Woudstra DM, Chandra S, 
Hofmeyr GJ, Dowswell T. 
Corticosteroids for HELLP 
(hemolysis, elevated liver 
enzymes, low platelets) 
syndrome in pregnancy. 
Cochrane Database of 
Systematic Reviews 2010, Issue 
9. 
Secondary outcomes for the child include: 
 Long‐term growth and development: blindness, deafness, 
seizures, poor growth, neurodevelopmental delay, and 
cerebral palsy 
"There was no clear evidence of any effect of corticosteroids on 
substantive clinical outcomes. Those receiving steroids showed 
significantly greater improvement in platelet counts, which was greater 
for those receiving dexamethasone than those receiving 
betamethasone. There is to date, insufficient evidence of benefits in 
terms of substantive clinical outcomes to support the routine use of 
steroids for the management of HELLP. The use of corticosteroids 
may be justified in clinical situations in which increased rate of 
recovery in platelet count is considered clinically worthwhile." 
Yamasmit W, 
Chaithongwongwatthana S, 
Tolosa JE, Limpongsanurak S, 
Pereira L, Lumbiganon P. 
Prophylactic oral betamimetics 
for reducing preterm birth in 
women with a twin pregnancy. 
Cochrane Database of 
Systematic Reviews 2015, Issue 
12. 
Secondary outcomes for the neonate or infant include: 
 Abnormal neurodevelopmental status at more than 12 
months corrected age (developmental delay, cerebral palsy, 
or both) 
"There is insufficient evidence to support or refute the use of 
prophylactic oral betamimetics for preventing preterm birth in women 
with a twin pregnancy." 
 
Abbreviations: CCB: calcium channel blockers; FENO‐based: Fractional exhaled nitric oxide‐based algorithm; GBS: Group B Streptococcus; hPL: human placental lactogen; MgSO4: 










Protocol citation Overview outcomes pre‐specified in protocol 
Abiramalatha T, Thomas N, Gupta V, 
Viswanathan A, McGuire W. High versus 
standard volumes of enteral feeds for preterm or 
low birth weight infants (Protocol). Cochrane 
Database of Systematic Reviews 2016, Issue 10. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcomes assessed after 12 months post term: neurological evaluations; developmental scores; 
and classifications of disability, including auditory and visual disability. We will define neurodevelopmental 
impairment as the presence of 1 or more of the following: non‐ambulant cerebral palsy; developmental quotient > 2 
SD below the population mean; and blindness (VA less than 6/60) or deafness (any hearing impairment requiring — 
or unimproved by — amplification) 
Amari S, Shahrook S, Ota E, Mori R. Branched‐
chain amino acid supplementation for improving 
nutrition in term and preterm neonates (Protocol). 
Cochrane Database of Systematic Reviews 2016, 
Issue 7. 
Primary outcomes pre‐specified include: 
 Neurological development 
o Major neurodevelopmental disability after 18 months' post‐term age 
 Cerebral palsy (yes/no) 
 Developmental delay (> 2 SD below the mean in a validated mental development test) or 
intellectual impairment (> 2 SD below the mean in a validated intelligence test) (yes/no) 
 Blindness (vision < 6/60 in both eyes) (yes/no) 
 Sensorineural deafness (requiring amplification) (yes/no) 
Askie LM, Darlow BA, Davis PG, Finer N, 
Stenson B, Vento M, Whyte R. Effects of 
targeting higher versus lower arterial oxygen 
saturations on death or disability in preterm 
infants (Protocol). Cochrane Database of 
Systematic Reviews 2014, Issue 7. 
Primary outcomes pre‐specified include: 
 Composite outcome of death or major disability by 18 to 24 months' corrected age (gestational age plus 
chronological age) 
Secondary outcomes pre‐specified include: 
 Major disability by 18 to 24 months' corrected age (gestational age plus chronological age) 
 Cerebral palsy with GMFCS level 2 or higher, or MACS level 2 or higher at 18 to 24 months' corrected age 
(gestational age plus chronological age) 
Choo YM, Ahmad Kamar A, Tengku Kamalden 
TAF, Looi ML, Tan K, Lai NM. Lutein and 
zeaxanthin for reducing morbidity and mortality 
in preterm infants (Protocol). Cochrane Database 
of Systematic Reviews 2016, Issue 5. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcome assessed at 18 months to 28 months (Newman 2012). We will accept any of the 
following outcomes alone or in combination: cerebral palsy, mental retardation (BSID MDI < 70), and hearing 
deficit (aided or < 60 dB on audiometric testing) or assessment via use of a validated 




Dawson JA, Davis PG, Foster JP. Routine 
oro/nasopharyngeal suction versus no suction in 
the delivery room (Protocol). Cochrane Database 
of Systematic Reviews 2013, Issue 1. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopmental outcome (rates of cerebral palsy on physician assessment; developmental delay, i.e. 
DQ > 2 SD < the mean on validated assessment tools, e.g. BSID MDI) 
Foster JP, Buckmaster A, Sinclair L, Lees S, 
Guaran R. Nasal continuous positive airway 
pressure (nCPAP) for term neonates with 
respiratory distress (Protocol). Cochrane Database 
of Systematic Reviews 2015, Issue 11. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental disability (after at least 18 months' postnatal age) defined as neurological abnormality 
including cerebral palsy on clinical examination, developmental delay > 2 SD below population mean on a 
standardised test of development, blindness (VA < 6/60), or deafness (any hearing impairment requiring 
amplification) 
Foster JP, Taylor C, Bredemeyer SL. Topical 
anaesthesia for needle‐related pain in newborn 
infants (Protocol). Cochrane Database of 
Systematic Reviews 2013, Issue 1. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental disability (after at least 18 months' postnatal age) defined as neurological abnormality 
including cerebral palsy on clinical examination, developmental delay > 2 SD below population mean on a 
standardised test of development 
Good M, Jones LJ, Osborn DA, Abdel‐Latif ME. 
Transfusion of fresh versus non‐fresh (older) red 
blood cell in neonates (Protocol). Cochrane 
Database of Systematic Reviews 2015, Issue 11. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental disability to at least 18 months' postnatal age (defined as neurological abnormality 
including cerebral palsy on clinical examination, developmental delay > 2 SD below population mean on a 
standardised test of development, blindness (VA < 6/60), or deafness (any hearing impairment requiring 
amplification) at any time after term corrected) 
Gordon A, Greenhalgh M, McGuire W. Early 
planned removal versus expectant management of 
peripherally inserted central catheters to prevent 
infection in newborn infants (Protocol). Cochrane 
Database of Systematic Reviews 2016, Issue 4. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcomes assessed after 12 months post term using validated tools: neurological evaluations; 
developmental scores; and classifications of disability, including auditory and visual disability. We will define 
neurodevelopmental impairment as the presence of 1 or more of the following: non‐ambulant cerebral palsy; DQ > 2 
SD below the population mean; and blindness (VA < 6/60) or deafness (any hearing impairment requiring or 
unimproved by amplification) 
 Death or neurological impairment assessed after 12 months post term 
Gordon A, Greenhalgh M, McGuire W. Early 
planned removal of umbilical venous catheters to 
prevent infection in newborn infants (Protocol). 
Cochrane Database of Systematic Reviews 2016, 
Issue 4. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcomes assessed after 12 months post term using validated tools: neurological evaluations; 
developmental scores; and classifications of disability, including auditory and visual disability. We will define 
neurodevelopmental impairment as the presence of 1 or more of the following: non‐ambulant cerebral palsy; DQ > 2 
SD below the population mean; and blindness (VA < 6/60) or deafness (any hearing impairment requiring or 
unimproved by amplification) 




Green DS, Abdel‐Latif ME, Jones LJ, Osborn 
DA. Pharmacological interventions for prevention 
and treatment of upper gastrointestinal bleeding 
in newborn infants (Protocol). Cochrane Database 
of Systematic Reviews 2015, Issue 7. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental disability (defined as neurological abnormality including cerebral palsy on clinical examination 
or global developmental delay (2 or more SD below population mean on BSID or GMDS at any time after term 
corrected at 1 year, 18 months', 2 years', and 5 years' postnatal age) 
Han S, Yu Z, Guo X, Dong X, Chen X, Soll R. 
Intratracheal instillation of corticosteroids using 
surfactant as a vehicle for the prevention of 
chronic lung disease in preterm infants with 
respiratory distress syndrome (Protocol). 
Cochrane Database of Systematic Reviews 2011, 
Issue 4 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcome at a later time point (> 1 year post‐conceptional age). Neurodevelopmental 
impairment is defined as the presence of cerebral palsy and/or mental retardation (BSID MDI < 70) and/or legal 
blindness (< 20/200 VA) and or deafness (aided or < 60 dB on audiometric testing) 
Hegarty JE, Harding JE, Crowther CA, Brown J, 
Alsweiler J. Oral dextrose gel for the prevention 
of hypoglycaemia in newborn infants (Protocol). 
Cochrane Database of Systematic Reviews 2016, 
Issue 4. 
Primary outcomes pre‐specified include: 
 Major neurological disability at 2 years of age or greater (any of legal blindness, sensorineural deafness requiring 
hearing aids, moderate or severe cerebral palsy, or developmental delay/intellectual impairment (defined as a DQ or 
IQ lower than 2 SD below the mean)) 
Secondary outcomes pre‐specified include: 
 Cerebral palsy and severity at 2 years of age or older 
Hyttel‐Sorensen S, Støy Saem L, Greisen G, Als‐
Nielsen B, Gluud C. Cerebral near‐infrared 
spectroscopy monitoring for prevention of brain 
injury in very preterm infants (Protocol). 
Cochrane Database of Systematic Reviews 2015, 
Issue 2. 
Primary outcomes pre‐specified include: 
 Major neurodevelopmental disability: 
o Cerebral palsy 
o Developmental delay or intellectual impairment: 
 BSID or GMDS assessment > 2 SD below the mean or intellectual impairment (IQ > 2 SD below 
mean) 
 Neuromotor development (BSID ‐ PDI) assessed in survivors 
 Mental development (BSID ‐ MDI) assessed in survivors 
o Blindness (vision < 6/60 in both eyes) 
Jauncey‐Cooke J, Bogossian F, Hough JL, 
Schibler A, Davies MW, Grant CA, Gibbons K, 
East CE. Lung recruitment manoeuvres for 
reducing respiratory morbidity in mechanically 
ventilated neonates (Protocol). Cochrane 
Database of Systematic Reviews 2012, Issue 7. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental impairment: cerebral palsy, sensorineural hearing loss, visual impairment or developmental 




Kaempfen S, Neumann RP, Jost K, Schulzke SM. 
Beta‐blockers for prevention and treatment of 
retinopathy of prematurity in preterm infants 
(Protocol). Cochrane Database of Systematic 
Reviews 2015, Issue 9. 
Secondary outcomes pre‐specified include: 
 Adverse neurodevelopmental outcomes at 18 to 24 months' corrected age 
o Cerebral palsy 
o Moderate to severe developmental delay as assessed by validated neurodevelopmental tests such as BSID 
Kent A, Kecskes Z. Magnesium sulfate for term 
infants following perinatal asphyxia (Protocol). 
Cochrane Database of Systematic Reviews 2003, 
Issue 2. 
Primary outcomes pre‐specified include: 
 Severe neurodevelopmental disability at or equal to 12 months of age or more. Severe neurodevelopmental disability 
is defined as cerebral palsy, developmental delay (DQ < 70), or blindness (VA < 6/60 in both eyes), or any 
combination of these disabilities 
Kulasekaran K, Sargent PH, Flenady V. 
Milrinone for the treatment of cardiac dysfunction 
in neonates (Protocol). Cochrane Database of 
Systematic Reviews 2004, Issue 4. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcome (neurodevelopmental outcome assessed by a standardised and validated assessment 
tool and/or a child developmental specialist) at any age reported (outcome data will be grouped at 12, 18, 24 months 
if available) ‐ cerebral palsy, developmental delay, blindness, sensorineural deafness 
Lai NM, Ahmad Kamar A, Choo YM, Kong JY, 
Ngim CF. Fluid supplementation for neonatal 
unconjugated hyperbilirubinaemia (Protocol). 
Cochrane Database of Systematic Reviews 2015, 
Issue 9. 
Primary outcomes pre‐specified include: 
 Proportion of infants with moderate or severe cerebral palsy, defined as a non‐progressive disorder with abnormal 
muscle tone in at least 1 arm or leg that was associated with abnormal control of movement or posture and a 
modified GMFCS score (Palisano 2008) ≥ 2 (Rosenbaum 2007), measured at predefined intervals, e.g. at 6, 12, 18, 
and 24 months 
Secondary outcomes pre‐specified include: 
 Proportion of infants with motor impairment, as indicated by a score of 2 or higher in the modified GMFCS 
evaluation (Palisano 2008) 
Lui K, Foster JP, Davis PG, Ching SK, Oei JL, 
Osborn DA. Higher versus lower oxygen 
concentrations titrated to target oxygen 
saturations during resuscitation of preterm infants 
at birth (Protocol). Cochrane Database of 
Systematic Reviews 2012, Issue 11. 
Primary outcomes pre‐specified include: 
 Neurodevelopmental disability (after > 18 months' postnatal age): 
o Neurological abnormality including cerebral palsy on clinical examination, developmental delay > 2 SD 
below population mean on any standard test of development 
o Blindness (VA < 6/60) 
o Deafness (any hearing impairment requiring amplification) 
Malhotra A, Veldman A. Recombinant activated 
Factor VII for prevention and treatment of 
intraventricular haemorrhage in neonates 
(Protocol). Cochrane Database of Systematic 
Reviews 2011, Issue 3. 
Primary outcomes pre‐specified include: 
 Severe neurodevelopmental disability as defined by cerebral palsy, low developmental scores (DQ < 2 SD or 
untestable), blindness, or any combination of these using validated assessment tools at 18 or 24 months: neurological 




McCarthy LK, Davis PG, O'Donnell CPF. Nasal 
airways (single or double prong, long or short) for 
neonatal resuscitation (Protocol). Cochrane 
Database of Systematic Reviews 2011, Issue 5. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopmental outcome (rates of cerebral palsy on physician assessment; developmental delay, i.e. 
DQ > 2 SD < the mean on validated assessment tools, e.g. BSID MDI) 
Molloy EJ, McCallion N, O'Donnell CPF, Davis 
PG. Heliox for prevention of morbidity and 
mortality in ventilated newborn infants 
(Protocol). Cochrane Database of Systematic 
Reviews 2008, Issue 3. 
Secondary outcomes pre‐specified include: 
 Death or long‐term (< 18 months) major neurodevelopmental disability (cerebral palsy, developmental delay (BSID 
or GMDS assessment > 2 SD below the mean) or intellectual impairment (IQ > 2 SD below mean), blindness (vision 
< 6/60 in both eyes), sensorineural deafness requiring amplification) 
Neary E, Ni Ainle F, El‐Khuffash A, Cotter M, 
Kirkham C, McCallion N. Plasma transfusion to 
prevent intraventricular haemorrhage in very 
preterm infants (Protocol). Cochrane Database of 
Systematic Reviews 2016, Issue 9. 
Primary outcomes pre‐specified include: 
 Neurodevelopmental disability at 2 years' postnatal age, defined as neurological abnormality on clinical 
examination, including cerebral palsy, developmental delay > 2 SD below the population mean on any standard test 
of development, blindness (VA < 6/60), or deafness (any hearing impairment requiring amplification) at any time 
after 2 years' corrected age 
O'Donnell CPF, Davis PG, Morley CJ. 
Endotracheal intubation versus face mask for 
newborns resuscitated with positive pressure 
ventilation at birth (Protocol). Cochrane Database 
of Systematic Reviews 2004, Issue 4. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopmental outcome (rates of cerebral palsy on physician assessment, developmental delay, i.e. 
IQ 2 SD < the mean on validated assessment tools, e.g. BSID MDI) 
O'Donnell CPF, Davis PG, Morley CJ. Manual 
ventilation devices for neonatal resuscitation 
(Protocol). Cochrane Database of Systematic 
Reviews 2004, Issue 3. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopmental outcome (rates of cerebral palsy on physician assessment, developmental delay, i.e. 
IQ 2 SD < the mean on validated assessment tools, e.g. BSID MDI) 
Onland W, De Jaegere APMC, Offringa M, van 
Kaam A. Systemic corticosteroid regimens for 
prevention of bronchopulmonary dysplasia in 
preterm infants (Protocol). Cochrane Database of 
Systematic Reviews 2014, Issue 1. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopmental sequelae, assessed after at least 1 year corrected gestational age and before a 
corrected gestational age of 4 years, and at the latest reported time point, including cerebral palsy and BSID (MDI) 
Onyango AB, Suresh G, Were F. Intermittent 
phototherapy versus continuous phototherapy for 
neonatal jaundice (Protocol). Cochrane Database 
of Systematic Reviews 2009, Issue 4. 
Primary outcomes pre‐specified include: 
 Kernicterus defined as either the pathological finding of deep‐yellow staining of neurons and neuronal necrosis of 
the basal ganglia and brainstem nuclei or acute or chronic neurological deficit including athetoid cerebral palsy, 
impaired upward gaze and deafness, isolated conditions like auditory neuropathy or dyssynchrony, and subtle 




Pierro M, Thébaud B, Soll R. Mesenchymal stem 
cells for the prevention and treatment of 
bronchopulmonary dysplasia in preterm infants 
(Protocol). Cochrane Database of Systematic 
Reviews 2015, Issue 11. 
Secondary outcomes pre‐specified include: 
 Cerebral palsy at 18 to 24 months' corrected age 
 Neurodevelopmental outcome at approximately 2 years' corrected age (acceptable range 18 months to 28 months) 
including cerebral palsy, delayed neurodevelopment (BSID MDI < 70), legal blindness (< 20/200 VA), and hearing 
deficit (aided or < 60 dB on audiometric testing). We will define the composite outcome 'neurodevelopmental 
impairment' as having any 1 of the aforementioned deficits 
Rivas‐Fernandez M, Roqué i Figuls M, Tobias A, 
Balaguer A. Different strains of probiotics for 
preventing morbidity and mortality in preterm 
infants: a network meta‐analysis (Protocol). 
Cochrane Database of Systematic Reviews 2016, 
Issue 8. 
Secondary outcomes pre‐specified include: 
 Neurodevelopment impairment (i.e. rates of cerebral palsy, cognitive delay, deafness, blindness or their composite 
reported at 18 months' corrected age or later) 
Romantsik O, Calevo MG, Bruschettini M. Head 
midline position for preventing the occurrence or 
extension of germinal matrix‐intraventricular 
hemorrhage in preterm infants (Protocol). 
Cochrane Database of Systematic Reviews 2016, 
Issue 9. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopmental outcomes (yes/no): cerebral palsy on physician assessment, developmental delay 
(i.e. IQ 2 SD below the mean on validated assessment tools such as BSID MDI) (Bayley 1993; Bayley 2006) 
 Major neurodevelopmental disability: cerebral palsy, developmental delay (BSID MDI (Bayley 1993; Bayley 2006) 
or GMDS (Griffiths 1954) assessment > 2 SDs below the mean), intellectual impairment (IQ > 2 SDs below the 
mean), blindness (vision < 6/60 in both eyes), or sensorineural deafness requiring amplification (Jacobs 2013). We 
plan to evaluate each of these components as a separate outcome and to extract data on each long‐term outcome 
from studies that evaluated children after 18 months' chronological age. We will separately assess data on children 
18 to 24 months of age and on those 3 to 5 years of age 
Seliem W, Bhutta ZA, Soll R, McGuire W. 
Topical emollient therapy for preventing infection 
in preterm infants in low‐ or middle‐income 
countries (Protocol). Cochrane Database of 
Systematic Reviews 2007, Issue 3. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcomes at > 12 months post term (measured using validated assessment tools) and 
classifications of disability, including auditory and visual disability. The composite outcome "severe 
neurodevelopmental disability" will be defined as any 1 or combination of the following: non‐ambulant cerebral 
palsy, severe developmental delay, auditory and visual impairment 
Shah D, Tracy M. Cutaneous antisepsis for 
prevention of intravascular catheter–associated 
infection in newborn infants (Protocol). Cochrane 
Database of Systematic Reviews 2014, Issue 3. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopmental outcome: neurodevelopmental outcome at approximately 2 years' corrected age 
(acceptable range 18 months to 28 months) including cerebral palsy, significant mental developmental delay (BSID 
MDI < 70), legal blindness (< 20/200 VA), and hearing deficit (aided or < 60 dB on audiometric testing). The 
composite outcome "neurodevelopmental impairment" was defined as having any 1 of the aforementioned deficits 
Sinn JKH, Kumar K, Osborn DA, Bolisetty S. 
Higher versus lower amino acid intake in 




parenteral nutrition for newborn infants 
(Protocol). Cochrane Database of Systematic 
Reviews 2006, Issue 2. 
 Neurodevelopmental disability at at least 18 months' postnatal age (defined as neurological abnormality 
including cerebral palsy on clinical examination, developmental delay > 2 SD below population mean on a 
standardised test of development, blindness (VA < 6/60), or deafness (any hearing impairment requiring 
amplification) at any time after term corrected) 
Secondary outcomes pre‐specified include: 
 Individual components of neurodevelopment at at least 18 months' postnatal age: 
o Cerebral palsy on clinical examination 
o Developmental delay > 2 SD below population mean on a standardised test of development 
o Blindness (VA < 6/60) 
o Deafness (any hearing impairment requiring amplification) at any time after term corrected 
Van Rostenberghe H, Ho JJ, Quah BS, Noraida 
R. The effects of thyroxine on end organ damage 
in asphyxiated neonates (Protocol). Cochrane 
Database of Systematic Reviews 2009, Issue 4. 
Primary outcomes pre‐specified include: 
 Any neurodevelopmental disability assessed at 12 months or more of age: 
o Presence of no/minor or major disabilities 
o Presence of cerebral palsy 
o Any objective quantitative assessments of neurodevelopmental assessment that are internationally 
recognised 
Xiong T, Chen H, Mu D. Effect of pre‐exchange 
albumin infusion on neonatal hyperbilirubinaemia 
and long‐term developmental outcomes 
(Protocol). Cochrane Database of Systematic 
Reviews 2014, Issue 2. 
Primary outcomes pre‐specified include: 
 Neurological deficits consistent with kernicterus at 2 years of age (including separate analysis of each component): 
athetoid cerebral palsy, impaired upward gaze and deafness, auditory neuropathy or dys‐synchrony (ABR 
abnormality), dental dysplasia, and subtle bilirubin‐induced neurological dysfunction 
Xiong T, Li H, Zhao J, Dong W, Qu Y, Wu T, 
Mu D. Hyperbaric oxygen for term newborns 
with hypoxic ischemic encephalopathy (Protocol). 
Cochrane Database of Systematic Reviews 2011, 
Issue 8. 
Primary outcomes pre‐specified include: 
 Long‐term (> 18 months) major neurodevelopmental disabilities among all participants or survivors (cerebral palsy, 
developmental delay (BSID or GMDS assessment > 2 SD below the mean), or intellectual impairment (IQ > 2 SD 
below mean), blindness (vision < 6/60 in both eyes), sensorineural deafness requiring amplification) 
Yu B, Li S, Zhou D, Davis PG. Subcutaneous 
reservoir drainage versus ventriculoperitoneal 
shunt for the treatment of posthemorrhagic 
hydrocephalus in preterm infants (Protocol). 
Cochrane Database of Systematic Reviews 2009, 
Issue 3. 
Primary outcomes pre‐specified include: 
 The incidence rates of death or neurodevelopmental disability in infancy (> 12 months' postnatal age). 
Neurodevelopmental disability includes developmental delay (e.g. the score of BSID < 2 SD below the mean 




Yu Z, Guo X, Han S, Lu J, Sun Q. Erythropoietin 
for term and late preterm infants with hypoxic 
ischemic encephalopathy (Protocol). Cochrane 
Database of Systematic Reviews 2010, Issue 1. 
Primary outcomes pre‐specified include: 
 The primary outcome measure will be either death or long‐term (1 year or 18 months) major neurodevelopmental 
disability (cerebral palsy, developmental delay (BDIS or GMDS assessment > 2 SD below the mean), or intellectual 
impairment (IQ > 2 SD below mean), blindness (vision < 6/60 in both eyes), sensorineural deafness requiring 
amplification) 
Secondary outcomes pre‐specified include: 
 Each component of the primary outcome: 
o Cerebral palsy 
o Developmental delay or intellectual impairment 
o Blindness 
o Sensorineural deafness requiring amplification patient 
Yu Z, Sun Q, Han S, Lu J, Ohlsson A, Guo X. 
Erythropoietin for preterm infants with hypoxic 
ischaemic encephalopathy (Protocol). Cochrane 
Database of Systematic Reviews 2012, Issue 12. 
Primary outcomes pre‐specified include: 
 Either death (at 28 days and at discharge) or long‐term (1 year or 24 months' corrected age) intellectual impairment 
(IQ > 2 SD below mean), blindness (vision < 6/60 in both eyes), sensorineural deafness requiring amplification 
Secondary outcomes pre‐specified include: 
 Each component of the primary outcome: 
o Death at 28 days and at discharge 
o Cerebral palsy at > 1 year (the criterion for the diagnosis of cerebral palsy was a fixed motor deficit 
diagnosed by a neurologist) 
o Developmental delay (BSID or GMDS > 2 SD below the mean) or intellectual impairment (IQ > 2 SD 
below mean) at 1 year or 24 months' corrected age 
o Blindness (vision < 6/60 in both eyes) at 1 year or 24 months' corrected age 
o Sensorineural deafness requiring amplification patient at 1 year or 24 months' corrected age 
 
Abbreviations: ABR: auditory brainstem response; BSID: Bayley Scales of Infant Development; DQ: developmental quotient; GMDS: Griffith Mental Development Scales; GMFCS: 
Gross Motor Function Classification System; IQ; intelligence quotient; MACS: Manual Ability Classification System; MDI: Mental Development Index; PDI: Psychomotor 







Reviews awaiting further classification 
 
Review citation Overview outcomes pre‐specified in review with no outcome data Main conclusion(s) of review 
Abdel‐Latif ME, Osborn DA. 
Intratracheal Clara cell secretory 
protein (CCSP) administration in 
preterm infants with or at risk of 
respiratory distress syndrome. 
Cochrane Database of Systematic 
Reviews 2011, Issue 5. 
Primary outcomes pre‐specified include: 
 Neurodevelopmental disability ≥ 18 months' postnatal age 
(defined as neurological abnormality including cerebral 
palsy on clinical examination, developmental delay > 2 SD 
below population mean on a standardised test of 
development, blindness (VA < 6/60), or deafness (any 
hearing impairment requiring amplification) at any time after 
term corrected) 
"There are insufficient data to determine the role of rhCC10 in 
clinical practice. Further studies are required to determine if 
rhCC10 reduces lung inflammation in infants at risk of CLD, and 
to determine dose and dosing strategy." 
Abdel‐Latif ME, Osborn DA. 
Laryngeal mask airway surfactant 
administration for prevention of 
morbidity and mortality in preterm 
infants with or at risk of respiratory 
distress syndrome. Cochrane 
Database of Systematic Reviews 
2011, Issue 7. 
Primary outcomes pre‐specified include: 
 Neurodevelopmental disability ≥ 18 months' postnatal age 
(defined as neurological abnormality including cerebral 
palsy on clinical examination, developmental delay > 2 SD 
below population mean on a standardised test of 
development, blindness (VA < 6/60), or deafness (any 
hearing impairment requiring amplification) at any time after 
term corrected) 
"There is evidence from a single small trial that LMA surfactant 
administration in preterm infants ≥ 1200 g with established RDS 
may have a short term effect in reducing oxygen requirements 
although the study is underpowered to detect important clinical 
effects. Adequately powered trials are required to determine the 
effect of LMA surfactant administration for prevention or 
treatment of RDS in preterm infants. LMA surfactant 
administration should be limited to clinical trials." 
Abdel‐Latif ME, Osborn DA. 
Pharyngeal instillation of surfactant 
before the first breath for prevention 
of morbidity and mortality in 
preterm infants at risk of respiratory 
distress syndrome. Cochrane 
Database of Systematic Reviews 
2011, Issue 3. 
Primary outcomes pre‐specified include: 
 Neurodevelopmental disability at ≥ 18 months' postnatal age, 
defined as neurological abnormality including cerebral 
palsy on clinical examination, developmental delay of > 2 SD 
below the population mean on a standardised test of 
development, blindness (VA < 6/60), or deafness (any 
hearing impairment requiring amplification) at any time after 
the age was term corrected 
No included trials. 
"There were no data from randomised controlled or quasi‐
randomised trials that evaluated the effect of intrapartum 
instillation of pharyngeal surfactant before the first breath. 
Evidence from animal and observational human studies suggest 
that pharyngeal instillation of surfactant before the first breath is 
potentially safe, feasible and may be effective. Well designed 
trials are needed." 
Abdel‐Latif ME, Osborn DA. 
Nebulised surfactant in preterm 
infants with or at risk of respiratory 
distress syndrome. Cochrane 
Database of Systematic Reviews 
2012, Issue 10. 
Primary outcomes pre‐specified include: 
 Neurodevelopmental disability assessed at 18 months' 
postnatal age or later defined as neurological abnormality 
including cerebral palsy on clinical examination, 
developmental delay > 2 SD below population mean on a 
standardised test of development, blindness (VA < 6/60), or 
"There are insufficient data to support or refute the use of 
nebulised surfactant in clinical practice. Adequately powered 
trials are required to determine the effect of nebulised surfactant 
administration for prevention or early treatment of RDS in 
preterm infants. Nebulised surfactant administration should be 




deafness (any hearing impairment requiring amplification) at 
any time after term corrected 
Ainsworth S, McGuire W. 
Percutaneous central venous 
catheters versus peripheral cannulae 
for delivery of parenteral nutrition 
in neonates. Cochrane Database of 
Systematic Reviews 2015, Issue 10. 
Primary outcomes pre‐specified include: 
 Neurodevelopmental outcomes during infancy and beyond, 
using validated assessment tools, such as BSID, and 
classifications of disability, including auditory and visual 
disability. Severe neurodevelopmental disability was defined 
as any one or combination of the following: non‐
ambulant cerebral palsy, developmental delay (DQ < 70), or 
auditory and visual impairment 
"Data from one small trial suggest that use of percutaneous 
central venous catheters to deliver parenteral nutrition increases 
nutrient input. The significance of this in relation to long‐term 
growth and developmental outcomes is unclear. Three trials 
suggest that use of percutaneous central venous catheters 
decreases the number of catheters/cannulae needed to deliver 
nutrition. No evidence suggests that percutaneous central venous 
catheter use increases risks of adverse events, particularly 
invasive infection, although none of the included trials was large 
enough to rule out an effect on uncommon severe adverse events 
such as pericardial effusion." 
Alcock GS, Liley H. 
Immunoglobulin infusion for 
isoimmune haemolytic jaundice in 
neonates. Cochrane Database of 
Systematic Reviews 2002, Issue 3. 
Outcomes pre‐specified include: 
 Incidence of cerebral palsy 
"Although the results show a significant reduction in the need for 
exchange transfusion in those treated with intravenous 
immunoglobulin, the applicability of the results is limited. The 
number of studies and infants included is small and none of the 
three included studies was of high quality. The protocols of two 
of the studies mandated the use of early exchange transfusion, 
limiting the generalizability of the results. Further well designed 
studies are needed before routine use of intravenous 
immunoglobulin can be recommended for the treatment of 
isoimmune haemolytic jaundice." 
Anabrees J, AlFaleh K. Fluid 
restriction and prophylactic 
indomethacin versus prophylactic 
indomethacin alone for prevention 
of morbidity and mortality in 
extremely low birth weight infants. 
Cochrane Database of Systematic 
Reviews 2011, Issue 7. 
Secondary outcomes pre‐specified include: 
 Neurosensory impairment defined as rates of cerebral palsy, 
cognitive delay, deafness, blindness at 18 to 24 months' 
corrected age as per BSID score (Bayley 1993) 
 The composite of death or neurosensory impairment at 18 to 
24 months' corrected age 
No included trials 
"We found no randomized controlled trials to investigate the 
possible interaction between fluid restriction and indomethacin 
prophylaxis versus indomethacin prophylaxis alone in ELBW 
infants. A well‐designed randomized trial is needed to address 
this question." 
Austin N, Cleminson J, Darlow BA, 
McGuire W. Prophylactic 
Primary outcomes pre‐specified include: "The finding of a reduction in risk of invasive fungal infection in 




oral/topical non‐absorbed antifungal 
agents to prevent invasive fungal 
infection in very low birth weight 
infants. Cochrane Database of 
Systematic Reviews 2015, Issue 10. 
 Neurodevelopmental outcomes assessed beyond infancy 
(neurological evaluations, developmental scores, and 
classifications of disability, including auditory and visual 
disability, non‐ambulant cerebral palsy, developmental 
delay); and cognitive and educational outcomes at 5 years or 
older (IQ and/or indices of educational achievement 
measured using a validated tool including school examination 
results) 
absorbed antifungal prophylaxis should be interpreted cautiously 
because of methodological weaknesses in the included trials. 
Further large randomised controlled trials in current neonatal 
practice settings are needed to resolve this uncertainty. These 
trials might compare oral/topical non‐absorbed antifungal agents 
with placebo, with each other, or with systemic antifungal agents 
and should include an assessment of effect on long‐term 
neurodevelopmental outcomes." 
Bahadue FL, Soll R. Early versus 
delayed selective surfactant 
treatment for neonatal respiratory 
distress syndrome. Cochrane 
Database of Systematic Reviews 
2012, Issue 11. 
Secondary outcomes pre‐specified include: 
 Cerebral palsy 
 Neurodevelopmental outcome at approximately 2 years' 
corrected age (acceptable range 18 months to 28 months) 
including cerebral palsy, mental retardation (BSID MDI < 
70), legal blindness (< 20/200 VA), and hearing deficit (aided 
or < 60 dB on audiometric testing). The composite outcome 
"neurodevelopmental impairment" will be defined as having 
any 1 of the aforementioned deficits 
"Early selective surfactant administration given to infants with 
RDS requiring assisted ventilation leads to a decreased risk of 
acute pulmonary injury (decreased risk of pneumothorax and 
pulmonary interstitial emphysema) and a decreased risk of 
neonatal mortality and chronic lung disease compared to delaying 
treatment of such infants until they develop worsening RDS." 
Rivas‐Fernandez M, Roqué i Figuls 
M, Diez‐Izquierdo A, Escribano J, 
Balaguer A. Infant position in 
neonates receiving mechanical 
ventilation. Cochrane Database of 
Systematic Reviews 2016, Issue 11. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopmental outcomes at age 2 years: 
rates of cerebral palsy as assessed by physician, 
developmental delay (i.e. IQ < 2 SD) on validated assessment 
tools (e.g. the S‐B Intelligence Scale or others), or sensory 
impairment 
"This update of our last review in 2013 supports previous 
conclusions. Evidence of low to moderate quality favours the 
prone position for slightly improved oxygenation in neonates 
undergoing mechanical ventilation. However, we found no 
evidence to suggest that particular body positions during 
mechanical ventilation of the neonate are effective in producing 
sustained and clinically relevant improvement." 
Balain M, Oddie SJ, McGuire W. 
Antimicrobial‐impregnated central 
venous catheters for prevention of 
catheter‐related bloodstream 
infection in newborn infants. 
Cochrane Database of Systematic 
Reviews 2015, Issue 9. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcomes assessed > 12 months' 
corrected age using validated tools: neurological evaluations; 
developmental scores; and classifications of disability, 
including auditory and visual disability. We will define 
neurodevelopmental impairment as the presence of 1 or more 
of the following: non‐ambulant cerebral palsy; DQ > 2 SD 
below the population mean; and blindness (VA < 6/60) or 
"Although the data from one small trial indicates that 
antimicrobial‐impregnated central venous catheters might prevent 
catheter‐related bloodstream infection in newborn infants, the 
available evidence is insufficient to guide clinical practice. A 
large, simple and pragmatic randomised controlled trial is needed 




deafness (any hearing impairment requiring or unimproved 
by amplification) 
 Death or neurological impairment assessed > 12 months' 
corrected age 
Bassler D, Kreutzer K, McNamara 
P, Kirpalani H. Milrinone for 
persistent pulmonary hypertension 
of the newborn. Cochrane Database 
of Systematic Reviews 2010, Issue 
11. 
Primary outcomes pre‐specified include: 
 Neurodevelopment (assessed by the presence of cerebral 
palsy, cognitive delay, blindness or deafness, and the BSID‐
II) assessed > 18 months of life 
"The efficacy and safety of milrinone in the treatment of PPHN 
are not known and its use should be restricted within the context 
of RCTs. Such studies should address a comparison of milrinone 
with placebo (in clinical situations where iNO is not available) 
or, in well resourced countries, should compare milrinone with 
iNO or as an adjunct to iNO compared with iNO alone." 
Basuki F, Hadiati DR, Turner T, 
McDonald S, Hakimi M. Dilute 
versus full strength formula in 
exclusively formula‐fed preterm or 
low birth weight infants. Cochrane 
Database of Systematic Reviews 
2013, Issue 11. 
Secondary outcomes pre‐specified include: 
 Neurodevelopment: 
o Death or severe neurodevelopmental disability 
defined as any 1 or a combination of the following: 
non‐ambulant cerebral palsy; developmental delay 
(DQ < 70); auditory and visual impairment (each 
component will be analysed individually as well as 
part of the composite outcome) 
o Neurodevelopmental scores in survivors aged ≥ 12 
months of age measured using validated assessment 
tools 
o Cognitive and educational outcomes in survivors 
aged > 5 years old 
"There is evidence from three small, old trials at unclear risk of 
bias that use of dilute formula in preterm or low birth weight 
formula‐fed infants leads to an important reduction in the time 
taken for these infants to attain an adequate energy intake. There 
was no evidence of important differences in feeding intolerance. 
The impact on serious gastrointestinal problems, including 
necrotising enterocolitis, was not reported. Further randomised 
trials are needed to confirm these results." 
Beveridge CJE, Wilkinson AR. 
Sodium bicarbonate infusion during 
resuscitation of infants at birth. 
Cochrane Database of Systematic 
Reviews 2006, Issue 1. 
Secondary outcomes pre‐specified include: 
 Long‐term severe neurodevelopmental disability reported at 
any time during follow‐up. Defined as any of cerebral palsy, 
cognitive delay (score > 2 SD below mean for a recognised 
psychometric test e.g. BSID), blindness, and deafness 
"There is insufficient evidence from randomised controlled trials 
to determine whether the infusion of sodium bicarbonate reduces 
mortality and morbidity in infants receiving resuscitation in the 
delivery room at birth." 
Bhola K, Foster JP, Osborn DA. 
Chest shielding for prevention of a 
haemodynamically significant 
patent ductus arteriosus in preterm 
infants receiving phototherapy. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental disability (after at least 18 months' 
postnatal age) defined as neurological abnormality 
including cerebral palsy on clinical examination, 
developmental delay > 2 SD below population mean on a 
"The available evidence is very low quality and insufficient to 
assess the safety or efficacy of chest shield during phototherapy 
for prevention of PDA in preterm infants. Further trials of chest 




Cochrane Database of Systematic 
Reviews 2015, Issue 11. 
standardised test of development, blindness (VA < 6/60), or 
deafness (any hearing impairment requiring amplification at 
any time after term corrected age) 
not receiving prophylactic or early echocardiographic targeted 
cyclo‐oxygenase inhibitors for PDA." 
Booth D, Evans DJ. 
Anticonvulsants for neonates with 
seizures. Cochrane Database of 
Systematic Reviews 2004, Issue 3. 
Primary outcomes pre‐specified include: 
 Significant neurodevelopmental impairment (any 1 or 
combination of: cerebral palsy, developmental delay DQ > 2 
SD, blindness) assessed at 1 to 2 years of age 
 Death or significant neurodevelopmental impairment (any 1 
or combination of: cerebral palsy, developmental delay DQ > 
2 SD, blindness) assessed at 1 to 2 years of age 
"At present there is little evidence from randomised controlled 
trials to support the use of any of the anticonvulsants currently 
used in the neonatal period. In the literature, there remains a body 
of opinion that seizures should be treated because of the concern 
that seizures in themselves may be harmful, although this is only 
supported by relatively low grade evidence (Levene 2002; 
Massingale 1993). Development of safe and effective treatment 
strategies relies on future studies of high quality (randomised 
controlled trials with methodology that assures validity) and of 
sufficient size to have the power to detect clinically important 
reductions in mortality and severe neurodevelopmental disability 
in addition to any short term reduction in seizure burden." 
Bottino M, Cowett RM, Sinclair JC. 
Interventions for treatment of 
neonatal hyperglycemia in very low 
birth weight infants. Cochrane 
Database of Systematic Reviews 
2011, Issue 10. 
Primary outcomes pre‐specified include: 
 Neurodevelopmental impairment, defined as presence of 1 or 
more of the following: cerebral palsy, MDI or PDI < 70, 
blindness or deafness assessed between 18 and 24 months' 
postmenstrual age or with latest assessment up to 24 months' 
postmenstrual age 
"Evidence from randomized trials in hyperglycemic VLBW 
neonates is insufficient to determine the effects of treatment on 
death or major morbidities. It remains uncertain whether the 
hyperglycemia per se is a cause of adverse clinical outcomes or 
how the hyperglycemia should be treated. Much larger 
randomized trials in hyperglycemic VLBW neonates that are 
powered on clinical outcomes are needed in order to determine 
whether, and how, the hyperglycemia should be treated." 
Brion LP, Bell EF, Raghuveer TS. 
Vitamin E supplementation for 
prevention of morbidity and 
mortality in preterm infants. 
Cochrane Database of Systematic 
Reviews 2003, Issue 4. 
Primary outcomes pre‐specified include: 
 Mortality, combined outcome at 18 months including 
mortality (mortality, bronchopulmonary dysplasia, blindness, 
mental retardation, or cerebral palsy), and combined outcome 
at 18 months excluding mortality (bronchopulmonary 
dysplasia, blindness, mental retardation, or cerebral palsy) 
"Vitamin E supplementation in preterm infants reduced the risk 
of intracranial hemorrhage but increased the risk of sepsis. In 
very low birth weight infants, vitamin E increased the risk of 
sepsis, and reduced the risk of severe retinopathy and blindness 
among those examined. Evidence does not support the routine 
use of vitamin E supplementation by intravenous route at high 
doses or aiming at serum tocopherol levels greater than 3.5 
mg/dl." 
Brown JVE, Embleton ND, Harding 
JE, McGuire W. Multi‐nutrient 
Primary outcomes pre‐specified include: "Limited available data do not provide strong evidence that 




fortification of human milk for 
preterm infants. Cochrane Database 
of Systematic Reviews 2016, Issue 
5. 
 Neurodevelopmental outcomes assessed after 12 months post 
term: neurological evaluations, developmental scores, and 
classifications of disability, including auditory and visual 
disability. We defined neurodevelopmental impairment as the 
presence of 1 or more of the following: non‐ambulant 
cerebral palsy, DQ > 2 SD below the population mean, and 
blindness (VA < 6/60) or deafness (any hearing impairment 
requiring or unimproved by amplification) 
compared with unfortified breast milk affects important 
outcomes, except that it leads to slightly increased in‐hospital 
growth rates." 
Brown JVE, Moe‐Byrne T, 
McGuire W. Glutamine 
supplementation for young infants 
with severe gastrointestinal disease. 
Cochrane Database of Systematic 
Reviews 2014, Issue 12. 
Primary outcomes pre‐specified include: 
 Neurodevelopmental outcomes assessed beyond infancy 
(neurological evaluations, developmental scores, and 
classifications of disability including auditory and visual 
disability, non‐ambulant cerebral palsy, and developmental 
delay) and cognitive and educational outcomes (IQ and/or 
indices of educational achievement measured using a 
validated tool, including school examination results) 
"The available data from randomised controlled trials do not 
suggest that glutamine supplementation has any important 
benefits for young infants with severe gastrointestinal disease." 
Bruschettini M, Romantsik O, 
Zappettini S, Banzi R, Ramenghi 
LA, Calevo MG. Antithrombin for 
the prevention of intraventricular 
hemorrhage in very preterm infants. 
Cochrane Database of Systematic 
Reviews 2016, Issue 3. 
Secondary outcomes pre‐specified include: 
 Major neurodevelopmental disability assessed at age of 12 
months or more (defined as cerebral palsy, developmental 
delay (BSID or GMDS assessment > 2 SD below the mean), 
intellectual impairment (IQ > 2 SD below mean), blindness 
(vision < 6/60 in both eyes), or sensorineural deafness 
requiring amplification) 
"The administration of antithrombin seems not to reduce the 
incidence and severity of intraventricular hemorrhage in very 
preterm infants. Limited evidence is available on other clinically 
relevant outcomes. Given the imprecision of the estimate, the 
results of this systematic review are consistent with either a 
benefit or a detrimental effect of antithrombin and do not provide 
a definitive answer to the review question." 
Bruschettini M, Zappettini S, Moja 
L, Calevo MG. Frequency of 
endotracheal suctioning for the 
prevention of respiratory morbidity 
in ventilated newborns. Cochrane 
Database of Systematic Reviews 
2016, Issue 3. 
Secondary outcomes pre‐specified include: 
 Major neurodevelopmental disability (cerebral palsy, 
developmental delay (BSID or GMDS assessment > 2 SD 
below the mean) or intellectual impairment (IQ > 2 SD below 
mean), blindness (vision less than 6/60 in both eyes), 
sensorineural deafness requiring amplification). We evaluated 
each component of major neurodevelopmental disability: 
o Cerebral palsy on physician assessment (yes/no) 
o Developmental delay or intellectual impairment: 
BSID or GMDS assessment > 2 SD below the mean 
"There was insufficient evidence to identify the ideal frequency 
of ETT suctioning in ventilated neonates. Future research should 
focus on the effects in the very preterm newborns, that is, the 
most vulnerable population as concerns the risk of both lung and 
brain damage. Assessment should include the cases of prolonged 
ventilation, when more abundant, dense secretions are common. 
Clinical trials might include comparisons between 'as‐scheduled' 
versus 'as‐needed' endotracheal suctioning, that is, based on 





or intellectual impairment (IQ > 2 SD below mean); 
neuromotor development (BSID PDI) assessed in 
survivors; mental development (BSID MDI) 
assessed in survivors 
o Blindness vision (less than 6/60 in both eyes) 
o Sensorineural deafness requiring amplification 
Bruschettini M, Romantsik O, 
Zappettini S, Banzi R, Ramenghi 
LA, Calevo MG. Heparin for the 
prevention of intraventricular 
haemorrhage in preterm infants. 
Cochrane Database of Systematic 
Reviews 2016, Issue 5. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopmental outcome (yes/no): cerebral 
palsy on physician assessment, developmental delay, i.e. IQ 2 
SD below the mean on validated assessment tools, e.g. BSID 
MDI (Bayley 1993; Bayley 2006) 
 Major neurodevelopmental disability: cerebral palsy, 
developmental delay (BSID MDI (Bayley 1993; Bayley 
2006) or GMDS assessment (Griffiths 1954) > 2 SD below 
the mean), intellectual impairment (IQ > 2 SD below mean), 
blindness (vision < 6/60 in both eyes), or sensorineural 
deafness requiring amplification (Jacobs 2013). We planned 
to evaluate each of these components as a separate outcome 
and to extract data on this long‐term outcome from studies 
that evaluated children after 18 months of chronological age. 
Data on children aged 18 to 24 months and those aged 3 to 5 
years were to be assessed separately 
"There is very limited data on the effect of prophylactic 
administration of heparin on the incidence and severity of IVH in 
very preterm neonates. Both the identified trials used heparin in 
the context of maintaining umbilical line patency and not 
specifically as an agent to prevent germinal matrix‐
intraventricular haemorrhage. Given the imprecision of our 
estimates, the results of this systematic review are consistent with 
either a benefit or a detrimental effect of heparin and do not 
provide a definitive answer to the review question. Limited 
evidence is available on other clinically relevant outcomes." 
Bruschettini M, Romantsik O, 
Zappettini S, Ramenghi LA, Calevo 
MG. Transcutaneous carbon dioxide 
monitoring for the prevention of 
neonatal morbidity and mortality. 
Cochrane Database of Systematic 
Reviews 2016, Issue 2. 
Primary outcomes pre‐specified include: 
 Major neurodevelopmental disability (cerebral palsy, 
developmental delay (BSID or GMDS > 2 SD below the 
mean) or intellectual impairment (IQ > 2 SD below mean), 
blindness (vision < 6/60 in both eyes), sensorineural deafness 
requiring amplification) (Jacobs 2013) 
Secondary outcomes pre‐specified include: 
 Each component of major neurodevelopmental disability: (a) 
cerebral palsy on physician assessment (yes/no); (b) 
developmental delay or intellectual impairment: BSID or 
GMDS assessment > 2 SD below the mean or intellectual 
No included trials 
"There was no evidence to recommend or refute the use of 
transcutaneous CO2 monitoring in neonates. Well‐designed, 
adequately powered randomized controlled studies are necessary 





impairment (IQ > 2 SD below mean); neuromotor 
development (BSID PDI) assessed in survivors; mental 
development (BSID MDI) assessed in survivors; (c) blindness 
vision (< 6/60 in both eyes); (d) sensorineural deafness 
requiring amplification. We will report these components of 
this long‐term outcome for all trials that have evaluated 
children after 18 months' chronological age. We will perform 
separate analyses for children aged 18 months to 24 months 
and those aged 3 years to 5 years 
Cleminson J, McGuire W. Topical 
emollient for preventing infection in 
preterm infants. Cochrane Database 
of Systematic Reviews 2016, Issue 
1. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcomes assessed at > 12 months post 
term (measured using validated assessment tools) and 
classifications of disability, including auditory and visual 
disability. A composite outcome "severe neurodevelopmental 
disability" was defined as any 1 or combination of the 
following: non‐ambulant cerebral palsy, severe 
developmental delay, auditory impairment, and visual 
impairment 
"The available data do not provide evidence that the use of 
emollient therapy prevents invasive infection or death in preterm 
infants in high‐, middle‐ or low‐income settings. Some evidence 
of an effect of topical vegetable oils on neonatal growth exists 
but this should be interpreted with caution because lack of 
blinding may have introduced caregiver or assessment biases. 
Since these interventions are low cost, readily accessible, and 
generally acceptable, further randomised controlled trials, 
particularly in both community‐ and health care facility‐based 
settings in low‐income countries, may be justified." 
Clerihew L, McGuire W. Antifungal 
therapy for newborn infants with 
invasive fungal infection. Cochrane 
Database of Systematic Reviews 
2012, Issue 6. 
Primary outcomes pre‐specified include: 
 Neurodevelopmental outcomes assessed beyond infancy 
(neurological evaluations, developmental scores, and 
classifications of disability, including auditory and visual 
disability, non‐ambulant cerebral palsy, developmental delay) 
and cognitive and educational outcomes (IQ and/or indices of 
educational achievement measured using a validated tool 
including school examination results) 
"There are insufficient data to inform practice. Large randomised 
controlled trials are required to compare antifungal drugs, drug 
preparations or drug combinations for treating newborn infants 
with invasive fungal infection." 
Cooke L, Steer PA, Woodgate PG. 
Indomethacin for asymptomatic 
patent ductus arteriosus in preterm 
infants. Cochrane Database of 
Systematic Reviews 2003, Issue 1. 
Outcomes pre‐specified include: 
 Neurodevelopmental outcome (cerebral palsy, sensorineural 
hearing loss, visual impairment, developmental delay) 
"This review demonstrates a significant decrease in the incidence 
of symptomatic PDA following treatment of an asymptomatic 
PDA with indomethacin. There is also a small but statistically 
significant decrease in the duration of requirement for 
supplemental oxygen. There are no reported long term outcomes 




possible long term effects. Further studies are required to 
determine the long term benefits or harms of closing a PDA prior 
to the onset of symptoms." 
Davies MW, Kimble RM, 
Woodgate PG. Ward reduction 
without general anaesthesia versus 
reduction and repair under general 
anaesthesia for gastroschisis in 
newborn infants. Cochrane 
Database of Systematic Reviews 
2002, Issue 3. 
Outcomes pre‐specified include: 
 Neurodevelopmental outcome (cerebral palsy, sensorineural 
hearing loss, visual impairment, and/or developmental delay) 
No included trials 
"There is no evidence from RCTs to support or refute the practice 
of ward reduction for the immediate management of 
gastroschisis. There is an urgent need for RCTs to compare ward 
reduction versus reduction under general anaesthesia in infants 
with gastroschisis. Initial trials would best be limited to those 
infants with uncomplicated gastroschisis (using pre‐defined 
selection criteria excluding infants that are unstable, have gut 
perforation, necrosis or atresia, have other organs requiring 
reduction besides bowel, or are considered to need a silo prior to 
any reduction). Trials should use adequate pain relief and specify 
a pre‐defined time period after which manual reduction is 
abandoned." 
Davies MW, Woodgate PG. 
Tracheal gas insufflation for the 
prevention of morbidity and 
mortality in mechanically ventilated 
newborn infants. Cochrane 
Database of Systematic Reviews 
2002, Issue 2. 
Outcomes pre‐specified include: 
 Neurodevelopmental outcome (cerebral palsy, sensorineural 
hearing loss, visual impairment, and/or developmental delay) 
at 1, 2, 3, 5, or 7 years 
"There is evidence from a single RCT that TGI may reduce the 
duration of mechanical ventilation in preterm infants ‐ although 
the data from this small study do not give sufficient evidence to 
support the introduction of TGI into clinical practice. The 
technical requirements for performing TGI (as performed in the 
single included study) are great. There is no statistically 
significant reduction in the total duration of respiratory support or 
hospital stay. TGI cannot be recommended for general use at this 
time." 
De Paoli AG, Davis PG, Faber B, 
Morley CJ. Devices and pressure 
sources for administration of nasal 
continuous positive airway pressure 
(NCPAP) in preterm neonates. 
Cochrane Database of Systematic 
Reviews 2008, Issue 1. 
Secondary outcomes pre‐specified include: 
 Long‐term neurosensory outcomes at 2 years' corrected age or 
older as defined by the incidence of: 
o Cerebral palsy 
o Moderate to severe developmental delay 
o Blindness 
o Deafness 
"Short binasal prong devices are more effective than single 
prongs in reducing the rate of re‐intubation. Although the Infant 
Flow Driver appears more effective than Medicorp prongs the 
most effective short binasal prong device remains to be 
determined. The improvement in respiratory parameters with 
short binasal prongs suggests they are more effective than 
nasopharyngeal CPAP in the treatment of early RDS. Further 




are also needed to determine the optimal pressure source for the 
delivery of NCPAP." 
Dimmick SJ, Badawi N, Randell T. 
Thyroid hormone supplementation 
for the prevention of morbidity and 
mortality in infants undergoing 
cardiac surgery. Cochrane Database 
of Systematic Reviews 2004, Issue 
3. 
Outcomes pre‐specified include: 
 Development: neurological abnormality (cerebral palsy) or 
developmental delay on standardised tests in the first year 
"At present, there is a lack of evidence concerning the effects of 
triiodothyronine supplementation in infants undergoing cardiac 
surgery. Further randomised controlled trials which include 
sufficiently large subject numbers in a variety of different age 
strata (neonates, infants and older children) need to be 
undertaken." 
Foster JP, Psaila K, Patterson T. 
Non‐nutritive sucking for increasing 
physiologic stability and nutrition in 
preterm infants. Cochrane Database 
of Systematic Reviews 2016, Issue 
10. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcomes at 12 months or more of age 
(corrected for preterm birth) measured using validated 
assessment tools such as BSID and classifications of 
disability, including auditory and visual disability. Severe 
neurodevelopmental disability will be defined as any one or 
combination of the following: non‐ambulant cerebral palsy, 
developmental delay (developmental quotient < 70), auditory 
and visual impairment 
"Meta‐analysis demonstrated a significant effect of NNS on the 
transition from gavage to full oral feeding, transition from start of 
oral feeding to full oral feeding, and length of hospital stay. None 
of the trials reported any adverse effects. Well‐designed, 
adequately powered studies using reliable methods of 
randomisation, concealment of treatment allocation and blinding 
of the intervention and outcome assessors are needed. In order to 
facilitate meta‐analysis of these data, future research should 
involve outcome measures consistent with those used in previous 
studies." 
Görk AS, Ehrenkranz RA, Bracken 
MB. Continuous infusion versus 
intermittent bolus doses of 
indomethacin for patent ductus 
arteriosus closure in symptomatic 
preterm infants. Cochrane Database 
of Systematic Reviews 2008, Issue 
1. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcome (sensorineural hearing loss, 
visual impairment, cerebral palsy, developmental delay at 24 
months' corrected age assessed by a standardised and 
validated assessment tool and/or a child developmental 
specialist) 
"The available data is insufficient to draw conclusions regarding 
the efficacy of continuous indomethacin infusion vs. bolus 
injections for the treatment of PDA. Although continuous 
indomethacin seems to cause less alterations in cerebral, renal 
and mesenteric circulations, the clinical meaning of this effect is 
unclear. Definitive recommendations about the preferred method 
of indomethacin administration in premature infants cannot be 
made based on the current findings of this review." 
Henderson G, Anthony MY, 
McGuire W. Formula milk versus 
maternal breast milk for feeding 
preterm or low birth weight infants. 
Cochrane Database of Systematic 
Reviews 2007, Issue 4. 
Primary outcomes pre‐specified include: 
 Development: 
o Neurodevelopmental outcomes at ≥ 12 months of 
age (corrected for preterm birth) measured using 
validated assessment tools 
No included trials 
"There are no data from randomised trials of formula milk versus 
maternal breast milk for feeding preterm or low birth weight 
infants. This may relate to a perceived difficulty of allocating an 
alternative feed to an infant whose mother wishes to feed with 




o Severe neurodevelopmental disability defined as any 
1 or combination of the following: non‐
ambulant cerebral palsy, developmental delay (DQ < 
70 or > 2 SD below the mean), severe auditory 
impairment (sensorineural deafness requiring (or too 
severe to (benefit from) hearing aids), or visual 
impairment (legal blindness). We plan to analyse 
each component individually as well as part of the 
composite outcome 
o Cognitive and educational outcomes at age > 5 
years: IQ and/or indices of educational achievement 
measured using a validated assessment tool 
(including school examination results) 
choice of enteral nutrition because observational studies, and 
meta‐analyses of trials comparing feeding with formula milk 
versus donor breast milk, suggest that feeding with breast milk 
has major non‐nutrient advantages for preterm or low birth 
weight infants." 
Henderson G, Fahey T, McGuire W. 
Nutrient‐enriched formula milk 
versus human breast milk for 
preterm infants following hospital 
discharge. Cochrane Database of 
Systematic Reviews 2007, Issue 4. 
Primary outcomes pre‐specified include: 
 Neurodevelopmental outcomes at ≥ 12 months of age 
(corrected for preterm birth) measured using validated 
assessment tools such as BSID and classifications of 
disability, including auditory and visual disability. Severe 
neurodevelopmental disability will be defined as any 1 or 
combination of the following: non‐ambulant cerebral palsy, 
developmental delay (DQ < 70), auditory and visual 
impairment 
No included trials 
"There are no data from randomised controlled trials to determine 
whether feeding preterm infants following hospital discharge 
with nutrient‐enriched formula milk versus human breast milk 
affects growth and development. Mothers who wish to breast 
feed, and their health care advisors, would require very clear 
evidence that feeding with a nutrient‐enriched formula milk had 
major advantages for their infants before electing not to feed (or 
to reduce feeding) with maternal breast milk. If evidence from 
trials that compared feeding preterm infants following hospital 
discharge with nutrient‐enriched versus standard formula milk 
demonstrated an effect on growth or development, then this 
might strengthen the case for undertaking trials of nutrient‐
enriched formula milk versus human breast milk." 
Henderson‐Smart DJ, Wilkinson 
AR, Raynes‐Greenow CH. 
Mechanical ventilation for newborn 
infants with respiratory failure due 
to pulmonary disease. Cochrane 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental abnormalities in childhood 
(developmental delay, cerebral palsy) 
"When MV was introduced in the 1960s to treat infants with 
severe respiratory failure due to pulmonary disease, trials showed 
an overall reduction in mortality which was most marked in 
infants born with a birthweight of more than 2 kg. This review 
does not provide information to evaluate the relative benefits or 




Database of Systematic Reviews 
2002, Issue 4. 
Ho JJ, Henderson‐Smart DJ, Davis 
PG. Early versus delayed initiation 
of continuous distending pressure 
for respiratory distress syndrome in 
preterm infants. Cochrane Database 
of Systematic Reviews 2002, Issue 
2. 
Secondary outcomes pre‐specified include: 
 Long‐term growth and neurodevelopmental outcome 
(cerebral palsy and abnormal mental development < 2 SD 
below the mean on a standardised score) 
"Early application of CDP has a clinical benefit in the treatment 
of RDS in that it reduces subsequent use of IPPV and thus may 
be useful in preventing the adverse effects of this treatment. 
However, many of the trials were done in the 1970s and 1980s 
and re‐evaluation of the strategy of early CDP in the era of 
antenatal steroid use and early surfactant administration is 
indicated focusing on administration methods." 
Ho JJ, Rasa G. Magnesium sulfate 
for persistent pulmonary 
hypertension of the newborn. 
Cochrane Database of Systematic 
Reviews 2007, Issue 3. 
Secondary outcomes pre‐specified include: 
 Cerebral palsy on physician assessment 
No included trials 
"On the basis of the current lack of evidence, the use of 
magnesium sulphate cannot be recommended in the treatment of 
PPHN. Randomised controlled trials are recommended." 
Hunt R, Osborn DA. Dopamine for 
prevention of morbidity and 
mortality in term newborn infants 
with suspected perinatal asphyxia. 
Cochrane Database of Systematic 
Reviews 2002, Issue 3. 
Primary outcomes pre‐specified include: 
 Neurodevelopmental disability (neurological abnormality 
including cerebral palsy, developmental delay > 2 SD below 
population mean, or sensory impairment) 
(Review reports on 'neurodevelopmental disability' for 1 RCT (14 
infants), which did not include cerebral palsy) 
"There is currently insufficient evidence from randomised 
controlled trials that the use of dopamine in term infants with 
suspected perinatal asphyxia improves mortality or long‐term 
neurodevelopmental outcome. The question of whether dopamine 
improves outcome for term infants with suspected perinatal 
asphyxia has not been answered. Further research is required to 
determine whether or not the use of dopamine improves mortality 
and long‐term morbidity for these infants and if so, issues such as 
which infants, at what dose and with what co‐interventions 
should be addressed." 
Hunt R, Davis PG, Inder TE. 
Replacement of estrogens and 
progestins to prevent morbidity and 
mortality in preterm infants. 
Cochrane Database of Systematic 
Reviews 2004, Issue 4. 
Primary outcomes pre‐specified include: 
 Neurodevelopmental disability defined as neurological 
abnormality including cerebral palsy on clinical examination 
> 12 months' postnatal age, developmental delay > 2 SD 
below population mean on any standard test of development, 
blindness (VA < 6/60), or deafness (any hearing impairment 
requiring amplification) at any time after term corrected 
"The one small randomised controlled trial demonstrated neither 
evidence of benefit or harm related to the replacement of 
estradiol and progesterone in preterm infants less than 30 weeks' 
gestation. A properly powered randomised controlled trial is 
required to determine whether or not administration of estradiol 
or progesterone, either alone or in combination, and at varying 
doses, confers any clinically significant benefits, or poses any 




Ibrahim H, Sinha IP, Subhedar NV. 
Corticosteroids for treating 
hypotension in preterm infants. 
Cochrane Database of Systematic 
Reviews 2011, Issue 12. 
Primary outcomes pre‐specified include: 
 Long‐term neurodevelopmental outcome (cerebral palsy, 
developmental delay, sensorineural impairment, abnormal 
neurological examination) 
"Hydrocortisone may be as effective as dopamine when used as a 
primary treatment for hypotension. But the long term safety data 
on the use of hydrocortisone in this manner is unknown. Steroids 
are effective in treatment of refractory hypotension in preterm 
infants without an increase in short term adverse consequences. 
However, long term safety or benefit data is lacking. With long 
term benefit or safety data lacking steroids cannot be 
recommended routinely for the treatment of hypotension in 
preterm infants." 
Ibrahim MDH, Sinn JKH, McGuire 
W. Iodine supplementation for the 
prevention of mortality and adverse 
neurodevelopmental outcomes in 
preterm infants. Cochrane Database 
of Systematic Reviews 2006, Issue 
2. 
Primary outcomes pre‐specified include: 
 Neurodevelopmental outcomes at ≥ 12 months of age 
(corrected for preterm birth) measured using validated 
assessment tools such as BSID 
 Severe neurodevelopmental disability defined as any 1 or 
combination of the following: non‐ambulant cerebral palsy, 
developmental delay (DQ < 70), auditory and visual 
impairment. We planned to analyse each component 
individually as well as part of the composite outcome 
"There are insufficient data at present to determine whether 
providing preterm infants with supplemental iodine (to match 
fetal accretion rates) prevents morbidity and mortality in preterm 
infants. Future randomised controlled trials of iodine 
supplementation should focus on extremely preterm and 
extremely low birth weight infants, the group at greatest risk of 
transient hypothyroxinaemia. These trials should aim to assess 
the effect of iodine supplementation on clinically important 
outcomes including respiratory morbidity and longer term 
neurodevelopment." 
Inglis GDT, Davies MW. 
Prophylactic antibiotics to reduce 
morbidity and mortality in neonates 
with umbilical venous catheters. 
Cochrane Database of Systematic 
Reviews 2005, Issue 4. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcome (cerebral palsy, sensorineural 
hearing loss, visual impairment and/or developmental delay 
will be considered as separate components ‐ at 1 year, 18 
months, 2 years, or 5 years) 
"There is insufficient evidence from randomised trials to support 
or refute the use of prophylactic antibiotics when UVCs are 
inserted in newborn infants. There is no evidence to support or 
refute continuing antibiotics once initial cultures rule out 
infection in newborn infants with UVCs." 
Inglis GDT, Jardine LA, Davies 
MW. Prophylactic antibiotics to 
reduce morbidity and mortality in 
ventilated newborn infants. 
Cochrane Database of Systematic 
Reviews 2007, Issue 3. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcome (cerebral palsy, sensorineural 
hearing loss, visual impairment and/or developmental delay at 
1 year, 18 months, 2 years, or 5 years) 
"There is insufficient evidence from randomised trials to support 
or refute the use of prophylactic antibiotics when starting 
mechanical ventilation in newborn infants, or to support or refute 
continuing antibiotics once initial cultures have ruled out 
infection in mechanically ventilated newborn infants." 
Inglis GDT, Jardine LA, Davies 
MW. Prophylactic antibiotics to 
Secondary outcomes pre‐specified include: "There is insufficient evidence from randomised trials to support 




reduce morbidity and mortality in 
neonates with umbilical artery 
catheters. Cochrane Database of 
Systematic Reviews 2007, Issue 4. 
 Neurodevelopmental outcome (cerebral palsy, sensorineural 
hearing loss, visual impairment and/or developmental delay ‐ 
at 1 year, 18 months, 2 years, or 5 years) 
catheters are inserted in newborn infants, and no evidence to 
support or refute continuing antibiotics once initial cultures rule 
out infection in newborn infants with umbilical artery catheters." 
Jardine LA, Inglis GDT, Davies 
MW. Prophylactic systemic 
antibiotics to reduce morbidity and 
mortality in neonates with central 
venous catheters. Cochrane 
Database of Systematic Reviews 
2008, Issue 1. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcome (cerebral palsy, sensorineural 
hearing loss, visual impairment, and/or developmental delay ‐ 
at 1 year, 18 months, 2 years, or 5 years) 
"Prophylactic systemic antibiotics in neonates with a central 
venous catheter reduces the rate of proven or suspected 
septicaemia. However, this may not be clinically important in the 
face of no significant difference in overall mortality and the lack 
of data on long‐term neurodevelopmental outcome. Furthermore, 
there is a lack of data pertaining to the potentially significant 
disadvantages of this approach such as the selection of resistant 
organisms. The routine use of prophylactic antibiotics in infants 
with central venous catheters in neonatal units cannot currently 
be recommended." 
Jardine LA, Inglis GDT, Davies 
MW. Strategies for the withdrawal 
of nasal continuous positive airway 
pressure (NCPAP) in preterm 
infants. Cochrane Database of 
Systematic Reviews 2011, Issue 2. 
Art. No.: CD006979. DOI: 
10.1002/14651858.CD006979.pub2. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcome (cerebral palsy, sensorineural 
hearing loss, visual impairment, and/or developmental delay ‐ 
at 1 year, 18 months, 2 years, or 5 years) 
"Infants who have their NCPAP pressure weaned to a predefined 
level and then stop NCPAP completely have less total time on 
NCPAP and shorter durations of oxygen therapy and hospital 
stay compared with those that have NCPAP removed for a 
predetermined number of hours each day. Future trials of 
withdrawing NCPAP should compare proposed strategies with 
weaning NCPAP pressure to a predefined level and then stopping 
NCPAP completely. Clear criteria need to be established for the 
definition of stability prior to attempting to withdraw NCPAP." 
Kaushal A, McDonnell CG, Davies 
MW. Partial liquid ventilation for 
the prevention of mortality and 
morbidity in paediatric acute lung 
injury and acute respiratory distress 
syndrome. Cochrane Database of 
Systematic Reviews 2013, Issue 2. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopment (cerebral palsy, sensorineural 
hearing loss, visual impairment, developmental delay) 
 Long‐term disability 
"There is no evidence from RCTs to support or refute the use of 
partial liquid ventilation in children with acute lung injury or 
acute respiratory distress syndrome. Adequately powered, high 
quality RCTs are still needed to assess its efficacy. Clinically 
relevant outcome measures should be assessed (mortality at 
discharge and later, duration of both respiratory support and 
hospital stay, and long‐term neurodevelopmental outcomes). The 
studies should be published in full." 
Kecskes Z, Healy G, Jensen A. 
Fluid restriction for term infants 





encephalopathy following perinatal 
asphyxia. Cochrane Database of 
Systematic Reviews 2005, Issue 3. 
 Severe neurodevelopmental disability at or equal to 12 
months of age or more. Severe neurodevelopmental disability 
was defined as cerebral palsy, developmental delay (DQ < 
70) or blindness (VA < 6/60 in both eyes), or any 
combination of these disabilities 
"Given that fluid restriction for the treatment of hypoxic 
ischaemic encephalopathy following perinatal asphyxia is 
recommended in standard textbooks, there is a need for 
randomised, controlled trials to establish if this practice affects 
mortality and morbidity. As it may not be ethical to include 
neonates with acute renal failure in a randomised trial, these 
babies will have to be excluded from the trial. These studies 
should investigate the effects of fluid management on outcomes 
such as mortality, seizure activity, evidence of cerebral damage 
on histology, and effects on renal function and electrolytes." 
Keir AK, Wilkinson D, Andersen C, 
Stark MJ. Washed versus unwashed 
red blood cells for transfusion for 
the prevention of morbidity and 
mortality in preterm infants. 
Cochrane Database of Systematic 
Reviews 2016, Issue 1. 
Primary outcomes pre‐specified include: 
 Cerebral palsy by physician assessment 
Secondary outcomes pre‐specified include: 
 Composite outcome of mortality or severe adverse 
neurosensory outcome (or its complement, survival without 
serious adverse neurosensory outcome) at a defined period of 
follow‐up at age 18 to 24 months' adjusted gestational age or 
older, where adverse neurosensory outcome is defined as: 
o Cerebral palsy by physician assessment 
o DQ (> 2 SD below the mean on validated 
assessment tool of cognitive function (e.g. BSID)) 
o Blindness (VA < 20/200 in best eye) 
o Deafness (hearing loss requiring amplification or 
cochlear implantation) 
"We identified a single small study. The results from this study 
show a high level of uncertainty, as the confidence intervals are 
consistent with both a large improvement or a serious harm 
caused by the intervention. Consequently, there is insufficient 
evidence to support or refute the use of washed RBCs to prevent 
the development of significant neonatal morbidities or mortality. 
Further clinical trials are required to assess the potential effects of 
pre‐transfusion washing of RBCs for preterm or very low birth 
weight infants, or both, on short‐ and long‐term outcomes." 
Kylat RI, Ohlsson A. Recombinant 
human activated protein C for 
severe sepsis in neonates. Cochrane 
Database of Systematic Reviews 
2012, Issue 4. 
Secondary outcomes pre‐specified include: 
 Severe disability, defined as any of blindness, deafness, 
cerebral palsy or cognitive delay (score > 2 SD below the 
mean for a recognised psychometric test for 
neurodevelopmental outcome assessed by a validated test, 
e.g. BSID), or adverse neurological outcome, at 18 months of 
age or later. These outcomes will be reported both as a 
composite outcome and individually 
 Cerebral palsy 
"Despite the scientific rationale for its use, there is insufficient 
data to use rhAPC for the management of severe sepsis in 
newborn infants. Due to the results among adults with lack of 
efficacy, an increase in bleeding and resulting withdrawal of 
rhAPC from the market, neonates should not be treated with 




Lai NM, Foong SC, Foong WC, 
Tan K. Co‐bedding in neonatal 
nursery for promoting growth and 
neurodevelopment in stable preterm 
twins. Cochrane Database of 
Systematic Reviews 2016, Issue 4. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopment, measured by validated scales 
such as BSID (Washington 1998), whereby average scores 
between twin pairs would be taken if data were available. 
Clinically diagnosed non‐ambulatory cerebral palsy or 
significant auditory and visual impairment would be accepted 
if data were available 
"Evidence on the benefits and harms of co‐bedding for stable 
preterm twins was insufficient to permit recommendations for 
practice. Future studies must be adequately powered to detect 
clinically important differences in growth and neurodevelopment. 
Researchers should assess harms such as infection, along with 
medication errors and caregiver satisfaction." 
Lai NM, Rajadurai SV, Tan K. 
Increased energy intake for preterm 
infants with (or developing) 
bronchopulmonary 
dysplasia/chronic lung disease. 
Cochrane Database of Systematic 
Reviews 2006, Issue 3. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental disabilities at or after 12 months' 
corrected age, assessed using validated tools like BSID, 
including diagnosed cerebral palsy, blindness, or deafness 
 Mortality or neurodevelopmental disabilities 
No included trials 
"To date, no randomised controlled trials are available that 
examine the effects of increased versus standard energy intake 
for preterm infants with (or developing) CLD/BPD. Research 
should be directed at evaluating the effects of various levels of 
energy intake on this group of infants on clinically important 
outcomes like mortality, respiratory status, growth and 
neurodevelopment. The benefits and harms of various ways of 
increasing energy intake, including higher energy density of milk 
feed and/or fluid volume (clinically realistic target volume should 
be set), parenteral nutrition, and the use of various constituents of 
energy like carbohydrate, protein and fat for this purpose also 
need to be assessed." 
Lai NM, Taylor JE, Tan K, Choo 
YM, Ahmad Kamar A, Muhamad 
NA. Antimicrobial dressings for the 
prevention of catheter‐related 
infections in newborn infants with 
central venous catheters. Cochrane 
Database of Systematic Reviews 
2016, Issue 3. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopmental outcomes, measured using 
validated scales such as the BSID (Washington 1998) at 12, 
18, or 24 months of age. Data on clinically diagnosed non‐
ambulatory cerebral palsy or significant auditory and visual 
impairment would be accepted if available 
"Based on moderate‐quality evidence, chlorhexidine 
dressing/alcohol skin cleansing reduced catheter colonisation, but 
made no significant difference in major outcomes like sepsis and 
CRBSI compared to polyurethane dressing/povidone‐iodine 
cleansing. Chlorhexidine dressing/alcohol cleansing posed a 
substantial risk of contact dermatitis in preterm infants, although 
it was unclear whether this was contributed mainly by the 
dressing material or the cleansing agent. While silver‐alginate 
patch appeared safe, evidence is still insufficient for a 
recommendation in practice. Future research that evaluates 
antimicrobial dressing should ensure blinding of caregivers and 
outcome assessors and ensure that all participants receive the 




outcomes like sepsis, CRBSI and mortality should be assessed in 
infants of different gestation and birth weight." 
Lai M, Inglis GDT, Hose K, Jardine 
LA, Davies MW. Methods for 
securing endotracheal tubes in 
newborn infants. Cochrane 
Database of Systematic Reviews 
2014, Issue 7. 
Secondary outcomes pre‐specified include: 
 Incidence of an adverse neurodevelopmental outcome 
(e.g. cerebral palsy, sensorineural hearing loss, visual 
impairment, developmental delay) whenever measured in the 
primary studies 
"This review highlighted the need for further well designed and 
completed studies to be conducted for this common neonatal 
procedure. Evidence is lacking to determine the most effective 
and safe method to stabilise the endotracheal tube in the 
ventilated neonate." 
Lawn CJ, Weir FJ, McGuire W. 
Base administration or fluid bolus 
for preventing morbidity and 
mortality in preterm infants with 
metabolic acidosis. Cochrane 
Database of Systematic Reviews 
2005, Issue 2. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcomes at ≥ 12 months of age 
(corrected for preterm birth) measured using validated 
assessment tools such as BSID and classifications of 
disability, including (a) auditory and (b) visual disability. The 
composite outcome of "severe neurodevelopmental disability" 
is defined as any 1 or combination of the following: non‐
ambulant cerebral palsy, developmental delay (DQ < 70), 
auditory and visual impairment 
"There is insufficient evidence from randomised controlled trials 
to determine whether infusion of base or fluid bolus reduces 
morbidity and mortality in preterm infants with metabolic 
acidosis. Further large randomised trials are needed." 
Malwade US, Jardine LA. Home‐ 
versus hospital‐based phototherapy 
for the treatment of non‐haemolytic 
jaundice in infants at more than 37 
weeks' gestation. Cochrane 
Database of Systematic Reviews 
2014, Issue 6. 
Primary outcomes pre‐specified include: 
 Incidence (percentage) of chronic bilirubin encephalopathy or 
kernicterus, defined by a tetrad of choreoathetoid cerebral 
palsy, high‐frequency sensorineural hearing loss, palsy of 
vertical gaze, and dental enamel hypoplasia 
No included trials 
"No high‐quality evidence is currently available to support or 
refute the practice of home‐based phototherapy for non‐
haemolytic jaundice in infants at more than 37 weeks' gestation." 
McGuire W, Fowlie PW, Evans DJ. 
Naloxone for preventing morbidity 
and mortality in newborn infants of 
greater than 34 weeks' gestation 
with suspected perinatal asphyxia. 
Cochrane Database of Systematic 
Reviews 2004, Issue 1. 
Primary outcomes pre‐specified include: 
 Severe neurodevelopmental disability assessed at ≥ 12 
months of age. Severe neurodevelopmental disability will be 
defined as any 1 or combination of the following: non‐
ambulant cerebral palsy, developmental delay (DQ < 70), 
auditory and visual impairment. Development should have 
been assessed by means of a previously validated tool, such 
as BSID PDI and MDI 
"There are insufficient data available to evaluate the safety and 
effectiveness of the routine use of naloxone for newborn infants 
of greater than 34 weeks' gestation with suspected perinatal 
asphyxia. A further randomised controlled trial is needed to 
determine if naloxone benefits newborn infants with suspected 
perinatal asphyxia. Such a trial should assess clinically important 





Morgan J, Bombell S, McGuire W. 
Early trophic feeding versus enteral 
fasting for very preterm or very low 
birth weight infants. Cochrane 
Database of Systematic Reviews 
2013, Issue 3. 
Secondary outcomes pre‐specified include: 
 Neurodevelopment: death or severe neurodevelopmental 
disability defined as any 1 or combination of the following: 
non‐ambulant cerebral palsy, developmental delay (DQ < 70), 
auditory and visual impairment. Each component will be 
analysed individually as well as part of the composite 
outcome 
"The available trial data do not provide evidence of important 
beneficial or harmful effects of early trophic feeding for very 
preterm or very low birth weight infants. The applicability of 
these findings to extremely preterm, extremely low birth weight 
or growth restricted infants is limited. Further randomised 
controlled trials would be needed to determine how trophic 
feeding compared with enteral fasting affects important outcomes 
in this population." 
Morgan J, Young L, McGuire W. 
Slow advancement of enteral feed 
volumes to prevent necrotising 
enterocolitis in very low birth 
weight infants. Cochrane Database 
of Systematic Reviews 2015, Issue 
10. 
Secondary outcomes pre‐specified include: 
 Neurodevelopment: 
o Death or severe neurodevelopmental disability 
defined as any 1 or a combination of the following: 
non‐ambulatory cerebral palsy, developmental delay 
(DQ < 70), auditory and visual impairment. Each 
component was to be analysed individually as well 
as part of the composite outcome 
o Neurodevelopmental scores in survivors aged 12 
months or greater measured using validated 
assessment tools 
o Cognitive and educational outcomes in survivors 
aged > 5 years 
"The available trial data suggest that advancing enteral feed 
volumes at daily increments of 30 to 40 mL/kg (compared to 15 
to 24 mL/kg) does not increase the risk of NEC or death in 
VLBW infants. Advancing the volume of enteral feeds at slow 
rates results in several days of delay in establishing full enteral 
feeds and increases the risk of invasive infection. The 
applicability of these findings to extremely preterm, extremely 
low birth weight, or growth‐restricted infants is limited. Further 
randomised controlled trials in these populations may be 
warranted to resolve this uncertainty." 
Morgan J, Young L, McGuire W. 
Delayed introduction of progressive 
enteral feeds to prevent necrotising 
enterocolitis in very low birth 
weight infants. Cochrane Database 
of Systematic Reviews 2014, Issue 
12. 
Secondary outcomes pre‐specified include: 
 Neurodevelopment: 
o Death or severe neurodevelopmental disability 
defined as any 1 or combination of the following: 
non‐ambulant cerebral palsy, developmental delay 
(DQ < 70), auditory and visual impairment. Each 
component was analysed individually as well as part 
of the composite outcome 
o Neurodevelopmental scores in survivors aged 12 
months or greater measured using validated 
assessment tools 
"The evidence available from randomised controlled trials 
suggested that delaying the introduction of progressive enteral 
feeds beyond four days after birth did not reduce the risk of 
developing NEC in very preterm or VLBW infants, including 
growth‐restricted infants. Delaying the introduction of 
progressive enteral feeds resulted in a few days' delay in 
establishing full enteral feeds but the clinical importance of this 
effect was unclear. The applicability of these findings to 
extremely preterm or extremely low birth weight was uncertain. 





o Cognitive and educational outcomes in survivors 
aged > 5 years 
Mosalli R, AlFaleh K. Prophylactic 
surgical ligation of patent ductus 
arteriosus for prevention of 
mortality and morbidity in 
extremely low birth weight infants. 
Cochrane Database of Systematic 
Reviews 2008, Issue 1. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental impairment (i.e. rates of cerebral palsy, 
cognitive delay defined as a MDI score < 70 (2 SD below the 
mean of 100) on the BSID II (Bayley 1993), deafness, 
blindness, or composite reported at 18 months' corrected age 
or later) 
"Prophylactic surgical ligation of the PDA did not decrease 
mortality or BPD in ELBW infants. A significant reduction of 
stage II or III NEC was noted. Based on the current evidence, the 
high rate of spontaneous closure, availability of effective safe 
medical therapies, and the potential short and long‐term 
complications of surgical ligation, the use such prophylactic 
surgical therapy is not indicated in the management of the 
preterm infants." 
O'Donnell CPF, Bruschettini M, 
Davis PG, Morley CJ, Moja L, 
Calevo MG, Zappettini S. Sustained 
versus standard inflations during 
neonatal resuscitation to prevent 
mortality and improve respiratory 
outcomes. Cochrane Database of 
Systematic Reviews 2015, Issue 7. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopmental outcome (rates of cerebral 
palsy on physician assessment, developmental delay, i.e. IQ 2 
SD < mean on validated assessment tools, e.g. BSID MDI) 
"At present there is insufficient evidence from clinical trials to 
determine the efficacy and safety of initial sustained lung 
inflation for newborn infants resuscitated with PPV. RCTs 
comparing PPV with and without sustained inflations at neonatal 
resuscitation are warranted." 
Ogunlesi TA, Odigwe CC, Oladapo 
OT. Adjuvant corticosteroids for 
reducing death in neonatal bacterial 
meningitis. Cochrane Database of 
Systematic Reviews 2015, Issue 11. 
Secondary outcomes pre‐specified include: 
 Presence of severe neurological deficits or developmental 
delay between 1 and 2 years of age (a neurological deficit 
was defined as a functional abnormality of a body area that is 
observed as the result of an abnormality in function of the 
brain, spinal cord, muscles, or nerves; developmental delay 
was defined as any significant lag in a child's physical or 
motor, cognitive, behavioural, emotional, or social 
development, in comparison with other children of the same 
age and sex within similar environments; formal evaluation 
tools were used to assess neurological deficits and 
developmental delay). Examples of neurological deficits 
include mental retardation, cerebral palsy, epilepsy, 
blindness, and behavioural disorders. We considered 
evaluation tools such as BSID or GMDS (for 
"Very low‐quality data from two randomised controlled trials 
suggest that some reduction in death and hearing loss may result 
from use of adjunctive steroids alongside standard antibiotic 
therapy for treatment of patients with neonatal meningitis. 
Benefit is not yet seen with regards to reduction in neurological 
sequelae. Researchers who wish to clarify these findings must 
conduct more robustly designed trials with greater numbers of 





neurodevelopmental deficits), the GMFCS or the Movement 
ABC (for cerebral palsy), the Sonken‐Silver VA test (for 
blindness), distraction tests (for behavioural disorders), and 
electroencephalography (for epilepsy) ‐ all applied between 1 
and 2 years of age. We also accepted other measures used by 
individual trialists to evaluate and document neurological 
deficits in their respective trials 
Onland W, Offringa M, van Kaam 
A. Late (≥ 7 days) inhalation 
corticosteroids to reduce 
bronchopulmonary dysplasia in 
preterm infants. Cochrane Database 
of Systematic Reviews 2012, Issue 
4. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopmental sequelae, assessed after at 
least 1 year CGA and before a CGA of 4 years including 
cerebral palsy and BSID (MDI) 
"Based on the results of the currently available evidence, 
inhalation corticosteroids initiated at ≥ 7 days of life for preterm 
infants at high risk of developing BPD cannot be recommended 
at this point in time. More and larger randomised, placebo‐
controlled trials are needed to establish the efficacy and safety of 
inhalation corticosteroids." 
Osborn DA, Evans NJ. Early 
volume expansion versus inotrope 
for prevention of morbidity and 
mortality in very preterm infants. 
Cochrane Database of Systematic 
Reviews 2001, Issue 2. 
Primary outcomes pre‐specified include: 
 Neurodevelopmental disability (neurological abnormality 
including cerebral palsy, developmental delay, or sensory 
impairment) 
"Dopamine was more successful than albumin at correcting low 
BP in hypotensive preterm infants, many of whom had already 
received volume. Neither intervention has been shown to be 
superior at improving blood flow or in improving mortality and 
morbidity in preterm infants. The trials do not allow any firm 
conclusions to be made as to whether or when volume or 
dopamine should be used in preterm infants." 
Osborn DA, Hunt R. Postnatal 
thyroid hormones for preterm 
infants with transient 
hypothyroxinaemia. Cochrane 
Database of Systematic Reviews 
2007, Issue 1. 
Primary outcomes pre‐specified include: 
 Neurodevelopmental status at follow‐up. 
Neurodevelopmental outcome was categorised as: 
o Abnormal mental developmental > 12 months' 
corrected age (a development or IQ > 2 SD below 
the mean of a standardised test) 
o Abnormal neurological outcome (infants with 
abnormal mental development or definite cerebral 
palsy) 
o Motor deficits 
o Sensorineural impairments including hearing deficit 
requiring aids; VA < 6/60 
"There is insufficient evidence to determine whether use of 
thyroid hormones for treatment of preterm infants with transient 
hypothyroxinaemia results in changes in neonatal morbidity and 
mortality, or reductions in neurodevelopmental impairments. 




Osborn DA, Hunt R. Postnatal 
thyroid hormones for respiratory 
distress syndrome in preterm 
infants. Cochrane Database of 
Systematic Reviews 2007, Issue 1. 
Primary outcomes pre‐specified include: 
 Abnormal neurodevelopmental outcome: 
o Abnormal mental development > 12 months' 
corrected age (a validated development or IQ > 2 SD 
below the mean of a standardised test) 
o Abnormal neurological outcome (infants with 
abnormal mental development or definite cerebral 
palsy) 
o Motor deficits 
o Sensorineural impairments (hearing deficit requiring 
aids or VA < 6/60) 
"There is no evidence from controlled clinical trials that postnatal 
thyroid hormone treatment reduces the severity of respiratory 
distress syndrome, neonatal morbidity or mortality in preterm 
infants with respiratory distress syndrome." 
Özek E, Soll R, Schimmel MS. 
Partial exchange transfusion to 
prevent neurodevelopmental 
disability in infants with 
polycythemia. Cochrane Database 
of Systematic Reviews 2010, Issue 
1. 
Primary outcomes pre‐specified include: 
 Neurodevelopmental status at 2 years of age, 
neurodevelopmental status at school age. This will include 
both combined and separate analyses of the components of 
severe neurodevelopmental delay defined as an MDI < 
70, cerebral palsy, vision loss, and hearing loss 
"There are no proven clinically significant short or long‐term 
benefits of PET in polycythemic newborn infants who are 
clinically well or who have minor symptoms related to 
hyperviscosity. PET may lead to an increase in the risk of NEC. 
The data regarding developmental follow‐up are extremely 
imprecise due to the large number of surviving infants who were 
not assessed and, therefore, the true risks and benefits of PET are 
unclear." 
Paradisis M, Osborn DA. 
Adrenaline for prevention of 
morbidity and mortality in preterm 
infants with cardiovascular 
compromise. Cochrane Database of 
Systematic Reviews 2004, Issue 1. 
Primary outcomes pre‐specified include: 
 Long‐term neurodevelopmental outcome: cerebral palsy and 
standardised assessment of developmental delay or 
sensorineural impairment 
"There are insufficient data on the use of adrenaline infusions in 
preterm infants with cardiovascular compromise to make 
recommendations for practice. There is a need for larger trials to 
determine whether adrenaline is effective in reducing morbidity 
and mortality in preterm infants with cardiovascular 
compromise." 
Pfister RH, Soll R, Wiswell TE. 
Protein‐containing synthetic 
surfactant versus protein‐free 
synthetic surfactant for the 
prevention and treatment of 
respiratory distress syndrome. 
Cochrane Database of Systematic 
Reviews 2009, Issue 4. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcome at approximately 2 years' 
corrected age (acceptable range 18 months to 28 months) 
including cerebral palsy, mental delay (BSID MDI < 70), 
legal blindness (< 20/200 VA), and hearing deficit (aided or < 
60 dB on audiometric testing). The composite outcome 
"neurodevelopmental impairment" was defined as having any 
1 of the aforementioned deficits 
"In the one trial comparing protein containing synthetic 
surfactants compared to protein free synthetic surfactant for the 
prevention of RDS, no statistically different clinical differences 
in death and chronic lung disease were noted. Clinical outcomes 
between the two groups were generally similar although the 
group receiving protein containing synthetic surfactants did have 
decreased incidence of respiratory distress syndrome. Further 




surfactant to the more widely used animal derived surfactant 
extracts are indicated." 
Pfister RH, Soll R, Wiswell TE. 
Protein containing synthetic 
surfactant versus animal derived 
surfactant extract for the prevention 
and treatment of respiratory distress 
syndrome. Cochrane Database of 
Systematic Reviews 2007, Issue 4. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcome at approximately 2 years' 
corrected age (range 18 months to 28 months) 
including cerebral palsy, mental retardation (BSID MDI < 
70), legal blindness (< 20/200 VA), and hearing deficit (aided 
or < 60 dB on audiometric testing). The composite outcome 
"neurodevelopmental impairment" was defined as having any 
1 of the aforementioned deficits 
"In two trials of protein containing synthetic surfactants 
compared to animal derived surfactant extract, no statistically 
different clinical differences in death and chronic lung disease 
were noted. In general, clinical outcomes between the two groups 
were similar. Further well designed studies of adequate size and 
power will help confirm and refine these findings." 
Pilley E, McGuire W. Pre‐discharge 
"car seat challenge" for preventing 
morbidity and mortality in preterm 
infants. Cochrane Database of 
Systematic Reviews 2006, Issue 1. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcomes at > 12 months post term 
measured using validated assessment tools such as BSID and 
classifications of disability, including auditory and visual 
disability. The composite outcome "severe 
neurodevelopmental disability" will be defined as any 1 or 
combination of the following: non‐ambulant cerebral palsy, 
developmental delay (DQ < 70), auditory and visual 
impairment 
No included trials 
"It is unclear whether undertaking a pre‐discharge car seat 
challenge is beneficial or harmful to preterm infants. Further 
studies are needed to determine whether the car seat challenge 
accurately predicts the risk of clinically significant adverse events 
in preterm infants travelling in car seats. If this is shown to be the 
case then a large randomised controlled trial is needed to provide 
an unbiased assessment of its utility in pre‐discharge 
assessment." 
Quigley M, McGuire W. Formula 
versus donor breast milk for feeding 
preterm or low birth weight infants. 
Cochrane Database of Systematic 
Reviews 2014, Issue 4. 
Primary outcomes pre‐specified include: 
 Death or severe neurodevelopmental disability defined as any 
1 or combination of the following: non‐ambulant cerebral 
palsy, developmental delay (DQ < 70), auditory and visual 
impairment. We analysed each component individually as 
well as part of the composite outcome 
"In preterm and low birth weight infants, feeding with formula 
compared with donor breast milk results in a higher rate of short‐
term growth but also a higher risk of developing necrotising 
enterocolitis. Limited data on the comparison of feeding with 
formula versus nutrient‐fortified donor breast milk are available. 
This limits the applicability of the findings of this review as 
nutrient fortification of breast milk is now a common practice in 
neonatal care. Future trials may compare growth, development 
and adverse outcomes in infants who receive formula milk versus 
nutrient‐fortified donor breast milk given as a supplement to 
maternal expressed breast milk or as a sole diet." 
Qureshi MJ, Kumar M. D‐
Penicillamine for preventing 
retinopathy of prematurity in 
Secondary outcomes pre‐specified include: "Administration of prophylactic D‐penicillamine in preterm 
infants does not prevent acute or severe ROP, death or 




preterm infants. Cochrane Database 
of Systematic Reviews 2013, Issue 
9. 
 Abnormal neurodevelopment defined as abnormal 
neurological examination, epilepsy, cerebral palsy, or DQ < 
70 diagnosed at 1 year of corrected age or older 
recommended for the prevention of ROP based on the available 
evidence." 
Rojas‐Reyes MX, Morley CJ, Soll 
R. Prophylactic versus selective use 
of surfactant in preventing 
morbidity and mortality in preterm 
infants. Cochrane Database of 
Systematic Reviews 2012, Issue 3. 
Secondary outcomes pre‐specified include: 
 Cerebral palsy 
 Neurodevelopmental outcome at approximately 2 years' 
corrected age (acceptable range 18 months to 28 months) 
including cerebral palsy, significant mental developmental 
delay (BSID < 70), legal blindness (< 20/200 VA), and 
hearing deficit (aided or < 60 dB on audiometric testing). The 
composite outcome "neurodevelopmental impairment" was 
defined as having any one of the aforementioned deficits 
(Review notes that 2 RCTs have reported on cerebral palsy, but not in 
the 'acceptable range' pre‐specified; therefore no results were 
reported: 
"Neurodevelopmental outcome: For this outcome, we considered any 
trial reporting at approximately 2 years' corrected age (acceptable 
range 18 months to 28 months) any of the following entities cerebral 
palsy, intellectual disability or developmental delay (Bayley Scales of 
Infant Development Mental Developmental Index < 70), legal 
blindness (< 20/200 visual acuity), and hearing deficit (aided or < 60 
dB on audiometric testing). The composite outcome 
"neurodevelopmental impairment" would be defined as having any one 
of the aforementioned deficits. Two trials Sinkin 1998; Vaucher 1993 
performed a follow‐up study including infants recruited in the Kendig 
1991 and Merritt 1991 trials respectively. Sinkin 1998 reported 
cerebral palsy but in 148 children at school age, no data were 
available from ages between 18 and 28 months. Vaucher 1993 
reported on cerebral palsy and developmental delay in 145 survivors 
at 12 months' corrected age. No one study reporting 
neurodevelopmental outcomes at 24 months' corrected age was 
found") 
"Although the early trials of prophylactic surfactant 
administration to infants judged to be at risk of developing RDS 
compared with selective use of surfactant in infants with 
established RDS demonstrated a decreased risk of air leak and 
mortality, recent large trials that reflect current practice 
(including greater utilization of maternal steroids and routine post 
delivery stabilization on CPAP) do not support these differences 
and demonstrate less risk of chronic lung disease or death when 
using early stabilization on CPAP with selective surfactant 




Rojas‐Reyes MX, Orrego‐Rojas PA. 
Rescue high‐frequency jet 
ventilation versus conventional 
ventilation for severe pulmonary 
dysfunction in preterm infants. 
Cochrane Database of Systematic 
Reviews 2015, Issue 10. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopmental outcome (measured at 
approximately 2 years' corrected age; acceptable range 18 
months to 28 months) including cerebral palsy, delayed 
neurodevelopment (BSID MDI < 70), legal blindness (< 
20/200 VA), and hearing deficit (aided or < 60 dB on 
audiometric testing); impairment defined as including any of 
the aforementioned deficits 
"Study authors reported no significant differences in overall 
mortality between rescue high‐frequency jet ventilation and 
conventional ventilation and presented highly imprecise results 
for important adverse effects such as intraventricular 
haemorrhage, new air leaks, airway obstruction and necrotising 
tracheobronchitis. The overall quality of evidence is affected by 
limitations in trial design and by imprecision due to the small 
number of infants in the included study. Existing evidence does 
not support the use of high‐frequency jet ventilation as rescue 
therapy in preterm infants. Studies that target populations at 
greatest risk and that have sufficient power to assess important 
outcomes are needed. These trials should incorporate long‐term 
pulmonary and neurodevelopmental outcomes." 
Romantsik O, Bruschettini M, 
Zappettini S, Ramenghi LA, Calevo 
MG. Heparin for the treatment of 
thrombosis in neonates. Cochrane 
Database of Systematic Reviews 
2016, Issue 11. 
Secondary outcomes pre‐specified include: 
 Major neurodevelopmental disability, that is, (1) cerebral 
palsy on physician assessment (yes/no); (2) developmental 
delay or intellectual impairment: BSID or GMDS assessment 
> 2 SD below the mean, or intellectual impairment (IQ > 2 
SD below the mean); neuromotor development (BSID PDI) 
assessed in survivors; mental development (BSID MDI) 
assessed in survivors; (3) blindness vision (< 6/60 in both 
eyes); or (4) sensorineural deafness requiring amplification. 
We will report these components of this long‐term outcome 
for all trials that have assessed children after 18 months' 
chronological age. We will perform separate analyses for 
children aged 18 to 24 months and for those aged 3 to 5 years 
"We found no studies that met our inclusion criteria and no 
evidence from randomized controlled trials to recommend or 
refute the use of heparin for treatment of neonates with 
thrombosis." 
Sankar MJ, Sankar J, Mehta M, 
Bhat V, Srinivasan R. Anti‐vascular 
endothelial growth factor (VEGF) 
drugs for treatment of retinopathy of 
prematurity. Cochrane Database of 
Systematic Reviews 2016, Issue 2. 
Secondary outcomes pre‐specified include: 
 Adverse neurodevelopmental outcomes at 18 months to 24 
months' corrected age: 
o Cerebral palsy and/or 
o Moderate to severe developmental delay as assessed 
on performance in formal neurodevelopmental 
testing such as the BSID scale 
"Implications for practice: Intravitreal bevacizumab reduces the 
risk of refractive errors during childhood when used as 
monotherapy while intravitreal pegaptanib reduces the risk of 
retinal detachment when used in conjunction with laser therapy in 
infants with type 1 ROP. Quality of evidence was, however, low 
for both the outcomes because of the risk of detection and other 




the long‐term systemic adverse effects of the drugs are not 
known. The insufficient data precludes strong conclusions 
favouring routine use of intravitreal anti‐VEGF agents in preterm 
infants with type 1 ROP. Implications for research: Further 
studies are needed to evaluate the effect of anti‐VEGF agents on 
structural and functional outcomes in childhood and delayed 
systemic adverse effects such as myocardial dysfunction and 
adverse neurodevelopmental outcomes." 
Schulzke SM, Kaempfen S, 
Trachsel D, Patole SK. Physical 
activity programs for promoting 
bone mineralization and growth in 
preterm infants. Cochrane Database 
of Systematic Reviews 2014, Issue 
4. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental abnormalities at 18 to 24 months' 
corrected age or later: 
o Cerebral palsy 
o Developmental delay (assessed by standardised and 
validated test, e.g. GMDS or BSID test, with 
abnormality defined as > 2 SD below the mean) 
o Intellectual impairment (IQ > 2 SD below the mean 
as assessed by a standardised and validated test) 
o Blindness (vision < 6/60 in both eyes) 
o Sensorineural deafness requiring amplification 
"Some evidence suggests that physical activity programs might 
promote short‐term weight gain and bone mineralization in 
preterm infants. Data are inadequate to allow assessment of harm 
or long‐term effects. Current evidence does not support the 
routine use of physical activity programs in preterm infants. 
Further trials incorporating infants with a high baseline risk of 
osteopenia are required. These trials should address adverse 
events, long‐term outcomes, and the effects of nutritional intake 
(calories, protein, calcium, phosphorus)." 
Shah PS, Ohlsson A. Alpha‐1 
proteinase inhibitor (a1PI) for 
preventing chronic lung disease in 
preterm infants. Cochrane Database 
of Systematic Reviews 2001, Issue 
3. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopmental outcome (frequency 
of cerebral palsy and/or mental retardation, legal blindness, 
and /or deafness) 
(Review reports on 'Developmental delay amongst infants assessed' for 
1 RCT (83 infants); however it was not clear whether this included 
cerebral palsy (in review or RCT (published as abstract only)) 
"Prophylactic administration of a1PI did not reduce the risk of 
CLD at 36 weeks or long term adverse developmental outcomes 
in preterm neonates." 
Shah PS, Kaufman DA. 
Antistaphylococcal 
immunoglobulins to prevent 
staphylococcal infection in very low 
birth weight infants. Cochrane 
Database of Systematic Reviews 
2009, Issue 2. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental disability at 18 to 24 months (including 
cerebral palsy, cognitive impairment, deafness, and 
blindness) 
"Antistaphylococcal immunoglobulins (INH A‐21 and Altastaph) 
are not recommended for prevention of staphylococcal infections 
in preterm or VLBW neonates. Further research to investigate the 




Shah SS, Ohlsson A, Halliday HL, 
Shah VS. Inhaled versus systemic 
corticosteroids for preventing 
chronic lung disease in ventilated 
very low birth weight preterm 
neonates. Cochrane Database of 
Systematic Reviews 2012, Issue 5. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopmental outcome: 
Neurodevelopmental impairment was defined as presence 
of cerebral palsy and/or mental retardation (BSID MDI < 70) 
and/or legal blindness (< 20/200 VA) and/or deafness (aided 
or < 60 dB on audiometric testing) assessed at 18 to 24 
months 
"This review found no evidence that early inhaled steroids confer 
important advantages over systemic steroids in the management 
of ventilator dependent preterm infants. Neither inhaled steroids 
nor systemic steroids can be recommended as a part of standard 
practice for ventilated preterm infants. Because they might have 
fewer adverse effects than systemic steroids, further randomised 
controlled trials of inhaled steroids are needed that address 
risk/benefit ratio of different delivery techniques, dosing 
schedules and long‐term effects, with particular attention to 
neurodevelopmental outcome." 
Shah SS, Ohlsson A, Halliday HL, 
Shah VS. Inhaled versus systemic 
corticosteroids for the treatment of 
chronic lung disease in ventilated 
very low birth weight preterm 
infants. Cochrane Database of 
Systematic Reviews 2012, Issue 5. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopmental outcome: 
Neurodevelopmental impairment is defined as presence 
of cerebral palsy and/or mental retardation (BSID MDI < 70) 
and/or legal blindness (< 20/200 VA) and/or deafness (aided 
or < 60 dB on audiometric testing) assessed at 18 to 24 
months 
"This review found no evidence that inhaled corticosteroids 
confer net advantages over systemic corticosteroids in the 
management of ventilator dependent preterm infants. Neither 
inhaled steroids nor systemic steroids can be recommended as 
standard treatment for ventilated preterm infants. There was no 
evidence of difference in effectiveness or side‐effect profiles for 
inhaled versus systemic steroids. A better delivery system 
guaranteeing selective delivery of inhaled steroids to the alveoli 
might result in beneficial clinical effects without increasing side‐
effects. To resolve this issue, studies are needed to identify the 
risk/benefit ratio of different delivery techniques and dosing 
schedules for the administration of these medications. The long‐
term effects of inhaled steroids, with particular attention to 
neurodevelopmental outcome, should be addressed in future 
studies." 
Shah PS, Ohlsson A. Sildenafil for 
pulmonary hypertension in 
neonates. Cochrane Database of 
Systematic Reviews 2011, Issue 8. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental disability at 18 to 24 months 
(including cerebral palsy, cognitive impairment, deafness, 
and blindness) 
"Sildenafil in the treatment of PPHN has significant potential 
especially in resource limited settings. However, a large scale 
randomised trial comparing sildenafil with the currently used 
vasodilator, inhaled nitric oxide, is needed to assess efficacy and 
safety." 
Sinclair JC, Bottino M, Cowett RM. 
Interventions for prevention of 
neonatal hyperglycemia in very low 
Primary outcomes pre‐specified include: 
 Neurodevelopmental impairment defined as presence of 1 or 
more of the following: cerebral palsy, MDI or PDI < 70, 
"Glucose infusion rate: There is insufficient evidence from trials 
comparing lower with higher glucose infusion rates to inform 




birth weight infants. Cochrane 
Database of Systematic Reviews 
2011, Issue 10. 
blindness or deafness assessed between 18 and 24 months' 
post‐menstrual age or at latest assessment up to 24 months' 
corrected age 
clinical outcomes including death, major morbidities and adverse 
neurodevelopment. Insulin infusion: The evidence reviewed does 
not support the routine use of insulin infusions to prevent 
hyperglycemia in VLBW neonates. Further randomized trials of 
insulin infusion may be justified. They should enrol extremely 
low birth weight neonates at very high risk for hyperglycemia 
and neonatal death. They might use real time glucose monitors if 
these are validated for clinical use. Refinement of algorithms to 
guide insulin infusion is needed to enable tight control of glucose 
concentrations within the target range." 
Singh N, Halliday HL, Stevens TP, 
Suresh G, Soll R, Rojas‐Reyes MX. 
Comparison of animal‐derived 
surfactants for the prevention and 
treatment of respiratory distress 
syndrome in preterm infants. 
Cochrane Database of Systematic 
Reviews 2015, Issue 12. 
Secondary outcomes pre‐specified include: 
 Cerebral palsy at approximately 2 years' corrected age (as 
defined by the study authors) 
 Neurodevelopmental outcome at approximately 2 years' 
corrected age (acceptable range 18 months to 28 months) 
including cerebral palsy, delayed neurodevelopment (BSID 
MDI < 70), legal blindness (< 20/200 VA), and hearing 
deficit (aided or < 60 dB on audiometric testing). The 
composite outcome 'neurodevelopmental impairment' was 
defined as having any 1 of the aforementioned deficits 
"Significant differences in clinical outcome were noted in the 
comparison trials of modified minced lung surfactant extract 
(beractant) compared with porcine minced lung surfactant extract 
(poractant alfa) including a significant increase in the risk of 
mortality prior to discharge, death or oxygen requirement at 36 
weeks' postmenstrual age, PDA requiring treatment and 
"receiving > 1 dose of surfactant" in infants treated with modified 
bovine minced lung surfactant extract compared with porcine 
minced lung surfactant extract. The difference in these outcomes 
was limited to studies using a higher initial dose of porcine 
minced lung surfactant extract. It is uncertain whether the 
observed differences are from differences in dose or from source 
of extraction (porcine vs. bovine) because of the lack of dose‐
equivalent comparison groups with appropriate sample size. No 
differences in clinical outcomes were observed in comparative 
trials between bovine lung lavage surfactant and modified bovine 
minced lung surfactants." 
Soll R, Özek E. Prophylactic animal 
derived surfactant extract for 
preventing morbidity and mortality 
in preterm infants. Cochrane 
Database of Systematic Reviews 
1997, Issue 4. 
Secondary outcomes pre‐specified include: 
 Cerebral palsy 
 Neurodevelopmental outcome at approximately 2 years' 
corrected age (acceptable range 18 months to 28 months) 
including cerebral palsy, mental retardation (BSID MDI < 
70), legal blindness (< 20/200 VA), and hearing deficit (aided 
"Prophylactic intratracheal administration of animal derived 
surfactant extract to infants judged to be at risk of developing 
respiratory distress syndrome has been demonstrated to improve 
clinical outcome. Infants who receive prophylactic animal 




or < 60 dB on audiometric testing). The composite outcome 
"neurodevelopmental impairment" will be defined as having 
any 1 of the aforementioned deficits 
a decreased risk of PIE, a decreased risk of mortality, and a 
decreased risk of BPD or death." 
Stevens TP, Blennow M, Myers EH, 
Soll R. Early surfactant 
administration with brief ventilation 
vs. selective surfactant and 
continued mechanical ventilation 
for preterm infants with or at risk 
for respiratory distress syndrome. 
Cochrane Database of Systematic 
Reviews 2007, Issue 4. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcome at hospital discharge and at a 
later time point (> 1 year post‐conceptional age). 
Neurodevelopmental impairment is defined as the presence 
of cerebral palsy and/or mental retardation (BSID MDI < 70) 
and/or legal blindness (< 20/200 VA) and/or deafness (aided 
or < 60 dB on audiometric testing) 
"Early surfactant replacement therapy with extubation to NCPAP 
compared with later selective surfactant replacement and 
continued mechanical ventilation with extubation from low 
ventilator support is associated with less need mechanical 
ventilation, lower incidence of BPD and fewer air leak 
syndromes. A lower treatment threshold (FIO2 < 0.45) confers 
greater advantage in reducing the incidences of airleak 
syndromes and BPD; moreover a higher treatment threshold 
(FIO2 at study > 0.45) was associated with increased risk of 
PDA. These data suggest that treatment with surfactant by 
transient intubation using a low treatment threshold (FIO2 < 
0.45) is preferable to later, selective surfactant therapy by 
transient intubation using a higher threshold for study entry 
(FIO2 > 0.45) or at the time of respiratory failure and initiation of 
mechanical ventilation." 
Stewart A, Inglis GDT, Jardine LA, 
Koorts P, Davies MW. Prophylactic 
antibiotics to reduce morbidity and 
mortality in newborn infants with 
intercostal catheters. Cochrane 
Database of Systematic Reviews 
2012, Issue 4. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcome (cerebral palsy, sensorineural 
hearing loss, visual impairment, or developmental delay) at 1 
year, 18 months, 2 years, or 5 years 
No included trials 
"There are no data from randomised trials to either support or 
refute the use of antibiotic prophylaxis for intercostal catheter 
insertion in neonates. Any randomised controlled trials of 
antibiotic prophylaxis would need to account for the fact that 
neonates who require insertion of an intercostal catheter may 
already be receiving antibiotics for other indications." 
Subramaniam P, Ho JJ, Davis PG. 
Prophylactic nasal continuous 
positive airway pressure for 
preventing morbidity and mortality 
in very preterm infants. Cochrane 
Database of Systematic Reviews 
2016, Issue 6. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental status at follow‐up: neurodevelopment 
measured on a validated scale that measures cognitive, motor, 
behavioural function, or blindness, deafness, or cerebral 
palsy at about 2 years of age 
"There is insufficient evidence to evaluate prophylactic CPAP 
compared to oxygen therapy and other supportive care. However 
when compared to mechanical ventilation prophylactic nasal 
CPAP in very preterm infants reduces the need for mechanical 
ventilation and surfactant and also reduces the incidence of BPD 




Tan K, Lai NM, Sharma A. 
Surfactant for bacterial pneumonia 
in late preterm and term infants. 
Cochrane Database of Systematic 
Reviews 2012, Issue 2. 
Secondary outcomes pre‐specified include: 
 Long‐term neurological outcomes (cerebral palsy, 
development measured by BSID or GMDS, intellectual 
function measured by IQ score, and presence of visual or 
hearing impairments) at 18 months of age or greater 
No included trials 
"There is no evidence from randomised controlled trials (RCTs) 
to support or refute the efficacy of surfactant in near‐term and 
term infants with proven or suspected bacterial pneumonia. RCTs 
are still required to answer this question." 
Thayyil S, Milligan D. Single 
versus double volume exchange 
transfusion in jaundiced newborn 
infants. Cochrane Database of 
Systematic Reviews 2006, Issue 4. 
Primary outcomes pre‐specified include: 
 Neurological deficits consistent with kernicterus at 2 years of 
age including athetoid cerebral palsy, impaired upward gaze 
and deafness, AN/AD, and subtle BIND (Shapiro 2005) 
Secondary outcomes pre‐specified include: 
 Neurological deficits or neurodisability defined as any of 
deafness, cerebral palsy, or cognitive delay (score > 2 SD 
below the mean for any recognised test for 
neurodevelopment, e.g. BSID) 
"There was insufficient evidence to support or refute the use of 
single volume exchange transfusion as opposed to double volume 
exchange transfusion in jaundiced newborns. A change from the 
current practice of double volume exchange transfusions for 
severe jaundice in newborns infant, cannot be recommended on 
current evidence." 
Vasudevan C, Oddie SJ, McGuire 
W. Early removal versus expectant 
management of central venous 
catheters in neonates with 
bloodstream infection. Cochrane 
Database of Systematic Reviews 
2016, Issue 4. 
Primary outcomes pre‐specified include: 
 Neurodevelopmental outcomes assessed after 12 months' 
post‐menstrual age using validated tools: neurological 
evaluations, developmental scores, and classifications of 
disability, including auditory and visual disability. We will 
define neurodevelopmental impairment as the presence of 1 
or more of the following: non‐ambulant cerebral palsy, 
developmental delay (DQ > 2 SD below population mean), 
blindness (VA < 6/60), or deafness (any hearing impairment 
requiring or unimproved by amplification) 
No included trials 
"There are no trial data to guide practice regarding early removal 
versus expectant management of central venous catheters in 
newborn infants with bloodstream infections. A simple and 
pragmatic randomised controlled trial is needed to resolve the 
uncertainty about optimal management in this common and 
important clinical scenario." 
Verner AM, McGuire W, Craig JS. 
Effect of taurine supplementation on 
growth and development in preterm 
or low birth weight infants. 
Cochrane Database of Systematic 
Reviews 2007, Issue 4. 
Secondary outcomes pre‐specified include: 
 Development 
o Neurodevelopmental outcomes at ≥ 12 months of 
age (corrected for preterm birth) measured using 
validated assessment tools 
o Severe neurodevelopmental disability defined as any 
1 or combination of the following: non‐
ambulant cerebral palsy, developmental delay (DQ < 
70), auditory and visual impairment 
"Despite that lack of evidence of benefit from randomised 
controlled trials, it is likely that taurine will continue to be added 
to formula milks and parenteral nutrition solutions used for 
feeding preterm and low birth weight infants given the putative 
association of taurine deficiency with various adverse outcomes. 
Further randomised controlled trials of taurine supplementation 
versus no supplementation in preterm or low birth weight infants 




o Cognitive and educational outcomes at > 5 years old: 
IQ and/or indices of educational achievement 
measured using a validated assessment tool 
(including school examination results) 
issues related to dose or duration of supplementation in specific 
subgroups of infants that merit further research." 
Watson J, McGuire W. Responsive 
versus scheduled feeding for 
preterm infants. Cochrane Database 
of Systematic Reviews 2016, Issue 
8. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcomes at > 12 months' corrected age 
measured using validated assessment tools such as BSID and 
classifications of disability including auditory and visual 
disability. We defined the composite outcome 'severe 
neurodevelopmental disability' as any 1 or combination of the 
following: non‐ambulant cerebral palsy, developmental delay 
(DQ < 70), auditory and visual impairment 
"Overall, the data do not provide strong or consistent evidence 
that responsive feeding affects important outcomes for preterm 
infants or their families. Some (low quality) evidence exists that 
preterm infants fed in response to feeding and satiation cues 
achieve full oral feeding earlier than infants fed prescribed 
volumes at scheduled intervals. This finding should be 
interpreted cautiously because of methodological weaknesses in 
the included trials. A large RCT would be needed to confirm this 
finding and to determine if responsive feeding of preterm infants 
affects other important outcomes." 
Wilkinson D, Andersen C, 
O'Donnell CPF, De Paoli AG, 
Manley BJ. High flow nasal cannula 
for respiratory support in preterm 
infants. Cochrane Database of 
Systematic Reviews 2016, Issue 2. 
Secondary outcomes pre‐specified include: 
 Long‐term neurodevelopmental outcome (rates of cerebral 
palsy on physician assessment, developmental delay, i.e. IQ 2 
SD < mean on validated assessment tools such as BSID 
MDI), blindness, hearing impairment requiring amplification 
"HFNC has similar rates of efficacy to other forms of non‐
invasive respiratory support in preterm infants for preventing 
treatment failure, death and CLD. Most evidence is available for 
the use of HFNC as post‐extubation support. Following 
extubation, HFNC is associated with less nasal trauma, and may 
be associated with reduced pneumothorax compared with nasal 
CPAP. Further adequately powered randomised controlled trials 
should be undertaken in preterm infants comparing HFNC with 
other forms of primary non‐invasive support after birth and for 
weaning from non‐invasive support. Further evidence is also 
required for evaluating the safety and efficacy of HFNC in 
extremely preterm and mildly preterm subgroups, and for 
comparing different HFNC devices." 
Wong V, Cheuk DKL, Chu V. 
Acupuncture for hypoxic ischemic 
encephalopathy in neonates. 
Cochrane Database of Systematic 
Reviews 2013, Issue 1. 
Primary outcomes pre‐specified include: 
 Long‐term (> 12 months) major neurodevelopmental 
disability such as cerebral palsy, developmental delay (BSID 
or GMDS assessment > 2 SD below the mean) or intellectual 
impairment (IQ > 2 SD below mean), blindness (vision < 
No included trials 
"The rationale for acupuncture in neonates with HIE is unclear 
and the evidence from randomized controlled trial is lacking. 
Therefore, we do not recommend acupuncture for the treatment 
of HIE in neonates. High quality randomized controlled trials on 




6/60 in both eyes), sensorineural deafness requiring 
amplification, or any combination of these disabilities 
Woodgate PG, Flenady V, Steer PA. 
Intramuscular penicillin for the 
prevention of early onset group B 
streptococcal infection in newborn 
infants. Cochrane Database of 
Systematic Reviews 2004, Issue 2. 
Secondary outcomes pre‐specified include: 
 Neurodevelopmental outcome (cerebral palsy, sensorineural 
hearing loss, visual impairment, developmental delay) 
"This review does not support the routine use of intramuscular 
penicillin to prevent EOGBSD in newborn infants. There is a 
discrepancy between this finding and the results of a number of 
larger non‐randomised trials. Explanations for this are proposed. 
There is a need for this intervention to be tested as a component 
of the existing prevention strategies in widespread use." 
Young L, Embleton ND, 
McCormick FM, McGuire W. 
Multinutrient fortification of human 
breast milk for preterm infants 
following hospital discharge. 
Cochrane Database of Systematic 
Reviews 2013, Issue 2. 
Primary outcomes pre‐specified include: 
 Development: 
o Neurodevelopmental outcomes assessed using 
validated tools at > 12 months' corrected age and 
classifications of disability, including non‐
ambulant cerebral palsy, developmental delay, 
auditory and visual impairment 
o Cognitive and educational outcomes at > 5 years: IQ 
and/or indices of educational achievement measured 
using a validated tool (including school examination 
results) 
"The limited available data do not provide convincing evidence 
that feeding preterm infants with multinutrient fortified breast 
milk compared with unfortified breast milk following hospital 
discharge affects important outcomes including growth rates 
during infancy. There are no data on long‐term growth. Since 
fortifying breast milk for infants fed directly from the breast is 
logistically difficult and has the potential to interfere with breast 
feeding, it is important to determine if mothers would support 
further trials of this intervention." 
Young L, Morgan J, McCormick 
FM, McGuire W. Nutrient‐enriched 
formula versus standard term 
formula for preterm infants 
following hospital discharge. 
Cochrane Database of Systematic 
Reviews 2012, Issue 3. 
Primary outcomes pre‐specified include: 
 Development: 
o Neurodevelopmental outcomes assessed using 
validated tools at > 12 months' corrected age and 
classifications of disability, including non‐ambulant 
cerebral palsy, developmental delay, auditory and 
visual impairment 
o Cognitive and educational outcomes at > 5 years: IQ 
and/or indices of educational achievement measured 
using a validated tool (including school examination 
results) 
"Current recommendations to prescribe "post‐discharge formula" 
for preterm infants following hospital discharge are not supported 
by the available evidence. Some limited evidence exists that 
feeding preterm infants following hospital discharge with 
"preterm formula" (which is generally only available for in‐
hospital use) may increase growth rates up to 18 months 
corrected age." 
Ziino AJA, Davies MW, Davis PG. 
Epinephrine for the resuscitation of 
apparently stillborn or extremely 
Primary outcomes pre‐specified include: 
 Severe disability at follow‐up at 12 months, 24 months, and 5 
years on, defined as any of blindness, deafness, cerebral 
No included trials 
"No randomised, controlled trials evaluating the administration of 




bradycardic newborn infants. 
Cochrane Database of Systematic 
Reviews 2002, Issue 3. 
palsy, or cognitive delay (score > 2 SD below the mean for a 
recognised psychometric test, e.g. BSID) 
Secondary outcomes pre‐specified include: 
 Cerebral palsy at 12 and 24 months, and at 5 years 
newborn infant were found. Similarly, no randomised, controlled 
trials that addressed the issues of optimum dosage and route of 
administration of epinephrine were found. Current 
recommendations for the use of epinephrine in newborn infants 
are based only on evidence derived from animal models and the 
human adult literature. Randomised trials in neonates are 
urgently required to determine the role of epinephrine in this 
population." 
 
Abbreviations: AN/AD: Auditory Neuropathy/Auditory Dyssynchrony; anti‐VEGF: anti‐vascular endothelial growth factor; BIND: bilirubin‐induced neurological dysfunction; BP: 
blood pressure; BPD: bronchopulmonary dysplasia; BSID: Bayley Scales of Infant Development; CDP: continuous distending pressure; CGA: corrected gestational age; CLD: chronic 
lung disease; CO2: carbon dioxide; CPAP: continuous positive airway pressure; CRBSI: catheter‐related bloodstream infection; DQ: developmental quotient; ELBW: extremely low 
birthweight; EOGBSD: early‐onset group B streptococcus disease; ETT: endotracheal tube; FIO2: fraction of inspired oxygen; GMDS: Griffith Mental Development Scales; GMFCS: 
Gross Motor Function Classification System; HFNC: high‐flow nasal cannula; HIE: hypoxic‐ischaemic encephalopathy; iNO: inhaled nitric oxide; IPPV: intermittent positive‐pressure 
ventilation; IQ; intelligence quotient; IVH: intraventricular haemorrhage; LMA: laryngeal mask airway; MDI: Mental Development Index; Movement ABC: Movement Assessment 
Battery for Children; MV mechanical ventilation; NCPAP: nasal continuous positive airway pressure; NEC: necrotising enterocolitis; PDA: patent ductus arteriosus; PDI: Psychomotor 
Development Index; PET: partial exchange transfusion; PIE: pulmonary interstitial emphysema; PPHN: persistent pulmonary hypertension of the newborn; PPV: positive‐pressure 
ventilation; RBCs: red blood cells; RCT: randomised controlled trial; RDS: respiratory distress syndrome; rhAPC: recombinant human activated protein C; ROP: retinopathy of 




Appendix 4: Supporting information for Chapter 4 publication 
 
Table S1: Birth state/territory cerebral palsy (CP) register status and 2-year outcomes 









OR (95% CI) p 
Birth state/territory CP register status 
Recently established 14 20 1 — 
Long-standing  21 9 3.33 (1.17–9.49) 0.02 
2-year paediatric assessment 
CP assessment 
Probably yes 5  11  1 — 
Definitely yes 30  18 3.67 (1.12–12.01) 0.03 
CP severity 
Mild 15 19 1 0.13a 
Moderate 14 9 1.97 (0.68–5.69) 0.21 
Severe 6  1 7.60 (0.82–70.16) 0.07 
CP type 
Monoplegia 1 2 1 0.44a 
Hemiplegia 10 4  5.00 (0.35–71.90) 0.24 
Diplegia 12 12  2.00 (0.16–25.38) 0.59 
Quadriplegia 8 3  5.33 (0.34–82.83) 0.23 
Ataxic 2 4 1.00 (0.05–18.92) 1.00 
Dystonic 1 1 2.00 (0.05–78.25) 0.71 
Mixed 1 3 0.67 (0.03–18.06) 0.81 
Walking freely 
Yes 13 18 1 — 
No 22 11 2.77 (1.02–7.55) 0.047 
Decreased limb tone 
No 31 23 1  
Yes 3 5 0.45 (0.10–2.06) 0.30 
Increased limb tone 
No 4 5 1 — 
Yes 30 23 1.63 (0.39–6.78) 0.50 
Ankle clonus, more than five beats 
No 27 26 1 — 
Yes 8 2 3.85 (0.74–19.93) 0.11 
Positive Babinski response 
No 12 13 1 — 
Yes 23 15 1.66 (0.60–4.64) 0.33 
Dorsiflexion of ankle limited 
No 10 14 1 — 
Yes 24 14 2.40 (0.84–6.87) 0.10 
Hip abduction limited 
No 19 20 1 — 
Yes 16 7 2.41 (0.82–7.06) 0.11 
Hip extension limited 
No 24 20 1 — 
Yes 11 7 1.31 (0.43–4.03) 0.64 
2-year psychological assessment 












2-year parental questionnaire 
Received care from physiotherapist 
No 4 7 1 — 
Yes 28 22 2.23 (0.58–8.62) 0.25 
Received care from occupational therapist 
No 13 13 1 — 
Yes 20 16 1.25 (0.45–3.51) 0.67 
Difficulty walking 
No 7 11 1 — 
Yes 27 18 2.36 (0.78–7.09) 0.13 
Difficulty sitting 
No 19 23 1 — 
Yes 15 6 3.03 (0.97–9.41) 0.06 
Difficulty using hands 
No 14 22 1 — 
Yes 20 7 4.49 (1.48–13.61) 0.008 
Difficulty with head control 
No 28 28 1 — 
Yes 5 1 5.00 (0.55–45.68) 0.15 
Odds ratios (ORs) calculated as the odds of a diagnosis of cerebral palsy (CP) on the 
Australian Cerebral Palsy Register (ACPR) for the given level of the characteristic over 
odds of CP diagnosis on the ACPR in the reference level. aGlobal p-value against the null 
hypothesis that the odds of being detected on the ACPR is the same across all levels of the 
characteristic. bMissing data for the Bayley Scales of Infant Development (2nd edition) 
Psychomotor Developmental Index (BSID-II PDI) because child considered untestable 
owing to severe disability (n=3) or behavioural problem (n=1), distance/unavailability of 
assessment (n=1), and parental refusal (n=3). cMissing data for BSID-II PDI because child 
considered untestable owing to severe disability (n=3) and distance/unavailability of 
assessment (n=2). dCorresponds to the relative change in odds associated with a one-unit 
increase in the PDI corrected score. ACTOMgSO4, Australasian Collaborative Trial of 






Table S2: Birth state/territory cerebral palsy (CP) register status and 2-year outcomes 









OR (95% CI) p 
Birth state/territory CP register status 
Recently established 4 426 1 — 
Long-standing 16 403 4.23 (1.41–12.73) 0.01 
2-year paediatric assessment 
CP assessment 
Probably no 7 69 1 — 
Definitely no 13 759 0.17 (0.07–0.44) <0.001 
Walking freely 
Yes 17 817 1 — 
No 3 12 12.02 (3.05–47.38) <0.001 
Decreased limb tone 
No 15 786 1  
Yes 5 34 7.71 (2.63–22.55) <0.001 
Increased limb tone 
No 18 792 1 — 
Yes 2 28 3.14 (0.69–14.28) 0.14 
Ankle clonus, more than five beats 
No 20 817 — — 
Yes 0 0 — — 
Positive Babinski response 
No 20 807 1 — 
Yes 0 11 — 1.00a 
Dorsiflexion of ankle limited 
No 17 803 1 — 
Yes 3 15 9.45 (2.47–36.11) 0.001 
Hip abduction limited 
No 19 808 1 — 
Yes 1 8 5.32 (0.63–44.63) 0.12 
Hip extension limited 
No 20 815 1 — 
Yes 0 1 — 1.00a 
2-year psychological assessment 







0.96 (0.93–0.99)d 0.003 
2-year parental questionnaire 
Received care from physiotherapist 
No 10 635 1 — 
Yes 8 158 3.22 (1.25–8.27) 0.015 
Received care from occupational therapist 
No 14 733 1 — 
Yes 4 64 3.27 (1.04–10.25) 0.04 
Difficulty walking 
No 14 782 1 — 
Yes 4 30 7.45 (2.31–24.03) 0.001 
Difficulty sitting 
No 19 808 1 — 
Yes 0 4 — 1.00a 




No 17 806 1 — 
Yes 2 6 15.80 (2.98–83.87) 0.001 
Difficulty with head control 
No 19 809 1 — 
Yes 0 1  1.00a 
Odds ratios (ORs) calculated as odds of CP diagnosis on the Australian Cerebral Palsy 
Register (ACPR)for the given level of the characteristic over odds of CP diagnosis on ACPR 
in the reference level. ap-value from Fisher’s exact test. bMissing data for for the Bayley 
Scales of Infant Development (2nd edition) Psychomotor Developmental Index (BSID-II 
PDI) owing to distance/unavailability of assessment (n=1). cMissing data for BSID-II PDI 
because child considered untestable owing to severe disability (n=3) or behavioural problem 
(n=26), distance/unavailability of assessment (n=39), and parental refusal (n=7). 
dCorresponds to the relative change in odds associated with a one-unit increase in the PDI 
corrected score. ACTOMgSO4, Australasian Collaborative Trial of Magnesium Sulphate; 
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S1 Appendix. Forest plots and funnel plots for comparisons 1-8 
 
Forest plots from randomised controlled trials 
 
 
Figure 1. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.1 Perinatal death 
 
 
Figure 2. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 






Figure 3.1. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 




Figure 3.2. Funnel plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 






Figure 4. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.4 Death > 28 days, before discharge 
 
Figure 5. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.5 Early neonatal death 
 
 
Figure 6. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.6 Late neonatal death 
 
 
Figure 7. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 






Figure 8. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.8 Apgar score < 7 at 5 minutes 
 
 
Figure 9. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.9 Meconium at delivery 
 
 
Figure 10. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 






Figure 11. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.11 Resuscitation in the delivery room 
 
 
Figure 12. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.12 Respiratory distress syndrome 
 
 
Figure 13. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 






Figure 14. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.14 Surfactant 
 
 
Figure 15. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.15 Mechanical ventilation 
*Additional data reported by How 1998: ventilatory support (magnesium sulphate group (84 
babies) median: 2.5 days (interquartile range: 11; range: 0.04 to 81) versus no treatment group (69 
babies) median: 5 days (interquartile range: 7; range 0.5 to 383; “P = not significant”). A further 
trial reported that “The average number of days with the use of the ventilator… were similar in the 




Figure 16. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 






Figure 17. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.17 Oxygen required* 
*Additional data reported by How 1998: oxygen required (magnesium sulphate group (84 babies) 
median: 4 days (interquartile range: 27; range: 0.04 to 95) versus no treatment group (69 babies) 
median: 5.5 days (interquartile range: 15.8; range 0.2 to 383; “P = not significant”) 
 
 
Figure 18. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.18 Chronic lung disease 
 
 
Figure 19. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 






Figure 20. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.20 Pneumothorax 
 
 
Figure 21. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.21 Pulmonary haemorrhage 
 
 
Figure 22. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 






Figure 23. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.23 Sepsis 
 
 
Figure 24. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.24 Hypoglycaemia on neonatal intensive care unit admission 
 
 
Figure 25. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 






Figure 26. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.26 Patent ductus arteriosus 
 
 
Figure 27. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.27 Hypotension 
 
 
Figure 28. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 






Figure 29. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.29 Mean blood pressure < 10th centile in first 24 hours 
 
 
Figure 30. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.30 Superior vena cava flow (< 41 mL/kg/min) in first 24 hours 
 
 
Figure 31 Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.31 Right ventricular output (< 120 mL/kg/min) in first 24 hours 
 
 
Figure 32 Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 






Figure 33 Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.33 Dopamine 
 
 
Figure 34 Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.34 Any inotrope 
 
 
Figure 35 Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.35 Retinopathy of prematurity 
 
 
Figure 36 Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 






Figure 37. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.37 Seizures 
 
 
Figure 38. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 






Figure 39.1. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.39 Intraventricular haemorrhage 
 
Figure 39.2. Funnel plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 







Figure 40. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.40 Intraventricular haemorrhage, grade III/IV 
 
 
Figure 41. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.41 Periventricular leucomalacia 
 
 
Figure 42. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.42 Any white matter injury 
 
 
Figure 43. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 






Figure 44. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.44 Severe white matter injury or death 
 
 
Figure 45. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.45 Persistent parenchymal echogenicity 
 
 
Figure 46. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.46 Echodensity 
 
 
Figure 47. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 






Figure 48. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.48 Ventriculomegaly 
 
 
Figure 49. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 




Figure 50. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 






Figure 51. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.51 Neonatal intensive care unit admission* 
*Two trials reported that “There were no differences between groups in… admissions to the NICU,” 
(Colon 2015) and “The average… newborn intensive care time for infants who did have 
complications were similar in the two groups” (Fox 1993), however did not provide data suitable 
for inclusion in a meta-analysis. 
 
 
Figure 52. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.52 Intensive care unit stay (days)* 
*Two trials reported the data in a format not suitable for meta-analysis, and similarly, did not see 
a clear difference between groups (magnesium sulphate group (620 babies): median: 76 days 
(range: 61 to 94) versus placebo group (615 babies) median: 74 days (range: 59 to 95); P = 0.66 
(Crowther 2003); (magnesium sulphate group (84 babies) median: 29 days (interquartile range: 28; 
range: 2 to 204) versus no treatment group (69 babies) median: 28 days (interquartile range: 22; 
range 2 to 383; “P = not significant”) (How 1998). 
 
 
Figure 53. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 






Figure 54. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.54 Special care baby unit admission > 7 days or death 
 
 
Figure 55. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.55 Special care baby unit admission > 7 days  
 
 
Figure 56. Forest plot of Comparison: 1 Magnesium sulphate versus placebo or no treatment, 
outcome: 1.56 Still in hospital at 6 weeks  
 
 
Figure 57. Forest plot of Comparison: 2 Lower versus higher dose regimens of magnesium 
sulphate, outcome: 2.1 Perinatal death* 
* One trial reported that “The neonatal outcome was similar in both the groups (p=0.911)” 






Figure 58. Forest plot of Comparison: 2 Lower versus higher dose regimens of magnesium 
sulphate, outcome: 2.2 Stillbirth 
 
 
Figure 59. Forest plot of Comparison: 2 Lower versus higher dose regimens of magnesium 






Figure 60. Forest plot of Comparison: 2 Lower versus higher dose regimens of magnesium 
sulphate, outcome: 2.4 Apgar score < 7 at 1 minute 
 
 
Figure 61. Forest plot of Comparison: 2 Lower versus higher dose regimens of magnesium 
sulphate, outcome: 2.5 Apgar score < 7 at 5 minutes 
 
 
Figure 62. Forest plot of Comparison: 2 Lower versus higher dose regimens of magnesium 






Figure 63. Forest plot of Comparison: 2 Lower versus higher dose regimens of magnesium 
sulphate, outcome: 2.7 Respiratory distress syndrome 
 
 
Figure 64. Forest plot of Comparison: 2 Lower versus higher dose regimens of magnesium 
sulphate, outcome: 2.8 Respiratory depression 
 
 
Figure 65. Forest plot of Comparison: 2 Lower versus higher dose regimens of magnesium 
sulphate, outcome: 2.9 Respiratory disorders 
 
 
Figure 66. Forest plot of Comparison: 2 Lower versus higher dose regimens of magnesium 






Figure 67. Forest plot of Comparison: 2 Lower versus higher dose regimens of magnesium 
sulphate, outcome: 2.11 Bradycardia 
 
 
Figure 68. Forest plot of Comparison: 2 Lower versus higher dose regimens of magnesium 
sulphate, outcome: 2.12 Jaundice 
 
 
Figure 69. Forest plot of Comparison: 2 Lower versus higher dose regimens of magnesium 
sulphate, outcome: 2.13 Hypoglycaemia 
 
 
Figure 70. Forest plot of Comparison: 2 Lower versus higher dose regimens of magnesium 






Figure 71. Forest plot of Comparison: 2 Lower versus higher dose regimens of magnesium 
sulphate, outcome: 2.15 Hypotonia 
 
 
Figure 72. Forest plot of Comparison: 2 Lower versus higher dose regimens of magnesium 
sulphate, outcome: 2.16 Requirement for calcium gluconate 
 
 
Figure 73. Forest plot of Comparison: 2 Lower versus higher dose regimens of magnesium 
sulphate, outcome: 2.17 Neonatal intensive care unit admission 
 
 
Figure 74. Forest plot of Comparison: 2 Lower versus higher dose regimens of magnesium 







Figure 75. Forest plot of Comparison: 3 Intramuscular versus intravenous maintenance dose of 
magnesium sulphate, outcome: 3.1 Perinatal death 
 
 
Figure 76. Forest plot of Comparison: 3 Intramuscular versus intravenous maintenance dose of 






Figure 77. Forest plot of Comparison: 3 Intramuscular versus intravenous maintenance dose of 




Figure 78. Forest plot of Comparison: 3 Intramuscular versus intravenous maintenance dose of 
magnesium sulphate, outcome: 3.4 Apgar score < 7 at 1 minute 
 
 
Figure 79. Forest plot of Comparison: 3 Intramuscular versus intravenous maintenance dose of 






Figure 80. Forest plot of Comparison: 3 Intramuscular versus intravenous maintenance dose of 
magnesium sulphate, outcome: 3.6 Respiratory distress syndrome 
 
 
Figure 81. Forest plot of Comparison: 3 Intramuscular versus intravenous maintenance dose of 
magnesium sulphate, outcome: 3.7 Jaundice 
 
 
Figure 82. Forest plot of Comparison: 3 Intramuscular versus intravenous maintenance dose of 






Figure 83. Forest plot of Comparison: 3 Intramuscular versus intravenous maintenance dose of 
magnesium sulphate, outcome: 3.9 Neonatal intensive care unit admission 
 
 
Figure 84. Forest plot of Comparison: 4 Loading dose versus loading and maintenance doses of 
magnesium sulphate, outcome: 4.1 Perinatal death 
 
 
Figure 85. Forest plot of Comparison: 4 Loading dose versus loading and maintenance doses of 
magnesium sulphate, outcome: 4.2 Stillbirth 
 
 
Figure 86. Forest plot of Comparison: 4 Loading dose versus loading and maintenance doses of 






Figure 87. Forest plot of Comparison: 4 Loading dose versus loading and maintenance doses of 
magnesium sulphate, outcome: 4.4 Neonatal death < 7 days 
 
 
Figure 88. Forest plot of Comparison: 4 Loading dose versus loading and maintenance doses of 
magnesium sulphate, outcome: 4.5 Apgar score < 7 at 0 minutes 
 
 
Figure 89. Forest plot of Comparison: 4 Loading dose versus loading and maintenance doses of 
magnesium sulphate, outcome: 4.6 Apgar score < 7 at 1 minute 
 
 
Figure 90. Forest plot of Comparison: 4 Loading dose versus loading and maintenance doses of 
magnesium sulphate, outcome: 4.7 Apgar score < 7 at 5 minutes 
 
 
Figure 91. Forest plot of Comparison: 4 Loading dose versus loading and maintenance doses of 




Figure 92. Forest plot of Comparison: 4 Loading dose versus loading and maintenance doses of 






Figure 93. Forest plot of Comparison: 4 Loading dose versus loading and maintenance doses of 
magnesium sulphate, outcome: 4.10 Neonatal intensive care unit admission for late onset sepsis 
 
 
Figure 94. Forest plot of Comparison: 4 Loading dose versus loading and maintenance doses of 




Figure 95. Forest plot of Comparison: 4 Loading dose versus loading and maintenance doses of 
magnesium sulphate, outcome: 4.12 Neonatal intensive care unit admission for birth asphyxia 
 
 
Figure 96. Forest plot of Comparison: 4 Loading dose versus loading and maintenance doses of 
magnesium sulphate, outcome: 4.13 Neonatal intensive care unit admission  
 
Figure 97. Forest plot of Comparison: 5 Serial intravenous boluses versus continuous 
maintenance infusion of magnesium sulphate, outcome: 5.1 Perinatal death 
 
 
Figure 98. Forest plot of Comparison: 5 Serial intravenous boluses versus continuous 






Figure 99. Forest plot of Comparison: 5 Serial intravenous boluses versus continuous 
maintenance infusion of magnesium sulphate, outcome: 5.3 Neonatal death 
 
 
Figure 100. Forest plot of Comparison: 5 Serial intravenous boluses versus continuous 
maintenance infusion of magnesium sulphate, outcome: 5.4 Intubated at birth 
 
 
Figure 101. Forest plot of Comparison: 5 Serial intravenous boluses versus continuous 
maintenance infusion of magnesium sulphate, outcome: 5.5 Mechanical ventilation 
 
 
Figure 102. Forest plot of Comparison: 5 Serial intravenous boluses versus continuous 




Figure 103. Forest plot of Comparison: 5 Serial intravenous boluses versus continuous 
maintenance infusion of magnesium sulphate, outcome: 5.7 Special care baby unit admission 
 
 
Figure 104. Forest plot of Comparison: 6 Short versus standard maintenance course of 






Figure 105. Forest plot of Comparison: 6 Short versus standard maintenance course of 
magnesium sulphate, outcome: 6.2 Birth asphyxia 
 
 
Figure 106. Forest plot of Comparison: 7 Slower versus standard rate of loading dose of 
magnesium sulphate, outcome: 7.1 Stillbirth 
 
 
Figure 107. Forest plot of Comparison: 8 Weaning versus no weaning of magnesium sulphate, 







S1 Fig. Risk of bias for randomised controlled trials 
Risk of bias summary showing judgements about each risk of bias item for the 40 included 








S1 PRISMA Checklist 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. 
 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both. 
Quote: “Antenatal magnesium sulphate and adverse neonatal outcomes: a systematic review and meta-analysis” 
Title 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review 
registration number.  
Quote: “Background. There is widespread, increasing use of magnesium sulphate in obstetric practice for pre-eclampsia, eclampsia, and 
preterm fetal neuroprotection; benefit for preventing preterm labour and birth (tocolysis) is unproven. We conducted a systematic review 
and meta-analysis to assess whether antenatal magnesium sulphate is associated with unintended adverse neonatal outcomes. Methods 





INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  
Quote: “Introduction. Antenatal magnesium sulphate is commonly used in obstetric practice. Systematic reviews and clinical practice 
guidelines support its use when given for maternal neuroprotection in pre-eclampsia or eclampsia [1-3], and for neuroprotection of the 




Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and 
study design (PICOS).  
Quote: “The aim of our study, therefore, was to conduct a comprehensive systematic review to assess whether antenatal magnesium 
sulphate is associated with including perinatal death and other unintended adverse neonatal outcomes.” 
Introduction, 
paragraph 4 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information 
including registration number. 
Quote: “We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA) guideline; the relevant checklist is provided in S1 PRISMA Checklist. Prior to conduct, this systematic review was registered 
with PROSPERO (International Prospective Register of Systematic Reviews; CRD42013004451) [18]. The Australian Cerebral Palsy 
Alliance Research Foundation-funded review protocol is available in S1 Text.” 
Methods, 
paragraph 1; 




Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication 
status) used as criteria for eligibility, giving rationale.  
Quote: “Inclusion criteria. We included randomised and quasi-randomised controlled trials as well as non-randomised controlled studies 
(non-randomised trials, cohort studies, and case-control studies), and case reports. We excluded cross-sectional studies and case series. 






7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the 
search and date last searched.  
Quote: “Search strategy. Comprehensive searches of the bibliographic databases CINAHL, Cochrane Library, LILACS, MEDLINE, 
Embase, TOXLINE, and Web of Science, were undertaken from their respective inceptions to 3 September 2019, using combinations of 
MeSH and free text terms. The search strategies are available in S2 Text.” 
Methods, 
paragraph 2; 
and S2 Text 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  S2 Text 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-
analysis).  
Quote: “Study selection. After screening all titles and abstracts, we obtained full-text articles for studies that appeared to meet the 
inclusion criteria. All full-text articles were assessed for inclusion. Each stage was carried out by 2 reviewers, and we resolved any 





10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and 
confirming data from investigators.  
Quote: “Data extraction and management. For included studies, data were extracted using a standardised form, including information 
regarding design, participants, the magnesium sulphate regimen(s), the control/comparison if applicable, neonatal adverse outcomes 
reported, results relevant to the review and the risk of bias…” 
Methods, 
paragraph 7 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.  Methods, 
paragraph 7 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or 
outcome level), and how this information is to be used in any data synthesis.  
Quote: “Assessment of risk of bias. Quality appraisal of intervention studies was undertaken utilising established guidelines provided in 
the Cochrane Handbook for Systematic Reviews of Interventions [19]. The quality assessment of observational studies was guided by the 





13 State the principal summary measures (e.g., risk ratio, difference in means).  
Quote: “Data synthesis and analysis. Data analyses were undertaken by study design. Statistical analyses for randomised trials were 
performed using Review Manager, version 5.3 [21]. We presented quantitative data from individual studies as risk ratios (RRs) for 








14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each 
meta-analysis.  
Quote: “For all outcomes, we carried out analyses as far as possible on an intention-to-treat basis. Pooled estimates were calculated 




Risk of bias 
across studies  




16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-
specified. 
Quote: “For our primary review outcome (perinatal death) and other mortality outcomes, we conducted subgroup analyses based on 
indication for use, and characteristics of the magnesium sulphate loading and maintenance dose regimens, as these factors were 




RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally 
with a flow diagram.  
Quote: “Results. Study selection. The results of the search strategy, including the sources of the studies, their assessment and final 
inclusion are shown in Fig 1. The database searching identified 5,890 records, and other searching identified a further 11 records. Review 
of the titles and abstracts and exclusion of irrelevant and duplicate records yielded 777. Of these, we excluded 572 for the documented 
reasons (see S3 Text for list of records excluded due to absence of an English translation). We included a total of 205 articles, relating to 
197 studies. See S4 Text for references for all included studies.” 
Results, 
paragraph 1; 
and Fig 1 
Study 
characteristics  
18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.  
Quote: “Evidence from randomised controlled trials. Forty randomised trials were included, the characteristics of which are detailed in S1 
Table, and the risk of bias assessments summarised in Fig 2, S1 Fig, and S2 Table [22-61]…” 
Quote: “Evidence from non-randomised comparative studies. One hundred and thirty-eight non-randomised studies were included: 5 non-
randomised trials, 35 prospective cohort studies (7 with nested case-control analyses), 82 retrospective cohort studies (16 with nested 
case-control analyses), 8 non-concurrent cohort studies, and 8 case-control studies [62-199]. The characteristics of the studies, and risk 
of bias assessments are detailed in S1 and S2 Tables…” 
Quote: “Evidence from case reports. Nineteen reports describing a total of 134 babies exposed to antenatal magnesium sulphate with 
adverse outcomes were included [200-218] (see Table 9; the detailed characteristics of cases are presented in S4 Table).” 
Results 
paragraphs 
2, 27-28 and 




Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  
Quote: “Forty randomised trials were included, the characteristics of which are detailed in S1 Table, and the risk of bias assessments 
summarised in Fig 2, S1 Fig, and S2 Table [22-61]…” 
Quote: “One hundred and thirty-eight non-randomised studies were included… The characteristics of the studies, and risk of bias 













20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect 
estimates and confidence intervals, ideally with a forest plot.  
Tables 1, 4 




21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Tables 1, 4, 
6; S1 
Appendix 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  Results 
paragraph 
2-3 and 27-
28; Fig 2 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  
Quote: “When considering indication for use, the tocolysis subgroup showed an increase in perinatal death (RR 7.99; 95% CI 1.00 to 
63.49; 2 trials, 257 babies; analysis 1.1.1) which was not observed in the pre-eclampsia or fetal neuroprotection subgroups...” 
Results, 
paragraphs 
5 and 9; 
Tables 2, 3, 
and 5 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., 
healthcare providers, users, and policy makers).  




Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, 
reporting bias).  
Quote: “Strengths and limitations. The main limitations of our review relate to missing data for important outcomes across most stud ies, 




Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  
Quote: “In conclusion, our findings do not support any clear associations between perinatal death or other adverse neonatal outcomes 
and antenatal magnesium sulphate exposure when given for the beneficial indications of maternal neuroprotection in pre-




FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.  
Quote: “This work was carried out with funding from the Cerebral Palsy Alliance Research Foundation, Australia 
(https://research.cerebralpalsy.org.au/), grant PG2015 (ES, PM, MM, CC). The funder had no role in study design, data collection and 






S1 Table. Characteristics of included studies 
 
Randomised controlled trials 
 
Study; design Setting Participants MgSO4 
indication 
Relevant comparison groups Outcome measure(s) Funding and conflicts 
Abdul 2013; RCT Nigeria 
2008 
N = 72 women and their babies  
Inclusions: women with 
antepartum, intrapartum or 
postpartum E including 
imminent E 
Exclusions: women with E in 
critical conditions, with 
hypotension and low RR 
E Lower dose regimen: modified ‘Dhaka 
regimen’: 4 g IV LD and 5 g IM LD; 2.5 
g/4 hours IM MD for 24 hours post 
birth or last convulsion, N = 39 women 
and their babies 
 
Higher dose regimen: ‘Pritchard’s 
regimen’’: 4 g IV LD and 10 g IM LD; 5 
g IM/4 hours MD for 24 hours post 
birth or convulsion, N = 33 women 
and their babies 
 
All women: 2 g IV given for 
breakthrough convulsions 
Perinatal death Funding: NR 
Conflicts: none 




N = 75 women and their babies 
Inclusions: women with E 
Exclusions: NR 
E Lower dose regimen: 4 g IV LD and 6 g 
IM LD; 3 g/4 hour IM MD until 24 
hours after birth, N = 36 women and 
their babies 
 
Higher dose regimen: “standard 
dose… Pritchard regimen”, N = 39 
women and their babies 
Not in meta-analysis: “neonatal 
outcome”  
NR 





N = 51 women and their babies 
Inclusions: women with a single 
or twin pregnancy at < 30 weeks 
GA, if birth was planned or 
expected within 24 hours 
FN Slower rate of LD: 4 g IV LD over 60 
minutes, N = 25 women and their 
babies 
 
Stillbirth Funding: 1 author 
supported by The 
University of Adelaide 
Conflicts: 2 authors report 
none; 2 authors were also 




Exclusions: women in the 2nd 
stage of labour, who had already 
received MgSO4, or had any of 
the following contraindications 
(absent patellar reflexes, 
hypocalcaemia, RR < 16 
breaths/minute, renal failure, 
urine output < 100 mL during 
last 4 hours) 
Standard rate of LD: 4 g IV LD over 20 
minutes, N = 26 women and their 
babies 
 
Both groups: 1 g/hour IV MD until 
birth or for up to 24 hours 
Cochrane review; 1 author 
was the PI of the 
ACTOMgSO4 RCT; 2 
authors were members of 
a guideline panel for 
relevant national 
guidelines 




N = 401 women and their babies 
Inclusions: women with E 
eligible for MgSO4 
Exclusions: contraindications for 
MgSO4 therapy (e.g. oliguria, 
renal failure, absence tendon 
reflex), comatose patients, 
women who received MgSO4 
from outside, women whose 
pregnancy was continued 
E LD only: 4 g IV LD over 15-20 minutes 
and 6 g IM LD, N = 202 women and 
their babies 
 
LD and MD: 4 g IV LD over 15-20 
minutes and 6 g IM LD; 2.5 g/4 hours 
IM MD for 24 hours after birth or last 
convulsion, N = 199 women and their 
babies  
 
All women: for recurrent convulsion, 
women in LD only group received 2.5 
g IV and MD was started for 24 hours; 
in women receiving MD already, a 
further 2.5 g IV given and MD 
continued 
Stillbirth NR 




N = 100 women and their babies 
Inclusions: singleton or twin 
gestation between 24 and 35 
weeks GA, spontaneous preterm 
labour (uterine contractions > 4 
per 20 minutes along with 1 of 
the following observations: 
cervical dilatation of ≥ 1 cm but 
< 5 cm, cervical effacement ≥  
80% and/or progressive cervical 
T Lower dose regimen: 4 g IV LD over 20 
minutes; 2 g/hour MD, N = 50 women 
and their babies 
 
Higher dose regimen: 6 g IV LD over 20 
minutes; 2 g/hour IV MD, increased if 
required up to 4 g/hour, N = 50 
women and their babies 
 
Perinatal death, stillbirth, neonatal 
death, Apgar score < 8 at 1 minute, 
Apgar score < 8 at 5 minutes, RDS, 
bradycardia, hypoglycaemia, 
hypocalcaemia, NICU admission, 





dilation and effacement), ability 
to provide informed consent 
Exclusions: higher order multiple 
gestations, ROM, non-reassuring 
fetal assessment (abnormalities 
of the fetal heart rate pattern), 
evidence of intrauterine 
infection (temperature of 38 or 
higher, leucocytosis, uterine 
tenderness, malodorous 
discharge), vaginal bleeding, 
patients with history of DM, 
myasthenia gravis or any other 
neuromuscular diseases, 
impaired renal function, 
hypotension, maternal 
bradycardia, atrioventricular 
block, and inability or refusal to 
provide informed consent 
All women: successful T = < 4 
contractions/hour with no further 
advancement in cervical 
dilation/effacement; failed T (and 
cessation of treatment) = dilation 
progressed to 6 cm and/or 






N = 144 women and their babies 
Inclusions: women admitted 
with antepartum, intrapartum or 
postpartum E 
Exclusions: E with added 
complications (e.g. 
cerebrovascular accident, heart 
failure, renal failure, pulmonary 
oedema), referred cases who 
had already received initial 
dosage of MgSO4 at the 
referring centre 
E IM MD: ‘Pritchard’s regimen’: 4 g IV 
slow bolus LD and 10 g IM LD; 5 g/4 
hours IM MD, N = 72 women and their 
babies 
 
IV MD: 4 g IV slow bolus LD; 6 g/8 
hours IV LD, N = 72 women and their 
babies 
 
All women: 2 g IV bolus if needed for 
recurrent convulsions 








N = 22 women and their babies 
 
Inclusions: women with 
singleton pregnancies at > 32 
FN MgSO4: 6 g IV LD over 20-30 minutes; 
2 g/hour IV MD until birth, N = 11 
women and their babies 
 
Neonatal death, CLD (BPD), NEC, 





weeks GA complicated by 
PPROM (< 37 weeks GA), PROM 
> 18 hours (GA > 18 weeks), or 
clinical chorioamnionitis 
Exclusions: any indication for 
MgSO4 therapy (seizure 
prophylaxis or T), known 
maternal hypersensitivity to 
MgSO4, fetal structural defects, 
FGR (birthweight < 10th 
percentile for GA), systemic 
maternal infection (e.g. 
pneumonia or pyelonephritis), 
advanced cervical dilation (≥ 8 
cm) or imminent delivery, 
women with medical disorders 
such as any renal, cardiac or 
pulmonary disease, pulmonary 
hypertension or myasthenia 
gravis 
Placebo: matched volume of Ringer’s 
lactate solution of 20-30 minutes as a 
LD; continuous infusion of matched 
volume Ringer’s lactate solution as 
MD until birth N = 11 women and 
their babies 
Charma 2013; RCT Nigeria 
2011 
N = 112 women and their babies 
Inclusions: women with E  
Exclusion criteria: women with E 
who had received any 
anticonvulsant elsewhere before 
referral; added complications 
like stroke, renal failure and 
heart failure 
E Short MD: 4 g IV slow bolus LD and 10 
g IM LD; 5 g/4 hours IM MD, for 2 
doses only, N = 56 women and their 
babies 
 
Standard MD: ‘Prichard’s regimen’: 4 g 
IV slow bolus LD and 10 g IM LD; 5 g/4 
hours IM MD for 24 hours after birth 
or last convulsion, N = 56 women and 
their babies 
 
All women: 2 g IV for recurrent 
convulsions 





Chen 1995; RCT Taiwan 
1989-1992 
N = 64 women and their babies 
Inclusions: signs of severe 
hypertension (BP > 150/100 
mmHg) with 1 or more features 
of severe PE (systolic BP 166 
mmHg or higher; diastolic BP 
110 mmHg or higher; 
proteinuria persistent 2+ or 
more; oliguria 500 mL or less in 
24 hours; serum creatinine 
elevated; thrombocytopenia; 
hyperbilirubinemia; sGOT 
elevation marked; visual 
disturbance; headache; upper 
abdominal pain; pulmonary 
oedema or cyanosis; obvious 
FGR) 
Exclusions: IUD, chronic 
hypertension superimposed 
with PE, E at admission 
PE MgSO4: 4 g IV LD over 10 minutes; 1 
g/hour IV MD until 1 day after birth, N 
= 34 women and their babies 
 
No treatment: no MgSO4, N = 30 
women and their babies 
Apgar score ≤ 6 at 1 minute NR 
Chissel 1994; RCT South Africa 
Time period 
NR 
N = 17 women and their babies 
Inclusions: women with severe 
PE and imminent E; proteinuria 
of at least 1+ assessed by a semi 
quantitative dipstick method, 
and diastolic BP of 120 mmHg or 
more which did not settle during 
a 4 hour observation period 
Exclusions: NR 
PE IM MD: ‘Pritchard’s regimen’: 4 g IV 
LD over 15 minutes and 10 g IM LD; 5 
g/4 hours IM MD for 24 hours, 
providing delivery had occurred, N = 9 
women and their babies 
 
IV MD: ‘Sibai’s regimen’: 6 g IV LD over 
15 minutes; 2 g/hour IV MD for 24 
hours, providing delivery had occurred 
N = 8 women and their babies 
Stillbirth Funding: support from 
South African Medical 
Research Council 
Conflicts: NR 
Coetzee 1998; RCT South Africa 
1991 
N = 822 women and their babies 
Inclusions: women with severe 
PE (2 or more of the following: 
diastolic BP ≥ 110 mmHg, 
significant proteinuria, and 
PE MgSO4: 4 g IV LD over 20 minutes; 1 
g/hour IV MD until 24 hours after 







symptoms of imminent E) where 
a decision to terminate 
pregnancy had been made 
[note: twin pregnancies were 
included] 
Exclusions: women younger than 
16 years, already receiving 
MgSO4 or other anticonvulsants 
Placebo: saline placebo as above, N= 
240 women and their babies 
(analysed) 






N = 30 women and their babies 
Inclusions: women between 24-
34 weeks GA presenting with 
vaginal bleeding and uterine 
contractions and diagnosed with 
non-severe placental abruption 
Exclusion criteria: NR 
T MgSO4: IV, N = 15 women and their 
babies 
 
Placebo: IV placebo, N = 15 women 
and their babies 
Not in meta-analysis: NICU 
admission  
NR 




N = 54 women and their babies 
Inclusions: women between 26 
and 34 weeks GA (and estimated 
fetal weight between 750-2000 
g) in preterm labour (where, 
following hydration, persistent 
uterine contractions occurred ≥ 
3 in 10 minutes, and cervical 
examination suggested active 
labour (any of the following: 1) 
evidence of progressive cervical 
dilatation overtime; 2) a 
dilatation of 2 cm or greater; 3) 
cervical effacement of ≥ 80%; or 
4) spontaneous ROM)); with 
singleton or twin pregnancies 
Exclusions: women with a 
cervical dilatation > 4 cm; 
women with evidence of fetal 
T MgSO4: 4 g IV LD over 15 minutes; 2 
g/hour IV MD – women with intact 
membranes, discontinued after 12 
hours if no uterine activity; in women 
with ROM, continued for > 48 hours, N 
= 16 women and their babies 
 
Placebo: continuous IV infusion of 
dextrose in lactated Ringer’s solution 
at 125 ml/hour, N = 19 women and 
their babies 
 
[19 women and their babies in 
terbutaline group not considered 
further] 
Neonatal death, RDS, NEC, sepsis 
(positive culture), hypoglycaemia 
on NICU admission, PDA (requiring 
either medical or surgical 
treatment), seizures, IVH (ICH) 
Funding: supported by NIH 







pulmonary maturity or bacteria 
on Gram’s stain 
Cox 1990; RCT USA 
1987-1989 
N = 156 women and their babies 
Inclusions: preterm labour 
(defined by regular uterine 
contractions associated with 
cervical dilation ≥ 1 cm but < 5 
cm); GA between 24-34 weeks; 
intact fetal membranes; no 
maternal or fetal complications 
necessitating delivery (singleton 
and twin pregnancies) 
Exclusions: NR 
T MgSO4: 4 g IV LD; 2 g/hour IV MD, 
increased to 3 g/hour if contractions 
persisted after 1 hour; continued for 
24 hours (with re-treatment later if 
needed), N = 76 women and their 
babies 
 
Placebo: IV physiologic saline solution 
at 80 mL/hour for 24 hours. N = 80 
women and their babies 
Perinatal death, stillbirth, neonatal 
death, death > 28 days, before 
discharge, RDS (requiring 
ventilator) NEC, IVH (ICH), NICU 
admission, hospital stay (mean ± 
SD) (days) 
NR 
Crowther 2003; RCT Australia and 
New Zealand 
1996-2000 
N = 1062 women and their 
babies 
Inclusions: women pregnant 
with single, twin, triplet or 
quadruplet foetuses < than 30 
weeks GA, where birth was 
planned or expected within 24 
hours 
Exclusions: women in the 2nd 
stage of labour, women who had 
received MgSO4 therapy in this 
pregnancy, or with 
contraindications to MgSO4 
therapy (RR < 16/minute, absent 
patellar reflexes, urine output < 
100 mL in the previous 4 hours, 
renal failure, hypocalcaemia) 
FN MgSO4: 4 g IV LD over 20 minutes; 1 
g/hour IV MD until birth or for up to 
24 hours, N = 535 women and their 
babies 
 
Placebo: 8 mL sodium chloride 
solution/20 minutes; 2 mL/hour until 
birth or for up to 24 hours, N = 527 
women and their babies 
Perinatal death, stillbirth, neonatal 
death, death > 28 days, before 
discharge, Apgar score < 7 at 5 
minutes, MV, CLD, NEC, IVH, IVH 
grade 3/4, PVL 
 
Not in meta-analyses: length of 
hospital stay (median, range) 
(days) 
 
Additional outcomes from Paradisis 
2012 (N = 87 babies), nested within 
Crowther: PDA treated, surfactant, 
volume expansion, dobutamine, 
dopamine, any inotrope, SVC flow 
< 41 mL/kg/min 1st 24 hours, RVO < 
120 mL/kg/min 1st 24 hours, mean 
BP < 10th centile 1st 24 hours, 
pneumothorax, pulmonary 
haemorrhage 
Funding: supported by 
NHMRC, Channel 7 
Research Foundation of 
SA, Queen Victoria 
Hospital Research 
Foundation, and The 










N = 200 women and their babies 
Inclusions: women with severe 
PE, pregnant or ≤ 24 hours 
postpartum, deemed to benefit 
from treatment with MgSO4 
Exclusions: women who had 
experienced an E seizure, who 
had received MgSO4 within 24 
hours of enrolment, or who had 
a serum creatinine > 1.2 mg/dL 
at the time of enrolment 
PE Serial IV bolus regimen: 6 g IV LD over 
30 minutes using Springfusor spring-
loaded pump, through flow control 
tubing; 2 g IV bolus over 10 minutes 
every 2 hours as MD, N = 100 women 
and their babies 
 
Continuous infusion regimen: 4 g IV LD 
over 20 minutes; 1 g/hour IV MD by 
mini-drip, N = 100 women and their 
babies 
Perinatal death, stillbirth, neonatal 
death, intubated at delivery, MV, 
bradycardia, SCBU admission 
Funding: supported by 
Merck for Mothers 
Conflicts: none 




N = 90 women and their babies 
Inclusions: patients between 34 
and 37 weeks GA, > 15 but < 45 
years of age, in documented 
preterm labour with cervical 
change, capable of giving 
informed consent 
Exclusions: cervical dilatation ≥ 3 
cm, unknown GA, ROM, or with 
medical or obstetric conditions 
necessitation delivery (such as 
PIH, cardiac disease, fetal 
distress, or haemorrhage); 
evidence of suspected 
anomalies and maternal allergy 
to MgSO4 
T MgSO4: 4 g IV bolus LD; 2-4 g/hour IV 
MD until uterine quiescence [oral 
magnesium gluconate used as further 
MD], N = 45 women and their babies 
 
No treatment: conservative 
management, with hydration, 
sedation and observation; labour was 
allowed to continue without 
intervention after admission to the 
labour suite, N = 45 women and their 
babies 
Perinatal death, stillbirth, neonatal 
death, RDS, TTN, NEC, poor 
feeding, hyperbilirubinaemia, IVH, 
IVH grade 3/4, hospital stay (mean 
± SD) (days) 
 
Not in meta-analyses: days with 
the use of the ventilator (mean), 
NICU time for infants who did have 
complications (mean) 
Funding: supported by 
Vicksburg Hospital Medical 
Foundation 
Conflicts: NR 
How 1998; RCT USA 
1992-1995 
N = 145 women and their babies 
Inclusions: patients between 24-
34 completed weeks GA with 
PPROM (documented by 
obvious vaginal pooling and/or 
confirmed by ferning and 
alkaline pH using nitrazine 
T MgSO4: in the presence of ≥ 6 
contractions/hour: 6 g IV LD; 2 g/hour 
IV MD, increased up to 5 g/hour; 
maintained for 4 hours, gradually 
decreased by 1-2 g/hour, maintained 
for 6-8 hours before discontinuation 
(could be re-started), N = 78 women 
and their babies 
Stillbirth, death > 28 days, before 
discharge, RDS (HMD), TTN, MV, 
oxygen required, CLD, apnoea and 
bradycardia, NEC, sepsis, IVH 
 
Not in meta-analyses: length of 
nursery stay (median, IQR, range) 





paper) (singleton and twin 
pregnancies) 
Exclusions: evidence of 
chorioamnionitis and/or fetal 
stress or advanced active labour 
(≥ 3 cm dilatation by sterile 
speculum exam) on admittance; 
patient’s refusal; obstetrical 
indications for expedient 
delivery (PE/E, abruptio 
placenta, lethal anomalies, 
severe IUGR) 
 
No treatment: expectant 
management, N = 67 women and their 
babies 
IQR, range) (days), oxygen required 





N = 402 women and their babies 
Inclusions: women with a 
singleton pregnancy 
complicated by severe PE  
Exclusions: women with plasma 
creatinine value ≥ 2 mg/dL, 
deranged coagulation profile, 
platelet count < 50,000/mm3, 
past diagnosis of myasthenia 
gravis, or seizure disorders, 
already on MgSO4 prophylaxis 
on admission 
PE LD only: 4 g IV LD over 10-15 minutes 
and 6 g IM LD, N = 201 women and 
their babies 
 
LD and MD: ‘Dhaka regimen’: 4 g IV LD 
over 10-15 minutes and 6 g IM LD; 2.5 
g/4 hours IM MD, for 24 hours 
postpartum, N = 201 women and their 
babies 
 
All women: 2 g IV given for recurrence 
of convulsions, and 2.5 g/4 hours IM 
MD continued until 24 hours post 
birth or last convulsion 
Perinatal death, stillbirth, neonatal 
death, neonatal death < 7 days, 
Apgar score < 7 at 5 minutes, NICU 
admission for RD, NICU admission 
Funding: NR 
Conflicts: none 
Lewis 1997; RCT USA 
1993-1996 
N = 144 women and their babies 
Inclusions: women with intact 
membranes between 24-35 
weeks GA who had undergone 
successful single-agent tocolysis 
with MgSO4; preterm labour: 
defined as regular uterine 
contractions with either 
documented cervical change or 
T Weaning: MgSO4 weaned by 
approximately 1 g every 4 hours; 
when the dose was < 1 g/hour it was 
discontinued, and women were 
monitored for 4 hours, N = 72 women 
and their babies analysed 
 




a cervix dilated ≥ 2 cm and 75% 
effaced; successful tocolysis: 
uterine quiescence for ≥ 12 
hours with no further cervical 
change (requiring approximately 
24 hours for completion) 
Exclusions: NR 
No weaning: MgSO4 abruptly stopped 
and women observed for 4 hours, N = 
69 women and their babies analysed 
 
All women had received: 6 g IV LD 





N = 222 women and their babies 
Inclusions: women at term or 
preterm, who developed mild PE 
(systolic BP ≥ 140 mmHg or 
diastolic BP ≥ 90 mmHg on 2 
occasions ≥ 6 hours apart, in 
association with new onset 
proteinuria, defined as +1 or 
greater on dipstick on ≥ 2 
occasions) before onset of 
labour; women admitted for 
planned caesarean birth and 
who developed mild PE during 
the postpartum period were also 
included (singleton and twin 
pregnancies) 
Exclusions: women with chronic 
hypertension or severe PE 
PE MgSO4: 6 g IV LD over 20 minutes; 2 
g/hour IV MD, continued for 12 hours, 
or until 12 hours postpartum, N = 109 
women and their babies 
 
Placebo: identical administration of 
indistinguishable IV saline, N = 113 
women and their babies 
 
Meconium at delivery NR 







N = 10,141 women and their 
babies 
Inclusions: women with PE and 
there was uncertainty about 
whether to use MgSO4; 
irrespective of whether they had 
had an anticonvulsant at a 
referring hospital, or whether 
the pregnancy was singleton or 
multiple (the woman had not 
PE MgSO4: 4 g IV LD over 10-15 minutes; 
MD of either: 1 g /hour IV for 24 
hours, or 5 g/4 hours IM (plus 10 g IM 
with LD) for 24 hours, N = 5071 
women and their babies 
 
Placebo: as above, N = 5070 women 
and their babies 
 
 
Perinatal death, stillbirth, neonatal 
death, death > 28 days, before 
discharge, early neonatal death, 
late neonatal death, Apgar score < 
7 at 5 minutes, intubated at 
delivery, MV, seizures, persistent 
parenchymal echogenicity, 
abnormal ventriculomegaly, NICU 
admission, SCBU admission > 7 
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given birth, or was 24 hours or 
less postpartum; BP was 90 mm 
Hg diastolic or 140 mm Hg 
systolic or more on ≥ 2 
occasions; proteinuria was ≥ 1+; 
and there was clinical 
uncertainty about whether 
MgSO4 would be beneficial) 
Exclusions: hypersensitivity to 
MgSO4, hepatic coma with a risk 
of renal failure, or myasthenia 
gravis 
All women: trial treatment could be 
continued > 24 hours if considered 
necessary by clinician; if woman had a 
convulsion, treatment stopped and 
MgSO4 used 
days or death, SCBU admission > 7 





N = 126 women and their babies 




E Lower dose regimen: for women with 
E: 4 g IV LD over 15-20 minutes; 2 g IM 
or slow IV/3 hours until 24 hours after 
last convulsion or abortion/birth, 
whichever was later; if convulsions 
recurred 30 minutes after LD, an 
additional 2 g IV/IM given and MD 
continued; therapy was considered 
failed if convulsions continued after 2 
additional doses; no LD for women 
with imminent E N = 72 women and 
their babies 
 
Higher dose regimen: ‘Pritchard’s 
regimen’: 4 g IV LD and 5 g IM as LD; 5 
g IM/4 hours MD until 24 hours after 
last convulsion or abortion/birth, N = 
54 women and their babies 




Marret 2007; RCT France 
1997-2003 
N = 573 women and their babies 
Inclusions: pregnant women 
with a singleton, twin or triplet 
very preterm fetus < 33 weeks 
FN MgSO4: 4 g IV LD over 30 minutes, N = 
286 women and their babies analysed 
 
Perinatal death, stillbirth, neonatal 
death, Apgar score < 7 at 5 
minutes, intubated at delivery 
(tracheal intubation and/or 
epinephrine), RDS, MV 
Funding: supported by the 
French Department of 
Health obtained in 1997 





GA if birth was expected or 
planned within 24 hours 
Exclusions: women could not 
have received betamimetics, 
aminoglycosides or steroids for 
≥1 hour; women with foetuses 
with severe malformations or 
chromosomal abnormalities, or 
if they met ≥ 1 of the following 
criteria: hypotension, cardiac 
rhythm abnormalities, 
hydroelectrolyte abnormalities, 
renal insufficiency, ingestion 
during last 24 hours of calcium 
channel blockers, digitalins or 
indomethacin, persistent signs 
of cardiovascular toxicity or 
tachycardia > 1 hour after 
cessation of tocolytic intake, 
myasthenia or indication for 
emergency caesarean; women 
with pregnancy-associated 
vascular disease (PE, FGR, 
haemolysis, elevated liver-
function test results, low-
platelet syndrome, 
retroplacental haematoma) 
Placebo: 40 mL infusion of isotonic 
saline over 30 minutes, N = 278 
women and their babies analysed 
(endotracheal ventilation), non-
invasive ventilation, CLD (oxygen 
dependency at 36 weeks), apnoea 
and bradycardia, NEC, 
hypotension, seizures, IVH, PVL, 







N = 92 women and their babies 
Inclusions: pregnant women 
with GA < 34 weeks, hospitalised 
for PROM and labour 
complaints; the absence of 
concomitant disease such as 
chorioamnionitis or a history of 
drug sensitivity to MgSO4; no 
T MgSO4: 4 g IV LD over 20 minutes; 2 
g/hour IV LD until 24 hours after 
complete cessation of uterine 
contractions, N = 46 women and their 
babies 
 
Placebo, N = 46 women and their 
babies 
Death > 28 days, before discharge 







previous use of ; to ‘curb’ labour 
complain in a recent pregnancy; 
the absence of twin or multiple 
pregnancy 
Exclusions: probable 
chorioamnionitis; progress of 
labour (4 cm cervical dilatation); 
allergy or medical complications 
in combination with MgSO4; 
fatal fetal anomalies; non-
reassuring fetal status; severe 







N = 57 women and their babies 
– in neuroprotective arm of the 
RCT 
Inclusions: women in active 
preterm labour (cervical dilation 
> 4 cm), with or without PROM, 
at > 24 but < 34 completed 
weeks GA, with reassuring fetal 
assessment, and absence of 
clinical features that were 
suggestive initially of infection 
or PE 
Exclusions: mothers with triplet 
or higher order gestations; 
women with PE 
FN MgSO4: 4 g IV bolus LD, N = 29 
women and their babies 
 
Placebo: saline control, N = 28 women 
and their babies 
Perinatal death, stillbirth, neonatal 
death, IVH, IVH grade 3/4, PVL 
Funding: the United 




Moodley 1994; RCT South Africa 
Time period 
NR 
N = 228 women and their babies 
Inclusions: women with severe 
proteinuric hypertension (PE) 
(diastolic BP 110 mm Hg or 
greater, not settled with bed 
rest and sedation within 4-6 
PE MgSO4: ‘Pritchard’s regimen’: 4 g IV 
LD over 20 minutes and 10 g IM LD; 5 
g/4 hours IM MD, with a maximum of 
6 doses, n = 112 women and their 
babies 
 
Perinatal death, stillbirth, neonatal 
death (early) 
Funding: support from 





hours, with proteinuria of + or 
greater, detected by a semi-
quantitative ‘dipstick’ method in 
either a clean-catch specimen or 
a catheter specimen of urine), or 
judged to have imminent E 
requiring delivery (severe 
hypertension and other 
symptoms such as severe 
persistent headache, nausea and 
omitting, visual disturbances, 
and epigastric pain or signs such 
as clonus and brisk reflexes) 
(including twins and singleton 
pregnancies) 
Exclusions: prior anticonvulsant 
therapy or antihypertensive 
drugs 
 
No treatment, N = 116 women and 
their babies 
Mundle 2012; RCT India 
2008-2009 
N = 300 women and their babies 
Inclusions: all pregnant women 
diagnosed with PE whose 
providers deemed would benefit 
from MgSO4 – systolic BP ≥ 140 
mm Hg or a diastolic BP ≥ 100 
mm Hg and proteinuria ≥ 1+; 
had not given birth or were 24 
hours or less postpartum; 
exhibited urine output > 100 mL 
or more during the previous 4 
hours or > 25 mL/hour; agreed 
to comply with the study 
procedures; 18 years or older.  
Exclusions: women with E or 
seizing at the time of enrolment; 
PE IM MD: ‘Pritchard’s regimen’: 4 g IV 
LD and 10 g IM LD; 5 g/4 hours IM MD 
continued for 24 hours and stopped 
when clinically indicated, N = 153 
women and their babies 
 
IV MD: ‘Zuspan’s regimen’: 4 g IV LD; 1 
g/hour IV MD (using Springfusor 
pump) continued for 24 hours and 
stopped when clinically indicated, N = 
147 women and their babies 
Perinatal death Funding: support from the 
John D. and Catherine T. 
Macarthur Foundation, 
and Go Medical, Subiaco, 
Australia (provided pump 






received MgSO4 therapy 24 
hours prior to study enrolment 




N = 170 women and their babies 
Inclusions: severe PE 
Exclusions: NR 
PE LD only: 4 g IV LD over 15 minutes, 
and 10 g IM MD, N = 85 women and 
their babies 
 
LD and MD: ‘Pritchard’s regimen’: 4 g 
IV LD over 15 minutes and 10 g IM LD; 
5 g IM/4 hours MD 24 hours, N = 85 
women and their babies 
Perinatal death NR 
Parashi 2017; RCT Iran 
Time period 
NR 
N = 120 women and their babies 
Inclusions: pregnant women 
with PROM at 34 weeks GA 
Exclusions: hypertension, PE, 
trauma, gestational or 
aggravated DM, any type of 
metabolic disease affecting the 
pregnancy outcome, long-term 
drug use, gestational histories 
affecting the pregnancy 
outcomes 
FN MgSO4: 6 g IV LD over 20-30 minutes; 
2 g/hour MD during 12 hours before 
labour, 
N = 60 women and their babies 
 
Placebo: “conventional treatment 
with normal saline infusion”, N = 60 
women and their babies 
Stillbirth, IVH, IVH grade 3/4H, 
intensive care unit stay (mean ± 
SD) (days) 
NR 
Pascoal 2019; RCT Brazil 
2015-2016 
N = 62 women and their babies 
Inclusions: women with severe 
PE (defined by ACOG criteria), 
prescribed MgSO4 
Exclusions: E prior to initial 
MgSO4 LD, use of other 
medicines or illicit drugs that 
could interfere with maternal 
haemodynamics, 
contraindications to MgSO4 
(known hypersensitivity to the 
drug, oliguria with urinary 
output below 25 mL per hour, or 
severe myasthenia), acute or 
PE Lower dose regimen: 6 g IV LD over 20 
minutes, 1 g/hour IV MD, N = 31 
women and their babies 
 
Higher dose regimen: 6 g IV LD over 30 
minutes; 2 g/hour IV MD, N = 31 
women and their babies 
Neonatal death, need for 
resuscitation, ‘respiratory 
disorders’, MV, NICU admission 






chronic kidney disease and a 
diminished level of 
consciousness 
Rimal 2017; RCT Nepal 
2014-2015 
N = 60 women and their babies 
Inclusions: diagnosed cases of 
severe PE who were admitted to 
the ward, gave written informed 
consent, and were in labour or 
planned for termination of 
pregnancy 
Exclusions: women < 20 GA, and 
who had received MgSO4 before 
admission to the ward 
PE LD only: 4 g IV LD over 5 minutes and 
10 g IM LD, N = 30 women and their 
babies 
 
LD and MD: ‘Pritchard’s regimen’: 4 g 
IV LD over 5 minutes and 10 g IM LD; 
MD every 3 hours IM for 24 hours 
from time of birth or last convulsion, 
N = 30 women and their babies 
 
All women: for recurrent convulsions, 
2 g IV given over 5 minutes; MD 
continued until 24 hours after 
birth/last dose 
Perinatal death, stillbirth, neonatal 
death, Apgar score < 7 at 0 
minutes, Apgar score < 7 at 1 
minute, Apgar score < 7 at 5 




Rouse 2008; RCT USA 
1997-2004 
N = 2241 women and their 
babies 
Inclusions: women carrying 
singletons or twins at 24 
through 31 weeks GA, at high 
risk for spontaneous delivery 
because of ROM at 22-31 weeks 
GA, or because of advanced 
preterm labour with dilatation 
of 4-8 cm and intact 
membranes; or if an indicated 
preterm delivery was 
anticipated within 2-24 hours 
(e.g. because of FGR) 
Exclusions: women where 
delivery was anticipated within < 
2 hours or if cervical dilatation > 
8 cm; with ROM < 22 weeks, 
FN MgSO4: 6 g IV LD over 20-30 minutes; 
2 g/hour IV MD until birth or 12 hours, 
N = 1096 women and their babies 
 
Placebo: identical appearing placebo 
as above, N = 1145 women and their 
babies 
 
All women: if delivery had not 
occurred after 12 hours, the infusion 
was discontinued and resumed when 
delivery was imminent; if at least 6 
hours had passed another LD was 
given 
Perinatal death (fetal or infant 
death < 1 year), Apgar score < 7 at 
5 minutes, intubated at delivery, 
resuscitation in delivery room 
(oxygen bag, mask or both; any; 
chest compressions), RDS, MV, CLD 
(BPD), NEC, sepsis (culture-
proven), hypotension (treated with 
vasopressors), PDA, ROP, 
generalised hypotonicity, seizures, 
IVH, IVH grade 3/4, PVL 
 
Hirtz 2015 (presents data for all 
children, term ultrasounds, N = 
1776 babies; children born < 32 
weeks GA, most severe findings, N 
= 1613 babies): IVH, IVH grade 3/4, 
PVL, ventriculomegaly, 
Funding; support from 
NICHD and the National 
Institute of Neurological 





with unwillingness of the 
obstetrician to intervene for the 
benefit of the fetus, major fetal 
anomalies or death, maternal 
hypertension or PE, maternal 
contraindications to MgSO4 (e.g. 
severe pulmonary disorders), 
and receipt of IV MgSO4 within 
the previous 12 hours 
echodensity, echolucency, any of 
above 
 
Horton 2015 (presents data for 
singleton children born to mothers 
with PPROM only, N = 1259 
babies): death (to hospital 
discharge), Apgar score < 7 at 5 
minutes, RDS, NEC, sepsis (culture-
proven), ROP, IVH grade 3/4, PVL, 
composite (any of RDS, NEC, sepsis, 
ROP, IVH grade 3/4, PVL, death) 
 
Vilchez 2018 (presents data for 
women with singleton pregnancies, 
with no documented congenital 
anomalies, that received MgSO4 or 
placebo, N = 1894 babies; and 
reports subgroup analyses based 
on race/ethnicity: African-America, 
N = 852; Caucasian, N = 686; 
Hispanic, N = 338; Asian, N = 18): 
stillbirth/death, low Apgar score, 
resuscitation, assisted ventilation, 
RD, TTN, surfactant use, NEC, ROP, 
NICU admission, composite 
outcome (≥ 1 complication) 
 
Vilchez 2018b (presents data for 
2096 children born to women with 
BMI data;  and reports subgroup 
analyses based on BMI): perinatal 





Saha 2017; RCT India 
Time period 
NR 
N = 41 women and their babies 
Inclusions: patients with 
antepartum and intrapartum E; 
E was diagnosed if a patient with 
PE or hypertension experienced 
convulsions after 20 weeks GA 
Exclusions: patients with E who 
experienced complications such 
as coma, pulmonary oedema, 
oliguria, ICH, who had already 
received MgSO4, phenytoin and 
diazepam before attending the 
hospital 
E IM MD: ‘Zuspan’s regimen’: 4 g IV LD; 
1 g/hour IV MD for 24 hours after last 
convulsion or birth, N = 20 women 
and their babies 
 
IV MD: ‘Dhaka regimen’: 4 g IV LD and 
6 g IM LD; 2.5 g/4 hour IM MD for 24 
hours after last convulsion or birth, N 
= 21 women and their babies 
 
All women: in cases of convulsion 
recurrence, 2 g IV administered 
Perinatal death, stillbirth, neonatal 
death, Apgar score < 7 at 1 minute, 
Apgar score < 7 at 5 minutes, RD, 
jaundice, hypotonia, NICU 
admission 
Funding: Department of 











N = 50 women and their babies 
Inclusions: women with 
antepartum E 
Exclusion: renal failure, 
pulmonary oedema, having 
received MgSO4 before coming 
into the hospital 
E Lower dose regimen: ‘Dhaka regimen’, 
N = 25 women and their babies 
 
Higher dose regimen, N = 25 women 
and their babies 
 
All women: in cases of convulsion 
recurrence, 2 g IV administered 
Perinatal death, stillbirth, neonatal 
death, Apgar score < 7 at 1 minute, 
Apgar score < 7 at 5 minutes, RD, 
respiratory depression, jaundice, 
hypotension, hypotonia, 
requirement for calcium gluconate, 
NICU admission 
NR 
Shreya 2014; qRCT India 
2010-2012 
N = 80 women and their babies 
Inclusions: all pregnant women 
with imminent E having one of 
the following: persistent 
headache, visual disturbances, 
epigastric pain; or pregnant 
women with E: convulsions in a 
pregnant woman that cannot be 
attributed to other causes 
Exclusions: not willing to 
participate; women receiving 
any anticonvulsant or MgSO4 
prior to arrival at the hospital; 
contraindications for MgSO4 
PE/E LD only: 4 g IV LD over not less than 3 
minutes, and 4 g IM LD, N = 40 women 
and their babies 
 
 
LD and MD: ‘Pritchard’s regimen’: 4 g 
IV LD over not less than 3 minutes, 
followed by 10 g IM LD; 5 g IM/4 
hours MD, for 24 hours following 
convulsion or birth, N = 40 women 
and their babies 
All women: 2 g IV over 2 minutes for 
convulsion recurrence after 30 
minutes 
NICU admission for RD, NICU 
admission for early onset sepsis, 
NICU admission for late onset 
sepsis, NICU admission for 
meconium aspiration syndrome, 






such as respiratory depression, 
renal failure, hypersensitivity, 
heart block, Addison’s disease, 
severe hepatitis, myocardial 
damage, myasthenia gravis 
Singh 2011; RCT India 
2 year 
period 
N = 158 women and their babies 
Inclusions: patients presenting 
with E 
Exclusions: women diagnosed 
with other causes of convulsions 
in pregnancy like cerebral 
malaria and epilepsy 
E IM: ‘Pritchard’s regimen’: 4 g IV LD 
over 3-5 minutes and 10 g IM LD; 5 
g/4 hours IM until 24 hours after 
delivery or last convulsion, N = 60 
women and their babies 
 
IV: ‘Zuspan’s regimen’: 
4 g IV LD over 5-10 minutes; 1 g/hour 
IV MD until 24 hours after delivery or 
last convulsion, N = 49 women and 
their babies 
 
IV: ‘Sibai’s regimen’: 
6 g IV LD over 15-20 minutes; 2 g/hour 
IV until 24 hours after delivery or last 
convulsion, N = 49 women and their 
babies 
 
All women: if convulsions persisted 15 
minutes post LD, 2 g IV given 
Perinatal death, stillbirth, neonatal 






N = 86 women and their babies 
Inclusions: women with PE with 
severe features (according to 
ACOG guideline), admitted with 
GA ≥ 24 weeks 
Exclusions: serum creatinine > 
1.3 mg/dL, hypersensitivity to 
MgSO4, myocardial damage, 
diabetic coma, heart block and 
myasthenia gravis. 
PE Lower dose regimen: Weight-adjusted 
protocol: 4 g IV LD; IV MD: 1.2 g/hour 
for < 60 kg, 1.3 g/hour for 60-79.9 kg, 
1.4 g/hour for 80-99.9 kg and 1.5 
g/hour for ≥ 100 kg; continued until 24 
hours after birth, N = 43 women and 
their babies 
 
Perinatal death, stillbirth, neonatal 
death, NICU admission 
Funding: support from Dr. 
Thammanoon 






Higher dose regimen: 4 g IV LD; 2 
g/hour IV MD, N = 43 women and 
their babies 
 
Serum concentrations monitored at 2 
and 4 hours, adjusted and continued 
until 24 hours after birth 
Terrone 2000; RCT USA 
1997-1998 
N = 160 women and their babies 
Inclusions: singleton or twin 
gestation between 24-34 weeks 
GA, spontaneous preterm labour 
(advancement seen on cervical 
examination with uterine 
contractions while the patient 
was admitted to the triage unit 
or dilatation of 2 cm and 
effacement of 80% with ≥ 6 
uterine contractions/hour), and 
ability to provide informed 
consent 
Exclusions: higher-order multiple 
gestations, ROM, non-reassuring 
fetal assessment, evidence of 
intrauterine infection, treatment 
with any tocolytic agent before 
maternal transport, and inability 
or refusal to provide informed 
consent, inability to tolerate 
high doses of MgSO4 (e.g. renal 
failure) 
T Lower dose regimen: 4 g IV LD over 20 
minutes; 2 g/hour IV MD, N = 78 
women and their babies 
 
Higher dose regimen: 4 g IV LD over 20 
minutes; 5 g/hour IV MD, N = 82 
women and their babies 
 
All women: if after 1st hour 
contractions/cervical dilation or 
effacement continued MD increased 
by 1 g/hour until successful T or 
treatment failure 
Apgar score < 7 at 1 minute, Apgar 
score < 7 at 5 minutes 
Funding: supported by 
Vicksburg Hospital Medical 
Foundation 
Conflicts: NR 
Witlin 1997; RCT USA 
1995-1996 
N = 135 women and their babies 
Inclusions: women with a GA of 
at least 37 weeks, with recent-
onset hypertension (systolic BP ≥ 
140 mm Hg or diastolic BP ≥ 90 
PE MgSO4: 6 g IV LD over 15-20 minutes; 
2 g/hour IV MD, continued until 12 
hours postpartum, N = 67 women and 
their babies 
 
Apgar score ≤ 6 at 1 minute, Apgar 





mm Hg) and proteinuria (≥ 300 
mg/24 hours) 
Exclusions: women meeting 
criteria for severe PE; fetal 
malpresentation; congenital 
anomalies; non-reassuring fetal 
testing; contraindications to the 
use of MgSO4; contraindications 
to a trial of labour 
Placebo: saline infusion identical in 
appearance, N = 68 women and their 
babies 
 
Abbreviations: ACOG: American College of Obstetrics and Gynecologists; BP: blood pressure; BPD: bronchopulmonary dysplasia; CLD: chronic lung disease; CP: cerebral palsy; dL: decilitre; DM: diabetes 
mellitus; DST: Defence Science and Technology; E: eclampsia; FGR: fetal growth restriction; g: grams; GA: gestational age; HMD: hyaline membrane disease; ICH: intracranial haemorrhage; IM: 
intramuscular; IMIP: Instituto de Medicina Integral Prof. Fernando Figueira; IQR: interquartile range; IUD: intrauterine death; IUGR: intrauterine growth restriction; IV: intravenous; IVH: intraventricular 
haemorrhage; kg: kilograms; LD: loading dose; MD: maintenance dose; mg: milligrams; MgSO4: magnesium sulphate; MRC: Medical Research Council; MV: mechanical ventilation; N: number; NEC: 
necrotising enterocolitis; NHMRC: National Health and Medical Research Council; NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development; NICU: neonatal intensive 
care unit; NIH: National Institutes of Health; NINDS: National Institute of Neurological Disorders and Stroke; NR: not reported; PDA: patent ductus arteriosus; PE; pre-eclampsia; PI: primary investigator; 
PIH: pregnancy-induced hypertension; PPROM: preterm premature rupture of membranes; PROM: premature rupture of membranes; PVL: periventricular leucomalacia; qRCT: quasi-randomised 
controlled trial; RCT: randomised controlled trial; RD: respiratory distress; RDS: respiratory distress syndrome; ROM: rupture of membranes; RR: respiratory rate; RVO: right ventricular output; SCBU: 
special care baby unit; SD: standard deviation; sGOT: serum glutamic-oxaloacetic transaminase; SVC: superior vena cava; TTN: transient tachypnoea of the newborn; UK: United Kingdom; 








Study; design Setting Participants MgSO4 
indication 




results appear to 
be presented as 
RCS with CCS(N)  
Togo 
2007-2009 
N = 170 women, 178 babies 
Inclusions: (singleton/twin) newborns > 28 
weeks GA from women diagnosed with E 
before birth (definition provided) 
Exclusions: NR 
E 1: Babies still living at the 7th day of 
life, N = 147 babies 
2: Stillbirths and neonatal deaths in 
the 1st 7 days, N = 31 babies 
MgSO4 exposure (10 g in 500 






N = from 72004 births, 87 women with E and 
their babies included in analyses 
Inclusions: women with and without GH 
(detailed definition provided) 
Exclusions: NR 
GH/PE 1: No GH and no MgSO4 with E, N = 
49 women and their babies 
2: GH and IV MgSO4 with E, N = 11 
and their babies 
3: GH and no MgSO4 with E, N = 27 
and their babies 
Adverse outcome composite, 
perinatal death 
NR 
Alston 2016; NCCS USA 
2004-2009 
N = 169 babies 
Inclusions: neonates born from singleton 
pregnancies between 24-34 weeks GA  
Exclusions: birth before 24 weeks GA or after 
34 weeks GA, indication for preterm birth was 
something other than spontaneous preterm 
labour, or the infant chart could not be linked 
to the maternal chart 
T 1: Period of MgSO4 use for T (2004-
2006) (6 g IV LD; 2 g/hour IV MD), N 
= 102 (90 babies in analyses) 
2: Period of no MgSO4 use for T 
(2007-2009), N = 67 (64 babies in 
analyses) 
Hospital stay (days) (mean, no 
measure of variance), neonatal 







1 year period 
N = 120 women and babies 
Inclusions: women admitted to labour ward ≥ 
34 weeks GA with PE/E 
Exclusions: women who received different 
dosages of MgSO4, who required 
discontinuation of MgSO4 due to toxicity, 
who had chronic medical disorders or 
anomalous fetuses, APH, or any other co-
existing major obstetric problem 
PE/E 1: MgSO4 (Pritchard’s regimen: 4 g 
IV over 10 minutes and 5 g IM LD; 5 
g/4 hours IM MD), N = 60 babies 
2: Matched patients with PE not 
requiring MgSO4 or any other 
anticonvulsant, N = 60 babies 
 
1: MgSO4 and NICU admission, yes, 
N = 13 babies 
2: MgSO4 and no NICU admission, 
N = 47 babies 
Neonatal death, NICU 
admission, hypotonia, RD, 
meconium passage (< 6, 6-12, > 
12 hours) 
 
NICU admission: MgSO4 dose 
(categories: LD, LD + 1, LD + 2, 
LD + 3, LD + 4, LD + 5, LD + 7 
doses), duration of MgSO4 (< 6, 
6-12, 12-18, ≥ 18 hours), time 







and birth (1-2, 2-3, 3-4, 4-5, > 5 
hours) 
Bajaj 2018; RCS USA 
2012-2013 
N = 7014 babies 
Inclusions: babies born at 29+0 to 33+6 weeks 
GA who were enrolled in the NRN MPT 
registry 
Exclusions: babies in whom a prenatal 
diagnosis caused a decision to withdraw or 
limit intensive care 
NR 1: Routine care without 
resuscitation, N = 1684 babies 
2: Oxygen or CPAP but not 
ventilation, intubation or CPR, N = 
2279 babies 
3: Bag and mask ventilation but not 
intubation or CPR, N = 1831 babies 
4:  ETT intubation but not CPR, N = 
1034 babies 
5: CPR, N = 186 babies 





Basu 2012; RCS USA 
2006-2010 
N = 475 babies 
Inclusions: preterm neonates born between 
24-32 weeks GA admitted to the NICU 
Exclusions: neonates with major congenital 
malformations or chromosomal anomalies, 
and those born to women who received 
MgSO4 for PE/E 
FN 1: MgSO4 (6 g IV LD over 30 
minutes; 2 g/hour IV MD until 
birth), N = 289 babies 
2: No MgSO4, N = 186 babies 
Survival without IVH/PVL, 
resuscitation, intubation, BPD, 
IVH/PVL. ROP, PDA, LOS (days) 




appear to be 




N = 83 babies born to 72 women 
Inclusions: neonates born at 24 weeks GA or 
greater who were admitted to the NICU and 
whose mothers received MgSO4 infusions 
prior to birth  
Exclusions: neonates with independent 
factors that could lead to feeding intolerance, 
including congenital abnormalities, such as 
gastroschisis and neonatal abstinence 
syndrome 
FN/PE 1: Enteral feeding intolerance, N = 
49 babies 
2: No feeding intolerance, N = 34 
babies 
 
1: MgSO4 > 80 g, N = NR 
2: MgSO4 ≤ 80 g, N = NR 
MgSO4 dose (g) (mean ± SD) 
 
Enteral feeding intolerance, 













N = 93 women and their babies 
Inclusions: women > 18 years with PE 
Exclusions: NR 
PE 1: MgSO4 IV ≤ 24 hours, N = 51 
women and their babies 
2: MgSO4 IV > 24 hours, N = 42 
women and their babies 
Neonatal death, respiratory 










N = 134 babies 
Inclusions: preterm infants who received 
neonatal care, < 35 weeks GA at birth and 
considered high-risk for developmental and 
health problems because they either weighed 
< 1,500 g at birth or required MV  
Exclusions: infants with congenital diagnoses 
associated with developmental problems 
(such as Down syndrome, congenital 
hydrocephalus, or microcephaly) or 
symptomatic from substance exposure; 
infants with family situations such that 




1: MgSO4 with (N = 45)/without (N 
= 5) steroids, N = 50 babies 
2: No MgSO4 with (N = 38)/without 
steroids (N = 46), N = 84 babies 
Ventilation (days) (mean ± SD), 
methylxanthines (days) (mean 










N = 39 babies 
Inclusions: term women (≥ 37 weeks GA) with 
PE (mild or severe) who received MgSO4, and 
controls who did not receive MgSO4 
Exclusions: FGR (birthweight < 10th centile 
for GA), multiple gestations, fetal structural 
anomalies, clinical chorioamnionitis or prior 
exposure to MgSO4 
PE 1: MgSO4 (6 g IV LD over 20-30 
minutes; 2 g/hour IV MD until 
birth), N = 13 babies 
2: No MgSO4, N = 26 babies 
Troponin I ≥ 1.0 ng/mL NR 




N = 379 women and babies 
Inclusions: women requiring IV MgSO4 who 
delivered while receiving treatment 
Exclusions: NR 
T 1: MgSO4 IV < 72 hours, N = 199 
babies 
2: MgSO4 IV > 72 hours, N = 45 
babies 
3: No MgSO4, N = 135 babies 
HsPDA treated with 
indomethacin 
NR 
Bozhurt 2016; RCS Turkey 
2010-2012 
N = 387 babies 
Inclusions: preterm infants < 32 weeks GA 
born to women with PE, who survived to 2 
years 
Exclusions: NR 
PE 1: MgSO4 (6 g IV LD over 20 
minutes; 2 g/hour IV MD for 24 
hours), N = 59 babies 
2: No MgSO4, N = 328 babies 
RDS, BPD, hypoglycaemia, 
apnoea, PDA, IVH grade 3/4 
and PVL, PVL only, culture 
proven sepsis, NEC grade ≥ II, 











N = 285 women and babies 
Inclusions: women who delivered non-
anomalous singleton fetuses at term by 
primary caesarean with a category 2 or 3 FHR 
tracing as an indication for birth 
Exclusions: NR 
NR 1: MgSO4, N = 16 babies 
2: No MgSO4, N = 271 babies 
[note discrepancy between total N 
and group Ns reported] 
Composite adverse neonatal 
outcome (defined as Apgar 
score < 7 at 5 minutes, arterial 
cord pH < 7.1 and/or base 
deficit ≥ 12, admission to the 
NICU, need for immediate 
neonatal resuscitation beyond 
bulb suction and stimulation, or 
hospitalisation ≥ 3 days) 
NR 
Brazy 1982; RCS USA 
1979 
N = 56 babies 
Inclusions: infants born before 36th week GA 
to women with early and severe hypertension 
in pregnancy (resting diastolic BP ≥ 110 
mmHg and proteinuria); for each infant of 
mother with hypertension, a control infant 
(born to a normotensive mother) was 
selected on the basis of GA and birth order  
Exclusions: no major congenital 
abnormalities, major disease (IDD, sickle cell 
anaemia, renal failure, heart disease), no 
known exposure to insulin or tocolytic agents; 
for control infants: no known exposure to 
sedatives, diuretics or drugs with 
antihypertensive properties 
ESHP 1: Hypertensive women treated 
with IV MgSO4, N = 28 babies 
2: Non-hypertensive women, with 
no MgSO4, N = 28 babies 
Days hospitalised (mean ± SD), 
thrombocytopenia, leukopenia, 
neutropenia, DIC, severe 
respiratory disease, TTN, 
delayed adaptation, PDA, 
hypotension, delayed stooling 
(> 24 hours), ileus, hypotonia, 
other disease (CNS 
haemorrhage, air block, acute 
renal failure, NEC), neonatal 
death, death after 28 days of 












N = 55 women and babies 
Inclusions: pregnant women prescribed 
MgSO4 for FN/PE < 32 weeks GA (4 g LD; 2 
g/hour MD) 
Exclusions: NR 
FN/PE 1: Resuscitation (oxygen, 
bag/mask, intubation, chest 
compressions), N = 27 babies 
2: No resuscitation, N = 28 babies 
MgSO4 dose (g) (mean ± SD) NR 
Brookfield 2016; 
RCS (secondary 




N = 1496 women and babies 
Inclusions: women who had received 1 course 
of antenatal steroids and had PPROM at < 32 
weeks 
Exclusions: NR 
FN 1: MgSO4, N = 735 babies 
2: No MgSO4, N = 761 babies 











N = 218 babies 
Inclusions: babies born < 31 weeks GA 
diagnosed with SH (SBP > 100 mmHg 
requiring treatment, before discharge from 
NICU, or on 3 consecutive occasions during 
outpatient follow-up), and controls matched 
for GA, sex and birthweight 
Exclusions: babies who died < 7 days of age 
NR 1: SH, N = 109 babies 
2: No SH, N = babies 





N = 918 babies 
Inclusions: inborn neonates with GA from 23-
34 weeks and birthweights from 500-1750 g 
Exclusions: major congenital anomalies, 
neonatal death by day 3, transfers before day 
3 
PE/T 1: MgSO4, N = 398 babies 
2: No MgSO4, N = 520 babies 
 
1: Abnormal cranial sonograms, N = 
39 babies 
2: Normal findings, N = 125 babies 
 
1: Severe lesions, N = 27 babies 
2: Normal findings, N = 127 babies 
Apgar score < 7 at 5 minutes, 
RD, neonatal death, abnormal 
sonograms (any PVL or IVH), 
severe lesions (any PVL, PVL 
with IVH, or IVH grade 3/4) 
NR 




N = 2468 women and their babies 
Inclusions: women with PE without severe 
features at any time in pregnancy, who 
delivered > 32 weeks GA 
Exclusions: NR 
PE 1: MgSO4 at any time during 
delivery hospitalisation, N = 1353 
babies 
2: No MgSO4, N = 1115 babies 
Perinatal or neonatal death, 
NICU admission 
NR 
Cho 2014; RCS 
Abstract 
NR N = 570 women and babies 
Inclusions: pregnant women with preterm 
birth and their paired neonates 
Exclusions: NR 
NR 1: MgSO4 IV, N = 101 babies 
2: No MgSO4, N =469 babies 
Hypocalcaemia NR 
Chowdhury 2009; 




N = 630 women (529 babies born to 
antepartum/intrapartum cases) 
Inclusions: consecutive women with clinical 
diagnosis of E regardless of when/where the 
convulsions occurred, whether pregnancy 
was single/multiple, and whether baby had 
been delivered 
Exclusions: women with convulsions due to 
epilepsy or other causes 
E 1: MgSO4 by Pritchard’s regimen (8 
g IV over 2-3 minutes and 5 g IM in 
each buttock LD; 5 g/4 hours IM 
MD for at least 24 hours after 
birth/last convulsion), N = 480 
women (406 babies born to 
antepartum/intrapartum cases) 
2: MgSO4 by low-dose IV regimen 
(4 g IV LD over 2-3 minutes; 0.6 
Stillbirth, early neonatal death 
due to birth asphyxia and 






g/hour IV MD for at least 24 hours 
after birth/last convulsion), N = 150 
women (123 babies born to 
antepartum/intrapartum cases) 
Chun 2014; RCS 
English abstract; 




N = 209 women and babies 
Inclusions: women who delivered vaginally 
with the diagnosis of PE 
Exclusions: CD 
PE 1: MgSO4, N = 119 babies 
2: No MgSO4, N = 90 babies 
Apgar score < 7 at 1 minute, 
Apgar score < 7 at 5 minutes, 
NICU admission 
CD 
Cuff 2018; RCS Authors 
from USA 
2014-2015 
N = 224 women and their babies: 44 women 
and 54 babies exposed to MgSO4 within 12 
hours of birth 
Inclusions: women who had a preterm birth < 
32 weeks GA and had received MgSO4 prior 
to birth 
Exclusions: women with PE, known fetal 
anomalies, and/or stillbirth 
FN 1: 2014 (dosing according to BEAM 
trial: 6 g IV LD; 2 g/hour IV MD for 
12 hours), N = 18 babies exposed 
within 12 hours of birth 
2: 2015 (dosing according to 
PREMAG trial: 4 g IV MD; no MD), 
N = 36 babies exposed within 12 
hours of birth 
Apgar score < 7 at 5 minutes, 
ROP grade 3/4, IVH grade 3/4 
Funding: NR 
Conflicts: none 
Das 2015; PCS India 
2011-2012 
N = 100 women and their babies 
Inclusions:  women with antepartum or 
intrapartum E (definition provided) > 20 
weeks GA, presenting in obstetric, labour 
and/or wards, who have informed consent 
Exclusions: women with complications such 
as renal failure, severe pulmonary oedema 
with respiratory failure, cerebrovascular 
accident, and DIC, who received MgSO4 
before coming to hospital, with known 
seizure disorders, with multiple pregnancies, 
with infants with congenital malformations or 
birthweights < 1000 g 
E 1: 8 g MgSO4, N = 20 babies 
2: > 8 g MgSO4, N = 80 babies 
 
MgSO4: low-dose regimen: 3 g IV 
over 15 minutes and 2.5 g IM in 
each buttock LD; 2.5 g/4 hours IM 
in alternate buttocks MD 
Apgar score < 7 at 1 minute, 
Apgar score < 7 at 5 minutes, 
Apgar score ≤ 3 at 1 minute, 
Apgar score ≤ 3 at 5 minutes, 
respiratory depression, 
intubation in delivery room, 
bradycardia, hypotonia, 
hyporeflexia, NICU admission, 
significant respiratory support 
in NICU, time to 1st stool > 24 
hours, time to 1st void > 48 
hours, number of episodes of 
feeding intolerance ≥ 3, 










Deering 2005; RCS USA 
12 month 
period 
N = 221 babies 
Inclusions: all preterm admissions 
Exclusions: congenital anomalies, admission > 
24 hours of life, hydrops fetalis, no SNAP 
score calculated, transport back to the 
referring hospital before all information could 
be obtained 
PE/T 1: MgSO4, N = 103 babies 
2: No MgSO4, N = 118 babies 
SNAP score (mean ± SD), SNAP 









N = 1544 babies 
Inclusions: infants born between 23+0-28+6 
weeks GA and enrolled in the generic 
database 
Exclusions: NR 
FN/PIH/T 1: MgSO4, N = 1091 babies 
2: No MgSO4, N = 453 babies  
Delivery room resuscitation 
(PPV via bag and mask, any 
CPAP devices, intubation, chest 
compression and epinephrine), 
delivery room intubation, day 1 
MV, day 1 ET MV, day 3 MV, 
day 3 ET MV, hypotension, PDA 
treated (medical or surgical), 
RDS, pulmonary haemorrhage, 
traditional BPD, late onset 
sepsis/meningitis, NEC stage II 
or greater, ROP any stage, IVH 
or parenchymal haemorrhage, 
cPVL, death, cumulative days 
on MV (median, Q1, Q3), 
cumulative days on oxygen 
support (median, Q1, Q3), LOS 
(median, Q1, Q3)    
Funding: NIH and 
NICHD 
Conflicts: none 




N = 954 babies included, 941 babies analysed 
Inclusions: neonates with birthweights 
between 500-1000 g admitted to NICU 
Exclusions: NR 
PE/T 1: MgSO4 (4-6 g IV bolus LD; 2 
g/hour IV MD), N = 546 babies 
2: No MgSO4, N = 395 babies 













N = 110 babies 
Inclusions: all VLBW 
Exclusions: NR 
NR 1: MgSO4, N = 34 babies 
2. No MgSO4, N = 76 babies 
Surfactant treatment, 
indomethacin treatment, PDA, 










N = 207 babies 
Inclusions: extremely preterm infants born 
24-28 weeks GA 
Exclusions: NR 
FN 1: 2 years post MgSO4 
implementation, N = 99 babies 
2: 2 years pre MgSO4 
implementation, N = 108 babies 
PWML at 30 and 40 weeks MRI, 
early intubation for respiratory 
insufficiency, hypotension 
NR 
De Silva 2018; RCS 




N = 14108 babies 
Inclusions: babies born at 24+0-31+6 weeks 
GA and collected information about use of 
MgSO4 for FN as well as pregnancy 
characteristics 
Exclusions: babies with congenital anomalies 
were excluded, as in prior CNN analyses 
FN 1: MgSO4 for FN, N = 5314 babies 
2: No MgSO4, N = 7238 babies 
3: MgSO4 for another indication, N 
= 1556 babies 
Intensive resuscitation (either 
chest compressions or 
intubation and ventilation or 
epinephrine administration in 








N = 73 women, 80 babies 
Inclusions: women with diagnosis of 
advanced preterm labour (occurrence of 
painful, palpable uterine contractions ≥ 2 
times in 10 minutes for > 1 hour); cervical 
dilation ≥ 3.5 cm on admission; estimated GA 
< 36 weeks; available information of labour 
course and pregnancy outcome 
Exclusions: documented ROM, amniocentesis 
documenting pulmonary maturity; history 
consistent with incompetent cervix ± cerclage 
in place; clinical evidence of amnionitis; 
vaginal bleeding on admission 
T 1: MgSO4 IV (4-6 g IV LD; 2-4 
g/hour IV MD for at least 48 hours 
and no longer than 7 days), N = 44 
women, 48 babies 
2: No MgSO4 tocolysis, N = 29 
women, 32 babies 
Days in hospital (mean ± SD), 
days intubated (mean ± SD), 
RDS (mild to severe), RDS 
severe, IVH grade I-IV, NEC, 
neonatal death, Apgar score < 7 
at 5 minutes 
NR 
Downey 2017; RCS USA 
2007-2013 
N = 28035 babies 
Inclusions: ELBW (≤ 1000 g) infants 
discharged during study period 
Exclusions: outborn infants, and infants with 
severe congenital anomalies 
FN/PE/T 1: MgSO4, N = 11789 
1: No MgSO4, N = 16246 
SIP, neonatal death in 1st 21 
days of life, surgical NEC, 
medical NEC, death, NEC or SIP, 





























N = 1047 women and babies 
Inclusions: non-anomalous, singleton 
pregnancies receiving MgSO4 or placebo, 
exposed for > 3 hours at time of birth 
Exclusions: women exposed for < 3 hours or if 
drug was discontinued prior to birth 
FN 1: MgSO4, N = 461 babies 
2: Placebo, N = 586 babies 
Composite of immediate 
outcomes (Apgar score < 7 at 5 
minutes, oxygen administration 
in delivery room, intubation, 
chest compressions, 
hypotension, hypotonicity), 
Apgar score < 7 at 5 minutes, 
oxygen bag, mask or both, 
intubation, chest compressions, 
hypotension treated with 
vasopressors, generalised 
hypotonicity, RDS, MV, 
seizures, IVH, death 
NR 
Duffy 2012; RCS USA 
4 year period 
N = 5387 women and babies 
Inclusions: women who reached the second 
stage of labour, born ≥ 37 weeks GA, and had 
≥ 10 minutes of EFM tracing in 30 minutes 
before birth and an available umbilical 
arterial cord blood gas, with singleton 
pregnancies, cephalic presentation and no 
known fetal anomalies 
Exclusions: women who delivered by 
caesarean before labour or before complete 
dilatation 
Severe PE 1: MgSO4 (6 g IV LD; 2 g/hour IV 
MD), N = 248 babies 
2: No MgSO4, N = 5139 babies 
Composite adverse outcome 
(fetal acidemia, base excess ≤ -
12.00, SCBU or NICU admission)  



















analysis of RCT), 
also presents 
CC(N) analysis 
Inclusions: women considered at high risk of 
preterm birth between 24-31 weeks GA (risk 
based on presentation with ROM between 
22-31 weeks GA, spontaneous labour with 
cervical dilation of 4-8 cm, or providers 
anticipated an indicated preterm birth within 
2-24 hours) 
Exclusions: multiple gestation, chromosomal 
abnormalities, stillbirth, congenital 
anomalies, or missing information regarding 
the presence or absence of clinical 
chorioamnionitis 
1: MgSO4, N = 109 babies 
2: No MgSO4, N = 119 babies 
 
No chorioamnionitis, N = 1716 
women and babies 
1: MgSO4, N = 839 babies 
2: No MgSO4, N = 877 babies 
 
MgSO4: 6 g IV LD over 20-30 
minutes; 2 g/hour IV MD until birth 
or 12 hours; re-treatment 
permitted 





Elimian 2002; RCS USA 
1998-2001 
N = 401 babies 
Inclusions: premature neonates born 
between 23-34 weeks GA following preterm 
labour with intact membranes or PPROM 
Exclusions: neonates exposed to MgSO4 for 
seizure prophylaxis 
T 1: MgSO4 (4 g IV LD; 2-3 g/hour IV 
MD), N = 190 babies 
2: No to MgSO4 with/without other 
tocolytics, N = 211 babies 
 
1: MgSO4 for > 24 hours, N = 79 
babies 
2. MgSO4 for ≤ 24 hours, N = 111 
babies 
Apgar score < 7 at 5 minutes, 
RDS, surfactant, antibiotics, 
PDA, IVH/PVL, NEC, sepsis, 
neonatal death (1st 28 days) 
NR 





N = 14092 babies 
N = 9782 babies in groups of interest 
(excluded terbutaline and combination T 
groups) 
Inclusions: 24-32 weeks GA at birth, no major 
congenital anomalies, no PE, birthweight > 
400 g 
Exclusions: NR 
T 1: MgSO4, N = 6186 babies 
2: No MgSO4, N = 3596 babies 
Neonatal death, IVH, NEC, ROP NR 
Farkouh 2001; RCS USA 
1997-2000 
N = 12876 babies 
Inclusions: non-anomalous live born babies 
admitted to the NICU between 23-34 
completed weeks GA 
PE/T 1: MgSO4, N = 4612 babies 
2: No MgSO4, N = 8264 babies 










Exclusions: newborns transferred to/from an 
outside facility < 28 days, or whose discharge 





N = 54 babies (from sample of 492) 
Inclusions: birthweight < 1750 g, survival for > 
7 days, ≥ 1 CUS > 7 days, with all information 
on infant’s chart/labour and birth record: GA, 
history of maternal complications and reason 
for prematurity, length of ROM, antenatal 
steroid exposure, MgSO4 exposure, other 
tocolytic agent exposure, mode of birth, 
evidence of PE, Apgar score, days intubation 
Additional inclusions for cases: cPVL 
Additional inclusions for controls: selected 
from pool infants with normal CUS or IVH 
grade 1; control pool infants with birthweight 
outside of range in cPVL group were 
removed; 2 controls selected per case 
Exclusions: NR 
PE/T 1: cPVL, N = 18 babies 
2: No cPVL, N = 36 babies 
MgSO4 exposure NR 
Gano 2016; 
unclear: results 
appear to be 
presented as PCS 
with CCS(N)  
USA 
2011-2015 
N = 73 babies 
Inclusions: premature newborns < 33 weeks 
GA admitted to NICU 
Exclusions: clinical evidence of a congenital 
malformation or syndrome, congenital 
infection or status too unstable for transport 
to MRI 
FN/PE/T 1: MgSO4, N = 49 babies 
2: No MgSO4, N = 24 babies 
 
1: Cerebellar haemorrhage, N = 27 
babies 
2: No cerebellar haemorrhage, N = 
46 babies 
Cerebellar haemorrhage (and 




















N = 118 babies 
Inclusions: infants born before 32 weeks GA 
whose mothers received MgS04 as a 
FN 1: MgSO4 (4 g IV LD over 30 
minutes; 1 g/hour IV MD until birth 
Resuscitation, IMV, surfactant, 








neuroprotective agent and who were 
admitted to the NICU, and infants with same 
GA, who were born in the same time period 
Exclusions: infants with other risk factors that 
contributed to an immediate poor 
development: a polymalformed patient and 
another patient who passed away during the 
1st hour of life after a placental abruption 
or 24 hours; re-treatment 
permitted), N = 62 babies 




article in Russian 
CD N = 62 women and babies 
Inclusions: neonates of recurrent delivering 
women born between 27-28 weeks GA 
Exclusions: CD 
FN 1: MgSO4, N = 37 babies 
2: No MgSO4, N = 25 babies 
IVH, IVH grade 3/4 CD 
Ghidini 2001; CCS USA 
1995-1996 
 
N = 69 babies 
Inclusions for cases: consecutive infants 
diagnoses with NEC 
Inclusions for controls: each case matched 
with 2 controls: next infants admitted to NICU 
with similar GA and gender, but no NEC 
Exclusions: infants with structural or 
chromosomal anomalies 
PE/T (4 g IV 
bolus LD; 2 
g/hour IV MD) 
1: NEC, N = 23 babies 
2: No NEC, N = 46 babies 
MgSO4 exposure NR 
Gibbins 2013; RCS USA 
2007-2011 
N = 373 women and their babies (313 born < 
32 weeks in analyses for relevant outcomes) 
Inclusions: selected pregnant women with 
threatened or planned birth < 32 weeks GA 
Women eligible for MgSO4 for FN protocol: 
admitted with viable fetus < 32 weeks with 
either 1) preterm labour, 2) PPROM, or 3) 








1: MgSO4 (6 g IV bolus LD; 2 g/hour 
IV MD until birth or when birth no 
longer considered imminent; 
repeat dosing permitted), N = 247 
women (223 babies born < 32 
weeks analysed) 
2: No MgSO4, N = 126 (90 babies 
born < 32 weeks analysed) 
Apgar score < 7 at 1 minute, 
Apgar score < 7 at 5 minutes, 
resuscitation (none, oxygen bag 
and mask, intubation, chest 
compressions), discharged 
alive, NICU admission, LOS 





Girsen 2015; RCS USA 
1999-2002 
N = 2166 women and babies 
Inclusions: singleton pregnancies from the 
Cesarean Registry that were coded for 
maternal PE and > 37 weeks GA at birth 
PE 1: MgSO4, N = 1747 babies 
2: No MgSO4, N = 419 babies 
 
NICU admission, NICU 
admission within 2 hours of 
birth, NICU LOS (days) (median, 
range), LOS (days) (median, 









Exclusions: cases with uterine rupture, 
chorioamnionitis and major congenital 
malformations, cases with absence of 
available data on each variable 
minute, Apgar score < 7 at 5 
minutes, Apgar score < 7 at 10 
minutes, RDS, ventilation 
support within 24 hours of 
birth, prolonged hypotonicity 
within 72 hours of birth, 
seizures, sepsis, HIE, neonatal 










N = 851 babies 
Inclusions: neonates with birthweights 500-
1000 g 
Exclusions: NR 
NR 1: MgSO4, N = 438 babies 
2: No MgSO4, N = 413 babies 
Overall survival, early survival 
(alive at 7 days), severe RDS, 
IVH, PDA, early PDA (< 7 days) 
NR 
Greenberg 2011; 
RCS with CCS(N)  
USA 
2006-2008 
N = 252 babies (note: discrepancies in text 
and tables) 
Inclusions: singleton newborn infants who 
were born at ≥ 35 weeks GA to mothers who 
received MgSO4 before birth for PE 
Exclusions: multiple gestations, neonates who 
met any antenatal criteria for automatic NICU 
admission (maternal clinical chorioamnionitis 
before birth and major fetal anomalies 
requiring immediate evaluation) 
PE 1: NICU admission, N = 52 babies 
2: Well baby nursery admission, N = 
200 babies 
 
MgSO4: 4 g IV LD over 20-30 
minutes; 1-2 g/hour IV MD 
Duration of MgSO4 (hours) 
(mean ± SD), MgSO4 dose (g) 
(mean ± SD), > 12 hours MgSO4 








N = 264 babies 
Inclusions: singleton newborns ≥ 37 weeks GA 
born to women with a diagnosis of PE 
Exclusions: multiple gestations, neonates who 
met any antenatal criteria for automatic NICU 
admission including a clinical diagnosis of 
maternal chorioamnionitis and major fetal 
anomalies requiring immediate evaluation 
PE 1: MgSO4, N = 190 babies 
2: No MgSO4, N = 74 babies 
 
1: < 12 hours MgSO4 (< 30 g), N = 
132 babies 
2: ≥ 12 hours (≥ 30 g), N = 58 babies 
 
MgSO4: 4 g IV LD over 20-30 
minutes; 2 g/hour IV MD 
Meconium stained AF, NICU 
admission, initial admission 
(NICU vs. well baby nursery), 
primary admit diagnosis (RDS, 




NICU LOS (days) (median, IQR), 
treatments needed 
(respiratory, fluids/nutritional 
Funding: Oscar G 









Grether 1998; CCS USA 
1983-1985 
N = 168 babies (128 analysed) 
Inclusions for cases: infants who weighed < 
1500 g at birth and died in 1st 28 days 
Exclusions for cases: death from congenital 
anomalies, in the context of home birth or 
birth in a military facility, birthweight < 500 g 
or GA < 22 weeks, birthweight > 1500 g, 
multiple congenital anomalies 
Inclusions for controls: singletons born 
weighing < 1500 g from the same birth years 
and counties as the neonatal deaths, who 
survived to age 3 years and did not have 
disabling CP 
T 1: Neonatal death, N = 85 babies 
(53 analysed) 
2: Survival to 3 years with no 
disabling CP, N = 85 babies (75 
analysed) 
 
1: Neonatal death no maternal PE, 
N = 21 babies  
2: Survival to 3 years with no 
disabling CP no maternal PE, N = 35 
babies 
MgSO4 exposure, MgSO4 
exposure for PE, MgSO4 








appear to be 






N = 175 babies 
Inclusions: neonates < 33 weeks GA at birth 
Exclusions: congenital anomalies or 
conditions that may adversely affect 
breathing or ventilation 
NR 1: Hypoglycaemia within 1st hour of 
birth, N = 69 babies 
2: No hypoglycaemia, N = 106 
babies 
MgSO4 exposure NR 
Gulcan 2006; PCS Turkey 
2003-2004 
N = 200 babies 
Inclusions: consecutive preterm newborns < 
37 weeks GA admitted to the NICU 
Exclusions: congenital anomaly, birth at 
another hospital and admission after 24 
hours of age with no information on stool 
passage, death before stool passage, and 
development of NEC before stool passage 
T 1: MgSO4 (4 g IV LD; 2-3 g/hour IV 
MD), N = 35 babies 
2: No MgSO4, N = 165 babies 
RDS NR 
Gursoy 2015; PCS Turkey 
2011-2013 
N = 50 babies 
Inclusions: AGA neonates born 26-34 weeks 
GA, whose mothers were exposed to MgSO4 
(cases); birthweight and GA matched 
neonates whose mothers did not received 
MgSO4 (controls) 
PE/T 1: MgSO4 (6 g IV LD over 30 
minutes; 0.8 g/hour IV MD until 
birth), N = 25 babies 
2: No MgSO4, N = 25 babies 
Hypotension, hypertension, 








Exclusions: neonates with absence of 
antenatal Doppler examination or presence 
of absent/reversed end diastolic velocity in 
umbilical artery, congenital malformation, 







N = 56 babies 
Inclusions: GA < 37 weeks, and birthweight < 
2500 g and AGA 
Exclusions: presence of major congenital 
anomalies, the administration of vasoactive 
drugs other than caffeine, or a diagnosis of 
anaemia or polycythaemia 
PE/T 1: MgSO4 in 24 hours prior to birth 
(4-6 g IV bolus LD; 2-3 g/hour IV 
MD prior to birth), N = 27 babies 
2: No MgSO4, N = 29 babies 
 
Caffeine treatment, ventilator 
support, phototherapy, 
umbilical artery catheter, 
enteral feedings day 1, death 
during hospitalisation, NEC 
NR 
Hechtman 2002; 






N = 85 babies 
Inclusions: singleton pregnancies ≥ 23 weeks 
GA, with birthweights between 500-1000 g 
Exclusions: women with PE, PROM or fetal 
structural or chromosomal abnormalities 
T 1: Neonatal deaths at < 28 days or 
prior to hospital discharge, N = 19 
babies 
2: Survivors, N = 66 babies 
MgSO4 exposure, MgSO4 dose 
(g) (median, range), exposure 
to > 48 g total MgSO4  
NR 
Holcomb 1991; 




N = 23 women, 33 babies 
Inclusions for exposed: infants born to 
women who received IV MgSO4 for T for > 7 
days 
Inclusions for non-exposed: 2 infants selected 
for each exposed infant (having no more than 
3 days exposure to MgSO4), matched for 
single/multiple pregnancies and for GA at 
birth ± 2 weeks 
Exclusions: women with pregnancies 
complicated by IDD, metabolic bone disease, 
thyroid disease, renal disease, infection with 
syphilis, toxoplasma, rubella, 
cytomegalovirus; neonates without chest 
radiograph in 1st 48 hours 
T 1: MgSO4 > 7 days IV, N = 11 babies 
2: No MgSO4, or MgSO4 for < 3 
days, N = 22 babies 
Definitely abnormal chest 
radiograph (proximal humeri, 
radiographic abnormalities: 











N = 52 women and babies 
Inclusions: women with PPROM up to 34 
weeks GA 
Exclusions: NR 
FN 1: MgSO4, N = 26 women and 
babies 
2: No MgSO4, N = 26 women and 
babies 
IVH Funding: NR 
Conflicts: none 
 





N = 598 babies 





1: January 2012-December 2013: 
MgSO4 for FN not adopted (16.2% 
exposure), N = 270 babies 
2: January 2014-March 2016: 
MgSO4 for FN used routinely 
(60.6% exposure), N = 264 babies 
3: April 2016-December 2016: 
MgSO4 abandoned (potential NEC 
risk) (14.0% exposure), N = 64 
babies 
 
1: MgSO4, N = 213 babies 
2: No MgSO4, N = 385 babies 
Neonatal death, neonatal death 
due to NEC, NEC, severe NEC 




unclear: RCS (or 
NCCS) 
English abstract; 
article in Japanese 
CD N = 42 babies 
Inclusions: hypermagnesemic preterm infants 
born to women treated with MgSO4 for T, 
and preterm infants born to normal women 
Exclusions: CD 
T 1: Hypermagnesemic infants 
exposed to MgSO4, N = 27 babies 
(with (N = 15) and without (N = 12) 
complications) 
2: Infants born to “normal 
mothers”, N = 15 babies 
Respiratory and cardiovascular 
symptoms (respiratory 
depression, hypotonia, 
hypotension, requirement for 







N = 53 babies 
Inclusions: neonates between 26-34 weeks 
GA 
Exclusions: neonates without antenatal 
Doppler examination and with 
absent/reversed end diastolic velocity in 
umbilical artery; neonates with clinical 
conditions such as congenital malformation, 
chromosomal anomaly, perinatal asphyxia, 
sepsis, PROM, chorioamnionitis, 
polycythaemia, anaemia and whose mothers 
had multiple pregnancies; neonates with 
PE/T 1: MgSO4 (6 g IV LD over 30 
minutes; 0.8 g/hour IV MD until 
birth), N = 20 babies 
2: No MgSO4, N = 33 babies 
RDS, PDA, IVH, caffeine 








uncertain GA; women having ritodrine for 
tocolysis; neonates who suffered from 
hypotension, exposed to drug therapies that 
could change CBF velocity or arterial blood 
pressure and any metabolic pathology 
James 2015; PCS Ireland 
2013-2014 
N = 38 babies 
Inclusions: preterm infants < 29 weeks GA 
exposed to MgSO4; infants not exposed to 
MgSO4 matched for birthweight, GA, mode of 
birth 
Exclusions: NR 
FN 1: MgSO4 within 4 hours of birth (4 
g IV LD over 20 minutes; no 
subsequent infusion), N = 19 babies 
2: No MgSO4, N = 19 babies 
IVH grade 3/4, inotropes (1st 
week), pulmonary 
haemorrhage, NEC, CLD, death 
before discharge, early onset 
sepsis, invasive ventilation days 
1 and 2, PDA days 1 and 2  
Funding: support 
from the EU and 
Friends of the 
Rotunda 
Conflicts: none 
Jazayeri 2003; RCS Authors 
from USA 
1998-2001 
N = 72 women and babies 
Inclusions: women who delivered after 
PPROM < 34 weeks GA who received 
corticosteroids and antibiotics (cases: 
received MgSO4; controls matched for GA 
within a week) 
Exclusions: women with clear indication for 
birth (chorioamnionitis, abnormal fetal 
surveillance, maternal haemorrhage) 
T 1: MgSO4, N = 36 babies 
2: No MgSO4, N = 36 babies 
NICU LOS (days) (mean ± SE), 
meconium, RDS, IVH, NEC, 








N = 119 women and their babies 
Inclusions: women with fetuses < 33 weeks 
GA whose birth was planned or expected 
within 24 hours 
Exclusions: NR 
FN 1: MgSO4 (4 g IV LD; 1 g/hour IV 
MD until birth or for 12 hours), N = 
81 women 
2: No MgSO4, N = 38 women 
Apgar score < 7 at 5 minutes, 









N = 120 babies 
Inclusions: infants born between 32+0-33+6 
weeks GA 
Exclusions: NR 
PE/T 1: MgSO4, N = NR 
2: No MgSO4, N = NR 





Jung 2018; RCS South Korea 
2005-2013 
N = 184 women and their babies 
Inclusions: singleton pregnancies complicated 
by PPROM at 23+0-31+6 weeks GA who were 
hospitalised and received MgSO4 for T 
(MgSO4 group) or did not receive T (MgSO4, 
T 1: MgSO4 (6 g IV LD over 30 
minutes; 1 g/hour IV MD until 
uterine quiescence), N = 143 
women and babies 
2: No MgSO4, N = 41 women and 
babies 
Stillbirth, neonatal death, early 
neonatal death, perinatal 
death, Apgar score < 7 at 5 
minutes, pulmonary 
hypoplasia, RDS, BPD, NEC, 







beta-adrenergic receptor agonists, or 
calcium-channel blockers) (no MgSO4 group) 
Exclusions: patients who were not candidates 
for expectant management of pregnancy at 
admission, such as those with intrauterine 
infection, significant vaginal bleeding, 
placental abruption, cord prolapse, non-
reassuring fetal status, or advanced labour, 
patients with multifetal gestations, pregnancy 
associated hypertension, fetal anomalies, and 
IUGR 
grade 2/3, hearing impairment, 
NICU LOS (days) (mean ± SD), 








2002-2004: N = 26752 births, 769 women 
with E, 474 women with 
antepartum/intrapartum E, 481 babies 
1995-1997: N = 31352 births, 877 women 
with E, 731 women with 
antepartum/intrapartum E, 724 babies 
Inclusions: all births; antepartum and 
intrapartum E included for assessment of 
perinatal death 
Exclusions: NR 
E 1: 2002-2004 (almost universal 
MgSO4 use), N = 481 babies  
2: 1995-1997 (no MgSO4 use), N = 
724 babies  







N = 271 babies 
Inclusions, non-anomalous singleton infants 
weighing ≤ 1000 g 
Exclusions: NR 
FN/PE/T 1: MgSO4, N = 133 babies 
2: No MgSO4, N = 138 babies 
Composite morbidity (IVH, PVL, 
BPD, NEC, RDS, ROP and/or 








N = 1246 babies 
Inclusions: infants born 23+0 to 31+6 weeks 
GA 
Exclusions: multiple gestations, fetal 
anomalies, aneuploidy 
FN/PE/T 1: MgSO4, N = 457 babies 
2: No MgSO4, N = 789 babies 
Composite morbidity 
(IVH, BPD, NEC, and/or death 










N = 2431 babies 
Inclusions: women with non-anomalous 
singleton and twin gestations born ≥ 24 
weeks GA 
Exclusions: NR 
FN Males, N = 1147 babies 
1: MgSO4, N = 643 babies 
2: No MgSO4, N = 504 babies 
 
Females, N = 1284 babies 
Composite severe morbidity 






1: MgSO4, N = 536 babies 
2: No MgSO4, N = 748 babies 
Kamyar 2016a; 
RCS (secondary 
analysis of RCT) 
See Rouse 
2008 
N = 396 babies 
Inclusions: women diagnosed with 
intrapartum clinical chorioamnionitis (clinical 
diagnosis of chorioamnionitis with ≥ 1 of: 
maternal temperature of > 37.8°C or 
antibiotic administration for the documented 
indication of chorioamnionitis; 
chorioamnionitis noted on placental 
pathology alone was not considered sufficient 
for a diagnosis of chorioamnionitis) 
Exclusions: no chorioamnionitis, twins, loss to 
follow up before birth 
FN 1: MgSO4 (6 g IV LD over 20-30 
minutes; 2 g/hour IV MD), N = 192 
babies 
2: Placebo, N = 204 babies 
Stillbirth or death by age 1, 
severe composite morbidity (1 
or more of: sepsis, severe IVH, 
PVL, NEC stage 2/3, BPD), 
sepsis, severe IVH, PVL, NEC 
















RCS with CCS(N) 
(secondary 
analysis of RCT) 
USA 
1997-2004 
N = 697 babies 
Inclusions: singleton and twin infants 
admitted, randomised, and born between 
23.0-27.9 weeks GA 
Exclusions: infants with chromosomal 
abnormalities, major congenital 
malformations, and/or with incomplete 
outcomes 
FN 1: MgSO4, N = 332 babies 
2: No MgSO4, N = 365 babies  
 
1: MgSO4, N = 148 babies born < 26 
weeks GA 
2: No MgSO4, N = 145 babies born 
< 26 weeks GA 
 
MgSO4 exposed babies 
1: NICU death and/or NEC stage 
2/3, N = 73 babies 
2: Survival without NEC stage 2/3, 
N = 259 babies 
Death and/or NEC stage 2/3  
 
MgSO4 infusing at birth, total 
amount of MgSO4 received (g) 









N = 160 babies 
Inclusions: extremely preterm neonates (GA < 
28 weeks), all who received prophylactic 
indomethacin within 6 hours of birth 
Exclusions: infants with chromosomal 
abnormalities 
T (1 woman 
for PE) 
1: MgSO4 (no LD; 0.5-1 g/hour IV 
MD), N = 41 babies 
2: No MgSO4, N = 119 babies 
 
MgSO4 
1: Low dose (< 50 g), N = 19 babies 
2: High dose (≥ 50 g), N = 22 babies 
Early closure of DA, 
symptomatic PDA, successful 
response to indomethacin of 
PDA, successful response to 
surgical treatment of PDA, 







Kelly 1992; PCS 
Abstract 
NR N = 10 women and babies 
Inclusions: women treated with continuous 
MgSO4 infusion for preterm labour, and 
controls (30-35 weeks GA) 
Exclusions NR 
T 1: MgSO4 IV, N = 5 babies 






N = 121 babies 
Inclusions: VLBW (< 1500 g) infants admitted 
(cases: IVH grade 3/4) 
Exclusions: deaths during the 1st 48 hours of 
life 
T 1: IVH grade 3/4, N = 39 babies 
2: No IVH grade 3/4, N = 82 babies 





N = 308 babies (363 in death analyses) 
Inclusions: singleton infants ≤ 1000 g with a 
GA ≥ 20 weeks who were not the product of 
an induced abortion or antepartum stillbirth, 
who survived > 2 days after birth, who were 
born without major anomalies, who were 
deemed potentially viable by the 
obstetricians, and would have undergone a 
caesarean birth for fetal indications 
Exclusions: infants born to women diagnosed 
with PE 
T 1: MgSO4, N = 124 babies (138 for 
death analyses) 
2: No MgSO4, N = 184 babies (225 
for death analyses) 
Death ≤ 2 days, death 3-120 
days, intact survival (survival to 
hospital discharge or 120 days 
without any serious 
morbidities), death at ≥ 2 days 
and < 120 days, IVH grade 3/4, 
ROP grade 3/4, abnormal 
neurological evaluation, seizure 
activity, NEC requiring surgery, 
oxygen dependence at 
discharge, duration of 
ventilation (days) (median, 
measure of variance NR), NICU 




appear to be 
presented as PCS 
with CCS(N)  
Turkey 
Year NR 
N = 120 babies 
Inclusions: live born infants with birthweights 
750-1500 g 
Exclusions: NR 
T 1: Infants with IVH; with severe 
abnormalities, grade 3/4 GMH-IVH 
or PVL, N = 18 babies 
2: Infants with minimal, grade 1/2 
GMH-IVH or no abnormalities, N = 
102 babies 
MgSO4 exposure NR 
Kuban 1992; PCS USA 
1984-1987 
N = 449 babies 
Inclusions: weighed 1500 g or less, and had a 
CUS performed within the 1st 15 days after 
birth 
Exclusions: NR 
PE/T 1: MgSO4, N = 90 babies 
2: No MgSO4, N = 359 babies 
GMH-IVH Funding: The 












N = NR 
Inclusions: women diagnosed with PE who 
delivered ≥ 37 weeks GA 
Exclusions: NR 
PE 1: MgSO4, N = NR 
2: No MgSO4, N = NR 
Muscle tone scores (units NR), 
SCBU admission, NICU 
admission, delayed adaptation 
NR 
Lee 2013; RCS 
English abstract; 
article in Korean 
Korea 
2005-2012 
N = 81 babies 
Inclusions: VLBW infants born to women with 
PE who had been admitted to the NICU 
Exclusions: NR 
PE 1: MgSO4, N = 20 babies 
2: No MgSO4, N = 61 babies 
 
1: MgSO4 and sPDA, N = 15 babies 
2: MgSO4 and no sPDA, N = 5 
babies 
RDS, ventilation, sPDA, 
operated PDA, ROP, NEC, IVH 
grade ≥ 1, PVL, death 
CD 




N = 570 women and babies 
Inclusions: pregnant women with preterm 
birth, and their neonates 
Exclusions: NR 
T 1: MgSO4 IV, N = 101 babies 




appear to be 
presented as PCS 
with CCS(N)  
USA 
1999-2003 
N = 289 babies 
Inclusions: neonates born < 33 weeks GA with 
birthweight < 1501 g who were enrolled in a 
prospective study of the relationship of 
inflammatory markers and invasive 
ureaplasma with respiratory and CUS 
outcomes; with documented hearing screen 
Exclusions: congenital brain/neural tube 
defects, confirmed congenital infections and 
no available cord blood or venous sample 
within 12 hours of birth 
PE/E/T 1: Passed hearing screen, N = 244 
babies 
2: Failed hearing screen, N = 45 
babies 
 
MgSO4 exposure, MgSO4 and 
betamethasone exposure 
Funding: 





Leviton 1997; PCS Authors 
from USA 
1991-1993 
N = 1331 women and 1518 babies 
Inclusions: infants weighing 500 to 1500 g 
when born 
Exclusions: death before CUS, or 
unavailability of CUS and information about 
receipt of MgSO4 and potential confounders 
Unclear 
(PE/PIH/T) 
1: MgSO4, N = 678 babies 
2: No MgSO4, N = 840 babies 
IVH, PEA: early, late, any, 
















N = 37 babies 
Inclusions: newborn infants (all between 33-
42 weeks GA) born to toxaemic women who 
received MgSO4 as per regimens to the right 
PE/E 1: MgSO4 IV LD and MD (2-4 g IV 
LD; 1 g/hour IV MD - Zuspan’s 
regimen), N = 29 babies 
Apgar score < 7 at 1 minute, 
Apgar score < 7 at 5 minutes, 
clinical score of 3, clinical score 





Exclusions: NR 2: MgSO4 IV LD, IM MD (2-3 g IV 
LD; IM MD), N = 8 babies 
maximum of 3, the greater the 
apparent toxicity of excess Mg: 
1 point for flaccidity and 
hyporeflexia, 1 for resuscitation 
or assisted ventilation, 1 for 
week or absent cry unrelated 






article in Spanish 
CD N = 107 babies 
Inclusions: preterm infants < 32 week 
exposed to MgSO4 for FN, and a historic 
group immediately prior to this treatment 
Exclusions: infants that had not reached lung 
maturity with corticosteroids 
FN 1: MgSO4, N = 56 babies 
2: No MgSO4, N =51 babies 
Resuscitation, Apgar score ≤ 5 
at 1 minute, Apgar ≤ 5 at 5 
minutes, CPAP/nasal IMV, 
CMV, HFOV, surfactant 
treatment, PDA treated, 
vasoactive drugs, blood 
products, sepsis confirmed, 
pathological brain ultrasound, 
no stools at 48 hours, no bowel 
movements at 72 hours , NEC, 
death, CRIB (median, range), 
meconium evacuation delay, 
parenteral nutrition 
CD 
Martin 1998; RCS Authors 
from USA 
1992-1994 
N = 193 women and babies 
Inclusions = pregnancies complicated by 
severe PE (according to the ACOG criteria) 
between 26-32 weeks GA, and (for 
comparison), pregnancies delivered due to 
preterm labour during the same period 
between 26-32 weeks GA 
Exclusions: diagnosis of PPROM 
PE/T 1: MgSO4, N = 118 babies 
2: No MgSO4, N = 75 babies 
IVH NR 
Matsuda 1997; 
RCS with CCS(N) 
Japan 
1992-1994 
N = 139 babies born to 114 women; and a 
further 51 control babies 
Inclusions: neonates born to all pregnant 
women who received IV MgSO4 (cases); 
PE/T 1: MgSO4 (according to Zuspan’s 
regimen: 4 g IV LD over 30 minutes; 
1-2 g/hour IV MD), N = 114 women 
and 139 babies 
2: No MgSO4, N = 51 babies 
Bone abnormalities 
 
GA at start of MgSO4 (weeks) 





neonates born to pregnant women given no 
MgSO4 in the same period (controls) 
Exclusions: pregnancies complicated by 
metabolic bone disease, thyroid disease, 
renal disease, congenital infections (syphilis, 
toxoplasmosis, cytomegalovirus) 
 
1: MgSO4 and bone abnormalities, 
N = 13 babies 
2: MgSO4 and no bone 
abnormalities, N = 101 babies 
MgSO4 (days) (mean ± SD), 






N = 37 women and their babies 
Inclusions: consecutive women with PE, 
thought clinically to be at term with 
appropriately grown infants (study group); 
normotensive women at term with 
appropriately grown infants (control group) 
Exclusions: NR 
PE 1: MgSO4 (4 g IV LD over 30 
minutes; 1-2 g/hour IV MD), N = 23 
women and their babies 
2: Dextrose-water or dextrose-
saline, N = 14 women and their 
babies 





analysis of RCT) 
USA 
1997-2004 
N = 933 women and their babies 
Inclusions: women at high risk for preterm 
delivery between 24-31 weeks GA because of 
ROM (between 22-31 weeks GA), 
spontaneous labour with cervical dilation of 
4-8 cm, or anticipated indicated preterm 
delivery within 2-24 hours, with singleton, 
non-anomalous fetuses (diagnosed before or 
after birth) randomised to MgSO4 who 
received the study drug  
Exclusions: NR 
FN 1: MgSO4 < 12 hours cumulative, N 
= 356 women and babies 
2: MgSO4 12-18 hours cumulative, 
N = 341 women and babies 
3: MgSO4 > 18 hours cumulative, N 
= 236 women and babies 
 
MgSO4: 6 g IV LD over 20-30 
minutes; 2 g/hour IV MD until birth 
or for 12 hours; re-treatment 
permitted 
Apgar score < 7 at 5 minutes, 
resuscitation in delivery room 
(oxygen blow-by, oxygen bag, 
mask or both, intubation, chest 
compressions), NEC, ROP, RDS, 
MV, BPD, seizures, any IVH, IVH 
grade 3/4, NICU admission 
Funding: NR 
Conflicts: none 
Mikhael 2019; RCS USA 
2010-2016 
N = 302 babies 
Inclusions: babies with a birthweight ≤ 1000 g 





1: MgSO4 ≤ 7 days prior to birth, N 
= 210 babies 
2: No MgSO4 ≤ 3 days prior to 
birth, N =192 babies 
 
1: MgSO4 ≤ 3 days prior to birth, N 
= 179 babies 
2: No MgSO4 ≤ 3 or ≤ 7 days prior 
to birth, N = 123 babies 
 
Death, early death, postnatal 
steroids, NEC, early NEC, SIP, 
early SIP, SIP or NEC or death, 
early SIP or NEC or death, late 
onset-sepsis, postnatal NSAIDs 
for PDA, IVH ≥ grade 3 
 







1: MgSO4 ≤ 3 days prior to birth, N 
= 179 babies 
2: No MgSO4 ≤ 3 days prior to 
birth, N = 31 babies 
 
1: Pre MgSO4 protocol 
implementation, N = 112 babies 
2: Post MgSO4 protocol 
implementation, N = 190 babies 
 
4 g IV LD over 30 minutes; 2 g/hour 
IV MD for 12 hours or until birth; 
repeated if birth not within 12 
hours (repeat LD if > 6 hours has 
passed since discontinuation) 




N = 425 babies 
Inclusions: single, spontaneous preterm 
births born between 22-31 weeks GA 
Exclusions: chromosomal abnormalities 
and/or anomalous births 
T 1: MgSO4 (4 g IV LD over 30 
minutes; 1-2 g/hour IV MD), N = 
236 babies 
2: No MgSO4, N = 189 babies 
 
1: Adverse outcome (IVH, PVL, CP, 
infantile death), N = 80 babies 
2: Good outcome, N = 315 babies 
 
1: < 2 days MgSO4, N = 49 babies 
2: > 2 days MgSO4, N = 174 babies 
 
1: MgSO4 and adverse outcome, N 
= 49 babies 
2: MgSO4 and good outcome, N = 
174 babies 
Fetal and neonatal death, 
Apgar score < 7 at 1 minute, 
Apgar score < 7 at 5 minutes, 




Combined adverse outcome 
(death, IVH, PVL, CP), IVH, PVL 
 










N = 146 babies 
Inclusions: surviving neonates with data on 
antenatal MgSO4 exposure and 
neuropathogenesis (IVH grade 2 and/or LSV) 
FN/T 1: MgSO4 0 to 4 g, N = 90 babies 
2: MgSO4 5 to 49 g, N = 23 babies 
3: MgSO4 ≥ 50 g, N = 33 babies 
 












N = 140 babies 
Inclusions: babies with HUS data linked to 
MgSO4 exposure 
Exclusions: NR 
FN/T 1: No MgSO4, N = 64 babies (note: 
women received other tocolytic) 
2: MgSO4 > 0 to < 10 g, N = 27 
babies 
3: MgSO4 10 to < 30 g, N = 8 babies 
4: 30 to < 50 g, N = 11 babies 
5: ≥ 50 g, N = 30 babies 
TSV NR 
Morag 2015; RCS Israel 
2015 
N = 645 women and 705 babies 
Inclusions for ‘study group’: infants born 
34+0-35+6 weeks GA, born alive 
Inclusions for matched term infants: infants 
born 37+0-41+6 weeks GA within 2 weeks of 
index case, matched for gender and mode of 
birth 
Exclusions: infants born at 36 weeks GA, 
diagnosed with genetic syndromes or major 
malformations 
PE 1: Preterm infants, N = 235 babies 
2: Term infants, N = 470 babies 
 
1: Preterm infants with MgSO4, N = 
10 women 
2: Preterm infants with no MgSO4, 
N = 168 women 
Respiratory disease (including 
RDS, TTN and disorders of air 





Morag 2016; RCS Authors 
from Israel 
2012-2013 
N = 190 babies 
Inclusions: infants admitted to a tertiary care 
NICU, born < 32 weeks GA without congenital 
anomalies or known genetic disorders 
Exclusions: NR 
FN/PE 1: MgSO4 (5 g IV LD over 30 
minutes; 2 g/hour IV MD), N = 145 
babies 
2: No MgSO4, N = 45 babies 
Apgar score < 7 at 1 minute, 
Apgar score < 7 at 5 minutes, IV 
(days) (mean ± SD), treated 
early hypotension, intubation, 
oxygen at 28 days, oxygen at 36 
weeks, proven NEC, sepsis, IVH 
grade 3/4/PVL, discharge 







2 year period N = 75 babies 
Inclusions: NEC cases, and controls matched 
for GA 
Exclusions: infants with structural or 
chromosomal anomalies 
NR 1: NEC, N = 25 babies 
2: No NEC, N = 50 babies 
MgSO4 exposure NR 
Murata 2005; 
unclear: results 
appear to be 
Japan 
1992-1997 
N = 201 babies 
Inclusions: all appropriate for date babies 
born at 24 to 33 weeks GA (maternal 
transports with predominant indications for 
T 1: cPVL, N = 35 babies 
2: No cPVL, N = 166 babies 
 




presented as RCS 
with CCS(N)  
maternal transfers and then all inborn 
neonates) 
Exclusions: babies with major anomalies, with 
IVH grade 3/4, or who died within 2 weeks 
after birth 
MgSO4: 1-4 g/hour IV LD; 0.5-2 




appear to be 
presented as RCS 
with CCS(N)  
Abstract 
NR N = 58 women and their babies 
Inclusions: premature or PE women treated 
with MgSO4 and their newborns (4 g IV LD 
over 30 minutes, 1-2.5 g/hour IV MD) 
Exclusions: NR 
PE 1: Ileus, N = NR 
2: No ileus, N = NR 





N = 304 women and babies 
Inclusions: neonates born at 24-33+6 weeks 
GA admitted to the NICU 
Exclusions: neonates with major congenital 
malformations or chromosomal anomalies, 
neonates transferred from outside facilities 
FN/PE 1: MgSO4 (4 g IV LD for PE, 6 g IV 
LD for FN; 2 g/hour IV MD), N = 237 
women and babies 
2: No MgSO4, N = 67 women and 
babies 
 
Apgar score ≤ 5 at 1 minute, 
Apgar score ≤ 5 at 5 minutes, 
delivery room resuscitation, 
hypotension, hypocalcaemia, 
IVH grade 3/4, BPD, ROP grade 
3+, PVL, intubation, NEC, PDA, 
death, composite outcome 
(death, IVH grade 3/4, BPD, 
ROP grade 3+, PVL, NEC), NICU 




Nassar 2006; RCS Lebanon 
1995-2003 
N = 155 women 
Inclusions: all women admitted for IV MgSO4 
T at ≥ 25 weeks GA 
Exclusions: women who required a 
combination of other tocolytics and those 
with an underlying maternal disease like pre-
existing hypertension or renal disease 
T 1: MgSO4 > 48 hours, N = 78 
women, 112 babies 
2: MgSO4 ≤ 48 hours, N = 77 
women, 86 babies 
 
MgSO4: 4 g IV LD over 20 minutes; 
2 g/hour, increased up to 4 g/hour 
IV MD 
Apgar score < 4 at 1 minute, 
Apgar score < 7 at 5 minutes, 
hypotonia, IVH, neonatal 
deaths (per 1,000), abnormal 
bone mineralisation 
NR 
Nelson 1995; CCS USA 
1983-1985 
N = 117 babies 
Inclusions for cases: singletons who weighed 
< 1500 g at birth, survived to age 3 years 
(residents in California to that age), with 
moderate or severe congenital CP 
PE/T 1: CP, N = 42 babies 
2: No CP, N = 75 babies 
 
For review outcomes: 
1: No CP, MgSO4, N = 27 babies 
[discrepancy in text/table] 











Exclusions: children with mild CP, with 
abnormalities of tone/reflexes but no 
functional impairment, and those with 
isolated hypotonia or disability acquired after 
1st 28 days of life, or non-accidental head 
trauma in 1st month of life 
Inclusions for controls: randomly selected, 
approximately 2 per case, from the 
population of infants < 1500 g at birth, born 
in same counties and birth years, who 
survived to age 3 years 
2: No CP, no MgSO4, N = 48 babies ATSDR, US Public 
Health Service, 





Nunes 2018; RCS Brazil 
2009-2014 
N = 75 women, 99 babies (94 available for 
analyses) 
Inclusions: patients with premature newborn 
deliveries between 24-32 weeks GA 
Exclusions: NR 
FN 1: MgSO4 (4 g IV LD over 30 
minutes; no MD), N = 26 babies 
2: No MgSO4, N = 68 babies 
Abnormal heart rate, abnormal 
respiratory rate (tachypnoea), 
abnormal temperature 
(hypothermia, hyperthermia), 














N = 103 women and their babies 
Inclusions: severe PE or E at the antenatal 
and labour ward (detailed definitions 
provided) 
Exclusions: women who had diazepam prior 
to arrival and those with history of chronic 
seizure disorder 
PE/E 1: MgSO4 10 g IM LD; 5 g/4 hours 
IM MD until 24 hours after birth or 
last convulsion, N = 54 women and 
their babies 
2: MgSO4 4 g IV and 10 g IM LD; 5 
g/4 hours IM MD until 24 hours 
after birth or last convulsion, N = 
49 women and their babies 
Apgar score < 7 at 5 minutes, 
perinatal death 
NR 
Ozlu 2019; RCS Turkey 
2011-2016 
N = 280 babies 
Inclusions: babies hospitalised in the NICU ≤ 
32 weeks GA with completed antenatal 
steroid doses 
FN 1: 2014-2016 (post MgSO4 
implementation; unclear uptake), N 
= 108 babies 
2: 2011-2012 (pre MgSO4 
implementation), N = 172 babies 
Death, resuscitation at birth, 
RDS, ventilator support, 
ventilation (days) (mean ± SD, 
and median, minimum and 






Exclusions: babies who did not receive 
complete antenatal steroid doses, who had 
congenital anomalies, who were exposed to 
MgSO4 for PE, or who were sent to another 
hospital 
 
MgSO4 implemented in 2013: 6 g 
IV LD over 30 minutes, 2 g/hour IV 
MD until birth or 24 hours 
(days) (mean ± SD, and median, 
minimum and maximum), NEC, 
early neonatal sepsis, feeding 
intolerance, could not get full 
enteral feeding, could not start 
any enteral feeding, starting 
day of enteral feeding (day) 
(mean ± SD, and median, 
minimum and maximum), time 
of full enteral feeding (day) 
(mean ± SD, and median, 
minimum and maximum), PDA, 
ROP, IVH, IVH grade 3/4, 
duration of hospital stay (days) 
(mean ± SD, and median, 
minimum and maximum) 




N = 100 babies 
Inclusions: preterm infants born 24-32 weeks 
GA whose mothers did/did not receive 
MgSO4 IV 
Exclusions: NR 
FN 1: MgSO4 IV, N = 55 babies 
2: No MgSO4, N = 45 babies 
Duration of intubation (hours) 
(median, variance measure NR) 
NR 
Palatnik 2019; CCS USA 
2011-2015 
N = 779 babies 
Inclusions: babies born from singleton/twin 
pregnancies at 23+1 to 31+6 weeks GA 
Cases: babies diagnosed with early onset 
neonatal sepsis on blood or CSF culture in 1st 
72 hours of life, or who died in the 1st week of 
life 
Controls: eligible babies who did not meet 
criteria for cases 
Exclusions: babies transferred from outside 
institutions, born following pregnancies 
complicated by major fetal anomaly or with 
no intent for resuscitation 
NR 1: Cases (early onset neonatal 
sepsis or death in 1st week of life), 
N = 73 babies 
2: Controls, N = 706 babies 





Paneth 1991; PCS USA 
1984-1987 
N = 1037 babies 
Inclusions: geographically representative 
sample of infants weighing 2000 g or less 
born or cared for in 3 NICUs 
Exclusions: infants with insufficient 
information about details of labour and birth 
to permit satisfactory classification of 
maternal exposure 
PE/PEH/T 1: MgSO4, N = 362 babies 
2: No MgSO4, N = 675 babies 










N = 1025 babies 
Inclusions: singleton preterm infants < 1500 g 
Exclusions: NR 
PIH 1: MgSO4, N = 192 babies 
2: No MgSO4, N = 833 babies 
PV-IVH, IVH grade 3/4 NR 





N = 140 women and babies 
Inclusions: pregnant women with monofetal 
pregnancies, from 26-33+6 weeks GA, who 
delivered to 34 weeks GA 
Exclusions NR 
FN 1: MgSO4 (IV LD over 15 minutes; 
1g/hour IV MD), N = 80 babies 




Petrova 2012; RCS 
with CCS(N)  
USA 
2004-2008 
N = 178 babies 
Inclusions: GA 23-31 weeks, no congenital 
malformations or reports of maternal 
hypertension or PE, HUS done during 1st 14 
days postpartum 
Inclusions for controls: double-match 
approach used, matched by exact GA in 
completed weeks and by same/similar 
birthweight (± 100 g); due to non-availability 
or > 1 control for ELBW infants, the authors 
selected 1 control; where several controls 
available, 1 randomly selected 
Exclusion criteria: NR 
T 1: IVH, N = 89 babies 
2: No IVH, N = 89 babies 
 
MgSO4: 4-6 g IV LD over 30 
minutes; 1-3 g/hour IV MD until 12-
24 hours uterine quiescence 
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N = 105 babies 
Inclusions: premature infants < 32 weeks GA 
and < 1500 g 
Exclusions: NR 
NR 1: MgSO4, N = 95 babies 









N = 55 babies (19 were in a ritodrine 
exposure group and not further considered) 
Inclusions: preterm infants consecutively 
born at < 33 weeks GA, with no major 
congenital malformations, and written 
informed consent 
Exclusions: no exclusions 
PE/T 1: MgSO4 (5 g IV LD over 20 
minutes; 1-2 g/hour IV MD), N = 19 
babies 
2: No MgSO4 (born immediately 
after exposed infants, with no T or 
anticonvulsants), N = 19 babies 
Dexamethasone, dopamine, 
dobutamine, surfactant, PDA, 
PV-IVH grade 1-4, PV-IVH grade 
3/4, HIE/increased echodensity, 
RDS and MV, NICU admission, 














Rasch 1982; PCS USA 
Time period 
NR 
N = 79 babies 
Inclusions: infants of mothers with PE treated 
with MgSO4, infants of women with PE not 
treated with MgSO4, and infants of normal 
women (definition for PE provided) 
Exclusions: 
Infants born to women with pre-existing 
hypertension or other chronic diseases, 
preterm infants and infants with complicating 
factors such as tight nuchal cord, 
documented late decelerations, signs of 
sepsis, or asphyxia, infants whose mothers 
had received general anaesthesia or doses of 
sedative drugs within 2.5 hours of birth 
PE 1: Born to PE women treated with 
MgSO4 (4 g IV and 10 g IM LD; 0.3 
g/hour IV MD until birth), N = 36 
babies 
2: Born to PE women with no 
MgSO4, N = 18 babies 
3: Born to normal women, N = 25 
babies 
Poor sucking and cry response, 
cyanosis during feedings, 
requirement for IV fluid 
treatment, neurologic section 
of the Dubowitz examination at 
birth, over 24 hours after birth, 








N = 155 babies 
Inclusion: singleton and twin gestation ELBW 
(< 1000 g) inborn and admitted to NICU 
Exclusions: infants born with major congenital 
malformations or chromosomal anomalies 
FN 1: Pre-MgSO4 FN protocol (January 
2009 – July 2010; 50.6% MgSO4), N 
= 81 babies 
2: During MgSO4 FN protocol (July 
– November 2010; 78.3% MgSO4), 
N = 23 babies 
3: After MgSO4 FN protocol 
(January – October 2011; 60.8% 
MgSO4), N = 51 babies 
Postnatal hydrocortisone, 









MgSO4: 6 g IV LD; 2 g/hour IV MD 
until birth or 12 hours; re-
treatment permitted 
Rauf 2017; RCS Turkey 
2011-2016 
N = 107 women and babies 
Inclusions: maternal age between 18-39 
years, with singleton pregnancies born before 
32nd week of pregnancy 
Exclusions: pregnant women who were 
treated with MgSO4 for T or E prophylaxis, 
multiple pregnancies, fetal death, associated 
fatal congenital anomalies or chromosomal 
abnormalities, women with contraindications 
for MgSO4 use 
FN 1: MgSO4 (6 g IV LD over 30 
minutes; 2 g/hour IV MD until birth 
or up to 12 hours), N = 46 babies 
2: No MgSO4, N = 61 babies 
 
Active resuscitation at birth 
(respiratory support with ET 
intubation), NICU LOS (days) 
(mean ± SD), respiratory 
support, MV, nasal CPAP, nasal 
SMIV, oxygen hood, IVH and 
grade 1-4, PVL, convulsion, 
hypotonia, encephalopathy, 
ROP, neonatal death 
NR 
Rhee 2012; PCS USA 
2001 
N = 23 women and 22 babies (with usable 
specimens) 
Inclusions for exposed: women exposed to 
MgSO4 for PE/T at the time of birth 
Inclusions for unexposed: women who 
presented in labour with no evidence of PE or 
preterm labour and did not require MgSO4 
Exclusions: women with multiple gestations 
and women unable to give consent 
PE/T 1: MgSO4 (‘standard protocol’), N = 
11 women, 10 babies 
2: No MgSO4, N = 12 women, 12 
babies 
 
NICU admission, Apgar score < 








N = 52 babies 
Inclusions: infants whose GA was ≥ 34 weeks 
and whose mothers received a minimum of 
12 hours of MgSO4 (study group), and the 
next infant of similar GA born after enrolment 
of study infant (control group) 
Exclusions: infants with severe congenital 
anomalies, neuromuscular disorders, 
significant parenchymal lung disease, and 
adverse intrapartum event 
PIH/T 1: MgSO4 (1-3 g/hour IV), N = 26 
babies 
2: No MgSO4, N = 26 babies 
 
1: MgSO4 and NICU admission, N = 
12 babies 
2: MgSO4 and no NICU admission, 
N = 14 babies 
Hypotonia, delivery room 
support (bag and mask 
ventilation), NICU admission, 
delayed adaptation, presumed 
or ruled-out sepsis, delayed 
feeding (1st feeding ≥ 8 hours 
after birth), feeding 
intolerance, hospital stay (days) 
(mean ± SD), apnoea density 
(mean ± SD), apnoea ≥ 15 
seconds (associated with 





apnoea ≥ 10 seconds (mean ± 
SD), pathologic apnoea (≥ 15 
seconds associated with 
bradycardia) 
 
MgSO4 dose (g) (mean ± SD), 
duration of MgSO4 (hours) 
(mean ± SD) 




N = 3788 babies 
Inclusions: babies born 23+0-28+6 weeks GA 
admitted to NICUs participating in the 
Canadian Neonatal Network 
Exclusions: NR 
FN 1: MgSO4, N = NR 
2: No MgSO4, N = NR 
Death or SNI (grade ≥ 3 IVH 
and/or PVL) 
NR 
Sahin 2001; PCS Turkey 
1995-1996 
N = 40 babies 
Inclusions for ‘cases’: newborns from women 
with PE or E who had been treated with 
MgSO4 
Inclusions for ‘controls’: newborn from 
normal pregnant women, who did not receive 
any drug that could affect the contractility of 
smooth muscles 
Exclusions: NR 
PE/E 1: MgSO4 (4 g IV and 10 g IM LD, 5 
g in each buttock; 5 g/4 hours IM 
MD until 24 hours after birth), N = 
20 babies 
2: No MgSO4, N = 20 babies 
Not voiding in 1st 24 hours, 
residual urine after 1st 
micturition (> 5 mL), urinary 
tract abnormality, neurologic 
pathology 
NR 
Sakae 2017; NCCS Japan 
2008-2015 
N = 45 women, 48 babies 
Inclusions: all women who had been 
diagnosed with early-onset severe PE and 
were treated (diagnosis made according to 
Japanese criteria (detail provided) 
Exclusions: NR 
PE 1: Post-protocol: April 2013 
onwards (100% MgSO4 use), N = 17 
women, 19 babies 
2: Pre-protocol: prior to April 2013 
(36% MgSO4 use), N = 28 women, 
29 babies 
 
1: > 48 hours MgSO4, N = 17 
women, 19 babies 
2: ≤ 48 hours MgSO4, N = 10 
women, 10 babies 
3: No MgSO4, N = 18 women, 19 
babies 
Composite of serious 
complications (1 or more of: 
neonatal death, assisted 
ventilation with ETT > 24 hours, 
RDS, PPH, PDA, BPD, cPVL, IVH 








MgSO4: 4 g IV LD; 1 g/hour IV MD 
until 24 hours after birth 
Salafia 1995; 
unclear: results 
appear to be 





N = 406 women and their babies 
Inclusions: all women delivering with GA < 32 
weeks 
Exclusions: stillbirth, fetal congenital 
anomalies, multiple gestation, maternal 
diabetes mellitus, chronic hypertension, 
hydrops fetalis, placenta previa, and elective 
birth for IUGR 
T (4 g IV LD 
over 20 
minutes; 2 
g/hour IV MD) 
1: Early GM-IVH (≤ 72 hours), N = 
44 babies 
2: Late GM-IVH (> 72 hours), N = 21 
babies 
3: No GM-IVH, N = 341 babies 
MgSO4 exposure NR 
Sarkar 2009; 
unclear: results 
appear to be 
presented as RCS 
with CCS(N)  
USA 
2001-2007 
N = 59 babies 
Inclusions: infants with birthweight < 1500 g 
admitted to the NICU, with severe IVH (grade 
3/4) determined by routine cranial 
sonography (during 1st 7-10 days of life) 
Exclusions: NR 
NR 1: IVH grade 3, N = 28 babies 
2: IVH grade 4, N = 31 babies 







N = 41 babies 
Inclusions: infants born pregnant women 
between 24-32 weeks GA; 1) preterm labour 
treated for > 1 week with strict bed rest and 
IV MgSO4; 2) similar women in whom strict 
bed rest was ordered for the obstetrical 
indications of either placenta praevia or 
preterm labour 
Exclusions: systemic illness (diabetes mellitus, 
chorioamnionitis, medications known to 
affect calcium metabolism) 
T 1: MgSO4 (6 g IV LD over 30 
minutes; 2 g/hour (1.5-3.5 g/hour) 
IV MD, discontinued in second 
stage of labour/at caesarean); N = 
16 women, 22 babies 
2: No MgSO4, N = 15 women, 19 
babies 
Apgar score < 7 at 5 minutes, 
LOS (days) (mean ± SD), HMD, 
PDA, IVH, NEC, birth 
depression, oxygen treatment, 
oxygen treatment > 1 month, 
MV, MV > 1 week, 















RCS with CCS(N)  
USA 
1986-1999 
N = 127 babies 
Inclusions: infants with birthweights 700-
1249 g, born following preterm labour 
treated with MgSO4 for T 
Exclusions: infants born to women with PE or 
PE superimposed on chronic hypertension, 
T 1: Fetal or neonatal deaths, N = 18 
babies 
2: Survivors, N = 109 babies 
 
1: MgSO4 ≤ 24 g, N = 43 babies 
MgSO4 for T > 48 g, and ≤ 48 g 











infants with birthweights < 700 g and > 1249 
g, fetuses and neonates with major 
congenital anomalies 
2: MgSO4 > 24 but ≤ 48 g, N = 25 
babies 
3: MgSO4 > 48 g, N = 59 babies 
Shalabi 2017; RCS Canada 
2011-2014 
N = 4355 babies 
Inclusions: infants born between 22-27 weeks 
GA and admitted to any of the 29 tertiary 
level neonatal units participating in the CNN 
Exclusion criteria: infants with a major 
congenital anomaly or who were moribund 
on admission, those who had missing data 
regarding MgSO4 administration  
Any 1: MgSO4 IV, N = 2055 babies 
2: No MgSO4, N = 2300 babies 
Apgar score < 7 at 5 minutes, 
SNAP-II score > 20, MV day 1, 
prophylactic indomethacin, 
PDA treated with 
indomethacin, postnatal 
steroids for hypotension, 
postnatal steroid for BPD, PDA 
treated (indomethacin or 
ibuprofen), postnatal steroids 
or PDA treatment, NEC stage II 
or higher, SIP, NEC or SIP, death 
prior to discharge, NEC or SIP 
associated death, IVH grade 3/4 
or PVL, ROP stage 3 or above or 












N = 265 women and their babies (207 
antepartum/intrapartum PE/E cases) 
Inclusions: women with E or severe PE; 
pregnancy > 28 weeks GA, blood pressure > 
140/100 mmHg, urine output > 30 mL/hour 
and respiratory rate > 16/minute 
Exclusions: urine output < 30 mL/hour, 
absent patellar reflex, respiratory rate < 
16/minute 
PE/E 1: MgSO4 LD at home before 
referral to hospital (4 g IV over 20 
minutes and 3 g IM LD in each 
buttock), N = 102 women and 
babies  
2: No MgSO4 before referral to 
hospital, N = 105 women and 
babies 
Asphyxia, stillbirth Funding: WHO 
Conflicts: NR 
Shokry 2010; PCS Saudi Arabia 
2007-2008 
N = 48 women and their babies 
Inclusions: singleton pregnancies with risk of 
preterm labour, intact fetal membranes, no 
major fetal congenital anomalies and no 
maternal or fetal complications necessitating 
immediate delivery, 30-34 weeks GA  
T 1: MgSO4 (4 g IV LD over 20 
minutes; 1-2 g/hour IV MD), N = 28 
women and their babies 
2: No MgSO4, N = 20 women and 
their babies 
RDS, PV-IVH, seizures, MV, 
surfactant use, inotropic drug 







Inclusions for ‘controls’: infants born 
immediately after reaching the hospital, 
where the mother had a contraindication for 
tocolysis/MgSO4 but fulfilled other inclusions 
Exclusions: women with any significant 
complications during pregnancy or birth such 
as PE and those with multiple pregnancies, all 
infants with perinatal asphyxia, infection, 






N = 110 babies 
Inclusions: children who received a CP 
diagnosis, delivered before 32 weeks GA 
Exclusions: NR 
FN/PE 1: 2002-2008 (pre-BEAM trial, 36% 
uptake MgSO4), N = 42 babies 
2: 2009-2014 (post-BEAM trial, 62% 
uptake MgSO4), N = 68 babies 








Stockley 2018; RCS Canada 
2010-2011 
N = 336 babies (defined according to fetal 
standards: estimated fetal weight < 10th 
centile); or 177 babies (defined according to 
neonatal standards: actual birthweight < 10th 
centile) 
Inclusions: growth-restricted babies < 28 
weeks GA admitted to 1 of the tertiary NICUs 
participating in the CNN, who were assessed 
in neurodevelopmental follow up clinics at 
18-36 months CA 
Exclusions: babies with major congenital or 
chromosomal anomalies, planned palliative 
care prior to birth, or with missing data 
NR Growth restriction (fetal standards) 
1: Intrapartum MgSO4 exposure, N 
= 112 babies 
2: No MgSO4, N = 224 babies 
 
Growth restriction (neonatal 
standards) 
1: Intrapartum MgSO4 exposure, N 
= 61 babies 
2: No MgSO4, N = 116 babies 
 
Death in NICU and post-
discharge, Apgar score < 7 at 5 
minutes, chest compression or 
epinephrine, SNAP-II score > 
20, BPD, NEC, late-onset sepsis, 
ROP stage 3/4/5 or treated, IVH 
grade 1/2, IVH grade 3/4,  
Funding: none 






Suh 2015; RCS 
English abstract; 




N = 586 babies 
N = 150 babies of relevance (excluded 
normotensive controls) 
Inclusions: term infants who were delivered 
from normotensive and antihypertensive 
drug ± MgSO4 treated women 
Exclusions: CD 
HD 1: Antihypertensive drugs and 
MgSO4, N = 40 babies 
2: Antihypertensive drugs only, N = 
110 babies 
LOS (days) (mean ± SD), 
duration of ventilation (days) 
(mean ± SD), duration of 
oxygen (days) (mean ± SD), 
RDS, BPD, moderate to severe, 
BPD, PDA treated (medication ± 
operation), ROP treated with 





appear to be 
presented as RCS 




N = 184 babies 
Inclusions: all viable singleton premature 
infants without lethal anomalies, born 
between 23-30 weeks GA and were admitted 
to the NICU 
Exclusions: NR 
PE/T 1: Early hypotension, N = 75 babies 
2: No early hypotension, N = 109 
babies 
MgSO4 exposure NR 
Verma 2006; 
unclear: results 
appear to be 




N = 45 babies 
Inclusions: all ELBW < 1000 g at birth infants 
admitted consecutively to the NICU 
Exclusions: infants suffering chromosomal 
anomalies, major congenital malformation or 
any organ system or hydrops fetalis 
PE/T 1: PIE on chest radiograph, N = 11 
babies 
2: no PIE on chest radiograph, N = 
34 babies 
MgSO4 dose (g) (mean ± SD), 









N = 2794 babies (have not considered the 263 
babies and 177 infants exposed to ritodrine 
and indomethacin) 
Inclusions: VLBW newborn infants 
(birthweight < 1500 g), at GA 24-32 weeks, 
with a CUS examination during the 1st 24 days 
of life 
Exclusions: death in delivery room, < 24 
weeks or > 32 weeks GA, born to mother with 
PIH, no CUS examination, receipt of 
combination of tocolytic drugs 
T 1: MgSO4 (≥ 12 hours before birth), 
N = 341 babies 
2: No tocolysis (for ≥12 hours 
before birth), N = 2013 babies 
 




Weisz 2015; RCS Canada 
2011-2012 
N = 6015 babies 
Inclusions: infants born 23+0 to 31+6 weeks 
GA 
Exclusions: infants with major congenital 
anomalies and those who were moribund on 
admission (i.e. a physician, in consultation 
with the parents, had made an explicit 
decision not to provide life support at the 
time of birth); infants whose MgSO4 
exposure status was missing 
FN/PE/T/UK 1: MgSO4 for FN, N = 1387 babies 
2: No MgSO4, N = 3868 babies 
 
23-28 weeks GA 
1: MgSO4 for FN, N = 731 babies 
2: No MgSO4, N = 1813 babies 
 
29-31 weeks GA 
1: MgSO4 for FN, N = 656 babies 
2: No MgSO4, N = 2055 babies 
 
1: MgSO4 for FN, N = 1387 babies 
2: MgSO4 for PE/T = 214 babies 
3: MgSO4 for UK = 546 babies 
 
1: MgSO4 for any indication, N = 
2147 babies 
2: No MgSO4, N = 3868 babies 
Any resuscitation (mask CPAP 
or PPV, ETT intubation and 
ventilation, chest compressions 
or epinephrine) , CPAP only, 
bag/mask or neopuff 
ventilation, intubation and 
ventilation, chest 
compressions, epinephrine (ETT 
or IV), Apgar score < 7 at 5 
minutes, surfactant use, SNAP-
II score > 20, intensive 
resuscitation (intubation and 
ventilation, or chest 
compressions or epinephrine 
administration in delivery 
room), death, BPD, NEC stage ≥ 
II, IVH grade 3/4 or PVL, ROP 
stage ≥ II, sepsis, composite 




















N = 118 babies 
Inclusions: non-anomalous infants ≤ 1000 g 
and/or < 28 weeks GA 
Exclusions: NR 
NR 1: MgSO4, N = NR 
2: No MgSO4, N = NR 
Death, late bacterial sepsis NR 
Whitten 2015; 
unclear: results 
appear to be 





N = 6791 babies 
Inclusions: term (> 37 weeks GA) singleton 
neonates 
Exclusions: NR  
NR 1: LOS ≤ 3 days, N = 6472 babies 
2: LOS ≥ 4 days, N = 319 babies 
MgSO4 exposure NR 





N = 137 babies 
Inclusions: ventilated preterm infants > 33 
weeks GA 
Exclusions: NR 
PIH/T 1: MgSO4, N = 61 babies 
2: No MgSO4, N = 76 babies 
NEC, ICH grade 3/4, cPVL in 
survivors ≥ 21 days, ICH grade 
3/4 or cPVL 
Funding: 
Supported in part 
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with CCS(N)  
Thailand 
2015 
N = 57 women, 63 babies 
Inclusions: pregnant women who received 
intrapartum MgSO4  
Exclusions: women with known fetal 
conditions affecting infant neurological 
ability, including congenital anomalies and 
major chromosomal abnormalities, women 
under general anaesthesia (risk of respiratory 
depression)  
PIH/T (4 g IV 
LD; 2 g/hour 
IV MD) 
1: Apnoeic episodes, N = 8 babies 
2: No apnoeic episodes, N = 55 
babies 
MgSO4 dose (reported as 











N = 117 babies 
Inclusions for ‘cases’: newborns whose 
mothers had received IV MgSO4 for > 5 days 
for T 
Inclusions for ‘cases’: newborns whose 
mothers did not received MgSO4 in same 
period; matched for GA, birthweight and 
number of multiple gestations 
Exclusions: NR 
T 1: MgSO4 (4 g IV LD over 1 hour; 1-
2 g/hour IV MD), N = 58 babies 
2: No MgSO4, N = 59 babies 
RDS, IVH, PDA, ROP, death, 
NEC, bone change (osteopenic 
radiolucent bands at 
metaphyses of long bones) 
NR 
Young 1977; NRT USA 
1974-1975 
N = 144 women and their babies 
Inclusions: women with PE or E based on 
criteria of the American Committee on 
Maternal Welfare 
Exclusions: NR 
PE/E 1: MgSO4 ‘push’ IV (10 g IM LD and 
2 g IV LD over 10 minutes; MD of 2 
g IV slow push over 10 minutes 
every 1-2 hours), N = 97 women 
and babies 
2: MgSO4 continuous IV (10 g IM 
LD; 1 g/hour IV MD), N = 47 women 
and babies 
Perinatal death NR 
 
Abbreviations: ACOG: American College of Obstetricians and Gynecologists; AF: amniotic fluid; AGA: appropriately grown for age; APH: antepartum haemorrhage; ATSDR: Agency for Toxic Substances 
and Disease Registry; BP: blood pressure; BPD: bronchopulmonary dysplasia; CA: corrected age; CBF: cerebral blood flow; CCS: case-control study; CCS(N): case-control study (nested); CD: cannot 
determine; CPR: cardiopulmonary resuscitation; CSF: cerebrospinal fluid; DC: Center for Disease Control and Prevention; CIHR: Canadian Institutes of Health Research; CLD: chronic lung disease; CMV: 
continuous mandatory ventilation; CNN: Canadian Neonatal Network; CNS: central nervous system; CP: cerebral palsy; CPAP: continuous positive airway pressure; cPVL: cystic periventricular 
leucomalacia; CRIB: clinical risk index for babies; CUS: cranial ultrasound; DA: ductus arteriosus; DHHS: Department of Health & Human Service; DIS: disseminated intravascular coagulation; E: eclampsia; 
EFM: electronic fetal monitoring; ELBW: extremely low birthweight; ESHP: early and severe hypertension in pregnancy; ET: endotracheal; ETT: endotracheal tube; EU: European Union; FDA: Food and 
Drug Administration; FGR: fetal growth restriction; FHR: fetal heart rate; FN: fetal neuroprotection; g: grams; GA: gestational age; GH: gestational hypertension; GM-IVH: germinal matrix intraventricular 




HUS: head ultrasound; ICH: intracranial haemorrhage; IDD: insulin-dependent diabetes; IM: intramuscular; IMV: intermittent mandatory ventilation; IQR: interquartile range; IV: intravenous; ITS: 
interrupted time series; IUGR: intrauterine growth restriction; IVH: intraventricular haemorrhage; LD: loading dose; LOS: length of stage; LSV: lenticulostriate vasculopathy; MD: maintenance dose; 
MFMU: Maternal Fetal Medicines Unit; Mg: magnesium; MgSO4: magnesium sulphate; mL: millilitres; MPT: moderately preterm; MRI: magnetic resonance imaging; MV: mechanical ventilation; N: 
number; NBRS: Neurobiologic Risk Scale; NCATS: National Center for Advancing Translational Sciences; NCCS: non-concurrent cohort study; NEC: necrotising enterocolitis; NHLBI: National Heart, Lung, 
and Blood Institute; NICHD: National Institute of Child Health and Human Development; NICU: neonatal intensive care unit; NINDS: National Institute of Neurological Disorders and Stroke; NINR: National 
Institute of Nursing Research; NIH: National Institutes of Health; NR: not reported; NRN: Neonatal Research Network; NRT: non-randomised trial; NS: not significant; NSAIDs: non-steroidal anti-
inflammatory drugs; PCS: prospective cohort study; PDA: patent ductus arteriosus; PE: pre-eclampsia; PEA: parenchymal echo abnormality; PIE: pulmonary interstitial emphysema; PIH: pregnancy-
induced hypertension; PPH: persistent pulmonary hypertension; PPROM: preterm premature rupture of membranes; PROM: premature rupture of membranes; PPV: positive pressure ventilation; 
PROM: premature rupture of membranes; PV-IVH: periventricular intraventricular haemorrhage; PVL: periventricular leucomalacia; PWML: punctate white matter lesions; RCS: retrospective cohort 
study; RCT: randomised controlled trial; RD: respiratory distress; RDS: respiratory distress syndrome; ROM: rupture of membranes; ROP: retinopathy of prematurity; SCBU: special care baby unit; SD: 
standard deviation; SE: standard error; SH: systemic hypertension; SIP: spontaneous intestinal perforation; SMIV: synchronized intermittent mandatory ventilation; SNAP: Score For Neonatal Acute 
Physiology; SNI: severe neurological injury; sPDA: significant PDA; T: tocolysis; TSV: thalamostriate or mineralising vasculopathy; TTN: transient tachypnoea of the newborn; UK; unknown; USA: United 




S2 Table. Risk of bias of included studies 
 
Randomised controlled trials 
 





Blinding of participants and 
personnel (performance bias) 






Selective reporting (reporting 
bias) 




Low risk: Quote: 
"delivered by sealed 
opaque envelope." 
High risk: Quote: "our trial was not 
blinded." 
High risk: Quote: "our 
trial was not blinded." 
Low risk: No 
apparent missing 
outcome data. 
Unclear risk: The study protocol 
is not available. Unclear whether 
the published report includes all 
pre-specified outcomes. Limited 
pre-specification of outcomes in 
methods of report. 
Agrawal 2013 
Abstract 
Low risk: Quote: 
"using a computer 
generated random 
table." 
Unclear risk: No detail 
provided (abstract 
only). 
High risk: No blinding (assumed 
due to nature of intervention and 
control). 
Unclear risk: No detail 
provided (abstract 
only). 
Unclear risk: No 
detail provided 
(abstract only). 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. Abstract only. 





Low risk: Quote: 
"treatment allocated by 
the telephone 
randomisation service 
at the University of 
Adelaide." 
High risk: Quote: "The midwives, 
who could not be blinded to the 
treatment group allocation…. 
Midwives and obstetricians were 
asked not to discuss treatment 
group allocation with the women." 
High risk: No blinding 
reported. 
Low risk: No 
apparent missing 
data. 
Low risk: Trial registration 
(ACTRN12605000765628) 
available, and outcomes 
reported as pre-specified. 
Begum 2002  Low risk: Quote: 
"patients were 
randomly assigned 
by lottery… we 
randomly selected a 
piece of paper from 
a box to determine 
if the patient was to 
receive only loading 
or both loading and 
Unclear risk: No detail 
provided. 
High risk: No blinding (assumed 
due to nature of intervention and 
control). 
High risk: No blinding 
reported. 
Low risk: No 
apparent missing 
data. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. No clear pre-
specification of outcomes in 
















High risk: No blinding (assumed 
due to nature of intervention and 
control). 
High risk: No blinding 
reported. 
Low risk: No 
apparent missing 
data. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. Limited pre-
specification of outcomes in 
methods of report. 
Bhattacharhee 
2011 





Low risk: Quote: "the 
allocation was 
concealed in sealed, 
sequentially numbered, 
brown envelopes, 
which had been 
prepared by the 
statistician at each 
centre." 
High risk: Quote: "Because of the 
nature of the drug administration, 
the patients and the doctors 
responsible for drug administration 
were not blinded to the 
randomisation allocation." 





outcome data not 




Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. Secondary outcomes 
included "maternal and perinatal 
outcomes." 





Unclear risk: As above. Low risk: Quote: "Patients received 
the study medication in unlabeled 
intravenous bags, and all clinicians, 
labor and delivery personnel, and 
research nurses were blinded to 
which medication each patient 
received." 
Low risk: As above, and 
"Placental examination 
was performed by 
pathologists blinded to 
patient study group." 
Low risk: No 
apparent missing 
data. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. Unclear pre-
specification of outcomes in 
methods of report. 
Charma 2013 Low risk: Quote: 




Low risk: Quote: "The 
allocation was 
concealed in sealed 
sequentially numbered 
brown envelops." 
High risk: Quote: "Because of the 
nature of drug administration, the 
doctors and nurses responsible for 
drug administration were not 
blinded to the randomization 
allocation." 
High risk: No blinding 
reported. 
Low risk: Relatively 
low proportion of 
missing data (6/56 
and 8/56), balanced 
between groups. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. "Both maternal and 
perinatal outcomes were 
recorded." 
Chen 1995 Unclear risk: Quote: 
"were all 
randomized." 
Unclear risk: As above. High risk: No blinding (no placebo 
used). 
High risk: No blinding 
reported. 
Low risk: No 
apparent missing 
data. 
Unclear risk: The study protocol 
is not available. It is unclear 




includes all pre-specified 
outcomes. "The clinical data, and 
fetal and maternal 
complications, and outcome of 
both groups were analysed." 




Unclear risk: As above. High risk: No blinding (assumed 
due to nature of intervention and 
control). 
High risk: No blinding 
reported. 
Low risk: No 
apparent missing 
data. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. "Clinical outcome... 
were recorded for both groups." 
Coetzee 1998 Unclear risk: Quote: 
"women were 
randomised." 
Low risk: Quote: 
"women were allocated 
using sealed opaque 
envelopes containing a 
card instructing the use 
of solution A or solution 
B. These cards (but not 
the envelopes) were 
consecutively 
numbered. Envelopes 
were distributed in 
mixed batches of 20 
and these always had 
equal numbers of A and 
B." 
Low risk: Placebo used. Quote: 
"The sterile solutions were 
prepared by the hospital 
pharmacy… The identity of the 
solutions marked A or B were 
changed periodically by pharmacy 
without the knowledge of the 
investigators. The identity of the 
solutions was revealed only on 
completion of the study." 
Low risk: As above. Unclear risk: On 
completion of the 
study 123/822 
random envelopes 
and data sheets 
could not be 
retrieved from 
patient records, and 
it was not possible 
to determine who 
had been 
randomised to the 
treatment and 
placebo groups – 
these women were 
excluded from there 
study. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. Only the primary 
outcome detailed in the 
methods of the report. 
Colon 2015 
Abstract 
Unclear risk: Quote: 
"were randomized." 
Unclear risk: No detail 
provided (abstract 
only). 
Unclear risk: Saline placebo used 
(limited detail provided; abstract 
only). 
Unclear risk: No detail 
provided (abstract 
only). 
Unclear risk: No 
detail provided 
(abstract only). 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 




Cotton 1984 Unclear risk: Quote: 
"patients were 
randomized." 
Unclear risk: As above. Low risk: Placebo used. Unclear risk: No 
detailed provided. 
Low risk: 1 women 
in the treatment 
group was lost to 
follow up and 
excluded from 
analyses. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. 




control groups by 
means of a random 
number table." 
Low risk: Quote: "group 
allocation 
predetermined and 
placed in consecutively 
numbers and sealed 
envelopes." 
Unclear risk: Saline used in control 
group; serial magnesium serum 
level determinations in the 
treatment group indicate that 
blinding may not have been 
achieved. 
Unclear risk: No detail 
provided. 
Low risk: No 
apparent missing 
data. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. Outcomes not clearly 
pre-specified in methods of 
report. 






Low risk: Quote: 
"managed by 
nonclinical staff at the 
University of Adelaide’s 
Maternal Perinatal 
Clinical Trials Unit… 
Each study number was 
placed on a masked 
treatment pack… 
Eligible women… were 
enrolled by taking the 
next treatment pack." 
Low risk: Placebo used. Quote: "All 
perinatal staff were blinded to 
treatment group allocation." 
Low risk: As above. 
Quote: "Surviving 
children were assessed 





to treatment group 
allocation." 
Low risk: Outcome 
data up to discharge 
available for all 1062 
women and 1255 
infants alive at 
randomisation; 2 
year corrected age 
outcomes available 
for 1047 children 
(99% of survivors); 
14 children (9 in the 
magnesium group 
and 5 in the placebo 
group) did not have 
2 year cerebral palsy 
assessment and 
were excluded from 
analyses. 
Low risk: The study protocol is 
not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes, however methods of 
report list detailed outcomes 
which are subsequently reported 
in the results. 
Easterling 2018 Low risk: Quote: 
“randomisation 
code based on a 
computerised 




High risk: Quote: “open-label.” High risk: No blinding 
reported. 
Unclear risk: 99.1% 
(105/106) neonates 
from serial IV bolus 
group analysed (1 
Unclear risk: The study protocol 
is not available. Unclear whether 
the published report includes all 










group analysed (2 
born to mothers 
enrolled 
postpartum, 6 
discharged prior to 





specification of outcomes in trial 
registration (NCT02091401). 
Fox 1993 Low risk: Quote: "in 
which the group 
selection was 
generated from a 




provided. Quote: "The 
randomization was 




party (the pharmacy) 
was in charge of 
selection of the 
envelope for each 
patient." 
High risk: Quote: "The treating 
physicians did not have access to 
the randomization envelopes but 
were not blinded to group 
assignment." No placebo used. 
High risk: No blinding 
reported. 
Low risk: No 
apparent missing 
data. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. Methods of report 
indicate other neonatal 
outcomes of interest which are 
not subsequently reported in 
results. 
How 1998 Low risk: Quote: 
"generated from a 






High risk: No blinding (no placebo 
used). 
High risk: No blinding 
reported. 
Low risk: No 
apparent missing 
data. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. Outcomes not clearly 









was done by a 
predetermined 
schedule that used 
a block approach… 
Randomisations 
schedule and the 
allocation 
concealment was 
done by a person 
unrelated to the 
study." 
Low risk: Quote: 
"Resident doctor on 
duty opened the 
randomisation schedule 
placed in sequential 
opaque envelopes." 
High risk: No blinding (due to 
nature of intervention and control). 
High risk: No blinding 
reported. 
Low risk: No 
apparent missing 
data. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. 
Lewis 1997 Low risk: Quote: 
"Randomization 
was accomplished 
by use of a random 
number table." 
Low risk: Quote: "The 
randomization cards 
were placed in an 
opaque envelope that 
remained sealed until 
informed consent was 
obtained after 
successful tocolysis. The 
randomization cards 
were stored in an area 
away from clinical 
care." 
High risk: No blinding (due to 
nature of intervention and control). 
High risk: No blinding 
reported. 
Unclear risk: 144 
women were 
included in the 
study, 3 delivered 
elsewhere and were 
not included in 
analyses (not 
reported from 




data does not 
appear to take into 
account the 18 sets 
of twins. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. Only primary 
outcome pre-specified in 
methods of report. 




Low risk: Quote: "Study 
group assignment was 
by sealed, consecutively 
Low risk: Placebo used. Quote: "All 
medication was mixed in the 
pharmacy and labelled “study 
Low risk: Quote: "data 
were collected from 
chart abstraction… 
Investigators remained 
Low risk: No 
apparent missing 
data. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 









drug” to maintain allocation 
concealment." 
blinded during data 
collection." 
outcomes. Outcomes not clearly 
pre-specified in methods of 
report. 
Magpie 2002 Low risk: Quote: 
"with an allocation 
sequence based on 
a block size of eight, 
also generated by 
the Clinical Trial 
Service Unit." 
Low risk: Quote: 
"Hospitals with reliable 
access to telephones 
used a central 
telephone 
randomisation service 
at the Clinical Trial 
Service Unit, in 
Oxford... Hospitals 
without reliable access 
to telephones used a 
local pack system." 
Low risk: Placebo used. Quote: 
"The magnesium sulphate and 
placebo ampoules were identical, 
and the solutions looked the 
same." 
Low risk: As above. Low risk: 5 women 
excluded (2 in each 
group due to no 
data; 1 in 
magnesium 
sulphate group due 
to wrong trial); 
follow up data 
available for 99.7% 
women randomised 
before delivery and 
98.6% of babies. 
Low risk: The study protocol is 
not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes, however methods of 
report list detailed outcomes 
which are subsequently reported 
in the results. 
Malapaka 2011 Unclear risk: Quote: 
"The women were 
randomly assigned 
to the groups." 
Unclear risk: As above. High risk: No blinding (assumed 
due to nature of intervention and 
control). 





numbers (N=72 and 
N=54) unbalanced. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. 





Low risk: Quote: 
"Central telephone 
randomisation was 
managed by staff of the 
NICU." 
Low risk: Quote: "The two solutions 
looked identical so that the women 
were unaware of whether they 
received a MgSO4 or placebo 
solution. Treatment assignment 
was single blind." 
Low risk: As above. 
Quote: "For all 
surviving infants, CUS 
was conducted by a 
senior neonatologist or 
radiologist in each 
centre separately and 
in a blind manner 
relative to treatment 
allocation." 




excluded from the 3 
centres that 
included < 5 
women; 564 women 
were analysed; all 




included in mortality 
analyses. 
Low risk: Quote: "This study is 
registered as an International 
Standard Randomised Controlled 
Trial, number 00120588." Not 
able to locate registration, 
however methods of report list 
detailed outcomes which are 





Mirzamoradi 2014 High risk: Quasi-
randomised. Quote: 
"those who had an 
odd code were 
allocated to the 
intervention group 
and others to the 
control group." 




control groups) were 
packed in separate 
packages and coded 
from 1 to 92 by an 
expert midwife. When 
an eligible patient was 
accepted into the 
study, another expert 
interviewed her and a 
code from 1 or 92 was 
assigned to 
questionnaires 
regardless of medicinal 
packages coding." 
Low risk: Placebo used. Quotes: 
"None of the research staff were 
aware of the treatment allocation 
of patients in order for blinding 
purposes;" "All steps were 
considered blinding principles in 
the control group too." 
Low risk: As above. Low risk: No 
apparent missing 
data. 
Unclear risk: While the trial 
registration 
(IRCT2012091810876N1) is 
available, this registration was 
retrospective. Outcomes not well 
pre-specified in methods of 
report, e.g. "fetal and maternal 
complications." 




Unclear risk: No detail 
provided. 
Low risk: Placebo used. Quote: 
"doubly masked." 
Low risk: Quote: "The 
technicians and 
researchers who 
processed all biologic 
specimens were 
masked to previous 
and subsequent health 
outcomes."; "The 
developmentalist was 
masked to the 
antenatal exposure 
variables." 
Low risk: No 
apparent missing 
data. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. 




Low risk: Quote: 
"randomly distributed… 
using the next of a set 
of consecutively 
High risk: No blinding (no placebo 
used). 
High risk: No blinding 
reported. 
Low risk: No 
apparent missing 
data. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 








pre-specified in the methods of 
report: "Main Outcome 
Measure: The onset of 
convulsions and both maternal 
and fetal complications between 
the groups." 
Mundle 2012 Low risk: Quote: "a 
randomization 
sequence generated 
by computer with 
blocks of 10." 
Low risk: Quote: 
"consecutive opaque 
envelopes." 
High risk: Quote: "However, it was 
not possible to blind women and 
providers to the treatment." 
High risk: No blinding 
reported. 
Low risk: No 
apparent missing 
data. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes; methods of report 
details additional neonatal 
outcomes which are not 








Unclear risk: No detail 
provided (abstract 
only). 
Unclear risk: Quote: "single blind." 
Unclear who was blinded. 
Unclear risk: As above. Unclear risk: No 
detail provided 
(abstract only). 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. Abstract only. 
Parashi 2017 Low risk: Quote: "by 




Low risk: Quote: "by 
using sealed opaque 
medication packets that 
numbers and used 
consecutively." 
Low risk: Placebo used. Low risk: Quotes: 
"double-blind"; "they 
all were assessed with 
ultrasonography by an 
experienced radiologist 
who was blind about 
the groups." 
Low risk: No 
apparent losses. 
Unclear risk: While the trial 
registration 
(IRCT2016080729223N1) is 
available, this registration was 
retrospective, and no clear pre-
specification of outcomes in 
methods of report. 
Pascoal 2019 Low risk: Quote: 
“randomization list 





Low risk: Quote: “The 
numbered envelopes 
were sent to the high-
risk unit and to the 
intensive care unit 
where the women were 
consecutively assigned 
to one of the 
Low risk: Quotes: “The pharmacist 
received the randomization list of 
numbers… defining whether the 
patient would be in the 1-
gram/hour or 2-grams/hour group. 
The pharmacist then prepared 
ampoules with distilled water for 
the 1-gram/hour group, and 
Low risk: Quote: 




and the patients 
remained unaware of 
the group to which the 
Low risk: No 
apparent missing 
data. 
High risk: Trial was terminated 
early due to poor recruitment; 
outcomes not reported as pre-








the ampoules was only 
opened at the time of 
preparation of the 
maintenance dose of 
magnesium sulfate.” 
ampoules with a total of 6 grams of 
magnesium sulfate for the 2-
grams/hour group. Both sets of 
ampoules were identical in color 
and size. Only the pharmacist was 
aware of the contents of the 
ampoules;” and “Throughout the 
entire study, the investigators, the 
attending physicians, and the 
patients remained unaware of the 
group to which the patient had 
been allocated.” 
patient had been 
allocated.” 
Rimal 2017 Unclear risk: Quote: 
"The participants 
were randomized." 
Unclear risk: No detail 
provided. 
High risk: No blinding (assumed 
due to nature of intervention and 
control). 
High risk: No blinding 
reported. 
Low risk: No 
apparent missing 
data. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. No clear pre-
specification of outcomes in 
methods of report. 
Rouse 2008 Low risk: Quote: 
"Group assignment 




Unclear risk: No detail 
provided. 
Low risk: Placebo used. Low risk: As above. 
Quote: "double-blind." 
Low risk: 9/1096 
and 4/1145 women 
in the magnesium 
and placebo groups 
were lost to follow 
up before delivery; 
thus 1087/1096 and 
1141/1145 women 
were included in 
maternal analyses; 
all live born infants 




included in primary 
Low risk: While the trial 
registration (NCT00014989) is 
available, this registration was 
retrospective, however methods 
of report list detailed outcomes 
which are subsequently reported 




outcome in the 
magnesium and 
placebo groups. 




Unclear risk: No detail 
provided. 
High risk: No blinding (assumed 
due to nature of intervention and 
control). 
High risk: No blinding 
reported. 
Low risk: No 
apparent missing 
data. 
Unclear risk: While the trial 
registration (CTRI/ 2009 000339, 
05–08-2009) is available, this 
registration appears to have 
been retrospective; need for 
calcium gluconate detailed in 
methods and trial registration as 
an outcome of interest but not 
subsequently reported. 
Shilva 2007 Low risk: Quote: 
"the patients were 
randomized using a 
Tippet table." 
Unclear risk: No detail 
provided (short report). 
High risk: No blinding (assumed 
due to nature of intervention and 
control). 
High risk: No blinding 
reported. 
Low risk: No 
apparent missing 
data. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. Outcomes not clearly 
pre-specified in short report: 
"compared for maternal and 
neonatal outcome." 
Shreya 2014 High risk: Quote: 
"Randomisation 
was done by giving 
above regimen 
alternatively." 
High risk: As above. High risk: No blinding (assumed 
due to nature of intervention and 
control). 
High risk: No blinding 
reported. 
Unclear risk: No 
apparent missing 
data. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. Outcomes not clearly 
pre-specified in short report: 
"Maternal and fetal 
complications." 
Singh 2011 Low risk: Quote: 
"Patients were 
randomly allocated 
by means of a 
random number 
generator." 
Unclear risk: No detail 
provided. 
High risk: No blinding (assumed 
due to nature of interventions and 
control). 
High risk: No blinding 
reported. 
Low risk: No 
apparent missing 
data. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. Outcomes not clearly 
pre-specified in methods, 














Low risk: Quote: 
“sealed in opaque 
envelops.” 
High risk: No blinding (assumed 
due to nature of intervention and 
control). 
High risk: No blinding 
reported. 
Low risk: No 
apparent missing 
data (unclear as to 
whether 1 and 2 
neonates are 





Unclear risk: The study protocol 
is not available. Unclear whether 
the published report includes all 
pre-specified outcomes. No pre-
specification of outcomes in trial 
registration (TCTR20180122001). 








High risk: No blinding (assumed 
due to nature of intervention and 
control). 
High risk: No blinding 
reported. 
Unclear risk: Quote: 
"Patients who were 
considered to have 
treatment failure 
were excluded from 
further analyses 
because the time to 
tocolysis could not 
be assessed"; 
148/160 women 
were included in 
analyses. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 
includes all pre-specified 
outcomes. 
Witlin 1997 Low risk: Quote: 
"Randomization 
was performed by 
the use of 
computer-
generated tables of 
random numbers." 




Low risk: Placebo used. Quote: 
"Women randomized to placebo 
infusion received saline solution 
that was identical in appearance to 
the magnesium sulfate infusion and 
was likewise prepared in and 
dispensed by the hospital 
pharmacy." 
Low risk: As above. Low risk: No 
apparent missing 
data. 
Unclear risk: The study protocol 
is not available. It is unclear 
whether the published report 

























not taken into 
account? 
(confounding) 























Does the study 































































Cannot determine Not further assessed, although study reports that logistic regression was used, and aORs 
were presented in tables, no detail was provided of variables adjusted for 
High 
Alexander 2006 Yes: prospective data 
collection with use of 
database (verified 
accuracy); though 
outcomes not clearly 











Yes Yes Not further assessed, although study reports a multivariable logistic regression model was 
used (considering variables found to differ in univariate comparisons), for the review 
outcomes of interest, there was no adjustment for confounders 
High 
Ambadkar 2017 Cannot determine: 
while neonatologists 
were reported to be 
‘blinded’ to study, 
unclear if this was 





reported to be 
“matched” 
Yes Not further assessed; no adjustment for confounders High 
Bajaj 2018 Yes: prospectively 




Yes Partially: multivariable 
logistic regression 
analysis performed to 
assess the association 
between levels of 
resuscitation with 
selected morbidities 
after adjusting for 
centre, GA, SGA 
status, any antenatal 




Yes, not blinded No No Moderate 
Basu 2012 Yes: retrospective 
chart review, though 
detail/definitions 
provided 
Yes Partially: adjustment 
for GA, birthweight 
and multiple 
gestations (for PDA, 
ROP and LOS only) 
No Cannot 
determine 















Belden 2017 Yes: retrospective 
chart review, though 
detail/definitions 
provided 











Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only Unclear 




No Yes Not further assessed; no adjustment for confounders High 




No Yes Not further assessed; no adjustment for confounders High 
Bonta 2000 
Abstract 
Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only Unclear 




outcomes of interest 
Yes Yes Not further assessed, although results of multinomial logistic regression analysis are 




Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (though logistic regression was used for univariate and 
multivariable analyses for the composite outcome) 
Unclear 






on GA and birth 
order 
Yes Not further assessed; no adjustment for confounders High 
Brookfield 2015 
Abstract 
Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (does report that multivariate techniques were used, 





Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (does report that multivariate logistic regression 




Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (though controls were matched, and aORs, from 









Yes Partially: adjustment 
for GA, birthweight, 
antenatal steroids, 
chorioamnionitis, 
mode of birth, Apgar 
score < 7 at 5 minutes, 









No No Moderate 
Cawyer 2016 
Abstract 
Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (though reports multivariable logistic regression was 




Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (does report that a multiple linear regression model 
was used) 
Unclear 




provided (and some 
data self-reported by 
women who were 
discharged 
undelivered) 
No Yes Not further assessed; no adjustment for confounders High 
Chun 2014 
English abstract 
Cannot determine Cannot 
determine 
Cannot determine Not further assessed; English abstract only (article in Korean) Unclear 




Yes Partially: binary 
logistic regression 
controlling for race, 






exposure, to control 
No Cannot 
determine 







linear variables, for 
IVH only 




No Yes Not further assessed; no adjustment for confounders High 
Deering 2005 Yes: retrospective 
database review, with 
detail/definitions 
provided 
Yes Partially: adjustment 





Yes, not blinded No No Moderate 
to high 






Yes Partially: adjustment 
for centre, GA, 
antenatal steroids and 
PIH/E (for delivery 
room intubation, day 
1 MV, day 1 ET MV, 
day 3 MV, day 3 ET 




Yes, not blinded No No Moderate 












Yes Partially: adjustment 
for GA or birthweight, 
race, gender, mode of 
birth, antenatal 
steroids, presence of 
chorioamnionitis, 








Cannot determine Cannot 
determine 






Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only Unclear 





Yes  Partially: adjustment 
for multiple gestation, 
gender, GA at birth, 
birthweight < 10th 
centile, outborn 





Yes, not blinded No No Moderate 




provided (e.g. for IVH, 
NEC) 
No Yes Not further assessed; no adjustment for confounders High 
Downey 2017 Yes: use of database 




Yes Partially: adjustment 
















Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (does report that log-linear regression was used to 
control for potential confounders, and two outcomes (composite, intubation) reported to 
be adjusted for GA at birth, sepsis, SGA and alcohol use) 
Unclear 
Duffy 2012 Yes: retrospective 
collection from ERMs, 
detail/definitions 
provided 
Yes Yes Not further assessed; although study reported multivariable logistic regression analyses, 





Edwards 2018* Cannot determine: 
prospective data 






definition used for 
chorioamnionitis to 
define groups 
Yes Partially: adjustment 
for sex only 
No Cannot 
determine 
No, original RCT 
was blinded 
No No Moderate 
to high 




Yes Partially: adjustment 
for antenatal 
confounding variables 
– assumed to be GA ≤ 
28 weeks, antibiotics, 
antenatal steroids, 
and chorioamnionitis 













Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (does report that multivariate analysis corrected for 
mode of delivery and exposure to antenatal steroids) 
Unclear 









Yes  Partially: controlled 
for GA and indication 




No  Cannot 
determine 
Yes, not blinded No No Moderate 
to high 
FineSmith 1997 Yes: retrospective 
record review, with 
blinded re-review of 
CUS 
Yes: controls 




GA, MgSO4, Apgar 
scores at 1 and 5 












minutes, duration of 
intubation, reason for 
prematurity and type 
of birth) 




Yes  Partially: adjustment 
for postmenstrual age 
at MRI, VLBW, 







No, MRI review 
blinded to clinical 
history; and case 
note review 
blinded to MRI 
findings 
No No Moderate 
Garcia Alonso 
2018 





matched by GA 
and time period 
Partially: for some 
outcomes 
(resuscitation, 
surfactant, BPD, ROP) 
control for GA and 
birthweight) 
Yes; no; no Cannot 
determine 














Cannot determine Cannot 
determine 
Cannot determine Not further assessed; English abstract only (article in Russian) Unclear 





matched by GA 
(similar) and 
gender 
Partially: control for 
diagnosis of preterm 
labour only 
Yes; no; no Cannot 
determine 
Yes, not blinded No No Moderate 
to high 






some outcomes (e.g. 












Yes Partially: adjustment 
for receipt of public 
insurance, maternal 
age, race type of birth, 
birthweight, GA at 
birth (for NICU 
admission and NICU 
admission ≥ 8 days) 
No Cannot 
determine 





Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (does report that logistic regression was used) Unclear 
Greenberg 2011 Yes: retrospective 
chart review, with 
detail/definitions 
provided 
Yes Partially: controlled 
for GA, Apgar score at 





Yes, not blinded No No Moderate 
to high 
Greenberg 2013 Yes: retrospective 
chart review, with 
detail/definitions 
provided 
Yes Partially: controlled 





and severe PE (for 
NICU admission only) 
No Cannot 
determine 
Yes No No Moderate 
to high 

















infection definite or 
possible, infection, 
Yes; no; no Cannot 
determine 




status; cases data 
collected with no 
















sex, maternal age, 
level of hospital care, 
maternal bleeding, 
presentation at birth, 
surgical birth, 









Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only Unclear 









Yes Not further assessed; no control for confounders for review outcomes of interest High 







Yes Not further assessed; no control for confounders High 
Havranek 2011 Cannot determine: 
limited 
detail/definitions 
provided re: clinical 
outcome collection 
methods 
Yes Yes Not further assessed; though linear regression analysis was used for superior mesenteric 





Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (does report that multiple stepwise logistic regression 
was used, and reports results controlling for GA, betamethasone therapy, clinical 
chorioamnionitis, and delivery mode) 
Unclear 
Holcomb 1991 Cannot determine: 
categories for defining 













Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only Unclear 
Hong 2019 
Abstract 
Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only Unclear 
Igarashi 1995 
English abstract 
Cannot determine Cannot 
determine 
Cannot determine Not further assessed; English abstract only (article in Japanese) Unclear 




No Yes Not further assessed; no control for confounders High 







GA, and mode 
of birth 
Yes/Partially Not further assessed; logistic regression used for CLD only and controlled only for 
antenatal steroid exposure; no control for confounders for other review outcomes 
High 
Jazayeri 2003 Yes: retrospective 





PPROM at same 
GA 
Yes Not further assessed; no control for confounders for review outcomes of interest High 
Jeanneteau 2014 
Abstract 
Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only Unclear 
Jones 2018 
Abstract 
Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only Unclear 






No Yes Not further assessed: no control for confounders High 
Kamilya 2005 Cannot determine: 
retrospective review; 
very limited detail 






Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (does report the use of multivariable models adjusting 




Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (does report the use of a multivariable logistic 




Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (does report the use of multivariable models that 
included GA as a covariate) 
Unclear 
Kamyar 2016a* Yes: prospective data 





definition used for 
chorioamnionitis to 
define inclusion 
Yes  Partially: adjusted for 
GA at birth, maternal 
years of education, 
maternal race, IUGR, 
illicit drug use, 
smoking status, sex 
No Cannot 
determine 
No, original RCT 
was blinded 
No No Moderate 
to high 
Kamyar 2016b* Yes: prospective data 
collection in original 
RCT, detail/definitions 
provided (though 
recognition of lack of 
SIP data, and 
possibility of 
diagnostic overlap) 
Yes  Partially: adjustment 
for birth GA, 











No, original RCT 
was blinded 
No No Moderate 
to high 
Katayama 2011 Yes: retrospective 
chart review, though 
detail/definitions 
provided 











Cannot determine Cannot 
determine 









Yes; no; no Cannot 
determine 







factors significant in 
univariate analyses: 
GA, birthweight, Apgar 
score at 5 minutes, 
resuscitation, tocolytic 
therapy, apnoea, MV, 
HMD, haematocrit, 
PaCO2 maximum in 1st 
3 days, symptomatic 
hypotension 1st 3 days 
Kimberlin 1998 Yes: retrospective 
review of 
prospectively 
collected data, with 
detail/definitions 
provided 
Yes Partially: controlled 
for birthweight, GA, 







Yes, not blinded No No Moderate 
to high 





interviews were used 
in conjunction with 
chart reviews) 
No Yes Not further assessed: no control for confounders High 





interviews were used 
in conjunction with 
chart/pharmacy sheet 
reviews) 
Yes Partially: stepwise 
logistic regression 
analysis included PE 
related variables; 
covariates (mode of 
birth, labour, 
birthweight, GA, 





No, assessment of 
CUS blinded to 
exposures 






allowed to compete 
Lai 2017 
Abstract 
Cannot determine Cannot 
determine 





Cannot determine Cannot 
determine 





Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (does report that a multiple linear regression model 
was used) 
Unclear 






Yes Partially: models 
included: GA, 
birthweight, Apgar 
























No No Moderate 





and record review 
used for some 
measures) 
Yes Partially: adjusted for 
GA, birthweight z 
score, antenatal 
corticosteroids, PE, 



















Cannot determine Cannot 
determine 
Cannot determine Not further assessed; English abstract only (article in Spanish) Unclear 





by time period 
and GA range 
Yes Not further assessed; no control for confounders High 





born in same 
period only 
Yes Not further assessed; no control for confounders High 
McGuiness 1980 Cannot determine: 
prospective collection, 
though outcomes not 
well defined in 
methods 
Yes: controls in 




Yes Not further assessed; no control for confounders High 
McPherson 2014* Yes: prospective data 




Yes Yes Not further assessed; no control for confounders for review outcomes of interest 
(multivariable regression analyses adjusted for confounders for CP/death assessment 
only) 
High 
Mikhael 2019 Cannot determine: 
methods for data 
collection not clearly 
reported 
Yes Partially: multivariate 
logistic regression 


















Mitani 2011 Yes: retrospective 
records review, with 
detail/definitions 
provided 
Yes Partially: reports that 
multivariate 
analyses/logistic 
regression used – 
assumed adjustment 
for GA on admission, 
corticosteroid, GA at 
birth, birthweight, 
Apgar scores at 1 and 













Cannot determine Cannot 
determine 





Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (does report that a logistic model controlling for 
birthweight and funisitis was used) 
Unclear 
Morag 2015 Cannot determine/no: 
retrospective review 
of prospective data, 
detail/definitions clear 
for ‘cases’; data for 
term ‘controls’ 
collected from records  
Yes: matched 
for birth date 
(within 2 
weeks), gender, 














Yes, not blinded No No Moderate 
to high 
Morag 2016 Yes: retrospective 
chart review, though 
detail/definitions 
provided 
Yes Yes Not further assessed; though multiple linear regression analysis was conducted for 
neurodevelopmental follow up outcomes, no control for confounders for review 
outcomes of interest; additionally, protocol deviation in defining groups for comparison: 
“The mean iMgC was used as a cut-off in exposed infants as a second option because a 









Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (does report the results of logistic regression analysis) Unclear 
Murata 2005 Yes: retrospective 
record review, though 
detail/definitions 
provided 
Yes  Partially: multivariate 
analysis included: 
Apgar score < 5 at 5 
minutes, cord length > 













Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only Unclear 







Yes Yes Not further assessed; for our comparison of interest, no control for confounding (though 
for comparisons of neonatal serum magnesium concentrations, logistic regression was 
used adjusting for birthweight and multiple gestation; and linear regression was used 
controlling for maternal MgSO4 dose) 
High 







No Yes Not further assessed; no control for confounders High 




(e.g. for availability of 
CUS), and limited 
detail/definitions for 






Yes Not further assessed; while multivariate logistic regression analyses were conducted for 





Nunes 2018 Yes: retrospective 
record review, though 
detail/definitions 
provided 
No Yes Not further assessed; no control for confounders High 






reporting for perinatal 
mortality unclear 
No Yes Not further assessed: no control for confounders; unclear reporting of perinatal mortality 
results 
High 
O Reilly 2016 
Abstract 
Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (does report that the data were controlled for GA) Unclear 




No Yes Not further assessed: no control for confounders High 
Palatnik 2019 Cannot determine: 
medical record 
review, with limited 
definitions provided  





associated with sepsis 
or death in bi-variable 
analyses were 
retained for further 
analyses (models of 
multivariable logistic 
regression for the 
outcome sepsis) 
Yes, no, no Cannot 
determine 
Yes, not blinded No No Moderate 
to high 






Yes  Partially: adjustment 
for GA, fetal growth 
ratio, gender, multiple 
birth status, mode of 
birth, labour status, 
















Cannot determine Cannot 
determine 





Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only Unclear 
Petrova 2012 Yes: retrospective 
collection with use of 
database/discharge 
files (though limited 
detail/definitions) 
Yes: matching 




ventilation after birth, 
severity of distress 
Yes; no; no Cannot 
determine 
Yes, no blinding 
(though matching 
was blinded) 




Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (does report that logistic regression correcting for GA 
and birthweight was used) 
Unclear 
Rantonen 2001 Yes: prospective data 
collection, with 
detail/definitions 
provided (limited for 
clinical outcomes) 
No Yes Not further assessed: no adjustment for confounders (for outcomes of interest; in 
haemodynamic analyses, PV-IVH and graded ductal shunting were taken for covariates) 
High 




No Yes Not further assessed; no adjustment for confounders High 
Rattray 2014 Cannot determine: 
retrospective 
collection, methods of 
collection not detailed 
Yes Partially: stepwise 
regression tested for 
an interaction effect 
between MgSO4 
exposure and GA and 









Yes, not blinded No No Moderate 
to high 
Rauf 2017 Cannot determine: 
retrospective record 




review, outcomes not 
well defined 




No Yes Not further assessed; no adjustment for confounders High 
Riaz 1998 Yes: prospective 
collection, including 






Yes Not further assessed; no adjustment for confounders High 
Rizzolo 2019 
Abstract 
Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (though reports multivariate logistic regression models 
adjusted for patient characteristics) 
Unclear 





No Yes Not further assessed; no adjustment for confounders High 
Sakae 2017 Cannot determine: 
retrospective 
collection, with 
unclear methods for 
collection and limited 
detail/definitions 
No Yes Not further assessed; while multiple logistic regression analysis was used to determine 
independent components of management protocol that contributed to the absence of 
serious neonatal complications, there was no adjustment for confounders for review 
outcome comparisons 
High 
Salafia 1995 Yes: retrospective 
record review, with 
detail/definitions 
provided 









Yes, not blinded No No Moderate 
to high 
Sarkar 2009 Yes: retrospective 
collection using 
database/records, 













related to severe IVH, 
controlling for effects 
of other potential 
confounders (GA, 
birthweight, 
prenatal steroid use, 
MgSO4, 
and 5-minute Apgar 
score < 6) 
Schanler 1997 Cannot determine: 
prospective data 







Yes Not further assessed; no adjustment for confounders High 
Scudiero 2000 Yes: retrospective 
records review, with 
detail/definitions 
provided 
Yes Partially: multivariate 
logistic regression 
used to assess effect 
of > 48 g MgSO4, 
taking into account 
other possible 
predictors (delivery 












No No Moderate 
to high 





limited for covariates) 
Yes Partially: multiple 
logistic regression 
included covariates: 
gender, GA, SGA, 
Apgar score < 7 at 5 
minutes, MV on day 1, 









indomethacin for PDA 
treatment 










Yes Not further assessed; no adjustment for confounders High 











Yes Yes/Partially  Not further assessed, multiple logistic regression analyses controlled for confounders for 
CP severity assessment, but no adjustment for outcomes of interest 
High 
Stockley 2018 Yes: data collected by 
CNN and CNFUN using 
standard manuals of 
operations and 
definitions; CNN has 
been shown to have 
high consistency and 
reliability 
Yes Partially: multivariable 
logistic regression 





GA, male sex, and 
SNAP-II score > 20 
No Cannot 
determine 
Yes, not blinded No No Moderate 
Suh 2015 
Abstract 
Cannot determine Cannot 
determine 
Cannot determine Not further assessed; English abstract only (articles in Korean) Unclear 





Yes Partially: factors 
significantly 
associated with early 
hypotension 
(birthweight, GA, 1 
No Cannot 
determine 





and 5 minute Apgar 
scores, presence of 





Verma 2006 Yes: retrospective 
record review, with 
detail/definitions 
provided 
Yes Partially: multivariate 
logistic regression 
controlled for 
maximum mean FiO2 
and MAP during first 7 
days of life, 
1 and 5 min Apgar 








No No Moderate 
to high 











amnionitis, mode of 
birth, GA, birthweight, 
1 and 5 minute Apgar 




Yes, not blinded No No Moderate 
to high 





Yes  Partially: adjusted for 
GA, sex, SGA, outborn 
status, 
chorioamnionitis, 
mode of birth, 
antenatal 
corticosteroid use and 
No Cannot 
determine 





(also accounting for 
correlated data within 




Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only (does report that multivariate logistic regression and 




Cannot determine Cannot 
determine 





Cannot determine Cannot 
determine 
Cannot determine Not further assessed; abstract only Unclear 




No Yes Not further assessed; no adjustment for confounders High 
Yokoyama 2010 Yes: retrospective 




and GA were 
matched 
Yes Not further assessed; though logistic regression analyses was used to assess risks for 
increasing ALP concentrations, there was no adjustment for confounding for outcomes of 
interest 
High 
Young 1977 Cannot determine: 
NRT with limited 
detail/definitions 
provided 
No Yes Not further assessed; no adjustment for confounders High  
 
Abbreviations: ALP: alkaline phosphatase; aOR: adjusted odds ratios; BPD: bronchopulmonary dysplasia; CCS: case-control study; CLD: chronic lung disease; CNFUN: Canadian Neonatal Follow-Up 
Network; CNN: Canadian Neonatal Network; CP: cerebral palsy; CUS: cranial ultrasound; E: eclampsia; EMR: electronic medical records; ET: endotracheal; FIRS: fetal inflammatory response syndrome; 
GA: gestational age; GM-IVH: germinal matrix intraventricular haemorrhage; HMD: hyaline membrane disease; IUGR: intrauterine growth restriction; IVH: intraventricular haemorrhage; LOS: length of 
stay; MAP: mean arterial pressure; MgSO4: magnesium sulphate; MRI: magnetic resonance imaging; MV: mechanical ventilation; NEC: necrotising enterocolitis; NICU: neonatal intensive care unit; NRT: 
non-randomised trial; NS: not significant; ORs: odds ratios; P: p value; PDA: patent ductus arteriosus; PE: pre-eclampsia; PIE: pregnancy induced hypertension; PINS: Perinatal Information System; PTL: 
preterm labour; PV-IVH: periventricular intraventricular haemorrhage; PPROM: preterm premature rupture of membranes; PROM: premature rupture of membranes; PVL periventricular leucomalacia; 
RCT: randomised controlled trial; RDS: respiratory distress syndrome; ROP: retinopathy of prematurity; ROM: rupture of membranes; SGA: small for gestational age; SIP: spontaneous intestinal 





S3 Table. Adverse outcomes from non-randomised studies 
 
Study; design; overall 
risk of bias 
Participants; MgSO4 
indication 










RCS with CCS(N); high 
N = 170 women, 178 
babies; E 
1: Babies still living at the 7th 
day of life, N = 147 babies 
2: Stillbirths and neonatal 
deaths in the 1st 7 days 
(perinatal deaths), N = 31 
babies 
MgSO4 exposure aOR 1.04; P > 0.05 ~ 
Alexander 2006; PCS; 
high 
N = from 72004 births, 
87 women with E and 
their babies included in 
analyses; GH/PE 
1: No GH and no MgSO4 with 
E, N = 49 women and their 
babies 
2: GH and MgSO4 with E, N = 
11 and their babies 
3: GH and no MgSO4 with E, 
N = 27 and their babies 
Adverse outcome composite (cord pH < 7.0, Apgar 
score < 4 at 5 minutes, stillbirth or neonatal death, 
and an unanticipated admission of a term infant to 
the NICU) 
12.2% vs. 9.1% vs. 11.1% NR 
Perinatal death 6.1% vs. 0% vs. 11.1% NR 
Alston 2016; NCCS; high N = 169 babies; T 1: MgSO4 use, N = 102 (90 
babies in analyses) 
2: No MgSO4 use, N = 67 (64 
babies in analyses) 
Hospital stay (days) (mean, no measure of 
variance) 
P = 0.89 ~ 
Neonatal death No events ~ 
RDS P = 0.17 ~ 
BPD P = 0.10 ~ 
Sepsis P = 0.74 ~ 
NEC P = 0.40 ~ 
IVH P = 0.47 ~ 
Ambadkar 2017; PCS; 
high 
N = 120 women and 
babies; PE/E 
1: MgSO4, N = 60 babies 
2: No MgSO4, N = 60 babies 
Neonatal death No events ~ 




 Hypotonia P = 0.028  
RD P = 0.143 ~ 
Meconium passage (< 6, 6-12, > 12 hours) P > 0.05 ~ 
1: MgSO4 and NICU 
admission, yes, N = 13 babies 
2: MgSO4 and no NICU 
admission, N = 47 babies 
MgSO4 dose (categories: LD, LD + 1, LD + 2, LD + 3, 
LD + 4, LD + 5, LD + 7 doses) 
P = 0.506 ~ 
Duration of MgSO4 (< 6, 6-12, 12-18, ≥ 18 hours) P = 0.341 ~ 
Time between last MgSO4 dose and birth (1-2, 2-3, 
3-4, 4-5, > 5 hours) 
P = 0.0441 “the closer the last dose… 
the higher the rate” 
 
Bajaj 2018; RCS; 
moderate 
N = 7014 babies; NR 1: Routine care without 
resuscitation, N = 1684 
babies 
2: Oxygen or CPAP, N = 2279 
babies 
3: Bag and mask ventilation, 
N = 1831 babies 
4:  ETT intubation, N = 1034 
babies 
5: CPR, N = 186 babies 
MgSO4 exposure (unadjusted) P < 0.0001  
MgSO4 exposure, 1 as reference, vs. 2 (adjusted 
for centre, GA, SGA status, any antenatal steroids, 
and multiple births) 
aOR 0.96; 95% CI 0.81-1.14 ~ 
MgSO4 exposure, 1 as reference, vs. 3 (adjusted as 
above) 
aOR 0.98; 95% CI 0.82-1.18 ~ 
MgSO4 exposure, 1 as reference, vs. 4 (adjusted as 
above) 
aOR 0.65; 95% CI 0.52-0.81  
MgSO4 exposure, 1 as reference, vs. 5 (adjusted as 
above) 
aOR 0.40; 95% CI 0.24-0.67  
Basu 2012; RCS; 
moderate to high 
N = 475 babies; FN 1: MgSO4, N = 289 babies 
2: No MgSO4, N = 186 babies 
Survival without IVH/PVL P = 0.25 ~ 
Resuscitation P = 0.42 ~ 
Intubation P = 0.34 ~ 
BPD P = 0.43 ~ 
IVH/PVL P = 0.36 ~ 
Neonatal death P = 0.52 ~ 
ROP P = 0.02  
PDA P = 0.01  
LOS (days) (mean ± SD)  P = 0.01  
PDA, ROP, LOS (days) (mean ± SD) (multivariate 
logistic regression, controlled for GA and 
birthweight; and multiple gestations) 
“Multivariate analysis performed 
showed that… the increased 
incidences of PDA, ROP, LOS… were no 
longer statistically significant, 
although the odds of developing these 





likely than in those exposed to 
antenatal magnesium.” 
Belden 2017; RCS with 
CCS(N); moderate to high 
N = 83 babies; FN/PE 1: Enteral feeding 
intolerance, N = 49 babies 
2: No feeding intolerance, N 
= 34 babies 
MgSO4 dose (g) (mean ± SD) P = 0.04  
MgSO4 dose (g) (mean ± SD) (multivariate logistic 
regression, accounting for differences between 
groups – assumed to be GA, birthweight, 1 and 5 
minute Apgar scores) 
“The strongest predictors were 
prematurity and cumulative maternal 
magnesium sulfate dose.” 
 
MgSO4 dose (g) (mean ± SD), in relation to 
birthweight, < 1250 g, 1250-1500 g, > 1500 g 
P = 0.47 
P = 0.57 
P = 0.48 
~ 
1: MgSO4 > 80 g, N = NR 
2: MgSO4 ≤ 80 g, N = NR 
Enteral feeding intolerance P = 0.04  
Parenteral nutrition (days) (measure NR)^ P < 0.01  
Bertello Grecco 2019; 
PCS; unclear 
Abstract 
N = 93 women and their 
babies; PE 
1: MgSO4 ≤ 24 hours, N = 51 
women and their babies 
2: MgSO4 < 24 hours, N = 42 
women and their babies 
“presence of respiratory depression, admission to 
intensive care unit, hypotonia, and neonatal 
mortality” 
“No statistically significant differences 
were observed comparing both 
groups in neonatal variables.” 
~ 
Black 2006; PCS; high N = 134 babies; 
PE/PIH/HELLP/T 
1: MgSO4 with (N = 
45)/without (N = 5) steroids, 
N = 50 babies 
2: No MgSO4 with (N = 
38)/without steroids (N = 46), 
N = 84 babies 
Ventilation (days) (mean ± SD) “no significant differences among 
groups.” 
~ 
Methylxanthines (days) (mean ± SD) “no significant differences among 
groups.” 
~ 
NBRS (mean ± SD)^ “no significant differences among 
groups.” 
~ 
IVH “no differences among the groups on 
frequency or severity of IVH.”” 
~ 
Blackwell 2002; PCS; high N = 39 babies; PE 1: MgSO4, N = 13 babies 
2: No MgSO4, N = 26 babies 
Troponin I ≥ 1.0 ng/mL (cardiac-specific protein 
used to detect myocardial injury)^ 
P = 0.4 ~ 
Bonta 2000; PCS; unclear 
Abstract 
N = 379 women and 
babies; T 
1: MgSO4 < 72 hours, N = 199 
babies 
2: MgSO4 > 72 hours, N = 45 
babies 
3: No MgSO4, N = 135 babies 
HsPDA treated with indomethacin 28.1% vs. 55.6% vs. 35.6%; 
“Incidence… was 2:1 (> 72 group vs < 
72 group)” 
 
Bozhurt 2016; RCS; high N = 387 babies; PE 1: MgSO4, N = 59 babies 
2: No MgSO4, N = 328 babies 
RDS “All of the p values are insignificant” ~ 
BPD “All of the p values are insignificant” ~ 




Apnoea “All of the p values are insignificant” ~ 
PDA “All of the p values are insignificant” ~ 
IVH grade 3/4 and PVL “All of the p values are insignificant” ~ 
PVL only “All of the p values are insignificant” ~ 
Culture proven sepsis “All of the p values are insignificant” ~ 
NEC grade ≥ 2 “All of the p values are insignificant” ~ 
ROP > 3 “All of the p values are insignificant” ~ 
Boyle 2018; RCS; unclear 
Abstract 
N = 285 women and 
their babies; NR 
1: MgSO4, N = 16 babies 
2: No MgSO4, N = 271 babies 
[note discrepancy between 
total N and group Ns 
reported] 
Composite adverse neonatal outcome (defined as 
Apgar score < 7 at 5 minutes, arterial cord pH < 7.1 
and/or base deficit ≥ 12, admission to the NICU, 
need for immediate neonatal resuscitation beyond 
bulb suction and stimulation, or hospitalisation ≥ 3 
days) (unadjusted OR from univariate logistic 
regression; aOR from multivariable logistic 
regression – confounders adjusted for NR) 
OR 5.74; 95% CI 1.80-18.30; P < 0.01 
 
aOR 4.29; 95% CI 1.24-14.81); P = 0.02 
 
Brazy 1982; RCS; high N = 56 babies; ESHP 1: Hypertensive women 
treated with MgSO4, N = 28 
babies 
2: Non-hypertensive women, 
with no MgSO4, N = 28 
babies 
Days hospitalised (mean ± SD) P < 0.01  
Thrombocytopenia^ P < 0.05  
Leukopenia^ P < 0.001  
Neutropenia^ P < 0.01  
DIC^ P = NS ~ 
Severe respiratory disease^ P = NS ~ 
TTN^ P = NS ~ 
Delayed adaptation P < 0.01  
PDA P < 0.01  
Hypotension P = NS ~ 
Delayed stooling (> 24 hours) P < 0.05  
Ileus P < 0.05  
Hypotonia P < 0.05  
Other disease (CNS haemorrhage, air block, acute 
renal failure,^ NEC) 
P = NS ~ 
Neonatal death 7% vs. 7% ~ 
Death after 28 days of age, before hospital 
discharge^ 
11% vs. 0%  




Brookfield 2015; PCS 
with CCS(N); unclear 
Abstract 
N = 55 women and 
babies; FN/PE 
1: Resuscitation, N = 27 
babies 
2: No resuscitation, N = 28 
babies 
MgSO4 dose (g) (mean ± SD) P = 0.9 ~ 
Brookfield 2016; RCS; 
unclear 
Abstract 
N = 1496 women and 
babies; FN 
1: MgSO4, N = 735 babies 
2: No MgSO4, N = 761 babies 
RDS (multivariate logistic regression, adjusted for 
diabetes, mode of birth, other tocolytics, GA at 
birth) 
aRR 0.97; 95% CI 0.84-1.12 ~ 
Ventilation (adjusted as above) aRR 0.93; 95% CI 0.81-1.07 ~ 
Brown 2019; CCS; 
unclear 
Abstract 
N = 218 babies; NR 1: SH, N = 109 babies 
2: No SH, N = 109 babies 
MgSO4 exposure (unadjusted P and aOR – 
confounders adjusted for NR) 
P < 0.001 
aOR 0.39; 95% CI: 0.20-0.75 
 
Canterino 1999; RCS; 
moderate 
N = 918 babies; PE/T 
 
1: MgSO4, N = 398 babies 
2: No MgSO4, N = 520 babies 
Apgar score < 7 at 5 minutes P = 0.79 ~ 
RD P = 0.38 ~ 
Neonatal death  P = 0.44 ~ 
Abnormal sonograms (any PVL or IVH) P = 0.06 ~ 
Severe lesions (any PVL, PVL with IVH, or IVH grade 
3/4) 
P = 0.004  
Severe lesions (any PVL, PVL with IVH, or IVH grade 
3/4) (adjusted for clinical group) 
aOR 1.11; 95% CI 0.73-1.68, P = 0.42  ~ 
Severe lesion (any PVL, PVL with IVH, or IVH grade 
3/4) (adjusted for GA, birthweight, antenatal 
steroids, chorioamnionitis, mode of birth, Apgar 
score < 7 at 5 minutes, RDS) 
aOR 1.10; 95% CI 0.70-1.74; P = 0.69 ~ 
Abnormal sonograms (any PVL or IVH) (adjusted 
for clinical group) 
aOR 1.09; 95% CI 0.78-1.52; P = 0.40 ~ 
Abnormal sonograms (any PVL or IVH) (adjusted 
for GA, birthweight, antenatal steroids, 
chorioamnionitis, mode of birth, Apgar score < 7 at 
5 minutes, RDS) 
aOR 1.01; 95% CI 0.70-1.44; P= 0.97  ~ 
1: Abnormal sonograms, N = 
39 babies 
2: Normal findings, N = 125 
babies 




1: Severe lesions, N = 27 
babies 
2: Normal findings, N = 127 
babies 
Duration of MgSO4 (mean, SD) (hours) P = 0.72 ~ 
Cawyer 2019; RCS; 
unclear 
Abstract 
N = 2468 women and 
their babies; PE 
1: MgSO4, N = 1353 babies 
2: No MgSO4, N = 1115 
babies 
Perinatal or neonatal death (unadjusted P) P = 1.00 ~ 
NICU admission (adjusted for maternal age, 
race/ethnicity, BMI, primary source of payment, 
tobacco use, illicit drug use, diabetes, chronic 
hypertension) 
aOR 0.94; 95% CI 0.74-1.2 ~ 
Cho 2014; RCS; unclear 
Abstract 
N = 570 babies; NR 1: MgSO4, N = 101 babies 
2: No MgSO4 = 469 babies 
Hypocalcaemia “not different between groups.” ~ 
Chowdhury 2009; PCS (or 
NRT); high 
N = 630 women (529 
babies born to 
antepartum/intrapartum 
cases); E 
1: MgSO4 by Pritchard’s 
regimen, N = 480 women 
(406 babies born to 
antepartum/intrapartum 
cases 
2: MgSO4 by low-dose IV 
regimen, N = 150 women 
(123 babies born to 
antepartum/intrapartum 
cases) 
Stillbirth 11.6% vs. 8.3% ~ 
Early neonatal death due to birth asphyxia and 
prematurity (1st 7 days) 
15.0% vs. 10.4% ~ 
Perinatal death  OR 1.58; 95% CI 0.93-2.61; P = 0.075 ~ 
Chun 2014; RCS; unclear 
English abstract 
N = 209 women and 
babies; PE 
1: MgSO4, N = 119 babies 
2: No MgSO4, N = 90 babies 
Apgar score < 7 at 1 minute, primiparous women P = 0.031  
Apgar score < 7 at 1 minute, multiparous women P = 0.147 ~ 
Apgar score < 7 at 5 minutes, primiparous women P = 0.017  
Apgar score < 7 at 5 minutes, multiparous women P = 0.792 ~ 
NICU admission, primiparous women P = 0.001  
NICU admission, multiparous women P = 0.179 ~ 
Cuff 2018; RCS; 
moderate to high 
N = 224 women and 
their babies: 44 women 
and 54 babies exposed 
to MgSO4 within 12 
hours of birth; FN 
1: 2014 (BEAM trial: 6 g IV 
LD; 2 g/hour IV MD for 12 
hours), N = 18 babies 
exposed within 12 hours of 
birth 
2: 2015 (PREMAG trial: 4 g IV 
MD; no MD), N = 36 babies 
Apgar score < 7 at 5 minutes,  P = 0.55 ~ 
ROP grade 3/4 P = 0.57 ~ 
IVH grade 3/4 (binary logistic regression controlling 
for race, PTL, GA at delivery, corticosteroid 
exposure, birthweight, and indomethacin 
exposure) 
 
P = 0.04 





exposed within 12 hours of 
birth 
Das 2015; PCS; high N = 100 women and 
their babies; E 
1: 8 g MgSO4, N = 20 babies 
2: > 8 g MgSO4, N = 80 babies 
Apgar score < 7 at 1 minute P = 0.000  
Apgar score < 7 at 5 minutes P = 0.021  
Apgar score ≤ 3 at 1 minute^ P = 0.002  
Apgar score ≤ 3 at 5 minutes^ P = 0.003  
Respiratory depression P = 0.02  
Intubation in delivery room P = 0.01  
Bradycardia^ P = 0.022  
Hypotonia P = 0.012  
Hyporeflexia^ P = 0.025  
NICU admission P = 0.03  
Significant respiratory support in NICU^ P = 0.000  
Time to 1st stool > 24 hours P = 0.011  
Time to 1st void > 48 hours P = 0.02  
Number of episodes of feeding intolerance ≥ 3^ P = 0.000  
Stillbirth P = 0.008  
Neonatal death due to complications of 
hypermagnesemia 
P = 0.043  
Deering 2005; RCS; 
moderate to high 
N = 221 babies; PE/T 1: MgSO4, N = 103 babies (77 
preterm labour) 
2: No MgSO4, N = 118 babies 
(108 preterm labour) 
SNAP score in 1st 24 hours (mean ± SD) (multiple 
linear regression controlling for GA, birthweight, 
chorioamnionitis, steroid use)^ 
P = 0.005 (“significant decrease”)  
SNAP score > 10 in 1st 24 hours (multiple linear 
regression as above) 
P < 0.001  
SNAP score in 1st 24 hours (mean ± SD), preterm 
labour only (multiple linear regression as above)^ 
P = 0.047  
SNAP score > 10 in 1st 24 hours, preterm labour 
only (multiple linear regression as above) 
P  = 0.001  
De Jesus 2015; RCS; 
moderate 
N = 1544 babies; 
FN/PIH/T 
1: MgSO4, N = 1091 babies 
2: No MgSO4, N = 453 babies 
Delivery room resuscitation (PPV via bag and mask, 
any CPAP devices, intubation, chest compression 
and epinephrine) 
P = 0.665 ~ 




Delivery room intubation (multivariate logistic 
regression adjusted for centre, GA, antenatal 
steroids, and PIH/E) 
aOR 1.20; 95% CI 0.88-1.65; P = 0.246 ~ 
Day 1 MV P = 0.670 ~ 
Day 1 MV (multivariate logistic regression adjusted 
as above) 
aOR 1.22; 95% CI 0.65-2.30; P = 0.540 ~ 
Day 1 ET MV P = 0.023  
Day 1 ET MV (multivariate logistic regression 
adjusted as above) 
aOR 0.78; 95% CI 0.58-1.06; P = 0.109 ~ 
Day 3 MV P = 0.190 ~ 
Day 3 MV (multivariate logistic regression adjusted 
as above) 
aOR 0.65; 95% CI 0.40-1.04; P = 0.070 ~ 
Day 3 ET MV P = 0.0002  
Day 3 ET MV (multivariate logistic regression 
adjusted as above) 
aOR 0.54; 95% CI 0.41-0.72; P <0.001  
Day 1 hypotension P = 0.043  
Day 1 hypotension (multivariate logistic regression 
adjusted as above) 
aOR 0.70; 95% CI 0.51-0.97; P = 0.031  
PDA treated (medical or surgical) P = 0.954 ~ 
PDA treated (medical or surgical) (multivariate 
logistic regression adjusted as above) 
aOR 1.06; 95% CI 0.80-1.40; P = 0.696 ~ 
RDS P = 0.747 ~ 
Pulmonary haemorrhage P = 0.289 ~ 
Traditional BPD P = 1.0 ~ 
Late onset sepsis/meningitis P = 0.085 ~ 
NEC stage 2 or greater  P = 0.351 ~ 
ROP any stage P = 0.359 ~ 
IVH or parenchymal haemorrhage P = 0.294 ~ 
cPVL P = 0.150 ~ 
Neonatal death P = 0.223 ~ 
Cumulative days on MV (median, Q1, Q3) P = 0.871 ~ 
Cumulative days on oxygen support  (median, Q1, 
Q3) 
P = 0.635 ~ 




del Moral 2007; RCS; 
moderate to high 
N = 941 babies; PE/T 
 
1: MgSO4, N = 546 babies 
2: No MgSO4, N = 395 babies 
PDA P = 0.0178  
PDA (methods report co-variables: GA or 
birthweight, race, gender, mode of birth, antenatal 
steroids, presence of chorioamnionitis, MgSO4 
indication) 
“Logistic regression analysis showed 
that after controlling for confounding 
variables there was an increased risk 
of PDA in infants exposed to MgSO4.”  
 
PDA, ≥ 26 weeks GA P = 0.0399  
“When stratified by gestational age 
the differences were significant only in 
the group of infants with a gestational 
age ≥ 26 weeks. Moreover, in these 
infants the incidence of PDA increased 
concomitantly with the dose of 
MgSO4 given to the mother.” 
 
PDA, ≥ 26 weeks GA (methods report co-variables 
as above) 
OR: 1.33; CI 1.12-1.58, per 50 g 
MgSO4 
“Logistic regression analysis to adjust 
for co-variables indicated an increased 
risk of PDA with higher doses of 
MgSO4.” 
 
PDA treated with surgical ligation 30% vs. 34% “not different.” ~ 
Neonatal death (up to hospital discharge) 18% vs. 22% “did not differ.” ~ 
IVH grade 3/4 12% vs. 13% “similar.” ~ 
PVL 2.3% vs. 1.1% “similar.” ~ 
delValle 1998; PCS; 
unclear 
Abstract 
N = 110 babies; NR 1: MgSO4, N = 34 babies 
2. No MgSO4, N = 76 babies 
Surfactant treatment, indomethacin treatment, 
PDA, NEC, IVH, PVL 
“Infants exposed to maternal 
magnesium were comparable to non-
exposed infants” 
~ 
Derks 2016; NCCS; 
unclear 
Abstract 
N = 207 babies; FN 1: Post MgSO4 
implementation, N = 99 
babies 
2: Pre MgSO4 
implementation, N = 108 
babies 
PWML at 30 weeks MRI^ P = 0.002  
PWML at 40 weeks MRI^ “not [reduced]” ~ 
“neonatal complications, including early intubation 
for respiratory insufficiency or hypotension.” 
“no increase” ~ 
De Silva 2018; RCS 
(within report of ITS); 
moderate 
N = 14108 babies; FN 1: MgSO4 for FN, N = 5314 
babies 
Intensive resuscitation (either chest compressions 
or intubation and ventilation or epinephrine 
administration in the delivery room) (adjusted for 






2: No MgSO4, N = 7238 
babies 
3: MgSO4 for another 
indication, N = 1556 babies 
multiple gestation, gender, GA at birth, 
birthweight < 10th centile, outborn status, mode of 
birth, antenatal corticosteroid use) 1 vs. 2 
Intensive resuscitation (adjusted as above) 1 vs. 3 aOR 0.81; 95% CI 0.66-0.99; P = 0.04  
de Veciana 1995; RCS; 
high 
N = 73 women, 80 
babies; T 
1: MgSO4, N = 44 women, 48 
babies 
2: No MgSO4, N = 29 women, 
32 babies 
Days in hospital (mean ± SD) P = NS ~ 
Days intubated (surviving neonates) (mean ± SD) P = NS ~ 
Days intubated (babies with RDS) (mean ± SD) P = 0.43 ~ 
RDS mild to severe P = NS ~ 
RDS severe (requiring high pressure ventilation for 
more than 24 hours) 
RR 0.47; CI 0.2-1.0; P = 0.04  
IVH grade 1-4 P = NS ~ 
NEC P = NS ~ 
Neonatal death P = NS ~ 
Apgar score < 7 at 5 minutes P = NS ~ 
Downey 2017; RCS; 
moderate 
N = 28035 babies; 
FN/PE/T 
 
1: MgSO4, N = 11789 babies 
1: No MgSO4, N = 16246 
babies 
SIP (adjusted for site, GA at birth, multiple 
gestation, antenatal steroid exposure, antenatal 
antibiotic exposure, prolonged ROM, SGA age, sex, 
discharge year, postnatal hydrocortisone exposure, 
and postnatal indomethacin exposure) 
aOR 1.08; 95% CI 0.91-1.29 ~ 
Neonatal death in 1st 21 days of life (adjusted as 
above) 
aOR 0.76; 95% CI 0.70-0.83  
Surgical NEC (adjusted as above) aOR 0.84; 95% CI 0.66-1.05 ~ 
Medical NEC (adjusted as above) aOR 1.11; 95% CI 0.89-1.37 ~ 
Neonatal death, NEC or SIP (adjusted as above) aOR 0.84; 95% CI 0.77-0.90  
IVH grade 3/4 (adjusted as above) aOR 0.97; 95% CI 0.88-1.06 ~ 
Drassinower 2015; RCS; 
unclear 
Abstract 
N = 1047 women and 
babies; FN 
1: MgSO4, N = 461 babies 
2: Placebo, N = 586 babies 
Composite of immediate outcomes (Apgar score < 
7 at 5 minutes, oxygen in delivery room, 
intubation, chest compressions, hypotension, 
hypotonicity) (adjusted for GA at birth, sepsis, SGA, 
and alcohol use) overall; and birth ≥ 30 weeks GA 
OR 0.92; 95% CI 0.79-1.08; P = 0.12 
OR 0.91; 95% CI 0.73-1.14; P = 0.24 
~ 
Apgar score < 7 at 5 minutes overall; and birth ≥ 30 
weeks GA 
OR 0.82; 95% CI 0.59-1.14; P = 0.25 
OR 1.13; 95% CI 0.56-2.28; P = 0.74 
~ 
Oxygen bag, mask or both  overall; and birth ≥ 30 
weeks GA 
OR 1.10; 95% CI 0.80-1.41; P = 0.62 





Intubation overall; and birth ≥ 30 weeks GA 
(adjusted for GA at birth, sepsis, SGA, and alcohol 
use) 
OR 0.89; 95% CI 0.71-1.11; P = 0.05 
OR 0.53; 95% CI 0.32-0.88; P = 0.01 
 
Chest compressions overall; and birth ≥ 30 weeks 
GA 
OR 1.2; 95% CI 0.6-2.5; P = 0.71 
OR 2.39; 95% CI 0.2-26.5; P = 0.46 
~ 
Hypotension treated with vasopressors overall; 
and birth ≥ 30 weeks GA 
OR 0.8; 95% CI 0.6-1.2; P = 0.30 
OR 0.55; 95% CI 0.28-1.09; P = 0.08 
~ 
Generalised hypotonicity overall; and birth ≥ 30 
weeks GA 
OR 0.78; 95% CI 0.46-1.22; P = 0.35 
OR 0.89; 95% CI 0.31-2.60; P = 0.83 
~ 
RDS overall; and birth ≥ 30 weeks GA OR 0.96; 95% CI 0.75-1.22; P = 0.72 
OR NR for ≥ 30 weeks GA 
~ 
MV overall; and birth ≥ 30 weeks GA OR 0.84; 95% CI 0.66-1.07; P = 0.16 
OR 0.80; 95% CI 0.54-1.18; P = 0.26 
~ 
Seizures overall; and birth ≥ 30 weeks GA OR 0.99; 95% CI 0.37-2.67; P = 0.98 
OR NR for ≥ 30 weeks GA 
~ 
IVH overall; and birth ≥ 30 weeks GA OR 0.81; 95% CI 0.60-1.1; P = 0.16 
OR NR for ≥ 30 weeks GA 
~ 
Neonatal death (assumed) overall; and birth ≥ 30 
weeks GA 
OR 1.27; 95% CI 0.78-2.08; P = 0.34 
OR 2.35; 95% CI 0.69-7.90; P = 0.16 
~ 
Duffy 2012; RCS; high N = 5387 women and 
babies; PE 
1: MgSO4, N = 248 babies 
2: No MgSO4, N = 5139 
babies 
Composite adverse outcome (fetal acidemia, base 
excess ≤ -12.00, SCBU or NICU admission) 
P = 0.11 ~ 
Edwards 2018; RCS; 
moderate to high 
N = 1944 women and 
babies; FN 
1: Chorioamnionitis, N = 228 
women and babies 
2: No chorioamnionitis, N = 
1716 women and babies 
MgSO4 exposure P = 0.76 ~ 
All below outcomes Breslow-Day test P > 0.05 for all ~ 
1: Chorioamnionitis and 
MgSO4, N = 109 babies 
2: Chorioamnionitis and no 
MgSO4, N = 119 babies 
IVH OR 0.72; 95% CI 0.40-1.28; P = 0.26 ~ 
IVH (logistic regression adjusted for sex) aOR 0.73; 95% CI 0.40-1.30 ~ 
NEC OR 1.23; 95% CI 0.52-2.91; P = 0.64 ~ 
NEC (logistic regression adjusted for sex) aOR 1.23; 95% CI 0.52-2.91 ~ 
BPD OR 1.26; 95% CI 0.67-2.36; P = 0.48 ~ 
BPD (logistic regression adjusted for sex) aOR 1.26; 95% CI 0.67-2.38 ~ 
1: No chorioamnionitis and 
MgSO4, N = 839 babies 
IVH OR 0.87; 95% CI 0.68-1.11; P = 0.26 ~ 




2: No chorioamnionitis and 
no MgSO4, N = 877 babies 
NEC OR 1.15; 95% CI 0.82-1.62; P = 0.42 ~ 
NEC (logistic regression adjusted for sex) aOR 1.17; 95% CI 0.83-1.64 ~ 
BPD OR 1.05; 95% CI 0.81-1.35; P = 0.73 ~ 
BPD (logistic regression adjusted for sex) aOR 1.03; 95% CI 0.79-1.33 ~ 
Elimian 2002; RCS; 
moderate to high 
N = 401 babies; T 1: MgSO4, N = 190 babies 
2: No MgSO4, N = 211 babies 
Apgar score < 7 at 5 minutes P = 0.79 ~ 
RDS P = 0.40 ~ 
Surfactant P = 0.42 ~ 
Antibiotics P = 0.0001  
PDA P = 0.16 ~ 
IVH/PVL P = 0.83 ~ 
NEC P = 0.20 ~ 
Sepsis P = 0.81 ~ 
Neonatal death (1st 28 days) P = 0.27 ~ 
Neonatal death (1st 28 days) (adjustment for 
antenatal confounding variables) 
aOR 0.66; 95% CI 0.28-1.54; P = 0.34 ~ 
1: MgSO4 > 24 hours, N = 79 
babies 
2. MgSO4 ≤ 24 hours, N = 111 
babies 
Apgar score < 7 at 5 minutes P = 0.32 ~ 
RDS P = 0.91 ~ 
Surfactant P = 0.31 ~ 
Antibiotics P = 0.19 ~ 
PDA P = 0.72 ~ 
IVH/PVL P = 0.93 ~ 
NEC P = 0.70 ~ 
Sepsis P = 1.0 ~ 
Neonatal death (1st 28 days) P = 0.81 ~ 
Elliot 2003; RCS; unclear 
Abstract 
N = 9782 babies; T 1: MgSO4, N = 6186 babies 
2: No MgSO4, N = 3596 
babies 
Neonatal death 7.2% vs. 7.3% ~ 
IVH 5.7% vs. 4.4% ~ 
NEC 4.3% vs. 4.8% ~ 
ROP 5.2% vs. 3.2% ~ 
Morbidities (as above) “Multivariate analysis… showed no 
difference” 
~ 
Farkouh 2001; RCS; 
moderate to high 
N = 12876 babies; PE/T 
 
1: MgSO4, N = 4612 babies 
2: No MgSO4, N = 8264 
babies 
Neonatal death (death in NICU < 28 days) OR 1.2; P = 0.06 ~ 
Neonatal death (death in NICU < 28 days) 
(stratified according to GA) 




Neonatal death (death in NICU < 28 days) 
(controlling for GA and MgSO4 indication) 
aOR 0.70; 95% CI 0.56-0.89; P = 0.003 
GA interaction: P = 0.653 
MgSO4 indication interaction: P = 
0.524 
 
Neonatal death (death in NICU < 28 days) (logistic 
regression, controlling for: GA, antenatal steroids, 
terbutaline use, bleeding, caesarean section) 
aOR 0.82; 95% CI 0.65-1.04; P = 0.108 ~ 
FineSmith 1997; CCS; 
moderate to high 
N = 54 babies; PE/T 1: cPVL, N = 18 babies 
2: No cPVL, N = 36 babies 
MgSO4 exposure OR 0.19; 95% CI 0.039-0.988; P > 
0.035 
 
MgSO4 exposure (logistic regression including: GA, 
MgSO4, Apgar scores at 1 and 5 minutes, number 
of days intubation, reason for prematurity, type of 
birth) 
Chi2 = 23.4; df = 12; P = 0.014 
R statistic P < 0.03; df = 1 
 
Gano 2016; PCS with 
CCS(N); moderate 
N = 73 babies; FN/PE/T 
 
1: MgSO4, N = 49 babies 
2: No MgSO4, N = 24 babies 
Cerebellar haemorrhage^ RR 0.45; 95% CI 0.26-0.81; P = 0.008  
Cerebellar haemorrhage, size: < 3 mm vs. > 3 mm^ P = 0.018  
Cerebellar haemorrhage, number of foci: 1-3 vs. > 
3^ 
P = 0.028  
WMI, absent/mild vs. moderate/severe^ P = 0.53 ~ 
IVH, none/grade 1 vs. grade 3/4 P = 0.23 ~ 
1: Cerebellar haemorrhage, N 
= 27 babies 
2: No cerebellar 
haemorrhage, N = 46 babies 
MgSO4 exposure (none, for PE/T, for FN)  P = 0.021  
MgSO4 exposure (univariate logistic regression)  OR 0.26; 95% CI 0.092-0.72; P = 0.010  
MgSO4 exposure (multivariable logistic regression: 
adjusting for postmenstrual age at MRI, VLBW, 
intubation at birth, prolonged MV, hypotensive, 
symptomatic PDA) 
aOR 0.18; 95% CI 0.049-0.65; P = 0.009  
MgSO4 exposure (multivariable logistic regression, 
adjusted as above, and further for prenatal steroid 
exposure) 
aOR 0.11; 95% CI 0.025-0.50; P = 0.004  
 
 
MgSO4 exposure (multivariable logistic regression, 
adjusted as above): MgSO4 for PE/T 
aOR 0.21; 95% CI 0.053-0.83; P = 0.026  
MgSO4 exposure (multivariable logistic regression, 
adjusted as above): MgSO4 for FN 
aOR 0.12; 95% CI, 0.019-0.77; P = 
0.025 
 




Garcia Alonso 2018; PCS; 
moderate to high 
2: No MgSO4, N = 56 babies Resuscitation (multivariate analysis in presence of 
GA and birthweight) 
“no longer statistically significant” ~ 
IMV P = NS ~ 
Surfactant P = 0.03  
Surfactant (multivariate analysis as above) “no longer statistically significant” ~ 
BPD P = 0.02  
BPD (multivariate analysis as above) “no longer statistically significant” ~ 
PDA P = NS ~ 
Neonatal death P = 0.04  
IVH P = NS ~ 
NEC P = NS ~ 
PVL P = NS ~ 
ROP P = 0.03  
ROP (multivariate analysis as above) “no longer statistically significant” ~ 
Gasparyan 2017; PCS; 
unclear 
English abstract 
N = 62 women and 
babies; FN 
1: MgSO4, N = 37 babies 
2: No MgSO4, N = 25 babies 
IVH “the conduction of neuroprotection 
does not significantly reduce IVH 
frequency.” 
~ 
IVH grade 3/4 27.7% vs. 69.2%; “pronounced 
influence” 
 
Ghidini 2001; CCS; 
moderate to high 
N = 69 babies; PE/T 
 
1: NEC, N = 23 babies 
2: No NEC, N = 46 babies 
MgSO4 exposure OR 1.5; 95% CI 0.5-4.9; P = 0.4 ~ 
MgSO4 exposure (logistic regression, controlling 
for diagnosis of preterm labour) 
P = 0.52 ~ 
Gibbins 2013; RCS; high N = 373 women and 
their babies (313 
delivered < 32 weeks in 
analyses for relevant 
outcomes); FN (unclear 
whether also given for 
PE/T) 
 
1: MgSO4, N = 223 babies 
2: No MgSO4, N = 90 babies 
Apgar score < 7 at 1 minute P = 0.26 ~ 
Apgar score < 7 at 5 minutes P = 0.58 ~ 
Resuscitation (none vs. oxygen vs. bag and mask 
vs. intubation vs. chest compressions) 
P = 0.73 ~ 
Discharged alive P = 0.52 ~ 
NICU admission P > 0.99 ~ 
NICU LOS (days) (median range)  P = 0.93 ~ 
Individual morbidities “did not differ significantly.” ~ 
Hypotonia “There were no reports… in neonates 
exposed to magnesium.” 
NA 




Girsen 2015; RCS; 
moderate to high 
N = 2166 women and 
babies; PE 
2: No MgSO4, N = 419 babies NICU admission (multivariable logistic regression 
adjusted for potential confounding variables 
including receipt of public insurance, maternal age, 
race, type of birth, birthweight, GA at birth) 
aOR 1.9; 95% CI 1.3-2.6  
NICU admission within 2 hours of birth P = 0.01  
NICU LOS (days) (median, range) P = 0.50 ~ 
LOS (days) (median, range) P = < 0.001  
Apgar score < 7 at 1 minute P = 0.01  
Apgar score < 7 at 5 minutes P = 0.008  
Apgar score < 7 at 10 minutes^ P = 0.86 ~ 
RDS P = 0.16 ~ 
Ventilation support within 24 hours of birth P = 0.07 ~ 
Prolonged hypotonicity within 72 hours of birth P = 0.08 ~ 
Seizures No events ~ 
Sepsis P = 0.63 ~ 
HIE P = 0.91 ~ 
Neonatal death P = 0.44 ~ 
NICU LOS ≥ 8 days^ OR 0.7; 95% CI 0.4-1.4 ~ 
NICU LOS ≥ 8 days (multivariable logistic regression 
adjusted as above)^ 




N = 851 babies; NR 1: MgSO4, N = 438 babies 
2: No MgSO4, N = 413 babies 
Overall survival “similar” ~ 
Early survival (alive at 7 days) 
Early survival, infants < 700 g 
P < 0.01 
“more apparent”, P < 0.01 
 
Severe RDS “Similar rates” ~ 
IVH “Similar rates” ~ 
PDA 
PDA, infants < 700 g 
OR 1.64; 95% CI 1.21-2.21; P < 0.01 
“more evident”, P < 0.01 
 
Early PDA (< 7 days of life) 50% vs. 45%; “not different” ~ 
Greenberg 2011; RCS 
with CCS(N); moderate 
to high 
N = 242 babies (note: 
discrepancies in text and 
tables); PE 
1: NICU admission, N = 52 
babies 
2: Well baby nursery 
admission, N = 200 babies 
Duration of MgSO4 (hours) (mean ± SD) P < 0.001  
Duration of MgSO4 (hours) (mean ± SD) 
(multivariable regression analysis, controlled for 
GA, Apgar score at 1 minute, birthweight, 
caesarean birth, severe PE)  
OR 1.06; 95% CI 1.02-1.10 
 
 




MgSO4 dose (g) (mean ± SD) (multivariable 
regression analysis controlled as above) 
OR 1.03; 95% CI 1.01-1.05  
> 12 hours MgSO4 exposure (multivariable 
regression analysis controlled as above) 
OR 2.81; 95% CI 1.31-6.03  
> 30 g MgSO4 exposure (multivariable regression 
analysis controlled as above) 
OR 2.59; 95% CI 1.22-5.51  
Above outcomes, limited to neonates at ≥ 37 
weeks GA, and controlling for operative birth for 
non-reassuring fetal status 
“associations… remained… (data not 
shown)” 
 
Greenberg 2013; RCS; 
moderate to high 
N = 264 babies; PE 1: MgSO4, N = 190 babies 
2: No MgSO4, N = 74 babies 
Meconium stained AF P = 0.9 ~ 
NICU admission  P = 0.04  
NICU admission (multivariable regression analysis, 
controlled for GA, public insurance, birthweight, 
caesarean birth, chronic hypertension and severe 
PE) 
aOR 3.69, 95% CI 1.13 to 11.99 
 
 
Initial admission (NICU vs. well baby nursery)^ P = 0.6 ~ 
Primary NICU admission diagnosis (RD, rule out 
sepsis, hypotonia, hypothermia, LBW, 
hyperbilirubinaemia, hypermagnesemia, other)^ 
P = 0.06 ~ 
NICU LOS (days) (median, IQR) P = 0.4 ~ 
Respiratory treatments needed^ P > 0.99 ~ 
Fluids/nutritional support needed P = 0.04  
Antibiotics needed P = 0.6 ~ 
Phototherapy needed P = 0.6 ~ 
1: < 12 hours MgSO4 
exposure (< 30 g), N = 132 
babies 
2: ≥ 12 hours (≥ 30 g), N = 58 
babies 
NICU admission P = 0.004  
NICU admission (multivariable regression analysis, 
assumed to be controlled as above) 
aOR 2.54; 95% CI 1.05 to 6.18  
NICU admission (logistic regression of MgSO4 dose 
(g) and MgSO4 exposure (hours)) 
“an increasing probability of NICU 
admission” [figures provided] 
 
Grether 1998; CCS; 
moderate to high 
N = 168 babies (128 
analysed); T 
1: Neonatal death, N = 53 
babies  
2: Survival to 3 years with no 
disabling CP, N = 75 babies  
MgSO4 exposure OR 0.11; 95% CI 0.03 to 0.40  
MgSO4 exposure for PE 0% vs. 17.3%  




1: Neonatal death no 
maternal PE, N = 21 babies  
2: Survival to 3 years with no 
disabling CP no maternal PE, 
N = 35 babies 
MgSO4 exposure (multiple linear logistic model 
adjusted for birthweight and GA)  
aOR 0.09; 95% CI 0.01 to 0.93; P = 
0.043 
 
Above, adjusted for clinical or histologic diagnosis 
of placental infection 
aOR 0.13; 95% CI 0.01-1.5 ~ 
Above, adjusted for clinical or histologic diagnosis 
of placental infection or suspected chorionitis 
aOR 0.10; 95% CI 0.01-1.1 ~ 
Above adjusted clinical or histologic diagnosis of 
placental infection or maternal infection, including 
urinary tract infection versus no infection. 
aOR 0.10; 95% CI 0.01-1.1 ~ 
Above adjusted for sex aOR 0.09; 95% CI 0.01-0.96  
Above, adjusted for maternal race aOR 0.09; 95% CI 0.01-1.1 ~ 
Above, adjusted for maternal age aOR 0.09; 95% CI 0.01-0.98  
Above, adjusted for level of hospital care aOR 0.09; 95% CI 0.01-0.93  
Above, adjusted for maternal bleeding on 
admission 
aOR 0.05; 95% CI 0.01-0.76  
Above, adjusted for presentation at birth aOR 0.11; 95% CI 0.01-1.2 ~ 
Above, adjusted for surgical birth aOR 0.09; 95% CI 0.01-0.93  
Above, adjusted for in utero exposure to 
corticosteroid 
aOR 0.10; 95% CI 0.01-0.94  
Above, adjusted for abruptio placentae aOR 0.09; 95% CI 0.01-0.97  
Above, adjusted for placenta praevia aOR 0.07; 95% CI 0.01-0.83  
Above, adjusted for hypertension or 
antihypertensive medications given during 
admission for birth 
Not able to calculate due to 0 cells NA 
Grimbly 2015; RCS with 
CCS(N); unclear 
Abstract 
N = 175 babies; NR 1: Hypoglycaemia, N = 69 
babies 
2: No hypoglycaemia, N = 106 
babies 
MgSO4 exposure RR 0.67, P = 0.095 
“antenatal administration of 
magnesium sulphate trended towards 
being protective” 
~ 
Gulcan 2006; PCS; high N = 200 babies; T 1: MgSO4, N = 35 babies 
2: No MgSO4, N = 165 babies 
RDS 0% vs. 27.9%  NR 
Gursoy 2015; PCS; high N = 50 babies; PE/T 1: MgSO4, N = 25 babies 
2: No MgSO4, N = 25 babies 
Hypotension No events ~ 
Hypertension No events ~ 
NEC  No events ~ 




PDA P = 0.83 ~ 
ICH stage I-2 P = 0.12 ~ 
Feeding intolerance  P = 0.3 ~ 
Havranek 2011; RCS; 
high 
N = 56 babies; PE/T 1: MgSO4 in 24 hours prior to 
birth, N = 27 babies 
2: No MgSO4, N = 29 babies 
Caffeine treatment P = 0.11 ~ 
Ventilator support P = 0.14 ~ 
Phototherapy P = 0.54 ~ 
Umbilical artery catheter^ P = 0.57 ~ 
Enteral feedings day 1^ P = 0.60 ~ 
Neonatal death (assumed) during hospitalisation 3.7% vs. 6.9% NR 
NEC 0% vs. 3.4% NR 
Hechtman 2002; RCS 
with CCS(N); unclear 
Abstract 
N = 85 babies; T 1: Neonatal deaths, N = 19 
babies 
2: Survivors, N = 66 babies 
MgSO4 exposure P = 0.2 ~ 
MgSO4 dose (g) (median, range) P = 0.2 ~ 
MgSO4 dose > 48 g  P = 0.4 ~ 
As above “After controlling for GA, 
betamethasone therapy, clinical 
chorioamnionitis, and delivery mode, 
neither MgSO4 exposure nor total 
dose of antenatal MgSO4 had an 
impact on neonatal survival.” 
~ 
Holcomb 1991; NCCS; 
unclear 
N = 23 women, 33 
babies; T 
1: MgSO4 > 7 days, N = 11 
babies 
2: No MgSO4 or < 3 days, N = 
22 babies 
Definitely abnormal chest radiograph (bones) 
(proximal humeri, radiographic abnormalities: 
transverse radiolucent and/or sclerotic bands) 
P < 0.001  
Hom 2018; RCS; unclear 
Abstract 
N = 52 women and 
babies; FN 
1: MgSO4, N = 26 babies 
2: No MgSO4, N = 26 babies 
IVH P = 0.35 ~ 
Hong 2019; RCS; unclear 
Abstract 
N = 598 babies; NR 
(includes FN) 
1: MgSO4 for FN not adopted 
(16.2% exposure), N = 270 
babies 
2: MgSO4 for FN routine 
(60.6% exposure), N = 264 
babies 
3: MgSO4 abandoned (14.0% 
exposure), N = 64 babies 
Neonatal death “not significantly different among the 
three periods” 
~ 
Neonatal death due to NEC P = 0.347 ~ 
NEC P = 0.346 ~ 
NEC (grade ≥ 2) “not significantly different among the 
three periods” 
~ 
Other neonatal outcomes^ “not significantly different among the 
three periods” 
~ 




2: No MgSO4, N = 385 babies Neonatal death due to NEC P = 0.885 ~ 
NEC P = 0.171 ~ 
NEC (grade ≥ 2) “two groups were similar” ~ 
Other neonatal outcomes^ “two groups were similar” ~ 
Imamoglu 2014; PCS; 
high 
N = 53 babies; PE/T 1: MgSO4, N = 20 babies 
2: No MgSO4, N = 33 babies 
RDS P = 0.8 ~ 
PDA P = 0.7 ~ 
IVH P = 0.52 ~ 
Caffeine treatment P = 0.8 ~ 
Ibuprofen^ P = 0.54 ~ 
Inotrope use P = 0.87 ~ 
Phototherapy P = 0.9 ~ 
Igarashi 1995; RCS; 
unclear 
English abstract 
N = 42 babies; T 1: Hypermagnesemic infants 
exposed to MgSO4, N = 27 
babies (with (N = 15) and 
without (N = 12) 
complications) 
2: Infants born to “normal 
mothers”, N = 15 babies 
See right “In both control group and non-
complication group, respiratory and 
cardiovascular symptoms were less 
found than in complication group. But 
the infants in complication group only 
had more symptoms such as 
respiratory depression, hypotonia, 
and hypotension than those in other 
groups. They required prolonged 
dopamine and calcium gluconate 
infusion. We speculated that 
complications could be attributed to 
disorders rather than 
hypermagnesemia." 
NR 
James 2015; PCS; high N = 38 babies; FN 1: MgSO4 within 4 hours of 
birth, N = 19 babies 
2: No MgSO4, N = 19 babies 
IVH grade 3/4 P = 0.2 ~ 
Inotropes (1st week) P = 1.0 ~ 
Pulmonary haemorrhage P = 0.1 ~ 
NEC P = 0.3 ~ 
CLD P = 0.04  
CLD (logistic regression, controlling for antenatal 
steroids) 
P = 0.06 ~ 
Neonatal death (assumed) before discharge P = 0.2 ~ 




Invasive ventilation, day 1 P = 1.0 ~ 
Invasive ventilation, day 2 P = 1.0 ~ 
PDA, day 1 “all infants” ~ 
PDA, day 2 89.5% vs. 89.5% ~ 
Jazayeri 2003; RCS; high N = 72 women and 
babies; T 
1: MgSO4, N = 36 babies 
2: No MgSO4, N = 36 babies 
NICU LOS (days) (mean ± SE) P > 0.05 ~ 
Meconium P = NS ~ 
RDS P = NS ~ 
IVH P = NS ~ 
NEC P = NS ~ 
Sepsis P = NS ~ 
Neonatal death P = NS ~ 
Jeanneteau 2014; RCS; 
unclear 
Abstract 
N = 119 women and 
their babies; FN 
1: MgSO4, N = 81 women 
2: No MgSO4, N = 38 women 
Apgar score < 7 at 5 minutes P = 0.03  
Closed cardiac massage^ P = 0.003  
Adrenaline P = 0.01  
“neonatal morbi-mortality”^ “no difference” ~ 
Jones 2018; RCS; unclear 
Abstract 
N = 120 babies; PE/T 1: MgSO4, N = NR 
2: No MgSO4, N = NR 
Adverse bowel events^ No events ~ 
Jung 2018; RCS; high N = 184 women and 
their babies; T 
1: MgSO4, N = 143 women 
and babies 
2: No MgSO4, N = 41 women 
and babies 
Stillbirth, all infants, PPROM 23-27+6 weeks GA, 
28-31+6 weeks GA 
P = 0.0012; P = 0.0070; P = 0.4873 , , ~ 
Neonatal death, all infants, PPROM 23-27+6 weeks 
GA, 28-31+6 weeks GA 
P = 0.6902; P = 0.8696; P = 0.4695 ~, ~, ~ 
Early neonatal death P = 0.9169 ~ 
Perinatal death, all infants, PPROM 23-27+6 weeks 
GA, 28-31+6 weeks GA 
P = 0.0375; P = 0.0651; P = 0.9051 , ~, ~ 
Apgar score < 7 at 5 minutes P = 0.7066 ~ 
Pulmonary hypoplasia^ P = 0.8039 ~ 
RDS P = 0.7255 ~ 
BPD P = 0.5091 ~ 
NEC P = 0.7437 ~ 
Early onset sepsis P = 0.2239 ~ 
ROP P = 0.7134 ~ 
ROP grade 2/3 P = 0.7759 ~ 
Hearing impairment P = 0.9028 ~ 




IVH, all infants, PPROM 23-27+6 weeks GA, 28-
31+6 weeks GA 
RR 0.40; 95% CI 0.25-0.88 
RR 0.35; 95% CI 0.17-0.71 
RR 0.66; 95% CI 0.23-1.91 
, , ~ 
IVH grade 3/4 RR 0.37; 95% CI 0.06-2.14 ~ 
PVL, all infants, PPROM 23-27+6 weeks GA, 28-
31+6 weeks GA 
RR 0.60; 95% CI 0.39-0.94 
RR 0.48; 95% CI 0.25-0.91 
RR 0.71; 95% CI 0.39-1.29 
, , ~ 
Bone abnormalities 1: 4 cases (exposed for 4, 5, 20, 45 
days respectively) 
NA 
Kamilya 2005; NCCS; 
high 
N = 1205 babies; E 1: 2002-2004 (MgSO4 use), N 
= 481 babies 
2: 1995-1997 (no MgSO4 
use), N = 724 babies 
Perinatal death 24.3% vs. 54.8%; “Recent changes in 
eclampsia management protocol by 
MgSO4 therapy and early CS have 
been instrumental in bringing down 
MMR and PNM in eclampsia cases.” 
 
Kamyar 2015a; RCS; 
unclear 
Abstract 
N = 271 babies; FN/PE/T 1: MgSO4, N = 133 babies 
2: No MgSO4, N = 138 babies 
Composite morbidity (IVH, PVL, BPD, NEC, RDS, 
ROP and/or neonatal death) (multivariable model) 
OR 1.19; CI 0.51-2.78; P = 0.69 ~ 
Neonatal death (multivariable model) OR 0.79; CI 0.31-2.02; P = 0.74 ~ 
Individual morbidities (multivariable model) “were also not increased.” ~ 
Kamyar 2015b; RCS; 
unclear 
Abstract 
N = 1246 babies; 
FN/PE/T 
1: MgSO4, N = 457 babies 
2: No MgSO4, N = 789 babies 
Composite morbidity (IVH, BPD, NEC, and/or 
neonatal death prior to hospital discharge) 
(multivariable model) 
OR 1.20; CI 0.91, 1.57; P = 0.20 ~ 
Neonatal death (multivariable model) OR 0.41; CI 0.16, 1.06; P = 0.07 ~ 
Kamyar 2015c; RCS; 
unclear 
Abstract 
N = 2431 babies; FN Males, N = 1147 babies 
1: MgSO4, N = 643 babies 
2: No MgSO4, N = 504 babies 
Composite severe morbidity (IVH grade 3/4, PVL, 
BPD, NEC, and/or neonatal death) 
Males (multivariable model including GA as 
covariate) 
OR 1.27; 0.94-1.72; P = 0.12 ~ 
Females, N = 1284 babies 
1: MgSO4, N = 536 babies 
2: No MgSO4, N = 748 babies 
Composite severe morbidity (IVH grade 3/4, PVL, 
BPD, NEC, and/or neonatal death) 
Females (multivariable model including GA as 
covariate) 
OR 1.06; 0.74-1.49; P = 0.72 ~ 
Males vs. females Interaction term for gender as above P = 0.44 ~ 
Kamyar 2016a; RCS; 
moderate to high 
N = 396 babies; FN 1: MgSO4, N = 192 babies 
2: Placebo, N = 204 babies 
Stillbirth or death by age 1: all babies, and ≤ 28 
weeks GA (adjusted multivariable log-binomial 
model, using backwards elimination (P < 0.20) for 
RR 1.68; 95% CI 0.85-3.32 





covariates: GA at birth, maternal years of 
education, maternal race/ethnicity, IUGR, illicit 
drug use, smoking status, and sex) 
Severe composite morbidity (1 or more of: sepsis, 
severe IVH, PVL, NEC stage 2/3, BPD): all babies, 
and ≤ 28 weeks GA (adjusted as above) 
RR 1.10; 95% CI 0.88-1.38 
RR 1.07; 95% CI 0.86-1.34 
 
~, ~ 
Sepsis: all babies, and ≤ 28 weeks GA (adjusted as 
above) 
RR 1.03; 95% CI 0.71-1.50 
RR 1.01; 95% CI 0.67-1.51 
~, ~ 
Severe IVH: all babies, and ≤ 28 weeks GA 
(adjusted as above) 
RR 0.36; 95% CI 0.10-1.27 
RR 0.41; 95% CI 0.12-1.49 
~, ~ 
PVL: all babies, and ≤ 28 weeks GA (adjusted as 
above) 
RR 0.37; 95% CI 0.08-1.78 
RR 0.64; 95% CI 0.12-3.38 
~, ~ 
NEC stage 2/3: all babies, and ≤ 28 weeks GA 
(adjusted as above) 
RR 1.36; 95% CI 0.58-3.20 
RR 1.36; 95% CI 0.47-3.91 
~, ~ 
BPD: all babies, and ≤ 28 weeks GA (adjusted as 
above) 
RR 1.29; 95% CI 0.91-1.82 
RR 1.13; 95% CI 0.80-1.58 
~, ~ 
Neonatal death before hospital discharge: all 
babies, and ≤ 28 weeks GA (adjusted as above) 
RR 1.46; 95% CI 0.64-3.33 
RR 1.45; 95% CI 0.47-2.89 
~, ~ 
Kamyar 2016b; RCS with 
CCS(N); moderate to high 
N = 697 babies; FN 1: MgSO4, N = 332 babies 
2: No MgSO4, N = 365 babies  
Neonatal death before NICU discharge and/or NEC 
stage 2/3 (multivariable regression, adjusted for 
confounders: birth GA, treatment group, fetal sex, 
SGA, chorioamnionitis, caesarean section, 
hypotension during initial resuscitation, postnatal 
exposure to indomethacin, sepsis, IVH) 
OR 1.01; 95% CI 0.69-1.47; P = 0.965 ~ 
Neonatal death before NICU discharge 
(multivariable regression, adjusted as above) 
“MgSO4 was also not associated with 
elevated odds of the individual 
outcomes… in multivariable models 
(data not shown).” 
~ 
NEC stage 2/3 (multivariable regression, adjusted 
as above) 
As above ~ 
1: MgSO4, N = 148 babies 
delivered < 26 weeks GA 
Neonatal death before NICU discharge and/or NEC 
stage 2/3 (unadjusted) 




2: No MgSO4, N = 145 babies 
delivered < 26 weeks GA 
Neonatal death before NICU discharge and/or NEC 
stage 2/3 (multivariable regression, controlled for 
confounders including birth GA and SGA) 
aOR 1.90; 95% CI 1.12-3.22; P = 0.017   
Neonatal death before NICU discharge 
(multivariable regression, adjusted as above) 
aOR of 1.83; 95% CI 1.03-3.27; P = 
0.040 
 
NEC stage 2/3 (multivariable regression, adjusted 
as above) 
aOR 1.38, 95% CI 0.64-3.00; P = 0.414 ~ 
MgSO4 exposed babies 
1: Neonatal death before 
NICU discharge and/or NEC 
stage 2/3, N = 73 babies 
2: Survival without NEC stage 
2/3, N = 259 babies 
MgSO4 infusing at birth P = 0.700 ~ 
Total amount of MgSO4 received (g) (mean ± SD) P = 0.595 ~ 
Katayama 2011; RCS; 
moderate to high 
N = 160 babies; T 1: MgSO4, N = 41 babies 
2: No MgSO4, N = 119 babies 
Early closure of the DA^ P = 0.002  
Symptomatic PDA P = 0.006  
Successful response to indomethacin of PDA^ P = 0.210 ~ 
PDA treated with surgery P = 0.210 ~ 
Failure of early closure of DA after indomethacin 
(univariate analysis)^ 
OR 3.73; 95% CI 1.69-8.23  
Failure of early closure of DA after indomethacin 
(multivariate logistic regression analysis, adjusted 
for confounders including antenatal steroids, 
ritodrine tocolysis, PROM)^ 
aOR 4.03; 95% CI 1.65-9.80; P = 0.002  
Symptomatic PDA (univariate analysis) OR 2.81; 95% CI 1.33-5.92  
Symptomatic PDA (multivariate logistic regression 
analysis, adjusted for confounders, assumed to be 
as above) 
aOR 2.26; 95% CI 1.01-5.04; P = 0.047  
MgSO4 
1: Low dose (< 50 g), N = 19 
babies 
2: High dose (≥ 50 g), N = 22 
babies 
Early closure of the DA^ 59% vs. 58%;“No significant 
differences” 
~ 
Symptomatic PDA 50% vs. 42%; “No significant 
differences” 
~ 






PDA treated with surgery 27% vs. 37%; “No significant 
differences” 
~ 
Kelly 1992; PCS; unclear 
Abstract 
N = 10 women and 
babies; T 
1: MgSO4, N = 5 babies 
2: No MgSO4, N = 5 babies 
See right^ “Infants… did not sustain any increase 
in morbidity as a result of their in 
utero MgSO4 exposure.” 
~ 
Khodapanahandeh 2008; 
CCS; moderate to high 
N = 121 babies; T 
 
1: IVH grade 3/4, N = 39 
babies 
2: No IVH grade 3/4, N = 82 
babies 
MgSO4 exposure P = 0.021  
MgSO4 exposure (multivariate logistic regression 
analysis, including factors significant in univariate 
analyses: GA, birthweight, Apgar score at 5 
minutes, resuscitation, tocolytic therapy, apnoea, 
MV, HMD, haematocrit, PaCO2 maximum in 1st 3 
days, symptomatic hypotension 1st 3 days) 
OR 4.4; 95% CI 1.10-24.5  
Kimberlin 1998; RCS; 
moderate to high 
N = 308 babies (363 in 
death analyses); T 
1: MgSO4, N = 124 babies 
(138 for death analyses) 
2: No MgSO4, N = 184 babies 
(225 for death analyses) 
Neonatal death ≤ 2 days^ 10.1% vs. 18.2%; “lower”  
Neonatal death between 3-120 days P = 0.10 ~ 
Intact survival (survival to hospital discharge or 120 
days without any serious morbidities)^ 
P = 0.54 ~ 
Intact survival (multiple logistic regression, 
controlling for birthweight, GA, race, gender, mode 
of birth, chorioamnionitis, surfactant treatment, 
antepartum steroid treatment)^ 
OR 1.07; 95% CI 0.60-1.92 ~ 
Neonatal death at ≥ 2 days and < 120 days P = 0.67 ~ 
IVH grade 3/4 P = 0.34 ~ 
IVH grade 3/4 (multiple logistic regression as 
above) 
OR 0.71; 95% CI 0.36-1.42 ~ 
ROP grade 3/4 P = 0.59 ~ 
ROP grade 3/4 (multiple logistic regression as 
above) 
OR 1.38; 95% CI 0.66-2.87 ~ 
Abnormal neurological evaluation^ P = 0.91 ~ 
Abnormal neurological evaluation (multiple logistic 
regression as above)^ 
OR 1.44; 95% CI 0.66-3.16 ~ 
Seizure activity P = 0.35 ~ 
Seizure activity (multiple logistic regression as 
above) 
OR 0.76; 95% CI 0.29-1.95 ~ 




NEC requiring surgery (multiple logistic regression 
as above) 
OR 0.39; 95% CI 0.12-1.25 ~ 
Oxygen dependence at discharge P = 0.97 ~ 
Oxygen dependence at discharge (multiple logistic 
regression as above) 
OR 1.37; 95% CI 0.71-2.66 ~ 
Duration of ventilation (days) (median, measure of 
variance NR) 
P = 0.08 ~ 
NICU LOS (days) (mean ± SD) P = 0.07 ~ 
Koksal 2002; PCS with 
CCS(N); high 
N = 120 babies; T 
 
1: GMH-IVH grade 3/4 or 
PVL, N = 18 babies 
2: GMH-IVH grade 1/2 or no 
abnormalities, N = 102 babies 
MgSO4 exposure P < 0.05  
Kuban 1992; PCS; 
moderate to high 
N = 449 babies; PE/T 1: MgSO4, N = 90 babies 
2: No MgSO4, N = 359 babies 
GMH-IVH 4.4% vs. 18.9% NR 
GMH-IVH (risk among babies born to women with 
hypertension and proteinuria vs. neither 
condition): with MgSO4 vs. with no MgSO4  
OR 0.4; 95% CI 0.1-3.1 vs. OR 0.4; 9% 
CI 0.1-1.4 
~; ~ 
GMH-IVH (risk among babies born to women with 
PE): with MgSO4; with no MgSO4  
OR 0.7; 9% CI 0.1-7.3; NC due to value 
of 0 in 1 cell 
~; NA 
GMH-IVH (risk among babies born to women who 
received MgSO4 vs. did not receive MgSO4): 
vaginal birth vs. abdominal birth 
OR 0.2; 95% 0-1.2 vs. OR 0.3; 95% 0.1-
1.2 
~; ~ 
GMH-IVH (risk among babies born to women who 
received MgSO4 vs. did not receive MgSO4): any 
labour vs. no labour 
OR 0.3; 95% CI 0.1-0.99 vs. NC ~; NA 
GMH-IVH (risk among babies born to women who 
received MgSO4 vs. did not receive MgSO4): 
birthweight < 1000 g vs. birthweight ≥ 1000 g 
OR 0.1; 95% 0-0.7 vs. OR 0.3; 95% CI 
0.1-1.5 
; ~ 
GMH-IVH (risk among babies born to women who 
received MgSO4 vs. did not receive MgSO4): GA ≤ 
30 weeks; GA > 30 weeks 
OR 0.1; 95% CI 0-0.6 vs. OR 0.7; 95% CI 
0.2-3.6 
; ~ 
GMH-IVH (risk among babies born to women who 
received MgSO4 vs. did not receive MgSO4): 
intubation vs. no intubation 






GMH-IVH (risk among babies born to women who 
received MgSO4 vs. did not receive MgSO4): 
lowest pH < 7.2 vs. lowest pH ≥ 7.2 
NC; OR 0.3; 95% CI 0.1-0.8 NA;   
GMH-IVH (risk among babies born to women who 
received MgSO4 vs. did not receive MgSO4): 
antenatal steroids vs. no antenatal steroids 
OR 0.1; 95% CI 0-0.98 vs. OR 0.3; 95% 
CI 0.1-1.3 
; ~ 
GMH-IVH (risk among babies born to women who 
received MgSO4 vs. did not receive MgSO4): 
mother’s weight/height > 75th percentile vs. 
mother’s weight/height ≤ 75th percentile 
OR 0.2; 95% CI 0-1.7 vs. OR 0.2; 95% CI 
0.1-1.0 
~; ~ 
See right “In an attempt to identify which of the 
preeclampsia variables contributed 
unique and significant information 
about GMH risk and to control for 
possible confounding, we carried out a 
stepwise logistic regression analysis. 
An initial model included as potential 
predictors of GMH-IVH all of the 
preeclampsia-related variables 
described above. Only two variables, 
however, remained in the model 
when a .05 significance level was 
needed for entry. Diagnosis of 
preeclampsia conveyed the most 
information about reduced risk of 
GMH-IVH, followed closely by receipt 
of magnesium sulfate. The other 
preeclampsia variables (eg, 
pregnancyinduced hypertension, 
hypertension not identified as 
pregnancy induced, and proteinuria) 
did not provide additional unique 
information. Very similar results were 
obtained when covariates (eg, 





intubation, ratio of prepregnancy 
maternal weight to height, etc) were 
allowed to compete.” 
Lai 2017; RCS; unclear 
Abstract 
N = NR; PE 1: MgSO4, N = NR 
2: No MgSO4, N = NR 
Muscle tone scores (units NR)^ “lower in the MgSO4-exposed 
neonates… the difference did not 
reach statistical significance.” 
~ 
SCBU admission (multinomial logistic regression)^ OR 5.02; 95% CI 1.98-12.70  
NICU admission (multinomial logistic regression) OR 3.90; 95% CI 0.49-30.99 ~ 
Delayed adaptation “the rate… was higher in the MgSO4-
exposed neonates, but again the 
difference was not statistically 
significant.” 
~ 
Lee 2013; RCS; unclear 
English abstract 
N = 81 babies; PE 1: MgSO4, N = 20 
2: No MgSO4, N = 61 
RDS (adjusted for GA) P = 0.076  
aOR 1.34; 95% CI 0.32-5.53; P = 0.69 
~ 
Ventilation (adjusted for GA) P = 0.277 
aOR 0.99; 95% CI 0.26-3.88; P = 0.99 
~ 
sPDA (adjusted for GA) P = 0.002 
aOR 4.13; 95% CI 1.25-13.62; P = 0.02 
 
PDA treated with operation (adjusted for GA) P = 1.0 
aOR 1.02; 95% CI 0.07-15.75; P = 0.99 
~ 
ROP (adjusted for GA) P = 0.149 
aOR = 1.97; 95% CI 0.11-36.53; P = 
0.65 
~ 
NEC (adjusted for GA) P = 0.440 
aOR = 0.35; 95% CI 0.41-2.98; P = 
0.335 
~ 
IVH grade ≥ I (adjusted for GA) P = 0.364 
aOR 0.39; 95% CI 0.17-1.31; P = 0.13 
~ 
PVL (adjusted for GA) P = 0.216 
aOR 0.24; 95% CI 0.43-1.30; P = 0.10 
~ 
Neonatal death (adjusted for GA) P = 1.0 
aOR 1.12; 95% CI 0.25-4.96; P = 0.88 
~ 
1: MgSO4 and sPDA, N = 15 
babies 




2: MgSO4 and no sPDA, N = 5 
babies 
Lee 2015; RCS; unclear 
Abstract 
N = 570 women and 
babies; T 
1: MgSO4, N = 101 babies 
2: No MgSO4, N = 469 babies 
Hypocalcaemia “incidence… was not different 
between two groups” 
~ 
Leung 2016; PCS with 
CCS(N); moderate 
N = 289 babies; PE/E/T 1: Passed hearing screen, N = 
244 babies 
2: Failed hearing screen, N = 
45 babies 
 
MgSO4 exposure OR 0.38; 95% CI 0.2-0.74; P = 0.004  
MgSO4 and betamethasone exposure OR 0.31; 95% CI 0.16-0.60; P < 0.001  
MgSO4 and betamethasone exposure (logistic 
regression model A: survivors failing hearing 
screen; factors entered into stepwise regression: 
GA, birthweight, Apgar score at 1 and 5 minutes, 
antenatal exposure to betamethasone, MgSO4 and 
an interaction term of betamethasone plus 
MgSO4, maternal antibiotics exposure, surfactant 
treatment, CUS abnormalities, duration of 
ventilation, CLD, duration on furosemide, 
gentamicin and amphotericin, FIRS, PDA treated 
with indomethacin) 
OR: 0.37 (95% CI 0.11-0.81); P = 0.013  
MgSO4 and betamethasone exposure (logistic 
regression model B: event-free survival, death 
(before discharge) or failure of hearing screen; 
factors entered into stepwise regression as above)  
OR 0.33; 95% CI 0.17-0.66; P = 0.002  
Leviton 1997; PCS; 
moderate to high 
N = 1331 women and 
1518 babies; unclear 
PE/PIH/T 
1: MgSO4, N = 678 babies 
2: No MgSO4, N = 840 babies 
IVH (logistic regression adjusted for GA, 
birthweight z score, antenatal corticosteroids, PE, 
PIH, route of birth and labour) 
RR 1.0; 95% CI 0.7-1.3; P = 0.94 ~ 
PEA: early (logistic regression adjusted as above)^ RR 1.3; 95% CI 0.8-2.2; P = 0.29 ~ 
PEA: late (logistic regression adjusted as above)^ RR 0.8; 95% CI 0.5-1.5; P = 0.57 ~ 
PEA: any (logistic regression adjusted as above)^ RR 1.0; 95% CI 0.7-1.5; P = 0.86 ~ 
PEA: hypoechoic image (logistic regression 
adjusted as above)^ 
RR 1.2; 95% CI 0.7-2.0; P = 0.50 ~ 
PEA: late hypoechoic image (logistic regression 
adjusted as above)^ 
RR 1.2; 95% CI 0.7-2.2; P = 0.51 ~ 
Ventriculomegaly^ RR 1.1; 95% CI 0.7-1.7; P = 0.62 ~ 
Lipsitz 1971; PCS (or 
NRT); high 
N = 37 babies; PE/E 1: MgSO4 IV LD and MD, N = 
29 babies 
Apgar score < 7 at 1 minute 75.9% vs. 37.5%  




2: MgSO4 IV LD, IM MD, N = 
8 babies 
Clinical score of 3^ 44.8% vs. 37.5%  
Clinical score > 0 (the higher the score, with a 
maximum of 3, the greater the apparent toxicity of 
excess Mg: 1 point for flaccidity and hyporeflexia, 1 
for resuscitation or assisted ventilation, 1 for week 
or absent cry unrelated to tracheal intubation)^ 
82.8% vs. 62.5%  
Neonatal death 17.2% vs. 0%  
Resuscitation 48.3% vs. 37.5%  
Assisted ventilation 24.1% vs. 12.5%  
Summary see right “When magnesium sulfate is given 
intramuscularly to the mother, the 
newborn is usually not compromised 
by excess magnesium but may be 
affected. If continuous intravenous 
infusion of magnesium sulfate is used 
and especially if given for more than 
24 hours, one can anticipate a 






N = 107 babies; FN 1: MgSO4, N = 56 babies 
2: No MgSO4, N = 51 babies 
Resuscitation overall, < 30 weeks GA, ≥ 30 weeks 
GA 
P = NS, P = NS, P = NS ~, ~, ~ 
Apgar score ≤ 5 at 1 minute overall, < 30 weeks 
GA, ≥ 30 weeks GA 
P = NS, P = NS, P = NS ~, ~, ~ 
Apgar score ≤ 5 at 5 minutes P = NS ~ 
CPAP/nasal IMV overall, < 30 weeks GA, ≥ 30 
weeks GA 
P = 0.03, P = NS, P = NS , ~, ~ 
CMV overall, < 30 weeks GA, ≥ 30 weeks GA P = NS, P = 0.016, P = NS ~, , ~ 
HFOV P = NS ~ 
Surfactant treatment overall, < 30 weeks GA, ≥ 30 
weeks GA 
P = NS, P = 0.074, P = NS ~, ~, ~ 
PDA treated overall, < 30 weeks GA, ≥ 30 weeks GA P = NS, P = NS, P = NS ~, ~, ~ 
Vasoactive drugs overall, < 30 weeks GA, ≥ 30 
weeks GA^ 




Blood products overall, < 30 weeks GA, ≥ 30 weeks 
GA^ 
P = NS, P = NS, P = 0.043 ~, ~,  
Sepsis confirmed overall, < 30 weeks GA, ≥ 30 
weeks GA 
P = NS, P = NS, P = NS ~, ~, ~ 
Pathological brain ultrasound overall, < 30 weeks 
GA, ≥ 30 weeks GA^ 
P = NS, P = NS, P = NS ~, ~, ~ 
No stools at 48 hours overall, < 30 weeks GA, ≥ 30 
weeks GA 
P = NS, P = 0.019, P = NS ~, , ~ 
No bowel movements at 72 hours^ P = NS ~ 
NEC overall, < 30 weeks GA, ≥ 30 weeks GA P = NS, P = NS, P = NS ~, ~, ~ 
Neonatal death overall, < 30 weeks GA, ≥ 30 weeks 
GA 
P = NS, P = NS, P = NS ~, ~, ~ 
CRIB (median, range)^ P = NS ~ 
Meconium evacuation delay P = NS ~ 
Parenteral nutrition^ P = NS ~ 
Martin 1998; RCS; high N = 193 women and 
babies; PE/T 
1: MgSO4, N = 118 babies 
2: No MgSO4, N = 75 babies 
IVH P = 0.09 ~ 
Matsuda 1997; RCS with 
CCS(N); high 
N= 139 babies born to 
114 women; and a 
further 51 control 
babies; PE/T 
1: MgSO4, N = 114 women 
and 139 babies 




P = 0.0101  
1: MgSO4 and bone 
abnormalities, N = 13 women 
2: MgSO4 and no bone 
abnormalities, N = 101 
women 
GA at start of MgSO4 (weeks) (mean ± SD) P < 0.05  
Duration of MgSO4 (days) (mean ± SD) P < 0.05  
MgSO4 dose (g) (mean ± SD) P < 0.05  
McGuiness 1980; NRT; 
high 
N = 37 women and their 
babies; PE 
1: MgSO4, N = 23 women 
and their babies 
2: Dextrose-water or 
dextrose-saline, N = 14 
women and their babies 
Significant birth asphyxia No events ~ 
Hypocalcaemia “Although magnesium sulfate infusion 
cause a significant decline in maternal 
total calcium and ionized calcium 
levels, it was not associated with 
neonatal hypocalcemia.” 
~ 
McPherson 2014; RCS; 
high 
N = 933 women and 
their babies; FN 
1: MgSO4 < 12 hours, N = 356 
women and babies 
Apgar score < 7 at 5 minutes 2 vs. 1: OR 0.95; 95% CI 0.64-1.41 
3 vs. 1: OR 0.73; 95% CI 0.46-1.16 
P = 0.37 




2: MgSO4 12-18 hours, N = 
341 women and babies 
3: MgSO4 > 18 hours, N = 236 
women and babies 
Resuscitation in delivery room (oxygen blow-by, 
oxygen bag, mask or both, intubation, chest 
compressions) 
P = 0.07 ~ 
NEC 2 vs. 1: OR 0.97; 95% CI 0.58-1.63 
3 vs. 1: OR 1.11; 95% CI 0.61-1.86 
P = 0.96 
~, ~, ~ 
ROP 2 vs. 1: OR 1.16; 95% CI 0.81-1.64 
3 vs. 1: OR 1.73; 95% CI 0.48-1.12 
P = 0.09 
~, ~, ~ 
RDS 2 vs. 1: OR 0.98; 95% CI 0.73-1.32 
3 vs. 1: OR 0.92; 95% CI 0.66-1.28 
P = 0.87 
~, ~, ~ 
MV 2 vs. 1: OR 0.93; 95% CI 0.69-1.25 
3 vs. 1: OR 0.86; 95% CI 0.62-1.20 
P = 0.68 
~, ~, ~ 
BPD 2 vs. 1: OR 0.96; 95% CI 0.66-1.41 
3 vs. 1: OR 0.87; 95% CI 0.56-1.36 
P = 0.84 
~, ~, ~ 
Seizures 2 vs. 1: OR 1.25; 95% CI 0.38-3.39 
3 vs. 1: OR 0.91; 95% CI 0.21-3.83 
P = 0.88 
~, ~, ~ 
Any IVH 2 vs. 1: OR 0.86; 95% CI 0.58-1.27 
3 vs. 1: OR 0.92; 95% CI 0.60-1.41 
P = 0.76 
~, ~, ~ 
IVH grade 3/4 2 vs. 1: OR 1.28; 95% CI 0.34-4.83 
3 vs. 1: OR 0.36; 95% CI 0.04-2.25 
P = 0.42 
~, ~, ~ 
NICU admission “not different among groups after 
adjusting for gestational age at 
delivery (data not shown).” 
~ 
Mikhael 2019; RCS; 
moderate to high 
N = 302 babies; NR 
(includes FN) 
1: MgSO4 ≤ 7 days prior to 
birth, N = 210 babies 
2: No MgSO4 ≤ 3 days prior 
to birth, N =192 babies 
Death; all babies, and < 26 weeks GA P = 0.69; P = 0.76 ~ 
Early death; all babies, and < 26 weeks GA P = 0.28; P = 0.31 ~ 
Postnatal steroids P = 0.67 ~ 




Early NEC; all babies, and < 26 weeks GA P = 0.61; P = 0.52 ~ 
SIP; all babies, and < 26 weeks GA P = 0.82; P = 0.73 ~ 
Early SIP; all babies, and < 26 weeks GA P = 0.68; P = 0.79 ~ 
SIP or NEC or death: all babies, and < 26 weeks GA 
(unadjusted P); for all babies: aOR and P – adjusted 
for maternal hypertension, antenatal steroids, and 
antenatal indomethacin)  
P = 0.81; P = 0.46 
aOR 0.69; 95% CI 0.35-1.38; P = 0.29 
~ 
Early SIP or NEC or death: all babies, and < 26 
weeks GA (unadjusted P); for all babies: aOR and P 
– adjusted for maternal hypertension, antenatal 
steroids, and antenatal indomethacin) 
P = 0.79; P = 1.0 
aOR 1.7; 95% CI 0.73-3.75; P = 0.22 
~ 
Late onset-sepsis P = 0.075 ~ 
Postnatal NSAIDs for PDA P = 0.15 ~ 
IVH ≥ grade 3 P = 0.4 ~ 
1: MgSO4 ≤ 3 days prior to 
birth, N = 179 babies 
2: No MgSO4 ≤ 3 or 7 days 
prior to birth, N = 123 babies 
Death; all babies, and < 26 weeks GA P = 0.23; P = 0.27 ~ 
Early death; all babies, and < 26 weeks GA P = 0.44; P = 0.43 ~ 
NEC; all babies, and < 26 weeks GA P = 0.98; P = 0.31 ~ 
Early NEC; all babies, and < 26 weeks GA P = 0.97; P = 0.84 ~ 
SIP; all babies, and < 26 weeks GA P = 0.57; P = 0.36 ~ 
Early SIP; all babies, and < 26 weeks GA P = 0.54; P = 0.44 ~ 
SIP or NEC or death; all babies, and < 26 weeks GA P = 0.58; P = 0.29 ~ 
Early SIP or NEC or death; all babies, and < 26 
weeks GA 
P = 0.8412; P = 0.9 ~ 
1: MgSO4 ≤ 3 days prior to 
birth, N = 179 babies  
2: No MgSO4 ≤ 3 days prior 
to birth, N = 31 babies 
Death; all babies, and < 26 weeks GA P = 0.13; P = 0.16 ~ 
Early death; all babies, and < 26 weeks GA P = 0.87; P = 1.0 ~ 
NEC; all babies, and < 26 weeks GA P = 0.87; P = 0.51 ~ 
Early NEC; all babies, and < 26 weeks GA P = 0.56; P = 0.65 ~ 
SIP; all babies, and < 26 weeks GA P = 0.53; P = 0.3 ~ 
Early SIP; all babies, and < 26 weeks GA P = 0.75; P = 0.69 ~ 
SIP or NEC or death; all babies, and < 26 weeks GA P = 0.55; P = 0.44 ~ 
Early SIP or NEC or death; all babies, and < 26 
weeks GA 
P = 0.99; P = 0.83 ~ 
1: Pre MgSO4 protocol, N = 
112 babies 
Death; all babies, and < 26 weeks GA P = 0.3; P = 0.4 ~ 




2: Post MgSO4 protocol, N = 
190 babies 
SIP; all babies, and < 26 weeks GA P = 0.6; P = 0.1 ~ 
1: MgSO4 ≤ 3 days prior to 
birth, N = 179 babies 
SIP or NEC or death, logistic regression modelling, 
each 10 g increase in MgSO4 cumulative dose 
“correlated with an 18.9% decrease in 
SIP/NEC/death prior to discharge (95% 
CI 2.2–32.8%, p = 0.028)” 
 
SIP or NEC or death, logistic regression modelling, 
number of MgSO4 loading doses 
“no significant association… OR = 1.07 
(95% CI 0.53–2.1, p = 0.86)” 
~ 
Early SIP or NEC or death, logistic regression 
modelling, each 10 g increase in MgSO4 
cumulative dose 
“correlated with … a 21.9% decrease 
in early SIP/NEC/death (95% CI 1.4 
38.1%, p = 0.037)” 
 
Early SIP or NEC or death, logistic regression 
modelling, number of MgSO4 loading doses 
“no significant association … early 
SIP/NEC/death, OR = 1.08 (95% CI 
0.48–2.4, p = 0.86)” 
~ 
1: MgSO4 ≤ 7 days prior to 
birth, N = 210 babies 
2: No MgSO4 ≤ 7 days prior 
to birth, N = 92 babies 
SIP or NEC or death, SGA status “found to be correlated with a 
reduction… by a likelihood ratio test 
with p = 0.07” 
~ 
Early SIP or NEC or death; SGA babies only, and 
non-SGA babies only 
OR 0.23; 95% CI 0.04-1.19; P = 0.079 
OR 1.19; 95% CI 0.58-2.47; P = 0.63 
~ 
Mitani 2011; RCS with 
CCS(N); moderate to high 
N = 425 babies; T 1: MgSO4, N = 236 babies 
2: No MgSO4, N = 189 babies 
Perinatal death P = 0.185 ~ 
Apgar score < 7 at 1 minute P = 0.246 ~ 
Apgar score < 7 at 5 minutes P = 0.817 ~ 
RDS P = 0.543 ~ 
IVH P = 0.879 ~ 
PVL P = 0.630 ~ 
1: Adverse outcome (IVH, 
PVL, CP, infantile death), N = 
80 babies 
2: Good outcome, N = 315 
babies 
MgSO4 exposure P = 0.801 ~ 
MgSO4 exposure (multivariate logistic regression 
analysis; confounders NR) 
OR 0.93; 95% CI 0.57-1.52 
aOR 0.82; 95% CI 0.48-1.40 
~ 
1: < 2 days MgSO4, N = 49 
babies 
2: > 2 days MgSO4, N = 174 
babies 
Combined adverse outcome (infantile death, IVH, 
PVL, CP) 
P > 0.999 ~ 
IVH P = 0.339 ~ 




1: MgSO4 and adverse 
outcome, N = 49 babies 
2: MgSO4 and good 
outcome, N = 174 babies 
Duration of MgSO4 (hours) (median, range) P = 0.31 ~ 
Mittendorf 2005; RCS; 
unclear 
Abstract 
N = 146 babies; FN/T 1: MgSO4 0-4 g, N = 90 
babies 
2: MgSO4 5-49 g, N = 23 
babies 
3: MgSO4 ≥ 50 g, N = 33 
babies 
IVH grade 3 and/or LSV (adjusted for confounding), 
2 vs. 3^ 
aOR 0.13; 95% CI -Inf to 0.96; P = 
0.045 
 
IVH grade 3 and/or LSV (adjusted for confounding), 
1 vs. 2^ 
“trended toward neuopathogenesis 
(not significant; StatXact).” 
~ 
Mittendorf 2009; RCS; 
unclear 
Abstract 
N = 140 babies; FN/T 1: MgSO4 > 0 to < 10 g, N = 
27 babies 
2: MgSO4 10 to < 30 g, N = 8 
babies 
3: 30 to < 50 g, N = 11 babies 
4: ≥ 50 g, N = 30 babies 
TSV (Cochran-Armitage trend test of increasing 
exposures to MgSO4)^ 
P = 0.22 ~ 
TSV (logistic model controlling for birthweight and 
funisitis), tocolytic MgSO4 : ≥ 50 g^ 
P = 0.03  
Morag 2015; RCS; 
moderate to high 
N = 645 women and 705 
babies (235 preterm 
babies further 
considered); PE 
1: Preterm infants with 
MgSO4 exposure, N = 10 
women 
2: Preterm infants with no 
MgSO4 exposure, N = 168 
women 
Respiratory disease (including RDS, TTN and 
disorders of air leak such as pneumothorax and 
pneumomediastinum) (multivariate logistic 
regression analysis - factors from multivariate 
analysis: maternal age, primiparity, antenatal 
steroids, SGA, caesarean birth, MgSO4 treatment)^ 
OR 5.17; 95% CI 1.29-20.64; P = 0.020  
Morag 2016; RCS; high N = 190 babies; FN/PE 1: MgSO4, N = 145 babies 
2: No MgSO4, N = 45 babies 
 
 
Apgar score < 7 at 1 minutes P = 0.28 ~ 
Apgar score < 7 at 5 minutes P = 0.03  
IV (days) (mean ± SD)^ 
 
P = 0.01 “explained by out unit 
protocol, which recommended delay 
of enteral feeding in infants whose Mg 
concentrations are elevated.” 
 
Treated early hypotension P = 0.16 ~ 
Intubation P = 0.44 ~ 
Oxygen at 28 days P = 0.41 ~ 
Oxygen at 36 weeks P = 0.34 ~ 
Proven NEC P = 0.10 ~ 




IVH 3-IV/PVL P = 0.55 ~ 
Discharge (week) (mean ± SD)^ P = 0.22 ~ 
Neonatal death P = 0.37 ~ 
Moschos 2001; CCS; 
unclear 
Abstract 
N = 75 babies; NR 1: NEC, N = 25 babies 
2: No NEC, N = 50 babies 
MgSO4 exposure (logistic regression analysis) OR 4; CI: 1.367-12.743; P = 0.016  
Murata 2005; RCS with 
CCS(N); moderate to high 
N = 201 babies; T 1: cPVL, N = 35 babies 
2: No cPVL, N = 166 babies 
 
MgSO4 exposure (univariate analysis) OR 0.14; 95% CI 0.040-0.95; P = 0.03   
MgSO4 exposure (multivariate analysis including 
variables that were significant in the univariate 
analysis [Apgar score < 5 at 5 minutes, cord length 
> 40 cm, indomethacin exposed], with birthweight 
and GA by the logistic procedure) 
OR 0.058; 95% CI 0.007-0.498; SE: 1.1  
Nakamura 1991; RCS 
with CCS(N); unclear 
Abstract 
N = 58 women and their 
babies; PE 
1: Ileus, N = NR 
2: No ileus, N = NR 
MgSO4 dose (g) (mean ± SD) P < 0.05  
Narasimhulu 2017; RCS; 
high 
N = 304 women and 
babies; FN/PE 
 
1: MgSO4, N = 237 women 
and babies 
2: No MgSO4, N = 67 women 
and babies 
Apgar score ≤ 5 at 1 minute P = 0.79 ~ 
Apgar score ≤ 5 at 5 minutes P = 0.49 ~ 
Delivery room resuscitation P = 0.56 ~ 
Hypotension P = 0.01  
Hypocalcaemia P = 0.01  
IVH grade 3/4 P = 0.29 ~ 
BPD P = 0.02  
ROP grade 3+ P = 0.07 ~ 
PVL P = 0.42 ~ 
Intubation P = 0.36 ~ 
NEC P = 0.75 ~ 
PDA P = 0.02  
Neonatal death P = 0.93 ~ 
Composite outcome (neonatal death, IVH grade 
3/4, BPD, ROP grade 3+, PVL, NEC) 
P = 0.06 ~ 
NICU LOS (days) (median, Q1-Q3) P < 0.01  
Nassar 2006; RCS; high N = 155 women, 198 
babies; T 
1: MgSO4 > 48 hours, N = 78 
women, 112 babies 
Apgar score < 4 at 1 minute^ P = 0.597 ~ 
Apgar score < 7 at 5 minutes P = 0.772 ~ 




2: MgSO4 ≤ 48 hours, N = 77 
women, 86 babies 
IVH P = 0.210 ~ 
Neonatal deaths (per 1,000) P = 0.614 ~ 
Abnormal bone mineralisation 1: 3 cases vs. 2: 0 cases; “Abnormal 
bone mineralization was encountered 
in 3 neonates whose mothers received 
4,400 and 5,500 g of MgSO4” 
NA 
Nelson 1995; CCS: high N = 117 babies; 75 
babies considered for 
review; PE/T 
1: No CP, MgSO4, N = 27 
babies [discrepancy in 
text/table 29 vs. 27] 
2: No CP, no MgSO4, N = 48 
babies 
Apgar score < 6 at 5 minutes 23% vs. 9%; “None of these 
differences alone was statistically 
significant” 
~ 
ICH/IVH, among those who underwent 
neuroimaging, among all 
OR 0.33; 95% CI .12-1.0 
OR 0.52; 95% CI .20-1.5  
~ 
~ 
Nunes 2018; RCS; high N = 75 women, 99 
babies (94 available for 
analyses); FN 
1: MgSO4, N = 26 babies 
2: No MgSO4, N = 68 babies 
Heart rate (normal vs. abnormal)^ OR 1.17; 95% CI 0.45-3.12; P = 0.106 ~ 
Respiratory rate (normal vs. abnormal)^ OR 0.94; 95% CI 0.35-2.62; P = 0.017 
(unclear why P value does not reflect 
OR) 
~  
Temperature (normal vs. abnormal)^ OR 1.06; 95% CI 0.34-3.09; P = 0.011 
(unclear why P value does not reflect 
OR) 
~  
Oxygen saturation (≥ 95% vs. < 95%)^ OR 1.47; 95% CI 0.40-7.11; P = 0.319 ~ 
Hemoglucotest (normal vs. abnormal)^ OR 1.20; 95% CI 0.42-3.72; P = 0.114 ~ 
Hemoglobin (≥ 16.4 vs. < 16.4 g/dL)^ OR 1.00; 95% CI 0.36-2.64; P < 0.001 
(unclear why P value does not reflect 
OR) 
~ 
Ventilation (non-invasive vs. ET) OR 2.01; 95% CI 0.80-5.23; P = 0.07 ~ 
Okusanya 2012; NRT; 
high 
N = 103 women and 
their babies; PE/E 
1: 10 g MgSO4 LD, N = 54 (25 
severe PE; 29 E) and their 
babies 
2: 14 g MgSO4 LD, N = 49 (30 
severe PE; 19 E) women and 
their babies 
Apgar score < 7 at 5 minutes: severe PE women P = 0.2373 ~ 
Apgar score < 7 at 5 minutes: E women P = 0.9396 ~ 
Perinatal death: severe PE women Results not clear 
1: reports 19 livebirths, 6 perinatal 
deaths, and PMR 240 per 1000 vs. 2: 
reports 26 livebirths, 1 perinatal 
death, and PMR 35 per 1000 
NR 
Perinatal death: E women Results not clear 
1: reports 6 perinatal deaths, and PMR 





IUFD prior to MgSO4] vs. 2: reports 0 
perinatal deaths 
O Reilly 2016; RCS; 
unclear 
Abstract 
N = 100 babies; FN 1: MgSO4, N = 55 babies 
2: No MgSO4, N = 45 babies 
Duration of intubation (hours) (median, variance 
measure NR) (controlled for GA) 
P = 0.0011  
1: MgSO4, N = 55 babies Duration of intubation (hours) (median, variance 
measure NR) 
“Babies born to mothers who had 
received MgS04 closest to time of 
delivery remained intubated for a 
longer median of hours compare to 
those born to mothers who received it 
the longest amount of time before 
delivery.” 
 
Duration of intubation (hours) (subgroups as 
reported to right) 
“There was a notably variation in the 
length of hours of intubation among 
the subgroups who received MgS04 at 
different time periods before delivery. 
Subgroups were divided into babies 
whose mothers received MgS04 < 1, 
0-4, > 4 h prior to delivery.” 
NR 
Ozlu 2019; RCS; high N = 280 babies; FN 1: 2014-2016 (post MgSO4 
implementation), N = 108 
babies 
2: 2011-2012 (pre MgSO4 
implementation), N = 172 
babies 
Neonatal death P = 0.64 ~ 
Resuscitation at birth P = 0.89 ~ 
RDS P = 0.01  
Ventilator support P = 0.85 ~ 
Ventilation (days) (mean ± SD, and median, 
minimum and maximum) 
P = 0.82 ~ 
BPD P = 0.36 ~ 
Oxygen use (days) (mean ± SD, and median, 
minimum and maximum) 
P = 0.65 ~ 
NEC “None of the babies had necrotizing 
enterocolitis.” 
~ 
Early neonatal sepsis P = 0.25 ~ 
Feeding intolerance P = 0.96 ~ 
Could not get full enteral feeding^ 1: 6.4% vs. 2: 6.4% NR 




Starting day of enteral feeding (day) (mean ± SD, 
and median, minimum and maximum)^ 
P = 0.12 ~ 
Time of full enteral feeding (day) (mean ± SD, and 
median, minimum and maximum)^ 
P = 0.82 ~ 
PDA P = 0.63 ~ 
ROP P = 0.11 ~ 
IVH P = 0.32 ~ 
IVH grade 3/4 P = 0.09 ~ 
Duration of hospital stay (days) (mean ± SD, and 
median, minimum and maximum) 
P = 0.56 ~ 
Palatnik 2019; CCS; 
moderate to high 
N = 779 babies; NR 1: Early onset sepsis or death 
in 1st week, N = 73 babies 
2: No early onset sepsis or 
death in 1st week, N = 706 
babies 
MgSO4 exposure P = 0.024  
MgSO4 exposure, model 1 (multivariable logistic 
regression, including GA at birth and birthweight 
as continuous variables, and the interaction 
between them) (confounders: maternal obesity, 
receipt of antibiotics prior to birth, receipt of 1 
dose of steroids prior to birth, MgSO4 in labour, 
fever in labour, presence of meconium, GA at 
birth, birthweight) 
aOR 0.82; 95% CI 0.35-1.94 ~ 
MgSO4 exposure, model 2 (multivariable logistic 
regression, including GA at birth as a continuous 
variable, birthweight dichotomised by VLBW, and 
the interaction between them) (confounders as 
above) 
aOR 0.84; 95% CI 0.36-1.95 ~ 
MgSO4 exposure, model 3 (multivariable logistic 
regression, including GA at birth dichotomised by < 
28 weeks, birthweight as a continuous variable, 
and the interaction between them) (confounders 
as above) 
aOR 0.86; 95% CI 0.37-2.00 ~ 
Paneth 1991; PCS; 
moderate 
N = 1037 babies; 
PE/PEH/T 
1: MgSO4, N = 362 babies 
2: No MgSO4, N = 675 babies 
GM/IVH OR 0.89; 95% CI 0.65-1.20 ~ 
GM/IVH (multiple logistic regression adjusted for 
GA, fetal growth ratio, gender, multiple birth 
status, mode of birth, labour status, amnionitis, PE, 
and pre-existing hypertension) 




PEL/VE^ OR 0.96; 95% CI 0.62-1.47 ~ 
PEL/VE (multiple logistic regression adjusted as 
above)^ 
aOR 0.94; 95% CI 0.59-1.49 ~ 
Neonatal death in 1st 28 days OR 0.77; 95% CI 0.54-1.10 ~ 
Neonatal death in 1st 28 days (multiple logistic 
regression adjusted as above) 
aOR 0.83; 95% CI 0.53-1.30 ~ 
Perlman 1995; RCS; 
unclear 
Abstract 
N = 1025 babies; PIH 1: MgSO4, N = 192 babies 
2: No MgSO4, N = 833 babies 
PV-IVH OR 2.1; 95% CI 1.4-3.3; P < 0.05 (and 
stepwise logistic regression “shows 
that GA and Mg+ are the most 
significant predictors of PV-IVH”) 
 
 
PV-IVH, infants < 28 weeks P = 0.70 ~ 
PV-IVH, infants 28-31 weeks OR 3; 95 %CI 1.2-7.4; P < 0.05  
IVH grade 3/4 P < 0.05  
Petrov 2013; NRT; 
unclear 
Abstract 
N = 140 women and 
babies; FN 
1: MgSO4, N = 80 babies 
2: Placebo, N = 60 babies 
Range of neurological complications^ RR 0.55; 95% CI 0.32-0.95  
Haemodynamic complications^ P > 0.05 ~ 
Petrova 2012; RCS with 
CCS(N); moderate to high 
N = 178 babies; T 
 
1: IVH, N = 89 babies 
2: No IVH, N = 89 babies 
 
MgSO4 exposure OR 0.494; 95% CI 0.271-0.901  
MgSO4 exposure (multiple logistic regression 
model, controlling for observed differences in 
frequency of PPROM, ventilation after birth, 
severity of distress - Apgar scores at 1 minute) 
aOR 0.471; 95% CI 0.241-0.906  
Qasim 2017; PCS with 
CCS(N); unclear 
Abstract 
N = 105 babies; NR 1: MgSO4, N = 95 babies 
2: No MgSO4, N = 10 babies 
HsPDA (Pearson correlation analysis) Negative correlation, r = -0.364, P < 
0.001 
 
HsPDA (regression model) Negative linear relationship, -0.525, P 
< 0.001 
 
Rantonen 2001; PCS; 
high 
N = 55 babies (17 in 
ritrodrine exposure 
group not further 
considered); PE/T 
1: MgSO4, N = 19 babies 
2: No MgSO4, N = 19 babies 
See right Note: below P values are reported for 
intergroup differences between 
groups 1, 2 and 3 (ritrodrine exposure) 
 
Dexamethasone P = 0.07 ~ 
Dopamine^ P = 0.3 ~ 
Dobutamine^ P = 0.8 ~ 
Surfactant P = 0.7 ~ 





group 2 vs. 
group 3 
(ritodrine) 
PIVH grade 1-4 P = 0.03  
PIVH grade 3/4 P = 0.07 ~ 
HIE/increased echodensity P = 0.8 ~ 
RDS and MV P = 0.2 ~ 
NICU admission All babies ~ 
Neonatal death No events ~ 
Blood-culture confirmed septicaemia No events ~ 
Rasch 1982; PCS; high N = 79 babies; PE 1: Born to PE women treated 
with MgSO4, N = 36 babies 
2: Born to PE women with no 
MgSO4, N = 18 babies 
3: Born to normal women, N 
= 25 babies 
Poor sucking and cry response, 1 vs. 2 and 3^  “poorer… until 48 hours of age” ~ 
Cyanosis during feedings 1: 2 events NA 
Requirement for IV fluid treatment^ 38.9% vs. 5.6% vs. 0%  
Neurologic section of the Dubowitz examination at 
birth, over 24 hours after birth, 1 vs. 2 and 3^ 
P < 0.001  
Individual measures on the Dubowitz 
examination^ 
“those tasks which required repetitive 
muscle activity (head lag and ventral 
suspension) were accomplished less 
effectively by infants in Group A. 
Ability to perform single or low-
frequency responses (arm and leg 
recoil) was also diminished at birth in 
Group A infants, but was similar for all 
groups by 6 hours of age.” 
 
Neuromuscular transmission at 6 and 12 hours, 
“significant fade” 1 vs. 2 and 3 combined^ 
P < 0.005  
Neuromuscular transmission at 24 hours, 
“significant fade”, 1 vs. 2 and 3 combined^ 
P < 0.01  
Rattray 2014; NCCS; 
moderate to high 
N = 155 babies; FN 1: Pre-MgSO4 FN protocol 
(50.6% MgSO4), N = 81 
babies 
2: During MgSO4 FN protocol 
(78.3% MgSO4), N = 23 
babies 
Postnatal hydrocortisone P = 0.44 ~ 
Postnatal NSAIDs P = 0.21 ~ 
SIP or neonatal death (before discharge), 1 vs. 2 vs. 
3 
P = 0.45 ~ 
SIP or neonatal death (before discharge), 1 and 3 
vs. 2 




3: After MgSO4 FN protocol 
(60.8% MgSO4), N = 51 
babies 
SIP or neonatal death (before discharge) 
(multivariable analysis, MgSO4 dose (g) x GA) 
P < 0.01  
SIP, 1 vs. 2 vs. 3 P = 0.09 ~ 
SIP, 1 and 3 vs. 2 P = 0.03  
Neonatal death (before discharge), 1 vs. 2 vs. 3 P = 0.07 ~ 
Neonatal death (before discharge), 1 and 3 vs. 2 P = 0.02  
Rauf 2017; RCS; high N = 107 women and 
babies; FN 
1: MgSO4, N = 46 babies 
2: No MgSO4, N = 61 babies 
Active resuscitation at birth (ET intubation) P = 0.015  
NICU LOS (days) (mean ± SD) P = 0.929 ~ 
Respiratory support, MV, nasal CPAP, nasal SIMV, 
oxygen hood 














IVH P = 0.049  
IVH grade 1-4 P = 0.91 ~ 
PVL P = 0.43 ~ 
Convulsion P = 0.63 ~ 
Hypotonia P = 0.032  
Encephalopathy P = 0.57 ~ 
ROP P = 0.04  
Neonatal death P = 0.015  
Rhee 2012; PCS; high N = 23 women and 22 
babies; PE/T 
1: MgSO4, N = 11 women, 10 
babies 
2: No MgSO4, N = 12 women, 
12 babies 
NICU admission P = 0.02  




Riaz 1998; PCS with 
CCS(N); high 
N = 52 babies; PIH/T 1: MgSO4, N = 26 babies 
2: No MgSO4, N = 26 babies 
Hypotonia 
 
P < 0.001 
“However, there was no association 
between either hypotonia at birth or 
Apgar scores, with… total maternal 
dose or duration of MgSO4 
administered (p ≥ 0.29 [data not 
shown]).” 
 
Delivery room support (bag and mask ventilation) P = 0.19 ~ 
NICU admission  P = 0.49 ~ 
Delayed adaptation P = 0.46 ~ 
Presumed or ruled-out sepsis P = 0.75 ~ 
Delayed feeding (1st feeding ≥ 8 hours after birth)^ P = 0.12 ~ 
Feeding intolerance P = 0.54 ~ 
Hospital stay (days) (mean ± SD) P = 0.11 ~ 
Apnoea density (mean ± SD)^ P = 0.37 ~ 
Apnoea ≥ 15 seconds (associated with bradycardia) 
(mean ± SD)^ 
P = 0.96 ~ 
Apnoea ≥ 10 seconds (mean ± SD)^ P = 0.16 ~ 
Pathologic apnoea (≥ 15 seconds associated with 
bradycardia) 
P = 1.0 ~ 
1: MgSO4 and NICU 
admission, N = 12 babies 
2: MgSO4 and no NICU 
admission, N = 14 babies 
MgSO4 dose (g) (mean ± SD),  P = 0.91 ~ 
Duration of MgSO4 (hours) (mean ± SD) P = 0.97 ~ 
Rizzolo 2019; RCS; 
unclear 
Abstract 
N = 3788 babies; FN 1: MgSO4, N = NR 
2: No MgSO4, N = NR 
Death or SNI (grade ≥ 3 IVH and/or PVL) (adjusted 
for GA, SGA, mode of birth, sex, multiple 
pregnancy and SNAP > 20) 
aOR 0.87; 95% CI 0.71-1.05 ~ 
Sahin 2001; PCS; high N = 40 babies; PE/E 1: MgSO4, N = 20 babies 
2: No MgSO4, N = 20 babies 
Not voiding in 1st 24 hours No events ~ 
Residual urine after 1st micturition (> 5 mL)^ No events ~ 
Urinary tract abnormality^ No events ~ 
Neurologic pathology^ No events ~ 
Sakae 2017; NCCS; high N = 45 women, 48 
babies; PE 
1: Post-protocol: April 2013 
onwards (100% MgSO4 use), 
N = 17 women, 19 babies 
Composite of serious complications (1 or more of: 
neonatal death, assisted ventilation with ETT > 24 
hours, RDS, PPH, PDA, BPD, cPVL, IVH grade ≥ 3, 






2: Pre-protocol: prior to April 
2013 (36% MgSO4 use), N = 
28 women, 29 babies 
NEC and sepsis) (multiple logistic regression 
analysis, using the components of our 
management protocol (antenatal corticosteroids, 
IV nicardipine, MgSO4, indication for birth) as 
predictor variables)  
1: > 48 hours MgSO4, N = 17 
women, 19 babies 
2: ≤ 48 hours MgSO4, N = 10 
women, 10 babies 
3: No MgSO4, N = 18 women, 
19 babies 
Composite of serious complications 1 vs. 2: P = 0.33 
1 vs. 3: P = 0.003 





Salafia 1995; RCS with 
CCS(N; moderate to high 
N = 406 women and 
their babies; T 
1: Early GM-IVH, N = 44 
babies 
2: Late GM-IVH, N = 21 
babies 
3: No GM-IVH, N = 341 
babies 
MgSO4 exposure (factors significantly related to 
early GM-IVH in multivariate logistic regression: 
GA, MgSO4, antenatal steroids, volume expansion 
in 1st 2 days, pressor agents in 1st 3 days, acute 
amnion inflammation) 
OR 2.33; 95% CI 1.128-4.814; P = 
0.022; β = 0.846 
 
Sarkar 2009; RCS with 
CCS(N); moderate to high 
N = 59 babies; NR 1: IVH grade 3, N = 28 babies 
2: IVH grade 4, N = 31 babies 
MgSO4 exposure P = 0.06 ~ 
MgSO4 exposure (multivariate logistic regression 
analysis, including GA, birthweight, prenatal 
steroid use, MgSO4 and Apgar score < 6 at 5 
minutes) 
OR 0.3; 95% CI 0.07-0.9; P = 0.04  
Schanler 1997; PCS; high N = 31 women, 41 
babies; T 
 
1: MgSO4; N = 16 women, 22 
babies 
2: No MgSO4, N = 15 women, 
19 babies 
Apgar score < 7 at 5 minutes 22.7% vs. 10.5% ~ 
LOS (days) (mean ± SD) 46 ± 38 vs. 35 ± 22 ~ 
HMD 36.4% vs. 10.5% ~ 
PDA 13.6% vs. 0% ~ 
IVH 22.7% vs. 10.5% ~ 
NEC 4.5% vs. 0% ~ 
Birth depression^ No events ~ 
Oxygen treatment 68.2% vs. 68.4% ~ 
Oxygen treatment > 1 month^ 13.6% vs. 5.3% ~ 
MV 50.0% vs. 47.4% ~ 
MV > 1 week^ 9.10% vs. 0% ~ 




Clinical diagnoses (as above) “similar between groups" ~ 
Scudiero 2000; RCS with 
CCS(N); moderate to high 
N = 127 babies; T 1: Fetal or neonatal deaths 
(perinatal deaths), N = 18 
babies 
2: Survivors, N = 109 babies 
MgSO4 for T > 48 g P = 0.03  
MgSO4 for T ≤ 48 g vs > 48 g (multivariable logistic 
regression analysis, included year of birth, receipt 
of betamethasone, acute maternal disease, 
maternal race, birthweight, MgSO4 dose) 
OR 4.72; 95% CI 1.12, 19.97; P = 0.035  
1: MgSO4 ≤ 24 g, N = 43 
babies 
2: MgSO4 > 24 but ≤ 48 g, N = 
25 babies 
3: MgSO4 > 48 g, N = 59 
babies 
Perinatal death (Cochrane–Armitage trend test) P = 0.03  
Perinatal death (1 vs. 2 only) P = 1.0 ~ 
Shalabi 2017; RCS; 
moderate 
N = 4355 babies; any 1: MgSO4, N = 2055 babies 
2: No MgSO4, N = 2300 
babies 
Apgar score < 7 at 5 minutes P < 0.0001  
SNAP-2 score > 20  P = 0.0005  
MV day 1 P < 0.0001  
Prophylactic indomethacin^ P < 0.0001  
PDA treated with indomethacin P = 0.31 ~ 
Postnatal steroids for hypotension^ P = 0.37 ~ 
Postnatal steroid for BPD P = 0.59 ~ 
PDA treated with indomethacin or ibuprofen  P = 0.33 ~ 
Postnatal steroid for BPD or hypotension; PDA 
treated with indomethacin or ibuprofen^  
P = 0.10 ~ 
NEC stage 2 or higher: all, 22-25 weeks GA, 26-27 
weeks GA 
P = 0.75; P = 0.45; P = 0.86 ~, ~, ~ 
NEC stage 2 or higher (multiple logistic regression, 
covariates included: gender, GA, SGA, Apgar score 
< 7 at 5 minutes, MV on day 1, antenatal steroid 
use, prophylactic indomethacin and indomethacin 
for PDA): all, 22-25 weeks GA, 26-27 weeks GA 
aOR 0.92; 95% CI 0.75-1.14; P = 0.45 
aOR 0.96; 95% CI 0.72-1.27; P = 0.81 




SIP: all, 22-25 weeks GA, 26-27 weeks GA P = 0.99; P = 0.69; P = 0.75 ~, ~, ~ 
SIP (multiple logistic regression, covariates as 
above): all, 22-25 weeks GA, 26-27 weeks GA 
aOR 1.05; 95% CI 0.75-1.48; P = 0.75 
aOR 1.13; 95% CI 0.74-1.72; P = 0.79 








NEC or SIP (multiple logistic regression, covariates 
as above): all, 22-25 weeks GA, 26-27 weeks GA^ 
aOR 0.88; 95% CI 0.73-1.07; P = 0.21 
aOR 0.91; 95% CI 0.71-1.18; P = 0.43 




Neonatal death prior to discharge: all, 22-25 weeks 
GA, 26-27 weeks GA 
P < 0.0001; P < 0.0001; P = 0.56 , , ~ 
Neonatal death prior to discharge (multiple logistic 
regression, covariates as above): all, 22-25 weeks 
GA, 26-27 weeks GA 
aOR 0.84; 95% CI 0.71-1.00; P = 0.054 
aOR 0.75; 95% CI 0.61-0.93; P = 0.02 




NEC or SIP associated death: all, 22-25 weeks GA, 
26-27 weeks GA 
P = 0.18; P = 0.57; P = 0.21 ~, ~, ~ 
NEC or SIP associated death (multiple logistic 
regression, covariates as above): all, 22-25 weeks 
GA, 26-27 weeks GA 
aOR 0.8; 95% CI 0.59-1.09; P = 0.16 
aOR 0.89; 95% CI 0.61-1.31; P = 0.44 




IVH grade 3/4 or PVL: all, 22-25 weeks GA, 26-27 
weeks GA 
P = 0.002; P = 0.001; P = 0.41 , , ~ 
IVH grade 3/4 or PVL (multiple logistic regression, 
covariates as above): all, 22-25 weeks GA, 26-27 
weeks GA 
aOR 0.91; 95% CI 0.78-1.07; P = 0.26 
aOR 0.80; 95% CI 0.65-0.99; P = 0.048 




ROP stage 3 or above or ROP treated: all, 22-25 
weeks GA, 26-27 weeks GA 
P = 0.09; P = 0.06; P = 0.4 ~, ~, ~ 
ROP stage 3 or above or ROP treated (multiple 
logistic regression, covariates as above): all, 22-25 
weeks GA, 26-27 weeks GA 
aOR 0.81; 95% CI 0.65-0.999; P = 0.049 
aOR 0.77; 95% CI 0.6-1.001; P = 0.063 




BPD: all, 22-25 weeks GA, 26-27 weeks GA P = 0.18; P = 0.36; P = 0.24 ~, ~, ~ 
BPD (multiple logistic regression, covariates as 
above): all, 22-25 weeks GA, 26-27 weeks GA 
aOR 0.92; 95% CI 0.79-1.06; P = 0.23 
aOR 0.9; 95% CI 0.72-1.12; P = 0.82 




Nosocomial infection: all, 22-25 weeks GA, 26-27 
weeks GA^ 
P = 0.04; P 0.0007; P = 0.85 , , ~ 
Nosocomial infection (multiple logistic regression, 
covariates as above): all, 22-25 weeks GA, 26-27 
weeks GA^ 
aOR 1.08; 95% CI 0.94-1.25; P = 0.26 
aOR 1.26; 95% CI 1.03-1.53; P = 0.04 








Shamsuddin 2005; NRT; 
high 
N = 265 women and 
their babies (207 
antepartum/intrapartum 
PE/E cases); PE/E 
1: MgSO4 LD at home before 
referral to hospital, N = 102 
women and their babies 
2: No MgSO4 before referral 
to hospital, N = 105 women 
and their babies 
Stillbirth P < 0.001  
Shokry 2010; PCS; high N = 48 women and their 
babies; T 
 
1: MgSO4, N = 28 women 
and their babies 
2: No MgSO4, N = 20 women 
and their babies 
RDS P = 0.762 ~ 
PIVH P = 0.036  
Seizures P = 0.011  
MV P = 0.836 ~ 
Surfactant use P = 0.874 ~ 
Inotropic drug use P = 0.498 ~ 
PDA P = 0.042  
Neonatal death P = 0.480 ~ 
Stetson 2019; NCCS; high 
Research Letter 
N = 110 babies; FN/PE 1: 2002-2008 (pre-BEAM 
trial, 36% uptake MgSO4), N 
= 42 babies 
2: 2009-2014 (post-BEAM 
trial, 62% uptake MgSO4), N 
= 68 babies 
BPD 
1: 67% babies exposed to MgSO4 vs. 56% not 
exposed 
2: 86% babies exposed to MgSO4 vs. 73% not 
exposed 
P = 0.049  
IVH 
1: 40% babies exposed to MgSO4 vs. 56% not 
exposed 
2: 60% babies exposed to MgSO4 vs. 62% not 
exposed 
P = 0.41 ~ 
Stockley 2018; RCS; 
moderate 
N = 336 babies; NR Growth restriction (fetal 
standards) 
1: MgSO4, N = 112 babies 
2: No MgSO4, N = 224 babies 
Death in NICU and post-discharge (adjusted for GA, 
sex, mode of birth, multiple birth, SNAP-II > 20, 
maternal hypertension) 
aOR (95% CI): 0.42 (0.19-0.95)  
Apgar score < 7 at 5 minutes P =  0.65 ~ 
Chest compression or epinephrine P = 0.70 ~ 
SNAP-II score > 20 P = 0.36 ~ 
BPD (adjusted as above) aOR 0.84; 95% CI 0.46-1.52 ~ 
NEC (adjusted as above) aOR 0.38; 95% CI 0.15-1.00 ~ 
Late-onset sepsis (adjusted as above) aOR 0.89; 95% CI 0.49-1.61 ~ 




IVH grade 1/2 (adjusted as above) aOR 1.02; 95% CI 0.53-1.94 ~ 
IVH grade 3/4 (adjusted as above) aOR 0.55; 95% CI 0.20-1.51 ~ 
Growth restriction (neonatal 
standards) 
1: MgSO4, N = 61 babies 
2: No MgSO4, N = 116 babies 
Death in NICU and post-discharge (adjusted as 
above) 
aOR 0.37; 95% CI 0.15-0.95  
Apgar score < 7 at 5 minutes P = 0.83 ~ 
Chest compression or epinephrine P = 0.49 ~ 
SNAP-II score > 20 P = 0.60 ~ 
BPD (adjusted as above) aOR 1.10; 95% CI 0.47-2.61 ~ 
NEC (adjusted as above) aOR 0.57; 95% CI 0.16-2.00 ~ 
Late-onset sepsis (adjusted as above) aOR 0.71; 95% CI 0.32-1.56 ~ 
ROP stage 3/4/5 or treated (adjusted as above) aOR 0.96; 95% CI 0.34-2.73 ~ 
IVH grade 1/2 (adjusted as above) aOR 0.54; 95% CI 0.20-1.42 ~ 
IVH grade 3/4 (adjusted as above) aOR 0.68; 95% CI 0.20-2.34 ~ 
Suh 2015; RCS; unclear 
English abstract 
N = 150 babies (of 
relevance); HD 
1: MgSO4, N = 40 babies 
2: No MgSO4, N = 110 babies 
LOS (days) (mean ± SD)  P = 0.181 ~ 
Duration of ventilation(days) (mean ± SD)  P = 0.078 ~ 
Duration of oxygen (days) (mean ± SD)  P = 0.205 ~ 
RDS P = 0.242 ~ 
BPD P = 0.264 ~ 
Moderate to severe  
BPD 
P = 0.576 ~ 
PDA treated (medication ± operation) P = 0.534 ~ 
ROP treated with laser P = 0.086 ~ 
NEC P = 0.528 ~ 
IVH grade ≥ 2 P = 0.151 ~ 
PVL P = 0.053 ~ 
Neonatal death P = 0.320 ~ 
Teng 2006; RCS with 
CCS(N); moderate to high 
N = 184 babies; PE/T 1: Early hypotension, N = 75 
babies 
2: No early hypotension, N = 
109 babies 
MgSO4 exposure (identified as one of eight 
variables associated with hypotension, by 
univariate analysis) 
OR 2.83; 95% CI 1.52-5.27; P < 0.01  
MgSO4 exposure (incorporated into multiple 
logistic regression model) 
No longer associated ~ 
Positive blood culture No events ~ 




Verma 2006; RCS with 
CCS(N); moderate to high 
2: No PIE, N = 34 babies MgSO4 dose ≥ 10 g P = 0.01  
MgSO4 dose ≥ 10 g (multivariate logistic regression 
analysis model, controlling for maximum mean 
FiO2 and MAP during 1st 7 days of life, Apgar 
scores at 1 and 5 minutes, GA and surfactant 
requirement) 
OR 19.8; 95% CI 1.5-263; P = 0.01  
Weintraub 2001; RCS; 
moderate to high 
N = 2794 babies (have 
not considered the 263 
babies and 177 infants 
exposed to ritodrine and 
indomethacin) 
1: MgSO4, N = 341 babies 
2: No MgSO4, N = 2013 
babies 
 
PVH/IVH grade 3/4 10.0% vs. 15.1%; P < 0.01 
(P relates to univariate analysis, 
considering tocolytic groups: 1: 
MgSO4, 2: no tocolysis, 3: ritodrine, 
and 4: indomethacin) 
NR 
PVH/IVH grade 3/4 (multivariate logistic regression 
analysis; considered for inclusion: tocolysis, 
antenatal steroids, multiple birth, PROM, 
amnionitis, mode of birth, GA, birthweight, Apgar 
score at 1 minute, Apgar score at 5 minutes, RDS, 
PDA, MV, pneumothorax, sepsis) 
aOR 0.8; 95% CI 0.5-1.2 ~ 
Weisz 2015; RCS; 
moderate 
N = 6015 babies; 
FN/PE/T/UK 
1: MgSO4 for FN, N = 1387 
babies 
2: No MgSO4, N = 3868 
babies 
Any resuscitation (mask CPAP or PPV, ETT 
intubation and ventilation, chest compressions or 
epinephrine) 
P < 0.01  
CPAP only^ P < 0.01  
Bag/mask or neopuff ventilation P < 0.01  
Intubation and ventilation P = 0.03  
Chest compressions P < 0.01  
Epinephrine (ETT or IV) P = 0.02  
Apgar score < 7 at 5 minutes P = 0.20 ~ 
Surfactant use P = 0.06 ~ 
SNAP-2 score > 20 P = 0.28 ~ 
Intensive resuscitation (intubation and ventilation, 
or chest compressions or epinephrine 
administration in delivery room), unadjusted, and 
multiple logistic regression (with GEE to account 
for correlated data within each site/site effects), 
adjusted for: GA, sex, SGA, outborn status, 
OR 0.87; 95% CI 0.76-0.98; P = 0.02 
aOR 0.88; 95% CI 0.66-1.17 




chorioamnionitis, mode of birth, antenatal 
corticosteroid use, multiple gestation 
Neonatal death, unadjusted, and adjusted as 
above 
OR 0.73; 95% CI 0.58-0.92; P < 0.01 
aOR 0.61; 95% CI 0.40-0.94 
,  
BPD, unadjusted, and adjusted as above OR 1.09; 95% CI 0.93-1.18; P = 0.28 
aOR 1.13; 95% CI 0.92-1.38 
~, ~ 
NEC stage ≥ 2, unadjusted, and adjusted as above OR 1.19; 95% CI 0.91-1.55; P = 0.20 
aOR 0.99; 95% CI 0.73-1.34 
~, ~ 
IVH grade 3/4 or PVL, unadjusted, and adjusted as 
above 
OR 0.95; 95% CI 0.79-1.15; P = 0.62 
aOR 1.01; 95% CI 0.76-1.34 
~, ~ 
ROP stage ≥ 3, unadjusted, and adjusted as above OR 1.01; 95% CI 0.74-1.36; P = 0.95 
aOR 0.88; 95% CI 0.61-1.28 
~, ~ 
Sepsis, unadjusted, and adjusted as above OR 1.09; 95% CI 0.92-1.29; P = 0.32 
aOR 0.96; 95% CI 0.80-1.14 
~, ~ 
Composite outcome (morality or any major 
morbidity), unadjusted, and adjusted as above 
OR 1.00; 95% CI 0.88-1.14; P = 0.97 
aOR 1.03; 95% CI 0.83-1.29 
~, ~ 
23-28 weeks GA 
1: MgSO4 for FN, N = 731 
babies 
2: No MgSO4, N = 1813 
babies 
Intensive resuscitation, and adjusted as above OR 0.79 (0.66 to 0.94); P < 0.01 
aOR 0.89 (0.67 to 1.18) 
, ~ 
Neonatal death, unadjusted, and adjusted as 
above 
OR 0.65 (0.51 to 0.85); P < 0.01 
aOR 0.65 (0.43 to 1.00) 
, ~ 
BPD, unadjusted, and adjusted as above OR 1.03 (0.85 to 1.25); P = 0.75 
aOR 1.30 (1.03 to 1.65) 
~, ~ 
NEC stage ≥ 2, unadjusted, and adjusted as above OR 1.15 (0.84 to 1.57); P = 0.38 
aOR 1.05 (0.78 to 1.42) 
~, ~ 
IVH grade 3/4 or PVL, unadjusted, and adjusted as 
above 
OR 0.96 (0.77 to 1.19); P = 0.69 
aOR 1.11 (0.77 to 1.60) 
~, ~ 
ROP stage ≥ 3, unadjusted, and adjusted as above OR 0.96 (0.70 to 1.31); P = 0.79 
aOR 0.86 (0.59 to 1.25) 
~, ~ 
Sepsis, unadjusted, and adjusted as above OR 0.97 (0.79 to 1.18); P = 0.76 
aOR 0.91 (0.75 to 1.11) 
~, ~ 
Composite outcome, unadjusted, and adjusted as 
above 
OR 0.92 (0.77 to 1.09); P = 0.33 
aOR 1.24 (0.97 to 1.61) 
~, ~ 
29-31 weeks GA Intensive resuscitation, and adjusted as above OR 0.67 (0.53 to 0.83); P < 0.01 





1: MgSO4 for FN, N = 656 
babies 
2: No MgSO4, N = 2055 
babies 
Neonatal death, unadjusted, and adjusted as 
above 
OR 0.44 (0.18 to 1.05); P = 0.06 
aOR 0.74 (0.36 to 1.51) 
~, ~ 
BPD, unadjusted, and adjusted as above OR 0.67 (0.44 to 0.99); P = 0.05 
aOR 0.73 (0.49 to 1.07) 
, ~ 
NEC stage ≥ 2, unadjusted, and adjusted as above OR 1.06 (0.63 to 1.78); P = 0.81 
aOR 1.03 (0.57 to 1.85) 
~, ~ 
IVH grade 3/4 or PVL, unadjusted, and adjusted as 
above 
OR 0.67 (0.43 to 1.04); P = 0.07 
aOR 0.66 (0.40 to 1.06) 
~, ~ 
ROP stage ≥ 3, unadjusted, and adjusted as above OR 1.53 (0.36 to 6.46); P = 0.56 
aOR NC 
~, ~ 
Sepsis, unadjusted, and adjusted as above OR 1.23 (0.81 to 1.58); P = 0.48 
aOR 1.23 (0.91 to 1.67) 
~, ~ 
Composite outcome, unadjusted, and adjusted as 
above 
OR 0.77 (0.59 to 1.01); P = 0.05 
aOR 0.77 (0.59 to 1.01) 
~, ~ 
1: MgSO4 for FN, N = 1387 
babies 
2: MgSO4 for PE/T = 214 
babies 
3: MgSO4 for UK = 546 
babies 
Any resuscitation, 1 vs. 2; 1 vs. 3 P = 0.97; P = 0.76 ~, ~ 
CPAP only, 1 vs. 2; 1 vs. 3^ P < 0.01; P < 0.01 ,  
Bag/mask or neopuff ventilation, 1 vs. 2; 1 vs. 3 P = 0.04; P = 0.35 , ~ 
Intubation and ventilation, 1 vs. 2; 1 vs. 3 P < 0.01; P < 0.28 , ~ 
Chest compressions, 1 vs. 2; 1 vs. 3 P = 0.82; P = 0.60 ~, ~ 
Epinephrine (ETT or IV) , 1 vs. 2; 1 vs. 3 P = 0.99; P = 0.54 ~, ~ 
Apgar score < 7 at 5 minutes, 1 vs. 2; 1 vs. 3 P = 0.14; P = 0.12 ~, ~ 
Surfactant use, 1 vs. 2; 1 vs. 3 P = 0.33; P = 0.53 ~, ~ 
SNAP-2 score > 20, 1 vs. 2; 1 vs. 3 P < 0.01; P < 0.01 ,  
1: MgSO4 for any indication, 
N = 2147 babies 
2: No MgSO4, N = 3868 
babies 
Intensive resuscitation, and adjusted as above OR 0.81; 95% CI 0.73-0.90; P < 0.01 
aOR 0.87; 95% CI 0.69-1.13 
,  ~ 
Neonatal death, unadjusted, and adjusted as 
above 
OR 0.67; 95% CI 0.54-0.82; P < 0.01 
aOR 0.64; 95% CI 0.46-0.89 
,  
BPD, unadjusted, and adjusted as above OR 1.05; 95% CI 0.92-1.21; P = 0.44 
aOR 1.11; 95% CI 0.94-1.30 
~, ~ 
NEC stage ≥ 2, unadjusted, and adjusted as above OR 0.99; 95% CI 0.79-1.27; P = 0.99 
aOR 0.89; 95% CI 0.768-1.17 
~, ~ 
IVH grade 3/4 or PVL, unadjusted, and adjusted as 
above 
OR 0.86; 95% CI 0.73-1.01; P = 0.06 
aOR 1.02; 95% CI 0.76-1.36 
~, ~ 




aOR 0.86; 95% CI 0.59-1.25 
Sepsis, unadjusted, and adjusted as above OR 1.12; 95% CI 0.97-1.30; P = 0.11 
aOR 1.02; 95% CI 0.87-1.20 
~, ~ 
Composite outcome, unadjusted, and adjusted as 
above 
OR 0.93; 95% CI 0.83-1.04; P = 0.19 
aOR 1.03; 95% CI 0.85-1.24 
~, ~ 
Whitsel 2004; RCS; 
unclear 
Abstract 
N = 118 babies; NR 1: MgSO4, N = NR 
2: No MgSO4, N = NR 
Neonatal death “did not change the mortality rate” ~ 
Late bacterial sepsis  P = 0.046  
Whitten 2015; RCS with 
CCS(N); unclear 
Abstract 
N = 6791 babies; NR 1: LOS ≤ 3 days^, N = 6472 
babies 
2: LOS ≥ 4 days, N = 319 
babies 
MgSO4 exposure OR 6.72; P = 0.000  
Wiswell 1996; PCS; 
unclear 
Abstractf 
N = 137 babies; T/PIH 1: MgSO4, N = 61 babies 
2: No MgSO4, N = 76 babies 
NEC P = 0.042  
ICH grade 3/4 P = 0.009  
cPVL in survivors ≥ 21 days P = 0.088 ~ 
ICH grade 3/4 or cPVL OR 4.1; 95% CI 2.0-8.5; P = 0.0001   
Wutthigate 2017; PCS 
with CCS(N); high 
N = 57 women, 63 
babies; PIH/T 
 
1: Apnoeic episodes, N = 8 
babies 
2: No apnoeic episodes, N = 
55 babies 
MgSO4 dose (reported as mg/dL) (mean ± SD) P = 0.06 ~ 
Yokoyama 2010; RCS; 
high 
N = 117 babies; T 1: MgSO4, N = 58 babies 
2: No MgSO4, N = 59 babies 
RDS P = 0.709 ~ 
IVH P = 0.496 ~ 
PDA P = 0.829 ~ 
ROP P = 0.053 ~ 
Neonatal death P = 0.243 ~ 
NEC No events ~ 
Bone change (abnormalities: osteopenic 
radiolucent bands at metaphyses of long bones; 
not suggestive of rickets) 
P = 0.496 ~ 
Young 1977; NRT; high N = 144 women and 
their babies; PE/E 
1: MgSO4 ‘push’ IV, N = 97 
women and babies 
2: MgSO4 continuous IV, N = 
47 women and babies 
Perinatal death 1: 2.1% vs. 2: 2.1% ~ 




Abbreviations: aOR: adjusted odds ratio; aRR: adjusted risk ratio; BMI: body mass index; BPD: bronchopulmonary dysplasia; CCS; case-control study; CCS(N): nested case-control study; CI: confidence 
interval; CMV: continuous mandatory ventilation; CPAP: continuous positive airway pressure; CPR: cardiopulmonary resuscitation; cPVL: cystic periventricular leucomalacia; CRIB: clinical risk index for 
babies; E: eclampsia; ETT: endotracheal tube; FN: fetal neuroprotection; g: grams; GA: gestational age; HD: hypertensive disorders; HFOV: high frequency oscillatory ventilation; HsPDA: 
haemodynamically significant patent ductus arteriosus; ICH: intracranial haemorrhage; IMV: intermittent mandatory ventilation; IV: intravenous; IVH: intraventricular haemorrhage; LD: loading dose; 
LOS: length of stay; LSV: lenticulostriate vasculopathy; MD: maintenance dose; MgSO4: magnesium sulphate; MRI: magnetic resonance imaging; N: number; MV: mechanical ventilation; N: number; 
NCCS: non-concurrent cohort study; NEC: necrotising enterocolitis; NICU: neonatal intensive care unit; NR: not reported; NRT: non-randomised trial; NS: non-significant; OR: odds ratio; P: p value; PCS: 
prospective cohort study; PDA: patent ductus arteriosus; PE: pre-eclampsia; PEA: parenchymal echo abnormality; PEL/VE: parenchymal lesions/ventricular enlargement; PIE: pulmonary interstitial 
emphysema; PIH: pregnancy-induced hypertension; ; PTL: preterm labour; PV-IVH: periventricular intraventricular haemorrhage; PVL: periventricular leucomalacia; PWML: punctate white matter 
lesions; RCS: retrospective cohort study; RCT: randomised controlled trial; RD: respiratory distress; RDS: respiratory distress syndrome; ROM: rupture of membranes; ROP: retinopathy of prematurity; 
RR: risk ratio; SCBU: special care baby unit; SD: standard deviation; SGA: small-for-gestational age; SH: systematic hypertension; SIP: spontaneous intestinal perforation; SNAP: Score For Neonatal Acute 






S4 Table. Adverse outcomes from case reports 
 
Common adverse outcome Authors’ conclusions Setting Neonatal 
characteristics 




Twin A: Apgar scores 1/1/0; resuscitated (including 
intratracheal epinephrine receipt); death at 30 minutes 
of age 
Twin B: Apgar scores 4/6/8; resuscitated (intubated); 
hypermagnesemic; elevated serum cardiac troponin T 
levels; non-specific ST-T wave abnormalities 
“it is conceivable that the mechanism of 
death… may be directly related to the toxic 
effects of magnesium on the myocardium of 
twin A, whereas the myocardium of twin B, 
although compromised, was sufficiently 
functional to maintain life.” 
USA 
Year NR 
2 neonates; twins; 
preterm; LBW 
4 g IV LD; 2.5 g/hour 
MD for ~ 1 day; 
total dose: 51.4 g 
T Herschel 
2001 
42 neonates: diagnosis of poisoning; abnormal clinical 
signs (suck failure, cyanosis, hypoactivity, hypotonia, 
hyporeflexia); IV calcium gluconate receipt; death of 
7/27 neonates exposed to MgSO4 as a single agent 
“in fact only two (2.7%) patients died of the 
secondary effects of overdose of drugs (one 




42 neonates with a 
diagnosis of 
poisoning; exposed 
to MgSO4 (27 as a 
single agent) 
18 to 40 g IV for 12 




Cardiopulmonary arrest after gentamicin exposure following hypermagnesemia at birth 
Respiratory arrest and cardiac arrest following IM 
gentamicin at 24 hours for suspected sepsis (in context 
of hypermagnesemia at birth with abnormal 
neuromuscular function tracings and clinical 
examination: peripheral motor weakness, rapid shallow 
respirations, poor suck, poor Moro reflex, decreased 
grasp reflexes) 
“aminoglycosides may potentiate a 
magnesium-induced impairment of 
neuromuscular transmission and cause 
muscular weakness in neonates.” 
USA 
Year NR 
1 neonate; term 24 g in 32 hours 
prior to birth 
PE L’Hommedieu 
1983 
Respiratory and cardiac arrest following IV gentamicin at 
48 hours for suspected sepsis (in context of 
hypermagnesemia at birth with neuromuscular 
compromise: ulnar nerve stimulation studies and 
neurologic examination) 
“depressed NMF [neuromuscular function] in 
a hypermagnesemic infant may be further 
compromised by aminoglycoside therapy.” 
USA 
Year NR 
1 neonate; term 28 g PE Rasch 1981 
Clinical features of magnesium ‘toxicity’ or ‘intoxication’ at birth 
Flaccid, apnoeic, cyanotic at birth (muscular paralysis, 
absent reflexes, respiratory failure); Apgar score 2 at 1 
minute; endotracheal intubation, ventilation and 
calcium gluconate receipt; hypermagnesemic 
“Magnesium Intoxication… “in our patient, 
peak serum levels from the mother’s first 
intramuscular dose could have coincided 
with the peak serum level from her second 
USA 
1966 
1 neonate; very 
preterm; LBW 
3 g IV, 6 g IM, and 2 
g IV, 3.5 hours, 2.5 
hours, 0.5 hours 




intravenous dose… the toxic effects of motor 
and respiratory paralysis were immediately 
reversed when the serum magnesium level 
lowered during an exchange transfusion.” 




Depressed, hypotonic, cyanotic, apnoeic, partially 
responsive to initial resuscitation; hypermagnesemic 
“a newborn with a history of maternal use of 




1 neonate; preterm 17 hours IV prior to 
birth 
PE Cruz 2009 
“CNS disturbances” “For appropriate treatment of neonates, it is 
necessary to take into consideration 




~25 neonates [225 
neonates with RDS, 




NR NR Jashi 2014 
“clinical and biochemical changes associated with 
hypermagnesemia in newborns”:  
Neonate 1: low Apgar score at 1 minute (intubation, 
ventilation), flaccid, unresponsive, shallow respirations, 
respiratory arrest 
Neonate 2: low Apgar score at 1 minute, bradycardia, 
minimal activity, weak cry 
Neonate 3: low Apgar score at birth, hypotonia, 
hyporeflexia 
Neonate 4: low Apgar score at 1 minute (intubation, 
ventilation), floppy, poor shallow respiratory movement, 
poor activity, weak cry 
Neonates 5 and 6: low Apgar scores (intubation and 
ventilation), flaccid, death [not attributed to MgSO4; 
rather HMD] 
Neonate 6: low Apgar at 1 minute (intubation and 
ventilation), flaccid, weak cry, poor reflexes, poor muscle 
tone 
“clinical and biochemical changes associated 






reports]; 3 term,  4 
preterm (1 set of 
twins) 
 
[Note: only detailed 
cases included; 
others presented as 
case series] 
1: 51.5 g in 33.5 
hours 
2: 21 g in 24 hours 
3: 30 g in 19 hours 
4: 31 g in 20 hours 
5: 41.3 g in 30 hours 
6: 60.4 g in 44 hours 
PE/E Lipsitz 1967 
Apgar scores 2/6, severe respiratory distress (intubated) 
at birth, hyporeflexic, hypotonic, lethargic; 
hypermagnesemic; hypocalcaemic; ventilated and IV 
calcium gluconate receipt 
“Hypermagnesemia was judged to be the 




1 neonate; preterm; 
LBW 
50 g IV in 46 hours 
prior to birth 





Microcolon or ‘meconium-plug syndrome’ 
Microcolon, with clinical signs and symptoms: failure to 
pass meconium within first 24 hours with progressive 
abdominal distention 
“In summary, the microcolon seen in our 
very premature infants seems secondary to 
functional obstruction on the basis of 
ganglion cell dysfunction and depressive 









NR PE Amodio 1986 
No passage or delayed massage of meconium and 
abdominal distension; findings consistent with 
“meconium plug syndrome” 
“The role of magnesium in depression 
smooth muscle cells and passing the 
placenta has been well documented and was 







[12 neonates not 
exposed to MgSO4 
excluded] 
NR PE/E Krasna 1996 
Abdominal distention and failure to pass meconium 
(“Meconium-plug syndrome”) 
1 neonate: depressed, shallow respirations, hypotonic, 
hyporeflexic; hypermagnesemic; hypocalcaemic 
1 neonate: lethargic, hypotonic, rapid and grunting 
respiration, lower extremities hypotonic, absent deep 
tendon reflexes; hypermagnesemic; hypocalcaemic; 
calcium gluconate IV receipt  
“We believe that the hypermagnesemia 
depressed function of the intestinal smooth 




2 neonates; 1 term, 
LBW; 1 preterm 
41 and 25 g in 24 
hours prior to birth 
respectively 
PE/E Sokal 1972 
Nonoliguric hyperkalaemia 
Neonatal non-oliguric hyperkalaemia (high risk for 
developing life-threatening cardiac arrhythmia) at 2 
hours after birth; insufficient urinary K excretion; 
hypermagnesemic; not hypocalcaemic with calcium 
sulphate receipt; transiently hyponatraemic 
“Maternal and fetal hypermagnesemia can 




1 neonate; preterm; 
VLBW 
0.1 g/hour IV on day 
1; 0.5 g/hour IV on 
days 2 to 5; 1 
g/hour IV days 6 to 
12; 2 g/hour IV on 
day 12 
PE Tanaka 2018 
Bone abnormalities with prolonged MgSO4 for tocolysis 
Laboratory abnormalities (“especially hypermagnesemia 
and hypocalcemia”) and skeletal abnormalities including 
osteopenia and fractures 
“The postmarket… data support an 
association between prolonged maternal 
administration of MgSO4 and neonatal 


















Radiographic changes in the metaphyses of long bones 
(discrete band of osteopenic metaphyseal bone); 
hypermagnesemic; not hypocalcaemic; elevated alkaline 
phosphatase 
“we believe it likely the abnormal ossification 
was due to hypermagnesemia.” 
USA 
Year NR 
1 neonate; very 
preterm; LBW 
1 to 4 g/hour IV 
from ~18 weeks 




Diffuse osteopenia of long bones (diffuse metaphyseal 
osteopenia); probable rib fracture (2 neonates); 
hypermagnesemic; severely hypocalcemic; elevated 
alkaline phosphatase; relative hypoparathyroidism; 
calcium and calcitriol receipt (5 neonates) 
“Premature infants who are exposed to large 
doses of MgSO4, especially those of multiple 
pregnancies, have an increased risk of 




10 neonates (twins 
or triplets); 




3.66 (SD: 0.8) kg per 
pregnancy over a 
mean of 10.0 (SD: 
0.5) weeks (1.75 to 
3 g/hour for 9 to 11 
weeks)  
T Kaplan 2006 
Triplets B and C: bone abnormalities “mimicking genetic 
bone disease”: at 3 weeks thin, demineralised bones 
with multiple fractures of the ribs, humeri and clavicle; 
skull bones were demineralised; very wide fontanelles, 
white sclera; not hypocalcaemic; mildly 
hypermagnesemic; elevated alkaline phosphatase; low 
bone density persisting at 3 months 
“The bone abnormalities were presumed to 
be related to prolonged prenatal exposure to 
magnesium, with genetic bone disease 
unlikely… This case points out the necessity 
of including prolonged magnesium therapy in 
the differential diagnosis of the newborn 
infant with multiple fractures.” 
NR 2 neonates (from 
triplets); very 
preterm 
2.5 g/hour IV for 8.5 
weeks 
T Kogan 2003 
Radiological, biochemical or clinical features of rickets 
1 neonate: radiographic bony abnormalities: frank 
rachitic changes and dental enamel hypoplasia; 
hypotonic, respiratory distress at birth; 
hypermagnesemic; hypocalcaemic; elevated alkaline 
phosphatase; IV calcium gluconate receipt (dental 
enamel hypoplasia persisting at 3 years) 
3 neonates: no bony abnormalities; mild respiratory 
distress; 1 hypotonic; hypermagnesemic; 1 
hypocalcaemic 
“We hypothesize that prolonged infusion of 
magnesium sulfate, especially when imitated 
during the second trimester, may lead to 
fetal parathyroid gland suppression with 







[1 neonate exposed 
to combination 
tocolysis excluded] 
1 neonate: 4 g IV 
LD; 2-3 g/hour IV 
MD for 13 weeks 
3 neonates: doses 
similar to above, for 
4 to 6 weeks 
T Lamm 1988 
Abnormal radiological findings: abnormal mineralisation 
of long-bone metaphyses 
Twin 1A and 1B: hypotonic, poor sucking capacity; 
widening of anterior ends of ribs and widening of femora 
and humeri metaphyses with radiolucency; 
hypermagnesemic 
“abnormal radiological findings consisting of 
abnormal mineralisation of long-bone 
metaphyses owing to fetal 
hypermagnesaemia.” 
Twin 2A not affected: “intrauterine growth 
restriction may be a protective factor against 
Lebanon 
Year NR 
3 neonates (from 2 
sets of twins); 
preterm; LBW 
 
[twin 2A VLBW, 
excluded] 
Twins 1A and B: 3 to 
3.5 g/hour IV for 12 
weeks 
Twins 2A and B: 3 to 
4 g/hour IV for 8 
weeks 




Twin 2B: radiolucency of metaphyses, mainly humeri; 
hypermagnesemic 
the development of bone abnormalities 
secondary to prolonged fetal 
hypermagnesaemia.” 
 
Abbreviations: CNS: central nervous system; E: eclampsia; g: grams; HMD: hyaline membrane disease; IM: intramuscular; IV: intravenous; LBW: low birthweight; LD: loading dose; MD: maintenance 
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Antenatal magnesium sulphate for cerebral palsy prevention 
 
Two landmark observational studies published in the 1990s provided the first descriptions of an 
association between in utero magnesium sulphate exposure and a reduced risk of cerebral 
palsy.1,2 Due to the limitations and discrepancies of findings from observational studies, a need 
to establish reliable evidence, through the conduct of randomised trials, was realised. From 1995 
to 2004, five placebo-controlled randomised trials (ACTOMgSO4;3 BEAM;4 MagNET;5 PREMAG6; 
MAGPIE7) were conducted, testing the hypotheses that antenatal magnesium sulphate reduces 
brain injury, cerebral palsy, or mortality for preterm infants. 
 
In the meta-analysis of the aforementioned trials in the 2009 Cochrane review, magnesium 
sulphate administered with neuroprotective intent reduced the risk of death or cerebral palsy (RR 
0.85, 95% CI 0.74-0.98; 4 trials, 4,446 infants).8 Overall magnesium sulphate reduced the risk of 
cerebral palsy (RR 0.68, 95% CI 0.54-0.87; 5 trials, 6,145 infants). This review confirmed the 
neuroprotective role for magnesium sulphate – 63 babies (95% CI 44-155) need to be exposed 
to magnesium sulphate in utero to benefit one preterm baby by avoiding cerebral palsy.8  
 
Additional systematic reviews and meta-analyses have reached similar conclusions.9,10 This has 
been regarded as a very important finding, as few interventions have been found to prevent the 
devastating consequences of cerebral palsy. Importantly, in a recent cost-effectiveness analysis, 
magnesium sulphate prior to very preterm birth was shown to be cost-effective from a societal 
and health system perspective.11 
 
Following this compelling evidence from randomised trials and reviews, in many countries, 
including Australia, New Zealand, the United Kingdom, Canada and the United States, clinical 
practice guidelines12,13 and opinion papers14-17 have recommended use of this therapy. Australian 
and New Zealand clinical practice guidelines, Antenatal magnesium sulphate prior to preterm birth 
for neuroprotection of the fetus, infant and child, endorsed by the National Health and Medical 
Research Council (NHMRC) in 2010, provided guidance in the form of nine evidence-based 
recommendations and six practice points.12 
 
With passive guideline dissemination alone, it was not anticipated that all health professionals 
would immediately begin using antenatal magnesium sulphate.18 The WISH Project (Working to 
Improve Survival and Health for babies born very preterm) was thus designed, funded by the 
Cerebral Palsy Alliance Research Foundation, to improve and monitor the use of this therapy in 
Australia and New Zealand.19 Through WISH, audit studies at lead hospitals have highlighted 
rapid translation – at the Women’s and Children’s Hospital, South Australia uptake increased from 
30% in 2010, to 78% in 2011-13,20,21 and in 2012, uptake at Auckland City Hospital, New Zealand, 
was 82%.22 While encouragingly in 2011, 76%, and in 2013, almost all Australian and New 
Zealand tertiary maternity hospitals had local practices to implement this therapy, fewer were 
formally auditing use, and uptake estimates have varied.23,24 The Australian and New Zealand 
Neonatal Network (ANZNN) data report increasing uptake bi-nationally (2012: 44%; 2013: 
60%).25,26 
 
Maternal adverse effects of antenatal magnesium sulphate: a systematic review 
 
Given the extensive use of antenatal magnesium sulphate in obstetric care, to prevent or treat 
pre-eclampsia (beneficial),27,28 for acute and maintenance tocolytic therapy for women during and 
following threatened preterm labour (not beneficial),29,30 and most recently, for fetal 
neuroprotection and cerebral palsy prevention (beneficial),8 the potential adverse effects for the 
mother are well known.  
 
High quality evidence regarding maternal adverse effects can be drawn from a recent systematic 
review (led by CI Bain), ‘Maternal adverse effects of different antenatal magnesium sulphate 
regimens for improving maternal and infant outcomes: a systematic review’.31 This review 
included 143 publications – 21 randomised controlled trials, 14 non-randomised comparative 




magnesium sulphate when given for treatment of pre-eclampsia, for cerebral palsy prevention, or 
for preterm labour tocolysis. Reassuringly, this review showed that antenatal magnesium sulphate 
was not associated with an increased risk of maternal death, cardiac arrest or respiratory arrest.31 
In this review, individual case reports, did, however support an association between iatrogenic 
overdose of magnesium sulphate and life-threatening consequences.31,32 Appropriate 
administration of therapy was shown to increase the risk of ‘any adverse maternal effects’ (RR 
4.62, 95% CI 2.42 to 8.83; 4 trials, 13,322 women), and treatment cessation due to maternal 
adverse effects (RR 2.77, 95% CI 2.32 to 3.30; 5 trials, 13,666 women).31 This systematic review 
concluded that for each antenatal indication for use, further trials designed to determine optimal 
regimens (aimed at achieving maximal effectiveness with minimal adverse effects) may be 
beneficial, and called for vigilance in the use of this therapy, in order to ensure women’s safety.31 
 
Potential neonatal or infant adverse effects of antenatal magnesium sulphate 
 
With the increased, widespread use of antenatal magnesium sulphate for cerebral palsy 
prevention, concern has been raised about potential unintended neonatal or infant adverse 
effects. In a recent evaluation of barriers and enablers to implementing antenatal magnesium 
sulphate for cerebral palsy prevention (as part of The WISH Project), the uncertainty surrounding 
adverse effects for very preterm neonates was specifically raised by health professionals, 
particularly neonatologists, as a potential barrier to increased use.33  
 
Magnesium has fundamental roles in many cellular process (such as gating of calcium channels; 
muscle contraction; neuronal activity; control of vasomotor tone; cardiac excitability; and 
neurotransmitter release)34, and thus above normal magnesium concentrations (associated with 
magnesium sulphate therapy), can plausibly be associated with fetal, neonatal or infant adverse 
effects. Magnesium is known to cross the placenta readily, with fetal serum concentrations 
correlated with maternal serum magnesium concentrations,35 and/or total maternal dose of 
magnesium sulphate given.36 Where there is delayed fetal urinary excretion, fetal serum and 
amniotic fluid concentrations can exceed maternal concentrations. 
 
In the Cochrane systematic reviews assessing magnesium sulphate for treating pre-
eclampsia,27,28 for cerebral palsy prevention,8 and for preterm labour tocolysis,29 no clear 
increased risks of adverse neonatal or infant outcomes were reported, however a borderline 
increased risk of total death (fetal, neonatal, infant) with prolonged use for tocolysis was observed 
(RR 4.56, 95% CI 1.00 to 20.86; 2 trials, 257 babies).29 These reviews were restricted to assessing 
randomised controlled trial evidence, and a limited number of pre-specified outcomes. 
 
Recently, a systematic review (including randomised trials and prospective observational studies) 
summarised the effects of magnesium sulphate given for treating pre-eclampsia, for cerebral 
palsy prevention, and for preterm labour tocolysis specifically on fetal heart rate.37 This review 
suggested a small negative effect on fetal heart rate, variability and accelerative pattern, “not 
sufficient clinically to warrant medical intervention”.37 To date, a comprehensive systematic review 
of all available evidence surrounding potential unintended neonatal or infant adverse effects of 
antenatal magnesium sulphate has not been conducted. 
 
While secondary analyses from the BEAM trial (one of the five randomised trials assessing 
magnesium sulphate for cerebral palsy prevention) have shown no clear effects of magnesium 
sulphate on neonatal resuscitation,38,39 and other cardiovascular parameters in the first 24 hours 
of life,40 numerous published observational studies have indicated higher risks of some adverse 
outcomes, necessitating further evaluation.  
 
For example, a retrospective cohort study (of 6,654 women and their babies) has shown 
increasing maternal serum magnesium concentrations (when given for pre-eclampsia) to be 
associated with lower one and five-minute Apgar scores, and higher risks of intubation in the 
delivery room, admission to special care nursery and neonatal hypotonia.41 Two retrospective 
cohort studies (of 160 neonates born at less than 28 weeks gestation; and 954 neonates born 
500 to 1000 g), and one prospective case-control study (of 48 neonates born 30 to 34 weeks 
gestation), have shown antenatal magnesium sulphate exposure (when given for pre-eclampsia 
or for tocolysis) to be associated with an increased risk of neonatal patent ductus arteriosus.42-44 
A recent retrospective cohort study (of 155 neonates born less than 1000 g) has shown 
magnesium sulphate (when given for cerebral palsy prevention), to be associated with 




perforation and death among infants with the lowest birthweights.45 Observational studies 
(including retrospective cohort studies and case reports) have shown prolonged magnesium 
sulphate exposure (when given for tocolysis) to be associated with abnormal bone metabolism 
for the neonate or infant,46 and rarely, bone fracture at birth.47 
 
Why it is important to conduct a systematic review of adverse effects for the neonate or 
infant 
 
Strong evidence from randomised trials and systematic reviews supports the use of antenatal 
magnesium sulphate for cerebral palsy prevention.3-6,8,48 Rapid translation into clinical practice 
across Australia and New Zealand has been observed.20,23,24 Concerns have however been 
raised surrounding potential neonatal and infant adverse effects of therapy, warranting further 
evaluation. A systematic review of all available evidence is thus now required in order to 
determine whether such adverse effects are associated with magnesium sulphate therapy, and if 
so, whether they vary according to factors such as different regimens for administration, or 
indications for use. Implementation of antenatal magnesium sulphate for cerebral palsy 
prevention can be strengthened, and safety improved, if clinical practice guidelines and their 




The primary aim of this systematic review is to assess whether antenatal exposure to magnesium 
sulphate, given to improve outcomes for mothers or their babies, including for cerebral palsy 
prevention, is associated with adverse effects for the neonate or infant. 
 
Secondary aims are to assess whether there are variations in adverse effects according to 
pregnancy and birth characteristics for the women/neonate (such as: indication for use of 
antenatal magnesium sulphate, antenatal co-interventions, mode of birth, gestational age at birth, 
and birthweight) or characteristics of the magnesium sulphate regimen received by women (such 






Systematic review of adverse effects. 
 




We will include interventional (e.g. randomised, cluster-randomised, quasi-randomised and non-
randomised comparative trials) and observational studies (e.g. cohort, case-control and cross-
sectional studies, case series and case reports). We will include studies available as abstract 




We will include neonates or infants who were exposed to antenatal magnesium sulphate, 
regardless of their gestational age at exposure or birth. 
 
Interventions and comparators 
 
We will include studies where antenatal magnesium sulphate was given for pre-eclampsia or 
eclampsia, for tocolysis to women in or following threatened preterm labour, or for neuroprotection 
of the fetus to women at risk of preterm birth (for cerebral palsy prevention). We will exclude 
studies where oral magnesium sulphate was given, and where magnesium sulphate was given 
as an adjuvant during anaesthesia. We will include studies in which magnesium sulphate was 
compared to no treatment, placebo, or a different magnesium sulphate regimen; and/or, for 








Primary: perinatal mortality (defined as stillbirth, neonatal or infant mortality up to the time of 
primary hospital discharge). 
 
Secondary outcomes for the neonate or infant will be comprehensive, including anticipated or 
unanticipated adverse effects, such as:  
 Stillbirth 
 Neonatal or infant death 
 Low Apgar scores at one and five minutes 
 Need for active resuscitation at birth 
 Neonatal respiratory depression 
 Neonatal hypotension 
 Need for neonatal nursery admission and duration of admission 
 Lethargy, hypotonia, or hyporeflexia 
 Patent ductus arteriosus 
 Spontaneous intestinal perforation 
 Osteopenia or bone fractures 




A comprehensive search of the following bibliographic databases will be performed: MEDLINE 
(PubMed/OVID which includes the Cochrane Library), EMBASE (OVID), CINAHL, Lilacs, Scopus, 
ISI Web of Science and Toxline, from their inceptions. We will use a combination of MeSH and 
free-text terms, and will not apply date or language restrictions. 
 
We will search research registers of ongoing trials (clinicaltrials.gov, international clinical trials 
registry), and search engines Google Scholar and Google using key words. The reference lists of 
eligible articles or reviews identified will be checked for additional references. 
 
Data collection and synthesis 
 
The methodology for data collection and synthesis will be based on current recommendations of 
the Cochrane Adverse Effects Methods Group.49 Where appropriate, the overview will be 




After screening all titles and abstracts, we will obtain the full-text article for any study which seems 
to meet the inclusion criteria based on the title and/or abstract, along with any reviews that may 
provide relevant references. Each stage will be carried out by two reviewers. We will resolve any 
discrepancies through discussion, or if required, we will consult a third reviewer. 
 
Data extraction and management 
 
Once a study is included, data will be extracted using a standardised form. Data extracted will 
include information regarding study design, participants, the magnesium sulphate regimen(s), the 
control or comparison if applicable, neonatal or infant adverse effects reported and results 
relevant to the review, the risk of bias, confounding and relevance. Extraction will be carried out 
by two reviewers independently. We will resolve any discrepancies through discussion, or if 




The levels of evidence will be assessed using the Australian National Health and Medical Council 
Levels of Evidence, and the quality (risk of bias) of randomised trials assessed using established 
guidelines provided in the Cochrane Handbook.52 The quality assessment of non-randomised 
studies will be based on recommendations from Cochrane (ACROBAT-NRSI).53 As it has been 
suggested that the quality of adverse effect detection and reporting is not always adequately 
assessed, the methods used to detect adverse effects and how rigorous these methods were, will 







The analysis and presentation of results will be categorised by study design, and according to 
indication for use. Statistical analyses will be performed using Review Manager.51 
 
For interventional studies we will present quantitative data from individual studies where possible 
as risk ratios (RR) with 95% confidence intervals (CI) for dichotomous outcomes. For all 
outcomes, we will carry out analyses as far as possible on an intention-to-treat basis. Pooled 
estimates (summary RR with 95% CI) will be calculated using fixed-effect meta-analysis where 
there is a sufficient quantity of data, with clinical homogeneity. Where we consider that there is 
clinical heterogeneity sufficient to expect that the underlying effects differ between trials, or there 
is substantial statistical heterogeneity (where I2 is greater than 30% and either Tau2 is greater 
than zero, or there is a low P value (less than 0.10) in the Chi2 test), summary estimates will be 
calculated using random-effects meta-analysis. 
 
Separate comparisons will be performed for those studies assessing magnesium sulphate versus 
no treatment or placebo, and those comparing different magnesium sulphate regimens. 
 
For observational studies (e.g. cohort, case-control and cross-sectional studies, and case series) 
we will present effect estimates where possible as percentages, RR or odds ratios (OR) with 95% 
CIs, or adjusted RR or OR if reported with 95% CIs, in tabular format based on study type; we will 
use narrative synthesis to summarise the results. Data from case reports will be tabulated, 
subsequently grouped according to common outcomes, and summarised narratively. 
 
Analysis of subgroups 
 
Subgroup analyses will be carried out if sufficient data are available based on pregnancy and 
birth characteristics, and characteristics of the magnesium sulphate regimens: 
 
Characteristics of the pregnancy and birth 
 Indication for magnesium sulphate administration (e.g. fetal neuroprotection and cerebral 
palsy prevention, pre-eclampsia/eclampsia treatment, preterm labour tocolysis, other) 
 Gestational age at magnesium sulphate administration (e.g. < 28, 28 to < 32, 32 to < 37, 
≥ 37 weeks gestation) 
 Birthweight (e.g. < 500, 500 to < 1000, 1000 to < 1500, 1500 to < 2500, 2500 to < 4000, 
≥ 4000 g) 
 Mode of birth (vaginal birth, caesarean section) 
 Concomitant maternal treatment including: antenatal or intrapartum drug therapy (e.g. 
corticosteroids, tocolytic agents, agents for pain relief). 
 
Characteristics of the magnesium sulphate regimen 
 Route of administration of magnesium sulphate (intravenous (IV), intramuscular (IM)) 
 Concentrated solution requiring dilution or pre-mixed solution 
 Dose of magnesium sulphate 
o Loading dose only, loading and maintenance dose, maintenance dose only 
o Loading dose: none, ≤ 4 g, > 4 g 
o Maintenance dose: none, ≤ 1 g/hour IV, > 1 g/hour IV (OR none, ≤ 10 g IM every 
4 hours, > 10 g IM every 4 hours) 
o Total dose prior to birth (< 4, 4 to < 14, 14 to < 28, ≥ 28 g) 
o Interval between treatment and birth (0 to < 1, 1 to < 4, 4 to < 8, 8 to < 12, 12 to 
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Date searched: 30/05/2016; with top-up searches conducted on 10/08/2018 and 03/09/2019 
Total records retrieved: 422 
 
1. (MH "magnesium sulfate+")   
2. “magnesium sulfate” or “magnesium sulphate” or mgso4 
3. S1 or S1 
4. (MH “Prenatal Care”) 
5. (MH “Pregnancy+”) 
6. (MH “Perinatal Care”) 
7. (MH “Maternal Exposure”) 
8. (pregnan* or labor or laboring or labour* or antepart* or prenatal* or antenatal* or perinatal* 
or intranatal* or obstetric* or intrapart* or preterm or prematur* or tocoly* or “maintenance 
therapy” or preeclamp* or pre-eclamp* or “pre eclamp*” or eclamp* or neuroprotection* or 
“cerebral palsy”)  
9. S4 OR S5 OR S6 OR S7 OR S8 
10.  (MH "Infant+")  
11. (MH "Infant, Newborn, Diseases+")  
12. (MH "Intensive Care, Neonatal+")  
13. (fetus* or fetal* or foetus* or foetal* or baby or babies or neonat* or infan* or newborn* or 
“new born”)  
14. S10 OR S11 OR S12 OR S13  




Date searched: 30/05/2016; with top-up search conducted on 10/08/2018 and 03/09/2019 
Total records retrieved: 494 
 
1. MeSH descriptor: [Magnesium Sulfate] explode all trees 
2. ((magnesium next sulfate) or (magnesium next sulphate) or MgSO4):ti,ab,kw 
3. #1 or #2 
4. MeSH descriptor: [Pregnancy] explode all trees 
5. MeSH descriptor: [Pregnancy Complications] explode all trees 
6. MeSH descriptor: [Prenatal Care] explode all trees 
7. MeSH descriptor: [Perinatal Care] explode all trees 
8. MeSH descriptor: [Maternal Exposure] explode all trees 
9. (pregnan* or labor or laboring or labour* or antepart* or prenatal* or antenatal* or perinatal* 
or intranatal* or obstetric* or intrapart* or preterm or prematur* or tocoly* or (maintenance 
NEXT therapy) or preeclamp* or pre-eclamp* or (pre NEXT eclamp*) or eclamp* or 
neuroprotection* or (cerebral NEXT palsy)):ti,ab,kw 
10. #4 or #5 or #6 or #7 or #8 or #9 
11. MeSH descriptor: [Infant] explode all trees 
12. MeSH descriptor: [Infant, Newborn, Diseases] explode all trees 
13. MeSH descriptor: [Intensive Care, Neonatal] explode all trees 
14. (fetus* or fetal* or foetus* or foetal* or baby or babies or neonat* or infan* or newborn* or 
(new NEXT born)):ti,ab,kw 
15. #11 or #12 or #13 or #14 







Date searched: 30/05/2016; with top-up search conducted on 10/08/2018 and 03/09/2019 
Total records retrieved: 58 
 
("magnesium sulphate" or "magnesium sulfate" or mgso4) and (fetus$ or fetal$ or foetus$ or 
foetal$ or baby or babies or neonat$ or infan$ or newborn$ or "new born") 
 
MEDLINE and Embase (OVID) 
 
Date searched: 30/05/2016; with top-up search conducted on 10/08/2018 and 03/09/2019 
Total records retrieved: 4044 
 
1. exp Magnesium Sulfate/ 
2. ((magnesium adj sulfate) or (magnesium adj sulphate) or MgSO4).mp. 
3. or/1-2 
4. exp Pregnancy/ 
5. exp Pregnancy Complications/ 
6. exp Prenatal Care/ 
7. exp Perinatal Care/ 
8. exp Maternal Exposure/ 
9. (pregnan$ or labor or laboring or labour$ or antepart$ or prenatal$ or antenatal$ or perinatal$ 
or intranatal$ or obstetric$ or intrapart$ or preterm or prematur$ or tocoly$ or (maintenance 
adj therapy) or preeclamp$ or pre-eclamp$ or (pre adj eclamp$) or eclamp$ or 
neuroprotection$ or (cerebral adj palsy)).mp. 
10. or/4-9 
11. exp Infant/ 
12. exp Infant, Newborn, Diseases/ 
13. Intensive Care, Neonatal/ 
14. (fetus$ or fetal$ or foetus$ or foetal$ or baby or babies or neonat$ or infan$ or newborn$ or 
(new adj born)).mp. 
15. or/11-14 
16. 3 and 10 and 15 
17. exp Animals/ 
18. exp Humans/ 
19. 17 not 18 
20. 16 not 19 




Date searched: 30/05/2016; with top-up search conducted on 10/08/2018 and 03/09/2019 
Total records retrieved: 319 
 
(“magnesium sulphate” OR “magnesium sulphate” OR MgSO4) AND (fetus* or fetal* or foetus* or 






Web of Science 
 
Date searched: 30/05/2016; with top-up search conducted on 10/08/2018 and 03/09/2019 
Total records retrieved: 553 
 
1. TS=(“magnesium sulphate” OR “magnesium sulphate” OR MgSO4) Timespan=All years 
2. TS=(fetus* or fetal* or foetus* or foetal* or baby or babies or neonat* or infan* or newborn* 
or “new born”) Timespan=All years 
3. TS=(pregnan* OR labor OR laboring OR labour* OR antepart* OR prenatal* OR antenatal* OR 
perinatal* OR intranatal* OR obstetric* OR intrapart* OR preterm OR prematur* OR tocoly* 
OR “maintenance therapy” OR preeclamp* OR pre-eclamp* OR “pre eclamp*” OR eclamp* OR 
neuroprotection* OR “cerebral palsy*”) Timespan=All years 
4. #3 AND #2 AND #1 Timespan=All years 
5. #3 AND #2 AND #1 Refined by: Databases: ( BCI OR SCIELO OR WOS OR BIOSIS OR KJD OR CCC 
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